"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2013/0276021 A1,187-034-638-737-659,2013-10-17,2013,US 201313912400 A,2013-06-07,US 201313912400 A;;AU 2011/205061 A;;US 201113341739 A;;US 2011/0039172 W;;US 201213440369 A,2011-06-03,EMBEDDED VIDEO PLAYER WITH MODULAR AD PROCESSING,"A method, device and/or system for operating or causing a video player embedded into a web page to play a video is disclosed. Embed code is placed into the web page. When the web page is loaded into a web browser, player code is loaded and optionally customized to display one or more videos that can be selected for playback with the player code. When an end user selects the video using the player code, any ad and/or analytics module associated with the video are retrieved. The functionality of the ad and/or analytics module is integrated into the player code to allow tracking of analytics and inserting advertizing into the video.",LIMELIGHT NETWORKS INC,CHO PAUL,LIMELIGHT NETWORKS INC (2013-06-13),https://lens.org/187-034-638-737-659,Patent Application,yes,3,8,3,5,0,H04N21/4782;;H04N21/812;;H04N21/84;;H04N21/80;;H04N21/44224;;H04N21/4782;;H04N21/812;;H04N21/84;;H04N21/44224;;H04N21/80,H04N21/80,725/32,0,0,,,,DISCONTINUED
2,AU,B1,AU 2011/205061 B1,091-735-446-021-032,2012-04-12,2012,AU 2011/205061 A,2011-06-03,US 2011/0039172 W,2011-06-03,Embedded video player with modular ad processing,"Attorney Docket No.: 88673-807982 Client Reference No.: 98-PC A method, device and/or system for operating or causing a video player embedded into a web page to play a video is disclosed. Embed code is placed into the web page. When the web page is loaded into a web browser, player code is loaded and optionally customized to display one or more videos that can be selected for playback with the player code. When an end user selects the video using the player code, any ad and/or analytics module associated with the video are retrieved. The functionality of the ad and/or analytics module is integrated into the player code to allow tracking of analytics and inserting advertizing into the video. 63122412 v1",LIMELIGHT NETWORKS INC,CHO PAUL,,https://lens.org/091-735-446-021-032,Granted Patent,no,1,1,2,5,0,G06Q30/0241,G06F17/30,,0,0,,,,INACTIVE
3,WO,A1,WO 2012/166154 A1,177-313-408-187-435,2012-12-06,2012,US 2011/0039172 W,2011-06-03,US 2011/0039172 W,2011-06-03,EMBEDDED VIDEO PLAYER WITH MODULAR AD PROCESSING,"A method, device and/or system for operating or causing a video player embedded into a web page to play a video is disclosed. Embed code is placed into the web page. When the web page is loaded into a web browser, player code is loaded and optionally customized to display one or more videos that can be selected for playback with the player code. When an end user selects the video using the player code, any ad and/or analytics module associated with the video are retrieved. The functionality of the ad and/or analytics module is integrated into the player code to allow tracking of analytics and inserting advertizing into the video.",LIMELIGHT NETWORKS INC;;CHO PAUL,CHO PAUL,,https://lens.org/177-313-408-187-435,Patent Application,yes,4,3,2,5,0,G06Q30/0241,G06F17/00;;G06F15/16;;G06Q30/00;;G11B20/10,,0,0,,,,PENDING
4,US,B2,US 8533754 B2,034-689-152-441-267,2013-09-10,2013,US 201113341739 A,2011-12-30,AU 2011/205061 A;;US 2011/0039172 W;;US 201113341739 A,2011-06-03,Embedded video player with modular ad processing,"A method, device and/or system for operating or causing a video player embedded into a web page to play a video is disclosed. Embed code is placed into the web page. When the web page is loaded into a web browser, player code is loaded and optionally customized to display one or more videos that can be selected for playback with the player code. When an end user selects the video using the player code, any ad and/or analytics module associated with the video are retrieved. The functionality of the ad and/or analytics module is integrated into the player code to allow tracking of analytics and inserting advertising into the video.",CHO PAUL;;LIMELIGHT NETWORKS INC,CHO PAUL,LIMELIGHT NETWORKS INC (2011-12-07),https://lens.org/034-689-152-441-267,Granted Patent,yes,18,1,3,5,0,H04N21/4782;;H04N21/812;;H04N21/84;;H04N21/80;;H04N21/44224;;H04N21/4782;;H04N21/812;;H04N21/84;;H04N21/44224;;H04N21/80,H04N7/025;;H04N7/10,725/34;;725/35;;725/38;;725/86;;725/110;;725/131;;725/139;;725/151;;709/202;;709/203;;715/202;;715/204;;715/719;;715/728;;715/730,1,0,,,"Australian First Examination Report dated Jan. 20, 2012 for Priority Australian Patent App. No. 2011205061, filed Jan. 3, 2011, 2 pages.",ACTIVE
5,US,A1,US 2012/0311627 A1,173-902-329-864-653,2012-12-06,2012,US 201113341739 A,2011-12-30,AU 2011/205061 A;;US 2011/0039172 W;;US 201113341739 A,2011-06-03,EMBEDDED VIDEO PLAYER WITH MODULAR AD PROCESSING,"A method, device and/or system for operating or causing a video player embedded into a web page to play a video is disclosed. Embed code is placed into the web page. When the web page is loaded into a web browser, player code is loaded and optionally customized to display one or more videos that can be selected for playback with the player code. When an end user selects the video using the player code, any ad and/or analytics module associated with the video are retrieved. The functionality of the ad and/or analytics module is integrated into the player code to allow tracking of analytics and inserting advertizing into the video.",CHO PAUL;;LIMELIGHT NETWORKS INC,CHO PAUL,LIMELIGHT NETWORKS INC (2011-12-07),https://lens.org/173-902-329-864-653,Patent Application,yes,13,8,3,5,0,H04N21/4782;;H04N21/812;;H04N21/84;;H04N21/80;;H04N21/44224;;H04N21/4782;;H04N21/812;;H04N21/84;;H04N21/44224;;H04N21/80,H04N21/80,725/32,0,0,,,,ACTIVE
6,US,A1,US 2013/0238757 A1,020-031-738-641-101,2013-09-12,2013,US 201213595841 A,2012-08-27,US 201213595841 A;;US 201213413260 A,2012-03-06,DISTRIBUTED PLAYBACK SESSION CUSTOMIZATION FILE MANAGEMENT,"A method, device and/or system for syndicating customization files, which define playback experience for content rendered on media players. The customization files are referenced by links distributed to the media players. Each customization file references a plurality of content objects that are stitched together to create the playback experience. A delivery network is used to distribute the customization files to the media players. Updates to the customization files can be done after distribution of their corresponding links. Usage information for the customization files are reported from the media players.",CHO PAUL;;NAZARIO EDGARDO;;LIMELIGHT NETWORKS INC,CHO PAUL;;NAZARIO EDGARDO,,https://lens.org/020-031-738-641-101,Patent Application,yes,39,2,2,2,0,H04L65/1089;;H04L65/1089,G06F15/16,709/218,0,0,,,,DISCONTINUED
7,US,B1,US 8266246 B1,000-293-183-183-526,2012-09-11,2012,US 201213413260 A,2012-03-06,US 201213413260 A,2012-03-06,Distributed playback session customization file management,"A method, device and/or system for syndicating customization files, which define playback experience for content rendered on media players. The customization files are referenced by links distributed to the media players. Each customization file references a plurality of content objects that are stitched together to create the playback experience. A delivery network is used to distribute the customization files to the media players. Updates to the customization files can be done after distribution of their corresponding links. Usage information for the customization files are reported from the media players.",CHO PAUL;;NAZARIO EDGARDO;;LIMELIGHT NETWORKS INC,CHO PAUL;;NAZARIO EDGARDO,LIMELIGHT NETWORKS INC (2012-03-05),https://lens.org/000-293-183-183-526,Granted Patent,yes,40,24,2,2,0,H04L65/1089;;H04L65/1089,G06F15/16,709/217;;709/218;;709/219;;709/230;;709/231;;709/232;;725/32;;725/33;;725/34;;725/35;;725/36,2,0,,,"IBM, ""IBM Digital Media Solutions for the media and entertainment industries"", Retrieved on May 3, 2012 from http://www-01.ibm.com/software/genservers/commerce/pdf/DMforEntertainment.pdf, 2003, p. 1-4.;;Grant Goodman, ""Syndication Strategies"", Retrieved on May 3, 2012 from http://support.brightcove.com/en/docs/syndication-strategies, 2009, p. 1-4.",ACTIVE
8,WO,A1,WO 2022/115936 A1,123-594-808-324-018,2022-06-09,2022,CA 2021000103 W,2021-12-04,US 202063121571 P,2020-12-04,TOY BUILDING BLOCKS,"A toy building block set comprises at least interchangeable pieces: a female coupling member which is either (or both) of a frame of hollowed cuboid-like box and/or a window of a hollowed cuboid-like box, and two or more male coupling members provided on mating plates (having male members on both sides) and on face plates (having male members on only one side).",CHO PAUL HYOUNG MOCK,CHO PAUL HYOUNG MOCK,,https://lens.org/123-594-808-324-018,Patent Application,yes,5,0,1,1,0,A63H33/102,A63H33/08,,0,0,,,,PENDING
9,US,B1,US 8099073 B1,172-674-258-524-29X,2012-01-17,2012,US 12411508 A,2008-05-20,US 12411508 A;;US 93947807 P,2007-05-22,Noise reduction in amplifier circuitry using single-sideband chopper stabilization,"A multi-path amplifier can include a high frequency path, a low frequency path, and a summing node to sum an output from the high frequency path with an output from the low frequency path. The low frequency path can include a flicker noise reduction mechanism including an image band rejection mechanism. The low frequency path can include an in-phase path and a quadrature path.",MULLER PAUL;;CHO THOMAS;;MARVELL INT LTD,MULLER PAUL;;CHO THOMAS,MARVELL SEMICONDUCTOR INC (2008-05-20);;MARVELL ASIA PTE LTD (2019-12-31);;MARVELL SWITZERLAND SARL (2008-05-20);;MARVELL INTERNATIONAL LTD (2008-09-04);;CAVIUM INTERNATIONAL (2019-12-31),https://lens.org/172-674-258-524-29X,Granted Patent,yes,14,17,1,1,0,H04B1/0483;;H04B1/0483;;H03F1/26;;H03F1/26;;H03F3/24;;H03F3/24;;H03F3/387;;H03F3/387;;H03F2200/336;;H03F2200/336;;H03F2200/429;;H03F2200/429,H04B1/10;;H03F1/02,455/296;;455/311;;455/341;;455/114.3;;330/9,7,6,131-050-123-112-99X;;008-098-424-262-59X;;053-037-712-397-301;;021-734-795-255-765;;134-420-977-786-95X;;059-903-867-838-016,10.1109/4.890300;;10.1109/isscc.2006.1696188;;10.1109/5.542410;;10.1109/jssc.1987.1052730;;10.1109/4.173096;;10.1109/jssc.2007.899080,"Bakker,T., et al. ""A CMOS Nested-Chopper Instrumentation Amplifier with 100-nV Offset"" IEEE Journal of solid-state circuits, vol. 35, No. 12, Dec. 2000 (7 pages).;;Burt, R., et al. ""A Micropower Chopper-Stabilized Operational Amplifier Using a SC Notch Filter With Synchronous Integration Inside the Continuous-Time Signal Path"" IEEE Journal of solid-state circuits, vol. 41, No. 12, Dec. 2006 (8 pages).;;Enz, C., et al. ""Circuit Techniques for Reducing the Effects of Op-Amp Imperfections: Autozeroing, Correlated Double Sampling, and Chopper Stabilization"" Proceedings of the IEEE, vol. 84, No. 11, Nov. 1996 (31 pages).;;Enz, C., et al., ""A CMOS Chopper Amplifier"" IEEE Journal of solid-state circuits, vol. SC-22, No. 3, Jun. 1987 (8 pages).;;Eschauzier, R., et al., ""A 100-MHz 100-dB Operational Amplifier with Multipath Nested Miller Compensation Structure"" IEEE Journal of solid-state circuits, vol. 27, No. 12, Dec. 1992 (9 pages).;;Ma, D., ""RF Receiver Systems and Circuits"" ECE1371 Term Paper (Printed from http://www.eecg.utoronto.ca/~kphang/ece1371/rfreceiver.pdf, on May 20, 2008) (14 pages).;;Witte, J., et al,. ""A CMOS Chopper Offset-Stabilized Opamp"" IEEE Journal of solid-state circuits, vol. 42, No. 7, Jul. 2007 (7 pages).",ACTIVE
10,US,A1,US 2012/0170685 A1,016-622-252-565-903,2012-07-05,2012,US 201213416877 A,2012-03-09,US 201213416877 A;;US 40457109 A;;US 98563604 A;;US 59831204 P,2004-08-02,Wireless Communication Using Beam Forming And Diversity,"A method and apparatus for wirelessly transmitting real-time data streams is described. To ensure continuous data flow, fast diversity and slow diversity can be used. Fast diversity chooses a receive antenna based on received signal parameters, such as signal strength, during the transmission header and prior to information transfer. Slow diversity stores received signal parameters from previous packets, associates the parameters with a selected antenna, and uses the parameter history to denote a “default” antenna. Additionally, receive and/or transmit beam forming can be used to maintain continuous communication between stations. Beam forming, which combines antenna signals to maximize performance, is possible when at least two transmit/receive signal processing chains are available.",CHO JAMES;;HUSTED PAUL J;;QUALCOMM ATHEROS INC,CHO JAMES;;HUSTED PAUL J,ATHEROS COMMUNICATIONS INC (2004-11-10);;QUALCOMM ATHEROS INC (2011-01-05);;QUALCOMM INCORPORATED (2012-10-22),https://lens.org/016-622-252-565-903,Patent Application,yes,2,1,11,11,0,H04B7/086;;H04B7/086;;H04B7/0617;;H04B7/0617;;H04B7/0814;;H04B7/0814;;H04W24/00;;H04W24/00,H04L27/06;;H04B1/02,375/316;;455/101,0,0,,,,INACTIVE
11,US,B2,US 8159967 B2,032-105-109-498-669,2012-04-17,2012,US 40457109 A,2009-03-16,US 40457109 A;;US 98563604 A;;US 59831204 P,2004-08-02,Wireless communication using beam forming and diversity,"A method and apparatus for wirelessly transmitting real-time data streams is described. To ensure continuous data flow, fast diversity and slow diversity can be used. Fast diversity chooses a receive antenna based on received signal parameters, such as signal strength, during the transmission header and prior to information transfer. Slow diversity stores received signal parameters from previous packets, associates the parameters with a selected antenna, and uses the parameter history to denote a “default” antenna. Additionally, receive and/or transmit beam forming can be used to maintain continuous communication between stations. Beam forming, which combines antenna signals to maximize performance, is possible when at least two transmit/receive signal processing chains are available.",CHO JAMES;;HUSTED PAUL J;;QUALCOMM ATHEROS INC,CHO JAMES;;HUSTED PAUL J,ATHEROS COMMUNICATIONS INC (2004-11-10);;QUALCOMM ATHEROS INC (2011-01-05);;QUALCOMM INCORPORATED (2012-10-22),https://lens.org/032-105-109-498-669,Granted Patent,yes,29,8,11,11,0,H04B7/086;;H04B7/086;;H04B7/0617;;H04B7/0617;;H04B7/0814;;H04B7/0814;;H04W24/00;;H04W24/00,H04J1/16;;H03C7/02;;H04J3/16,370/252;;370/465;;455/101,0,0,,,,ACTIVE
12,US,A1,US 2006/0034279 A1,115-228-833-929-959,2006-02-16,2006,US 98563604 A,2004-11-10,US 98563604 A;;US 59831204 P,2004-08-02,Wireless communication using beam forming and diversity,"A method and apparatus for wirelessly transmitting real-time data streams is described. To ensure continuous data flow, fast diversity and slow diversity can be used. Fast diversity chooses a receive antenna based on received signal parameters, such as signal strength, during the transmission header and prior to information transfer. Slow diversity stores received signal parameters from previous packets, associates the parameters with a selected antenna, and uses the parameter history to denote a “default” antenna. Additionally, receive and/or transmit beam forming can be used to maintain continuous communication between stations. Beam forming, which combines antenna signals to maximize performance, is possible when at least two transmit/receive signal processing chains are available.",CHO JAMES;;HUSTED PAUL J,CHO JAMES;;HUSTED PAUL J,ATHEROS COMMUNICATIONS INC (2004-11-10);;QUALCOMM ATHEROS INC (2011-01-05);;QUALCOMM INCORPORATED (2012-10-22),https://lens.org/115-228-833-929-959,Patent Application,yes,10,24,11,11,0,H04B7/086;;H04B7/086;;H04B7/0617;;H04B7/0617;;H04B7/0814;;H04B7/0814;;H04W24/00;;H04W24/00,H04L12/56,370/390;;455/101,0,0,,,,ACTIVE
13,TW,A,TW 200614713 A,108-060-080-085-092,2006-05-01,2006,TW 94126282 A,2005-08-02,US 59831204 P;;US 98563604 A,2004-08-02,Wireless communication using beam forming and diversity,"A method and apparatus for wirelessly transmitting real-time data streams is described. To ensure continuous data flow, fast diversity and slow diversity can be used. Fast diversity chooses a receive antenna based on received signal parameters, such as signal strength, during the transmission header and prior to information transfer. Slow diversity stores received signal parameters from previous packets, associates the parameters with a selected antenna, and uses the parameter history to denote a ""default"" antenna. Additionally, receive and/or transmit beam forming can be used to maintain continuous communication between stations. Beam forming, which combines antenna signals to maximize performance, is possible when at least two transmit/receive signal processing chains are available.",ATHEROS COMM INC,CHO JAMES;;HUSTED PAUL J,,https://lens.org/108-060-080-085-092,Patent of Addition,no,0,1,11,11,0,H04B7/086;;H04B7/086;;H04B7/0617;;H04B7/0617;;H04B7/0814;;H04B7/0814;;H04W24/00;;H04W24/00,,,0,0,,,,INACTIVE
14,AU,B1,AU 2011/201674 B1,124-116-416-947-486,2012-07-19,2012,AU 2011/201674 A,2011-04-14,AU 2011/201674 A,2011-04-14,Advanced embed code,"An embed code that can be copied from a first web site for placement in a second web site by users is disclosed- The embed code will render a content object from the second web site on a number of supported platforms. Autonomously, the embed code chooses from multiple playback options to choose one for the web browser rendering the embed code, for example, FlashTM HTML5, Silverlight,TM or a media player. Wherever the embed code is placed in a web site, a wide range of end user devices are supported without needing to reference other locations on the Internet, i.e., the embed code alone can automatically configure to play on that wide range of end user devices. The content object may be hosted or stored in various locations with the embed code accessing the proper version of the end user device.",LIMELIGHT NETWORKS INC,ROBERTS W JARED;;CHO PAUL,,https://lens.org/124-116-416-947-486,Granted Patent,no,1,0,3,3,0,G06F16/9577;;G06F16/9577,G06F3/048;;G06F15/16;;G06F17/30,,1,0,,,"Pile, A. 'Three New Features: Universal Player, Watch Later and Roku', [retrieved on 24 February 2012] Retrieved from Internet",INACTIVE
15,SG,A,SG 10201906394R A,168-642-966-217-601,2020-02-27,2020,SG 10201906394R A,2019-07-10,SG 10201805971S A,2018-07-11,GOLF CLUB AND METHOD OF MANUFACTURING SAME,,ATTOMETAL TECH PTE LTD,CHOONGNYUN PAUL KIM;;CHO GEUNSANG,,https://lens.org/168-642-966-217-601,Unknown,no,0,0,24,24,0,C22C33/0285;;C22C2200/02;;B33Y80/00;;C22C33/0292;;B33Y70/10;;B22F2998/10;;B22F2998/00;;B22F9/082;;B22F2999/00;;C23C4/08;;C23C4/06;;C23C4/134;;C23C4/129;;Y02P10/25;;C22C33/003;;C22C45/02;;C22C38/22;;C22C45/10;;C22C1/04;;B22F2998/00;;A63B53/047;;B05D7/14;;B05D2202/15;;B05D2202/25;;B05D2202/35;;B05D2202/40;;C22C45/10;;B33Y10/00;;B33Y70/00;;C23C4/067;;C23C4/129;;C23C4/134;;B22F3/10;;B22F9/082;;B22F2998/10;;B22F2999/00;;C22C1/04;;C22C33/0292;;C22C38/22;;C22C38/32;;C22C2200/02;;C22C33/0285,,,0,0,,,,PENDING
16,US,A1,US 2005/0089944 A1,105-521-002-763-943,2005-04-28,2005,US 69527303 A,2003-10-27,US 69527303 A,2003-10-27,High sensitivity amperometric biosensor with side-to-side hybrid configuration,An amperometric glucose biosensor comprises a sensing electrode and a reference electrode arranged in a side-by-side parallel configuration on an electrically insulating sheet. A passive cover electrode is placed over the side-by-side sensing electrode and reference electrode so that the active surface of the passive cover electrode opposes the active surfaces of the side-by-side electrodes. Physical contact between the passive covering electrode and the side-by-side electrodes is prevented by insulating spacers. The sensing electrode comprises a conductive graphite track coated with a formulation comprising a redox mediator and enzyme and the reference electrode is a parallel track comprising an Ag/AgCl formulation while the passive cover electrode comprising a conductive graphite track coated with a formulation comprising the same redox mediator as used in the sensing electrode but not including an enzyme. An opening either located in the middle or at one side of the passive cover electrode allows a liquid test sample to be introduced into the sensor. The biosensor of the present invention exhibits a sensitivity and response time equal to or surpassing that of the simple face-to-face configuration while can be efficiently manufactured and permit use with conventional electrical connectors.,BIOMEDIX INC,SHIEH PAUL;;CHO CHING-HSIN,BIOMEDIX INC (2003-10-08),https://lens.org/105-521-002-763-943,Patent Application,yes,0,24,1,1,0,C12Q1/006;;C12Q1/006,C12Q1/00;;C12Q1/54,435/14,0,0,,,,DISCONTINUED
17,US,A1,US 2012/0266060 A1,007-840-320-811-467,2012-10-18,2012,US 201113340369 A,2011-12-29,AU 2011/201674 A,2011-04-14,ADVANCED EMBED CODE,"An embed code that can be copied from a first web site for placement in a second web site by users is disclosed. The embed code will render a content object from the second web site on a number of supported platforms. Autonomously, the embed code chooses from multiple playback options to choose one for the web browser rendering the embed code, for example, Flash,™ HTML5, Silverlight,™ or a media player. Wherever the embed code is placed in a web site, a wide range of end user devices are supported without needing to reference other locations on the Internet, i.e., the embed code alone can automatically configure to play on that wide range of end user devices. The content object may be hosted or stored in various locations with the embed code accessing the proper version of the end user device.",ROBERTS W JARED;;CHO PAUL;;LIMELIGHT NETWORKS INC,ROBERTS W JARED;;CHO PAUL,LIMELIGHT NETWORKS INC (2011-12-07),https://lens.org/007-840-320-811-467,Patent Application,yes,3,30,3,3,0,G06F16/9577;;G06F16/9577,G06F17/00,715/234,4,0,,,"Mark R Robertson, How To Publish HTML5 video Tag With Fallback Mechanism, 6/15/2010, REELSEO, pages 1-5 http://web.archive.org/web/20101013082941/http://www.reelseo.com/html-5-tutorial-video-fallback/;;Michael, HTML5 Video with Flash Fallback / Flash Video with Mobile Fallback, 07/28/2010, Labs.byHook, pages 1-8 http://labs.byhook.com/2010/07/28/html5-video-with-flash-fallback-and-vice-versa/;;Fabio Sonnati, Flash to HTML5 Fallback, 01/12/2011, Flsah Video Technology and Optimizations, pages 1-4 http://sonnati.wordpress.com/2011/01/12/flash-to-htm5-fallback/;;John Dyer, Simple Cross-Browser HTML5 video with a single H.264 file and Fallback options, 06/06/2010, John Dyer's code Pages 1-5, http://johndyer.name/simple-cross-browser-html5-video-with-a-single-h-264-file-and-fallback-options/",ACTIVE
18,US,B2,US 7525926 B2,018-237-766-188-422,2009-04-28,2009,US 98563604 A,2004-11-10,US 98563604 A;;US 59831204 P,2004-08-02,Wireless communication using beam forming and diversity,"A method and apparatus for wirelessly transmitting real-time data streams is described. To ensure continuous data flow, fast diversity and slow diversity can be used. Fast diversity chooses a receive antenna based on received signal parameters, such as signal strength, during the transmission header and prior to information transfer. Slow diversity stores received signal parameters from previous packets, associates the parameters with a selected antenna, and uses the parameter history to denote a “default” antenna. Additionally, receive and/or transmit beam forming can be used to maintain continuous communication between stations. Beam forming, which combines antenna signals to maximize performance, is possible when at least two transmit/receive signal processing chains are available.",ATHEROS COMM INC,CHO JAMES;;HUSTED PAUL J,ATHEROS COMMUNICATIONS INC (2004-11-10);;QUALCOMM ATHEROS INC (2011-01-05);;QUALCOMM INCORPORATED (2012-10-22),https://lens.org/018-237-766-188-422,Granted Patent,yes,18,6,11,11,0,H04B7/086;;H04B7/086;;H04B7/0617;;H04B7/0617;;H04B7/0814;;H04B7/0814;;H04W24/00;;H04W24/00,G01R31/08;;H01Q3/00;;H04J3/16,370/252;;370/334;;370/465;;342/372,0,0,,,,ACTIVE
19,US,B2,US 8745484 B2,181-267-108-752-156,2014-06-03,2014,US 201113340369 A,2011-12-29,AU 2011/201674 A,2011-04-14,Advanced embed code,"An embed code that can be copied from a first web site for placement in a second web site by users is disclosed. The embed code will render a content object from the second web site on a number of supported platforms. Autonomously, the embed code chooses from multiple playback options to choose one for the web browser rendering the embed code, for example, Flash,™ HTML5, Silverlight,™ or a media player. Wherever the embed code is placed in a web site, a wide range of end user devices are supported without needing to reference other locations on the Internet, i.e., the embed code alone can automatically configure to play on that wide range of end user devices. The content object may be hosted or stored in various locations with the embed code accessing the proper version of the end user device.",ROBERTS W JARED;;CHO PAUL;;LIMELIGHT NETWORKS INC,ROBERTS W JARED;;CHO PAUL,LIMELIGHT NETWORKS INC (2011-12-07),https://lens.org/181-267-108-752-156,Granted Patent,yes,16,6,3,3,0,G06F16/9577;;G06F16/9577,G06F17/00,715/234;;715/238;;715/205,8,0,,,"Mark R Robertson, How to Publish HTML5 video Tag With Fallback Mechanism, Jun. 15, 2010, REELSEO, pp. 1-5 http://web.archive.org/web/20101013082941/http://www.reelseo.com/html-5-tutorial-video-fallback/.;;Michael, HTML5 Video with Flash Fallback / Flash Video with Mobile Fallback, Jul. 28, 2010, Labs.byHook, pp. 1-8 http://labs.byhook.com/2010/07/28/html5-video-with-flash-fallback-and-vice-versa/.;;Fabio Sonnati, Flash to HTML5 Fallback, Jan. 12, 2011, Flsah Video Technology and Optimizations, pp. 1-4 http://sonnati.wordpress.com/2011/01/12/flash-to-htm5-fallback/.;;John Dyer, Simple Cross-Browser HTML5 video with a single H.264 file and Fallback options, Jun. 6, 2010, John Dyer's code pp. 1-5, http://johndyer.name/simple-cross-browser-html5-video-with-a-single-h-264-file-and-fallback-options/.;;Pile, A., ""Three New Features: Universal Player, Watch Later and Roku,"" Staff Blog in Vimeo.com, retrieved on Feb. 24, 2012 from http://web.archive.org/web/20100821053657/http://vimeo.com/blog:334, Aug. 21, 2012, 20 pages.;;Yokto ,Video Encoding and Transcoding, 2010, 4 pages.;;VideoJs,HTML5 Video Player, 2011, 5 pages.;;International Preliminary Report on Patentability for PCT/US2011/039172 mailed on Dec. 4, 2013, 5 pages.",ACTIVE
20,US,B2,US 9054766 B2,185-232-586-697-02X,2015-06-09,2015,US 201213416877 A,2012-03-09,US 201213416877 A;;US 40457109 A;;US 98563604 A;;US 59831204 P,2004-08-02,Wireless communication using beam forming and diversity,"A method and apparatus for wirelessly transmitting real-time data streams is described. To ensure continuous data flow, fast diversity and slow diversity can be used. Fast diversity chooses a receive antenna based on received signal parameters, such as signal strength, during the transmission header and prior to information transfer. Slow diversity stores received signal parameters from previous packets, associates the parameters with a selected antenna, and uses the parameter history to denote a “default” antenna. Additionally, receive and/or transmit beam forming can be used to maintain continuous communication between stations. Beam forming, which combines antenna signals to maximize performance, is possible when at least two transmit/receive signal processing chains are available.",CHO JAMES;;HUSTED PAUL J;;QUALCOMM INC,CHO JAMES;;HUSTED PAUL J,ATHEROS COMMUNICATIONS INC (2004-11-10);;QUALCOMM ATHEROS INC (2011-01-05);;QUALCOMM INCORPORATED (2012-10-22),https://lens.org/185-232-586-697-02X,Granted Patent,yes,31,2,11,11,0,H04B7/086;;H04B7/086;;H04B7/0617;;H04B7/0617;;H04B7/0814;;H04B7/0814;;H04W24/00;;H04W24/00,H04B7/216;;H04B7/06;;H04B7/08;;H04B7/212;;H04W24/00,,1,0,,,"International Search Report and Written Opinion-PCT/US2005/027171, ISA/US, Jan. 31, 2006.",INACTIVE
21,US,A1,US 2009/0175383 A1,119-164-109-606-142,2009-07-09,2009,US 40457109 A,2009-03-16,US 40457109 A;;US 98563604 A;;US 59831204 P,2004-08-02,Wireless Communication Using Beam Forming And Diversity,"A method and apparatus for wirelessly transmitting real-time data streams is described. To ensure continuous data flow, fast diversity and slow diversity can be used. Fast diversity chooses a receive antenna based on received signal parameters, such as signal strength, during the transmission header and prior to information transfer. Slow diversity stores received signal parameters from previous packets, associates the parameters with a selected antenna, and uses the parameter history to denote a “default” antenna. Additionally, receive and/or transmit beam forming can be used to maintain continuous communication between stations. Beam forming, which combines antenna signals to maximize performance, is possible when at least two transmit/receive signal processing chains are available.",CHO JAMES;;HUSTED PAUL J,CHO JAMES;;HUSTED PAUL J,ATHEROS COMMUNICATIONS INC (2004-11-10);;QUALCOMM ATHEROS INC (2011-01-05);;QUALCOMM INCORPORATED (2012-10-22),https://lens.org/119-164-109-606-142,Patent Application,yes,28,14,11,11,0,H04B7/086;;H04B7/086;;H04B7/0617;;H04B7/0617;;H04B7/0814;;H04B7/0814;;H04W24/00;;H04W24/00,H04L27/00;;H04B7/00;;H04B7/02,375/316;;455/101;;455/277.2,0,0,,,,ACTIVE
22,TW,B,TW I382693 B,085-589-196-984-484,2013-01-11,2013,TW 94126282 A,2005-08-02,US 59831204 P;;US 98563604 A,2004-08-02,Wireless communication using beam forming and diversity,,QUALCOMM ATHEROS INC,JAMES CHO;;PAUL J HUSTED,,https://lens.org/085-589-196-984-484,Granted Patent,no,3,1,11,11,0,H04B7/086;;H04B7/086;;H04B7/0617;;H04B7/0617;;H04B7/0814;;H04B7/0814;;H04W24/00;;H04W24/00,,,0,0,,,,INACTIVE
23,IN,B,IN 159536 B,062-268-596-679-911,1987-05-23,1987,IN 345CA1983 A,1983-03-23,US 36471482 A,1982-04-02,IMPROVED PROCESS FOR MAKING A SINTERED HIGH STRENGTH POLYCRYSTALLINE ABRASIVE COMPACT,,GEN ELECTRIC,GIGL PAUL DONALD;;CHO HYUN SAM,,https://lens.org/062-268-596-679-911,Granted Patent,no,0,0,17,18,0,B01J3/062;;B01J2203/062;;B01J2203/0645;;B01J2203/0655;;B01J2203/066;;B01J2203/0685;;C04B35/5831,B01J3/06;;C04B35/583;;C04B35/52;;C04B35/5831;;C22C26/00;;C22C29/16,,0,0,,,,EXPIRED
24,EP,A1,EP 3813661 A1,095-158-201-966-183,2021-05-05,2021,EP 19825430 A,2019-06-27,US 201862691818 P;;CA 2019050887 W,2018-06-29,HUMAN POSE ANALYSIS SYSTEM AND METHOD,,WRNCH INC,CHO DONGWOOK;;ZHANG MAGGIE;;KRUSZEWSKI PAUL,"HINGE HEALTH, INC. (2023-02-08)",https://lens.org/095-158-201-966-183,Patent Application,yes,0,0,8,8,0,G06T7/11;;G06T7/73;;G06T2207/20081;;G06T2207/20084;;G06T2207/30196;;G06V40/10;;G06V10/454;;G06V10/82;;G06N3/084;;G06V10/764;;G06N3/045;;G06T7/73;;G06T7/11;;G06T2207/20081;;G06T2207/20084;;G06T2207/30196;;G06V40/10;;G06V10/454;;G06N3/045;;G06V10/764;;G06V10/82;;G06N3/084;;G06V40/103;;G06V40/171;;G06F18/214;;G06N3/045;;G06T7/11;;G06V10/764;;G06V10/82;;G06V10/454;;G06V40/10,A61B5/103;;G06N3/04;;G06T1/40;;G06T7/00;;G06V10/764,,0,0,,,,PENDING
25,WO,A1,WO 2020/000096 A1,135-603-232-792-683,2020-01-02,2020,CA 2019050887 W,2019-06-27,US 201862691818 P,2018-06-29,HUMAN POSE ANALYSIS SYSTEM AND METHOD,"System and method for extracting human pose information from an image, comprising a feature extractor connected to a database, a convolutional neural network (CNN) with a plurality of CNN layers. Said system/method further comprising at least one of the following modules: a 2D body skeleton detector for determining 2D body skeleton information from the human-related image features; a body silhouette detector for determining body silhouette information from the human-related image features; a hand silhouette detector for determining hand silhouette detector from the human-related image features; a hand skeleton detector for determining hand skeleton from the human-related image features; a 3D body skeleton detector for determining 3D body skeleton from the human-related image features; and a facial keypoints detector for determining facial keypoints from the human-related image features.",WRNCH INC,CHO DONGWOOK;;ZHANG MAGGIE;;KRUSZEWSKI PAUL,,https://lens.org/135-603-232-792-683,Patent Application,yes,3,12,8,8,0,G06T7/11;;G06T7/73;;G06T2207/20081;;G06T2207/20084;;G06T2207/30196;;G06V40/10;;G06V10/454;;G06V10/82;;G06N3/084;;G06V10/764;;G06N3/045;;G06T7/73;;G06T7/11;;G06T2207/20081;;G06T2207/20084;;G06T2207/30196;;G06V40/10;;G06V10/454;;G06N3/045;;G06V10/764;;G06V10/82;;G06N3/084;;G06V40/103;;G06V40/171;;G06F18/214;;G06N3/045;;G06T7/11;;G06V10/764;;G06V10/82;;G06V10/454;;G06V40/10,A61B5/103;;G06N3/04;;G06T1/40;;G06T7/00;;G06V10/764,,1,0,,,See also references of EP 3813661A4,PENDING
26,DE,D1,DE 3371483 D1,141-212-423-386-732,1987-06-19,1987,DE 3371483 T,1983-03-23,US 36471482 A,1982-04-02,IMPROVED SWEEP THROUGH PROCESS FOR MAKING POLYCRYSTALLINE COMPACTS,,GEN ELECTRIC,GIGL PAUL DONALD;;CHO HYUN SAM,,https://lens.org/141-212-423-386-732,Granted Patent,no,0,0,17,18,0,B01J3/062;;B01J2203/062;;B01J2203/0645;;B01J2203/0655;;B01J2203/066;;B01J2203/0685;;C04B35/5831,B01J3/06;;C04B35/52;;C04B35/583;;C04B35/5831;;C22C26/00;;C22C29/16,,0,0,,,,EXPIRED
27,US,A1,US 2009/0099604 A1,151-123-826-457-433,2009-04-16,2009,US 17207408 A,2008-07-11,FR 0705066 A,2007-07-12,Transverse Spinal Linking Device and System,"A transverse spinal linking device links at least one spinal osteosynthesis bar to a transverse bar. The device may include a first part that has a vertical axis and a first jaw, a second part that has a second jaw, and a clamping resource. The first part may include a sliding surface, which may be inclined in relation to the vertical axis, and which may mate with at least one sliding surface of the second part. The sliding surfaces may be configured so that the descent of the second part results in an approach of the jaws, with the clamping action of the clamping resource causing the fixing and/or the locking of the device on the osteosynthesis bar and the fixing and/or the locking of the transverse bar.",CHO PAUL;;HOFFMAN GREGORY;;CHATAIGNER HERVE,CHO PAUL;;HOFFMAN GREGORY;;CHATAIGNER HERVE,LDR MEDICAL (2008-10-01),https://lens.org/151-123-826-457-433,Patent Application,yes,5,52,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,606/250;;606/278;;606/277,0,0,,,,ACTIVE
28,WO,A1,WO 2021/145628 A1,183-624-317-749-098,2021-07-22,2021,KR 2021000353 W,2021-01-11,KR 20200006229 A;;KR 20210000549 A,2020-01-16,HEAT-RESISTANT COATING COMPOSITION,"A heat-resistant coating composition according to an aspect of the present invention comprises: an inorganic filler which comprises an amorphous phase and is Fe-based amorphous alloy powder having an average particle diameter of 0.5 to 15 ㎛; and a binder, wherein the thermal expansion coefficient of the inorganic filler is smaller than the thermal expansion coefficient of the binder.",KOLON INC,KIM CHOONGNYUN PAUL;;CHO GEUN SANG,,https://lens.org/183-624-317-749-098,Patent Application,yes,8,1,6,7,0,C09D7/61;;B22F7/04;;B22F1/10;;B22F1/08;;B22F1/05;;C09D127/12;;C09D5/38;;C08K3/08;;C09D127/18;;C08K2003/0856;;C09D7/69;;C09D7/61;;C09D7/68;;C09D5/18;;C09D123/283,C09D201/00;;B22F9/00;;C09D7/61,,1,0,,,See also references of EP 4092090A4,PENDING
29,JP,A,JP 2013118372 A,192-560-562-817-062,2013-06-13,2013,JP 2012255219 A,2012-11-21,US 201113309294 A,2011-12-01,TERNARY THERMOELECTRIC MATERIAL CONTAINING NANOPARTICLES AND METHOD FOR MANUFACTURING THE SAME,"PROBLEM TO BE SOLVED: To provide a ternary main group semiconductor material having improved properties, and a method for manufacturing the same.SOLUTION: This invention includes a thermoelectric material that comprises a ternary matrix material and nanoparticle inclusions. Examples of the nanoparticles include particles of materials having the formulas MO and/or M, where M represents a group 2 or 12 element in a 2+ oxidation state. The matrix material is a ternary main group or chalcogenide semiconductor material, preferably includes elements Bi, Se and Te, preferably has the formula BixSeyTez, where x represents from 1 to 3, y represents from 0 to 3.2, z represents from 0 to 3.3, and x, y and z represent the molar ratio based on the total moles of Bi, Se and Te, and more preferably has the formula (BiSe)Te.",TOYOTA ENG & MFG NORTH AMERICA,MICHAEL PAUL LAW;;CHO LI KIM,,https://lens.org/192-560-562-817-062,Patent Application,no,5,2,4,4,0,C01B19/007;;C01P2002/72;;C01P2006/40;;C04B35/547;;C04B35/645;;C04B2235/3284;;C04B2235/3298;;C04B2235/449;;B82Y30/00;;H10N10/852;;H10N10/17;;C01B19/007;;C04B2235/3284;;C04B35/547;;C01P2002/72;;C04B2235/449;;C04B2235/3298;;C04B35/645;;C01P2006/40;;B82Y30/00;;H10N10/17;;H10N10/852,H01L35/16;;H01L35/34,,0,0,,,,ACTIVE
30,EP,B1,EP 0094147 B1,004-972-335-461-493,1987-05-13,1987,EP 83301631 A,1983-03-23,US 36471482 A,1982-04-02,IMPROVED SWEEP THROUGH PROCESS FOR MAKING POLYCRYSTALLINE COMPACTS,,GENERAL ELECTRIC COMPANY,"GIGL, PAUL DONALD;;CHO, HYUN SAM",,https://lens.org/004-972-335-461-493,Granted Patent,yes,0,0,17,18,0,B01J3/062;;B01J2203/062;;B01J2203/0645;;B01J2203/0655;;B01J2203/066;;B01J2203/0685;;C04B35/5831,B01J3/06;;C04B35/52;;C04B35/583;;C04B35/5831;;C22C26/00;;C22C29/16,,0,0,,,,EXPIRED
31,JP,A,JP 2013118371 A,155-059-378-375-611,2013-06-13,2013,JP 2012255200 A,2012-11-21,US 201113309321 A,2011-12-01,BINARY THERMOELECTRIC MATERIAL CONTAINING NANOPARTICLES AND METHOD FOR MANUFACTURING THE SAME,"PROBLEM TO BE SOLVED: To provide a thermoelectric composite material having improved properties and a method for manufacturing the thermoelectric composite material, in a thermoelectric material comprising a binary main group matrix material and nanoparticles and/or nano-inclusions.SOLUTION: A thermoelectric composition contains a binary main group semiconductor material BiTe, and metal oxide nanoparticles represented by the formula MO, where M represents at least one element selected from the group consisting of the group 2 elements and the group 12 elements. The nanoparticles are dispersed in a matrix of the binary main group semiconductor material.",TOYOTA ENG & MFG NORTH AMERICA,MICHAEL PAUL LAW;;CHO LI KIM,,https://lens.org/155-059-378-375-611,Patent Application,no,22,1,6,6,0,B82Y30/00;;C04B35/547;;C04B2235/3284;;C04B2235/441;;C04B2235/444;;C04B2235/449;;C04B2235/80;;H10N10/852;;B82Y30/00;;C04B2235/3284;;C04B2235/441;;C04B2235/449;;C04B35/547;;C04B2235/444;;C04B2235/80;;H10N10/852,H01L35/16;;H01L35/34,,0,0,,,,INACTIVE
32,CN,A,CN 113661309 A,009-743-858-558-131,2021-11-16,2021,CN 202080029383 A,2020-04-16,DE 102019205551 A;;EP 2020060657 W,2019-04-17,"METHOD FOR DETERMINING THE OXYGEN LOAD OF A CATALYTIC CONVERTER OF AN INTERNAL COMBUSTION ENGINE, AND EXHAUST SYSTEM OF AN INTERNAL COMBUSTION ENGINE","The present invention relates to a method for determining the oxygen load of a catalytic converter (100), preferably a three-way catalytic converter, arranged in an exhaust system (10) of an internal combustion engine, to a catalytic converter (100) and to an internal combustion engine. An exhaust gas sensor (110) is arranged downstream of the catalytic converter (100). The method according to the invention comprises: producing at least one signal by means of the exhaust gas sensor (110), which at least one signal indicates the concentration of nitrogen oxide and/or ammonia in the exhaust gas; and determining the oxygen load of the catalytic converter (100) at least partially on the basis of the at least one signal of the exhaust gas sensor (110). In this way, the oxygen load of a catalytic converter (100), preferably a three-way catalytic converter, can be determined in a simple manner by means of an exhaust gas sensor (110) arranged downstream of the catalytic converter (100).",VITESCO TECH GMBH,RODATZ PAUL;;HAFT GERHARD;;CHO HIROSHI,,https://lens.org/009-743-858-558-131,Patent Application,no,5,0,6,6,0,F01N2900/1624;;F01N2560/026;;F01N3/00;;F01N13/009;;F01N2550/02;;F01N2570/16;;Y02T10/12;;F01N11/007;;F02D41/0295;;F02D2200/0814;;F01N2570/16;;F01N9/007;;F01N2900/1624;;F01N2900/0416;;F01N2560/025,F01N3/00;;F01N13/00,,0,0,,,,PENDING
33,EP,A1,EP 4092090 A1,098-286-385-291-680,2022-11-23,2022,EP 21740767 A,2021-01-11,KR 20200006229 A;;KR 20210000549 A;;KR 2021000353 W,2020-01-16,HEAT-RESISTANT COATING COMPOSITION,"A heat-resistant coating composition according to an aspect of the present invention comprises: an inorganic filler which comprises an amorphous phase and is Fe-based amorphous alloy powder having an average particle diameter of 0.5 to 15  µ m; and a binder, wherein the thermal expansion coefficient of the inorganic filler is smaller than the thermal expansion coefficient of the binder.",KOLON INC,KIM CHOONGNYUN PAUL;;CHO GEUN SANG,,https://lens.org/098-286-385-291-680,Patent Application,yes,0,0,6,7,0,C09D7/61;;B22F7/04;;B22F1/10;;B22F1/08;;B22F1/05;;C09D127/12;;C09D5/38;;C08K3/08;;C09D127/18;;C08K2003/0856;;C09D7/69;;C09D7/61;;C09D7/68;;C09D5/18;;C09D123/283,C09D201/00;;B22F9/00;;C09D7/61,,0,0,,,,PENDING
34,CA,A,CA 1206340 A,003-230-184-037-177,1986-06-24,1986,CA 427056 A,1983-04-29,CA 427056 A,1983-04-29,SWEEP THROUGH PROCESS FOR MAKING POLYCRYSTALLINE COMPACTS,"IMPROVED SWEEP THROUGH PROOESS FOR MARING POLYCCRYSTALLINE CCMPACTS The high pressure/high temperature catalyst sweep through process for making diamond and cubic boron nitride compacts has been improved by adding an intermediate metal or metal alloy. The added metal (whether alone or contained in an alloy) has a melting point below that of the catalyst (e.g. cobalt), is miscible with the catalyst, and preferably sweeps through the mass of abrasive crystals first. This modification has reduced flaw formation in such compacts.",GEN ELECTRIC,GIGL PAUL D;;CHO HYUN S,,https://lens.org/003-230-184-037-177,Granted Patent,no,0,0,1,1,0,,C22C26/00;;C22C29/16,57-15,0,0,,,,EXPIRED
35,US,A,US 4518659 A,050-488-477-518-452,1985-05-21,1985,US 53622183 A,1983-09-23,US 53622183 A;;US 36471482 A,1982-04-02,Sweep through process for making polycrystalline compacts,"The high pressure/high temperature catalyst sweep through process for making diamond and cubic boron nitride compacts has been improved by adding an intermediate metal or metal alloy. The added metal (whether alone or contained in an alloy) has a melting point below that of the catalyst (e.g. cobalt), is miscible with the catalyst, and preferably sweeps through the mass of abrasive crystals first. This modification has reduced flaw formation in such compacts.",GEN ELECTRIC,GIGL PAUL D;;CHO HYUN S,DIAMOND INNOVATIONS INC (2003-12-31);;GE SUPERABRASIVES INC (2003-12-31);;GENERAL ELECTRIC COMPANY A NY CORP (1983-09-23),https://lens.org/050-488-477-518-452,Granted Patent,yes,21,97,1,18,0,B01J3/062;;B01J3/062;;B01J2203/062;;B01J2203/062;;B01J2203/0645;;B01J2203/0645;;B01J2203/0655;;B01J2203/0655;;B01J2203/066;;B01J2203/066;;B01J2203/0685;;B01J2203/0685;;C04B35/5831;;C04B35/5831,B01J3/06;;C04B35/5831,428/539.5;;75/231;;75/243;;75/244;;51/307;;51/309;;X156DIG 68;;423/290;;423/446;;419/2;;419/11;;419/13;;419/26;;419/47,0,0,,,,EXPIRED
36,EP,A4,EP 4092090 A4,047-994-686-628-037,2024-02-14,2024,EP 21740767 A,2021-01-11,KR 20200006229 A;;KR 20210000549 A;;KR 2021000353 W,2020-01-16,HEAT-RESISTANT COATING COMPOSITION,,KOLON INC,KIM CHOONGNYUN PAUL;;CHO GEUN SANG,,https://lens.org/047-994-686-628-037,Search Report,no,3,0,6,7,0,C09D7/61;;B22F7/04;;B22F1/10;;B22F1/08;;B22F1/05;;C09D127/12;;C09D5/38;;C08K3/08;;C09D127/18;;C08K2003/0856;;C09D7/69;;C09D7/61;;C09D7/68;;C09D5/18;;C09D123/283,C09D201/00;;B22F1/05;;B22F1/08;;B22F1/10;;B22F7/04;;B22F9/00;;C08K3/08;;C09D5/38;;C09D7/61;;C09D127/12;;C09D127/18,,2,1,089-775-543-707-102,10.1016/s0032-5910(03)00048-2,"RENLIANG XU ET AL: ""Comparison of sizing small particles using different technologies"", POWDER TECHNOLOGY, ELSEVIER, BASEL (CH), vol. 132, no. 2-3, 24 June 2003 (2003-06-24), pages 145 - 153, XP002711749, ISSN: 0032-5910, DOI: 10.1016/S0032-5910(03)00048-2;;See also references of WO 2021145628A1",PENDING
37,EP,A2,EP 0094147 A2,067-876-820-913-997,1983-11-16,1983,EP 83301631 A,1983-03-23,US 36471482 A,1982-04-02,Improved sweep through process for making polycrystalline compacts.,"The conventional high pressure/high temperature catalyst sweep through process for making diamond and cubic boron nitride compacts is modified by adding an intermediate metal or metal alloy, which has a melting point below that of the catalyst (e.g. cobalt), is miscible with the catalyst, and preferably sweeps through the mass of abrasive crystals first, whereby there is reduced flaw formation in such compacts.",GEN ELECTRIC,GIGL PAUL DONALD;;CHO HYUN SAM,,https://lens.org/067-876-820-913-997,Patent Application,yes,0,6,17,18,0,B01J3/062;;B01J2203/062;;B01J2203/0645;;B01J2203/0655;;B01J2203/066;;B01J2203/0685;;C04B35/5831,B01J3/06;;C04B35/52;;C04B35/583;;C04B35/5831;;C22C26/00;;C22C29/16,,0,0,,,,EXPIRED
38,US,A1,US 2023/0394075 A1,175-992-719-485-012,2023-12-07,2023,US 202217831651 A,2022-06-03,US 202217831651 A,2022-06-03,METHODS AND ARRANGEMENTS FOR SIMILARITY SEARCH BASED ON MULTI-LABEL TEXT CLASSIFICATION,"Logic may provide a hierarchical label structure for a document with a predicted set of hierarchical labels. Logic may provide a historical label performance database comprising performance data associated with each assignee in a complete set of assignees for each label in a complete set of the hierarchical labels. Logic may generate a first vector for the hierarchical label structure for the document. Logic may generate a second vector for the assignees in an identified set of assignees, comprising each hierarchical label in the predicted set of hierarchical labels for the document, the identified set comprising one or more of the assignees in the complete set of assignees. Logic may perform a similarity search to identify a predicted assignee from the identified set of assignees and logic may predict a selected assignee of the identified set of assignees to associate with the document via the similarity search.",CAPITAL ONE SERVICES LLC,NGUYEN BRIAN;;CHO PAUL;;ANKUR ANKUR,CAPITAL ONE SERVICES LLC (2022-05-25),https://lens.org/175-992-719-485-012,Patent Application,yes,3,0,1,1,0,G06Q10/06316;;G06Q30/01;;H04M3/51;;G06F16/353;;G06F16/335;;G06F16/3347;;G06F16/35,G06F16/35;;G06F16/33,,0,0,,,,PENDING
39,CN,A,CN 101686843 A,171-293-010-925-545,2010-03-31,2010,CN 200880023812 A,2008-07-11,IB 2008001815 W;;FR 0705066 A,2007-07-12,Transverse spinal linking device and system,"A transverse spinal linking device (1 ) links at least one spinal osteosynthesis bar (2) to a transverse bar (3). The device (1 ) may include a first part (11 ) that has a vertical axis and a first jaw (111 ), a second part (12) that has a second jaw (121 ), and a clamping resource (13). The first part (11 ) may include a sliding surface (114), which may be inclined in relation to the vertical axis, and which may mate with at least one sliding surface (124) of the second part (12). The sliding surfaces (114, 124) may be configured so that the descent of the second part (12) results in an approach of the jaws (121, 111 ), with the clamping action of the clamping resource (13) causing the fixing and/or the locking of the device (1 ) on the osteosynthesis bar (2) and the fixing and/or the locking of the transverse bar (3).",LDR MEDICAL,PAUL CHO;;GREGORY HOFFMAN;;HERVE CHATAIGNER,,https://lens.org/171-293-010-925-545,Patent Application,no,0,3,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,,0,0,,,,INACTIVE
40,EP,A4,EP 3813661 A4,020-777-654-145-718,2022-04-06,2022,EP 19825430 A,2019-06-27,US 201862691818 P;;CA 2019050887 W,2018-06-29,HUMAN POSE ANALYSIS SYSTEM AND METHOD,,WRNCH INC,CHO DONGWOOK;;ZHANG MAGGIE;;KRUSZEWSKI PAUL,"HINGE HEALTH, INC. (2023-02-08)",https://lens.org/020-777-654-145-718,Search Report,no,0,0,8,8,0,G06T7/11;;G06T7/73;;G06T2207/20081;;G06T2207/20084;;G06T2207/30196;;G06V40/10;;G06V10/454;;G06V10/82;;G06N3/084;;G06V10/764;;G06N3/045;;G06T7/73;;G06T7/11;;G06T2207/20081;;G06T2207/20084;;G06T2207/30196;;G06V40/10;;G06V10/454;;G06N3/045;;G06V10/764;;G06V10/82;;G06N3/084;;G06V40/103;;G06V40/171;;G06F18/214;;G06N3/045;;G06T7/11;;G06V10/764;;G06V10/82;;G06V10/454;;G06V40/10,A61B5/103;;G06N3/04;;G06T1/40;;G06T7/00;;G06V10/44;;G06V10/764;;G06V10/82;;G06V40/10,,6,5,141-945-396-975-82X;;125-186-398-431-960;;017-370-209-588-569;;007-056-162-652-560;;167-784-275-511-008,10.1109/cvprw.2014.78;;29990235;;10.1109/tpami.2017.2781233;;10.1145/2964284.2964322;;10.1109/cvpr.2014.214;;10.1109/cvpr.2016.511,"LI SIJIN ET AL: ""Heterogeneous Multi-task Learning for Human Pose Estimation with Deep Convolutional Neural Network"", 2014 IEEE CONFERENCE ON COMPUTER VISION AND PATTERN RECOGNITION WORKSHOPS, IEEE, 23 June 2014 (2014-06-23), pages 488 - 495, XP032649680, DOI: 10.1109/CVPRW.2014.78;;RAJEEV RANJAN ET AL: ""HyperFace: A Deep Multi-Task Learning Framework for Face Detection, Landmark Localization, Pose Estimation, and Gender Recognition"", 11 May 2016 (2016-05-11), XP055552344, Retrieved from the Internet <URL:https://arxiv.org/pdf/1603.01249v2> [retrieved on 20190206], DOI: 10.1109/TPAMI.2017.2781233;;WANG KEZE KEZEWANG@GMAIL COM ET AL: ""Human Pose Estimation from Depth Images via Inference Embedded Multi-task Learning"", PROCEEDINGS OF THE 2017 ACM ON CONFERENCE ON INFORMATION AND KNOWLEDGE MANAGEMENT , CIKM '17, ACM PRESS, NEW YORK, NEW YORK, USA, 1 October 2016 (2016-10-01), pages 1227 - 1236, XP058629670, ISBN: 978-1-4503-4918-5, DOI: 10.1145/2964284.2964322;;TOSHEV ALEXANDER ET AL: ""DeepPose: Human Pose Estimation via Deep Neural Networks"", 2014 IEEE CONFERENCE ON COMPUTER VISION AND PATTERN RECOGNITION, IEEE, 23 June 2014 (2014-06-23), pages 1653 - 1660, XP032649134, DOI: 10.1109/CVPR.2014.214;;WEI SHIH-EN ET AL: ""Convolutional Pose Machines"", 2016 IEEE CONFERENCE ON COMPUTER VISION AND PATTERN RECOGNITION (CVPR), IEEE, 27 June 2016 (2016-06-27), pages 4724 - 4732, XP033021664, DOI: 10.1109/CVPR.2016.511;;See also references of WO 2020000096A1",PENDING
41,US,A1,US 2010/0250385 A1,060-047-474-740-495,2010-09-30,2010,US 41521109 A,2009-03-31,US 41521109 A,2009-03-31,METHOD AND SYSTEM FOR A COMBINATION VOUCHER,"A voucher system for redeeming vouchers via a network. The voucher has an associated voucher code that permits access to one or more first items and/or one or more second items. A redemption module accepts a voucher code such that a user, upon validation of the voucher code, selects one or more of the first items and/or selects one or more of the second items. Upon redeeming the voucher, the user receives the selected first items at a designated user account and receives the selected second items at a designated user account.",LEMPEL ERIC;;CHO JENNIFER;;PURDY PAUL,LEMPEL ERIC;;CHO JENNIFER;;PURDY PAUL,SONY INTERACTIVE ENTERTAINMENT AMERICA LLC (2009-03-30),https://lens.org/060-047-474-740-495,Patent Application,yes,42,20,2,2,0,G06F2221/2109;;G06F2221/2117;;G06F2221/2137;;G06Q30/02;;G06Q30/0601;;G06Q30/02;;G06F2221/2137;;G06F2221/2117;;G06F2221/2109;;G06Q30/0601,G06F21/00;;G06Q30/00,705/26;;726/3;;705/1.1,0,0,,,,DISCONTINUED
42,WO,A1,WO 2010/114579 A1,172-091-563-331-959,2010-10-07,2010,US 2009/0061149 W,2009-10-19,US 41521109 A,2009-03-31,METHOD AND SYSTEM FOR A COMBINATION VOUCHER,"A voucher system for redeeming vouchers via a network. The voucher has an associated voucher code that permits access to one or more first items and/or one or more second items. A redemption module accepts a voucher code such that a user, upon validation of the voucher code, selects one or more of the first items and/or selects one or more of the second items. Upon redeeming the voucher, the user receives the selected first items at a designated user account and receives the selected second items at a designated user account.",SONY COMP ENTERTAINMENT US;;LEMPEL ERIC;;CHO JENNIFER;;PURDY PAUL,LEMPEL ERIC;;CHO JENNIFER;;PURDY PAUL,,https://lens.org/172-091-563-331-959,Patent Application,yes,2,4,2,2,0,G06F2221/2109;;G06F2221/2117;;G06F2221/2137;;G06Q30/02;;G06Q30/0601;;G06Q30/02;;G06F2221/2137;;G06F2221/2117;;G06F2221/2109;;G06Q30/0601,G06Q30/00,,0,0,,,,PENDING
43,EP,A3,EP 0094147 A3,057-636-537-899-899,1983-12-28,1983,EP 83301631 A,1983-03-23,US 36471482 A,1982-04-02,IMPROVED SWEEP THROUGH PROCESS FOR MAKING POLYCRYSTALLINE COMPACTS,"The conventional high pressure/high temperature catalyst sweep through process for making diamond and cubic boron nitride compacts is modified by adding an intermediate metal or metal alloy, which has a melting point below that of the catalyst (e.g. cobalt), is miscible with the catalyst, and preferably sweeps through the mass of abrasive crystals first, whereby there is reduced flaw formation in such compacts.",GENERAL ELECTRIC COMPANY,"GIGL, PAUL DONALD;;CHO, HYUN SAM",,https://lens.org/057-636-537-899-899,Search Report,yes,6,0,17,18,0,B01J3/062;;B01J2203/062;;B01J2203/0645;;B01J2203/0655;;B01J2203/066;;B01J2203/0685;;C04B35/5831,B01J3/06;;C04B35/52;;C04B35/583;;C04B35/5831;;C22C26/00;;C22C29/16,,0,0,,,,EXPIRED
44,FR,A1,FR 2918555 A1,163-369-991-469-943,2009-01-16,2009,FR 0705066 A,2007-07-12,FR 0705066 A,2007-07-12,DISPOSITIF ET SYSTEME DE LIAISON RACHIDIENNE TRANSVERSE,"La présente invention concerne un dispositif (1) de liaison rachidienne transverse, solidarisant au moins une barre (2) d'ostéosynthèse rachidienne avec une barre (3) transversale et comportant une première pièce (11), comportant un axe vertical et une première mâchoire (111), une seconde pièce (12) comportant une seconde mâchoire (121) et des moyens (13) de serrage, la première pièce (11) comportant au moins une surface (114) de glissement, inclinée par rapport à l'axe vertical et coopérant avec au moins une surface (124) de glissement de la seconde pièce (12) pour que la descente de la seconde pièce (12) résulte en un rapprochement des mâchoires (121, 111), le serrage des moyens (13) de serrage provoquant alors la fixation et/ou le blocage du dispositif (1) sur la barre (2) d'ostéosynthèse et la fixation et/ou le blocage de la barre (3) transversale.",LDR MEDICAL SOC PAR ACTIONS SI,CHO PAUL;;HOFFMAN GREGORY;;CHATAIGNIER HERVE,,https://lens.org/163-369-991-469-943,Patent Application,no,7,0,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,,0,0,,,,INACTIVE
45,CN,B,CN 101686843 B,184-357-724-580-886,2012-08-08,2012,CN 200880023812 A,2008-07-11,IB 2008001815 W;;FR 0705066 A,2007-07-12,Transverse spinal linking device and system,"A transverse spinal linking device (1 ) links at least one spinal osteosynthesis bar (2) to a transverse bar (3). The device (1 ) may include a first part (11 ) that has a vertical axis and a first jaw (111 ), a second part (12) that has a second jaw (121 ), and a clamping resource (13). The first part (11 ) may include a sliding surface (114), which may be inclined in relation to the vertical axis, and which may mate with at least one sliding surface (124) of the second part (12). The sliding surfaces (114, 124) may be configured so that the descent of the second part (12) results in an approach of the jaws (121, 111 ), with the clamping action of the clamping resource (13) causing the fixing and/or the locking of the device (1 ) on the osteosynthesis bar (2) and the fixing and/or the locking of the transverse bar (3).",LDR MEDICAL,PAUL CHO;;GREGORY HOFFMAN;;HERVE CHATAIGNER,,https://lens.org/184-357-724-580-886,Granted Patent,no,0,0,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,,0,0,,,,INACTIVE
46,US,B2,US 8262700 B2,030-864-962-893-038,2012-09-11,2012,US 17207408 A,2008-07-11,FR 0705066 A,2007-07-12,Transverse spinal linking device and system,"A transverse spinal linking device links at least one spinal osteosynthesis bar to a transverse bar. The device may include a first part that has a vertical axis and a first jaw, a second part that has a second jaw, and a clamping resource. The first part may include a sliding surface, which may be inclined in relation to the vertical axis, and which may mate with at least one sliding surface of the second part. The sliding surfaces may be configured so that the descent of the second part results in an approach of the jaws, with the clamping action of the clamping resource causing the fixing and/or the locking of the device on the osteosynthesis bar and the fixing and/or the locking of the transverse bar.",CHO PAUL;;HOFFMAN GREGORY;;CHATAIGNER HERVE;;LDR MEDICAL,CHO PAUL;;HOFFMAN GREGORY;;CHATAIGNER HERVE,LDR MEDICAL (2008-10-01),https://lens.org/030-864-962-893-038,Granted Patent,yes,27,49,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,606/250;;606/277;;606/278,31,0,,,"U.S. Appl. No. 10/492,753, filed Aug. 9, 2004, Progressive approach osteosynthesis device and preassembly method.;;U.S. Appl. No. 10/498,234, filed Dec. 7, 2004, Implant for Osseous Anchoring with Polyaxial Head.;;U.S. Appl. No. 10/570,080, filed Jun. 9, 2006, Osseous anchoring implant with a polyaxial head and method for installing the implant.;;U.S. Appl. No. 10/575,065, filed Apr. 7, 2006, Device and method for sectioning a vertebral lamina.;;U.S. Appl. No. 11/051,710, filed Feb. 4, 2005, Intervertebral Disc Prosthesis.;;U.S. Appl. No. 11/362,253, filed Feb. 24, 2006, Intervertebral Disc Prosthesis and Instrumentation for Insertion of the Prosthesis Between the Vertebrae.;;U.S. Appl. No. 11/378,165, filed Mar. 17, 2006, Transforanimal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage.;;U.S. Appl. No. 11/676,237, filed Feb. 16, 2007, Intervertebral disc prosthesis insertion assemblies.;;U.S. Appl. No. 11/767,386, filed Jun. 22, 2007, Intersomatic cage with unified grafts.;;U.S. Appl. No. 11/874,144, filed Oct. 17, 2007, Modular intervertebral prosthesis.;;U.S. Appl. No. 11/958,285, filed Dec. 17, 2007, Vertebral Support Device.;;U.S. Appl. No. 12/025,677, filed Feb. 4, 2008, Intervertebral disc prosthesis, surgical methods, and fitting tools.;;U.S. Appl. No. 12/134,884, filed Jun. 6, 2008, Intersomatic cage, intervertebral prosthesis, anchoring device and implantation instruments.;;U.S. Appl. No. 12/172,074, filed Jul. 11, 2008, Transverse spinal linking device and system.;;U.S. Appl. No. 12/279,664, filed Apr. 22, 2009, Transforaminal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage.;;U.S. Appl. No. 12/360,050, filed Jan. 26, 2009, Intervertebral Disc Prosthesis.;;U.S. Appl. No. 12/409,327, filed Mar. 23, 2009, Spinal Osteosynthesis Device and Preparation Method.;;U.S. Appl. No. 12/424,364, filed Apr. 15, 2009, Intervertebral Disk Prosthesis.;;U.S. Appl. No. 12/435,955, filed May 5, 2009, Instrumentation and Methods for Inserting an Intervertebral Disc Prosthesis.;;U.S. Appl. No. 12/527,373, filed Aug. 14, 2009, Intervertebral disc prosthesis insertion assemblies.;;U.S. Appl. No. 12/562,704, filed Sep. 18, 2009, Implant for Osseous Anchoring with Polyaxial Head.;;U.S. Appl. No. 12/955,898, filed Nov. 29, 2010, Intervertebral Disc Prosthesis.;;U.S. Appl. No. 13/158,761, filed Jun. 13, 2011, Instruments and Methods for Removing Fixation Devices from Intervertebral Implants.;;U.S. Appl. No. 13/215,123, filed Aug. 22, 2011, Intervertebral Disc Prosthesis.;;U.S. Appl. No. 13/369,650, filed Feb. 9, 2012, Interspinous Implant and Implantation Instrument.;;U.S. Appl. No. 13/438,352, filed Apr. 3, 2012, Vertebral Cage Device With Modular Fixation.;;U.S. Appl. No. 13/454,927, filed Apr. 24, 2012, Plate for osteosynthesis device and method of preassembling such device.;;World Intellectual Property Organization; International Preliminary Report on Patentability for PCT Pub'n No. WO2009007838; Aug. 14.;;World Intellectual Property Organization; International Search Report for PCT Pub'n No. WO2009007838; Feb. 13.;;World Intellectual Property Organization; Written Opinon of the International Searching Authority for PCT Pub'n No. WO2009007838; Feb. 13.;;European Patent Office; Prosecution History for EP App'n. No. 20080826187; Jul. 11, 2008; EPO; Munich, Germany; all pages.",ACTIVE
47,CA,A1,CA 3105272 A1,067-356-833-877-762,2020-01-02,2020,CA 3105272 A,2019-06-27,US 201862691818 P;;CA 2019050887 W,2018-06-29,HUMAN POSE ANALYSIS SYSTEM AND METHOD,"System and method for extracting human pose information from an image, comprising a feature extractor connected to a database, a convolutional neural network (CNN) with a plurality of CNN layers. Said system/method further comprising at least one of the following modules: a 2D body skeleton detector for determining 2D body skeleton information from the human-related image features; a body silhouette detector for determining body silhouette information from the human-related image features; a hand silhouette detector for determining hand silhouette detector from the human-related image features; a hand skeleton detector for determining hand skeleton from the human-related image features; a 3D body skeleton detector for determining 3D body skeleton from the human-related image features; and a facial keypoints detector for determining facial keypoints from the human-related image features.",WRNCH INC,CHO DONGWOOK;;KRUSZEWSKI PAUL;;ZHANG MAGGIE,,https://lens.org/067-356-833-877-762,Patent Application,no,0,0,8,8,0,G06T7/11;;G06T7/73;;G06T2207/20081;;G06T2207/20084;;G06T2207/30196;;G06V40/10;;G06V10/454;;G06V10/82;;G06N3/084;;G06V10/764;;G06N3/045;;G06T7/73;;G06T7/11;;G06T2207/20081;;G06T2207/20084;;G06T2207/30196;;G06V40/10;;G06V10/454;;G06N3/045;;G06V10/764;;G06V10/82;;G06N3/084;;G06V40/103;;G06V40/171;;G06F18/214;;G06N3/045;;G06T7/11;;G06V10/764;;G06V10/82;;G06V10/454;;G06V40/10,A61B5/103;;G06N3/04;;G06T1/40;;G06T7/00;;G06V10/764,,0,0,,,,PENDING
48,EP,A1,EP 3815755 A1,090-926-695-587-34X,2021-05-05,2021,EP 19835019 A,2019-07-11,SG 10201805971S A;;KR 2019008573 W,2018-07-11,GOLF CLUB AND MANUFACTURING METHOD THEREOF,"Disclosed is a golf club and a method of manufacturing the same, whereby an Fe-based amorphous alloy layer is coated on a surface of a base part of a clubface provided on a side of a clubhead to maintain an amorphous structure after coating, thus ensuring that a repulsive force, durability, surface hardness, and the like of the clubface are improved. The golf club includes: a clubhead; and a shaft connected to the clubhead, wherein the clubhead includes a clubface provided on a side thereof, and the clubface includes: a base part; and a coating layer provided on a surface of the base part and including an Fe-based amorphous alloy.",KOLON INC;;ATTOMETAL TECH PTE LTD,KIM CHOONGNYUN PAUL;;CHO GEUN SANG,,https://lens.org/090-926-695-587-34X,Patent Application,yes,0,0,24,24,0,C22C33/0285;;C22C2200/02;;B33Y80/00;;C22C33/0292;;B33Y70/10;;B22F2998/10;;B22F2998/00;;B22F9/082;;B22F2999/00;;C23C4/08;;C23C4/06;;C23C4/134;;C23C4/129;;Y02P10/25;;C22C33/003;;C22C45/02;;C22C38/22;;C22C45/10;;C22C1/04;;B22F2998/00;;A63B53/047;;B05D7/14;;B05D2202/15;;B05D2202/25;;B05D2202/35;;B05D2202/40;;C22C45/10;;B33Y10/00;;B33Y70/00;;C23C4/067;;C23C4/129;;C23C4/134;;B22F3/10;;B22F9/082;;B22F2998/10;;B22F2999/00;;C22C1/04;;C22C33/0292;;C22C38/22;;C22C38/32;;C22C2200/02;;C22C33/0285,A63B53/04;;C22C38/22;;C22C38/32,,0,0,,,,PENDING
49,US,A1,US 2023/0043932 A1,123-534-302-795-715,2023-02-09,2023,US 202117758714 A,2021-01-11,KR 20200006229 A;;KR 20210000549 A;;KR 2021000353 W,2020-01-16,HEAT-RESISTANT COATING COMPOSITION,"According to an aspect of the present disclosure, a heat-resistant coating composition includes: an inorganic filler which is iron (Fe)-based amorphous alloy powder having an amorphous phase and an average particle diameter of 0.5 μm to 15 μm; and a binder, where the coefficient of thermal expansion of the inorganic filler is lower than the coefficient of thermal expansion of the binder.",KOLON INC,KIM CHOONGNYUN PAUL;;CHO GEUN SANG,KOLON INDUSTRIES INC (2022-03-10),https://lens.org/123-534-302-795-715,Patent Application,yes,0,1,6,7,0,C09D7/61;;B22F7/04;;B22F1/10;;B22F1/08;;B22F1/05;;C09D127/12;;C09D5/38;;C08K3/08;;C09D127/18;;C08K2003/0856;;C09D7/69;;C09D7/61;;C09D7/68;;C09D5/18;;C09D123/283,C09D5/18;;C09D7/40;;C09D7/61;;C09D123/28,,0,0,,,,PENDING
50,US,A1,US 2021/0264144 A1,019-779-723-851-91X,2021-08-26,2021,US 201917256307 A,2019-06-27,US 201917256307 A;;US 201862691818 P;;CA 2019050887 W,2018-06-29,HUMAN POSE ANALYSIS SYSTEM AND METHOD,"System and method for extracting human pose information from an image, comprising a feature extractor connected to a database, a convolutional neural network (CNN) with a plurality of CNN layers. Said system/method further comprising at least one of the following modules: a 2D body skeleton detector for determining 2D body skeleton information from the human-related image features; a body silhouette detector for determining body silhouette information from the human-related image features; a hand silhouette detector for determining hand silhouette detector from the human-related image features; a hand skeleton detector for determining hand skeleton from the human-related image features; a 3D body skeleton detector for determining 3D body skeleton from the human-related image features; and a facial keypoints detector for determining facial keypoints from the human-related image features.",WRNCH INC,CHO DONGWOOK;;ZHANG MAGGIE;;KRUSZEWSKI PAUL,WRNCH INC (2020-12-22);;HINGE HEALTH INC (2021-09-15),https://lens.org/019-779-723-851-91X,Patent Application,yes,6,6,8,8,0,G06T7/11;;G06T7/73;;G06T2207/20081;;G06T2207/20084;;G06T2207/30196;;G06V40/10;;G06V10/454;;G06V10/82;;G06N3/084;;G06V10/764;;G06N3/045;;G06T7/73;;G06T7/11;;G06T2207/20081;;G06T2207/20084;;G06T2207/30196;;G06V40/10;;G06V10/454;;G06N3/045;;G06V10/764;;G06V10/82;;G06N3/084;;G06V40/103;;G06V40/171;;G06F18/214;;G06N3/045;;G06T7/11;;G06V10/764;;G06V10/82;;G06V10/454;;G06V40/10,G06N3/04;;G06V10/764,,1,1,020-505-230-186-621,10.1109/lsp.2016.2603342,"Zhang et al., ""Joint Face Detection and Alignment Using Multitask Cascaded Convolutional Networks,"" October 26, 2016, IEEE Signal Processing Letters, Vol. 23, pp. 1499-1503.",PENDING
51,KR,A,KR 20210028185 A,069-053-384-923-835,2021-03-11,2021,KR 20217000622 A,2019-06-27,US 201862691818 P;;CA 2019050887 W,2018-06-29,사람 자세 분석 시스템 및 방법,"데이터베이스에 연결되는 특징 추출기, 복수의 컨볼루션 신경망(CNN) 계층을 갖는 CNN를 포함하는, 영상으로부터 사람 자세 정보를 추출하기 위한 시스템 및 방법이 제공된다. 상기 시스템/방법은 상기 사람 관련 영상 특징으로부터 2D 신체 골격 정보를 결정하기 위한 2D 신체 골격 검출기; 상기 사람 관련 영상 특징으로부터 신체 윤곽 정보를 결정하기 위한 신체 윤곽 검출기; 상기 사람 관련 영상 특징으로부터 손 윤곽 검출기를 결정하기 위한 손 윤곽 검출기; 상기 사람 관련 영상 특징으로부터 손 골격을 결정하기 위한 손 골격 검출기; 상기 사람 관련 영상 특징으로부터 3D 신체 골격을 결정하기 위한 3D 신체 골격 검출기; 및 상기 사람 관련 영상 특징으로부터 안면 특징점을 결정하기 위한 안면 특징점 검출기 중 적어도 하나를 더 포함한다.",WRNCH INC,CHO DONGWOOK;;ZHANG MAGGIE;;KRUSZEWSKI PAUL,,https://lens.org/069-053-384-923-835,Patent Application,no,0,0,8,8,0,G06T7/11;;G06T7/73;;G06T2207/20081;;G06T2207/20084;;G06T2207/30196;;G06V40/10;;G06V10/454;;G06V10/82;;G06N3/084;;G06V10/764;;G06N3/045;;G06T7/73;;G06T7/11;;G06T2207/20081;;G06T2207/20084;;G06T2207/30196;;G06V40/10;;G06V10/454;;G06N3/045;;G06V10/764;;G06V10/82;;G06N3/084;;G06V40/103;;G06V40/171;;G06F18/214;;G06N3/045;;G06T7/11;;G06V10/764;;G06V10/82;;G06V10/454;;G06V40/10,A61B5/11;;G06N3/04;;G06N3/08;;G06T7/73;;G06V10/764,,0,0,,,,PENDING
52,KR,A,KR 20210092679 A,187-200-728-463-269,2021-07-26,2021,KR 20210000549 A,2021-01-04,KR 20200006229 A,2020-01-16,Heat resistant coating composition,"A heat-resistant coating composition according to an aspect of the present invention includes: an inorganic filler which is iron (Fe)-based amorphous alloy powder comprising an amorphous phase and having an average particle diameter of 0.5 to 15 μm; and a binder, wherein a coefficient of thermal expansion of the inorganic filler is smaller than the coefficient of thermal expansion of the binder.",KOLON INC,KIM CHOONGNYUN PAUL;;CHO GEUN SANG,,https://lens.org/187-200-728-463-269,Patent Application,no,2,0,1,7,0,C09D201/00;;C09D7/61;;B22F9/002,C09D201/00;;B22F9/00;;C09D7/61,,0,0,,,,PENDING
53,WO,A8,WO 2009/007838 A8,064-306-126-359-267,2010-02-18,2010,IB 2008001815 W,2008-07-11,FR 0705066 A,2007-07-12,TRANSVERSE SPINAL LINKING DEVICE AND SYSTEM,"A transverse spinal linking device (1) links at least one spinal osteosynthesis bar (2) to a transverse bar (3). The device (1) includes a first part (11) that has a vertical axis and a first jaw (111), a second part (12) that has a second jaw (121), and a clamping means (13). The first part (11) includes a sliding surface (114), which is inclined in relation to the vertical axis, and which mates with at least one sliding surface (124) of the second part (12). The sliding surfaces (114, 124) are configured so that the descent of the second part (12) results in an approach of the jaws (121, 111), with the clamping action of the clamping resource (13) causing the fixing and/or the locking of the device (1) on the osteosynthesis bar (2) and the fixing and/or the locking of the transverse bar (3).",LDR MEDICAL;;CHO PAUL;;HOFFMAN GREGORY;;CHATAIGNER HERVE,CHO PAUL;;HOFFMAN GREGORY;;CHATAIGNER HERVE,,https://lens.org/064-306-126-359-267,Amended Application,yes,0,0,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,,0,0,,,,PENDING
54,FR,B1,FR 2918555 B1,093-228-848-074-221,2010-04-02,2010,FR 0705066 A,2007-07-12,FR 0705066 A,2007-07-12,DISPOSITIF ET SYSTEME DE LIAISON RACHIDIENNE TRANSVERSE,,LDR MEDICAL,CHO PAUL;;HOFFMAN GREGORY;;CHATAIGNIER HERVE,,https://lens.org/093-228-848-074-221,Granted Patent,no,0,0,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,,0,0,,,,INACTIVE
55,ZA,B,ZA 831881 B,052-695-037-890-562,1984-06-27,1984,ZA 831881 A,1983-03-17,US 36471482 A,1982-04-02,SWEEP THROUGH PROCESS FOR MAKING POLYCRYSTALLINE COMPACTS,,GEN ELECTRIC,GIGL PAUL DONALD;;HYUN SAM CHO,,https://lens.org/052-695-037-890-562,Granted Patent,no,0,0,17,18,0,B01J3/062;;B01J2203/062;;B01J2203/0645;;B01J2203/0655;;B01J2203/066;;B01J2203/0685;;C04B35/5831,B01J3/06;;C04B35/52;;C04B35/5831;;C22C26/00;;C04B35/583;;C22C29/16,,0,0,,,,EXPIRED
56,JP,A,JP 2018093220 A,140-636-337-857-131,2018-06-14,2018,JP 2018030431 A,2018-02-23,US 201113309321 A,2011-12-01,BINARY THERMOELECTRIC MATERIAL CONTAINING NANOPARTICLES AND METHOD FOR MANUFACTURING THE SAME,"PROBLEM TO BE SOLVED: To provide thermoelectric composite material having improved properties.SOLUTION: A thermoelectric composition contains binary main group semiconductor material, and metal oxide nanoparticles represented by the formula MO, where M represents at least one element selected from a group consisting of group 2 elements and group 12 elements. The nanoparticles are dispersed in a matrix of the binary main group semiconductor material.SELECTED DRAWING: None",TOYOTA ENG & MFG NORTH AMERICA,MICHAEL PAUL LAW;;CHO LI KIM,,https://lens.org/140-636-337-857-131,Patent Application,no,8,0,6,6,0,B82Y30/00;;C04B35/547;;C04B2235/3284;;C04B2235/441;;C04B2235/444;;C04B2235/449;;C04B2235/80;;H10N10/852;;B82Y30/00;;C04B2235/3284;;C04B2235/441;;C04B2235/449;;C04B35/547;;C04B2235/444;;C04B2235/80;;H10N10/852,H01L35/16;;C01B19/04;;H01L35/22;;H01L35/34,,0,0,,,,ACTIVE
57,WO,A1,WO 2020/013633 A1,019-909-310-784-272,2020-01-16,2020,KR 2019008573 W,2019-07-11,SG 10201805971S A,2018-07-11,GOLF CLUB AND MANUFACTURING METHOD THEREOF,"A golf club capable of maintaining an amorphous structure after a coating by means of coating iron-based amorphous alloy powder on a surface of a base substrate of a club face formed on one surface of a club head, so as to enhance repulsion, durability, surface hardness, etc. of the club face, and a manufacturing method thereof are provided. The golf club comprises the club head and a shaft coupled to the club head, wherein the club head comprises the club face formed on the one surface thereof, and the club face comprises: the base substrate; and a coating layer comprising the iron-based amorphous alloy provided on the surface of the base substrate.",ATTOMETAL TECH PTE LED;;KOLON INC,KIM CHOONG NYUN PAUL;;CHO GEUN SANG,,https://lens.org/019-909-310-784-272,Patent Application,yes,6,1,24,24,0,C22C33/0285;;C22C2200/02;;B33Y80/00;;C22C33/0292;;B33Y70/10;;B22F2998/10;;B22F2998/00;;B22F9/082;;B22F2999/00;;C23C4/08;;C23C4/06;;C23C4/134;;C23C4/129;;Y02P10/25;;C22C33/003;;C22C45/02;;C22C38/22;;C22C45/10;;C22C1/04;;B22F2998/00;;A63B53/047;;B05D7/14;;B05D2202/15;;B05D2202/25;;B05D2202/35;;B05D2202/40;;C22C45/10;;B33Y10/00;;B33Y70/00;;C23C4/067;;C23C4/129;;C23C4/134;;B22F3/10;;B22F9/082;;B22F2998/10;;B22F2999/00;;C22C1/04;;C22C33/0292;;C22C38/22;;C22C38/32;;C22C2200/02;;C22C33/0285,A63B53/04;;C22C38/22;;C22C38/32,,1,0,,,See also references of EP 3815755A4,PENDING
58,CN,A,CN 101479397 A,054-823-557-854-035,2009-07-08,2009,CN 200780024499 A,2007-06-29,US 2007/0072513 W;;US 81740306 P,2006-06-30,"High strength, heat treatable al-zn-mg aluminum alloy","A high strength aluminum alloy is suitable for ultra thick gauge wrought product. The alloy can have 6 to 8 wt % zinc, 1 to 2 wt % magnesium, and dispersoid forming elements such as Zr, Mn, Cr, Ti, and /or Sc with the balance made of aluminum and incidental elements and/or impurities. The alloy is suitable for many uses, including in moulds for injection-molded plastics.",ALCAN ROLLED PRODUCTS RAVENSWOOD LLC,ALEX CHO;;PAUL SMITH KENNETH;;VIC DANGERFIELD,,https://lens.org/054-823-557-854-035,Patent Application,no,0,10,18,18,0,C22C21/08;;C22C21/10;;C22C21/10;;C22C21/06;;C22F1/053;;C22F1/047;;C22C21/10;;C22C21/08,C22C21/10,,0,0,,,,ACTIVE
59,EP,A2,EP 2182868 A2,115-899-727-792-300,2010-05-12,2010,EP 08826187 A,2008-07-11,IB 2008001815 W;;FR 0705066 A,2007-07-12,TRANSVERSE SPINAL LINKING DEVICE AND SPINAL STABILIZATION SYSTEM,,LDR MEDICAL,CHO PAUL HENRY;;HOFFMAN GREGORY;;CHATATGNER HERVE,,https://lens.org/115-899-727-792-300,Patent Application,yes,0,0,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,,1,0,,,See references of WO 2009007838A2,ACTIVE
60,EP,B1,EP 2049696 B1,035-154-925-529-013,2016-03-02,2016,EP 07799189 A,2007-06-29,US 2007/0072513 W;;US 81740306 P,2006-06-30,"HIGH STRENGTH, HEAT TREATABLE AL-ZN-MG ALUMINUM ALLOY",,CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SMITH KENNETH PAUL;;DANGERFIELD VIC,"CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC (2012-01-04)",https://lens.org/035-154-925-529-013,Granted Patent,yes,16,2,18,18,0,C22C21/08;;C22C21/10;;C22C21/10;;C22C21/06;;C22F1/053;;C22F1/047;;C22C21/10;;C22C21/08,C22C21/10;;C22F1/053,,1,0,,,"HUFNAGEL W: ""Key to Aluminium Alloys, 4th Edition"" ALUMINIUM-SCHLUESSEL = KEY TO ALUMINIUM ALLOYS, 1991, pages 195-205, XP002194851",ACTIVE
61,CN,B,CN 101479397 B,074-616-729-469-912,2013-03-13,2013,CN 200780024499 A,2007-06-29,US 2007/0072513 W;;US 81740306 P,2006-06-30,"High strength, heat treatable al-zn-mg aluminum alloy",,CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;DANGERFIELD VIC;;SMITH KENNETH PAUL,,https://lens.org/074-616-729-469-912,Granted Patent,no,0,1,18,18,0,C22C21/08;;C22C21/10;;C22C21/10;;C22C21/06;;C22F1/053;;C22F1/047;;C22C21/10;;C22C21/08,C22F1/053;;C22C21/10,,0,0,,,,ACTIVE
62,WO,A1,WO 2023/085692 A1,129-240-926-872-170,2023-05-19,2023,KR 2022017133 W,2022-11-03,KR 20210154507 A,2021-11-11,CARTRIDGE AND AEROSOL GENERATING DEVICE INCLUDING THE SAME,A cartridge for an aerosol generating device includes a mouthpiece through which an aerosol formed by heating an aerosol-forming substrate is discharged and an information storage element formed at an end portion of a side where the cartridge couples to a device and configured to store unique information of the cartridge. Different pieces of the unique information of the cartridge may be stored according to a physical structure of the information storage element which forms a specific pattern.,KT & G CORP,LEE WONKYEONG;;SUNWOO PAUL JOON;;CHO BYUNGSUNG,,https://lens.org/129-240-926-872-170,Patent Application,yes,5,0,4,4,0,A24F40/10;;A24F40/53;;A24F40/42;;A24F40/42;;A24F40/485;;A24F40/60;;A24F40/10;;A24F40/46;;A24F40/44,A24F40/42;;A24F40/10;;A24F40/44;;A24F40/46;;A24F40/485;;A24F40/60,,0,0,,,,PENDING
63,WO,A1,WO 1996/007714 A1,006-164-066-723-754,1996-03-14,1996,US 9510364 W,1995-08-15,US 30390894 A,1994-09-09,GASOLINE UPGRADING PROCESS,"Low sulfur gasoline of relatively high octane number is produced from a cracked, sulfur-containing olefinic naphthas by hydrodesulfurization followed by treatment over an acidic catalyst comprising an intermediate pore size zeolite such as zeolite ZSM-5 in combination with molybdenum. The use of the molybdenum in combination with the zeolite has been found to give improved catalytic activity coupled with lower coking, longer catalyst life and other advantages.",MOBIL OIL CORP,DURAND PAUL PIERCE;;TIMKEN HYE KYUNG CHO,,https://lens.org/006-164-066-723-754,Patent Application,yes,4,4,18,18,0,C10G35/095;;C10G69/08;;C10G67/00;;C10G69/08;;C10G35/095,B01J29/48;;B01J29/40;;C10G35/095;;C10G69/08,,1,0,,,See also references of EP 0781315A4,PATENTED
64,KR,A,KR 20100031699 A,054-724-309-352-999,2010-03-24,2010,KR 20097027319 A,2008-07-11,FR 0705066 A;;IB 2008001815 W,2007-07-12,TRANSVERSE SPINAL LINKING DEVICE AND SYSTEM,"A transverse spinal linking device (1) links at least one spinal osteosynthesis bar (2) to a transverse bar (3). The device (1) may include a first part (11) that has a vertical axis and a first jaw (111), a second part (12) that has a second jaw (121), and a clamping resource (13). The first part (11) may include a sliding surface (114), which may be inclined in relation to the vertical axis, and which may mate with at least one sliding surface (124) of the second part (12). The sliding surfaces (114, 124) may be configured so that the descent of the second part (12) results in an approach of the jaws (121, 111), with the clamping action of the clamping resource (13) causing the fixing and/or the locking of the device (1) on the osteosynthesis bar (2) and the fixing and/or the locking of the transverse bar (3).",LDR MEDICAL,CHO PAUL HENRY;;HOFFMAN GREGORY;;CHATATGNER HERVE,,https://lens.org/054-724-309-352-999,Patent Application,no,0,0,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/82,,0,0,,,,INACTIVE
65,FI,A0,FI 970973 A0,042-817-261-771-023,1997-03-07,1997,FI 970973 A,1997-03-07,US 30390894 A;;US 9510364 W,1994-09-09,Bensiinin laatua parantava menetelmä,,MOBIL OIL CORP,DURAND PAUL PIERCE;;TIMKEN HYE KYUNG-CHO,,https://lens.org/042-817-261-771-023,Patent Application,no,0,0,18,18,0,C10G35/095;;C10G69/08;;C10G67/00;;C10G69/08;;C10G35/095,B01J29/48;;B01J29/40;;C10G35/095;;C10G69/08,,0,0,,,,DISCONTINUED
66,CN,A,CN 112739429 A,049-258-758-982-789,2021-04-30,2021,CN 201980045994 A,2019-07-11,SG 10201805971S A;;KR 2019008573 W,2018-07-11,GOLF CLUB AND MANUFACTURING METHOD THEREOF,"A golf club capable of maintaining an amorphous structure after a coating by means of coating iron-based amorphous alloy powder on a surface of a base substrate of a club face formed on one surface of a club head, so as to enhance repulsion, durability, surface hardness, etc. of the club face, and a manufacturing method thereof are provided. The golf club comprises the club head and a shaft coupled to the club head, wherein the club head comprises the club face formed on the one surface thereof, and the club face comprises: the base substrate; and a coating layer comprising the iron-based amorphous alloy provided on the surface of the base substrate.",ATTOMETAL TECH PTE LED;;KOLON INC,KIM CHOONG-NYUN PAUL;;CHO GEUN-SANG,,https://lens.org/049-258-758-982-789,Patent Application,no,6,0,24,24,0,C22C33/0285;;C22C2200/02;;B33Y80/00;;C22C33/0292;;B33Y70/10;;B22F2998/10;;B22F2998/00;;B22F9/082;;B22F2999/00;;C23C4/08;;C23C4/06;;C23C4/134;;C23C4/129;;Y02P10/25;;C22C33/003;;C22C45/02;;C22C38/22;;C22C45/10;;C22C1/04;;B22F2998/00;;A63B53/047;;B05D7/14;;B05D2202/15;;B05D2202/25;;B05D2202/35;;B05D2202/40;;C22C45/10;;B33Y10/00;;B33Y70/00;;C23C4/067;;C23C4/129;;C23C4/134;;B22F3/10;;B22F9/082;;B22F2998/10;;B22F2999/00;;C22C1/04;;C22C33/0292;;C22C38/22;;C22C38/32;;C22C2200/02;;C22C33/0285,A63B53/04;;A63B102/32;;C22C38/22;;C22C38/32,,0,0,,,,ACTIVE
67,CA,A1,CA 2657331 A1,080-296-693-259-944,2008-01-10,2008,CA 2657331 A,2007-06-29,US 81740306 P;;US 2007/0072513 W,2006-06-30,"A HIGH STRENGTH, HEAT TREATABLE ALUMINUM ALLOY","A high strength aluminum alloy. is suitable for ultra thick gauge wrought product. The alloy can have 6 to 8 wt % zinc, 1 to 1.9 wt % magnesium, wher ein Mg is present in an amount from (0.2 2m,- 0.3) wt. % to (0.2 Zm + 0.3) w t. %, and dispersoid forming elements such as Zr, Mn, Cr, Ti, and /or Sc wit h the balance made of aluminum and incidental elements and/or impurities. Th e alloy is suitable for many uses, including in moulds for injection-molded plastics.",ALCAN ROLLED PRODUCTS RAVENSWOOD LLC,SMITH KENNETH PAUL;;CHO ALEX;;DANGERFIELD VIC,,https://lens.org/080-296-693-259-944,Patent Application,no,0,0,18,18,0,C22C21/08;;C22C21/10;;C22C21/10;;C22C21/06;;C22F1/053;;C22F1/047;;C22C21/10;;C22C21/08,C22C1/10;;C22F1/053,,0,0,,,,ACTIVE
68,KR,A,KR 20200006945 A,154-091-513-306-955,2020-01-21,2020,KR 20190083779 A,2019-07-11,SG 10201805971S A,2018-07-11,Golf club and method for preparing the same,"Provided are a golf club and a manufacturing method thereof, wherein the golf club, by coating an iron-based amorphous alloy powder on the surface of a base surface of a club face formed on one surface of a club head, can improve repulsive force, durability, and surface hardness of the club face since it is possible to maintain an amorphous structure even after coating. The golf club is the golf club comprising a shaft connected to the club head, wherein the club head comprises the club face formed on one surface and the club face comprises a base substrate and a coating layer comprising an iron-based amorphous alloy provided on the surface of the base substrate.",ATTOMETAL TECH PTE LTD;;KOLON INC,KIM CHOONG NYUN PAUL;;CHO GEUN SANG,,https://lens.org/154-091-513-306-955,Patent Application,no,8,0,24,24,0,C22C33/0285;;C22C2200/02;;B33Y80/00;;C22C33/0292;;B33Y70/10;;B22F2998/10;;B22F2998/00;;B22F9/082;;B22F2999/00;;C23C4/08;;C23C4/06;;C23C4/134;;C23C4/129;;Y02P10/25;;C22C33/003;;C22C45/02;;C22C38/22;;C22C45/10;;C22C1/04;;B22F2998/00;;A63B53/047;;B05D7/14;;B05D2202/15;;B05D2202/25;;B05D2202/35;;B05D2202/40;;C22C45/10;;B33Y10/00;;B33Y70/00;;C23C4/067;;C23C4/129;;C23C4/134;;B22F3/10;;B22F9/082;;B22F2998/10;;B22F2999/00;;C22C1/04;;C22C33/0292;;C22C38/22;;C22C38/32;;C22C2200/02;;C22C33/0285,A63B53/04;;C22C45/02;;C23C4/06;;C23C4/18,,0,0,,,,ACTIVE
69,CN,A,CN 108513059 A,089-792-996-635-775,2018-09-07,2018,CN 201810155270 A,2018-02-23,KR 20170024824 A,2017-02-24,Image processing method and apparatus thereof and automatic drive vehicle,An image processing method and an apparatus thereof and an automatic drive vehicle are provided. The image processing method includes recognizing a target object in a first frame of an input image; adjusting an exposure of a second frame of the input image based on a brightness of the target object; and generating a synthesized image by synthesizing the first frame and the second frame.,SAMSUNG ELECTRONICS CO LTD,SEOYOUNGWAN;;PAUL BAROM JEON;;BAEK HWAN CHO,,https://lens.org/089-792-996-635-775,Patent Application,no,9,13,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,H04N5/232;;G01C21/16;;G01C21/26;;G01C21/34;;G01S19/47;;G06V10/141;;G06V10/25;;H04N5/235,,0,0,,,,ACTIVE
70,CA,C,CA 2689655 C,143-805-201-462-337,2014-06-10,2014,CA 2689655 A,2008-07-11,FR 0705066 A;;IB 2008001815 W,2007-07-12,TRANSVERSE SPINAL LINKING DEVICE AND SYSTEM,"A transverse spinal linking device (1 ) links at least one spinal osteosynthesis bar (2) to a transverse bar (3). The device (1 ) includes a first part (11 ) that has a vertical axis and a first jaw (111 ), a second part (12) that has a second jaw (121 ), and a clamping means (13). The first part (11 ) includes a sliding surface (114), which is inclined in relation to the vertical axis, and which mates with at least one sliding surface (124) of the second part (12). The sliding surfaces (114, 124) are configured so that the descent of the second part (12) results in an approach of the jaws (121, 111 ), with the clamping action of the clamping resource (13) causing the fixing and/or the locking of the device (1 ) on the osteosynthesis bar (2) and the fixing and/or the locking of the transverse bar (3).",LDR MEDICAL,CHO PAUL HENRY;;HOFFMAN GREGORY;;CHATATGNER HERVE,,https://lens.org/143-805-201-462-337,Granted Patent,no,0,0,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,,0,0,,,,INACTIVE
71,WO,A1,WO 2023/149885 A1,176-761-120-114-416,2023-08-10,2023,US 2022/0015078 W,2022-02-03,US 2022/0015078 W,2022-02-03,URETEROSCOPE DEVICES AND SYSTEMS HAVING A FIBER TIP POSITION SENSOR,"A ureteroscope system including a handpiece, a catheter, one or more sensors, and a processor is described. The handpiece includes a working channel port and a working channel in fluid communication with the working channel port. The catheter is secured to the handpiece and includes a distal end defining a working channel opening in fluid communication with the working channel. The one or more sensors are positioned and configured to detect a position of at least a portion of a laser fiber. The processor is configured to determine if an emitting end of the laser fiber configured to emit laser light is outside the working channel and spaced at least a predetermined distance from the distal end of the catheter.",BARD INC C R,CHO YOUNG;;HESS PAUL ROBERT;;O’BRIEN KILLIAN,,https://lens.org/176-761-120-114-416,Patent Application,yes,5,0,1,1,0,A61B2017/00066;;A61B2018/00982;;A61B2018/00517;;A61B18/26;;A61B18/24;;A61B2018/00898;;A61B2018/00196,A61B18/26;;A61B18/24,,0,0,,,,PENDING
72,BR,A2,BR PI0813561 A2,000-091-505-886-545,2015-06-16,2015,BR PI0813561 A,2008-07-11,FR 0705066 A;;IB 2008001815 W,2007-07-12,Dispositivo e sistema de ligação espinhal transversal,,LDR MEDICAL,CHO PAUL HENRY;;HOFFMAN GREGORY;;CHATAIGNER HERVÉ,,https://lens.org/000-091-505-886-545,Patent Application,no,0,0,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,,0,0,,,,DISCONTINUED
73,CN,A,CN 114981374 A,130-367-865-269-151,2022-08-30,2022,CN 202180009362 A,2021-01-11,KR 20200006229 A;;KR 20210000549 A;;KR 2021000353 W,2020-01-16,HEAT RESISTANT COATING COMPOSITION,"The heat-resistant coating composition according to one embodiment of the present invention comprises: an inorganic filler which contains an amorphous phase and is an iron (Fe)-based amorphous alloy powder having an average particle diameter of 0.5 [mu] m to 15 [mu] m; and a binder, in which the coefficient of thermal expansion of the inorganic filler is less than the coefficient of thermal expansion of the binder.",KOLON INC,KIM CHUNG-NYUN PAUL;;CHO GEUN-SANG,,https://lens.org/130-367-865-269-151,Patent Application,no,6,0,6,7,0,C09D7/61;;B22F7/04;;B22F1/10;;B22F1/08;;B22F1/05;;C09D127/12;;C09D5/38;;C08K3/08;;C09D127/18;;C08K2003/0856;;C09D7/69;;C09D7/61;;C09D7/68;;C09D5/18;;C09D123/283,C09D201/00;;B22F9/00;;C09D7/61,,0,0,,,,ACTIVE
74,FI,A,FI 970973 A,179-465-528-412-188,1997-05-06,1997,FI 970973 A,1997-03-07,US 30390894 A;;US 9510364 W,1994-09-09,Bensiinin laatua parantava menetelmä,,MOBIL OIL CORP,DURAND PAUL PIERCE;;TIMKEN HYE KYUNG-CHO,,https://lens.org/179-465-528-412-188,Patent Application,no,0,0,18,18,0,C10G35/095;;C10G69/08;;C10G67/00;;C10G69/08;;C10G35/095,B01J29/48;;B01J29/40;;C10G35/095;;C10G69/08,,0,0,,,,DISCONTINUED
75,EP,A4,EP 0781315 A4,050-607-756-167-404,1998-05-20,1998,EP 95929542 A,1995-08-15,US 9510364 W;;US 30390894 A,1994-09-09,GASOLINE UPGRADING PROCESS,,MOBIL OIL CORP,DURAND PAUL PIERCE;;TIMKEN HYE KYUNG CHO,EXXONMOBIL OIL CORPORATION (2001-10-31),https://lens.org/050-607-756-167-404,Search Report,no,2,0,18,18,0,C10G35/095;;C10G69/08;;C10G67/00;;C10G69/08;;C10G35/095,B01J29/48;;B01J29/40;;C10G35/095;;C10G69/08,,1,0,,,See also references of WO 9607714A1,EXPIRED
76,NO,B1,NO 315124 B1,096-713-566-333-385,2003-07-14,2003,NO 971067 A,1997-03-07,US 30390894 A;;US 9510364 W,1994-09-09,Fremgangsmåte for oppgradering av bensin,,MOBIL OIL CORP,DURAND PAUL PIERCE;;TIMKEN HYE KYUNG CHO,,https://lens.org/096-713-566-333-385,Granted Patent,no,0,0,18,18,0,C10G35/095;;C10G69/08;;C10G67/00;;C10G69/08;;C10G35/095,B01J29/48;;C10G35/095;;B01J29/40;;C10G69/08,,0,0,,,,EXPIRED
77,EP,A2,EP 2049696 A2,158-054-895-119-583,2009-04-22,2009,EP 07799189 A,2007-06-29,US 2007/0072513 W;;US 81740306 P,2006-06-30,"HIGH STRENGTH, HEAT TREATABLE AL-ZN-MG ALUMINUM ALLOY",,ALCAN ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SMITH KENNETH PAUL;;DANGERFIELD VIC,"CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC (2012-01-04)",https://lens.org/158-054-895-119-583,Patent Application,yes,0,0,18,18,0,C22C21/08;;C22C21/10;;C22C21/10;;C22C21/06;;C22F1/053;;C22F1/047;;C22C21/10;;C22C21/08,C22C21/10;;C22F1/053,,0,0,,,,ACTIVE
78,WO,A3,WO 2008/005852 A3,050-310-220-528-024,2008-04-17,2008,US 2007/0072513 W,2007-06-29,US 81740306 P,2006-06-30,"HIGH STRENGTH, HEAT TREATABLE AL-ZN-MG ALUMINIUM ALLOY","A high strength aluminum alloy. is suitable for ultra thick gauge wrought product. The alloy can have 6 to 8 wt % zinc, 1 to 1.9 wt % magnesium, wherein Mg is present in an amount from (0.2 2m,- 0.3) wt. % to (0.2 Zm + 0.3) wt. %, and dispersoid forming elements such as Zr, Mn, Cr, Ti, and /or Sc with the balance made of aluminum and incidental elements and/or impurities. The alloy is suitable for many uses, including in moulds for injection-molded plastics.",ALCAN ROLLED PRODUCTS RAVENSWOOD LLC;;CHO ALEX;;SMITH KENNETH PAUL;;DANGERFIELD VIC,CHO ALEX;;SMITH KENNETH PAUL;;DANGERFIELD VIC,,https://lens.org/050-310-220-528-024,Search Report,yes,16,0,18,18,0,C22C21/08;;C22C21/10;;C22C21/10;;C22C21/06;;C22F1/053;;C22F1/047;;C22C21/10;;C22C21/08,C22F1/053;;C22C1/10,,1,0,,,"HUFNAGEL W: ""Key to Aluminium Alloys, 4th Edition"", ALUMINIUM-SCHLUESSEL = KEY TO ALUMINIUM ALLOYS, 1991, pages 195 - 205, XP002194851",PENDING
79,RU,C2,RU 2473710 C2,064-964-039-281-46X,2013-01-27,2013,RU 2009102968 A,2007-06-29,US 81740306 P;;US 2007/0072513 W,2006-06-30,HIGH-STRENGTH HEAT-TREATABLE ALUMINIUM ALLOY,"FIELD: metallurgy.SUBSTANCE: ingot, at least, 4in-thick, is made from aluminium-based alloy containing, at least, 6.5 wt % of zinc and magnesium at zinc-to-magnesium ratio of 5:1. Said ingot features, at quarter of thickness, the tensile strength of, at least, 61 kgft/sq.in and yield points of, at least, 54.5 kgft/sq.in. Proposed method comprises the following stages: 12 in-thick ingot is cast from aluminium-based alloy containing: 6-8 wt % of Zn, 1-2 wt % of Mg, with Mg content making (0.2 × Zn - 0.3) wt %-(0.2 × Zn + 0.3) wt %, at least, one element forming intermetallic dispersoids, aluminium and unavoidable impurities making the rest. Then, ingot is homogenised at 820°F to 980°F, and cooled by one of below methods: forced feed of air, water mist and water spray. Then, it is artificially aged at 240°F to 320°F to allow age-hardening.EFFECT: high strength, low sensitivity to quenching.12 cl, 8 dwg, 6 tbl, 2 ex",CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SMITH KENNETH PAUL;;DANGERFIELD VIC,,https://lens.org/064-964-039-281-46X,Granted Patent,no,4,4,18,18,0,C22C21/08;;C22C21/10;;C22C21/10;;C22C21/06;;C22F1/053;;C22F1/047;;C22C21/10;;C22C21/08,C22C21/10;;C22F1/053,,0,0,,,,ACTIVE
80,EP,B1,EP 0781315 B1,066-382-908-357-239,2001-10-31,2001,EP 95929542 A,1995-08-15,US 9510364 W;;US 30390894 A,1994-09-09,GASOLINE UPGRADING PROCESS,,EXXONMOBIL OIL CORP,DURAND PAUL PIERCE;;TIMKEN HYE KYUNG CHO,EXXONMOBIL OIL CORPORATION (2001-10-31),https://lens.org/066-382-908-357-239,Granted Patent,yes,6,0,18,18,0,C10G35/095;;C10G69/08;;C10G67/00;;C10G69/08;;C10G35/095,B01J29/48;;C10G35/095;;B01J29/40;;C10G69/08,,0,0,,,,EXPIRED
81,MX,A,MX 9701508 A,128-435-867-971-227,1997-05-31,1997,MX 9701508 A,1995-08-15,US 9510364 W;;US 30390894 A,1994-09-09,GASOLINE UPGRADING PROCESS.,"Low sulfur gasoline of relatively high octane number is produced from a cracked, sulfur-containing olefinic naphthas by hydrodesulfurization followed by treatment over an acidic catalyst comprising an intermediate pore size zeolite such as zeolite ZSM-5 in combination with molybdenum. The use of the molybdenum in combination with the zeolite has been found to give improved catalytic activity coupled with lower coking, longer catalyst life and other advantages.",MOBIL OIL CORP,DURAND PAUL PIERCE;;TIMKEN HYE KYUNG CHO,,https://lens.org/128-435-867-971-227,Patent Application,no,0,0,18,18,0,C10G35/095;;C10G69/08;;C10G67/00;;C10G69/08;;C10G35/095,B01J29/48;;B01J29/40;;C10G35/095;;C10G69/08,,0,0,,,,PENDING
82,CA,A1,CA 2689655 A1,007-588-008-471-320,2009-01-15,2009,CA 2689655 A,2008-07-11,FR 0705066 A;;IB 2008001815 W,2007-07-12,TRANSVERSE SPINAL LINKING DEVICE AND SYSTEM,"A transverse spinal linking device (1 ) links at least one spinal osteosy nthesis bar (2) to a transverse bar (3). The device (1 ) includes a first pa rt (11 ) that has a vertical axis and a first jaw (111 ), a second part (12) that has a second jaw (121 ), and a clamping means (13). The first part (11 ) includes a sliding surface (114), which is inclined in relation to the ve rtical axis, and which mates with at least one sliding surface (124) of the second part (12). The sliding surfaces (114, 124) are configured so that the descent of the second part (12) results in an approach of the jaws (121, 11 1 ), with the clamping action of the clamping resource (13) causing the fixi ng and/or the locking of the device (1 ) on the osteosynthesis bar (2) and t he fixing and/or the locking of the transverse bar (3).",LDR MEDICAL,CHO PAUL HENRY;;CHATATGNER HERVE;;HOFFMAN GREGORY,,https://lens.org/007-588-008-471-320,Patent Application,no,0,0,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,,0,0,,,,INACTIVE
83,CA,C,CA 2198214 C,016-767-366-753-563,2003-09-23,2003,CA 2198214 A,1995-08-15,US 30390894 A;;US 9510364 W,1994-09-09,GASOLINE UPGRADING PROCESS,"Low sulfur gasoline of relatively high octane number is produced from a cracked, sulfur-containing olefinic naphthas by hydrodesulfurization followe d by treatment over an acidic catalyst comprising an intermediate pore size zeolite such as zeolite ZSM-5 in combination with molybdenum. The use of the molybdenum in combination with the zeolite has been found to give improved catalytic activity coupled with lower coking, longer catalyst life and other advantages.",MOBIL OIL CORP,DURAND PAUL PIERCE;;TIMKEN HYE KYUNG CHO,,https://lens.org/016-767-366-753-563,Granted Patent,no,0,0,18,18,0,C10G35/095;;C10G69/08;;C10G67/00;;C10G69/08;;C10G35/095,B01J29/40;;B01J29/48;;C10G35/095;;C10G69/08,,0,0,,,,EXPIRED
84,MX,A,MX 2008016076 A,030-155-330-891-120,2009-01-15,2009,MX 2008016076 A,2007-06-29,US 81740306 P;;US 2007/0072513 W,2006-06-30,"HIGH STRENGTH, HEAT TREATABLE AL-ZN-MG ALUMINIUM ALLOY.","A high strength aluminum alloy. is suitable for ultra thick gauge wrought product. The alloy can have 6 to 8 wt % zinc, 1 to 1.9 wt % magnesium, wherein Mg is present in an amount from (0.2 2m,- 0.3) wt. % to (0.2 Zm + 0.3) wt. %, and dispersoid forming elements such as Zr, Mn, Cr, Ti, and /or Sc with the balance made of aluminum and incidental elements and/or impurities. The alloy is suitable for many uses, including in moulds for injection-molded plastics.",ALCAN ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SMITH KENNETH PAUL;;DANGERFIELD VIC,ABBVIE DEUTSCHLAND GMBH & CO. KG (2013-10-30),https://lens.org/030-155-330-891-120,Patent Application,no,0,0,18,18,0,C22C21/08;;C22C21/10;;C22C21/10;;C22C21/06;;C22F1/053;;C22F1/047;;C22C21/10;;C22C21/08,C22C1/10;;C22F1/053,,0,0,,,,ACTIVE
85,EP,B1,EP 2182868 B1,025-784-465-891-954,2014-04-30,2014,EP 08826187 A,2008-07-11,IB 2008001815 W;;FR 0705066 A,2007-07-12,TRANSVERSE SPINAL LINKING DEVICE AND SPINAL STABILIZATION SYSTEM,,LDR MEDICAL,CHO PAUL HENRY;;HOFFMAN GREGORY;;CHATATGNER HERVE,,https://lens.org/025-784-465-891-954,Granted Patent,yes,6,0,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,,0,0,,,,ACTIVE
86,IN,B,IN 192236 B,009-200-146-128-722,2004-03-20,2004,IN 1063MA1995 A,1995-08-22,IN 1063MA1995 A,1995-08-22,A process for te production of low sulfur containing gasoline of high octane number,,MOBIL OIL,DURAND PAUL PIERCE;;TIMKEN HYE KYUNG CHO,,https://lens.org/009-200-146-128-722,Granted Patent,no,0,0,1,1,0,,C10G69/02,,0,0,,,,EXPIRED
87,CA,C,CA 2657331 C,087-990-389-381-528,2016-11-08,2016,CA 2657331 A,2007-06-29,US 81740306 P;;US 2007/0072513 W,2006-06-30,"A HIGH STRENGTH, HEAT TREATABLE ALUMINUM ALLOY","A high strength aluminum alloy. is suitable for ultra thick gauge wrought product. The alloy can have 6 to 8 wt % zinc, 1 to 1.9 wt % magnesium, wherein Mg is present in an amount from (0.2 2m,- 0.3) wt. % to (0.2 Zm + 0.3) wt. %, and dispersoid forming elements such as Zr, Mn, Cr, Ti, and /or Sc with the balance made of aluminum and incidental elements and/or impurities. The alloy is suitable for many uses, including in moulds for injection-molded plastics.",ALCAN ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SMITH KENNETH PAUL;;DANGERFIELD VIC,,https://lens.org/087-990-389-381-528,Granted Patent,no,0,0,18,18,0,C22C21/08;;C22C21/10;;C22C21/10;;C22C21/06;;C22F1/053;;C22F1/047;;C22C21/10;;C22C21/08,C22C21/10;;C22F1/053,,0,0,,,,ACTIVE
88,KR,A,KR 20090026337 A,117-608-201-834-246,2009-03-12,2009,KR 20097000501 A,2009-01-09,US 81740306 P,2006-06-30,"A HIGH STRENGTH, HEAT TREATABLE ALUMINUM ALLOY","A high strength aluminum alloy is suitable for ultra thick gauge wrought product. The alloy can have 6 to 8 wt % zinc, 1 to 2 wt % magnesium, and dispersoid forming elements such as Zr, Mn, Cr, Ti, and /or Sc with the balance made of aluminum and incidental elements and/or impurities. The alloy is suitable for many uses, including in moulds for injection-molded plastics.",ALCAN ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SMITH KENNETH PAUL;;DANGERFIELD VIC,,https://lens.org/117-608-201-834-246,Patent Application,no,0,0,18,18,0,C22C21/08;;C22C21/10;;C22C21/10;;C22C21/06;;C22F1/053;;C22F1/047;;C22C21/10;;C22C21/08,C22C21/10;;C22C21/06;;C22F1/047;;C22F1/053,,0,0,,,,DISCONTINUED
89,BR,A2,BR PI0713870 A2,137-804-976-308-894,2012-12-18,2012,BR PI0713870 A,2007-06-29,US 81740306 P;;US 2007/0072513 W,2006-06-30,"liga de alumìnio, de alta resistência, tratável por calor","LIGA DE ALUMìNIO, DE ALTA RESISTêNCIA, TRATáVEL POR CALOR. A presente invenção refere-se a uma liga de alumínio de alta resistência é adequada para a produção de um produto acabado de medidas ultra-espessas. A liga pode possuir de 6% em peso a 8% em peso de zinco, de 1% em peso a 2% em peso de magnésio, e elementos dispersóides de formação tais como Zr, Mn, Cr, Ti, e/ou Sc com o balanço final feito com alumínio e elementos acessórios e/ou impureza. Liga é adequada para muitos usos, incluindo moldes para moldagem de plásticos por injeção.",ALCAN ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SMITH KENNETH PAUL;;DANGERFIELD VIC,"CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC (US) (2013-09-03)",https://lens.org/137-804-976-308-894,Patent Application,no,0,0,18,18,0,C22C21/08;;C22C21/10;;C22C21/10;;C22C21/06;;C22F1/053;;C22F1/047;;C22C21/10;;C22C21/08,C22F1/053;;C22C1/10,,0,0,,,,ACTIVE
90,EP,A1,EP 0781315 A1,174-244-004-472-015,1997-07-02,1997,EP 95929542 A,1995-08-15,US 9510364 W;;US 30390894 A,1994-09-09,GASOLINE UPGRADING PROCESS,,MOBIL OIL CORP,DURAND PAUL PIERCE;;TIMKEN HYE KYUNG CHO,EXXONMOBIL OIL CORPORATION (2001-10-31),https://lens.org/174-244-004-472-015,Patent Application,yes,0,0,18,18,0,C10G35/095;;C10G69/08;;C10G67/00;;C10G69/08;;C10G35/095,B01J29/48;;C10G35/095;;B01J29/40;;C10G69/08,,0,0,,,,EXPIRED
91,CA,A1,CA 2198214 A1,174-968-004-606-259,1996-03-14,1996,CA 2198214 A,1995-08-15,US 30390894 A;;US 9510364 W,1994-09-09,GASOLINE UPGRADING PROCESS,"Low sulfur gasoline of relatively high octane number is produced from a cracked, sulfur-containing olefinic naphthas by hydrodesulfurization followed by treatment over an acidic catalyst comprising an intermediate pore size zeolite such as zeolite ZSM-5 in combination with molybdenum. The use of the molybdenum in combination with the zeolite has been found to give improved catalytic activity coupled with lower coking, longer catalyst life and other advantages.",MOBIL OIL CORP,DURANT PAUL PIERCE;;TIMKEN HYE KYUNG CHO,,https://lens.org/174-968-004-606-259,Patent Application,no,0,0,18,18,0,C10G35/095;;C10G69/08;;C10G67/00;;C10G69/08;;C10G35/095,B01J29/40;;B01J29/48;;C10G35/095;;C10G69/08,,0,0,,,,EXPIRED
92,WO,A2,WO 2008/005852 A2,177-961-424-713-605,2008-01-10,2008,US 2007/0072513 W,2007-06-29,US 81740306 P,2006-06-30,"A HIGH STRENGTH, HEAT TREATABLE ALUMINUM ALLOY","A high strength aluminum alloy is suitable for ultra thick gauge wrought product. The alloy can have 6 to 8 wt % zinc, 1 to 2 wt % magnesium, and dispersoid forming elements such as Zr, Mn, Cr, Ti, and /or Sc with the balance made of aluminum and incidental elements and/or impurities. The alloy is suitable for many uses, including in moulds for injection-molded plastics.",ALCAN ROLLED PRODUCTS RAVENSWOOD LLC;;CHO ALEX;;SMITH KENNETH PAUL;;DANGERFIELD VIC,CHO ALEX;;SMITH KENNETH PAUL;;DANGERFIELD VIC,,https://lens.org/177-961-424-713-605,Patent Application,yes,0,5,18,18,0,C22C21/08;;C22C21/10;;C22C21/10;;C22C21/06;;C22F1/053;;C22F1/047;;C22C21/10;;C22C21/08,C22F1/053;;C22C21/10,,0,0,,,,PENDING
93,ES,T3,ES 2468249 T3,110-377-084-605-064,2014-06-16,2014,ES 08826187 T,2008-07-11,FR 0705066 A;;IB 2008001815 W,2007-07-12,Dispositivo de unión raquídea transversal y sistema de estabilización raquídea,"Un dispositivo de unión raquídea transversal (1), para fijar al menos una barra de osteosíntesis raquídea (2) a una barra transversal (3), y que incluye al menos dos mandíbulas (111, 121) previstas para sujetar la barra de osteosíntesis raquídea (2) aproximándose entre sí a lo largo de un llamado ""eje de aproximación de las mandíbulas"", y al menos una superficie portante (120) prevista para soportar la barra transversal (3), incluyendo dicho dispositivo (1): - una primera pieza (11) que tiene una primera mandíbula (111), y una cabeza de fijación (112) que encaja con recursos de sujeción (13), - una segunda pieza (12) que tiene una segunda mandíbula (121) y un cuerpo de fijación que incluye un pasaje (123) de dimensiones que son mayores, al menos a lo largo del eje de aproximación de las mandíbulas, que la cabeza de fijación (112) de la primera pieza (11) a la que está previsto que se enrosque a lo largo de un eje, llamado eje vertical, orientado hacia la barra de osteosíntesis (2), - al menos una superficie deslizante (114) de la primera pieza (11), que está inclinada con respecto a dicho eje vertical, y que encaja con al menos una superficie deslizante (124) de la segunda pieza (12) de modo que el descenso de la segunda pieza (12) con respecto a la primera pieza (11) da como resultado una aproximación de las mandíbulas (121, 111), con el dispositivo (1) estando caracterizado por que: - los recursos de sujeción (13), la primera pieza (11) y la segunda pieza (12) están dispuestos de modo que la acción de sujeción de los recursos de sujeción (13) induce su descenso con respecto a la cabeza (112) de la primera pieza (11), presionando de este modo dichos recursos de sujeción (13) directamente sobre la barra transversal (3) y haciendo que la barra transversal (3) presione contra la superficie portante (120) de la segunda pieza (12), lo que causa el descenso de la segunda pieza (12) con respecto a la primera pieza (11), causando de este modo la fijación y/o el bloqueo de la barra transversal (3) y, al mismo tiempo, la fijación y/o el bloqueo del dispositivo (1) sobre la barra de osteosíntesis (2), gracias a que las mandíbulas se aproximan entre sí.",LDR MEDICAL,CHO PAUL HENRY;;HOFFMAN GREGORY;;CHATATGNER HERVÉ,,https://lens.org/110-377-084-605-064,Granted Patent,no,0,0,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,,0,0,,,,ACTIVE
94,PH,A,PH 15856 A,071-412-940-343-414,1983-04-13,1983,PH 20009 A,1977-07-19,US 71075576 A,1976-08-02,CLOSURED AND DIVIDED BOX,,DART IND INC,BATEMAN ROBERT FRANCIS;;BEAUCHAMP ROGER PAUL;;KAZUNOBU CHO,,https://lens.org/071-412-940-343-414,Granted Patent,no,0,0,48,49,0,B65D25/04,B65D25/04;;B65D1/24;;B65D43/08,,0,0,,,,EXPIRED
95,FI,C,FI 66737 C,128-142-715-644-172,1984-12-10,1984,FI 772162 A,1977-07-11,US 71075576 A,1976-08-02,MED LOCK OCH MELLANVAEGG FOERSEDD ASK,,DART IND INC,BATEMAN ROBERT FRANCIS;;BEAUCHAMP ROGER PAUL;;CHO KAZUNOBU,,https://lens.org/128-142-715-644-172,Granted Patent,no,0,0,48,49,0,B65D25/04,B65D25/04;;B65D1/24;;B65D43/08,,0,0,,,,EXPIRED
96,CN,A,CN 106163548 A,157-658-565-017-147,2016-11-23,2016,CN 201580017492 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,Methods of treating alzheimer's disease,"Methods of treating Alzheimer's disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/157-658-565-017-147,Patent Application,no,1,3,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,2,0,,,"OSKAR等: ""An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique AβBinding Properties Promotes Neuroprotection and Glial Engulfment of Aβ"", 《THE JOURNAL OF NEUROSCIENCE》;;RACHELLE等: ""Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer’s Disease"", 《THE NEW ENGLAND JOURNAL OF MEDICINE》",PENDING
97,CA,C,CA 2938466 C,039-234-254-106-743,2021-11-02,2021,CA 2938466 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/039-234-254-106-743,Granted Patent,no,0,0,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,ACTIVE
98,US,A1,US 2014/0101165 A1,150-466-886-620-501,2014-04-10,2014,US 201313950983 A,2013-07-25,US 201313950983 A;;US 201213648956 A,2012-10-10,SEARCHABLE AND SIZE-CONSTRAINED LOCAL LOG REPOSITORIES FOR TRACKING VISITORS' ACCESS TO WEB CONTENT,"A method and system for tracking visitors' access to web content using a searchable and size-constrained local log repository is disclosed. A repository indexer receives visitor logs from a remote source and indexes the logs to include a usage field indicating when or how frequently an associated visitor log was accessed from a local log repository by a report request manager. The local log repository stores the logs and is size constrained. A repository manager removes a subset of the logs in the local log repository based on parameters within the subset of the logs' usage field. The report request manager receives a request from a requestor for a report indicating visitors' access to a content object, searches for logs within the local log repository pertinent to the request, aggregates data across the logs responsive to the search, and generates a report presenting the aggregated data.",LIMELIGHT NETWORKS INC,ACHARYA SOAM;;CHO PAUL;;CORNWELL JONATHAN;;KWOK CHRIS,LIMELIGHT NETWORKS INC (2012-09-19),https://lens.org/150-466-886-620-501,Patent Application,yes,7,1,3,3,0,G06Q30/0201;;G06F16/951;;G06F16/958;;G06F16/951;;G06F16/958;;G06Q30/0201,G06F17/30,707/741,0,0,,,,ACTIVE
99,DK,B,DK 158196 B,027-253-128-062-16X,1990-04-09,1990,DK 343677 A,1977-08-01,US 71075576 A,1976-08-02,BEHOLDER NAVNLIG TIL MADVARER,,DART IND INC,BATEMAN ROBERT FRANCIS;;BEAUCHAMP ROGER PAUL;;CHO KAZUNOBU,,https://lens.org/027-253-128-062-16X,Patent Application,no,0,0,48,49,0,B65D25/04,B65D25/04;;B65D43/08;;B65D1/24,,0,0,,,,EXPIRED
100,WO,A1,WO 2015/169878 A1,047-343-930-894-558,2015-11-12,2015,EP 2015060001 W,2015-05-06,FR 1454102 A;;US 201514638746 A,2014-05-06,"VERTEBRAL IMPLANT, DEVICE FOR VERTEBRAL ATTACHMENT OF THE IMPLANT AND INSTRUMENTATION FOR IMPLANTATION THEREOF","The present invention relates to a vertebral implant, in particular for corpectomy, to a device for attaching a vertebral implant and to implantation instrumentation, the implant including at least one first body (2) and at least one second body (3) each having at least one face having shapes and dimensions mating those of at least one face of another body (3, 2) and forming mutual fitting means, in order to allow assembling of said bodies (2, 3) by sliding along a sliding axis and, on the other hand, at least one locking means (4) retained in at least one of the bodies (2, 3) and at least one abutment portion of which is laid out for passing from a so-called open position, allowing sliding for the assembling of said bodies (2, 3), to a so-called closed position, locking said bodies (2, 3) assembled together by the contact between at least said abutment portion and at least one abutment (42, 43) of at least one of said bodies (2, 3), said abutment (42, 43) being oriented not parallel to the sliding axis and said abutment portion passing from the open position to the closed position elastically by flexure or torsion.",LDR MEDICAL,AMEIL MARC;;LEE DANIEL D;;CHO PAUL HENRY,,https://lens.org/047-343-930-894-558,Patent Application,yes,4,2,14,14,0,A61B17/86;;A61B17/8872;;A61F2/44;;A61F2/4455;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2002/448;;A61F2/44;;A61F2/4455;;A61F2/4465;;A61F2/4637;;A61F2002/30387;;A61F2002/30481;;A61F2002/30505;;A61F2002/30579;;A61F2002/30593;;A61F2002/30604;;A61F2002/30841;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2220/0016;;A61F2/4603;;A61F2/447;;A61F2/4611;;A61B17/86;;A61B17/8872;;A61F2002/448;;A61F2002/4629;;A61F2/44;;A61F2/4455;;A61F2002/30841;;A61F2002/30481;;A61F2002/30579;;A61F2002/30593;;A61F2002/30387;;A61F2/4637;;A61F2/4465;;A61F2002/30604;;A61F2002/30505;;A61F2/4603;;A61F2/442;;A61F2/4425;;A61F2220/0016,A61F2/44,,0,0,,,,PENDING
101,AU,A1,AU 2015/257671 A1,100-487-738-909-054,2016-11-10,2016,AU 2015/257671 A,2015-05-06,US 201514638746 A;;FR 1454102 A;;EP 2015060001 W,2014-05-06,"Vertebral implant, device for vertebral attachment of the implant and instrumentation for implantation thereof","The present invention relates to a vertebral implant, in particular for corpectomy, to a device for attaching a vertebral implant and to implantation instrumentation, the implant including at least one first body (2) and at least one second body (3) each having at least one face having shapes and dimensions mating those of at least one face of another body (3, 2) and forming mutual fitting means, in order to allow assembling of said bodies (2, 3) by sliding along a sliding axis and, on the other hand, at least one locking means (4) retained in at least one of the bodies (2, 3) and at least one abutment portion of which is laid out for passing from a so-called open position, allowing sliding for the assembling of said bodies (2, 3), to a so-called closed position, locking said bodies (2, 3) assembled together by the contact between at least said abutment portion and at least one abutment (42, 43) of at least one of said bodies (2, 3), said abutment (42, 43) being oriented not parallel to the sliding axis and said abutment portion passing from the open position to the closed position elastically by flexure or torsion.",LDR MEDICAL,AMEIL MARC;;LEE DANIEL D;;CHO PAUL HENRY,,https://lens.org/100-487-738-909-054,Patent Application,no,0,2,14,14,0,A61B17/86;;A61B17/8872;;A61F2/44;;A61F2/4455;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2002/448;;A61F2/44;;A61F2/4455;;A61F2/4465;;A61F2/4637;;A61F2002/30387;;A61F2002/30481;;A61F2002/30505;;A61F2002/30579;;A61F2002/30593;;A61F2002/30604;;A61F2002/30841;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2220/0016;;A61F2/4603;;A61F2/447;;A61F2/4611;;A61B17/86;;A61B17/8872;;A61F2002/448;;A61F2002/4629;;A61F2/44;;A61F2/4455;;A61F2002/30841;;A61F2002/30481;;A61F2002/30579;;A61F2002/30593;;A61F2002/30387;;A61F2/4637;;A61F2/4465;;A61F2002/30604;;A61F2002/30505;;A61F2/4603;;A61F2/442;;A61F2/4425;;A61F2220/0016,A61F2/44,,0,0,,,,DISCONTINUED
102,WO,A2,WO 2009/007838 A2,196-383-209-788-812,2009-01-15,2009,IB 2008001815 W,2008-07-11,FR 0705066 A,2007-07-12,TRANSVERSE SPINAL LINKING DEVICE AND SYSTEM,"A transverse spinal linking device (1 ) links at least one spinal osteosynthesis bar (2) to a transverse bar (3). The device (1 ) may include a first part (11 ) that has a vertical axis and a first jaw (111 ), a second part (12) that has a second jaw (121 ), and a clamping resource (13). The first part (11 ) may include a sliding surface (114), which may be inclined in relation to the vertical axis, and which may mate with at least one sliding surface (124) of the second part (12). The sliding surfaces (114, 124) may be configured so that the descent of the second part (12) results in an approach of the jaws (121, 111 ), with the clamping action of the clamping resource (13) causing the fixing and/or the locking of the device (1 ) on the osteosynthesis bar (2) and the fixing and/or the locking of the transverse bar (3).",LDR MEDICAL;;CHO PAUL HENRY L;;HOFFMAN GREGORY;;CHATATGNER HERVE,CHO PAUL HENRY L;;HOFFMAN GREGORY;;CHATATGNER HERVE,,https://lens.org/196-383-209-788-812,Patent Application,yes,5,1,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,,,0,0,,,,PENDING
103,US,A1,US 2015/0246963 A1,057-573-101-037-256,2015-09-03,2015,US 201514616261 A,2015-02-06,US 201514616261 A;;US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,GENENTECH INC (2015-05-18),https://lens.org/057-573-101-037-256,Patent Application,yes,1,5,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,C07K16/18;;A61K31/56,,1,1,011-451-856-283-514,10.2967/jnumed.107.045385;;18287270;;pmc3703818,"Mosconi et al., Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer’s Disease, and Other Dementias. THE JOURNAL OF NUCLEAR MEDICINE • Vol. 49 • No. 3 • March 2008, 390-398",DISCONTINUED
104,CA,A1,CA 2946234 A1,066-887-287-340-955,2015-11-12,2015,CA 2946234 A,2015-05-06,FR 1454102 A;;US 201514638746 A;;EP 2015060001 W,2014-05-06,"VERTEBRAL IMPLANT, DEVICE FOR VERTEBRAL ATTACHMENT OF THE IMPLANT AND INSTRUMENTATION FOR IMPLANTATION THEREOF","The present invention relates to a vertebral implant, in particular for corpectomy, to a device for attaching a vertebral implant and to implantation instrumentation, the implant including at least one first body (2) and at least one second body (3) each having at least one face having shapes and dimensions mating those of at least one face of another body (3, 2) and forming mutual fitting means, in order to allow assembling of said bodies (2, 3) by sliding along a sliding axis and, on the other hand, at least one locking means (4) retained in at least one of the bodies (2, 3) and at least one abutment portion of which is laid out for passing from a so-called open position, allowing sliding for the assembling of said bodies (2, 3), to a so-called closed position, locking said bodies (2, 3) assembled together by the contact between at least said abutment portion and at least one abutment (42, 43) of at least one of said bodies (2, 3), said abutment (42, 43) being oriented not parallel to the sliding axis and said abutment portion passing from the open position to the closed position elastically by flexure or torsion.",LDR MEDICAL,AMEIL MARC;;LEE DANIEL D;;CHO PAUL HENRY,,https://lens.org/066-887-287-340-955,Patent Application,no,0,2,14,14,0,A61B17/86;;A61B17/8872;;A61F2/44;;A61F2/4455;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2002/448;;A61F2/44;;A61F2/4455;;A61F2/4465;;A61F2/4637;;A61F2002/30387;;A61F2002/30481;;A61F2002/30505;;A61F2002/30579;;A61F2002/30593;;A61F2002/30604;;A61F2002/30841;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2220/0016;;A61F2/4603;;A61F2/447;;A61F2/4611;;A61B17/86;;A61B17/8872;;A61F2002/448;;A61F2002/4629;;A61F2/44;;A61F2/4455;;A61F2002/30841;;A61F2002/30481;;A61F2002/30579;;A61F2002/30593;;A61F2002/30387;;A61F2/4637;;A61F2/4465;;A61F2002/30604;;A61F2002/30505;;A61F2/4603;;A61F2/442;;A61F2/4425;;A61F2220/0016,A61F2/44,,0,0,,,,DISCONTINUED
105,FR,A1,FR 3020756 A1,081-351-209-459-852,2015-11-13,2015,FR 1454102 A,2014-05-06,FR 1454102 A,2014-05-06,"IMPLANT VERTEBRAL, DISPOSITIF DE FIXATION VERTEBRALE D'IMPLANT ET INSTRUMENTATION D'IMPLANTATION","La présente invention concerne un implant vertébral, en particulier de corporectomie, un dispositif de fixation d'implant vertébral et une instrumentation d'implantation, l'implant comportant au moins un premier corps (2) et au moins un second corps (3) possédant, chacun, au moins une face ayant des formes et dimensions complémentaires à celles d'au moins une face d'un autre corps (3, 2) et formant des moyens d'emboitement réciproque, pour permettre un assemblage desdits corps (2, 3) par coulissement selon un axe de coulissement et, d'autre part, au moins un moyen de verrouillage (4) retenu dans au moins un des corps (2, 3) et dont au moins une portion de butée est agencée pour passer d'une position, dite ouverte, autorisant le coulissement pour l'assemblage desdits corps (2, 3) à une position, dite fermée, verrouillant lesdits corps (2, 3) assemblés ensemble par le contact entre au moins ladite portion de butée et au moins une butée (42, 43) d'au moins un desdits corps (2, 3), ladite butée (42, 43) étant orientée non parallèlement à l'axe de coulissement et ladite portion de butée passant de la position ouverte à la position fermée, de manière élastique par flexion ou par torsion",LDR MEDICAL,AMEIL MARC;;LEE DANIEL D;;CHO PAUL HENRY,,https://lens.org/081-351-209-459-852,Patent Application,no,4,7,14,14,0,A61B17/86;;A61B17/8872;;A61F2/44;;A61F2/4455;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2002/448;;A61F2/44;;A61F2/4455;;A61F2/4465;;A61F2/4637;;A61F2002/30387;;A61F2002/30481;;A61F2002/30505;;A61F2002/30579;;A61F2002/30593;;A61F2002/30604;;A61F2002/30841;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2220/0016;;A61F2/4603;;A61F2/447;;A61F2/4611;;A61B17/86;;A61B17/8872;;A61F2002/448;;A61F2002/4629;;A61F2/44;;A61F2/4455;;A61F2002/30841;;A61F2002/30481;;A61F2002/30579;;A61F2002/30593;;A61F2002/30387;;A61F2/4637;;A61F2/4465;;A61F2002/30604;;A61F2002/30505;;A61F2/4603;;A61F2/442;;A61F2/4425;;A61F2220/0016,A61F2/44,,0,0,,,,ACTIVE
106,US,A,US 4034299 A,108-574-062-392-644,1977-07-05,1977,US 64500275 A,1975-12-29,US 64500275 A,1975-12-29,Audio signal quality indicator,"An FM radio receiver with a discriminator having connected thereto a plurality of bandpass filters, each tuned to pass a different portion of the audio spectrum from the discriminator, and circuitry connected to the bandpass filters for selecting the filter with the lowest output signal which is an indication of the amplitude of the noise and, hence, the quality of the signal being received by the receiver.",MOTOROLA INC,CHO SUSUMU;;ERICKSON PAUL MILTON;;REYNOLDS GARY RAYMOND,,https://lens.org/108-574-062-392-644,Granted Patent,yes,5,14,1,1,0,H04B17/20;;H04B17/20,H04B17/00,325/363,0,0,,,,EXPIRED
107,SG,A,SG 10201913637R A,141-772-691-592-909,2020-03-30,2020,SG 10201913637R A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,,GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/141-772-691-592-909,Unknown,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,,,0,0,,,,PENDING
108,US,B2,US 10702391 B2,194-209-249-144-484,2020-07-07,2020,US 201515309197 A,2015-05-06,US 201515309197 A;;FR 1454102 A;;US 201514638746 A;;EP 2015060001 W,2014-05-06,"Vertebral implant, device for vertebral attachment of the implant and instrumentation for implantation thereof","The present invention relates to a vertebral implant, in particular for corpectomy, to a device for attaching a vertebral implant and to implantation instrumentation, the implant including at least one first body ( 2 ) and at least one second body ( 3 ) each having at least one face having shapes and dimensions mating those of at least one face of another body ( 3, 2 ) and forming mutual fitting means, in order to allow assembling of said bodies ( 2, 3 ) by sliding along a sliding axis and, on the other hand, at least one locking means ( 4 ) retained in at least one of the bodies ( 2, 3 ) and at least one abutment portion of which is laid out for passing from a so-called open position, allowing sliding for the assembling of said bodies ( 2, 3 ), to a so-called closed position, locking said bodies ( 2, 3 ) assembled together by the contact between at least said abutment portion and at least one abutment ( 42, 43 ) of at least one of said bodies ( 2, 3 ), said abutment ( 42, 43 ) being oriented not parallel to the sliding axis and said abutment portion passing from the open position to the closed position elastically by flexure or torsion.",LDR MEDICAL;;LDR MEDICAL S A S,AMEIL MARC;;LEE DANIEL D;;CHO PAUL HENRY,,https://lens.org/194-209-249-144-484,Granted Patent,yes,478,3,14,14,0,A61B17/86;;A61B17/8872;;A61F2/44;;A61F2/4455;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2002/448;;A61F2/44;;A61F2/4455;;A61F2/4465;;A61F2/4637;;A61F2002/30387;;A61F2002/30481;;A61F2002/30505;;A61F2002/30579;;A61F2002/30593;;A61F2002/30604;;A61F2002/30841;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2220/0016;;A61F2/4603;;A61F2/447;;A61F2/4611;;A61B17/86;;A61B17/8872;;A61F2002/448;;A61F2002/4629;;A61F2/44;;A61F2/4455;;A61F2002/30841;;A61F2002/30481;;A61F2002/30579;;A61F2002/30593;;A61F2002/30387;;A61F2/4637;;A61F2/4465;;A61F2002/30604;;A61F2002/30505;;A61F2/4603;;A61F2/442;;A61F2/4425;;A61F2220/0016,A61F2/44;;A61B17/86;;A61B17/88;;A61F2/30;;A61F2/46,,28,0,,,"“U.S. Appl. No. 14/246,442, Final Office Action dated Mar. 6, 2017”, 10 pgs.;;“U.S. Appl. No. 14/246,442, Non Final Office Action dated Aug. 15, 2017”, 11 pgs.;;“U.S. Appl. No. 14/246,442, Non Final Office Action dated Nov. 1, 2016”, 8 pgs.;;“U.S. Appl. No. 14/246,442, Response filed Feb. 1, 2017 to Non Final Office Action dated Nov. 1, 2016”, 10 pgs.;;“U.S. Appl. No. 14/246,442, Response filed May 6, 2017 to Final Office Action dated Mar. 6, 2017”, 17 pgs.;;“U.S. Appl. No. 14/246,442, Response filed Nov. 15, 2017 to Non Final Office Action dated Aug. 15, 2017”, 15 pgs.;;“U.S. Appl. No. 14/638,746, Examiner Interview Summary dated Nov. 15, 2017”, 3 pgs.;;“U.S. Appl. No. 14/638,746, Final Office Action dated Oct. 12, 2017”, 8 pgs.;;“U.S. Appl. No. 14/638,746, Non Final Office Action dated Feb. 6, 2018”, 10 pgs.;;“U.S. Appl. No. 14/638,746, Non Final Office Action dated Jun. 13, 2017”, 16 pgs.;;“U.S. Appl. No. 14/638,746, Response filed Jan. 12, 2018 to Final Office Action dated Oct. 12, 2017”, 9 pgs.;;“U.S. Appl. No. 14/638,746, Response filed Apr. 12, 2018 to Non Final Office Action dated Feb. 6, 2018”, 11 pgs.;;“U.S. Appl. No. 14/638,746, Response filed Sep. 13, 2017 to Non Final Office Action dated Jun. 13, 2017”, 12 pgs.;;“Chinese Application Serial No. 201480028167.7, Office Action dated May 16, 2016”.;;“Chinese Application Serial No. 201480028167.7, Office Action dated May 26, 2016”, w/English Translation, 18 pgs.;;“France Application Serial No. 1354421, Search Report dated Feb. 12, 2014”, 5 pgs.;;“France Application Serial No. 1454102, Search Report dated Jan. 29, 2015”.;;“International Application Serial No. PCT/EP2014/060135, International Preliminary Report on Patentability dated Sep. 18, 2015”, 16 pgs.;;“International Application Serial No. PCT/EP2014/060135, International Search Report dated Aug. 26, 2014”, 7 pgs.;;“International Application Serial No. PCT/EP2014/060135, Response filed Jun. 27, 2016 to Written Opinion dated Aug. 26, 2014”.;;“International Application Serial No. PCT/EP2014/060135, Written Opinion dated Aug. 26, 2014”, 14 pgs.;;“International Application Serial No. PCT/EP2015/060001, International Preliminary Report on Patentability dated Nov. 17, 2016”, 6 pgs.;;“International Application Serial No. PCT/EP2015/060001, International Search Report dated Oct. 2, 2015”, 3 pgs.;;“International Application Serial No. PCT/EP2015/060001, Written Opinion dated Oct. 2, 2015”, 4 pgs.;;“U.S. Appl. No. 14/638,746, Non Final Office Action dated Feb. 5, 2019”, 4 pgs.;;“European Application Serial No. 15724950.9, Response filed Jul. 13, 2017 to Communication Pursuant to Rules 161(1) and 162 EPC dated Jan. 3, 2017”, 15 pgs.;;“U.S. Appl. No. 14/638,746, Notice of Allowance dated Jul. 18, 2019”, 6 pgs.;;“U.S. Appl. No. 14/638,746, Response filed May 6, 2019 to Non Final Office action dated Feb. 5, 2019”, 6 pgs.",ACTIVE
109,ZA,B,ZA 201605341 B,194-657-618-352-246,2021-01-27,2021,ZA 201605341 A,2016-08-02,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,,GENENTECH INC A CORP ORGANISED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE,WILLIAM CHO;;MICHEL FRIESENHAHN;;ROBERT PAUL;;MICHAEL WARD,,https://lens.org/194-657-618-352-246,Granted Patent,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,,,0,0,,,,ACTIVE
110,CA,A1,CA 2938466 A1,027-253-429-463-645,2015-08-13,2015,CA 2938466 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/027-253-429-463-645,Patent Application,no,0,0,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,ACTIVE
111,JP,A,JP 2020073507 A,132-775-128-333-85X,2020-05-14,2020,JP 2019230200 A,2019-12-20,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"To provide methods of treating Alzheimer's disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD.SOLUTION: A humanized monoclonal anti-amyloid beta (Aβ) antibody that binds within residues 13 and 24 of amyloid β (1-42)(SEQ ID NO:1) is administered in an amount effective to slow the decline in cognitive capacity.SELECTED DRAWING: Figure 7",GENENTECH INC,WILLIAM CHO;;MICHEL FRIESENHAHN;;ROBERT PAUL;;MICHAEL WARD,,https://lens.org/132-775-128-333-85X,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/395;;A61K31/13;;A61K31/135;;A61K31/185;;A61K31/198;;A61K31/27;;A61K31/277;;A61K31/381;;A61K31/4045;;A61K31/405;;A61K31/428;;A61K31/445;;A61K31/4453;;A61K31/455;;A61K31/473;;A61K31/4745;;A61K31/48;;A61K31/55;;A61K31/565;;A61K31/573;;A61K45/00;;A61P25/28;;A61P43/00,,0,0,,,,PENDING
112,KR,A,KR 20160111039 A,139-940-973-532-03X,2016-09-23,2016,KR 20167024829 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"본원에서는 ApoE4 양성 환자 및 경증 AD를 앓는 환자를 포함하는, 약하거나 중등도의 AD를 앓는 환자에서 알츠하이머 질환(AD)을 치료하는 방법이 제공된다.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/139-940-973-532-03X,Patent Application,no,0,2,36,75,18,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K31/56;;A61K39/00;;C07K16/18,,0,0,,,,DISCONTINUED
113,AU,B2,AU 2015/214058 B2,159-203-413-863-864,2020-07-09,2020,AU 2015/214058 A,2015-02-06,US 201462081992 P;;US 201462010259 P;;US 201461971479 P;;US 201461937472 P;;US 2015/0014758 W,2014-02-08,Methods of treating Alzheimer's Disease,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/159-203-413-863-864,Granted Patent,no,1,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,C07K16/18;;A61K39/00;;A61P25/28,,4,4,015-169-910-449-13X;;086-932-421-807-452;;131-216-810-326-268;;044-966-041-336-742,24450890;;10.1056/nejmoa1312889;;24216217;;pmc3978826;;10.1186/alzrt220;;pmc6622286;;22787053;;10.1523/jneurosci.4742-11.2012;;22871696;;10.1038/nbt0812-731,"DOODY, R.S. ET AL, ""Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease"", NEW ENGLAND JOURNAL OF MEDICINE, (2014), vol. 370, no. 4, pages 311 - 321;;PRINS, N.D. ET AL, ""Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future"", ALZHEIMERS RES THER, (2013), vol. 5, no. 6, page 56;;ADOLFSSON, O. ET AL, ""An Effector-Reduced Anti-Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A"", JOURNAL OF NEUROSCIENCE, (2012), vol. 32, no. 28, pages 9677 - 9689;;GARBER, K., ""Genentech's Alzheimer's antibody trial to study disease prevention"", Nature Biotechnology (2012), vol. 30, no.8 pages 731-732",ACTIVE
114,SG,A,SG 11201606316X A,017-781-349-176-925,2016-08-30,2016,SG 11201606316X A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,,GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/017-781-349-176-925,Unknown,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,PENDING
115,US,A1,US 2011/0235860 A1,073-697-094-820-22X,2011-09-29,2011,US 93206011 A,2011-02-16,US 93206011 A;;US 33831110 P,2010-02-16,Method to estimate 3D abdominal and thoracic tumor position to submillimeter accuracy using sequential x-ray imaging and respiratory monitoring,"A method of estimating target motion for image guided radiotherapy (IGRT) systems is provided. The method includes acquiring by a kV imaging system sequential images of a target motion, computing by the kV imaging system from the sequential images an image-based estimation of the target motion expressed in a patient coordinate system, transforming by the kV imaging system the image-based estimation in the patient coordinate system to an estimate in a projection coordinate system, reformulating by the kV imaging system the projection coordinate system in a converging iterative form to force a convergence of the projection coordinate system to output a resolved estimation of the target motion, and displaying by the kV imaging system the resolved estimation of the target motion.",KEALL PAUL J;;POULSEN PER RUGAARD;;CHO BYUNGCHUL,KEALL PAUL J;;POULSEN PER RUGAARD;;CHO BYUNGCHUL,BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY THE (2011-04-23),https://lens.org/073-697-094-820-22X,Patent Application,yes,3,11,2,2,0,A61B6/486;;A61B6/486;;A61B6/022;;A61B6/022;;A61B6/5217;;A61B6/5217;;A61B6/527;;A61B6/527;;A61N5/1049;;A61N5/1049;;A61N2005/1061;;A61N2005/1061;;G06T7/285;;G06T7/285;;G06T2207/10021;;G06T2207/10021;;G06T2207/10116;;G06T2207/10116;;G06T2207/30004;;G06T2207/30004;;G16H50/30,G06K9/00,382/103,0,0,,,,INACTIVE
116,EP,B1,EP 3139867 B1,092-042-836-357-986,2022-12-28,2022,EP 15724950 A,2015-05-06,FR 1454102 A;;US 201514638746 A;;EP 2015060001 W,2014-05-06,"VERTEBRAL IMPLANT, DEVICE FOR VERTEBRAL ATTACHMENT OF THE IMPLANT AND INSTRUMENTATION FOR IMPLANTATION THEREOF",,LDR MEDICAL,AMEIL MARC;;LEE DANIEL D;;CHO PAUL HENRY,,https://lens.org/092-042-836-357-986,Granted Patent,yes,3,0,14,14,0,A61B17/86;;A61B17/8872;;A61F2/44;;A61F2/4455;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2002/448;;A61F2/44;;A61F2/4455;;A61F2/4465;;A61F2/4637;;A61F2002/30387;;A61F2002/30481;;A61F2002/30505;;A61F2002/30579;;A61F2002/30593;;A61F2002/30604;;A61F2002/30841;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2220/0016;;A61F2/4603;;A61F2/447;;A61F2/4611;;A61B17/86;;A61B17/8872;;A61F2002/448;;A61F2002/4629;;A61F2/44;;A61F2/4455;;A61F2002/30841;;A61F2002/30481;;A61F2002/30579;;A61F2002/30593;;A61F2002/30387;;A61F2/4637;;A61F2/4465;;A61F2002/30604;;A61F2002/30505;;A61F2/4603;;A61F2/442;;A61F2/4425;;A61F2220/0016,A61F2/44,,0,0,,,,ACTIVE
117,US,B1,US 8521719 B1,101-801-482-270-566,2013-08-27,2013,US 201213648956 A,2012-10-10,US 201213648956 A,2012-10-10,Searchable and size-constrained local log repositories for tracking visitors' access to web content,"A method and system for tracking visitors' access to web content using a searchable and size-constrained local log repository is disclosed. A repository indexer receives visitor logs from a remote source and indexes the logs to include a usage field indicating when or how frequently an associated visitor log was accessed from a local log repository by a report request manager. The local log repository stores the logs and is size constrained. A repository manager removes a subset of the logs in the local log repository based on parameters within the subset of the logs' usage field. The report request manager receives a request from a requestor for a report indicating visitors' access to a content object, searches for logs within the local log repository pertinent to the request, aggregates data across the logs responsive to the search, and generates a report presenting the aggregated data.",LIMELIGHT NETWORKS INC,ACHARYA SOAM;;CHO PAUL;;CORNWELL JONATHAN;;KWOK CHRIS,LIMELIGHT NETWORKS INC (2012-09-19),https://lens.org/101-801-482-270-566,Granted Patent,yes,10,4,3,3,0,G06Q30/0201;;G06F16/951;;G06F16/958;;G06F16/951;;G06F16/958;;G06Q30/0201,G06F17/30;;G06F7/02,707/711;;707/740;;707/741;;707/746,4,0,,,"SOLUTIONS4SME, ""Privacy Statement"", Retrieved on Nov. 17, 2012 from http://www.solutions4sme.com/privacy-statement.html, p. 1-3.;;Proquest, ""Privacy Policy"", Retrieved on Nov. 17, 2012 from http://www.proquest.co.uk/en-UK/site/privacy.shtml, p. 1-6.;;BIOAWARE SA NV, ""Biolomics Software & Services"", Retrieved on Nov. 17, 2012 from http://www.bio-aware.com/Documents/BioloMICSDoc.pdf, Nov. 2010, p. 1-12.;;SOCMA, ""SOCMA Website Privacy Policy"", Retrieved on Nov. 17, 2012 from http://www.socma.com/terms/?articleid?475, p. 1-2.",ACTIVE
118,NO,L,NO 772118 L,103-921-207-154-973,1978-02-03,1978,NO 772118 A,1977-06-16,US 71075576 A,1976-08-02,BEHOLDER.,,DART IND INC,BATEMAN ROBERT FRANCIS;;BEAUCHAMP ROGER PAUL;;CHO KAZUNOBU,,https://lens.org/103-921-207-154-973,Abstract,no,0,0,48,49,0,B65D25/04,B65D25/04;;B65D43/08;;B65D1/24,,0,0,,,,EXPIRED
119,FR,A1,FR 2522442 A1,126-905-710-163-396,1983-09-02,1983,FR 8302491 A,1983-02-16,US 35251882 A,1982-02-26,Indium gallium arsenide fet - includes thin film of silicon nitride and has high transconductance,"Field effect transistor contains semi-conducting regions of source, drain and canal all with the same type of conductivity but the source and drain regions more highly doped than the canal which is of In Ga As. The source and drain electrodes are in contact with the source and drain regions and the grid electrode is separated from the canal region by a thin layer of SiN. The canal region has a crystalline network coinciding with a semi-conducting layer of higher resistivity which in turn coincides with the network of a semi-insulating substrate of SiN of thickness 150 to 1000 microns. Useful in memories, signal treatment and microwave transmission. Transistors have a reduced grid leakage current and a high trans-conductance.",WESTERN ELECTRIC CO,CHO ALFRED YI;;O'CONNOR PAUL;;PEARSALL THOMAS PERINE,,https://lens.org/126-905-710-163-396,Patent Application,no,0,0,4,4,0,H01L29/78;;H01L29/201;;H01L29/518,H01L21/338;;H01L27/12;;H01L29/201;;H01L29/51;;H01L29/78;;H01L29/812,,3,2,010-405-722-273-763;;010-589-770-616-475,10.1109/edl.1981.25391;;10.1109/edl.1981.25345,"IBM TECHNICAL DISCLOSURE BULLETIN, vol. 24, no. 7A, décembre 1981, New York D.J. DIMARIA ""Stable GaAs MOSFET"", page 3232;;IEEE ELECTRON DEVICE LETTERS, vol. EDL-2, no. 7, juillet 1981, New York K.P. PANDE et al. ""Ge3N4-InP MIS structures"", pages 182-184;;IEEE ELECTRON DEVICE LETTERS, vol. EDL-2, no. 3, mars 1981, New York H.H. WIEDER et al. ""Inversion-mode insulated gate Ga0.47In0.53As field-effect transistors"", pages 73-74",EXPIRED
120,MX,A,MX 2016010173 A,135-718-202-673-19X,2016-10-13,2016,MX 2016010173 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE.,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,WARD MICHAEL;;PAUL ROBERT;;WILLIAM CHO;;MICHEL FRIESENHAHN,,https://lens.org/135-718-202-673-19X,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61P25/28;;A61K39/00;;C07K16/18,,0,0,,,,PENDING
121,CA,A,CA 1196111 A,187-867-953-531-710,1985-10-29,1985,CA 421665 A,1983-02-15,US 35251882 A,1982-02-26,INGAAS FIELD EFFECT TRANSISTOR,"InGaAs FIELD EFFECT TRANSISTOR InGaAs FETs using a silicon nitride layer, between the metal and the channel layer reduce the gate leakage current and yield desirable FET characteristics, particularly high transconductance.",WESTERN ELECTRIC CO,CHO ALFRED Y;;O'CONNOR PAUL;;PEARSALL THOMAS P,,https://lens.org/187-867-953-531-710,Granted Patent,no,0,0,4,4,0,H01L29/78;;H01L29/201;;H01L29/518,H01L21/338;;H01L27/12;;H01L29/201;;H01L29/51;;H01L29/78;;H01L29/812,356-149,0,0,,,,EXPIRED
122,TW,B,TW I705824 B,049-823-157-855-492,2020-10-01,2020,TW 104104180 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,Methods of treating alzheimer's disease,,GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/049-823-157-855-492,Granted Patent,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,,,1,1,086-932-421-807-452,24216217;;pmc3978826;;10.1186/alzrt220,"Doody et. al., “Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer’s Disease” Th e new england journal of medicine, 370;4, January 23, 2014 Niels D Prins and Philip Scheltens “Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future” Prins and Scheltens Alzheimer's Research & Therapy, 5:56, 2013",ACTIVE
123,US,A1,US 2015/0320568 A1,050-774-243-440-311,2015-11-12,2015,US 201514638746 A,2015-03-04,FR 1454102 A,2014-05-06,"VERTEBRAL IMPLANT, DEVICE FOR VERTEBRAL ATTACHMENT OF THE IMPLANT AND INSTRUMENTATION FOR IMPLANTATION THEREOF","This disclosure provides various vertebral implants, devices for attaching a vertebral implant and implantation instrumentations. In some embodiments, the implant includes a first body and a second body, each having a face with shapes and dimensions mating that of the other body and forming mutual fitting means, thus allowing assembly of the bodies by sliding along a sliding axis. In some embodiments, a locking means is retained in one of the bodies and an abutment portion may move from an open position allowing sliding for the assembling of the bodies to a closed position locking the bodies in assembly by the contact between the abutment portion, by contact with an abutment of the other body, the abutment being oriented angularly to the sliding axis and the abutment portion passing from the open position to the closed position elastically by flexure or torsion.",LDR MEDICAL,AMEIL MARC;;LEE DANIEL D;;CHO PAUL HENRY,,https://lens.org/050-774-243-440-311,Patent Application,yes,8,53,14,14,0,A61B17/86;;A61B17/8872;;A61F2/44;;A61F2/4455;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2002/448;;A61F2/44;;A61F2/4455;;A61F2/4465;;A61F2/4637;;A61F2002/30387;;A61F2002/30481;;A61F2002/30505;;A61F2002/30579;;A61F2002/30593;;A61F2002/30604;;A61F2002/30841;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2220/0016;;A61F2/4603;;A61F2/447;;A61F2/4611;;A61B17/86;;A61B17/8872;;A61F2002/448;;A61F2002/4629;;A61F2/44;;A61F2/4455;;A61F2002/30841;;A61F2002/30481;;A61F2002/30579;;A61F2002/30593;;A61F2002/30387;;A61F2/4637;;A61F2/4465;;A61F2002/30604;;A61F2002/30505;;A61F2/4603;;A61F2/442;;A61F2/4425;;A61F2220/0016,A61F2/44;;A61B17/86;;A61B17/88;;A61F2/46,,0,0,,,,ACTIVE
124,US,A,US 4028627 A,088-864-332-292-507,1977-06-07,1977,US 64500375 A,1975-12-29,US 64500375 A,1975-12-29,Sample and hold valley detector,An audio signal quality detector connected to receive an audio signal from the discriminator of a radio receiver and including an envelope detector connected to the output of the discriminator and supplying a signal indicative of the envelope of the audio to a resettable valley detector which stores a voltage indicative of the lowest valley applied thereto subsequent to a reset pulse and a sample and hold gate connected to the valley detector for sampling the voltage stored in the valley detector prior to periodic reset pulses applied to the valley detector. Circuitry is also included for inhibiting the operation of the sample and hold gate when there is no output from the valley detector.,MOTOROLA INC,CHO SUSUMU;;ERICKSON PAUL MILTON;;NULL MICHAEL WILLIAM,,https://lens.org/088-864-332-292-507,Granted Patent,yes,3,19,1,1,0,G01R19/04;;G11C27/024;;H04B1/10;;G11C27/024;;G01R19/04;;H04B1/10,G01R19/04;;G11C27/02;;H04B1/10,325/349,0,0,,,,EXPIRED
125,HK,A1,HK 1231401 A1,104-588-642-184-210,2017-12-22,2017,HK 17105176 A,2017-05-22,US 2015/0014758 W;;US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMERS DISEASE,,GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/104-588-642-184-210,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K/;;A61P/;;C07K/,,0,0,,,,PENDING
126,US,B2,US 8935285 B2,138-402-775-854-551,2015-01-13,2015,US 201313950983 A,2013-07-25,US 201313950983 A;;US 201213648956 A,2012-10-10,Searchable and size-constrained local log repositories for tracking visitors' access to web content,"A method and system for tracking visitors' access to web content using a searchable and size-constrained local log repository is disclosed. A repository indexer receives visitor logs from a remote source and indexes the logs to include a usage field indicating when or how frequently an associated visitor log was accessed from a local log repository by a report request manager. The local log repository stores the logs and is size constrained. A repository manager removes a subset of the logs in the local log repository based on parameters within the subset of the logs' usage field. The report request manager receives a request from a requestor for a report indicating visitors' access to a content object, searches for logs within the local log repository pertinent to the request, aggregates data across the logs responsive to the search, and generates a report presenting the aggregated data.",LIMELIGHT NETWORKS INC,ACHARYA SOAM;;CHO PAUL;;CORNWELL JONATHAN;;KWOK CHRIS,LIMELIGHT NETWORKS INC (2012-09-19),https://lens.org/138-402-775-854-551,Granted Patent,yes,7,1,3,3,0,G06Q30/0201;;G06F16/951;;G06F16/958;;G06F16/951;;G06F16/958;;G06Q30/0201,G06F7/02;;G06F17/30;;G06Q30/02,707/776;;707/758;;707/746,0,0,,,,ACTIVE
127,FI,A,FI 772162 A,166-709-279-738-369,1978-02-03,1978,FI 772162 A,1977-07-11,US 71075576 A,1976-08-02,FI 772162 A,,DART IND INC,BATEMAN ROBERT FRANCIS;;BEAUCHAMP ROGER PAUL;;CHO KAZUNOBU,,https://lens.org/166-709-279-738-369,Patent Application,no,0,0,48,49,0,B65D25/04,B65D25/04;;B65D1/24;;B65D43/08,,0,0,,,,EXPIRED
128,FI,B,FI 66737 B,194-307-023-606-673,1984-08-31,1984,FI 772162 A,1977-07-11,US 71075576 A,1976-08-02,MED LOCK OCH MELLANVAEGG FOERSEDD ASK,,DART IND INC,BATEMAN ROBERT FRANCIS;;BEAUCHAMP ROGER PAUL;;CHO KAZUNOBY,,https://lens.org/194-307-023-606-673,Patent Application,no,0,0,48,49,0,B65D25/04,B65D25/04;;B65D1/24;;B65D43/08,,0,0,,,,EXPIRED
129,NO,B,NO 143964 B,198-528-878-025-924,1981-02-09,1981,NO 772118 A,1977-06-16,US 71075576 A,1976-08-02,LAGRINGSBEHOLDER MED TETTLUKKENDE LOKK.,,DART IND INC,BATEMAN ROBERT FRANCIS;;BEAUCHAMP ROGER PAUL;;CHO KAZUNOBU,,https://lens.org/198-528-878-025-924,Unknown,no,0,0,48,49,0,B65D25/04,B65D25/04;;B65D43/08;;B65D1/24,,0,0,,,,EXPIRED
130,KR,A,KR 20230056800 A,021-127-057-236-875,2023-04-27,2023,KR 20237013210 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;KR 20217030556 A;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"본원에서는 ApoE4 양성 환자 및 경증 AD를 앓는 환자를 포함하는, 약하거나 중등도의 AD를 앓는 환자에서 알츠하이머 질환(AD)을 치료하는 방법이 제공된다.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/021-127-057-236-875,Patent Application,no,0,0,36,75,18,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,C07K16/18;;A61K39/00;;A61P25/28,,0,0,,,,DISCONTINUED
131,US,S,US D0679278 S,025-735-704-789-615,2013-04-02,2013,US 201129405278 F,2011-10-31,US 201129405278 F,2011-10-31,Case for tablet computer,,CHO SUN HEE;;TANNER CHRISTOPHER PAUL;;PICHETTE TRACI;;REISCHLING PRESS INC,CHO SUN HEE;;TANNER CHRISTOPHER PAUL;;PICHETTE TRACI,REISCHLING PRESS INC (2011-11-03),https://lens.org/025-735-704-789-615,Design Right,no,0,11,1,1,0,,,1402;;D14/440,0,0,,,,ACTIVE
132,US,B2,US 10604070 B2,092-163-763-137-78X,2020-03-31,2020,US 201715646862 A,2017-07-11,KR 20160148670 A,2016-11-09,Method and apparatus for informing pedestrian and occupant of vehicle of each other's approach,"Disclosed is a method and apparatus of detecting an object approaching a vehicle, the method includes a user from the image, extracting feature points associated with the device or a portion of the user's body from the image of the user, detecting the object using a device based on the feature point, and issuing an alert of the approaching object.",SAMSUNG ELECTRONICS CO LTD,SEO YOUNGWAN;;CHO BAEK HWAN;;JEON PAUL BAROM,SAMSUNG ELECTRONICS CO. LTD (2017-02-23),https://lens.org/092-163-763-137-78X,Granted Patent,yes,23,0,3,3,0,B60Q1/525;;B60Q5/006;;B60Q9/008;;B60R1/00;;B60R2300/307;;B60W50/14;;B60W40/02;;B60W50/16;;B60R21/34;;B60Y2400/90;;B60Y2400/902;;B60Q1/525;;B60Q5/006;;B60Q9/008;;B60R2300/307,B60Q1/00;;B60Q1/52;;B60Q5/00;;B60Q9/00;;B60R1/00,,0,0,,,,ACTIVE
133,US,A1,US 2018/0126902 A1,175-147-747-166-694,2018-05-10,2018,US 201715646862 A,2017-07-11,KR 20160148670 A,2016-11-09,METHOD AND APPARTUS FOR INFORMING PEDETRIAN AND OCCUPANT OF VEHICLE OF EACH OTHER'S APPROACH,"Disclosed is a method and apparatus of detecting an object approaching a vehicle, the method includes a user from the image, extracting feature points associated with the device or a portion of the user's body from the image of the user, detecting the object using a device based on the feature point, and issuing an alert of the approaching object.",SAMSUNG ELECTRONICS CO LTD,SEO YOUNGWAN;;CHO BAEK HWAN;;JEON PAUL BAROM,SAMSUNG ELECTRONICS CO. LTD (2017-02-23),https://lens.org/175-147-747-166-694,Patent Application,yes,12,8,3,3,0,B60Q1/525;;B60Q5/006;;B60Q9/008;;B60R1/00;;B60R2300/307;;B60W50/14;;B60W40/02;;B60W50/16;;B60R21/34;;B60Y2400/90;;B60Y2400/902;;B60Q1/525;;B60Q5/006;;B60Q9/008;;B60R2300/307,B60Q9/00;;B60Q5/00;;B60R1/00,,0,0,,,,ACTIVE
134,CN,A,CN 106456224 A,002-067-131-725-028,2017-02-22,2017,CN 201580030812 A,2015-05-06,FR 1454102 A;;EP 2015060001 W;;US 201514638746 A,2014-05-06,"Vertebral implant, device for vertebral attachment of the implant and instrumentation for implantation thereof","The present invention relates to a vertebral implant, in particular for corpectomy, to a device for attaching a vertebral implant and to implantation instrumentation, the implant including at least one first body (2) and at least one second body (3) each having at least one face having shapes and dimensions mating those of at least one face of another body (3, 2) and forming mutual fitting means, in order to allow assembling of said bodies (2, 3) by sliding along a sliding axis and, on the other hand, at least one locking means (4) retained in at least one of the bodies (2, 3) and at least one abutment portion of which is laid out for passing from a so-called open position, allowing sliding for the assembling of said bodies (2, 3), to a so-called closed position, locking said bodies (2, 3) assembled together by the contact between at least said abutment portion and at least one abutment (42, 43) of at least one of said bodies (2, 3), said abutment (42, 43) being oriented not parallel to the sliding axis and said abutment portion passing from the open position to the closed position elastically by flexure or torsion.",LDR MEDICAL,AMEIL MARC;;LEE DANIEL D;;CHO PAUL HENRY,,https://lens.org/002-067-131-725-028,Patent Application,no,4,0,14,14,0,A61B17/86;;A61B17/8872;;A61F2/44;;A61F2/4455;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2002/448;;A61F2/44;;A61F2/4455;;A61F2/4465;;A61F2/4637;;A61F2002/30387;;A61F2002/30481;;A61F2002/30505;;A61F2002/30579;;A61F2002/30593;;A61F2002/30604;;A61F2002/30841;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2220/0016;;A61F2/4603;;A61F2/447;;A61F2/4611;;A61B17/86;;A61B17/8872;;A61F2002/448;;A61F2002/4629;;A61F2/44;;A61F2/4455;;A61F2002/30841;;A61F2002/30481;;A61F2002/30579;;A61F2002/30593;;A61F2002/30387;;A61F2/4637;;A61F2/4465;;A61F2002/30604;;A61F2002/30505;;A61F2/4603;;A61F2/442;;A61F2/4425;;A61F2220/0016,A61B17/86;;A61B17/88;;A61F2/44;;A61F2/46,,0,0,,,,DISCONTINUED
135,EP,A1,EP 3718563 A1,096-910-687-905-821,2020-10-07,2020,EP 19188687 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;EP 15710295 A;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients suffering from mild AD are provided.",HOFFMANN LA ROCHE,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/096-910-687-905-821,Patent Application,yes,89,0,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,114,82,086-932-421-807-452;;131-216-810-326-268;;015-169-910-449-13X;;008-670-508-863-063;;029-200-906-160-107;;043-348-573-940-487;;069-494-908-751-119;;015-467-620-003-813;;122-558-490-060-539;;057-789-082-803-869;;142-314-510-790-905;;001-553-770-517-492;;077-495-150-106-187;;162-646-650-680-173;;062-950-628-293-493;;030-607-398-087-475;;006-574-964-805-278;;065-608-090-342-50X;;020-855-322-534-259;;011-962-497-035-168;;048-564-471-521-204;;049-134-753-209-354;;040-428-679-610-399;;089-899-040-309-502;;002-490-451-363-036;;034-331-211-704-877;;076-294-679-339-389;;001-779-867-387-972;;044-522-255-085-902;;107-783-742-795-839;;022-133-574-143-973;;051-208-529-712-079;;030-323-674-660-051;;009-746-604-420-355;;009-483-512-107-343;;015-395-754-996-662;;106-032-800-597-23X;;003-570-249-164-056;;010-953-281-569-514;;017-695-622-077-055;;170-311-024-328-514;;006-895-260-696-111;;107-330-806-519-859;;013-584-945-188-940;;005-119-615-003-591;;012-268-510-926-843;;039-981-636-470-013;;054-876-950-584-376;;072-378-691-723-546;;031-063-853-127-197;;005-112-559-456-657;;104-212-297-137-759;;035-232-534-898-963;;010-916-105-450-247;;016-251-721-517-200;;026-048-786-530-595;;085-727-974-637-837;;018-694-084-068-187;;037-445-639-149-821;;009-275-403-380-31X;;156-501-805-490-709;;116-831-294-654-564;;022-725-321-473-914;;008-274-774-541-556;;070-280-057-407-994;;012-900-923-946-056;;020-126-213-879-311;;054-717-629-774-351;;068-264-897-850-380;;060-301-220-665-473;;035-796-690-562-525;;008-587-496-850-953;;065-430-968-783-392;;021-430-782-622-770;;051-940-176-386-905;;048-536-112-681-339;;049-637-391-464-722;;018-622-691-667-330;;018-622-691-667-330;;019-349-924-670-963;;022-988-712-445-94X;;099-150-317-608-133,24216217;;pmc3978826;;10.1186/alzrt220;;pmc6622286;;22787053;;10.1523/jneurosci.4742-11.2012;;24450890;;10.1056/nejmoa1312889;;10.1016/j.exger.2014.05.002;;24835192;;10.1001/archneur.60.8.1119;;12925369;;19595937;;10.1016/j.jalz.2007.04.381;;15229308;;10.1056/nejmra040223;;10.1212/wnl.43.8.1467;;8350998;;pmc1861657;;8669492;;15459432;;10.1161/01.str.0000143452.85382.d1;;16909007;;10.1159/000090366;;pmc4063417;;10.1016/s1474-4422(12)70015-7;;22305802;;10.1016/0958-1669(94)90053-1;;7765176;;10.1016/0959-440x(92)90091-k;;6375662;;10.1016/s0006-291x(84)80190-4;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1038/321522a0;;3713831;;8654676;;10.1042/bst0231035;;1748994;;10.1016/0022-2836(91)90498-u;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;10.4049/jimmunol.133.6.3001;;6092464;;10.1016/0022-2836(87)90412-8;;3681981;;10.1073/pnas.90.6.2551;;8460171;;pmc46126;;8459850;;10.1038/362255a0;;17161664;;10.1016/j.jchromb.2006.11.018;;10.1038/352624a0;;1907718;;pmc3693547;;21784348;;10.1016/j.jalz.2011.05.2351;;10.1006/jmbi.1999.3192;;10543973;;9377574;;12514726;;10.1038/nm0103-129;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;17981654;;10.2741/2786;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;9099717;;10.1074/jbc.272.16.10678;;10.1074/jbc.271.37.22611;;8798431;;18606226;;10.1016/j.coi.2008.06.004;;10.1038/nbt1135;;16151405;;3500259;;pmc2189658;;10.1084/jem.166.5.1351;;16505368;;10.1073/pnas.0511285103;;pmc1383494;;15944943;;10.14670/hh-20.927;;10.1358/mf.2005.27.3.890876;;15834451;;10.1182/blood-2002-06-1761;;12393541;;10.1016/0022-2836(92)90639-2;;1507232;;15037082;;10.3410/f.1020100.229441;;10.1016/j.jmb.2004.01.007;;15306681;;10.1073/pnas.0401786101;;pmc515084;;14736422;;10.1016/j.jim.2003.11.001;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;10.1126/science.3925553;;3925553;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.152.11.5368;;8189055;;10.1038/nbt0792-779;;1368267;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;10.1016/0378-1119(95)00821-7;;8647439;;7897213;;10.4049/jimmunol.154.7.3310;;10.1126/science.2471267;;2471267;;10.1016/0003-9861(86)90031-7;;2428310;;16609957;;10.1002/bit.20880;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;10.1073/pnas.83.18.7059;;pmc386652;;3462743;;pmc397290;;3856277;;10.1073/pnas.82.5.1499;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;9107305;;10.1016/s0022-1759(97)00002-1;;14551143;;10.1182/blood-2003-06-2031;;17077181;;10.1093/intimm/dxl110;;10.4049/jimmunol.164.8.4178;;10754313;;10.4049/jimmunol.117.2.587;;950463;;16087878;;pmc1187972;;10.1073/pnas.0502680102;;10.1038/nbt1028;;15529166;;886304;;10.1099/0022-1317-36-1-59;;10.1095/biolreprod23.1.243;;6774781;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;10.1212/wnl.34.7.939;;6610841;;10.1056/nejmoa1304839;;pmc4159618;;24450891;;10.1176/ajp.141.11.1356;;6496779;;10.1176/ajp.141.11.1356;;6496779;;14716731;;10.1002/sim.1718;;1202204;;10.1016/0022-3956(75)90026-6;;0001202204;;10.1093/geront/9.3_part_1.179;;5349366,"NIELS D PRINS ET AL: ""Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future"", ALZHEIMERS RES THER, BIOMED CENTRAL LTD, LONDON, UK, vol. 5, no. 6, 11 November 2013 (2013-11-11), pages 56, XP021193607, ISSN: 1758-9193, DOI: 10.1186/ALZRT220;;O. ADOLFSSON ET AL: ""An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A"", JOURNAL OF NEUROSCIENCE, vol. 32, no. 28, 11 July 2012 (2012-07-11), pages 9677 - 9689, XP055097358, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.4742-11.2012;;CHARLOTTE JAGO: ""Alzheimer's Disease: One Year Later"", 3 February 2014 (2014-02-03), XP055183816, Retrieved from the Internet <URL:http://lsconnect.thomsonreuters.com/alzheimers-disease-year-later/> [retrieved on 20150417];;""Crenezumab Phase II cognition data in Alzheimer's disease presented"", 16 July 2014 (2014-07-16), XP055183813, Retrieved from the Internet <URL:http://www.acimmune.com/content/img/pages/ACImmune_crenezumab_phase2_ENGLISH_20140716_final.pdf> [retrieved on 20150417];;RACHELLE S. DOODY ET AL: ""Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease"", NEW ENGLAND JOURNAL OF MEDICINE, vol. 370, no. 4, 23 January 2014 (2014-01-23), pages 311 - 321, XP055183832, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1312889;;JONATHAN CEDERNAES ET AL: ""Efficacy of antibody-based therapies to treat Alzheimer's disease: Just a matter of timing?"", EXPERIMENTAL GERONTOLOGY, vol. 57, 1 September 2014 (2014-09-01), pages 104 - 106, XP055187152, ISSN: 0531-5565, DOI: 10.1016/j.exger.2014.05.002;;HEBERT ET AL., ARCH. NEUROL., vol. 60, 2003, pages 1119 - 22;;BROOKMEYER ET AL., ALZHEIMERS DEMENT, vol. 3, 2007, pages 186 - 91;;CUMMINGS, N. ENGL. J. MED., vol. 351, 2004, pages 56 - 67;;SAUNDERS ET AL., NEUROLOGY, vol. 43, 1993, pages 1467 - 72;;PREKUMAR ET AL., AM. J. PATHOL., vol. 148, 1996, pages 2083 - 95;;HAASSSELKOE, NATURE, vol. 8, 2007, pages 656 - 67;;DEANE ET AL., STROKE, vol. 35, no. I, 2004, pages 2628 - 31;;MORGAN, NEURODEGENER. DIS., vol. 2, 2005, pages 261 - 6;;MILES ET AL.: ""Scientific Reports"", vol. 3, 6 August 2012, JOHNSTON & JOHNSON PRESS, article ""Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-To-Moderate Alzheimer's Disease"", pages: 1 - 4;;MILES ET AL., SCIENTIFIC REPORTS, vol. 3, 2013, pages 1 - 4;;ELI LILLYCOMPANY PRESS RELEASE, ELI LILLY AND COMPANY AANOUNCES TOP-LINE RESULTS ON SOLANEZUMAB PHASE 3 CLINICAL TRIALS IN PATIENTS WITH ALZHEIMER'S DISEASE, 24 August 2012 (2012-08-24);;SPERLING ET AL., THE LANCET, vol. 11, 2012, pages 241 - 249;;HURLEGROSS, CURR. OP. BIOTECH., vol. 5, 1994, pages 428 - 433;;PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596;;GLENNERWONG, BIOCHEM BIOPHYS RES. COMM., vol. 129, 1984, pages 885 - 890;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 322, 1988, pages 738 - 329;;VASWANIHAMILTON, ANN. ALLERGY, ASTHMA & IMMUNOL., vol. 1, 1998, pages 105 - 115;;HARRIS, BIOCHEM. SOC. TRANSACTIONS, vol. 23, 1995, pages 1035 - 1038;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597;;HOOGENBOOM ET AL., NUCL. ACIDS RES., vol. 19, 1991, pages 4133 - 4137;;KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001;;CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;BOERNER ET AL., J. IMMUNOL., vol. 147, 1991, pages 60;;JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI USA, vol. 90, 1993, pages 2551;;JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255;;BRUGGERMANN ET AL., YEAR IN IMMUNOL., vol. 7, 1993, pages 33;;FLATMAN ET AL., J. CHROMATOGR. B, vol. 848, 2007, pages 79 - 87;;KINDT ET AL.: ""Kuby Immunology"", 2007, FREEMAN AND CO., pages: 91;;PORTOLANO ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623 - 887;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;PADLAN, MOL. IMMUNOL., vol. 28, 1991, pages 3242 - 498;;PREKUMAR ET AL., AM. J PATHOL., vol. 148, 1996, pages 2083 - 95;;SPERLING ET AL., ALZHEIMER'S & DEMENTIA, vol. 7, 2011, pages 367 - 385;;CHALEIA JAGOMES J, EXPERT REV. NEUROTHER., vol. 4, 2004, pages 267;;GREENBERG ET AL., LANCET NEUROL, vol. 8, 2009, pages 165 - 74;;KUMARA-N, AM J NEURORADIOL, vol. 31, 2010, pages 5;;CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881;;PRESTA ET AL., CANCER RES., vol. 57, 1997, pages 4593 - 4599;;HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134;;WINTER ET AL., ANN. REV. IMMUNOL., vol. 113, 1994, pages 433 - 455;;HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;ALMAGROFRANSSON, FRONT. BIOSCI., vol. 13, 2008, pages 1619 - 1633;;QUEEN ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033;;DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 61 - 68;;KLIMKA ET AL., BR. J. CANCER, vol. 83, 2000, pages 252 - 260;;CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285;;BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684;;ROSOK ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 22611 - 22618;;VAN DIJKVAN DE WINKEL, CURR. OPIN. PHARMACOL., vol. 5, 2001, pages 368 - 74;;LONBERG, CURR. OPIN. IMMUNOL., vol. 20, 2008, pages 450 - 459;;LONBERG, NAT. BIOTECH., vol. 23, 2005, pages 1117 - 1125;;BRUGGEMANN, M. ET AL., J. EXP. MED., vol. 166, 1987, pages 1351 - 1361;;LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562;;NIXIANDAI, MIANYIXUE, vol. 26, no. 4, 2006, pages 265 - 268;;VOLLMERSBRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, vol. 20, no. 3, 2005, pages 927 - 937;;VOLLMERSBRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 27, no. 3, 2005, pages 185 - 91;;CRAGG, M.S. ET AL., BLOOD, vol. 101, 2003, pages 1045 - 1052;;MCCAFFERTY ET AL., NATURE, vol. 305, 1983, pages 537 - 554;;HOOGENBOOMWINTER, J. MOL. BIOL., vol. 226, 1992, pages 889 - 896;;OKAZAKI ET AL., J. MOL. BIOL., vol. 336, no. 5, 2004, pages 1239 - 1249;;FELLOUSE, PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 2004, pages 12467 - 12472;;LEE ET AL., J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553;;GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368;;MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783;;BARBAS ET AL., PROC NAT. ACAD. SCI, vol. 91, 1994, pages 3809 - 3813;;SCHIER ET AL., GENE, vol. 169, 1996, pages 147 - 155;;JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 2004;;CHOWDHURY, METHODS MOL. BIOL., vol. 207, 2008, pages 179 - 196;;CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;WRIGHT ET AL., TIBTECH, vol. 15, 1997, pages 26 - 32;;YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., vol. 87, 2004, pages 614;;RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 249, 1986, pages 533 - 545;;KANDA, Y. ET AL., BIOTECHNOL. BIOENG., vol. 94, no. 4, 2006, pages 680 - 688;;RAVETCHKINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457 - 492;;HELLSTROM, I. ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 83, 1986, pages 7059 - 7063;;HELLSTROM, I ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 82, 1985, pages 1499 - 1502;;CLYNES ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 95, 1998, pages 652 - 656;;GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, vol. 202, 1996, pages 163;;CRAGG, M.S.M.J. GLENNIE, BLOOD, vol. 103, 2004, pages 2738 - 2743;;PETKOVA, S.B. ET AL., INT'L. IMMUNOL., vol. 18, no. 12, 2006, pages 1759 - 1769;;SHIELDS ET AL., J. BIOL. CHEM., vol. 9, no. 2, 2001, pages 6591 - 6604;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184;;GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587;;KAM ET AL., PROC. NATL. ACAD. SCI., vol. 102, 2005, pages 11600 - 11605;;YAZAKIWU: ""Methods in Molecular Biology"", vol. 248, 1996, HUMANA PRESS, article ""Epitope Mapping Protocols"", pages: 255 - 268;;GERNGROSS, NAT. BIOTECH., vol. 22, 2004, pages 1409 - 1414;;LI ET AL., NAT. BIOTECH., vol. 24, 2006, pages 210 - 215;;GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59;;MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251;;MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68;;URLAUB ET AL.: ""77"", PROC. NATL. ACAD. SCI. USA, 1980, pages 4216;;HARLOWLANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY;;""Remington's Pharmaceutical Sciences"", 1980;;MCKHANN ET AL., NEUROLOGY, vol. 34, 1984, pages 939 - 44;;SALLOWAY ET AL., N. ENGL. J. MED., vol. 370, 2014, pages 322 - 333;;ROSEN ET AL., AMER. J. PSYCH., vol. 141, 1984, pages 1356 - 1364;;MOHS ET AL., ALZHEIMER'S DISEASE ASSOC. DISORDERS, vol. 11, no. 2, 1997, pages S13 - S21;;ROSEN ET AL., AM J PSYCHIATR, vol. 141, 1984, pages 1356 - 64;;MOHS ET AL., ALZHEIMER DIS ASSOC DISORD, vol. 11, no. S2, 1997, pages S13 - S21;;MANI, STAT MED, vol. 23, 2004, pages 305 - 14;;FOLSTEIN ET AL., J. PSYCHIATR. RES., vol. 12, 1975, pages 189 - 98;;LAWTON, M.P.BRODY, E.M., GERONTOLOGIST, vol. 9, 1969, pages 179 - 186",DISCONTINUED
136,EP,B1,EP 3102231 B1,039-281-328-146-775,2019-09-11,2019,EP 15710295 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,,HOFFMANN LA ROCHE,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/039-281-328-146-775,Granted Patent,yes,2,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,5,0,,,"RACHELLE S. DOODY ET AL: ""Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease"", NEW ENGLAND JOURNAL OF MEDICINE, vol. 370, no. 4, 23 January 2014 (2014-01-23), pages 311-321, XP055183832, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1312889;;NIELS D PRINS ET AL: ""Treating Alzheimer?s disease with monoclonal antibodies: current status and outlook for the future"", ALZHEIMERS RES THER, BIOMED CENTRAL LTD, LONDON, UK, vol. 5, no. 6, 11 November 2013 (2013-11-11), page 56, XP021193607, ISSN: 1758-9193, DOI: 10.1186/ALZRT220;;O. ADOLFSSON ET AL: ""An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A"", JOURNAL OF NEUROSCIENCE, vol. 32, no. 28, 11 July 2012 (2012-07-11) , pages 9677-9689, XP055097358, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.4742-11.2012;;Charlotte Jago: ""Alzheimer's Disease: One Year Later"", , 3 February 2014 (2014-02-03), XP055183816, Retrieved from the Internet: URL:http://lsconnect.thomsonreuters.com/al zheimers-disease-year-later/ [retrieved on 2015-04-17];;""Crenezumab Phase II cognition data in Alzheimer's disease presented"", , 16 July 2014 (2014-07-16), XP055183813, Retrieved from the Internet: URL:http://www.acimmune.com/content/img/pa ges/ACImmune_crenezumab_phase2_ENGLISH_201 40716_final.pdf [retrieved on 2015-04-17]",ACTIVE
137,EP,B1,EP 3367303 B1,046-033-521-551-132,2022-09-21,2022,EP 18158136 A,2018-02-22,KR 20170024824 A,2017-02-24,AUTONOMOUS DRIVING IMAGE PROCESSING METHOD AND APPARATUS THEREOF,,SAMSUNG ELECTRONICS CO LTD,SEO YOUNGWAN;;JEON PAUL BAROM;;CHO BAEK HWAN,,https://lens.org/046-033-521-551-132,Granted Patent,yes,1,0,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,G06T5/00;;G06V10/10;;G06V10/141;;G06V10/24;;G06V10/25;;G06V20/56;;H04N5/235,,0,0,,,,ACTIVE
138,EP,A1,EP 3139867 A1,082-481-145-253-864,2017-03-15,2017,EP 15724950 A,2015-05-06,FR 1454102 A;;US 201514638746 A;;EP 2015060001 W,2014-05-06,"VERTEBRAL IMPLANT, DEVICE FOR VERTEBRAL ATTACHMENT OF THE IMPLANT AND INSTRUMENTATION FOR IMPLANTATION THEREOF",,LDR MEDICAL,AMEIL MARC;;LEE DANIEL D;;CHO PAUL HENRY,,https://lens.org/082-481-145-253-864,Patent Application,yes,0,2,14,14,0,A61B17/86;;A61B17/8872;;A61F2/44;;A61F2/4455;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2002/448;;A61F2/44;;A61F2/4455;;A61F2/4465;;A61F2/4637;;A61F2002/30387;;A61F2002/30481;;A61F2002/30505;;A61F2002/30579;;A61F2002/30593;;A61F2002/30604;;A61F2002/30841;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2220/0016;;A61F2/4603;;A61F2/447;;A61F2/4611;;A61B17/86;;A61B17/8872;;A61F2002/448;;A61F2002/4629;;A61F2/44;;A61F2/4455;;A61F2002/30841;;A61F2002/30481;;A61F2002/30579;;A61F2002/30593;;A61F2002/30387;;A61F2/4637;;A61F2/4465;;A61F2002/30604;;A61F2002/30505;;A61F2/4603;;A61F2/442;;A61F2/4425;;A61F2220/0016,A61F2/44,,0,0,,,,ACTIVE
139,WO,A1,WO 2020/164807 A1,117-610-166-033-621,2020-08-20,2020,EP 2020025061 W,2020-02-12,US 201962804808 P;;US 202016787292 A,2019-02-13,LED LIGHTING SIMULATION SYSTEM,"A lighting device simulation system simulates operation of luminaires in a facility according to scene by using location and capability data for the luminaires and mapping it to structural feature data for the facility. In response to receiving a selection of a scene, the system will play the selected scene on a display. The display may be a two-dimensional representation of the facility, or it may be a three-dimensional representation on an augmented reality or mixed reality device.",SIGNIFY HOLDING BV,BOUDREAU PAUL;;JOSHI PARTH;;GROSSE DEBORA;;CHO NAM,,https://lens.org/117-610-166-033-621,Patent Application,yes,6,0,4,4,0,G06T19/006;;H05B47/00;;H05B47/155;;H05B47/175;;G06T11/00;;G06F30/20;;G06F30/13;;H05B47/115;;H05B47/17;;G06T15/50;;G06T2210/04;;Y02B20/40;;G06F30/13;;G06T19/006;;G06F30/20;;G06T2210/04;;G06T11/00;;G06T17/00;;H05B47/11;;G06T15/506,H05B47/155;;G06T15/50;;G06T19/00;;H05B47/00,,0,0,,,,PENDING
140,US,A1,US 2020/0399352 A1,158-954-528-925-712,2020-12-24,2020,US 202016782654 A,2020-02-05,US 202016782654 A;;US 201514616261 A;;US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/158-954-528-925-712,Patent Application,yes,0,0,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,C07K16/18;;A61K31/56,,0,0,,,,DISCONTINUED
141,FR,B1,FR 3020756 B1,164-114-642-999-243,2022-03-11,2022,FR 1454102 A,2014-05-06,FR 1454102 A,2014-05-06,"IMPLANT VERTEBRAL, DISPOSITIF DE FIXATION VERTEBRALE D'IMPLANT ET INSTRUMENTATION D'IMPLANTATION","La présente invention concerne un implant vertébral, en particulier de corporectomie, un dispositif de fixation d'implant vertébral et une instrumentation d'implantation, l'implant comportant au moins un premier corps (2) et au moins un second corps (3) possédant, chacun, au moins une face ayant des formes et dimensions complémentaires à celles d'au moins une face d'un autre corps (3, 2) et formant des moyens d'emboitement réciproque, pour permettre un assemblage desdits corps (2, 3) par coulissement selon un axe de coulissement et, d'autre part, au moins un moyen de verrouillage (4) retenu dans au moins un des corps (2, 3) et dont au moins une portion de butée est agencée pour passer d'une position, dite ouverte, autorisant le coulissement pour l'assemblage desdits corps (2, 3) à une position, dite fermée, verrouillant lesdits corps (2, 3) assemblés ensemble par le contact entre au moins ladite portion de butée et au moins une butée (42, 43) d'au moins un desdits corps (2, 3), ladite butée (42, 43) étant orientée non parallèlement à l'axe de coulissement et ladite portion de butée passant de la position ouverte à la position fermée, de manière élastique par flexion ou par torsion",LDR MEDICAL,AMEIL MARC;;LEE DANIEL D;;CHO PAUL HENRY,,https://lens.org/164-114-642-999-243,Granted Patent,no,0,0,14,14,0,A61B17/86;;A61B17/8872;;A61F2/44;;A61F2/4455;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2002/448;;A61F2/44;;A61F2/4455;;A61F2/4465;;A61F2/4637;;A61F2002/30387;;A61F2002/30481;;A61F2002/30505;;A61F2002/30579;;A61F2002/30593;;A61F2002/30604;;A61F2002/30841;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2220/0016;;A61F2/4603;;A61F2/447;;A61F2/4611;;A61B17/86;;A61B17/8872;;A61F2002/448;;A61F2002/4629;;A61F2/44;;A61F2/4455;;A61F2002/30841;;A61F2002/30481;;A61F2002/30579;;A61F2002/30593;;A61F2002/30387;;A61F2/4637;;A61F2/4465;;A61F2002/30604;;A61F2002/30505;;A61F2/4603;;A61F2/442;;A61F2/4425;;A61F2220/0016,A61F2/44,,0,0,,,,ACTIVE
142,CH,A5,CH 609299 A5,001-241-693-187-668,1979-02-28,1979,CH 759777 A,1977-06-21,US 71075576 A,1976-08-02,Storage container with sealed (fluid/tight) lid,"The container (11) with lid (13) has a bottom (15), side walls (17) and end walls (18). The side walls (17) have protrusions (24) onto which the ends (22, 23) of a separator element (12) can engage. The container can receive an auxiliary container (14) and its lid (14a). The storage container is applied in the provision of prepared meals. <IMAGE>",DART IND INC,BATEMAN ROBERT FRANCIS;;BEAUCHAMP ROGER PAUL;;CHO KAZUNOBU,"DART INDUSTRIES, INC. (1985-07-31)",https://lens.org/001-241-693-187-668,Granted Patent,no,0,0,48,49,0,B65D25/04,B65D25/04;;B65D43/08;;B65D1/24,,0,0,,,,EXPIRED
143,US,B2,US 8396270 B2,037-461-094-177-506,2013-03-12,2013,US 93206011 A,2011-02-16,US 93206011 A;;US 33831110 P,2010-02-16,Method to estimate 3D abdominal and thoracic tumor position to submillimeter accuracy using sequential x-ray imaging and respiratory monitoring,"A method of estimating target motion for image guided radiotherapy (IGRT) systems is provided. The method includes acquiring by a kV imaging system sequential images of a target motion, computing by the kV imaging system from the sequential images an image-based estimation of the target motion expressed in a patient coordinate system, transforming by the kV imaging system the image-based estimation in the patient coordinate system to an estimate in a projection coordinate system, reformulating by the kV imaging system the projection coordinate system in a converging iterative form to force a convergence of the projection coordinate system to output a resolved estimation of the target motion, and displaying by the kV imaging system the resolved estimation of the target motion.",KEALL PAUL J;;POULSEN PER RUGAARD;;CHO BYUNGCHUL;;UNIV LELAND STANFORD JUNIOR,KEALL PAUL J;;POULSEN PER RUGAARD;;CHO BYUNGCHUL,BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY THE (2011-04-23),https://lens.org/037-461-094-177-506,Granted Patent,yes,3,2,2,2,0,A61B6/486;;A61B6/486;;A61B6/022;;A61B6/022;;A61B6/5217;;A61B6/5217;;A61B6/527;;A61B6/527;;A61N5/1049;;A61N5/1049;;A61N2005/1061;;A61N2005/1061;;G06T7/285;;G06T7/285;;G06T2207/10021;;G06T2207/10021;;G06T2207/10116;;G06T2207/10116;;G06T2207/30004;;G06T2207/30004;;G16H50/30,G06K9/00,382/128,0,0,,,,INACTIVE
144,BR,A2,BR 112016018170 A2,104-256-812-808-516,2018-02-20,2018,BR 112016018170 A,2015-02-06,US 2015/0014758 W;;US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,métodos para tratar doença de alzheimer,"métodos para tratar doença de alzheimer (ad) em pacientes sofrendo de ad suave a moderada, incluindo pacientes apoe4 positivos e pacientes sofrendo de ad suave são fornecidos.",GENENTECH INC,MICHAEL WARD;;MICHEL FRIESENHAHN;;ROBERT PAUL;;WILLIAM CHO,,https://lens.org/104-256-812-808-516,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,PENDING
145,DK,C,DK 158196 C,117-415-913-779-969,1990-09-03,1990,DK 343677 A,1977-08-01,US 71075576 A,1976-08-02,BEHOLDER NAVNLIG TIL MADVARER,,DART IND INC,BATEMAN ROBERT FRANCIS;;BEAUCHAMP ROGER PAUL;;CHO KAZUNOBU,,https://lens.org/117-415-913-779-969,Granted Patent,no,0,0,48,49,0,B65D25/04,B65D25/04;;B65D43/08;;B65D1/24,,0,0,,,,EXPIRED
146,WO,A3,WO 2009/007838 A3,148-043-452-048-812,2009-07-16,2009,IB 2008001815 W,2008-07-11,FR 0705066 A,2007-07-12,TRANSVERSE SPINAL LINKING DEVICE AND SYSTEM,"A transverse spinal linking device (1 ) links at least one spinal osteosynthesis bar (2) to a transverse bar (3). The device (1 ) includes a first part (11 ) that has a vertical axis and a first jaw (111 ), a second part (12) that has a second jaw (121 ), and a clamping means (13). The first part (11 ) includes a sliding surface (114), which is inclined in relation to the vertical axis, and which mates with at least one sliding surface (124) of the second part (12). The sliding surfaces (114, 124) are configured so that the descent of the second part (12) results in an approach of the jaws (121, 111 ), with the clamping action of the clamping resource (13) causing the fixing and/or the locking of the device (1 ) on the osteosynthesis bar (2) and the fixing and/or the locking of the transverse bar (3).",LDR MEDICAL;;CHO PAUL HENRY L;;HOFFMAN GREGORY;;CHATATGNER HERVE,CHO PAUL HENRY L;;HOFFMAN GREGORY;;CHATATGNER HERVE,,https://lens.org/148-043-452-048-812,Search Report,yes,6,0,19,19,0,A61B17/7049;;A61B17/7049;;A61B17/82;;A61B17/70;;A61B17/701;;A61B17/701,A61B17/70,,0,0,,,,PENDING
147,NZ,A,NZ 723884 A,140-177-423-348-667,2023-02-24,2023,NZ 72388415 A,2015-02-06,US 2015/0014758 W;;US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,Methods of treating alzheimer’s disease,"Methods of treating Alzheimer’s Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/140-177-423-348-667,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61P25/28;;A61K39/00;;C07K16/18,,0,0,,,,PENDING
148,US,B2,US 10478310 B2,181-765-243-621-505,2019-11-19,2019,US 201514638746 A,2015-03-04,FR 1454102 A,2014-05-06,"Vertebral implant, device for vertebral attachment of the implant and instrumentation for implantation thereof","This disclosure provides various vertebral implants, devices for attaching a vertebral implant and implantation instrumentations. In some embodiments, the implant includes a first body and a second body, each having a face with shapes and dimensions mating that of the other body and forming mutual fitting means, thus allowing assembly of the bodies by sliding along a sliding axis. In some embodiments, a locking means is retained in one of the bodies and an abutment portion may move from an open position allowing sliding for the assembling of the bodies to a closed position locking the bodies in assembly by the contact between the abutment portion, by contact with an abutment of the other body, the abutment being oriented angularly to the sliding axis and the abutment portion passing from the open position to the closed position elastically by flexure or torsion.",LDR MEDICAL;;LDR MEDICAL S A S,AMEIL MARC;;LEE DANIEL D;;CHO PAUL HENRY,,https://lens.org/181-765-243-621-505,Granted Patent,yes,477,3,14,14,0,A61B17/86;;A61B17/8872;;A61F2/44;;A61F2/4455;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2002/448;;A61F2/44;;A61F2/4455;;A61F2/4465;;A61F2/4637;;A61F2002/30387;;A61F2002/30481;;A61F2002/30505;;A61F2002/30579;;A61F2002/30593;;A61F2002/30604;;A61F2002/30841;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2220/0016;;A61F2/4603;;A61F2/447;;A61F2/4611;;A61B17/86;;A61B17/8872;;A61F2002/448;;A61F2002/4629;;A61F2/44;;A61F2/4455;;A61F2002/30841;;A61F2002/30481;;A61F2002/30579;;A61F2002/30593;;A61F2002/30387;;A61F2/4637;;A61F2/4465;;A61F2002/30604;;A61F2002/30505;;A61F2/4603;;A61F2/442;;A61F2/4425;;A61F2220/0016,A61F2/44;;A61B17/86;;A61B17/88;;A61F2/46,,151,0,,,"Apparatus and Method for Fusing Opposing Spinal Vertebrae, Bramlet, Dale G. et al., U.S. Appl. No. 09/635,436, filed Aug. 11, 2000.;;Intervertebral nucleus prosthesis and surgical procedure for implanting the same, Gau, Michel, U.S. Appl. No. 10/060,862, filed Jan. 30, 2002.;;Intersomatic cage with unified grafts, Huppert, Jean, U.S. Appl. No. 10/276,712, filed Mar. 26, 2003.;;Spinal Osteosynthesis Device and Preparation Method, Beaurain, Jacques et al., U.S. Appl. No. 10/473,999, filed Apr. 12, 2004.;;Intervertebral Disc Prosthesis and Fitting Tools, Beaurain, Jacques et al., U.S. Appl. No. 10/476,565, filed Jun. 8, 2004.;;Vertebral Cage Device With Modular Fixation, Louis, Christian et al., U.S. Appl. No. 10/483,563, filed May 21, 2004.;;Progressive approach osteosynthesis device and preassembly method, Delecrin, Joel et al., U.S. Appl. No. 10/492,753, filed Aug. 9, 2004.;;Plate for osteosynthesis device and method of preassembling such device, Delecrin, Joel et al., U.S. Appl. No. 10/492,827, filed Jul. 15, 2004.;;Osseous anchoring device for a prosthesis, Huppert, Jean et al., U.S. Appl. No. 10/494,418, filed Jul. 22, 2004.;;Implant for Osseous Anchoring with Polyaxial Head, Beaurain, Jacques et al., U.S. Appl. No. 10/498,234, filed Dec. 7, 2004.;;Intervertebral Disc Prosthesis, Beaurain, Jacques et al., U.S. Appl. No. 10/533,846, filed Nov. 11, 2005.;;Osseous anchoring implant with a polyaxial head and method for installing the implant, Renaud, Christian et al., U.S. Appl. No. 10/570,080, filed Jun. 9, 2006.;;Device and method for sectioning a vertebral lamina, Mangione, Paolo, U.S. Appl. No. 10/575,065, filed May 30, 2006.;;Intervertebral Disc Prosthesis, Hovorka, Istvan et al., U.S. Appl. No. 11/051,710, filed Feb. 4, 2005.;;Intervertebral Disc Prosthesis, Zeegers, M. Willem, U.S. Appl. No. 11/098,266, filed Apr. 4, 2005.;;Intervertebral Disc Prosthesis, Zeegers, Willem, U.S. Appl. No. 11/109,276, filed Apr. 18, 2005.;;Instrumentation and Methods for Inserting an Intervertebral Disc Prosthesis, Dinville, Herve, U.S. Appl. No. 11/180,868, filed Jul. 13, 2005.;;Intervertebral Disc Prosthesis, Rashbaum, Ralph et al., U.S. Appl. No. 11/341,007, filed Jan. 27, 2006.;;Intervertebral Disc Prosthesis and Instrumentation for Insertion of the Prosthesis Between the Vertebrae, Rashbaum, Ralph et al., U.S. Appl. No. 11/362,253, filed Feb. 24, 2006.;;Transforaminal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage, Davis, Reginald James et al., U.S. Appl. No. 11/378,165, filed Mar. 17, 2006.;;Intervertebral nucleus prosthesis and surgical procedure for implanting the same, Gau, Michel, U.S. Appl. No. 11/390,711, filed Mar. 27, 2006.;;Intervertebral disc prosthesis insertion assemblies, Jodaitis, Alexandre et al., U.S. Appl. No. 11/676,237, filed Feb. 16, 2007.;;Intersomatic cage with unified grafts, Huppert, Jean, U.S. Appl. No. 11/767,386, filed Jun. 22, 2007.;;Nucleus Prostheses, Vila, Thierry et al., U.S. Appl. No. 11/874,144, filed Oct. 17, 2007.;;Vertebral Support Device, Cho, Paul et al., U.S. Appl. No. 11/958,285, filed Dec. 17, 2007.;;Intervertebral disc prosthesis, surgical methods, and fitting tools, Beaurain, Jacques et al., U.S. Appl. No. 12/025,677, filed Feb. 4, 2008.;;Intersomatic cage, intervertebral prosthesis, anchoring device and implantation instruments, Allain, Jerome et al., U.S. Appl. No. 12/134,884, filed Jun. 6, 2008.;;Transverse spinal linking device and system, Cho, Paul, U.S. Appl. No. 12/172,074, filed Jul. 11, 2008.;;Transforaminal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage, Davis, Reginald James et al., U.S. Appl. No. 12/279,664, filed Apr. 22, 2009.;;Intervertebral Disc Prosthesis, Zeegers, Willem, U.S. Appl. No. 12/360,050, filed Jan. 26, 2009.;;Intervertebral Disc Prosthesis, Zeegers, M. Willem, U.S. Appl. No. 12/391,086, filed Feb. 23, 2009.;;Spinal Osteosynthesis Device and Preparation Method, Beaurain, Jacques et al., U.S. Appl. No. 12/409,327, filed Mar. 23, 2009.;;Intervertebral disc prosthesis, Beaurain, Jacques et al., U.S. Appl. No. 12/424,364, filed Apr. 15, 2009.;;Vertebral Cage Device With Modular Fixation, Louis, Christian et al., U.S. Appl. No. 12/430,768, filed Apr. 27, 2009.;;Instrumentation and Methods for Inserting an Intervertebral Disc Prosthesis, Dinville, Herve, U.S. Appl. No. 12/435,955, filed May 5, 2009.;;Interveterbral disc prosthesis insertion assemblies, Jodaitis, Alexandre et al., U.S. Appl. No. 12/527,373, filed Mar. 19, 2010.;;Intervertebral implant having extendable bone fixation members, Brett, Darrell C., U.S. Appl. No. 12/884,664, filed Sep. 17, 2010.;;Intervertebral Dic Prosthesis, Rashbaum, Ralph et al., U.S. Appl. No. 12/955,898, filed Nov. 29, 2010.;;Instruments and Methods for Removing Fixation Devices from Intervertebral Implants, Dinville, Herve et al., U.S. Appl. No. 13/158,761, filed Jun. 13, 2011.;;Intervertebral Disc Prosthesis, Zeegers, M. Willem, U.S. Appl. No. 13/215,123, filed Aug. 22, 2011.;;Interspinous Implant and Implantation Instrument, Dinville, Hervé et al., U.S. Appl. No. 13/369,650, filed Feb. 9, 2012.;;Vertebral Cage Device With Modular Fixation, Louis, Christian et al., U.S. Appl. No. 13/438,352, filed Apr. 3, 2012.;;Plate for osteosynthesis device and method of preassembling such device, Delecrin, Joel et al., U.S. Appl. No. 13/454,927, filed Apr. 24, 2012.;;Anchoring Device and System for an Intervertebral Implant, Intervertebral Implant and Implantation Instrument, Dinville, Hervé et al., U.S. Appl. No. 13/520,041, filed Nov. 26, 2012.;;Anchoring Device and System for an Intervertebral Implant, Intervertebral Implant and Implantation Instrument, Dinville, Hervé et al., U.S. Appl. No. 13/538,078, filed Jun. 29, 2012.;;Transforaminal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage, Davis, Reginald James et al., U.S. Appl. No. 13/585,063, filed Aug. 14, 2012.;;Intervertebral Disc Prosthesis, Zeegers, Willem, U.S. Appl. No. 13/603,043, filed Sep. 4, 2012.;;Intervertebral Disc Prosthesis, Beaurain, Jacques et al., U.S. Appl. No. 13/616,448, filed Sep. 14, 2012.;;Intervertebral Disc Prosthesis and Instrumentation for Insertion of the Prosthesis Between the Vertebrae, Rashbaum, Ralph et al., U.S. Appl. No. 13/620,797, filed Sep. 15, 2012.;;Intersomatic cage, intervertebral prosthesis, anchoring device and implantation instruments, Allain, Jerome et al., U.S. Appl. No. 13/732,244, filed Dec. 31, 2012.;;Anchoring device and system for an intervertebral implant, intervertebral implant and implantation instrument, Chataigner, Hervé et al., U.S. Appl. No. 13/774,547, filed Feb. 22, 2013.;;Transforaminal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage, Davis, Reginald James et al., U.S. Appl. No. 13/854,808, filed Apr. 1, 2013.;;Spinal Osteosynthesis Device and Preparation Method, Beaurain, Jacques et al., U.S. Appl. No. 13/873,190, filed Apr. 29, 2013.;;Instrumentation and Methods for Inserting an Intervertebral Disc Prosthesis, Dinville, Herve, U.S. Appl. No. 13/892,933, filed May 13, 2013.;;Intervertebral Disc Prosthesis Insertion Assemblies, Jodaitis, Alexandre et al., U.S. Appl. No. 13/919,704, filed Jun. 17, 2013.;;Intervertebral implant having extendable bone fixation members, Brett, Darrell C., U.S. Appl. No. 14/064,434, filed Oct. 28, 2013.;;Interspinous Implant and Instrument for Implanting an Interspinous Implant, Dinville, Hervé et al., U.S. Appl. No. 14/130,286, filed Jul. 3, 2014.;;Intersomatic cage with unified grafts, Huppert, Jean, U.S. Appl. No. 14/149,357, filed Jan. 7, 2014.;;Nucleus Prosthesis, Vila, Thierry et al., U.S. Appl. No. 14/159,161, filed Jan. 20, 2014.;;Interveterbral disc prosthesis insertion assemblies, Jodaitis, Alexandre et al., U.S. Appl. No. 14/242,177, filed Apr. 1, 2014.;;Vertebral implant, vertebral fastening device of the implant and implant instrumentation, Dinville, Hervé et al., U.S. Appl. No. 14/246,442, filed Apr. 7, 2014.;;Interspinous Implant and Instrument for Implanting an Interspinous Implant, Dinville, Hervé et al., U.S. Appl. No. 14/252,754, filed Apr. 14, 2014.;;Anchoring device for a spinal implant, spinal implant and implantation instrumentation, Chataigner, Hervé et al., U.S. Appl. No. 14/252,852, filed Apr. 15, 2014.;;Intervertebral Disc Prosthesis, Beaurain, Jacques et al., U.S. Appl. No. 14/306,785, filed Jun. 17, 2014.;;Intervertebral Disc Prosthesis and Instrumentation for Insertion of the Prosthesis Between the Vertebrae, Steib, Jean-Paul, U.S. Appl. No. 14/325,317, filed Jul. 7, 2014.;;Anchoring device and system for an intervertebral implant, intervertebral implant and implantation instrument, Chataigner, Hervé et al., U.S. Appl. No. 14/380,714, filed Aug. 23, 2014.;;Cage Having Spike, Kim, Seo-Kon et al., U.S. Appl. No. 14/460,536, filed Aug. 15, 2014.;;Osseous anchoring implant with a polyaxial head and method for installing the implant, Renaud, Christian et al., U.S. Appl. No. 14/497,321, filed Sep. 26, 2014.;;Intervertebral Disc Prosthesis, Hovorka, Istvan et al., U.S. Appl. No. 14/513,818, filed Oct. 14, 2014.;;Plate for osteosynthesis device and preassembly method, Delecrin, Joel et al., U.S. Appl. No. 14/584,674, filed Dec. 29, 2014.;;Intervertebral Implant Having Extendable Bone Fixation Members, Brett, Darrell C., U.S. Appl. No. 14/594,770, filed Jan. 12, 2015.;;Vertebral implant, device for vertebral attachment of the implant and instrumentation for implantation thereof, Ameil, Marc et al., U.S. Appl. No. 14/638,746, filed Mar. 4, 2015.;;Intervertebral Disc Prosthesis, Zeegers, Willem, U.S. Appl. No. 14/642,696, filed Mar. 9, 2015.;;Vertebral Support Device, Cho, Paul et al., U.S. Appl. No. 14/642,752, filed Mar. 10, 2015.;;Intervertebral Disc Prosthesis, Rashbaum, Ralph et al., U.S. Appl. No. 14/659,587, filed Mar. 16, 2015.;;Anchoring device and system for an intervertebral implant, intervertebral implant and implantation instrument, Chataigner, Hervé et al., U.S. Appl. No. 14/721,818, filed May 26, 2015.;;Intervertebral Disc Prosthesis, Zeegers, Willem, U.S. Appl. No. 14/726,557, filed May 31, 2015.;;Anchoring Device and System for an Intervertebral Implant, Intervertebral Implant and Implantation Instrument, Dinville, Hervé et al., U.S. Appl. No. 14/726,558, filed May 31, 2015.;;Vertebral Cage Device With Modular Fixation, Louis, Christian et al., U.S. Appl. No. 14/798,900, filed Jul. 14, 2015.;;Bone Implants, Lavigne, Christophe et al., U.S. Appl. No. 14/815,900, filed Jul. 31, 2015.;;Devices, Methods, and Systems to Implant and Secure a Fusion Cage or Intervertebral Prosthesis for Spinal Treatment, Stewart, Will et al., U.S. Appl. No. 14/827,297, filed Aug. 15, 2015.;;Vertebral implant, vertebral fastening device of the implant and implant instrumentation, Dinville, Hervé et al., U.S. Appl. No. 14/891,322, filed Nov. 13, 2015.;;Instruments and Methods for Removing Fixation Devices from Intervertebral Implants, Dinville, Herve et al., U.S. Appl. No. 14/931,007, filed Nov. 3, 2015.;;Instrumentation and Methods for Inserting an Intervertebral Disc Prosthesis, Dinville, Herve, U.S. Appl. No. 15/012,815, filed Feb. 1, 2016.;;Intervertebral Disc Prosthesis, Beaurain, Jacques et al., U.S. Appl. No. 15/049,934, filed Feb. 22, 2016.;;Intervertebral Disc Prosthesis and Instrumentation for Insertion of the Prosthesis Between the Vertebrae, Steib, Jean-Paul, U.S. Appl. No. 15/049,995, filed Feb. 22, 2016.;;Anchoring device for a spinal implant, spinal implant and implantation instrumentation, Chataigner, Hervé et al., U.S. Appl. No. 15/115,659, filed Jul. 29, 2016.;;Interspinous Implant and Implantation Instrument, Dinville, Hervé et al., U.S. Appl. No. 15/145,413, filed May 3, 2016.;;Implant for Osseous Anchoring with Polanial Head, Beaurain, Jacques et al., U.S. Appl. No. 15/145,431, filed May 3, 2016.;;Intervertebral disc prosthesis, surgical methods, and fitting tools, Beaurain, Jacques et al., U.S. Appl. No. 15/150,316, filed May 9, 2016.;;Interspinous Implant and Instrument for Implanting an Interspinous Implant, Dinville, Hervé et al., U.S. Appl. No. 15/225,612, filed Aug. 1, 2016.;;Intervertebral Disc Prosthesis, Zeegers, M. Willem, U.S. Appl. No. 15/269,923, filed Sep. 19, 2016.;;Intervertebral Implant Having Extendable Bone Fixation Members, Brett, Darrell C., U.S. Appl. No. 15/289,861, filed Oct. 10, 2016.;;Vertebral implant, device for vertebral attachment of the implant and instrumentation for implantation thereof, Ameil, Marc et al., U.S. Appl. No. 15/309,197, filed Nov. 6, 2016.;;Intervertebral Disc Prosthesis Insertion Assemblies, Jodaitis, Alexandre et al., U.S. Appl. No. 15/340,565, filed Nov. 1, 2016.;;Nucleus Prosthesis, Vila, Thierry et al., U.S. Appl. No. 15/391,305, filed Dec. 27, 2016.;;Plate for osteosynthesis device and preassembly method, Delecrin, Joel et al., U.S. Appl. No. 15/414,523, filed Jan. 24, 2017.;;Implant for Osseous Anchoring with Polyaxial Head, Beaurain, Jacques et al., U.S. Appl. No. 15/426,938, filed Feb. 7, 2017.;;Intervertebral Disc Prosthesis, Zeegers, Willem, U.S. Appl. No. 15/432,795, filed Feb. 14, 2017.;;System of spinal arthodesis implants, Mercier, Alexis et al., U.S. Appl. No. 15/442,591, filed Feb. 24, 2017.;;Intervertebral Disc Prosthesis, Rashbaum, Ralph et al., U.S. Appl. No. 15/464,639, filed Mar. 21, 2017.;;Transforaminal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage, Davis, Reginald James et al., U.S. Appl. No. 15/465,143, filed Mar. 21, 2017.;;Bone Implants, Lavigne, Christophe et al., U.S. Appl. No. 15/501,166, filed Feb. 1, 2017.;;Bone anchoring system, associated implant and instrumentation, Lequette, Samuel et al., U.S. Appl. No. 15/582,568, filed Apr. 28, 2017.;;Vertebral System, Implant and Inserts for Vertebral System, Joly, Florian et al., U.S. Appl. No. 15/586,003, filed May 3, 2017.;;Vertebral Cage Device With Modular Fixation, Louis, Christian et al., U.S. Appl. No. 15/597,130, filed May 16, 2017.;;Intervertebral Disc Prosthesis, Hovorka, Istvan et al., U.S. Appl. No. 15/603,429, filed May 23, 2017.;;Transforaminal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage, Davis, Reginald James et al., U.S. Appl. No. 15/659,602, filed Jul. 25, 2017.;;Vertebral Support Device, Cho, Paul et al., U.S. Appl. No. 15/677,310, filed Aug. 15, 2017.;;Intervertebral Implant Having Extendable Bone Fixation Members, Brett, Darrell C., U.S. Appl. No. 15/682,549, filed Aug. 22, 2017.;;Anchoring Device and System for an Intervertebral Implant, Intervertebral Implant and Implantation Instrument, Dinville, Hervé et al., U.S. Appl. No. 15/708,860, filed Sep. 19, 2017.;;Spinal Osteosynthesis Device and Preparation Method, Beaurain, Jacques et al., U.S. Appl. No. 15/708,907, filed Sep. 19, 2017.;;Cage Having Spike, Kim, Seo-Kon et al., U.S. Appl. No. 15/723,174, filed Oct. 3, 2017.;;Devices, Methods and Systems to Implant and Secure an Intervertebral Implant for Spinal Treatment, Stewart, Will et al., U.S. Appl. No. 15/753,168, filed Feb. 15, 2018.;;Intervertebral disc prosthesis, surgical methods, and fitting tools, Beaurain, Jacques et al., U.S. Appl. No. 15/784,559, filed Oct. 16, 2017.;;Intersomatic cage, intervertebral prosthesis, anchoring device and implantation instruments, Allain, Jerome et al., U.S. Appl. No. 15/792,123, filed Oct. 24, 2017.;;Expansible Intervertebral Implant, Bernard, Pierre et al., U.S. Appl. No. 15/796,732, filed Oct. 27, 2017.;;Expansible Intersomatic Cage, Bernard, Pierre et al., U.S. Appl. No. 15/796,733, filed Oct. 27, 2017.;;Expansible Intersomatic Cage, Bernard, Pierre et al., U.S. Appl. No. 15/796,735, filed Oct. 27, 2017.;;Anchoring Device and System for an Intervertebral Implant, Intervertebral Implant and Implantation Instrument, Dinville, Hervé et al., U.S. Appl. No. 15/832,101, filed Dec. 5, 2017.;;Intervertebral Disc Prosthesis, Zeegers, Willem, U.S. Appl. No. 15/872,937, filed Jan. 16, 2018.;;Anchoring device for a spinal implant, spinal implant and implantation instrumentation, Chataigner, Hervé et al., U.S. Appl. No. 15/883,199, filed Jan. 30, 2018.;;Intervertebral Disc Prosthesis, Zeegers, M. Willem, U.S. Appl. No. 15/895,463, filed Feb. 13, 2018.;;Interspinous Implant and Instrument for Implanting an Intersninous Implant, Dinville, Hervé et al., U.S. Appl. No. 15/919,220, filed Mar. 13, 2018.;;Anchoring device for a spinal implant, spinal implant and implantation instrumentation, Chataigner, Hervé et al., U.S. Appl. No. 15/937,845, filed Mar. 27, 2018.;;Vertebral implant, vertebral fastening device of the implant and implant instrumentation, Dinville, Hervé et al., U.S. Appl. No. 15/949,292, filed Apr. 10, 2018.;;Implant for Osseous Anchoring with Polyaxial Head, Beaurain, Jacques et al., U.S. Appl. No. 15/955,643, filed Apr. 17, 2018.;;Intervertebral Fusion Cage with Retractable-Extrudable Pins, Brett, Darrell C., U.S. Appl. No. 61/243,297, filed Sep. 17, 2009.;;Intervertebral Fusion Cage with Retractable-Extrudable Pins, Brett, Darrell C., U.S. Appl. No. 61/260,364, filed Nov. 11, 2009.;;World Intellectual Property Organization; International Search Report and Written Opinion of the International Searching Authority for International App. No. WO2015169878, PCT Pub'n No. PCT/EP2015/060001; dated Oct. 2, 2016; WIPO; Geneva, Switzerland; all pages.;;World Intellectual Property Organization; International Preliminary Report on Patentability for International App. No. WO2015169878, PCT Pub'n No. PCT/EP2015/060001; dated Nov. 8, 2016; WIPO; Geneva, Switzerland; all pages.;;China State Intellectual Property Office; Search Report for Pub'n No. CN105208975, Application No. CN201480028167; dated May 16, 2016; China State Intellectual Property Office; Beijing, China; all pages.;;China State Intellectual Property Office; Office Action for Pub'n No. CN105208975, Application No. CN201480028167; dated May 26, 2016; China State Intellectual Property Office; Beijing, China; all pages.;;National Institute of Industrial Property (France); Search Report in Fench Pub. No. FR3005569, App. No. FR1354421; dated Feb. 12, 2014; National Institute of Industrial Property (France); France; all pages.;;World Intellectual Property Organization; International Search Report and Written Opinion of the International Searching Authority for International App. No. WO2014184367, PCT Pub'n No. PCT/EP2014/060135; dated Aug. 26, 2014; WIPO; Geneva, Switzerland; all pages.;;World Intellectual Property Organization; Response to Written Opinion of ISA for International App. No. WO2014184367, PCT Pub'n No. PCT/EP2014/060135; dated Jun. 27, 2016; WIPO; Geneva, Switzerland; all pages.;;World Intellectual Property Organization; International Preliminary Report on Patentability for International App. No. WO2014184367, PCT Pub'n No. PCT/EP2014/060135; dated Sep. 18, 2015; WIPO; Geneva, Switzerland; all pages.;;U.S. Patent & Trademark Office; Office Action in U.S. Appl. No. 14/246,442; dated Nov. 1, 2016; USPTO; Alexandria, Virgina; All Pages.;;LDR Medical, by its attorneys; Reply to Office Action in U.S. Appl. No. 14/246,442; dated Feb. 1, 2017; USPTO; Alexandria, Virgina; All Pages.;;U.S. Patent & Trademark Office; Office Action in U.S. Appl. No. 14/246,442; dated Mar. 6; 2017; USPTO; Alexandria, Virgina; All Pages.;;LDR Medical, by its attorneys; Reply to Office Action in Application U.S. Appl. No. 14/246,442; dated Jun. 6, 2017; USPTO; Alexandria, Virgina; All Pages.;;US. Patent & Trademark Office; Office Action in U.S. Appl. No. 14/246,442; dated Aug. 15, 2017; USPTO; Alexandria; Virgina; All Pages.;;LDR Medical, by its attorneys; Reply to Office Action in U.S. Appl. No. 14/246,442; dated Nov. 15, 2017; USPTO; Alexandria, Virgina; All Pages.;;National Institute of Industrial Property (France); Search Report in Fench Pub. No. FR3020756, App. No. FR1454102; dated Jan. 29, 2015; National Institute of Industrial Property (France); France; all pages.;;“U.S. Appl. No. 15/309,197, Non Final Office Action dated Feb. 5, 2019”, 7 pgs.;;“U.S. Appl. No. 15/309,197, Notice of Non-Compliant Amendment dated Feb. 7, 2017”, 3 pgs.;;“U.S. Appl. No. 15/309,197, Preliminary Amendment filed Nov. 6, 2016”, 9 pgs.;;“U.S. Appl. No. 15/309,197, Response filed Apr. 7, 2017 to Notice of Non-Compliant Amendment dated Feb. 7, 2017”, 2 pgs.;;“European Application Serial No. 15724950.9, Response filed Jul. 13, 2017 to Communication Pursuant to Rules 161(1) and 162 EPC dated Jan. 3, 2017”, 15 pgs.;;“U.S. Appl. No. 15/309,197, Response filed May 6, 2019 to Non Final Office Action dated Feb. 5, 2019”, 11 pgs.;;“U.S. Appl. No. 15/309,197, Restriction Requirement dated Jul. 15, 2019”, 6 pgs.",ACTIVE
149,RU,C2,RU 2724190 C2,014-958-576-827-742,2020-06-23,2020,RU 2016136081 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"FIELD: medicine.SUBSTANCE: present invention relates to a method for delaying the development of Alzheimer's disease (AD) or slowing the progression of AD in a patient with an MMSE score of 20 points or higher, without increasing the risk of adverse side effect in the given patient compared to placebo, where the adverse side effect is selected from: detectable pathology, associated with amyloid deposition, in the form of an edema (ARIA-E) and a pathology associated with deposition of amyloid in the form of hemorrhage (ARIA-H), comprising administering to patient Crenezumab in dose of 15 mg/kg to 100 mg/kg of patient's body weight, wherein said dose is introduced repeatedly every 4 weeks or every month.EFFECT: what is presented is a new effective method for delaying development or progression of asthma, which enables to reduce undesirable side effects.27 cl, 15 dwg, 1 tbl, 2 ex",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/014-958-576-827-742,Granted Patent,no,1,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61P25/28;;A61K39/00;;C07K16/18,,3,1,015-169-910-449-13X,24450890;;10.1056/nejmoa1312889,"Rachelle S. Doody et al, New England Journal of Medicine, 23.01.2014, vol. 370, N4, 311-321;;Niels D Prins et al, Alzheimers Res Ther, Biomed Central LTD, 2013, vol. 5, N 6, 56, стр. 1-6. O. Addlfsson et al, Journal of Neuroscience, 2012, vol. 32, N 28, 9677-9689;;Charlotte Jago, ""Alzheimer`s Disease: One Year later"" Clarivate. FEBRUARY 3, 2014, https://clarivate.com/cortellis/article/alzheimers-disease-one-year-later/",ACTIVE
150,AU,A,AU 1977/025941 A,025-430-366-028-68X,1978-12-14,1978,AU 1977/025941 A,1977-06-08,US 71075576 A,1976-08-02,CLOSURED AND DIVIDED BOX,,DART IND INC,BATEMAN ROBERT FRANCIS;;BEAUCHAMP ROGER PAUL;;CHO KAZUNOBU,,https://lens.org/025-430-366-028-68X,Patent Application,no,0,0,48,49,0,B65D25/04,B65D1/24;;B65D25/04;;B65D43/08,,0,0,,,,EXPIRED
151,KR,A,KR 20130031534 A,075-765-274-916-119,2013-03-29,2013,KR 20110095167 A,2011-09-21,KR 20110095167 A,2011-09-21,"METHOD FOR ESTIMATING 3-DIMENSIONAL TRAJECTORY OF MOVING TARGET USING MULTI ANGLE RADIOGRAPHIC IMAGE DATA, AND APPARATUS THEREOF","PURPOSE: A method for estimating a 3D trajectory of a moving target by using multiple x-ray image data and a device thereof are provided to estimate the 3D trajectory of the moving target from the multiple X-ray 2D image data which photographs the moving target. CONSTITUTION: A location setting unit sets a location of a moving target as an X-axis, a Y-axis, and a Z-axis on a reference coordinate system(S100). An image data obtainment unit obtains multiple X-ray image data which photographs the target by rotating an image detector for the target up to a predetermined range(S110). A 3D trajectory of the target is estimated by using relation among the X-axis, the Y-axis, and the Z-axis of the target in the multiple X-ray image data and the reference coordinate system(S120). [Reference numerals] (AA) Start; (BB) End; (S100) Setting a location of a moving target as an X-axis, a Y-axis, and a Z-axis; (S110) Obtaining multiple X-ray image data for the target; (S120) Estimating a 3D trajectory of the target by using relation among the X-axis, the Y-axis, and the Z-axis",UNIV ULSAN FOUND FOR IND COOP,CHO BYUNG CHUL;;PER RUGAARD POULSEN;;PAUL KEALL,,https://lens.org/075-765-274-916-119,Patent Application,no,0,0,2,2,0,A61B6/022;;A61B6/52;;G06T7/20,G06T7/20;;A61B6/00,,0,0,,,,ACTIVE
152,KR,A,KR 20210121288 A,136-197-161-540-90X,2021-10-07,2021,KR 20217030556 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;KR 20167024829 A;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"본원에서는 ApoE4 양성 환자 및 경증 AD를 앓는 환자를 포함하는, 약하거나 중등도의 AD를 앓는 환자에서 알츠하이머 질환(AD)을 치료하는 방법이 제공된다.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/136-197-161-540-90X,Patent Application,no,0,0,36,75,18,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/395;;A61K31/56;;A61K39/00;;C07K16/18,,0,0,,,,DISCONTINUED
153,NO,C,NO 143964 C,146-988-870-467-235,1981-05-20,1981,NO 772118 A,1977-06-16,US 71075576 A,1976-08-02,LAGRINGSBEHOLDER MED TETTLUKKENDE LOKK.,,DART IND INC,BATEMAN ROBERT FRANCIS;;BEAUCHAMP ROGER PAUL;;CHO KAZUNOBU,,https://lens.org/146-988-870-467-235,Granted Patent,no,0,0,48,49,0,B65D25/04,B65D25/04;;B65D43/08;;B65D1/24,,0,0,,,,EXPIRED
154,TW,B,TW I692152 B,181-815-221-611-018,2020-04-21,2020,TW 106103882 A,2017-02-07,TW 106103882 A,2017-02-07,TW I692152 B,,MOLEX LLC,RISHWORTH PAUL;;GOH HOON-CHAN;;CHO CHONG-THIAM,,https://lens.org/181-815-221-611-018,Granted Patent,no,2,0,4,4,0,H01R12/7082;;H01R12/73;;H01R12/79;;H05K1/144;;H05K1/147;;H05K1/189;;H05K2201/042;;H05K2201/10189;;H01R12/7023;;H01R13/506;;H01R12/716;;H01R12/7082;;H01R12/73;;H01R12/79;;H05K1/144;;H05K1/147;;H05K1/189;;H05K2201/042;;H05K2201/10189,,,0,0,,,,ACTIVE
155,WO,A3,WO 2005/119955 A3,041-944-142-306-327,2006-12-21,2006,US 2005/0018664 W,2005-05-26,US 57498904 P;;US 66970205 P;;US 90875605 A,2004-05-26,"SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR VALIDATING AN IDENTITY CLAIMED BY A SUBJECT","Embodiments of a system, method and computer program product for validating an identity claimed by a subject are described. Information for logging in under an identity claimed by a subject is obtained (102) from the subject and then submitted in an attempt to login (112) under the claimed identity. The response to the login attempt is then analyzed (114) to determine whether the identity with the site claimed by the subject is valid (120).",OPINITY INC;;CHO WONGYU TED;;KIM DOYON;;CHOI JINKEUN PAUL,CHO WONGYU TED;;KIM DOYON;;CHOI JINKEUN PAUL,,https://lens.org/041-944-142-306-327,Search Report,yes,5,0,3,4,0,G06F21/31;;G06F21/31,G06F7/04;;G06F7/58;;G06F15/16;;G06F17/30;;G06F21/00;;G06K9/00;;G06K19/00;;H04K1/00,,0,0,,,,PENDING
156,MY,A,MY 179105 A,054-286-749-120-879,2020-10-28,2020,MY PI2016702789 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,PAUL ROBERT;;WARD MICHAEL;;CHO WILLIAM;;FRIESENHAHN MICHEL,,https://lens.org/054-286-749-120-879,Granted Patent,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,,,0,0,,,,ACTIVE
157,WO,A2,WO 2005/119955 A2,067-519-158-653-207,2005-12-15,2005,US 2005/0018664 W,2005-05-26,US 57498904 P;;US 66970205 P;;US 90875605 A,2004-05-26,"SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR VALIDATING AN IDENTITY CLAIMED BY A SUBJECT","Embodiments of a system, method and computer program product for validating an identity claimed by a subject are described. Information for logging in under an identity claimed by a subject is obtained (102) from the subject and then submitted in an attempt to login (112) under the claimed identity. The response to the login attempt is then analyzed (114) to determine whether the identity with the site claimed by the subject is valid (120).",OPINITY INC;;CHO WONGYU TED;;KIM DOYON;;CHOI JINKEUN PAUL,CHO WONGYU TED;;KIM DOYON;;CHOI JINKEUN PAUL,,https://lens.org/067-519-158-653-207,Patent Application,yes,0,0,3,4,0,G06F21/31;;G06F21/31,G06F21/00;;H04K1/00,,0,0,,,,PENDING
158,CL,A1,CL 2017002781 A1,078-384-919-761-880,2018-04-13,2018,CL 2017002781 A,2017-11-03,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,Métodos de tratamiento de enfermedad de alzheimer,"<p>Se proporcionan métodos de tratamiento de enfermedad de Alzheimer (AD) en pacientes que sufren de AD leve a moderada, incluyendo pacientes ApoE4 positivos y pacientes que sufren de AD leve.</p>",GENENTECH INC,WARD MICHAEL;;FRIESENHAHN MICHEL;;PAUL ROBERT;;CHO WILLIAMS,,https://lens.org/078-384-919-761-880,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,PENDING
159,US,B2,US 8357249 B2,128-282-638-605-763,2013-01-22,2013,US 77164707 A,2007-06-29,US 77164707 A;;US 81740306 P,2006-06-30,"High strength, heat treatable aluminum alloy","A high strength aluminum alloy is suitable for ultra thick gauge wrought product. The alloy can have 6 to 8 wt % zinc, 1 to 2 wt % magnesium, and dispersoid forming elements such as Zr, Mn, Cr, Ti, and/or Sc with the balance made of aluminum and incidental elements and/or impurities. The alloy is suitable for many uses, including in molds for injection-molded plastics.",CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD LLC;;CHO ALEX;;SMITH KENNETH PAUL;;DANGERFIELD VICTOR B,CHO ALEX;;SMITH KENNETH PAUL;;DANGERFIELD VICTOR B,CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD LLC (2007-09-25),https://lens.org/128-282-638-605-763,Granted Patent,yes,17,2,18,18,0,C22C21/08;;C22C21/10;;C22C21/10;;C22C21/06;;C22F1/053;;C22F1/047;;C22C21/10;;C22C21/08,C22C21/10,148/440;;148/439;;420/511,5,1,090-315-010-237-070,10.1002/14356007.a01_481,"Lyle et al. ""Aluminum Alloys."" Ullmann's Encyclopedia of Industrial Chemistry. 2002.;;Hufnagel, ""Key to Aluminum Alloys, 4th Edition,"" Aluminum-Schluessel = Key to Aluminum Alloys, 1991, pp. 195-205, XP002194851 p. 9; Examples 7046, 7146.;;International Search Report dated Dec. 18, 2007, from PCT/US2007/072513.;;Hatch, John E., Constitution of Alloys, Book, 1984, Aluminum Property and Physical Metallurgy.;;JP Office Action dated Aug. 21, 2012, for Application No. 2009-518579.",ACTIVE
160,TW,A,TW 201613636 A,166-433-853-572-996,2016-04-16,2016,TW 104104180 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,Methods of treating Alzheimer's Disease,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/166-433-853-572-996,Patent of Addition,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/395;;A61P25/28;;C07K16/18;;C07K16/46,,0,0,,,,ACTIVE
161,EP,A1,EP 3367303 A1,186-539-227-609-537,2018-08-29,2018,EP 18158136 A,2018-02-22,KR 20170024824 A,2017-02-24,AUTONOMOUS DRIVING IMAGE PROCESSING METHOD AND APPARATUS THEREOF,"A processor implemented image processing method includes recognizing a target object in a first frame of an input image; adjusting an exposure of a second frame of the input image based on a brightness of the target object; and generating a synthesized image by synthesizing the first frame and the second frame.
",SAMSUNG ELECTRONICS CO LTD,SEO YOUNGWAN;;JEON PAUL BAROM;;CHO BAEK HWAN,,https://lens.org/186-539-227-609-537,Patent Application,yes,3,0,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,G06T5/00;;G06V10/141;;G06V10/25;;H04N5/235,,3,3,061-048-595-006-271;;051-626-542-773-142;;015-156-610-229-239,10.1155/2007/80971;;10.1109/tip.2006.877312;;16948325;;10.1145/882262.882270,"STEFANO MARSI ET AL: ""Video Enhancement and Dynamic Range Control of HDR Sequences for Automotive Applications"", EURASIP JOURNAL ON ADVANCES IN SIGNAL PROCESSING, vol. 2007, no. 1, 27 June 2007 (2007-06-27), XP055493207, DOI: 10.1155/2007/80971;;MEYLAN L ET AL: ""High dynamic range image rendering with a retinex-based adaptive filter"", IEEE TRANSACTIONS ON IMAGE PROCESS, IEEE SERVICE CENTER, PISCATAWAY, NJ, US, vol. 15, no. 9, 1 September 2006 (2006-09-01), pages 2820 - 2830, XP009108457, ISSN: 1057-7149, DOI: 10.1109/TIP.2006.877312;;SING BING KANG ET AL: ""High dynamic range video"", ACM TRANSACTIONS ON GRAPHICS (TOG), ACM, US, vol. 22, no. 3, 1 July 2003 (2003-07-01), pages 319 - 325, XP058249526, ISSN: 0730-0301, DOI: 10.1145/882262.882270",ACTIVE
162,US,A1,US 2022/0195020 A1,084-138-430-511-257,2022-06-23,2022,US 202117394053 A,2021-08-04,US 202117394053 A;;US 202017097237 A;;US 202016782654 A;;US 201514616261 A;;US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/084-138-430-511-257,Patent Application,yes,2,0,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,C07K16/18;;A61K31/56,,1,1,044-966-041-336-742,22871696;;10.1038/nbt0812-731,Garber K. Genentech's Alzheimer's antibody trial to study disease prevention. Nat Biotechnol. 2012 Aug;30(8):731-2. doi: 10.1038/nbt0812-731. PMID: 22871696. (Year: 2012),DISCONTINUED
163,EP,A1,EP 3102231 A1,085-829-519-263-965,2016-12-14,2016,EP 15710295 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,,HOFFMANN LA ROCHE,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/085-829-519-263-965,Patent Application,yes,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,ACTIVE
164,DE,A1,DE 2729737 A1,111-852-946-556-347,1978-02-09,1978,DE 2729737 A,1977-07-01,US 71075576 A,1976-08-02,"DICHT VERSCHLIESSBARER, UNTERTEILBARER BEHAELTER",,DART IND INC,CHO KAZUNOBU;;BATEMAN ROBERT FRANCIS;;BEAUCHAMP ROGER PAUL,,https://lens.org/111-852-946-556-347,Patent Application,no,0,1,48,49,0,B65D25/04,B65D25/04;;B65D1/24;;B65D43/08,,0,0,,,,EXPIRED
165,MX,A,MX 144139 A,127-638-972-755-079,1981-08-31,1981,MX 16947177 A,1977-07-14,US 71075576 A,1976-08-02,MEJORAS EN RECIPIENTE PARA EL ALMACENAMIENTO DE ALIMENTOS,,DART IND INC,BATEMAN ROBERT FRANCIS;;BEAUCHAMP ROGER PAUL;;CHO KAZUNOBU,,https://lens.org/127-638-972-755-079,Granted Patent,no,0,0,48,49,0,B65D25/04,B65D25/04;;B65D1/24;;B65D43/08,76-8,0,0,,,,EXPIRED
166,WO,A1,WO 2015/120233 A1,198-252-799-711-745,2015-08-13,2015,US 2015/0014758 W,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC;;HOFFMANN LA ROCHE,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/198-252-799-711-745,Patent Application,yes,89,15,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,140,104,015-169-910-449-13X;;086-932-421-807-452;;131-216-810-326-268;;029-200-906-160-107;;043-348-573-940-487;;069-494-908-751-119;;015-467-620-003-813;;122-558-490-060-539;;057-789-082-803-869;;142-314-510-790-905;;001-553-770-517-492;;062-950-628-293-493;;030-607-398-087-475;;006-574-964-805-278;;042-204-626-457-327;;162-646-650-680-173;;065-608-090-342-50X;;077-495-150-106-187;;020-855-322-534-259;;011-962-497-035-168;;048-564-471-521-204;;040-428-679-610-399;;089-899-040-309-502;;002-490-451-363-036;;015-239-659-590-870;;049-134-753-209-354;;076-294-679-339-389;;082-273-702-755-722;;001-779-867-387-972;;044-522-255-085-902;;001-779-867-387-972;;107-783-742-795-839;;110-088-048-889-302;;051-208-529-712-079;;030-323-674-660-051;;064-667-501-146-970;;022-023-983-891-895;;006-338-973-732-491;;004-601-819-239-79X;;009-746-604-420-355;;093-067-181-692-392;;009-483-512-107-343;;069-144-826-896-138;;015-395-754-996-662;;106-032-800-597-23X;;003-570-249-164-056;;010-953-281-569-514;;003-984-734-905-938;;170-311-024-328-514;;006-895-260-696-111;;107-330-806-519-859;;034-345-578-106-977;;030-630-100-818-462;;034-331-211-704-877;;020-855-322-534-259;;005-283-943-871-819;;079-666-119-599-514;;039-981-636-470-013;;054-876-950-584-376;;022-133-574-143-973;;072-378-691-723-546;;032-071-991-081-664;;117-775-899-628-564;;031-063-853-127-197;;005-112-559-456-657;;104-212-297-137-759;;035-232-534-898-963;;022-375-749-274-329;;010-916-105-450-247;;016-251-721-517-200;;026-048-786-530-595;;085-727-974-637-837;;005-119-615-003-591;;018-694-084-068-187;;012-268-510-926-843;;037-445-639-149-821;;009-275-403-380-31X;;156-501-805-490-709;;116-831-294-654-564;;022-725-321-473-914;;017-695-622-077-055;;008-274-774-541-556;;070-280-057-407-994;;013-584-945-188-940;;012-900-923-946-056;;020-126-213-879-311;;054-717-629-774-351;;068-264-897-850-380;;011-842-849-963-456;;060-301-220-665-473;;020-126-164-125-029;;035-796-690-562-525;;008-587-496-850-953;;065-430-968-783-392;;021-430-782-622-770;;051-940-176-386-905;;048-536-112-681-339;;076-294-679-339-389;;049-637-391-464-722;;018-622-691-667-330;;018-622-691-667-330;;019-349-924-670-963;;022-988-712-445-94X;;099-150-317-608-133,24450890;;10.1056/nejmoa1312889;;24216217;;pmc3978826;;10.1186/alzrt220;;pmc6622286;;22787053;;10.1523/jneurosci.4742-11.2012;;10.1001/archneur.60.8.1119;;12925369;;19595937;;10.1016/j.jalz.2007.04.381;;15229308;;10.1056/nejmra040223;;10.1212/wnl.43.8.1467;;8350998;;pmc1861657;;8669492;;15459432;;10.1161/01.str.0000143452.85382.d1;;16909007;;10.1159/000090366;;pmc4063417;;10.1016/s1474-4422(12)70015-7;;22305802;;6375662;;10.1016/s0006-291x(84)80190-4;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1016/0959-440x(92)90091-k;;8654676;;10.1042/bst0231035;;10.1016/0958-1669(94)90053-1;;7765176;;1748994;;10.1016/0022-2836(91)90498-u;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;10.4049/jimmunol.133.6.3001;;6092464;;10.1073/pnas.90.6.2551;;8460171;;pmc46126;;8459850;;10.1038/362255a0;;17161664;;10.1016/j.jchromb.2006.11.018;;10.4049/jimmunol.150.3.880;;8423344;;10.1016/0022-2836(87)90412-8;;3681981;;pmc3693547;;21784348;;10.1016/j.jalz.2011.05.2351;;10.1586/14737175.4.2.267;;15853568;;10.1006/jmbi.1999.3192;;10543973;;9377574;;10.1006/jmbi.1999.3192;;10543973;;12514726;;10.1038/nm0103-129;;10.1007/978-3-642-78432-3_11;;17981654;;10.2741/2786;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;15848072;;10.1016/j.ymeth.2005.01.003;;10.1016/0161-5890(91)90163-e;;1905784;;15848074;;10.1016/j.ymeth.2005.01.005;;15848075;;10.1016/j.ymeth.2005.01.006;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;7688398;;10.4049/jimmunol.151.4.2296;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;8360482;;10.4049/jimmunol.151.5.2623;;9099717;;10.1074/jbc.272.16.10678;;10.1074/jbc.271.37.22611;;8798431;;18606226;;10.1016/j.coi.2008.06.004;;10.1038/nbt1135;;16151405;;10.4049/jimmunol.147.1.86;;2051030;;16505368;;10.1073/pnas.0511285103;;pmc1383494;;15944943;;10.14670/hh-20.927;;10.1358/mf.2005.27.3.890876;;15834451;;11968478;;10.1385/1-59259-240-6:001;;10.1038/348552a0;;2247164;;10.1038/352624a0;;1907718;;1748994;;10.1016/0022-2836(91)90498-u;;15066433;;10.1016/j.jmb.2004.02.050;;15236968;;10.1016/j.jmb.2004.05.051;;15306681;;10.1073/pnas.0401786101;;pmc515084;;14736422;;10.1016/j.jim.2003.11.001;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90894-p;;1404359;;10.1038/305537a0;;6137772;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;10.1126/science.3925553;;3925553;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.152.11.5368;;8189055;;1675655;;10.4049/jimmunol.147.1.60;;10.1038/nbt0792-779;;1368267;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;10.1016/0378-1119(95)00821-7;;8647439;;7897213;;10.4049/jimmunol.154.7.3310;;10.1016/0022-2836(92)90639-2;;1507232;;10.1126/science.2471267;;2471267;;15037082;;10.3410/f.1020100.229441;;10.1016/j.jmb.2004.01.007;;10.1016/0003-9861(86)90031-7;;2428310;;16609957;;10.1002/bit.20880;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;10.1073/pnas.83.18.7059;;pmc386652;;3462743;;pmc397290;;3856277;;10.1073/pnas.82.5.1499;;3500259;;pmc2189658;;10.1084/jem.166.5.1351;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;9107305;;10.1016/s0022-1759(97)00002-1;;10.1182/blood-2002-06-1761;;12393541;;14551143;;10.1182/blood-2003-06-2031;;17077181;;10.1093/intimm/dxl110;;10.4049/jimmunol.164.8.4178;;10754313;;10.4049/jimmunol.117.2.587;;950463;;3258649;;10.1038/332738a0;;16087878;;pmc1187972;;10.1073/pnas.0502680102;;14970501;;10.1385/1-59259-666-5:245;;10.1038/nbt1028;;15529166;;886304;;10.1099/0022-1317-36-1-59;;10.1095/biolreprod23.1.243;;6774781;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;10.1212/wnl.34.7.939;;6610841;;pmc3693547;;21784348;;10.1016/j.jalz.2011.05.2351;;10.1056/nejmoa1304839;;pmc4159618;;24450891;;10.1176/ajp.141.11.1356;;6496779;;10.1176/ajp.141.11.1356;;6496779;;14716731;;10.1002/sim.1718;;1202204;;10.1016/0022-3956(75)90026-6;;0001202204;;10.1093/geront/9.3_part_1.179;;5349366,"RACHELLE S. DOODY ET AL: ""Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease"", NEW ENGLAND JOURNAL OF MEDICINE, vol. 370, no. 4, 23 January 2014 (2014-01-23), pages 311 - 321, XP055183832, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1312889;;NIELS D PRINS ET AL: ""Treating Alzheimer?s disease with monoclonal antibodies: current status and outlook for the future"", ALZHEIMERS RES THER, BIOMED CENTRAL LTD, LONDON, UK, vol. 5, no. 6, 11 November 2013 (2013-11-11), pages 56, XP021193607, ISSN: 1758-9193, DOI: 10.1186/ALZRT220;;O. ADOLFSSON ET AL: ""An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A"", JOURNAL OF NEUROSCIENCE, vol. 32, no. 28, 11 July 2012 (2012-07-11), pages 9677 - 9689, XP055097358, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.4742-11.2012;;CHARLOTTE JAGO: ""Alzheimer's Disease: One Year Later"", 3 February 2014 (2014-02-03), XP055183816, Retrieved from the Internet <URL:http://lsconnect.thomsonreuters.com/alzheimers-disease-year-later/> [retrieved on 20150417];;""Crenezumab Phase II cognition data in Alzheimer's disease presented"", 16 July 2014 (2014-07-16), XP055183813, Retrieved from the Internet <URL:http://www.acimmune.com/content/img/pages/ACImmune_crenezumab_phase2_ENGLISH_20140716_final.pdf> [retrieved on 20150417];;HEBERT ET AL., ARCH. NEUROL., vol. 60, 2003, pages 1119 - 22;;BROOKMEYER ET AL., ALZHEIMERS DEMENT., vol. 3, 2007, pages 186 - 91;;CUMMINGS, N. ENGL. J. MED., vol. 351, 2004, pages 56 - 67;;SAUNDERS ET AL., NEUROLOGY, vol. 43, 1993, pages 1467 - 72;;PREKUMAR ET AL., AM. J. PATHOL., vol. 148, 1996, pages 2083 - 95;;HAASS; SELKOE, NATURE, vol. 8, 2007, pages 656 - 67;;DEANE ET AL., STROKE, vol. 35, no. I, 2004, pages 2628 - 31;;MORGAN, NEURODEGENER. DIS., vol. 2, 2005, pages 261 - 6;;MILES ET AL.: ""Scientific Reports"", vol. 3, 6 August 2012, JOHNSTON & JOHNSON PRESS, article ""Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-To-Moderate Alzheimer's Disease"", pages: 1 - 4;;MILES ET AL., SCIENTIFIC REPORTS, vol. 3, 2013, pages 1 - 4;;SPERLING ET AL., THE LANCET, vol. 11, 2012, pages 241 - 249;;SINGLETON: ""Dictionary of Microbiology and Molecular Biology"", 1994, J. WILEY & SONS;;MARCH: ""Advanced Organic Chemistry Reactions, Mechanisms and Structure"", 1992, JOHN WILEY & SONS;;GLENNER; WONG, BIOCHEM BIOPHYS RES. COMM., vol. 129, 1984, pages 885 - 890;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596;;VASWANI; HAMILTON, ANN. ALLERGY, ASTHMA & IMMUNOL., vol. 1, 1998, pages 105 - 115;;HARRIS, BIOCHEM. SOC. TRANSACTIONS, vol. 23, 1995, pages 1035 - 1038;;HURLE; GROSS, CURR. OP. BIOTECH., vol. 5, 1994, pages 428 - 433;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597;;HOOGENBOOM ET AL., NUCL. ACIDS RES., vol. 19, 1991, pages 4133 - 4137;;KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001;;BRODEUR ET AL.: ""Monoclonal Antibody Production Techniques and Applications"", 1987, MARCEL DEKKER, INC., pages: 55 - 93;;BOERNER ET AL., J. IMMUNOL., vol. 147, no. 86, 1991;;JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI USA, vol. 90, 1993, pages 2551;;JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255;;BRUGGERMANN, YEAR IN IMMUNOL., vol. 7, 1993, pages 33;;FLATMAN ET AL., J. CHROMATOGR. B, vol. 848, 2007, pages 79 - 87;;KINDT ET AL.: ""Kuby Immunology"", 2007, W.H. FREEMAN AND CO, pages: 91;;PORTOLANO ET AL., J. IMMUNOL., vol. 150, 1993, pages 880 - 887;;CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NATIONAL INSTITUTES OF HEALTH;;CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", vol. 1-3, 1991, NIH PUBLICATION 91-3242;;PREKUMAR ET AL., AM. J PATHOL., vol. 148, 1996, pages 2083 - 95;;SPERLING ET AL., ALZHEIMER'S & DEMENTIA, vol. 7, 2011, pages 367;;CHALELA J A.; GOMES J., EXPERT REV. NEUROTHER, vol. 4, 2004, pages 267;;GREENBERG ET AL., LANCET NEUROL., vol. 8, 2009, pages 165 - 74;;KUMARA-N, AM J NEURORADIOL., vol. 31, 2010, pages 5;;CHEN, J. MOL. BIOL., vol. 293, 1999, pages 865 - 881;;PRESTA ET AL., CANCER RES., vol. 57, 1997, pages 4593 - 4599;;CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881;;HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134;;PLUCKTHUN: ""The Pharmacology of Monoclonal Antibodies"", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315;;HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;ALMAGRO; FRANSSON, FRONT. BIOSCI., vol. 13, 2008, pages 1619 - 1633;;QUEEN ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033;;KASHMIRI ET AL., METHODS, vol. 36, 2005, pages 25 - 34;;PADLAN, MOL. IMMUNOL., vol. 28, 1991, pages 489 - 498;;DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 43 - 60;;OSBOURN ET AL., METHODS, vol. 36, 2005, pages 61 - 68;;KLIMKA ET AL., BR. J. CANCER, vol. 83, 2000, pages 252 - 260;;SIMS, J. IMMUNOL., vol. 151, 1993, pages 2296;;CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285;;PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623;;BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684;;ROSOK ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 22611 - 22618;;VAN DIJK; VAN DE WINKEL, CURR. OPIN. PHARMACOL., vol. 5, 2001, pages 368 - 74;;LONBERG, CURR. OPIN. IMMUNOL., vol. 20, 2008, pages 450 - 459;;LONBERG, NAT. BIOTECH., vol. 23, 2005, pages 1117 - 1125;;BRODEUR ET AL.: ""Monoclonal Antibody Production Techniques and Applications"", 1987, MARCEL DEKKER, INC., pages: 51 - 63;;BOERNER ET AL., J. IMMUNOL., vol. 147, 1991, pages 86;;LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562;;NI, XIANDAI MIANYIXUE, vol. 26, no. 4, 2006, pages 265 - 268;;VOLLMERS; BRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, vol. 20, no. 3, 2005, pages 927 - 937;;VOLLMERS; BRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 27, no. 3, 2005, pages 185 - 91;;HOOGENBOOM ET AL.: ""Methods in Molecular Biology"", vol. 178, 2001, HUMAN PRESS, pages: 1 - 37;;MCCAFFERTY ET AL., NATURE, vol. 348, pages 552 - 554;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1992, pages 581 - 597;;MARKS; BRADBURY: ""Methods in Molecular Biology"", vol. 248, 2003, HUMAN PRESS, pages: 161 - 175;;SIDHU ET AL., J. MOL. BIOL., vol. 338, no. 2, 2004, pages 299 - 310;;LEE ET AL., J. MOL. BIOL., vol. 340, no. 5, 2004, pages 1073 - 1093;;FELLOUSE, PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 2004, pages 12467 - 12472;;LEE ET AL., J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132;;WINTER ET AL., ANN. REV. IMMUNOL., vol. 12, 1994, pages 433 - 455;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1992, pages 381 - 388;;MILSTEIN; CUELLO, NATURE, vol. 305, 1983, pages 537;;TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553;;GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368;;TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60;;MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783;;BARBAS ET AL., PROC NAT. ACAD. SCI, USA, vol. 91, 1994, pages 3809 - 3813;;SCHIER ET AL., GENE, vol. 169, 1996, pages 147 - 155;;YELTON ET AL., J. IMMUNOL., vol. 155, 1995, pages 1994 - 2004;;JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 9;;HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896;;CHOWDHURY, METHODS MOL. BIOL., vol. 207, 2008, pages 179 - 196;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;WRIGHT ET AL., TIBTECH, vol. 15, 1997, pages 26 - 32;;OKAZAKI ET AL., J. MOL. BIOL., vol. 336, 2004, pages 1239 - 1249;;YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., vol. 87, 2004, pages 614;;RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 249, 1986, pages 533 - 545;;KANDA, Y. ET AL., BIOTECHNOL. BIOENG., vol. 94, no. 4, 2006, pages 680 - 688;;RAVETCH; KINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457 - 492;;HELLSTROM, I. ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 83, 1986, pages 7059 - 7063;;HELLSTROM, I ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 82, 1985, pages 1499 - 1502;;BRUGGEMANN, M. ET AL., J. EXP. MED., vol. 166, 1987, pages 1351 - 1361;;CLYNES ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 95, 1998, pages 652 - 656;;GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, vol. 202, 1996, pages 163;;CRAGG, M.S. ET AL., BLOOD, vol. 101, 2003, pages 1045 - 1052;;CRAGG, M.S.; M.J. GLENNIE, BLOOD, vol. 103, 2004, pages 2738 - 2743;;PETKOVA, S.B. ET AL., INT'L. IMMUNOL., vol. 18, no. 12, 2006, pages 1759 - 1769;;SHIELDS ET AL., J. BIOL. CHEM., vol. 9, no. 2, 2001, pages 6591 - 6604;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184;;GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587;;KIM ET AL., J. IMMUNOL., vol. 24, 1994, pages 249;;DUNCAN; WINTER, NATURE, vol. 322, 1988, pages 738 - 40;;KAM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 11600 - 11605;;CHARLTON: ""Methods in Molecular Biology"", vol. 248, 2003, HUMANA PRESS, pages: 245 - 254;;GERNGROSS, NAT. BIOTECH., vol. 22, 2004, pages 1409 - 1414;;LI ET AL., NAT. BIOTECH., vol. 24, 2006, pages 210 - 215;;GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59;;MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251;;MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68;;URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216;;YAZAKI; WU: ""Methods in Molecular Biology"", vol. 248, 2003, HUMANA PRESS, pages: 255 - 268;;MORRIS: ""Methods in Molecular Biology"", vol. 66, 1996, HUMANA PRESS, article ""Epitope Mapping Protocols"";;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY;;""Remington's Pharmaceutical Sciences"", 1980;;MCKHANN ET AL., NEUROLOGY, vol. 34, 1984, pages 939 - 44;;SPERLING ET AL., ALZHEIMER'S & DEMENTIA, vol. 7, 2011, pages 367 - 385;;SALLOWAY ET AL., N. ENGL. J. MED., vol. 370, 2014, pages 322 - 333;;ROSEN ET AL., AMER. J. PSYCH., vol. 141, 1984, pages 1356 - 1364;;MOHS ET AL., ALZHEIMER'S DISEASE ASSOC. DISORDERS, vol. 11, no. 2, 1997, pages S13 - S21;;ROSEN ET AL., AM J PSYCHIATR, vol. 141, 1984, pages 1356 - 64;;MOHS ET AL., ALZHEIMER DIS ASSOC DISORD, vol. 11, no. S2, 1997, pages S 13,S21;;MANI, STAT MED, vol. 23, 2004, pages 305 - 14;;FOLSTEIN ET AL., J. PSYCHIATR. RES., vol. 12, 1975, pages 189 - 98;;LAWTON, M.P.; BRODY, E.M., GERONTOLOGIST, vol. 9, 1969, pages 179 - 186",PENDING
167,CL,A1,CL 2016001979 A1,086-970-408-918-358,2017-02-10,2017,CL 2016001979 A,2016-08-05,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,Métodos de tratamiento de enfermedad de alzheimer.,"<p>MÉTODO DE TRATAMIENTO DE ENFERMEDAD DE ALZHEIMER QUE COMPRENDE LA ADMINISTRACIÓN DE UN ANTICUERPO HUMANIZADO ANTI-AMILOIDE BETA, QUE SE UNE A UN EPITOPE ESPECÍFICO.</p>",GENENTECH INC,WARD MICHAEL;;CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT,,https://lens.org/086-970-408-918-358,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,PENDING
168,US,A1,US 2017/0056198 A1,142-937-042-217-446,2017-03-02,2017,US 201515309197 A,2015-05-06,US 201515309197 A;;FR 1454102 A;;US 201514638746 A;;EP 2015060001 W,2014-05-06,"Vertebral implant, device for vertebral attachment of the implant and instrumentation for implantation thereof","The present invention relates to a vertebral implant, in particular for corpectomy, to a device for attaching a vertebral implant and to implantation instrumentation, the implant including at least one first body ( 2 ) and at least one second body ( 3 ) each having at least one face having shapes and dimensions mating those of at least one face of another body ( 3, 2 ) and forming mutual fitting means, in order to allow assembling of said bodies ( 2, 3 ) by sliding along a sliding axis and, on the other hand, at least one locking means ( 4 ) retained in at least one of the bodies ( 2, 3 ) and at least one abutment portion of which is laid out for passing from a so-called open position, allowing sliding for the assembling of said bodies ( 2, 3 ), to a so-called closed position, locking said bodies ( 2, 3 ) assembled together by the contact between at least said abutment portion and at least one abutment ( 42, 43 ) of at least one of said bodies ( 2, 3 ), said abutment ( 42, 43 ) being oriented not parallel to the sliding axis and said abutment portion passing from the open position to the closed position elastically by flexure or torsion.",LDR MEDICAL,AMEIL MARC;;LEE DANIEL D;;CHO PAUL HENRY,,https://lens.org/142-937-042-217-446,Patent Application,yes,3,6,14,14,0,A61B17/86;;A61B17/8872;;A61F2/44;;A61F2/4455;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2002/448;;A61F2/44;;A61F2/4455;;A61F2/4465;;A61F2/4637;;A61F2002/30387;;A61F2002/30481;;A61F2002/30505;;A61F2002/30579;;A61F2002/30593;;A61F2002/30604;;A61F2002/30841;;A61F2/447;;A61F2/4611;;A61F2002/4629;;A61F2220/0016;;A61F2/4603;;A61F2/447;;A61F2/4611;;A61B17/86;;A61B17/8872;;A61F2002/448;;A61F2002/4629;;A61F2/44;;A61F2/4455;;A61F2002/30841;;A61F2002/30481;;A61F2002/30579;;A61F2002/30593;;A61F2002/30387;;A61F2/4637;;A61F2/4465;;A61F2002/30604;;A61F2002/30505;;A61F2/4603;;A61F2/442;;A61F2/4425;;A61F2220/0016,A61F2/44;;A61F2/46,,0,0,,,,ACTIVE
169,US,S,US D0680120 S,191-925-630-877-634,2013-04-16,2013,US 201129405282 F,2011-10-31,US 201129405282 F,2011-10-31,Case for tablet computer,,CHO SUN HEE;;TANNER CHRISTOPHER PAUL;;PICHETTE TRACI;;REISCHLING PRESS INC,CHO SUN HEE;;TANNER CHRISTOPHER PAUL;;PICHETTE TRACI,REISCHLING PRESS INC (2011-11-03),https://lens.org/191-925-630-877-634,Design Right,no,0,18,1,1,0,,,1402;;D14/440,0,0,,,,ACTIVE
170,AU,A1,AU 2015/214058 A1,185-575-849-200-762,2016-08-11,2016,AU 2015/214058 A,2015-02-06,US 201462081992 P;;US 201462010259 P;;US 201461971479 P;;US 201461937472 P;;US 2015/0014758 W,2014-02-08,Methods of treating Alzheimer's Disease,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/185-575-849-200-762,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,C07K16/18;;A61K39/00;;A61P25/28,,0,0,,,,ACTIVE
171,TW,A,TW 201830781 A,192-662-415-487-726,2018-08-16,2018,TW 106103882 A,2017-02-07,TW 106103882 A,2017-02-07,"Electrical connection device and board-to-board electrical connection assembly wherein the electrical connection between the electrical connection device and the board-to-board electrical connection assembly is more stable, reliable and suitable for high-speed multi-signal transmission","The present invention provides an electrical connection device and a board-to-board electrical connection assembly. The board-to-board electrical connection assembly comprises an electrical connection device, a first circuit board and a second circuit board. The electrical connection device comprises a supporting frame and a switching circuit board. The supporting frame has a top and a bottom. The switching circuit board includes an upper end portion supported on the top of the supporting frame, a lower end portion held at the bottom of the supporting frame, and a side portion disposed between the upper end portion and the lower end portion. The upper end portion includes a first connector, and the lower end portion includes a second connector. The first circuit board is provided with a first docking connector for docking with the first connector. The second circuit board is provided with a second docking connector for docking with the second connector. The electrical connection between the electrical connection device and the board-to-board electrical connection assembly is more stable, reliable and suitable for high-speed multi-signal transmission. Moreover, the supporting frame adopts a combination of two frames, and the two frames have the same structure. In addition to easy assembly, easy manufacture and cost saving, the height adjustment of the supporting frame can also be achieved by adjusting the height of the produced frame. Further, since the side portion of the switching circuit board can be used to set up electronic components, the signal processing switched during the high-speed transmission process can be facilitated and the electronic component layout of the circuit board can be reduced. In addition, the supporting frame itself is a hollow frame structure helpful for ventilation and heat dissipation.",MOLEX LLC,RISHWORTH PAUL;;GOH HOON-CHAN;;CHO CHONG-THIAM,,https://lens.org/192-662-415-487-726,Patent of Addition,no,0,0,4,4,0,H01R12/7082;;H01R12/73;;H01R12/79;;H05K1/144;;H05K1/147;;H05K1/189;;H05K2201/042;;H05K2201/10189;;H01R12/7023;;H01R13/506;;H01R12/716;;H01R12/7082;;H01R12/73;;H01R12/79;;H05K1/144;;H05K1/147;;H05K1/189;;H05K2201/042;;H05K2201/10189,H01R12/52,,0,0,,,,ACTIVE
172,EP,A4,EP 2796454 A4,037-364-752-380-131,2015-06-17,2015,EP 12835158 A,2012-07-09,KR 20110099424 A;;KR 2012005408 W,2011-09-29,METHOD FOR PRODUCING 5- HYDROXYMETHYL-2- FURFURAL OR ALKYL ETHER DERIVATIVES THEREOF USING AN ION EXCHANGE RESIN IN THE PRESENCE OF AN ORGANIC SOLVENT,,KOREA IND TECH INST;;SK CHEMICALS CO LTD,CHO JIN KU;;KIM SANG YONG;;CHO JAE HOON;;KIM BO RA;;JOO PAUL,,https://lens.org/037-364-752-380-131,Search Report,no,0,0,13,13,0,C07D307/46;;C07D307/50;;C07D307/50;;C07D307/50;;C07D307/44;;C07D307/46;;C07D307/46;;C07D307/48;;C07D307/48;;C07D307/48;;C07H1/00,C07D307/50;;C07D307/48;;C07H1/00,,4,3,106-326-057-296-548;;082-796-402-432-828;;081-366-970-624-91X,10.1016/j.apcata.2010.05.040;;10.1126/science.1126337;;16809536;;10.1016/j.catcom.2006.04.001,"M. OHARA ET. AL.: ""Syntheses of 5-hydroxymethylfurfural and levoglucosan by selective dehydration of glucose using solid acid and base catalysts."", APPLIED CATALYSIS A:GENERAL, vol. 383, 4 June 2010 (2010-06-04), pages 149 - 155, XP002738322, DOI: 10.1016/j.apcata.2010.05.040;;Y. ROMAN-LESHKOV ET. AL.: ""Phase Modifiers Promote Efficient Production of Hydroxymethylfurfural from Fructose."", SCIENCE, vol. 312, 30 June 2006 (2006-06-30), pages 1933 - 1937, XP002738323;;C. MOREAU ET. AL.: ""Determination of the basic strength of solid catalysts in water by means of a kinetic tracer"", CATALYSIS COMMUNICATIONS, vol. 7, 1 December 2006 (2006-12-01), pages 941 - 944, XP002738324;;See also references of WO 2013047984A1",ACTIVE
173,CN,A,CN 103842349 A,164-542-452-678-263,2014-06-04,2014,CN 201280048186 A,2012-07-09,KR 2012005408 W;;KR 20110099424 A,2011-09-29,Method for producing 5- hydroxymethyl-2- furfural or alkyl ether derivatives thereof using an ion exchange resin in the presence of an organic solvent,"The present invention relates to a method for producing a furan-based compound using an ion exchange resin in the presence of an organic solvent. In the method for producing a furan-based compound according to the present invention, a furan-based compound is made from an aldose-type hexose compound in the presence of an organic solvent by using an anion exchange resin and a cation exchange resin. Thus, the aldose-type hexose compound obtained from biomass by simultaneously or consecutively using the anion/cation exchange resins as catalysts can be made into 5- hydroxymethyl-2- furfural (HMF) or alkyl ether derivatives thereof such as 5- alkoxymethyl-2- furfural (AMF) without using an expensive reagent. Also, since the selection of an organic solvent is not limitative and a heterogeneous catalyst can be used, separation and purification is easy and chemically stable AMF can be directly obtained. Further, the conversion efficiency of the aldose-type hexose compound is excellent, and the hexose compound can be used at a high concentration.",KOREA IND TECH INST,CHO JIN KU;;KIM SANG YONG;;CHO JAE HOON;;KIM BO RA;;JOO PAUL,,https://lens.org/164-542-452-678-263,Patent Application,no,4,2,13,13,0,C07D307/46;;C07D307/50;;C07D307/50;;C07D307/50;;C07D307/44;;C07D307/46;;C07D307/46;;C07D307/48;;C07D307/48;;C07D307/48;;C07H1/00,C07D307/50;;C07D307/48;;C07H1/00,,1,1,106-326-057-296-548,10.1016/j.apcata.2010.05.040,"MIKA OHARA, ATSUSHI ET AL.: ""Syntheses of 5-hydroxymethylfurfural and levoglucosan by selective dehydration of glucose using solid acid and base catalysts"", 《APPLIED CATALYSIS A: GENERAL》, vol. 383, 4 June 2010 (2010-06-04), pages 149 - 155, XP002738322, DOI: 10.1016/j.apcata.2010.05.040",ACTIVE
174,US,A1,US 2014/0235881 A1,047-067-599-192-469,2014-08-21,2014,US 201214348566 A,2012-07-09,KR 20110099424 A;;KR 2012005408 W,2011-09-29,METHOD FOR PRODUCING 5-HYDROXYMETHYL-2-FURFURAL OR ALKYL ETHER DERIVATIVES THEREOF USING AN ION EXCHANGE RESIN IN THE PRESENCE OF AN ORGANIC SOLVENT,"The present invention relates to a method for producing a furan-based compound using an ion exchange resin in the presence of an organic solvent. In the method for producing a furan-based compound according to the present invention, a furan-based compound is made from an aldose-type hexose compound in the presence of an organic solvent by using an anion exchange resin and a cation exchange resin. Thus, the aldose-type hexose compound obtained from biomass by simultaneously or consecutively using the anion/cation exchange resins as catalysts can be made into 5-hydroxymethyl-2-furfural (HMF) or alkyl ether derivatives thereof such as 5-alkoxymethyl-2-furfural (AMF) without using an expensive reagent. Also, since the selection of an organic solvent is not limitative and a heterogeneous catalyst can be used, separation and purification is easy and chemically stable AMF can be directly obtained. Further, the conversion efficiency of the aldose-type hexose compound is excellent, and the hexose compound can be used at a high concentration.",CHO JIN KU;;KIM SANG YONG;;CHO JAE HOON;;KIM BO RA;;JOO PAUL;;KOREA IND TECH INST,CHO JIN KU;;KIM SANG YONG;;CHO JAE HOON;;KIM BO RA;;JOO PAUL,KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (2014-03-25),https://lens.org/047-067-599-192-469,Patent Application,yes,0,6,13,13,0,C07D307/46;;C07D307/50;;C07D307/50;;C07D307/50;;C07D307/44;;C07D307/46;;C07D307/46;;C07D307/48;;C07D307/48;;C07D307/48;;C07H1/00,C07D307/50,549/488,0,0,,,,ACTIVE
175,US,B2,US 9206147 B2,068-853-996-629-37X,2015-12-08,2015,US 201214348566 A,2012-07-09,KR 20110099424 A;;KR 2012005408 W,2011-09-29,Method for producing 5-hydroxymethyl-2-furfural or alkyl ether derivatives thereof using an ion exchange resin in the presence of an organic solvent,"The present invention relates to a method for producing a furan-based compound using an ion exchange resin in the presence of an organic solvent. In the method for producing a furan-based compound according to the present invention, a furan-based compound is made from an aldose-type hexose compound in the presence of an organic solvent by using an anion exchange resin and a cation exchange resin. Thus, the aldose-type hexose compound obtained from biomass by simultaneously or consecutively using the anion/cation exchange resins as catalysts can be made into 5-hydroxymethyl-2-furfural (HMF) or alkyl ether derivatives thereof such as 5-alkoxymethyl-2-furfural (AMF) without using an expensive reagent. Also, since the selection of an organic solvent is not limitative and a heterogeneous catalyst can be used, separation and purification is easy and chemically stable AMF can be directly obtained. Further, the conversion efficiency of the aldose-type hexose compound is excellent, and the hexose compound can be used at a high concentration.",CHO JIN KU;;KIM SANG YONG;;CHO JAE HOON;;KIM BO RA;;JOO PAUL;;KOREA IND TECH INST,CHO JIN KU;;KIM SANG YONG;;CHO JAE HOON;;KIM BO RA;;JOO PAUL,KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (2014-03-25),https://lens.org/068-853-996-629-37X,Granted Patent,yes,3,1,13,13,0,C07D307/46;;C07D307/50;;C07D307/50;;C07D307/50;;C07D307/44;;C07D307/46;;C07D307/46;;C07D307/48;;C07D307/48;;C07D307/48;;C07H1/00,C07D407/00;;C07D307/46;;C07D307/48;;C07D307/50,,1,0,,,PCT International Search Report for PCT/KR2012/005408.,ACTIVE
176,JP,A,JP 2017128600 A,132-313-298-482-800,2017-07-27,2017,JP 2017074905 A,2017-04-05,KR 20110099424 A,2011-09-29,METHOD FOR PRODUCING 5-HYDROXYMETHYL-2-FURFURAL OR ALKYL ETHER DERIVATIVES THEREOF USING ION EXCHANGE RESIN IN PRESENCE OF ORGANIC SOLVENT,"PROBLEM TO BE SOLVED: To provide a method for producing a furan-based compound, using an ion exchange resin in the presence of an organic solvent.SOLUTION: In a method for producing a furan-based compound according to the present invention, a furan-based compound is made from an aldose-type hexose compound in the presence of an organic solvent by using an anion exchange resin and a cation exchange resin. Thus, the aldose-type hexose compound obtained from biomass by simultaneously or consecutively using the anion/cation exchange resins as catalysts can be made into 5-hydroxymethyl-2-furfural (HMF) or alkyl ether derivatives thereof such as 5-alkoxymethyl-2-furfural (AMF) without using an expensive reagent. Also, since the selection of an organic solvent is not limitative and a heterogeneous catalyst can be used, separation and purification is easy and chemically stable AMF can be directly obtained. Further, the conversion efficiency of the aldose-type hexose compound is excellent, and the hexose compound can be used at high concentration.SELECTED DRAWING: None",SK CHEMICALS CO LTD;;KOREA IND TECH INST,CHO JIN KU;;KIM SANG YONG;;CHO JE FUN;;KIM BO RA;;JOO PAUL,,https://lens.org/132-313-298-482-800,Patent Application,no,12,0,13,13,0,C07D307/46;;C07D307/48;;C07D307/46;;C07D307/50;;C07D307/50;;C07D307/48;;C07D307/44;;C07H1/00;;C07D307/48;;C07D307/46;;C07D307/50,C07D307/50,,6,1,082-796-402-432-828,10.1126/science.1126337;;16809536,"ファインケミカル, vol. 39(6), JPN6016005922, 2010, pages 28 - 35, ISSN: 0003910341;;CHEMICAL COMMUNICATIONS, vol. (41), JPN7016000368, 2009, pages 6276 - 6278, ISSN: 0003910342;;APPLIED CATALYSIS, A: GENERAL, vol. 383(1-2), JPN6016005923, 2010, pages 149 - 155, ISSN: 0003910343;;SCIENCE, vol. 312(5782), JPN6016005924, 2006, pages 1933 - 1937, ISSN: 0003910344;;CATALYSIS COMMUNICATIONS, vol. 7(12), JPN6016005925, 2006, pages 941 - 944, ISSN: 0003910345;;CATALYSIS COMMUNICATIONS, vol. 9(13), JPN6016005926, 2008, pages 2244 - 2249, ISSN: 0003910346",ACTIVE
177,EP,B1,EP 2796454 B1,007-402-384-017-289,2017-09-06,2017,EP 12835158 A,2012-07-09,KR 20110099424 A;;KR 2012005408 W,2011-09-29,METHOD FOR PRODUCING 5- HYDROXYMETHYL-2- FURFURAL OR ALKYL ETHER DERIVATIVES THEREOF USING AN ION EXCHANGE RESIN IN THE PRESENCE OF AN ORGANIC SOLVENT,,KOREA IND TECH INST;;SK CHEMICALS CO LTD,CHO JIN KU;;KIM SANG YONG;;CHO JAE HOON;;KIM BO RA;;JOO PAUL,,https://lens.org/007-402-384-017-289,Granted Patent,yes,3,0,13,13,0,C07D307/46;;C07D307/48;;C07D307/46;;C07D307/50;;C07D307/50;;C07D307/48;;C07D307/44;;C07H1/00;;C07D307/48;;C07D307/46;;C07D307/50,C07D307/50;;C07D307/48;;C07H1/00,,3,0,,,"M. OHARA ET. AL.: ""Syntheses of 5-hydroxymethylfurfural and levoglucosan by selective dehydration of glucose using solid acid and base catalysts."", APPLIED CATALYSIS A:GENERAL, vol. 383, 4 June 2010 (2010-06-04), pages 149-155, XP002738322, DOI: 10.1016/j.apcata.2010.05.040;;Y. ROMAN-LESHKOV ET. AL.: ""Phase Modifiers Promote Efficient Production of Hydroxymethylfurfural from Fructose."", SCIENCE, vol. 312, 30 June 2006 (2006-06-30), pages 1933-1937, XP002738323,;;C. MOREAU ET. AL.: ""Determination of the basic strength of solid catalysts in water by means of a kinetic tracer"", CATALYSIS COMMUNICATIONS, vol. 7, 1 December 2006 (2006-12-01), pages 941-944, XP002738324,",ACTIVE
178,EP,A1,EP 2796454 A1,040-648-008-775-330,2014-10-29,2014,EP 12835158 A,2012-07-09,KR 20110099424 A;;KR 2012005408 W,2011-09-29,METHOD FOR PRODUCING 5- HYDROXYMETHYL-2- FURFURAL OR ALKYL ETHER DERIVATIVES THEREOF USING AN ION EXCHANGE RESIN IN THE PRESENCE OF AN ORGANIC SOLVENT,"The present invention relates to a method for producing a furan-based compound using an ion exchange resin in the presence of an organic solvent. In the method for producing a furan-based compound according to the present invention, a furan-based compound is made from an aldose-type hexose compound in the presence of an organic solvent by using an anion exchange resin and a cation exchange resin. Thus, the aldose-type hexose compound obtained from biomass by simultaneously or consecutively using the anion/cation exchange resins as catalysts can be made into 5-hydroxymethyl-2-furfural (HMF) or alkyl ether derivatives thereof such as 5-alkoxymethyl-2- furfural (AMF) without using an expensive reagent. Also, since the selection of an organic solvent is not limitative and a heterogeneous catalyst can be used, separation and purification is easy and chemically stable AMF can be directly obtained. Further, the conversion efficiency of the aldose-type hexose compound is excellent, and the hexose compound can be used at a high concentration.",KOREA IND TECH INST;;SK CHEMICALS CO LTD,CHO JIN KU;;KIM SANG YONG;;CHO JAE HOON;;KIM BO RA;;JOO PAUL,,https://lens.org/040-648-008-775-330,Patent Application,yes,0,0,13,13,0,C07D307/46;;C07D307/50;;C07D307/50;;C07D307/50;;C07D307/44;;C07D307/46;;C07D307/46;;C07D307/48;;C07D307/48;;C07D307/48;;C07H1/00,C07D307/50;;C07D307/48;;C07H1/00,,0,0,,,,ACTIVE
179,KR,A,KR 20130035167 A,065-671-388-756-248,2013-04-08,2013,KR 20120074366 A,2012-07-09,KR 20110099424 A,2011-09-29,METHOD FOR MANUFACTURING 5-HYDROXYMETHYL-2-FURFURAL OR ITS ALKYL ETHER DERIVATIVES IN ORGANIC SOLVENTS USING ION EXCHANGE RESINS,"PURPOSE: A method for preparing 5-hydroxymethyl-2-furfural or an alkyl ether derivative thereof using ion exchange resin under the presence of an organic solvent is provided to enable easy isolation and purification, and to directly prepare chemically stable AMF(5-alkoxymethyl2-furfural). CONSTITUTION: A method for preparing a furan-based compound comprises: a step of reacting aldose type hexose compounds using an anion exchange resin by isomerization, and preparing ketose type hexose compounds; and a step of dehydrating the ketose type hexose compounds using a cation exchange resin.",KOREA IND TECH INST,CHO JIN KU;;KIM SANG YONG;;KIM BO RA;;CHO JAE HOON;;JOO PAUL,,https://lens.org/065-671-388-756-248,Patent Application,no,0,3,13,13,0,C07D307/46;;C07D307/50;;C07D307/50;;C07D307/50;;C07D307/44;;C07D307/46;;C07D307/46;;C07D307/48;;C07D307/48;;C07D307/48;;C07H1/00,C07D307/50;;C07D307/44;;C07D307/48;;C07H1/00,,0,0,,,,ACTIVE
180,WO,A1,WO 2013/047984 A1,097-209-214-572-749,2013-04-04,2013,KR 2012005408 W,2012-07-09,KR 20110099424 A,2011-09-29,METHOD FOR PRODUCING 5- HYDROXYMETHYL-2- FURFURAL OR ALKYL ETHER DERIVATIVES THEREOF USING AN ION EXCHANGE RESIN IN THE PRESENCE OF AN ORGANIC SOLVENT,"The present invention relates to a method for producing a furan-based compound using an ion exchange resin in the presence of an organic solvent. In the method for producing a furan-based compound according to the present invention, a furan-based compound is made from an aldose-type hexose compound in the presence of an organic solvent by using an anion exchange resin and a cation exchange resin. Thus, the aldose-type hexose compound obtained from biomass by simultaneously or consecutively using the anion/cation exchange resins as catalysts can be made into 5- hydroxymethyl-2- furfural (HMF) or alkyl ether derivatives thereof such as 5- alkoxymethyl-2- furfural (AMF) without using an expensive reagent. Also, since the selection of an organic solvent is not limitative and a heterogeneous catalyst can be used, separation and purification is easy and chemically stable AMF can be directly obtained. Further, the conversion efficiency of the aldose-type hexose compound is excellent, and the hexose compound can be used at a high concentration.",KOREA IND TECH INST;;CHO JIN KU;;KIM SANG YONG;;CHO JAE HOON;;KIM BO RA;;JOO PAUL,CHO JIN KU;;KIM SANG YONG;;CHO JAE HOON;;KIM BO RA;;JOO PAUL,,https://lens.org/097-209-214-572-749,Patent Application,yes,4,4,13,13,0,C07D307/46;;C07D307/48;;C07D307/46;;C07D307/50;;C07D307/50;;C07D307/48;;C07D307/44;;C07H1/00;;C07D307/48;;C07D307/46;;C07D307/50,C07D307/50;;C07D307/48;;C07H1/00,,2,2,135-024-938-573-021;;082-796-402-432-828,17569858;;10.1126/science.1141199;;10.1126/science.1126337;;16809536,"SCIENCE, vol. 316, 2007, pages 1597 - 1600;;SCIENCE, vol. 312, 2006, pages 1933 - 1937",PENDING
181,CN,A,CN 111741229 A,011-833-702-186-301,2020-10-02,2020,CN 202010776945 A,2018-02-23,KR 20170024824 A;;CN 201810155270 A,2017-02-24,Image processing method and apparatus,The invention provides an image processing method and apparatus. The image processing method comprises the following steps: identifying a road in a first frame of an input image; setting the area on the road as an identification area; scanning the identification area without scanning the entire area of the input image; identifying at least one target object in the identification area in the inputimage; and adjusting the exposure of a second frame of the input image.,SAMSUNG ELECTRONICS CO LTD,SEO YOUNG-WAN;;JEON PAUL-BAROM;;CHO BAEK-HWAN,,https://lens.org/011-833-702-186-301,Patent Application,no,9,2,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,H04N5/235;;G01C21/16;;G01C21/26;;G01C21/34;;G01S19/47;;G05D1/00;;G05D1/02;;G06T5/00;;G06T5/50;;G06T7/73;;G06V10/141;;G06V10/25;;H04N5/232,,0,0,,,,ACTIVE
182,EP,B1,EP 3902490 B1,043-650-987-173-633,2024-02-14,2024,EP 19901545 A,2019-12-04,US 201816233935 A;;US 2019/0064447 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/043-650-987-173-633,Granted Patent,yes,5,0,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B18/12;;A61B5/0507;;A61B18/00;;A61B18/04;;A61B18/10;;A61B18/14;;A61B18/18,,0,0,,,,ACTIVE
183,US,B2,US 10739783 B2,042-779-193-192-171,2020-08-11,2020,US 201715818347 A,2017-11-20,KR 20170024824 A,2017-02-24,Image processing method for autonomous driving and apparatus thereof,A processor implemented image processing method includes recognizing a target object in a first frame of an input image; adjusting an exposure of a second frame of the input image based on a brightness of the target object; and generating a synthesized image by synthesizing the first frame and the second frame.,SAMSUNG ELECTRONICS CO LTD,SEO YOUNG WAN;;JEON PAUL BAROM;;CHO BAEK HWAN,SAMSUNG ELECTRONICS CO. LTD (2017-11-08),https://lens.org/042-779-193-192-171,Granted Patent,yes,13,1,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,G05D1/02;;G01C21/16;;G01C21/26;;G01C21/34;;G01S19/47;;G05D1/00;;G06T5/00;;G06T5/50;;G06T7/73;;G06V10/141;;G06V10/25;;H04N5/232;;H04N5/235,,4,3,015-156-610-229-239;;051-626-542-773-142;;061-048-595-006-271,10.1145/882262.882270;;10.1109/tip.2006.877312;;16948325;;10.1155/2007/80971,"Kang, Sing Bing, et al. “High Dynamic Range Video.” ACM Transactions on Graphics (TOG), vol. 22,. No. 3., 2003 (pp. 319-325).;;Meylan, Laurence, et al., “High Dynamic Range Image Rendering With a Retinex-Based Adaptive Filter”, IEEE Transactions on Image Processing, vol. 15, No. 9, Sep. 2006 (pp. 2820-2830).;;Marsi, Stefano, et al. “Video Enhancement and Dynamic Range Control of HDR Sequences for Automotive Applications”, EURASIP Journal on Advances in Signal Processing, May 13, 2007 (9 pages in English).;;Extended European Search Report dated Jul. 30, 2018, in corresponding European Application No. 18158136.4 (11 pages in English).",ACTIVE
184,US,A1,US 2016/0341469 A1,046-955-961-704-463,2016-11-24,2016,US 201615157546 A,2016-05-18,US 201615157546 A;;US 201562162919 P,2015-05-18,DRAWER SYSTEM INCLUDING COVER,"A drawer system includes a drawer and a drawer cover. The drawer can include an open top and be configured to be supported at a supporting structure, such as a refrigerator fresh food compartment for example, for selective sliding movement outwardly from the supporting structure and sliding movement inwardly toward the supporting structure. The drawer cover can be configured to be mounted at the supporting structure in engagement with the drawer at the open top of the drawer for movement directly vertically upwardly at the supporting structure away from the open top of the drawer when the drawer is moved outwardly from the supporting structure and for movement directly vertically downwardly at the supporting structure toward the open top of the drawer when the drawer is moved inwardly toward the supporting structure.",ELECTROLUX HOME PROD INC,HANSON JOSHUA;;SHRADER BENJAMIN PAUL;;RIZZI SABA;;CHO NATHAN,ELECTROLUX HOME PRODUCTS INC (2016-05-16),https://lens.org/046-955-961-704-463,Patent Application,yes,0,17,3,3,0,A47B2210/08;;A47B2210/08;;A47B2210/175;;A47B2210/175;;F25D25/025;;F25D25/025;;F25D23/062;;F25D2323/02;;F25D2325/00,F25D25/02;;F25D23/06,,0,0,,,,ACTIVE
185,CN,A,CN 113624360 A,099-043-234-982-513,2021-11-09,2021,CN 202110813939 A,2019-12-04,US 201816233959 A;;CN 201980086810 A,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,The invention relates to a method and a system for monitoring tissue temperature. Disclosed are a system and a method utilizing thermoacoustic imaging to estimating tissue temperature within a region of interest that includes an object of interest and a reference which are separated by at least one boundary located at least at two boundary locations. The system and the method use a thermoacoustic imaging system and one or more processors. The thermoacoustic imaging system includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein and an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest. The one or more processors are able to: process received bipolar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the bipolar acoustic signals and a distance between the boundary locations.,ENDRA LIFE SCIENCES INC,CHO JANG-HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/099-043-234-982-513,Patent Application,no,0,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,G01K11/22;;G01K13/20,,0,0,,,,PENDING
186,WO,A1,WO 2020/139528 A1,178-691-394-953-585,2020-07-02,2020,US 2019/0064450 W,2019-12-04,US 201816233959 A,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,A system and method utilizing thermoacoustic imaging to estimate tissue temperature within a region of interest (ROI) that includes an object of interest and a reference which are separated by at least one boundary with at least two boundary locations. The system and method use a thermoacoustic imaging system that includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue ROI and heat tissue therein and an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the ROI; and one or more processors that are able to: process received bipolar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the bipolar acoustic signals and a distance between the boundary locations.,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/178-691-394-953-585,Patent Application,yes,6,2,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/00;;A61B18/18;;A61B5/01;;A61B8/00,,0,0,,,,PENDING
187,US,B2,US 10170656 B2,048-021-941-988-749,2019-01-01,2019,US 201514623883 A,2015-02-17,US 201514623883 A;;US 201213463069 A;;US 40115709 A,2009-03-10,Inverted metamorphic multijunction solar cell with a single metamorphic layer,"The present disclosure provides a multijunction solar cell that includes: a first sequence of layers of semiconductor material forming a first set of one or more solar subcells; a graded interlayer adjacent to said first sequence of layers; a second sequence of layers of semiconductor material forming a second set of one or more solar subcells; and a high band gap contact layer adjacent said second sequence of layers, wherein the high band gap contact layer is composed of p++ type InGaAlAs or InGaAs.",SOLAERO TECH CORP,NEWMAN FRED;;CHO BENJAMIN;;STAN MARK A;;SHARPS PAUL,SOLAERO TECHNOLOGIES CORP (2015-08-06),https://lens.org/048-021-941-988-749,Granted Patent,yes,115,0,2,111,0,H01L31/06875;;H01L31/06875;;H01L31/03046;;H01L31/03046;;H01L31/0693;;H01L31/0725;;H01L31/0725;;H01L31/0735;;H01L31/0735;;H01L31/078;;H01L31/078;;H01L31/1844;;H01L31/1844;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02P70/50;;Y02P70/50,H01L31/18;;H01L31/0304;;H01L31/0352;;H01L31/0687;;H01L31/0693;;H01L31/0725;;H01L31/0735,,46,19,026-281-940-590-23X;;015-557-396-201-987;;015-557-396-201-987;;073-300-069-664-773;;115-973-926-256-941;;083-287-525-840-54X;;025-407-739-778-403;;164-535-659-415-932;;007-176-082-871-508;;106-513-576-934-63X;;076-989-478-838-81X;;015-717-993-971-840;;030-787-136-717-28X;;038-574-682-896-969;;052-700-785-133-704;;093-340-948-123-836;;026-862-096-577-376;;026-862-096-577-376;;107-582-530-482-098,10.1109/wcpec.2006.279587;;10.1109/pvsc.2010.5614498;;10.1109/pvsc.2010.5614498;;10.1109/wcpec.2006.279527;;10.1063/1.2753729;;10.1109/pvsc.2008.4922452;;10.1109/pvsc.2002.1190685;;10.1016/0022-0248(84)90363-4;;10.1016/0379-6787(88)90047-6;;10.1109/pvsc.1990.111608;;10.1109/iscs.1998.711543;;10.1002/pip.449;;10.1016/j.jcrysgro.2009.10.059;;10.1002/pip.642;;10.1109/pvsc.1991.169189;;10.1063/1.106494;;10.1109/wcpec.2006.279559;;10.1109/wcpec.2006.279559;;10.1134/1.1187812,"U.S. Appl. No. 12/265,113, filed Nov. 5, 2008, Varghese.;;U.S. Appl. No. 12/708,361, filed Feb. 18, 2010, Cornfeld et al.;;U.S. Appl. No. 12/730,018, filed Mar. 23, 2010, Cornfeld.;;U.S. Appl. No. 12/756,926, filed Apr. 8, 2010, Cornfeld et al.;;U.S. Appl. No. 12/813,408, filed Jun. 10, 2010, Patel et al.;;U.S. Appl. No. 12/844,673, filed Jul. 27, 2010, Stan et al.;;U.S. Appl. No. 13/569,794, filed Aug. 8, 2012, Stan et al.;;U.S. Appl. No. 13/604,883, filed Sep. 6, 2012, Tourino et al.;;U.S. Appl. No. 14/026,818, filed Sep. 13, 2013, Miller et al.;;U.S. Appl. No. 14/485,121, filed Sep. 12, 2014, Lin et al.;;U.S. Appl. No. 14/485,378, filed Sep. 12, 2014, Yang et al.;;Advisory Action dated Mar. 15, 2011. U.S. Appl. No. 11/445,793.;;Aiken et al. “Consideration of High Bandgap Subcells for Advanced Multijunction Solar Cells,” Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 1, 2006, pp. 838-841.;;Cornfeld et al., “Development of a Large Area Inverted Metamorphic Multi-junction (IMM) Highly Efficient AM0 Solar Cell,” 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Cornfeld et al., “Development of a Large Area Inverted Metamorphic Multi-junction Highly Efficient AM0 Solar Cell,” Conference paper presented at the 33rd IEEE Photovoltaic Specialists Conference (May 11-16, 2008) on May 12, 2008. San Diego, CA, USA. 17 pages.;;Cornfeld et al., “Advances in the Performance of Inverted Metamorphic Multi-junction Solar Cells,” 23rd European Photovoltaic Energy Conference, Sep. 1-5, 2008, Valencia, Spain.;;“European Search Report,” Application No. EP 08 01 3466, dated Dec. 18, 2009. European Patent Office, Berlin, Germany.;;Friedman et al., “0.7-eV GaInAs Junction for a GaInP/GaAs/GaInAs(1eV)/GaInAs(0.7eV) Four-Junction Solar Cell,” 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA.;;Geisz et al., “High-efficiency GaInP/GaAs/InGaAs triple-junction solar cells grown inverted with a metamorphic bottom junction,” Applied Physics Letters, 2007; 91(023502):023502-1-023502-3. Online publication Jul. 10, 2007. American Institute of Physics, Melville, NY, USA.;;Geisz, et al., “Inverted GaInP/(In)GaAs/InGaAs Triple-Junction Solar Cells with Low-Stress Metamorphic Bottom Junctions,” 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;King et al., “Next-Generation, High-Efficiency III-V Multijunction Solar Cells,” 28th IEEE Photovoltaic Specialists Conference, Sep. 15-22, 2000, Anchorage, AK, USA.;;King et al., “High-Efficiency Space and Terrestrial Multijunction Solar Cells Through Bandgap Control in Cell Structures,” 2002 Photovoltaic Specialists Conference, Conference Record of the 29th IEEE, May 19-24, 2002, pp. 776-781. New Orleans, LA, USA.;;Lewis et al., “The Crystallographic Connection of MOCVD-Grown Monolithic Cascade Subcells via Transparent Graded Layers,” Journal of Crystal Growth, 1984; 69:515-526.;;Lewis et al., “Recent Developments in Multijunction Solar Cell Research,” Solar Cells, 1988; 24:171-183.;;Office Action dated Nov. 9, 2010 (double patenting rejection). U.S. Appl. No. 11/860,183.;;Office Action dated Nov. 10, 2010 (double patenting rejection). U.S. Appl. No. 12/102,550.;;Office Action dated Dec. 22, 2010 (double patenting rejection). U.S. Appl. No. 11/956,069.;;Office Action dated Jan. 4, 2011. U.S. Appl. No. 11/445,793. (Sexl reference, double patenting rejection).;;“Partial European Search Report,” Application No. EP 08 01 3466, dated Feb. 12, 2009. European Patent Office, Berlin, Germany.;;Schultz et al. “High Efficiency 1.0 eV GaInAs Bottom Solar Cell for 3-junction Monolithic Stack,” Conference Record of the Twenty First IEEE Photovoltaic Specialists Conference. Kissimmee, Florida; May 21-25, 1990. New York: The Institute of Electrical and Electronics Engineers, Inc., pp. 148-152.;;Sexl et al., “MBE Growth of Metamorphic In(Ga)AIAs Buffers,” 1997 IEEE International Symposium on Compound Semiconductors, Sep. 1997, pp. 49-52. IEEE, Piscataway, NJ.;;Sharps et al., “Inverting the triple junction improves efficiency and flexibility,” Compound Semiconductor, Oct. 2007; 13(9):25-28.;;Sinharoy et al., “Progress in the Development of Metamorphic Multi junction III-V Space Solar Cells,” Progress in Photovoltaics: Research and Applications, Feb. 2002; 10:427-432.;;Stan et al., “Very High Efficiency Triple Junction Solar Cells by MOVPE,” 14th International Conference of Metalorganic Vapor Phase Epitaxy. Jun. 1-6, 2008, Metz, France.;;Stan, et al., “High-efficiency quadruple junction solar cells using OMVPE with inverted metamorphic device structures,” Journal of Crystal Growth, 2010; 312:1370-1374. Elsevier, Amsterdam, Netherlands.;;Takamoto, et al., “Future Development of InGaP/(In)GaAs Based Multijunction Solar Cells,” Proceedings of the 31st IEEE PVSC, Jan. 3-7, 2005, pp. 519-524. Lake Buena Vista, FL.;;Takamoto et al., “InGaP/GaAs-based Multijunction Solar Cells,” Progress in Photovoltaics: Research and Applications, 2005; 13(495-511).;;Venkatasubramanian et al., “An Inverted-Growth Approach to Development of an IR-Transparent, High-Efficiency AIGaAs/GaAs Cascade Solar Cell,” 22nd IEEE Photovoltaic Specialists Conference, Oct. 7-11, 1991, Las Vegas, NV, USA.;;Venkatasubramanian et al., “High-quality eutectic-metal-bonded AIGaAs—GaAs thin films on Si substrates,” Applied Physics Letters, Feb. 17, 1992; 60(7):886-888.;;Wanlass et al., “Lattice-Mismatched Approaches for High-Performance, III-V Photovoltaic Energy Converters,” Proceedings of the 31st IEEE PVSC, Jan. 3-7, 2005. Lake Buena Vista, FL, USA.;;Wanlass et al., “Lattice-Mismatched Approaches for High-Performance, III-V Photovoltaic Energy Converters,” Conference Record of the 31st IEEE PVSC, Jan. 3, 2005; pp. 530-535. Piscataway, NJ, USA.;;Wanlass et al., “Monolithic, Ultra-Thin GaInP/GaAs/GalnAs Tandem Solar Cells,” 2006 4th IEEE World Conference on Photovoltaic Energy Conversion, May 1, 2006; pp. 729-732.;;Wanlass et al., “Monolithic, Ultra-Thin GaInP/GaAs/GaInAs Tandem Solar Cells,” 2006 IEEE World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA.;;Wurfel. Physics of Solar Cells: from Basic Principles to Advanced Concepts, 2nd Updated and Expanded Edition, 2009. Sections 6.4, 6.5 and 6.8; 20 pages. Wiley-VCH, Weinheim, Germany.;;Yamaguchi, “Physics and Technologies of Superhigh-Effficiency Tandem Solar Cells,” Semiconductors, Sep. 1999; 33(9):961-964, Toyota Technological Institute, Nagoya, Japan, © 1999, American Institute of Physics.;;Yoon et al., “Progress of Inverted Metamorphic III-V Solar Cell Development at Spectrolab,” 33rd IEEE Photovoltaic Specialists Conference, May 11-16 2008, San Diego, CA, USA.",ACTIVE
188,US,A1,US 2020/0333796 A1,157-137-998-337-628,2020-10-22,2020,US 202016917118 A,2020-06-30,US 202016917118 A;;KR 20170024824 A;;US 201715818347 A,2017-02-24,IMAGE PROCESSING METHOD FOR AUTONOMOUS DRIVING AND APPARATUS THEREOF,A processor implemented image processing method includes recognizing a target object in a first frame of an input image; adjusting an exposure of a second frame of the input image based on a brightness of the target object; and generating a synthesized image by synthesizing the first frame and the second frame.,SAMSUNG ELECTRONICS CO LTD,SEO YOUNG WAN;;JEON PAUL BAROM;;CHO BAEK HWAN,,https://lens.org/157-137-998-337-628,Patent Application,yes,0,1,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,G05D1/02;;G01C21/16;;G01C21/26;;G01C21/34;;G01S19/47;;G05D1/00;;G06T5/00;;G06T5/50;;G06T7/73;;G06V10/141;;G06V10/25;;H04N5/232;;H04N5/235,,0,0,,,,ACTIVE
189,US,A1,US 2023/0056819 A1,159-355-351-289-424,2023-02-23,2023,US 202117758734 A,2021-01-14,KR 20200006342 A;;KR 2021000569 W,2020-01-17,COMPOSITE MATERIAL,A brake body according to the present disclosure has a coating layer which contains an iron-based amorphous alloy and is formed on a contact surface at which a friction means rubs against the brake body to generate braking force which the brake body is rotated. The coating layer has a low friction coefficient and thus generates less dust during braking. The coating layer also has high corrosion resistance and wear resistance and may thus guarantee high performance and good price competitiveness when applied to a brake base material produced at low cost.,KOLON INC,CHO GEUN SANG;;KIM CHOONGNYUN PAUL;;CHOI KWAN MIN,KOLON INDUSTRIES INC (2022-03-10),https://lens.org/159-355-351-289-424,Patent Application,yes,0,0,6,6,0,F16D69/027;;F16D2250/0046;;F16D65/125;;F16D65/127;;B32B15/011;;C22C45/02;;C22C33/003;;C23C4/129;;C23C4/06;;C23C4/067;;C23C30/00;;C23C4/134;;C23C24/04;;C23C24/08;;C23C24/082;;C23C24/10;;F16D69/027;;F16D2250/0046;;F16D65/123;;F16D65/125;;F16D65/127;;F16D69/027;;F16D2200/0008;;F16D2250/0046,F16D65/12;;F16D69/02,,0,0,,,,PENDING
190,US,B2,US 7723405 B2,190-302-490-370-93X,2010-05-25,2010,US 62027607 A,2007-01-05,US 62027607 A;;US 75684106 P,2006-01-05,Self-healing coating system,"A self-healing coating includes a polymer matrix, a polymerizer, and a set of capsules containing a corresponding activator for the polymerizer. The polymerizer may be present in another set of capsules, or the polymerizer may be phase separated from the polymer matrix. The coating may be prepared by depositing a coating composition on a substrate and solidifying the coating composition, where the coating composition includes the polymerizer, the activator capsules and a matrix precursor. A combination of polymerizer capsules and activator capsules may be part of a kit, which may be used to provide self-healing properties to a coating. The polymerizer and the activator may be wet-curable, and coatings containing the polymerizer and activator may be able to self-heal when in contact with water.",UNIV ILLINOIS,BRAUN PAUL V;;CHO SOO HYOUN;;WHITE SCOTT R,THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2007-03-07),https://lens.org/190-302-490-370-93X,Granted Patent,yes,97,67,5,5,0,B29C73/163;;B29C73/22;;C08G77/04;;C08G77/60;;C08K5/098;;C08K9/10;;C08L83/04;;C08L101/00;;C09D5/00;;C09D183/04;;C09D7/67;;C09D7/68;;C09D7/69;;C09D7/70;;Y10T428/2985;;C09D7/65;;Y10T428/2985;;C08L83/04;;C08L101/00;;C08G77/04;;C09D5/00;;B29C73/163;;C08K9/10;;B29C73/22;;C09D183/04;;C08K5/098;;C08G77/60;;C09D7/70;;C09D7/68;;C09D7/67;;C09D7/69;;C09D7/65,C08K9/06;;C09D7/65,523/212;;528/38;;528/71,70,47,162-520-781-772-058;;016-049-804-950-318;;004-661-793-312-956;;002-892-432-405-378;;015-788-629-510-755;;131-620-028-146-501;;000-298-832-501-604;;013-490-090-949-021;;083-533-256-589-668;;012-205-744-526-158;;011-897-357-168-534;;186-535-924-711-344;;076-798-598-569-712;;082-384-453-424-130;;014-792-882-849-045;;170-610-332-806-274;;093-484-358-134-335;;077-764-439-479-366;;086-894-629-121-172;;009-662-627-686-297;;154-394-767-357-056;;046-200-523-560-505;;069-332-614-378-599;;065-000-446-201-13X;;170-516-225-875-150;;043-116-372-017-853;;139-315-047-775-506;;008-881-194-036-259;;097-278-256-690-742;;111-202-917-015-053;;041-817-229-792-055;;175-787-606-249-651;;060-619-020-427-518;;032-060-047-479-30X;;007-053-882-979-496;;002-382-271-095-013;;116-086-960-052-69X;;002-382-271-095-013;;012-054-779-954-464;;006-768-208-140-560;;155-552-614-776-505;;139-351-452-102-573;;048-708-929-094-081;;042-776-607-112-28X;;116-234-691-305-864;;025-361-036-003-520;;077-348-794-905-566,10.1021/ja01665a002;;10.1103/physrevlett.45.569;;10.1016/j.compscitech.2007.07.021;;10.1016/j.solmat.2004.12.008;;10.1002/htj.20138;;10.1039/b411359d;;12411700;;10.1126/science.1074868;;10.1351/pac200476071365;;10.1126/science.1109164;;15845850;;10.1002/app.21438;;2654353;;10.3109/02652048909019898;;10.1002/pi.1125;;10.1088/0964-1726/5/3/007;;10.1088/0964-1726/3/2/006;;10.1016/0263-8223(96)00033-5;;10.1016/s0040-4020(97)10427-6;;10.1021/ja963136z;;10.1016/0079-6700(93)90012-2;;10.1021/om9708788;;10.1021/ma970292x;;10.1021/ma00125a030;;10.1021/ma00016a003;;10.1016/s1359-8368(98)00034-1;;10.1038/35057232;;11236987;;10.1021/ma010438z;;10.1038/35057412;;11236978;;10.1023/b:jmsc.0000016173.73733.dc;;10.1080/0265204031000154160;;14594661;;10.3109/02652040309178083;;10.1177/001448502321548193;;10.1002/pola.10317;;10.1016/s1359-835x(03)00138-6;;10.1021/ma0209489;;10.1021/ja952676d;;10.1021/jo030005p;;12868947;;10.1063/1.328526;;10.1002/adma.200501814;;10.1016/j.corsci.2004.10.018;;10.1002/adma.200501814;;10.1177/0021998305055188;;10.1016/0020-7403(92)90060-t;;10.1016/j.matchemphys.2004.06.043;;10.1016/s0079-6700(02)00010-2;;10.1080/02652040110055243;;11695640;;10.1021/ma012214m;;10.1016/0376-7388(94)00306-j;;10.1002/macp.200290052;;10.1021/la001276n,"International Search Report and Written Opinion dated Oct. 24, 2007 for PCT application No. PCT/US2007/069981.;;International Search Report and Written Opinion dated Feb. 22, 2008 for PCT application No. PCT/US2007/060149.;;Keller, M.W. et al., ""An elastomeric self-healing material"", Proceedings of the 2006 SEM Annual Conference and Exposition on Experimental and Applied Mechanics 2006, vol. 1, pp. 379-382, (2006).;;Pickering, S.U., ""Emulsions"", Journal of the Chemical Society, Transactions, vol. 91, pp. 2001-2021, (1907).;;Finkle, P. et al., ""The theory of emulsification"", Journal of the American Chemical Society, vol. 45, No. 12, pp. 2780-2788, (1923).;;Pieranski, P. ""Two-dimensional interfacial colloidal crystals"", Physical Review Letters, vol. 45, No. 7, pp. 569-572, (1980).;;Gotro, J. et al., ""Thermosets"", Encyclopedia of Polymer Science and Technology, vol. 12, pp. 207-260, John Wiley & Sons, (2004).;;Blaiszik, B.J. et al., ""Nanocapsules for self-healing materials"", Composites Science and Technology, vol. 68, pp. 978-986, (2008).;;Gschwander, S. et al., ""Micro-encapsulated paraffin in phase-change slurries"", Solar Energy Materials & Solar Cells, vol. 89, pp. 307-315, (2005).;;Rao, Y. et al.,""Preparation and thermal properties of microencapsulated phase change material for enhancing fluid flow heat transfer"", Heat Transfer-Asian Research, vol. 36, No. 1, pp. 28-37, (2007), originally published in 2005.;;Wei, L. et al., ""Preparation and characterization of microencapsulated phase change material with low remnant formaldehyde content"", Materials Chemistry and Physics, vol. 106, pp. 437-442, (2007).;;Cayre, O.J. et al., ""Fabrication of novel colloidosome microcapsules with gelled aqueous cores"", Journal of Materials Chemistry, vol. 14, pp. 3351-3355, (2004).;;Dinsmore, A.D. et al., ""Colloidosomes: Selectively permeable capsules composed of colloidal particles"", Science, vol. 298, pp. 1006-1009, (2002).;;Croll, L.M. et al., ""Composite tectocapsules via the self-assembly of functionalized poly(divinylbenzene) microspheres"", Pure Appl. Chemistry, vol. 76, No. 7-8, pp. 1365-1374, (2004).;;Utada, A.S. et al., ""Monodisperse double emulsions generated from a microcapillary device"", Science, vol. 308, pp. 537-541, (2005).;;Shin, Y. et al., ""Development of thermoregulating textile materials with microencapsulated phase change materials (PCM). II. Preparation and application of PCM Microcapsules"", Journal of Applied Polymer Science, vol. 96, pp. 2005-2010, (2005).;;Arshady, R., ""Preparation of microspheres and microcapsules by interfacial polycondensation techniques"", Journal of Microencapsulation, vol. 6, issue 1, pp. 13-28, (1989).;;Mayya, K.S. et al., ""Micro-encapsulation by complex coacervation: influence of surfactant"", Polymer International, vol. 52, pp. 644-647, (2003).;;Karukstis, K.K. et al., ""Chemistry Connections: The chemical basis of everyday phenomena"", Academic Press, second edition, p. 88, (2003).;;Stevens, M.P., Polymer Chemistry, p. 184-186, 1999.;;Stevens, M.P. Polymer Chemistry, p. 378-381, 1999.;;Dry, C., et al., ""Three part methylmethacrylate adhesive system as an internal delivery system for smart responsive concrete"", Smart Mater. Struct., 5, p. 297-300, 1996.;;Dry, C. ""Matrix cracking repair and filling using active and passive modes for smart time release of chemicals from fibers into cement matrices"", Smart Mater. Struct., 3, p. 118-123, 1994.;;Dry, C., ""Procedures developed for self-repair of polymer matrix composite materials"", Composite Structures, 35, p. 263-269, 1996.;;Dry, C. et al., ""Passive smart self-repair in polymer matrix composite materials"", SPIE, vol. 1916, p. 438-444, 1993.;;D. Jung, et al., ""Self-healing composites using embedded microspheres"", K. Jacob, N. Katsube and W. Jones, ed., vol. MD-80, in Proceedings of the ASME International Mechanical Engineering Conference and Exposition, 265-275 (1997).;;Beckwith, et al., ""Resin Transfer Molding: A Decade of Technology Advances"", SAMPE Journal, vol. 34, No. 6, p. 7-19, 1998.;;Grubbs, R.H., et al., ""Recent Advances in Olefin Metathesis and Its Application in Organic Synthesis"", Tetrahedron 54, p. 4413-4450, 1998.;;Dias, E.L., et al., ""Well-Defined Ruthenium Olefin Metathesis Catalyst: Mechanism and Activity"", J. Am. Chem. Soc., 119, p. 3887-3897, 1997.;;Breslow, D.S., ""Metathesis Polymerization"", Prog. Polym. Sci. Vol. 18, p. 1141-1195, 1993.;;Dias, E.L., et al., ""Synthesis and Investigation of Homo- and Heterobimetallic Ruthenium Olefin Metathesis Catalysts Exhibiting Increased Activities"", Organometallics, 17, p. 2758-2767, 1998.;;Weck, M., et al., ""Synthesis of Discotic Columnar Side-Chain Liquid Crystalline Polymers by Ring-Opening Metathesis Polymerization (ROMP)"", Macromolecules, 30, p. 6430-6437, 1997.;;Fraser, C., et al., ""Synthesis of Glycopolymers of Controlled Molecular Weight by Ring-Opening Metathesis Polymerization Using Well-Defined Functional Group Tolerant Ruthenium Carbene Catalysts"", Macromolecules, 28, p. 7248-7255, 1995.;;Bazan, G.C., et al., ""Polymerization of Functionalized Norbornenes Employing Mo (CH-t-Bu) (NAr) (O-t-Bu)2 as the Initiator"", Macromolecules, 24, p. 4495-4502, 1991.;;Li, Victor C., et al., ""Feasibility Study of a Passive Smart Self-healing cementitious composite."", Composites Part B, 29B, p. 819-827, 1998.;;International Search Report dated Oct. 4, 2002 for Application No. PCT/US02/04163.;;White, S.R., et al., ""Autonomic healing of polymer composites"", Nature, vol. 41, pp. 794-797, (2001).;;Dean, K., ""Near-Infrared and Rheological Investigations of Epoxy-Vinyl Ester Interpenetrating Polymer Networks"", Macromolecules, 34: 6623-6630, 2001.;;Wool, Richard P., ""A material fix"", Nature, vol. 409, p. 773-774, 2001.;;EPON, Resin 160 Epoxy Novolac Resin, Product Bulletin, p. 1-3, 2001.;;Brown, E.N., et al., ""Microcapsule Induced Toughening in a Self-Healing Polymer Composite"", J. Mater. Sci.,39:1703-1710, 2004.;;Brown, E.N., et al., ""In Situ Poly(Urea-Formaldehyde) Microencapsulation of Dicyclopentadiene"", J. Microencapsulation, 20: 719-730, 2003.;;Brown, E.N., et al., ""Fracture Testing of a Self-Healing Polymer Composite"", Exp. Mech., 42: 372-379, 2002.;;Kessler, M.R., et al., ""Cure Kinetics of the Ring-Opening Metathesis Polymerization of Dicyclopentadiene"", J. Polym. Sci. A: Polym. Chem., 40: 2373-2383, 2002.;;Kessler, M.R., et al., ""Self-Healing Structural Composite Materials"", Composites: Part A, 34: 743-753, 2003.;;Mostovoy, S., et al., ""Use of Crack-Line-Loaded Specimens for Measuring Plane-Strain Fracture Toughness"", J. Mater. , 2: 661-681, 1967.;;Rule, J.D., et al., ""ROMP Reactivity of Endo- and Exo-Dicyclopentadiene"", Macromolecules, 35: 7878-7882, 2002.;;Schwab, P., et al., ""Synthesis and Applications of RuCl2(=CHR') (PR3)2: The Influence of the Alkylidene Moiety on Metathesis Activity"", J. Am. Chem, Soc., 118: 100-110, 1996.;;Taber, D.F., et al., ""Grubbs' Catalyst in Paraffin: An Air-Stable Preparation for Alkene Metathesis"", J. Org. Chem., 68 6047-6048, 2003.;;Wool, R.P., et al., ""A Theory of Crack Healing in Polymers"", J. Appl. Phys., 52: 5953-5963, 1981.;;International Search Report dated Nov. 9, 2005 for PCT application No. PCT/US2005/015783.;;Holden, G. ""Elastomers, Thermoplastic"" Encyclopedia of Polymer Science and Technology, John Wiley & Sons, 1-25, 2002.;;Cho, S.H., ""Polydimethylsiloxane-Based Self-Healing Materials"", Advanced Materials, vol. 18, Issue 8, 997-100, Apr. 7, 2006.;;International Search Report dated Aug. 1, 2006 for PCT Application No. PCT/US2006/015703.;;Cook, D.C., ""Spectroscopic identification of protective and non-protective corrosion coatings on steel structures in marine environments"", Corrosion Science, vol. 47, pp. 2550-2570, (2005).;;Wessling, B., ""Scientific engineering of anti-corrosion coating systems based on organic metals (polyaniline)"", Journal of Corrosion Science and Engineering, vol. 1, paper 15, 19 pages, found at www.jcse.org, ISSN 1466-8858, (1999).;;Cho, S.H., et al., ""Polydimethylsiloxane-based self-healing materials"", Advanced Materials, vol. 18, issue 8, pp. 997-1000, (2006).;;Rzeszutko, A.A. et al., ""Tensile properties of self-healing epoxy"", TAM Techinical Reports-1041: Proceedings of the Fifth Undergraduate Research Conference in Mechanics, pp. 27-33, (2004).;;Sudduth, R.D., ""Analysis of the maximum tensile strength of a composite with spherical particulates"", Journal of Composite Materials, vol. 40, No. 4, pp. 301-331, (2006); published on-line (2005).;;Tvergaard, V., ""Effect of ductile particle debonding during crack bridging in ceramics"", International Journal of Mechanical Sciences, vol. 34, No. 8, pp. 635-649, (1992).;;Zhang, X.X. et al., ""Fabrication and properties of microcapsules and nanocapsules containing n-octadecane"", Materials Chemistry and Physics, vol. 88, pp. 300-307, (2004).;;Asua, J.M., ""Miniemulsion Polymerization"", Prog. Polymer Science, vol. 27, pp. 1283-1346, (2002).;;Schork, F.J., ""Miniemulsion Polymerization"", Adv. Polym. Sci., vol. 175, pp. 129-255, (2005).;;Blaiszik, B.J. et al., ""Nanocapsules for self-healing composites"", Proceedings of the SEM annual meeting on experimental and applied mechanics, Society for Experimental Mechanics, St. Louis, MO, 6 pages, Jun. 4-7, 2006.;;Alexandridou, S. et al., ""Surface characterization of oil-containing polyterephthalamide microcapsules prepared by interfacial polymerization"", J. Microencapsulation, vol. 18, No. 6, pp. 767-781, (2001).;;IUPAC, ""emulsion"", IUPAC Compendium of Chemical Terminology: IUPAC Recommendations, 2nd Edition, compiled by A.D. McNaught and A. Wilkinson, Blackwell, Oxford, 1 page, (1997).;;Lansalot, M. et al., ""RAFT miniemulsion polymerization: Influence of the structure of the RAFT agent"", Macromolecules, vol. 35, No. 20, pp. 7582-7591, (2002).;;Ni, P. et al., ""Effect of operating variables and monomers on the formation of polyurea microcapsules"", Journal of Membrane Science, vol. 103, pp. 51-55, (1995).;;Ramirez, L.P. et al.,""Magnetic polystyrene nanoparticles with a high magnetite content obtained by miniemulsion processes"", Macromolecular Chemistry and Physics, vol. 204, No. 1, pp. 22-31, (2003).;;Tiarks, F. et al., ""Preparation of polymeric nanocapsules by miniemulsion polymerization"", Langmuir, vol. 17, No. 3, pp. 908-918, (2001).",ACTIVE
191,WO,A1,WO 2020/139527 A1,047-096-629-011-589,2020-07-02,2020,US 2019/0064447 W,2019-12-04,US 201816233935 A,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,"A thermoacoustic imaging system and method for monitoring tissue temperature within a region of interest, which has an object of interest and a reference that are separated by at least one boundary. The system and method include a thermoacoustic imaging system with an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein, an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest, and one or more processors that process at least one received bipolar acoustic signal generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof and calculate a temperature at the at least one boundary using the peak-to-peak amplitude of the at least one bipolar acoustic signal.",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/047-096-629-011-589,Patent Application,yes,5,0,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B18/12;;A61B18/04;;A61B18/10;;A61B18/14,,1,0,,,See also references of EP 3902490A4,PENDING
192,EP,A4,EP 3902490 A4,034-173-911-597-450,2022-09-14,2022,EP 19901545 A,2019-12-04,US 201816233935 A;;US 2019/0064447 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/034-173-911-597-450,Search Report,no,2,0,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B18/12;;A61B5/0507;;A61B18/00;;A61B18/04;;A61B18/10;;A61B18/14;;A61B18/18,,1,0,,,See also references of WO 2020139527A1,ACTIVE
193,US,B2,US 11141067 B2,104-305-631-432-618,2021-10-12,2021,US 201816233935 A,2018-12-27,US 201816233935 A,2018-12-27,Method and system for monitoring tissue temperature,"A thermoacoustic imaging system and method for monitoring tissue temperature within a region of interest, which has an object of interest and a reference that are separated by at least one boundary. The system and method include a thermoacoustic imaging system with an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein, an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest, and one or more processors that process at least one received bipolar acoustic signal generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof and calculate a temperature at the at least one boundary using the peak-to-peak amplitude of the at least one bipolar acoustic signal.",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/104-305-631-432-618,Granted Patent,yes,8,0,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B5/00;;A61B5/01;;A61B5/20;;A61B8/00;;A61B8/08,,2,1,013-000-205-460-222,pmc2774978;;19895126;;10.1117/1.3247155,"Blaine R. Copenheaver; PCT International Search Report and Written Opinion; dated Feb. 21, 2020; 9 pages total; WIPO Alexandria, VA, United States.;;Manojit Pramanik, Lihong V. Wang; Thermoacoustic and photoacoustic sensing of temperature; Journal of Biomedical Optics 14(5), 054024,Sep./Oct. 2009; pp. 054024-1 through 054024-7; published online Oct. 12, 2009.",ACTIVE
194,EP,A2,EP 1973972 A2,098-056-276-852-473,2008-10-01,2008,EP 07709966 A,2007-01-05,US 2007/0060149 W;;US 75684106 P,2006-01-05,SELF-HEALING COATING SYSTEM,,UNIV ILLINOIS,BRAUN PAUL V;;CHO SOO HYOUN;;WHITE SCOTT R,,https://lens.org/098-056-276-852-473,Patent Application,yes,0,1,5,5,0,B29C73/163;;B29C73/22;;C08G77/04;;C08G77/60;;C08K5/098;;C08K9/10;;C08L83/04;;C08L101/00;;C09D5/00;;C09D183/04;;C09D7/67;;C09D7/68;;C09D7/69;;C09D7/70;;Y10T428/2985;;C09D7/65;;Y10T428/2985;;C08L83/04;;C08L101/00;;C08G77/04;;C09D5/00;;B29C73/163;;C08K9/10;;B29C73/22;;C09D183/04;;C08K5/098;;C08G77/60;;C09D7/70;;C09D7/68;;C09D7/67;;C09D7/69;;C09D7/65,C08L101/00;;C08L83/04;;C09D7/65,,0,0,,,,DISCONTINUED
195,WO,A3,WO 2007/082153 A3,152-203-171-868-595,2008-04-17,2008,US 2007/0060149 W,2007-01-05,US 75684106 P,2006-01-05,SELF-HEALING COATING SYSTEM,"A self-healing coating includes a polymer matrix, a polymerizer, and a set of capsules containing a corresponding activator for the polymerizer. The polymerizer may be present in another set of capsules, or the polymerizer may be phase separated from the polymer matrix. The coating may be prepared by depositing a coating composition on a substrate and solidifying the coating composition, where the coating composition includes the polymerizer, the activator capsules and a matrix precursor. A combination of polymerizer capsules and activator capsules may be part of a kit, which may be used to provide self-healing properties to a coating. The polymerizer and the activator may be wet-curable, and coatings containing the polymerizer and activator may be able to self-heal when in contact with water.",UNIV ILLINOIS;;BRAUN PAUL V;;CHO SOO HYOUN;;WHITE SCOTT R,BRAUN PAUL V;;CHO SOO HYOUN;;WHITE SCOTT R,,https://lens.org/152-203-171-868-595,Search Report,yes,4,0,5,5,0,B29C73/163;;B29C73/22;;C08G77/04;;C08G77/60;;C08K5/098;;C08K9/10;;C08L83/04;;C08L101/00;;C09D5/00;;C09D183/04;;C09D7/67;;C09D7/68;;C09D7/69;;C09D7/70;;Y10T428/2985;;C09D7/65;;Y10T428/2985;;C08L83/04;;C08L101/00;;C08G77/04;;C09D5/00;;B29C73/163;;C08K9/10;;B29C73/22;;C09D183/04;;C08K5/098;;C08G77/60;;C09D7/70;;C09D7/68;;C09D7/67;;C09D7/69;;C09D7/65,C08L101/00;;C08L83/04;;C09D7/65,,0,0,,,,PENDING
196,KR,A,KR 20210093176 A,165-141-582-349-563,2021-07-27,2021,KR 20210005451 A,2021-01-14,KR 20200006341 A,2020-01-17,Pipe and method for manufaturing thereof,"The present invention is to provide a pipe with an improved lifespan by preventing wear or corrosion in a harsh corrosive environment of high temperature and acid. According to the present invention, the pipe comprises: a hollow tube body through which fluids having different temperatures pass inside and outside; and a coating layer provided on an outer surface of the hollow tube body and having an alloy including an amorphous phase. The alloy contains: at least one first component containing Fe and selected from a group consisting of Cr, Mo and Co; and at least one second component selected from a group consisting of B, C, Si and Nb.",KOLON INC,CHO GEUN SANG;;KIM CHOONGNYUN PAUL;;CHOI KWAN MIN,,https://lens.org/165-141-582-349-563,Patent Application,no,1,0,7,7,0,C23C4/16;;F16L58/08;;C23C4/067;;C23C24/08;;C23C24/04;;C23C4/129;;C23C4/134;;C23C4/137;;C23C4/18;;C23C4/06;;Y02E20/12;;F16L58/08;;C23C4/067;;C23C4/16;;C23C24/08;;F16L58/08,F16L58/08;;C23C4/067;;C23C4/16,,0,0,,,,PENDING
197,US,A1,US 2018/0246521 A1,062-463-766-426-794,2018-08-30,2018,US 201715818347 A,2017-11-20,KR 20170024824 A,2017-02-24,IMAGE PROCESSING METHOD FOR AUTONOMOUS DRIVING AND APPARATUS THEREOF,A processor implemented image processing method includes recognizing a target object in a first frame of an input image; adjusting an exposure of a second frame of the input image based on a brightness of the target object; and generating a synthesized image by synthesizing the first frame and the second frame.,SAMSUNG ELECTRONICS CO LTD,SEO YOUNG WAN;;JEON PAUL BAROM;;CHO BAEK HWAN,SAMSUNG ELECTRONICS CO. LTD (2017-11-08),https://lens.org/062-463-766-426-794,Patent Application,yes,0,11,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,G05D1/00;;G05D1/02;;G06T5/50;;G06T7/73;;G06V10/141;;G06V10/25;;H04N5/235,,0,0,,,,ACTIVE
198,EP,A4,EP 4092309 A4,065-730-244-328-436,2023-05-24,2023,EP 21741005 A,2021-01-14,KR 20200006341 A;;KR 2021000570 W,2020-01-17,PIPE AND MANUFACTURING METHOD THEREFOR,,KOLON INC,CHO GEUN SANG;;KIM CHOONGNYUN PAUL;;CHOI KWAN MIN,,https://lens.org/065-730-244-328-436,Search Report,no,4,0,7,7,0,C23C4/16;;F16L58/08;;C23C4/067;;C23C24/08;;C23C24/04;;C23C4/129;;C23C4/134;;C23C4/137;;C23C4/18;;C23C4/06;;Y02E20/12;;F16L58/08;;C23C4/067;;C23C4/16;;C23C24/08;;F16L58/08,F16L58/08;;C23C4/06;;C23C4/067;;C23C4/129;;C23C4/134;;C23C4/137;;C23C4/16;;C23C4/18;;C23C24/04;;C23C24/08,,1,0,,,See also references of WO 2021145710A1,PENDING
199,US,A1,US 2020/0237234 A1,085-778-316-559-005,2020-07-30,2020,US 202016848376 A,2020-04-14,US 202016848376 A;;US 201816233959 A,2018-12-27,SYSTEM FOR MONITORING TISSUE TEMPERATURE,A system utilizing thermoacoustic imaging to estimate tissue temperature within a region of interest that includes an object of interest and a reference which are separated by at least one boundary located at least at two boundary locations. The system uses a thermoacoustic imaging system that includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein and an acoustic receiver configured to receive multi-polar acoustic signals generated in response to heating of tissue in the region of interest; and one or more processors that are able to: process received multi-polar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the multi-polar acoustic signals and a distance between the boundary locations.,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/085-778-316-559-005,Patent Application,yes,0,1,2,13,0,A61B5/0095;;A61B5/015;;A61B5/4872;;A61B5/0507;;A61B5/4887;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B8/5223;;A61B8/5261;;A61B5/015;;A61B5/4872;;A61B5/0095;;A61B5/05,A61B5/01;;A61B5/00;;A61B5/05,,0,0,,,,ACTIVE
200,CN,A,CN 113260329 A,025-689-350-163-855,2021-08-13,2021,CN 201980086810 A,2019-12-04,US 201816233959 A;;US 2019/0064450 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,A system and method utilizing thermoacoustic imaging to estimate tissue temperature within a region of interest (ROI) that includes an object of interest and a reference which are separated by at least one boundary with at least two boundary locations. The system and method use a thermoacoustic imaging system that includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue ROI and heat tissue therein and an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the ROI; and one or more processors that are able to: process received bipolar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the bipolar acoustic signals and a distance between the boundary locations.,ENDRA LIFE SCIENCES INC,CHO JANG-HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/025-689-350-163-855,Patent Application,no,7,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B18/18;;A61B5/00;;A61B5/01;;A61B8/00,,0,0,,,,ACTIVE
201,WO,A1,WO 2016/187255 A1,017-086-554-600-292,2016-11-24,2016,US 2016/0032995 W,2016-05-18,US 201562162919 P,2015-05-18,DRAWER SYSTEM INCLUDING COVER,"A drawer system includes a drawer (22) and a drawer cover (24). The drawer (22) can include an open top and be configured to be supported at a supporting structure, such as a refrigerator fresh food compartment for example, for selective sliding movement outwardly from the supporting structure and sliding movement inwardly toward the supporting structure. The drawer cover (24) can be configured to be mounted at the supporting structure in engagement with the drawer (22) at the open top of the drawer (22) for movement directly vertically upwardly at the supporting structure away from the open top of the drawer (22) when the drawer (22) is moved outwardly from the supporting structure and for movement directly vertically downwardly at the supporting structure toward the open top of the drawer (22) when the drawer (22) is moved inwardly toward the supporting structure.",ELECTROLUX HOME PROD INC,HANSON JOSHUA;;SHRADER BENJAMIN PAUL;;RIZZI SABA;;CHO NATHAN,,https://lens.org/017-086-554-600-292,Patent Application,yes,4,1,3,3,0,A47B2210/08;;A47B2210/175;;F25D25/025;;A47B2210/08;;A47B2210/175;;F25D25/025;;F25D23/062;;F25D2323/02;;F25D2325/00,F25D25/02,,0,0,,,,PENDING
202,US,A1,US 2018/0248285 A1,059-370-531-673-597,2018-08-30,2018,US 201815889408 A,2018-02-06,TW 106103882 A,2017-02-07,BOARD-TO-BOARD CONNECTING SYSTEM,"An electrical connection device and a board-to-board electrical connection assembly, the board-to-board electrical connection assembly comprises an electrical connection device, a first circuit board and a second circuit board. The electrical connection device comprises a support frame and an adapter circuit board, the support frame has a top portion and a bottom portion. The adapter circuit board comprises an upper end portion retained to the top portion of the support frame, a lower end portion retained to the bottom portion of the support frame and a side portion positioned between the upper end portion and the lower end portion, the upper end portion comprises a first connector, the lower end portion comprises a second connector. The first circuit board is provided with a first mating connector for mating with the first connector. The second circuit board is provided with a second mating connector for mating with the second connector.",MOLEX LLC,RISHWORTH PAUL L;;GOH HOON CHAN;;CHO CHONG THIAM,MOLEX LLC (2018-02-06),https://lens.org/059-370-531-673-597,Patent Application,yes,46,3,4,4,0,H01R12/7082;;H01R12/73;;H01R12/79;;H05K1/144;;H05K1/147;;H05K1/189;;H05K2201/042;;H05K2201/10189;;H01R12/7023;;H01R13/506;;H01R12/716;;H01R12/7082;;H01R12/73;;H01R12/79;;H05K1/144;;H05K1/147;;H05K1/189;;H05K2201/042;;H05K2201/10189,H01R12/70;;H01R12/71;;H01R13/506,,0,0,,,,ACTIVE
203,CN,A,CN 113226208 A,085-160-756-228-395,2021-08-06,2021,CN 201980086822 A,2019-12-04,US 201816233935 A;;US 2019/0064447 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,"A thermoacoustic imaging system and method for monitoring tissue temperature within a region of interest, which has an object of interest and a reference that are separated by at least one boundary. The system and method include a thermoacoustic imaging system with an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein, an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest, and one or more processors that process at least one received bipolar acoustic signal generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof and calculate a temperature at the at least one boundary using the peak-to-peak amplitude of the at least one bipolar acoustic signal.",ENDRA LIFE SCIENCES INC,CHO JANG-HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/085-160-756-228-395,Patent Application,no,6,1,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B18/12;;A61B18/04;;A61B18/10;;A61B18/14,,0,0,,,,PENDING
204,US,A1,US 2015/0221527 A1,148-400-352-434-508,2015-08-06,2015,US 201514604764 A,2015-01-26,US 201514604764 A;;US 201461934698 P,2014-01-31,ENCAPSULANT COMPOSITION,"Compositions that have relatively high Tg, relatively low CTE, and relatively low modulus are suitable for use as encapsulants with stress-sensitive electronic assemblies, such as those containing low k dielectrics. These compositions are used in methods of die attachment, encapsulation, and solder bump reinforcement.",ROHM & HAAS ELECT MAT,MORGANELLI PAUL L;;CHO JAE-KYU;;CORDERO JENNA M,ROHM AND HAAS ELECTRONIC MATERIALS LLC (2014-10-29),https://lens.org/148-400-352-434-508,Patent Application,yes,1,3,1,1,0,H01L2924/0002;;H01L23/296;;H01L21/563;;C08K5/5435;;C08L63/00;;C08L63/00;;C08K3/36;;H01L2924/0002;;H01L21/563;;H01L23/296;;C08K5/5435,H01L21/56;;C08K3/36;;C08L63/00;;H01L23/22;;H01L23/31,,1,1,128-871-504-747-403,10.1002/pola.1990.080280303,"Crivello (Journal of Polymer Science: Part A: Polymer Chemistry, 28 (1990) 479-503)",DISCONTINUED
205,EP,A4,EP 3902495 A4,189-205-669-121-642,2022-10-12,2022,EP 19902376 A,2019-12-04,US 201816233959 A;;US 2019/0064450 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/189-205-669-121-642,Search Report,no,2,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/01;;A61B5/05;;A61B8/00,,0,0,,,,ACTIVE
206,US,B2,US 9869506 B2,005-787-422-801-793,2018-01-16,2018,US 201615157546 A,2016-05-18,US 201615157546 A;;US 201562162919 P,2015-05-18,Drawer system including cover,"A drawer system includes a drawer and a drawer cover. The drawer can include an open top and be configured to be supported at a supporting structure, such as a refrigerator fresh food compartment for example, for selective sliding movement outwardly from the supporting structure and sliding movement inwardly toward the supporting structure. The drawer cover can be configured to be mounted at the supporting structure in engagement with the drawer at the open top of the drawer for movement directly vertically upwardly at the supporting structure away from the open top of the drawer when the drawer is moved outwardly from the supporting structure and for movement directly vertically downwardly at the supporting structure toward the open top of the drawer when the drawer is moved inwardly toward the supporting structure.",ELECTROLUX HOME PROD INC,HANSON JOSHUA;;SHRADER BENJAMIN PAUL;;RIZZI SABA;;CHO NATHAN,ELECTROLUX HOME PRODUCTS INC (2016-05-16),https://lens.org/005-787-422-801-793,Granted Patent,yes,16,1,3,3,0,A47B2210/08;;A47B2210/08;;A47B2210/175;;A47B2210/175;;F25D25/025;;F25D25/025;;F25D23/062;;F25D2323/02;;F25D2325/00,F25D25/00;;F25D23/06;;F25D25/02,,1,0,,,"International Search Report and Written Opinion from Corresponding Application No. PCT/US2016/032995; dated Jul. 27, 2016.",ACTIVE
207,EP,A1,EP 3954280 A1,029-899-425-178-463,2022-02-16,2022,EP 21188055 A,2019-12-04,US 201816233959 A;;EP 19902376 A;;US 2019/0064450 W,2018-12-27,SYSTEM FOR MONITORING TISSUE TEMPERATURE,"A system utilizing thermoacoustic imaging to estimate tissue temperature within a region of interest that includes an object of interest and a reference which are separated by at least one boundary located at least at two boundary locations. The system uses a thermoacoustic imaging system that includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein and an acoustic receiver configured to receive multi-polar acoustic signals generated in response to heating of tissue in the region of interest; and one or more processors that are able to: process received multi-polar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the multi-polar acoustic signals and a distance between the boundary locations.
",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/029-899-425-178-463,Patent Application,yes,2,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/01;;A61B5/05,,0,0,,,,ACTIVE
208,EP,B1,EP 3954280 B1,054-562-224-536-474,2023-03-15,2023,EP 21188055 A,2019-12-04,US 201816233959 A;;EP 19902376 A;;US 2019/0064450 W,2018-12-27,SYSTEM FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/054-562-224-536-474,Granted Patent,yes,1,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/01;;A61B5/05,,0,0,,,,ACTIVE
209,KR,A,KR 20220139729 A,087-743-376-018-334,2022-10-17,2022,KR 20210046076 A,2021-04-08,KR 20210046076 A,2021-04-08,Medical stent and medical tube,"One aspect of the present invention relates to a medical stent that is a medical molded body implantable in a living body and is implantable in a human body. The medical stent is made of a flexible hollow tube body in which a plurality of wires are connected, wherein at least one of the wires includes an amorphous alloy.",KOLON INC,KIM CHOONGNYUN PAUL;;LEE JONG HWAN;;CHO GEUN SANG,,https://lens.org/087-743-376-018-334,Patent Application,no,1,0,1,1,0,A61F2/86;;A61L31/022;;A61L31/16;;A61F2/0077;;A61F2/844;;A61F2/04;;A61L27/04;;A61L27/54;;A61L2300/404;;A61L2300/606;;A61F2250/0067,A61F2/86;;A61F2/00;;A61F2/04;;A61F2/06;;A61L27/54;;A61L31/02;;A61L31/16,,0,0,,,,PENDING
210,US,B1,US 10631734 B1,090-573-432-910-132,2020-04-28,2020,US 201816233959 A,2018-12-27,US 201816233959 A,2018-12-27,Method and system for monitoring tissue temperature,A system and method utilizing thermoacoustic imaging to estimating tissue temperature within a region of interest that includes an object of interest and a reference which are separated by at least one boundary located at least at two boundary locations. The system and method use a thermoacoustic imaging system that includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein and an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest; and one or more processors that are able to: process received bipolar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the bipolar acoustic signals and a distance between the boundary locations.,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/090-573-432-910-132,Granted Patent,yes,6,2,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/05;;A61B5/00;;A61B5/01;;A61B5/20,,7,7,033-786-059-395-583;;003-447-272-638-21X;;012-545-815-382-384;;142-401-383-484-74X;;010-411-063-187-44X;;013-000-205-460-222;;093-756-081-427-464,10.1109/tbme.2012.2210218;;22851231;;10841427;;10.1118/1.598984;;28066714;;10.1016/j.pacs.2016.10.001;;pmc5200938;;8938024;;10.1088/0031-9155/41/11/001;;10.1088/0031-9155/41/11/002;;8938025;;pmc2774978;;19895126;;10.1117/1.3247155;;10.3109/02656731003592035;;20345268,"X. Wang et al., “Microwave-induced thermoacoustic imaging model for potential breast cancer detection,” IEEE Trans. Biomed. Eng., vol. 59, No. 10, pp. 2782-2791, Oct. 2012.;;G. Ku and L. V. Wang, “Scanning thermoacoustic tomography in biological tissue,” Med. Phys., vol. 27, No. 5, pp. 1195-202, May 2000.;;X. L. Dean-Ben, “On the link between the speckle free nature of optoacoustics and visibility of structures in limited-view tomography,” Photoacoustics, vol. 4, No. 4, pp. 133-140, Jul. 2016.;;C. Gabriel et al., “The dielectric properties of biological tissues: I. Literature survey,” Med. Phys., vol. 41, No. 11, pp. 2231-2249, Nov. 1996.;;S. Gabriel et al., “The dielectric properties of biological tissues: II. Measurements in the frequency range 10 Hz to 20 GHz,” Med. Phys., vol. 41, No. 11, pp. 2251-2269, Nov. 1996.;;M. Pramanik et al., “Thermoacoustic and photoacoustic sensing of temperature,” J. of Biomedical Optics, vol. 14, No. 5, Sep. 2009.;;C. Lou et al., “Temperature monitoring utilising thermoacoustic signals during pulsed microwave thermotherapy: A feasibility study,” Int. J. Hyperthermia, vol. 26, No. 4, pp. 338-346, 2010.",ACTIVE
211,US,A1,US 2014/0208138 A1,119-137-887-934-982,2014-07-24,2014,US 201313922159 A,2013-06-19,US 201313922159 A;;US 201361756422 P,2013-01-24,SYSTEM AND METHOD FOR REDUCING POWER CONSUMPTION,"Systems and methods are disclosed for operating an interface of an electronic device in an active mode or a power save mode based, at least in part, on a condition of a data exchange module buffer. When buffer space is available, incoming data may be stored locally and the interface used to access remote memory storage may be in a power save mode. The interface may revert to active mode to transfer data to the remote memory, such as after a configurable reception interval. Outgoing data may also be stored in a buffer, allowing the interface to be in a power save mode with information transmitted from the buffer.",QUALCOMM INC,HOMCHAUDHURI SANDIP;;CHO JAMES SIMON;;HUSTED PAUL;;SHRIVASTAVA SARVESH,QUALCOMM INCORPORATED (2013-07-30),https://lens.org/119-137-887-934-982,Patent Application,yes,5,31,2,2,0,G06F1/3225;;G06F1/3278;;H04W52/0267;;H04W52/028;;H04W52/0287;;G06F1/3209;;Y02D10/00;;Y02D30/70;;G06F1/3225;;G06F1/3278;;H04W52/0267;;H04W52/0287;;H04W52/028;;Y02D10/00;;Y02D30/70;;G06F1/3209;;H04W52/00,G06F1/32,713/320,0,0,,,,INACTIVE
212,DE,D1,DE 3470448 D1,027-602-556-507-965,1988-05-26,1988,DE 3470448 T,1984-10-24,US 54491283 A,1983-10-24,PROCESS FOR PRODUCING A HYDROLYZED VEGETABLE PROTEIN ISOLATE AND THE USE THEREOF,,RALSTON PURINA CO,CIPOLLO KENT LEE;;CHO IUE CHUNG;;WARNER GREGORY PAUL,"PROTEIN TECHNOLOGIES INTERNATIONAL, INC. (N.D. GES (2001-07-19)",https://lens.org/027-602-556-507-965,Granted Patent,no,0,0,9,9,0,A23J3/00;;A23J3/346;;A23C20/00,A23J3/00;;A23C20/00;;A23J3/30;;A23J3/34,,0,0,,,,EXPIRED
213,US,B1,US 8043122 B1,041-429-475-737-110,2011-10-25,2011,US 85549010 A,2010-08-12,US 85549010 A,2010-08-12,Portable dock and power adapter system,"A portable dock and power adapter system includes a dock member having a power adapter member coupling, a plurality of IHS component connectors, and a dock plug that is electrically coupled to the plurality of IHS component connectors and extends from the dock member. The portable dock and power adapter system also includes power adapter member including a dock member coupling and a power adapter plug that is electrically coupled to the dock plug and that extends from the power adapter member. A connecting member extends between the power adapter member and the dock member. The connecting member is operable to orient the power adapter member and the dock member such that the dock member coupling is spaced apart from the power adapter member coupling. The connecting member is also operable to orient the power adapter member and the dock member such that the dock member coupling engages the power adapter member coupling.",DELL PRODUCTS LP,CHO SUDONG;;LATTO ANTONIO;;MUSGRAVE KENNETH C;;DOCZY PAUL,DELL PRODUCTS L.P (2010-08-02),https://lens.org/041-429-475-737-110,Granted Patent,yes,5,13,1,1,0,H01R13/501;;H01R13/72;;H01R24/30;;H01R31/005;;H01R31/065;;H01R2201/06;;H01R31/005;;H01R2201/06;;H01R24/30;;H01R13/72;;H01R13/501;;H01R31/065,H01R25/00,439/638;;439/501;;439/652;;439/639,0,0,,,,ACTIVE
214,EP,A4,EP 3815755 A4,069-481-516-197-734,2022-06-22,2022,EP 19835019 A,2019-07-11,SG 10201805971S A;;KR 2019008573 W,2018-07-11,GOLF CLUB AND MANUFACTURING METHOD THEREOF,,KOLON INC;;ATTOMETAL TECH PTE LTD,KIM CHOONGNYUN PAUL;;CHO GEUN SANG;;PARK JAE KYU,,https://lens.org/069-481-516-197-734,Search Report,no,4,0,24,24,0,C22C33/0285;;C22C2200/02;;B33Y80/00;;C22C33/0292;;B33Y70/10;;B22F2998/10;;B22F2998/00;;B22F9/082;;B22F2999/00;;C23C4/08;;C23C4/06;;C23C4/134;;C23C4/129;;Y02P10/25;;C22C33/003;;C22C45/02;;C22C38/22;;C22C45/10;;C22C1/04;;B22F2998/00;;A63B53/047;;B05D7/14;;B05D2202/15;;B05D2202/25;;B05D2202/35;;B05D2202/40;;C22C45/10;;B33Y10/00;;B33Y70/00;;C23C4/067;;C23C4/129;;C23C4/134;;B22F3/10;;B22F9/082;;B22F2998/10;;B22F2999/00;;C22C1/04;;C22C33/0292;;C22C38/22;;C22C38/32;;C22C2200/02;;C22C33/0285,B22F3/10;;B22F9/08;;B33Y80/00;;C22C1/04;;C22C33/00;;C22C33/02;;C22C45/02;;C23C4/06;;C23C4/08;;C23C4/129;;C23C4/134,,1,0,,,See also references of WO 2020013633A1,PENDING
215,US,A1,US 2023/0053703 A1,165-171-932-358-61X,2023-02-23,2023,US 202117758778 A,2021-01-14,KR 20200006341 A;;KR 2021000570 W,2020-01-17,PIPE AND MANUFACTURING METHOD THEREFOR,"A pipe according to the present disclosure comprises: a hollow tube body in which fluids of different temperatures pass through the inside and outside thereof; and a coating layer which is provided on an external surface of the hollow tube body, and which has an alloy comprising an amorphous phase, wherein the alloy comprises Fe, and comprises at least one or more first component selected from the group consisting of Cr, Mo and Co, and at least one or more second component selected from the group consisting of B, C, Si and Nb.",KOLON INC,CHO GEUN SANG;;KIM CHOONGNYUN PAUL;;CHOI KWAN MIN,KOLON INDUSTRIES INC (2022-03-10),https://lens.org/165-171-932-358-61X,Patent Application,yes,9,0,7,7,0,C23C4/16;;F16L58/08;;C23C4/067;;C23C24/08;;C23C24/04;;C23C4/129;;C23C4/134;;C23C4/137;;C23C4/18;;C23C4/06;;Y02E20/12;;F16L58/08;;C23C4/067;;C23C4/16;;C23C24/08;;F16L58/08,C23C24/08,,0,0,,,,PENDING
216,US,A1,US 2021/0291023 A1,164-827-096-868-667,2021-09-23,2021,US 201917257573 A,2019-07-11,SG 10201805971S A;;KR 2019008573 W,2018-07-11,GOLF CLUB AND MANUFACTURING METHOD THEREOF,"Disclosed is a golf club and a method of manufacturing the same, whereby an Fe-based amorphous alloy layer is coated on a surface of a base part of a clubface provided on a side of a clubhead to maintain an amorphous structure after coating, thus ensuring that a repulsive force, durability, surface hardness, and the like of the clubface are improved. The golf club includes: a clubhead; and a shaft connected to the clubhead, wherein the clubhead includes a clubface provided on a side thereof, and the clubface includes: a base part; and a coating layer provided on a surface of the base part and including an Fe-based amorphous alloy.",ATTOMETAL TECH PTE LTD;;KOLON INC,KIM CHOONGNYUN PAUL;;CHO GEUN SANG;;PARK JAE KYU,ATTOMETAL TECH PTE. LTD (2020-12-30);;KOLON INDUSTRIES INC (2020-12-30),https://lens.org/164-827-096-868-667,Patent Application,yes,0,0,24,24,0,C22C33/0285;;C22C2200/02;;B33Y80/00;;C22C33/0292;;B33Y70/10;;B22F2998/10;;B22F2998/00;;B22F9/082;;B22F2999/00;;C23C4/08;;C23C4/06;;C23C4/134;;C23C4/129;;Y02P10/25;;C22C33/003;;C22C45/02;;C22C38/22;;C22C45/10;;C22C1/04;;B22F2998/00;;A63B53/047;;B05D7/14;;B05D2202/15;;B05D2202/25;;B05D2202/35;;B05D2202/40;;C22C45/10;;B33Y10/00;;B33Y70/00;;C23C4/067;;C23C4/129;;C23C4/134;;B22F3/10;;B22F9/082;;B22F2998/10;;B22F2999/00;;C22C1/04;;C22C33/0292;;C22C38/22;;C22C38/32;;C22C2200/02;;C22C33/0285,A63B53/04;;B05D7/14;;C22C45/10,,0,0,,,,DISCONTINUED
217,US,A1,US 2010/0229926 A1,196-894-944-457-133,2010-09-16,2010,US 40115709 A,2009-03-10,US 40115709 A,2009-03-10,Four Junction Inverted Metamorphic Multijunction Solar Cell with a Single Metamorphic Layer,"A multijunction solar cell including an upper first solar subcell having a first band gap; a second solar subcell adjacent to the first solar subcell and having a second band gap smaller than the first band gap; a graded interlayer adjacent to the second solar subcell; the first graded interlayer having a third band gap greater than the second band gap; and a third solar subcell adjacent to the graded interlayer, the third subcell having a fourth band gap smaller than the second band gap such that the third subcell is lattice mismatched with respect to the second subcell. A lower fourth solar subcell is provided adjacent to the third subcell and lattice matched thereto, the lower fourth subcell having a fifth band gap smaller than the fourth band gap.",EMCORE SOLAR POWER INC,NEWMAN FRED;;CHO BENJAMIN;;STAN MARK A;;SHARPS PAUL,EMCORE SOLAR POWER INC (2009-03-04),https://lens.org/196-894-944-457-133,Patent Application,yes,91,73,3,111,0,H01L31/06875;;H01L31/0725;;H01L31/1844;;Y02E10/544;;H01L31/0735;;Y02P70/50;;H01L31/06875;;H01L31/0725;;H01L31/1844;;Y02E10/544;;Y02P70/50;;H01L31/0735,H01L31/00;;H01L21/02,136/255;;438/73;;X257E21002,0,0,,,,DISCONTINUED
218,WO,A1,WO 2021/145709 A1,103-118-250-918-008,2021-07-22,2021,KR 2021000569 W,2021-01-14,KR 20200006342 A,2020-01-17,BRAKE BODY AND BRAKE DEVICE,"A brake body according to the present invention has a coating layer which contains an iron-based amorphous alloy and is formed on a contact surface at which a friction means rubs against the rotating brake body to generate braking force. The coating layer has a low friction coefficient, and thus less dust is generated during braking. The coating layer also has excellent corrosion resistance and abrasion resistance, and thus has excellent performance and excellent price competitiveness when applied to a brake base material that can be produced at low cost.",KOLON INC,CHO GEUN SANG;;KIM CHOONGNYUN PAUL;;CHOI KWAN MIN,,https://lens.org/103-118-250-918-008,Patent Application,yes,5,0,6,6,0,F16D69/027;;F16D2250/0046;;F16D65/125;;F16D65/127;;B32B15/011;;C22C45/02;;C22C33/003;;C23C4/129;;C23C4/06;;C23C4/067;;C23C30/00;;C23C4/134;;C23C24/04;;C23C24/08;;C23C24/082;;C23C24/10;;F16D69/027;;F16D2250/0046;;F16D65/123;;F16D65/125;;F16D65/127;;F16D69/027;;F16D2200/0008;;F16D2250/0046,F16D69/02,,0,0,,,,PENDING
219,EP,A1,EP 3902495 A1,138-426-098-540-008,2021-11-03,2021,EP 19902376 A,2019-12-04,US 201816233959 A;;US 2019/0064450 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/138-426-098-540-008,Patent Application,yes,0,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B18/18;;A61B5/00;;A61B5/01;;A61B8/00,,0,0,,,,ACTIVE
220,EP,B1,EP 3902495 B1,180-249-510-464-333,2023-08-02,2023,EP 19902376 A,2019-12-04,US 201816233959 A;;US 2019/0064450 W,2018-12-27,METHOD FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/180-249-510-464-333,Granted Patent,yes,1,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/01;;A61B5/05;;A61B8/00,,0,0,,,,ACTIVE
221,US,B2,US 10431911 B2,030-405-670-611-171,2019-10-01,2019,US 201815889408 A,2018-02-06,TW 106103882 A,2017-02-07,Board-to-board connecting system,"An electrical connection device and a board-to-board electrical connection assembly, the board-to-board electrical connection assembly comprises an electrical connection device, a first circuit board and a second circuit board. The electrical connection device comprises a support frame and an adapter circuit board, the support frame has a top portion and a bottom portion. The adapter circuit board comprises an upper end portion retained to the top portion of the support frame, a lower end portion retained to the bottom portion of the support frame and a side portion positioned between the upper end portion and the lower end portion, the upper end portion comprises a first connector, the lower end portion comprises a second connector. The first circuit board is provided with a first mating connector for mating with the first connector. The second circuit board is provided with a second mating connector for mating with the second connector.",MOLEX LLC,RISHWORTH PAUL L;;GOH HOON CHAN;;CHO CHONG THIAM,MOLEX LLC (2018-02-06),https://lens.org/030-405-670-611-171,Granted Patent,yes,27,0,4,4,0,H01R12/7082;;H01R12/73;;H01R12/79;;H05K1/144;;H05K1/147;;H05K1/189;;H05K2201/042;;H05K2201/10189;;H01R12/7023;;H01R13/506;;H01R12/716;;H01R12/7082;;H01R12/73;;H01R12/79;;H05K1/144;;H05K1/147;;H05K1/189;;H05K2201/042;;H05K2201/10189,H05K1/00;;H01R12/70;;H01R12/71;;H01R12/73;;H01R12/79;;H01R13/506;;H05K1/14;;H05K1/18,,0,0,,,,ACTIVE
222,WO,A1,WO 2021/145710 A1,060-692-637-511-438,2021-07-22,2021,KR 2021000570 W,2021-01-14,KR 20200006341 A,2020-01-17,PIPE AND MANUFACTURING METHOD THEREFOR,"A pipe according to the present invention comprises: a hollow pipe in which fluids of different temperatures pass through the inside and outside thereof; and a coating layer which is provided on the outer surface of the hollow pipe, and which has an alloy comprising an amorphous phase, wherein the alloy comprises Fe, and comprises at least one first component selected from the group consisting of Cr, Mo and Co, and at least one second component selected from the group consisting of B, C, Si and Nb.",KOLON INC,CHO GEUN SANG;;KIM CHOONGNYUN PAUL;;CHOI KWAN MIN,,https://lens.org/060-692-637-511-438,Patent Application,yes,5,0,7,7,0,C23C4/16;;F16L58/08;;C23C4/067;;C23C24/08;;C23C24/04;;C23C4/129;;C23C4/134;;C23C4/137;;C23C4/18;;C23C4/06;;Y02E20/12;;F16L58/08;;C23C4/067;;C23C4/16;;C23C24/08;;F16L58/08,F16L58/08;;C23C4/067;;C23C4/16,,1,0,,,See also references of EP 4092309A4,PENDING
223,US,B2,US 8969712 B2,095-508-607-916-626,2015-03-03,2015,US 201213463069 A,2012-05-03,US 201213463069 A;;US 40115709 A,2009-03-10,Four junction inverted metamorphic multijunction solar cell with a single metamorphic layer,"A multijunction solar cell including an upper first solar subcell having a first band gap; a second solar subcell adjacent to the first solar subcell and having a second band gap smaller than the first band gap; a graded interlayer adjacent to the second solar subcell, the graded interlayer having a third band gap greater than the second band gap; and a third solar subcell adjacent to the graded interlayer, the third subcell having a fourth band gap smaller than the second band gap such that the third subcell is lattice mismatched with respect to the second subcell. A lower fourth solar subcell is provided adjacent to the third subcell and lattice matched thereto, the lower fourth subcell having a fifth band gap smaller than the fourth band gap.",NEWMAN FRED;;CHO BENJAMIN;;STAN MARK A;;SHARPS PAUL;;SOLAERO TECHNOLOGIES CORP,NEWMAN FRED;;CHO BENJAMIN;;STAN MARK A;;SHARPS PAUL,SOLAERO TECHNOLOGIES CORP (2015-01-08),https://lens.org/095-508-607-916-626,Granted Patent,yes,100,20,3,111,0,H01L31/06875;;H01L31/0725;;H01L31/1844;;Y02E10/544;;H01L31/0735;;Y02P70/50;;H01L31/06875;;H01L31/0725;;H01L31/1844;;Y02E10/544;;Y02P70/50;;H01L31/0735,H01L31/00;;H01L31/0687;;H01L31/0725;;H01L31/0735;;H01L31/18,136/255,42,19,026-281-940-590-23X;;015-557-396-201-987;;015-557-396-201-987;;073-300-069-664-773;;115-973-926-256-941;;083-287-525-840-54X;;025-407-739-778-403;;106-513-576-934-63X;;076-989-478-838-81X;;015-717-993-971-840;;030-787-136-717-28X;;038-574-682-896-969;;052-700-785-133-704;;093-340-948-123-836;;026-862-096-577-376;;026-862-096-577-376;;107-582-530-482-098;;164-535-659-415-932;;007-176-082-871-508,10.1109/wcpec.2006.279587;;10.1109/pvsc.2010.5614498;;10.1109/pvsc.2010.5614498;;10.1109/wcpec.2006.279527;;10.1063/1.2753729;;10.1109/pvsc.2008.4922452;;10.1109/pvsc.2002.1190685;;10.1109/pvsc.1990.111608;;10.1109/iscs.1998.711543;;10.1002/pip.449;;10.1016/j.jcrysgro.2009.10.059;;10.1002/pip.642;;10.1109/pvsc.1991.169189;;10.1063/1.106494;;10.1109/wcpec.2006.279559;;10.1109/wcpec.2006.279559;;10.1134/1.1187812;;10.1016/0022-0248(84)90363-4;;10.1016/0379-6787(88)90047-6,"U.S. Appl. No. 12/265,113, filed Nov. 5, 2008, Varghese.;;U.S. Appl. No. 12/708,361, filed Feb. 18, 2010, Cornfeld et al.;;U.S. Appl. No. 12/716,814, filed Mar. 3, 2010, Cornfeld.;;U.S. Appl. No. 12/730,018, filed Mar. 23, 2010, Cornfeld.;;U.S. Appl. No. 12/756,926, filed Apr. 8, 2010, Cornfeld et al.;;U.S. Appl. No. 12/813,408, Jun. 10, 2010, Patel et al.;;U.S. Appl. No. 12/844,673, filed Jul. 27, 2010, Stan et al.;;Advisory Action mailed Mar. 15, 2011. U.S. Appl. No. 11/445,793.;;Aiken et al. ""Consideration of High Bandgap Subcells for Advanced Multijunction Solar Cells,"" Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 1, 2006, pp. 838-841.;;Cornfeld et al., ""Development of a Large Area Inverted Metamorphic Multi-junction (IMM) Highly Efficient AM0 Solar Cell,"" 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Cornfeld et al., ""Development of a Large Area Inverted Metamorphic Multi-junction Highly Efficient AM0 Solar Cell,"" Conference paper presented at the 33rd IEEE Photovoltaic Specialists Conference (May 11-16, 2008) on May 12, 2008. San Diego, CA, USA. 17 pages.;;Cornfeld et al., ""Advances in the Performance of Inverted Metamorphic Multi-junction Solar Cells,"" 23rd European Photovoltaic Energy Conference, Sep. 1-5, 2008, Valencia, Spain.;;""European Search Report,"" Application No. EP 08 01 3466. Dec. 18, 2009. European Patent Office, Berlin, Germany.;;Friedman et al., ""0.7-eV GaInAs Junction for a GaInP/GaAs/GaInAs(1eV)/GaInAs(0.7eV) Four-Junction Solar Cell,"" 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA.;;Geisz et al., ""High-efficiency GaInP/GaAs/InGaAs triple junction solar cells grown inverted with a metamorphic bottom junction,"" Applied Physics Letters, 2007; 91(023502):023502-1-023502-3. Online publication Jul. 10, 2007. American Institute of Physics, Melville, NY, USA.;;Geisz, et al., ""Inverted GaInP/(In)GaAs/InGaAs Triple-Junction Solar Cells with Low-Stress Metamorphic Bottom Junctions,"" 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;King et al., ""Next-Generation, High-Efficiency III-V Multijunction Solar Cells,"" 28th IEEE Photovoltaic Specialists Conference, Sep. 15-22, 2000, Anchorage, AK, USA.;;King et al., ""High-Efficiency Space and Terrestrial Multijunction Solar Cells Through Bandgap Control in Cell Structures,"" 2002 Photovoltaic Specialists Conference, Conference Record of the 29th IEEE, May 19-24, 2000 pp. 776-781. New Orleans, LA, USA.;;Office Action mailed Nov. 9, 2010 (double patenting rejection). U.S. Appl. No. 11/860,183.;;Office Action mailed Nov. 10, 2010 (double patenting rejection). U.S. Appl. No. 12/102,550.;;Office Action mailed Dec. 22, 2010 (double patenting rejection). U.S. Appl. No. 11/956,069.;;Office Action mailed Jan. 4, 2011. U.S. Appl. No. 11/445,793. (Sexl reference, double patenting rejection).;;""Partial European Search Report,"" Application No. EP 08 01 3466. Feb. 12, 2009. European Patent Office, Berlin, Germany.;;Schultz et al. ""High Efficiency 1.0 eV GaInAs Bottom Solar Cell for 3-junction Monolithic Stack,"" Conference Record of the Twenty First IEEE Photovoltaic Specialists Conference. Kissimmee, Florida; May 21-25, 1990. New York: The Institute of Electrical and Electronics Engineers, Inc., pp. 148-152.;;Sexl et al., ""MBE Growth of Metamorphic In(Ga)AIAs Buffers,"" 1997 IEEE International Symposium on Compound Semiconductors, Sep. 1997 pp. 49-52. IEEE, Piscataway, NJ.;;Sharps et al., ""Inverting the triple junction improves efficiency and flexibility,"" Compound Semiconductor, Oct. 2007; 13(9):25-28.;;Sinharoy et al., ""Progress in the Development of Metamorphic Multi-junction III-V Space Solar Cells,"" Progress in Photovoltaics: Research and Applications, Feb. 2002; 10:427-432.;;Stan et al., ""Very High Efficiency Triple Junction Solar Cells by MOVPE,"" 14th International Conference of Metalorganic Vapor Phase Epitaxy. Jun. 1-6, 2008 Metz, France.;;Stan, et al., ""High-efficiency quadruple junction solar cells using OMVPE with inverted metamorphic device structures,"" Journal of Crystal Growth, 2010; 312:1370-1374. Elsevier, Amsterdam, Netherlands.;;Takamoto, et al., ""Future Development of InGaP/(In)GaAs Based Multijunction Solar Cells,"" Proceedings of the 31st IEEE PVSC, Jan. 3-7, 2005, pp. 519-524. Lake Buena Vista, FL.;;Takamoto et al., ""InGaP/GaAs-based Multijunction Solar Cells,"" Progress in Photovoltaics: Research and Applications, 2005; 13(495-511).;;Venkatasubramanian et al., ""An Inverted-Growth Approach to Development of an IR-Transparent, High-Efficiency AIGaAs/GaAs Cascade Solar Cell,"" 22nd IEEE Photovoltaic Specialists Conference, Oct. 7-11, 1991, Las Vegas, NV, USA.;;Venkatasubramanian et al., ""High-quality eutectic-metal-bonded AIGaAs-GaAs thin films on Si substrates,"" Applied Physics Letters, Feb. 17, 1992; 60(7):886-888.;;Wanlass et al., ""Lattice-Mismatched Approaches for High-Performance, III-V Photovoltaic Energy Converters,"" Proceedings of the 31st IEEE PVSC, Jan. 3-7, 2005. Lake Buena Vista, FL, USA.;;Wanlass et al., ""Lattice-Mismatched Approaches for High-Performance, III-V Photovoltaic Energy Converters,"" Conference Record of the 31st IEEE PVSC, Jan. 3, 2005; pp. 530-535. Piscataway, NJ, USA.;;Wanlass et al., ""Monolithic, Ultra-Thin GaInP/GaAs/GaInAs Tandem Solar Cells,"" 2006 4th IEEE World Conference on Photovoltaic Energy Conversion, May 1, 2006; pp. 729-732.;;Wanlass et al., ""Monolithic, Ultra-Thin GaInP/GaAs/GaInAs Tandem Solar Cells,"" 2006 IEEE World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA.;;Wurfel. Physics of Solar Cells: from Basic Principles to Advanced Concepts, 2nd Updated and Expanded Edition, 2009. Sections 6.4, 6.5 and 6.8; 20 pages. Wiley-VCH, Weinheim, Germany.;;Yamaguchi, ""Physics and Technologies of Superhigh-Effficiency Tandem Solar Cells,"" Semiconductors, Sep. 1999; 33(9):961-964, Toyota Technological Institute, Nagoya, Japan, ©1999, American Institute of Physics.;;Yoon et al., ""Progress of Inverted Metamorphic III-V Solar Cell Development at Spectrolab,"" 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Lewis et al., ""The Crystallographic Connection of MOCVD-Grown Monolithic Cascade Subcells Via Transparent Graded Layers,"" Journal of Crystal Growth, 1984; 69:515-526.;;Lewis et al., ""Recent Developments in Multijunction Solar Cell Research,"" Solar Cells, 1988; 24:171-183.",ACTIVE
224,US,S,US D0359960 S,089-970-543-830-462,1995-07-04,1995,US 2335294 F,1994-05-23,US 2335294 F,1994-05-23,Clip-on earpiece for a portable handset telephone,,MOTOROLA INC,KENNEDY PAUL R;;CHO FREDERICK Y;;COOK ROBERT A,GENERAL DYNAMICS C4 SYSTEMS INC (2005-01-01);;GENERAL DYNAMICS DECISION SYSTEMS INC (2001-09-28);;MOTOROLA INC (1994-05-13),https://lens.org/089-970-543-830-462,Design Right,yes,10,5,1,1,0,,,D14/249,0,0,,,,EXPIRED
225,US,B2,US 11478153 B2,150-464-835-333-618,2022-10-25,2022,US 202016848376 A,2020-04-14,US 202016848376 A;;US 201816233959 A,2018-12-27,System for monitoring tissue temperature,A system utilizing thermoacoustic imaging to estimate tissue temperature within a region of interest that includes an object of interest and a reference which are separated by at least one boundary located at least at two boundary locations. The system uses a thermoacoustic imaging system that includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein and an acoustic receiver configured to receive multi-polar acoustic signals generated in response to heating of tissue in the region of interest; and one or more processors that are able to: process received multi-polar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the multi-polar acoustic signals and a distance between the boundary locations.,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/150-464-835-333-618,Granted Patent,yes,6,0,2,13,0,A61B5/0095;;A61B5/015;;A61B5/4872;;A61B5/0507;;A61B5/4887;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B8/5223;;A61B8/5261;;A61B5/015;;A61B5/4872;;A61B5/0095;;A61B5/05,A61B5/00;;A61B5/01;;A61B5/05,,7,7,033-786-059-395-583;;003-447-272-638-21X;;012-545-815-382-384;;142-401-383-484-74X;;010-411-063-187-44X;;013-000-205-460-222;;093-756-081-427-464,10.1109/tbme.2012.2210218;;22851231;;10841427;;10.1118/1.598984;;28066714;;10.1016/j.pacs.2016.10.001;;pmc5200938;;8938024;;10.1088/0031-9155/41/11/001;;10.1088/0031-9155/41/11/002;;8938025;;pmc2774978;;19895126;;10.1117/1.3247155;;10.3109/02656731003592035;;20345268,"X. Wang et al., “Microwave-induced thermoacoustic imaging model for potential breast cancer detection,” IEEE Trans. Biomed. Eng., vol. 59, No. 10, pp. 2782-2791, Oct. 2012.;;G. Ku and L. V. Wang, “Scanning thermoacoustic tomography in biological tissue,” Med. Phys., vol. 27, No. 5, pp. 1195-1202, May 2000.;;X. L. Dean-Ben, “On the link between the speckle free nature of optoacoustics and visibility of structures in limited-view tomography,” Photoacoustics, vol. 4, No. 4, pp. 133-140, Jul. 2016.;;C. Gabriel et al., “The dielectric properties of biological tissues: I. Literature survey,” Med. Phys., vol. 41, No. 11, pp. 2231-2249, Nov. 1996.;;S. Gabriel et al., “The dielectric properties of biological tissues: II. Measurements in the frequency range 10 Hz to 20 GHz,” Med. Phys., vol. 41, No. 11, pp. 2251-2269, Nov. 1996.;;M. Pramanik et al., “Thermoacoustic and photoacoustic sensing of temperature,” J. of Biomedical Optics, vol. 14, No. 5, Sep. 2009.;;C. Lou et al., “Temperature monitoring utilising thermoacoustic signals during pulsed microwave thermotherapy: A feasibility study,” Int. J. Hyperthermia, vol. 26, No. 4, pp. 338-346, 2010.",ACTIVE
226,US,A1,US 2017/0047466 A1,162-146-920-677-011,2017-02-16,2017,US 201514623883 A,2015-02-17,US 201514623883 A;;US 201213463069 A;;US 40115709 A,2009-03-10,INVERTED METAMORPHIC MULTIJUNCTION SOLAR CELL WITH A SINGLE METAMORPHIC LAYER,"The present disclosure provides a multijunction solar cell that includes: a first sequence of layers of semiconductor material forming a first set of one or more solar subcells; a graded interlayer adjacent to said first sequence of layers; a second sequence of layers of semiconductor material forming a second set of one or more solar subcells; and a high band gap contact layer adjacent said second sequence of layers, wherein the high band gap contact layer is composed of p++ type InGaAlAs or InGaAs.",SOLAERO TECH CORP,NEWMAN FRED;;CHO BENJAMIN;;STAN MARK A;;SHARPS PAUL,SOLAERO TECHNOLOGIES CORP (2015-08-06),https://lens.org/162-146-920-677-011,Patent Application,yes,3,0,2,111,0,H01L31/06875;;H01L31/06875;;H01L31/03046;;H01L31/03046;;H01L31/0693;;H01L31/0725;;H01L31/0725;;H01L31/0735;;H01L31/0735;;H01L31/078;;H01L31/078;;H01L31/1844;;H01L31/1844;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02P70/50;;Y02P70/50,H01L31/0687;;H01L31/0304;;H01L31/0352;;H01L31/0693;;H01L31/18,,0,0,,,,ACTIVE
227,US,B2,US 11409303 B2,007-093-130-632-736,2022-08-09,2022,US 202016917118 A,2020-06-30,US 202016917118 A;;KR 20170024824 A;;US 201715818347 A,2017-02-24,Image processing method for autonomous driving and apparatus thereof,A processor implemented image processing method includes recognizing a target object in a first frame of an input image; adjusting an exposure of a second frame of the input image based on a brightness of the target object; and generating a synthesized image by synthesizing the first frame and the second frame.,SAMSUNG ELECTRONICS CO LTD,SEO YOUNG WAN;;JEON PAUL BAROM;;CHO BAEK HWAN,,https://lens.org/007-093-130-632-736,Granted Patent,yes,30,0,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,G05D1/02;;G01C21/16;;G01C21/26;;G01C21/34;;G01S19/47;;G05D1/00;;G06T5/00;;G06T5/50;;G06T7/73;;G06V10/141;;G06V10/25;;G06V20/56;;G06V20/58;;H04N5/232;;H04N5/235,,6,3,015-156-610-229-239;;051-626-542-773-142;;061-048-595-006-271,10.1145/882262.882270;;10.1109/tip.2006.877312;;16948325;;10.1155/2007/80971,"Communication dated Jul. 2, 2021, from the China National Intellectual Property Administration in Chinese Application No. 202010776945.8.;;Communication dated Sep. 11, 2020 issued by the China National Intellectual Property Administration in counterpart Chinese Application No. 201810155270.8.;;Kang, Sing Bing, et al. “High Dynamic Range Video”, 4, vol. 22, No. 3, 2003 (pp. 319-325).;;Meylan, Laurence, et al., “High Dynamic Range Image Rendering With a Retinex-Based Adaptive Filter”, IEEE Transactions on Image Processing, vol. 15, No. 9, Sep. 2006 (pp. 2820-2830).;;Marsl, Stefano, et al., “Video Enhancement and Dynamic Range Control of HDR Sequences for Automotive Applications”. EURASIP Journal on Advances in Signal Processing, May 13, 2007 (9 pages in English).;;Extended European Search Report dated Jul. 30, 2018, in corresponding European Application No. 18158136.4 (11 pages in English).",ACTIVE
228,KR,A,KR 20230068573 A,046-002-176-413-502,2023-05-18,2023,KR 20210154507 A,2021-11-11,KR 20210154507 A,2021-11-11,CARTRIDGE FOR AEROSOL-GENERATING DEVICE AND AEROSOL-GENERATING DEVICE,"일 실시 예에 따른 에어로졸 발생 장치용 카트리지는 에어로졸 형성 기재가 가열되어 형성된 에어로졸이 배출되는 개구부 및 상기 카트리지가 디바이스와 결합되는 측의 단부에 형성되며 상기 카트리지의 고유 정보를 담고 있는 정보 저장부를 포함하고, 상기 정보 저장부의 특정 패턴을 갖는 물리적 구조에 따라 상이한 카트리지의 고유 정보가 저장될 수 있다.",KT & G CORP,LEE WON KYEONG;;SUNWOO PAUL JOON;;CHO BYUNG SUNG,,https://lens.org/046-002-176-413-502,Patent Application,no,0,0,4,4,0,A24F40/10;;A24F40/53;;A24F40/42;;A24F40/42;;A24F40/485;;A24F40/60;;A24F40/10;;A24F40/46;;A24F40/44,A24F40/42;;A24F40/10;;A24F40/44;;A24F40/46;;A24F40/485;;A24F40/60,,0,0,,,,ACTIVE
229,EP,C0,EP 3902495 C0,084-378-149-188-93X,2023-08-02,2023,EP 19902376 A,2019-12-04,US 201816233959 A;;US 2019/0064450 W,2018-12-27,METHOD FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/084-378-149-188-93X,Unknown,no,0,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/01;;A61B5/05;;A61B8/00,,0,0,,,,ACTIVE
230,US,A1,US 2012/0211071 A1,149-402-116-738-062,2012-08-23,2012,US 201213463069 A,2012-05-03,US 201213463069 A;;US 40115709 A,2009-03-10,FOUR JUNCTION INVERTED METAMORPHIC MULTIJUNCTION SOLAR CELL WITH A SINGLE METAMORPHIC LAYER,"A multijunction solar cell including an upper first solar subcell having a first band gap; a second solar subcell adjacent to the first solar subcell and having a second band gap smaller than the first band gap; a graded interlayer adjacent to the second solar subcell, the first graded interlayer having a third band gap greater than the second band gap; and a third solar subcell adjacent to the graded interlayer, the third subcell having a fourth band gap smaller than the second band gap such that the third subcell is lattice mismatched with respect to the second subcell. A lower fourth solar subcell is provided adjacent to the third subcell and lattice matched thereto, the lower fourth subcell having a fifth band gap smaller than the fourth band gap.",NEWMAN FRED;;CHO BENJAMIN;;STAN MARK A;;SHARPS PAUL;;EMCORE SOLAR POWER INC,NEWMAN FRED;;CHO BENJAMIN;;STAN MARK A;;SHARPS PAUL,SOLAERO TECHNOLOGIES CORP (2015-01-08),https://lens.org/149-402-116-738-062,Patent Application,yes,4,27,3,111,0,H01L31/06875;;H01L31/0725;;H01L31/1844;;Y02E10/544;;H01L31/0735;;Y02P70/50;;H01L31/06875;;H01L31/0725;;H01L31/1844;;Y02E10/544;;Y02P70/50;;H01L31/0735,H01L31/0725;;H01L31/18,136/255;;438/64;;X257E31039,0,0,,,,ACTIVE
231,WO,A2,WO 2007/082153 A2,011-653-495-776-131,2007-07-19,2007,US 2007/0060149 W,2007-01-05,US 75684106 P,2006-01-05,SELF-HEALING COATING SYSTEM,"A self-healing coating includes a polymer matrix, a polymerizer, and a set of capsules containing a corresponding activator for the polymerizer. The polymerizer may be present in another set of capsules, or the polymerizer may be phase separated from the polymer matrix. The coating may be prepared by depositing a coating composition on a substrate and solidifying the coating composition, where the coating composition includes the polymerizer, the activator capsules and a matrix precursor. A combination of polymerizer capsules and activator capsules may be part of a kit, which may be used to provide self-healing properties to a coating. The polymerizer and the activator may be wet-curable, and coatings containing the polymerizer and activator may be able to self-heal when in contact with water.",UNIV ILLINOIS;;BRAUN PAUL V;;CHO SOO HYOUN;;WHITE SCOTT R,BRAUN PAUL V;;CHO SOO HYOUN;;WHITE SCOTT R,,https://lens.org/011-653-495-776-131,Patent Application,yes,0,13,5,5,0,B29C73/163;;B29C73/22;;C08G77/04;;C08G77/60;;C08K5/098;;C08K9/10;;C08L83/04;;C08L101/00;;C09D5/00;;C09D183/04;;C09D7/67;;C09D7/68;;C09D7/69;;C09D7/70;;Y10T428/2985;;C09D7/65;;Y10T428/2985;;C08L83/04;;C08L101/00;;C08G77/04;;C09D5/00;;B29C73/163;;C08K9/10;;B29C73/22;;C09D183/04;;C08K5/098;;C08G77/60;;C09D7/70;;C09D7/68;;C09D7/67;;C09D7/69;;C09D7/65,C08L101/00;;C08L83/04;;C09D7/65,,0,0,,,,PENDING
232,US,A1,US 2007/0166542 A1,019-867-215-082-632,2007-07-19,2007,US 62027607 A,2007-01-05,US 62027607 A;;US 75684106 P,2006-01-05,SELF-HEALING COATING SYSTEM,"A self-healing coating includes a polymer matrix, a polymerizer, and a set of capsules containing a corresponding activator for the polymerizer. The polymerizer may be present in another set of capsules, or the polymerizer may be phase separated from the polymer matrix. The coating may be prepared by depositing a coating composition on a substrate and solidifying the coating composition, where the coating composition includes the polymerizer, the activator capsules and a matrix precursor. A combination of polymerizer capsules and activator capsules may be part of a kit, which may be used to provide self-healing properties to a coating. The polymerizer and the activator may be wet-curable, and coatings containing the polymerizer and activator may be able to self-heal when in contact with water.",BRAUN PAUL V;;CHO SOO H;;WHITE SCOTT R,BRAUN PAUL V;;CHO SOO H;;WHITE SCOTT R,THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2007-03-07),https://lens.org/019-867-215-082-632,Patent Application,yes,24,68,5,5,0,B29C73/163;;B29C73/22;;C08G77/04;;C08G77/60;;C08K5/098;;C08K9/10;;C08L83/04;;C08L101/00;;C09D5/00;;C09D183/04;;C09D7/67;;C09D7/68;;C09D7/69;;C09D7/70;;Y10T428/2985;;C09D7/65;;Y10T428/2985;;C08L83/04;;C08L101/00;;C08G77/04;;C09D5/00;;B29C73/163;;C08K9/10;;B29C73/22;;C09D183/04;;C08K5/098;;C08G77/60;;C09D7/70;;C09D7/68;;C09D7/67;;C09D7/69;;C09D7/65,B32B15/02;;B32B17/02;;C09D7/65,428/402.21,0,0,,,,ACTIVE
233,KR,A,KR 20220124381 A,023-619-992-921-13X,2022-09-14,2022,KR 20210027900 A,2021-03-03,KR 20210027900 A,2021-03-03,Bone screw,"A bone screw according to the present invention is a bone screw provided with a screw, and comprises: a cylindrical screw part having at least one screw thread on the outer circumferential surface; and a head part disposed on the upper side of the screw part. The screw thread includes a first flank located on the front side in the screw part fastening direction, and a second flank located on the rear side in the screw part fastening direction, wherein the first flank includes an amorphous alloy on at least one area of a surface thereof. The bone screw according to one aspect of the present invention has an advantage of reducing tissue damage due to friction in the first flank where stress is mainly concentrated during screw coupling or fastening.",KOLON INC,KIM CHOONGNYUN PAUL;;CHO GEUN SANG;;LEE JONG HWAN,,https://lens.org/023-619-992-921-13X,Patent Application,no,1,0,1,1,0,A61B17/8625;;A61B17/866;;A61L31/022;;A61C8/0022;;A61C8/0012;;A61B2017/8655,A61B17/86;;A61C8/00;;A61L31/02,,0,0,,,,PENDING
234,EP,A1,EP 4092309 A1,030-765-643-663-063,2022-11-23,2022,EP 21741005 A,2021-01-14,KR 20200006341 A;;KR 2021000570 W,2020-01-17,PIPE AND MANUFACTURING METHOD THEREFOR,"A pipe according to the present invention comprises: a hollow pipe in which fluids of different temperatures pass through the inside and outside thereof; and a coating layer which is provided on the outer surface of the hollow pipe, and which has an alloy comprising an amorphous phase, wherein the alloy comprises Fe, and comprises at least one first component selected from the group consisting of Cr, Mo and Co, and at least one second component selected from the group consisting of B, C, Si and Nb..",KOLON INC,CHO GEUN SANG;;KIM CHOONGNYUN PAUL;;CHOI KWAN MIN,,https://lens.org/030-765-643-663-063,Patent Application,yes,0,0,7,7,0,C23C4/16;;F16L58/08;;C23C4/067;;C23C24/08;;C23C24/04;;C23C4/129;;C23C4/134;;C23C4/137;;C23C4/18;;C23C4/06;;Y02E20/12;;F16L58/08;;C23C4/067;;C23C4/16;;C23C24/08;;F16L58/08,F16L58/08;;C23C4/067;;C23C4/16,,0,0,,,,PENDING
235,KR,A,KR 20210093177 A,058-555-652-949-54X,2021-07-27,2021,KR 20210005452 A,2021-01-14,KR 20200006342 A,2020-01-17,Brake body and brake,"According to the present invention, a rotating brake body is rubbed by a friction means to form a coating layer comprising a ferrous amorphous alloy on a contact surface generating braking force, wherein the coating layer has a less friction factor to reduce generation of dust during braking. The present invention has excellent corrosion resistance and abrasion resistance to have excellent performance and excellent economic competitiveness when the present invention is applied to a base material for a braking device which can be produced at low cost.",KOLON INC,CHO GEUN SANG;;KIM CHOONGNYUN PAUL;;CHOI KWAN MIN,,https://lens.org/058-555-652-949-54X,Patent Application,no,1,1,6,6,0,F16D69/027;;F16D2250/0046;;F16D65/125;;F16D65/127;;B32B15/011;;C22C45/02;;C22C33/003;;C23C4/129;;C23C4/06;;C23C4/067;;C23C30/00;;C23C4/134;;C23C24/04;;C23C24/08;;C23C24/082;;C23C24/10;;F16D69/027;;F16D2250/0046;;F16D65/123;;F16D65/125;;F16D65/127;;F16D69/027;;F16D2200/0008;;F16D2250/0046,F16D69/02,,0,0,,,,PENDING
236,AU,A,AU 1984/034201 A,065-566-819-615-806,1985-05-02,1985,AU 1984/034201 A,1984-10-12,US 54491283 A,1983-10-24,HYDROLYZED PROTEIN ISOLATE AND PROCESS OF PRODUCING,,RALSTON PURINA CO,CIPOLLO KENT LEE;;CHO IUE CHUNG;;WARNER GREGORY PAUL,,https://lens.org/065-566-819-615-806,Patent Application,no,0,0,9,9,0,A23J3/00;;A23J3/346;;A23C20/00,A23J3/00;;A23C20/00;;A23J3/30;;A23J3/34,,0,0,,,,EXPIRED
237,EP,B1,EP 0141615 B1,078-078-514-956-043,1988-04-20,1988,EP 84307306 A,1984-10-24,US 54491283 A,1983-10-24,PROCESS FOR PRODUCING A HYDROLYZED VEGETABLE PROTEIN ISOLATE AND THE USE THEREOF,,RALSTON PURINA COMPANY,"CIPOLLO, KENT LEE;;CHO, IUE CHUNG;;WARNER, GREGORY PAUL",PROTEIN TECHNOLOGIES INTERNATIONAL INC. (2002-02-01),https://lens.org/078-078-514-956-043,Granted Patent,yes,3,0,9,9,0,A23J3/00;;A23J3/346;;A23C20/00,A23J3/00;;A23C20/00;;A23J3/30;;A23J3/34,,1,0,,,"CHEMICAL ABSTRACTS, vol. 88, no. 21, 22 May 1978, Columbus, Ohio (US); S.UDENFRIEND et al.: ""Fluorescent techniques for ultramicro peptide and proteine chemistry"", p. 251, no. 148327z",EXPIRED
238,EP,A1,EP 3902490 A1,079-911-853-087-288,2021-11-03,2021,EP 19901545 A,2019-12-04,US 201816233935 A;;US 2019/0064447 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/079-911-853-087-288,Patent Application,yes,0,0,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B18/12;;A61B18/04;;A61B18/10;;A61B18/14,,0,0,,,,ACTIVE
239,US,B2,US 9152206 B2,129-673-175-766-783,2015-10-06,2015,US 201313922159 A,2013-06-19,US 201313922159 A;;US 201361756422 P,2013-01-24,System and method for reducing power consumption,"Systems and methods are disclosed for operating an interface of an electronic device in an active mode or a power save mode based, at least in part, on a condition of a data exchange module buffer. When buffer space is available, incoming data may be stored locally and the interface used to access remote memory storage may be in a power save mode. The interface may revert to active mode to transfer data to the remote memory, such as after a configurable reception interval. Outgoing data may also be stored in a buffer, allowing the interface to be in a power save mode with information transmitted from the buffer.",QUALCOMM INC,HOMCHAUDHURI SANDIP;;CHO JAMES SIMON;;HUSTED PAUL;;SHRIVASTAVA SARVESH,QUALCOMM INCORPORATED (2013-07-30),https://lens.org/129-673-175-766-783,Granted Patent,yes,15,0,2,2,0,G06F1/3225;;G06F1/3278;;H04W52/0267;;H04W52/028;;H04W52/0287;;G06F1/3209;;Y02D10/00;;Y02D30/70;;G06F1/3225;;G06F1/3278;;H04W52/0267;;H04W52/0287;;H04W52/028;;Y02D10/00;;Y02D30/70;;G06F1/3209;;H04W52/00,H04M1/00;;G06F1/32;;H04W52/00,,0,0,,,,INACTIVE
240,AU,B2,AU 569548 B2,006-230-164-701-068,1988-02-04,1988,AU 1984/034201 A,1984-10-12,US 54491283 A,1983-10-24,HYDROLYZED PROTEIN ISOLATE AND PROCESS OF PRODUCING,,RALSTON PURINA CO,CIPOLLO KENT LEE;;CHO IUE CHUNG;;WARNER GREGORY PAUL,,https://lens.org/006-230-164-701-068,Granted Patent,no,1,1,9,9,0,A23J3/00;;A23J3/346;;A23C20/00,A23J3/00;;A23C20/00;;A23J3/30;;A23J3/34,,0,0,,,,EXPIRED
241,EP,A1,EP 0141615 A1,043-622-478-021-625,1985-05-15,1985,EP 84307306 A,1984-10-24,US 54491283 A,1983-10-24,Process for producing a hydrolyzed vegetable protein isolate and the use thereof.,"A hydrolyzed vegetable protein isolate is prepared by aqueous extraction of a vegetable protein material, adjusting the pH of the extract to the isoelectric point of the protein to precipitate the protein, slurrying the precipitated protein and enzymatically hydrolyzing the slurry to product a protein having a predetermined number of available amino end groups, as measured by fluorescamine reaction. The resulting product is suitable for use as an ingredient in a variety of products, but particularly in imitation cheese products.",RALSTON PURINA CO,CIPOLLO KENT LEE;;CHO IUE CHUNG;;WARNER GREGORY PAUL,PROTEIN TECHNOLOGIES INTERNATIONAL INC. (2002-02-01),https://lens.org/043-622-478-021-625,Patent Application,yes,3,1,9,9,0,A23J3/00;;A23J3/346;;A23C20/00,A23J3/00;;A23C20/00;;A23J3/30;;A23J3/34,,1,0,,,"CHEMICAL ABSTRACTS, vol. 88, no. 21, 22nd May 1978, page 251, no. 148327z, Columbus, Ohio, US; S. UDENFRIEND et al.: ""Fluorescent techniques for ultramicro peptide and protein chemistry"" & PEPT. PROC. AM. PEPT. SYMP., 5th 1977, 14-26",EXPIRED
242,US,A1,US 2020/0205668 A1,132-948-843-398-399,2020-07-02,2020,US 201816233935 A,2018-12-27,US 201816233935 A,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,"A thermoacoustic imaging system and method for monitoring tissue temperature within a region of interest, which has an object of interest and a reference that are separated by at least one boundary. The system and method include a thermoacoustic imaging system with an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein, an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest, and one or more processors that process at least one received bipolar acoustic signal generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof and calculate a temperature at the at least one boundary using the peak-to-peak amplitude of the at least one bipolar acoustic signal.",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/132-948-843-398-399,Patent Application,yes,0,1,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B5/00;;A61B5/01;;A61B5/20,,0,0,,,,ACTIVE
243,EP,A1,EP 4092287 A1,167-223-658-931-368,2022-11-23,2022,EP 21741713 A,2021-01-14,KR 20200006342 A;;KR 2021000569 W,2020-01-17,BRAKE BODY AND BRAKE DEVICE,"A brake body according to the present invention has a coating layer which contains an iron-based amorphous alloy and is formed on a contact surface at which a friction means rubs against the rotating brake body to generate braking force. The coating layer has a low friction coefficient, and thus less dust is generated during braking. The coating layer also has excellent corrosion resistance and abrasion resistance, and thus has excellent performance and excellent price competitiveness when applied to a brake base material that can be produced at low cost.",KOLON INC,CHO GEUN SANG;;KIM CHOONGNYUN PAUL;;CHOI KWAN MIN,,https://lens.org/167-223-658-931-368,Patent Application,yes,0,0,6,6,0,F16D69/027;;F16D2250/0046;;F16D65/125;;F16D65/127;;B32B15/011;;C22C45/02;;C22C33/003;;C23C4/129;;C23C4/06;;C23C4/067;;C23C30/00;;C23C4/134;;C23C24/04;;C23C24/08;;C23C24/082;;C23C24/10;;F16D69/027;;F16D2250/0046;;F16D65/123;;F16D65/125;;F16D65/127;;F16D69/027;;F16D2200/0008;;F16D2250/0046,F16D69/02,,0,0,,,,PENDING
244,US,B1,US 8495221 B1,102-507-476-270-614,2013-07-23,2013,US 201213654197 A,2012-10-17,US 201213654197 A,2012-10-17,Targeted and dynamic content-object storage based on inter-network performance metrics,"Methods and systems for coordinating provisions of storage service for clients are provided. For each storage provider of a set of storage providers, a service-provider database stores a metric characterizing a property of a service provided by the service provider. The storage providers are independently owned and operated relative to each other. The metrics are repeatedly updated. A selection engine repeatedly selects a service provider from the set of service providers to store a content object of a client of the content delivery system. The selection is based on the repeatedly updated metrics for the set of service providers. For each service provider selected by the selection engine to store the content object of the client, a service manager coordinates with the service provider such that the service provider stores the content object of the client.",LIMELIGHT NETWORKS INC,TSUNODA KOICHI;;ASAVAREUNGCHAI MICHAEL;;CHO PAUL;;ACHARYA SOAM;;THIBEAULT JASON,LIMELIGHT NETWORKS INC (2012-10-08),https://lens.org/102-507-476-270-614,Granted Patent,yes,55,13,3,3,0,H04L67/1097;;H04L65/1073;;H04L65/403;;H04L67/1097;;H04L67/60;;H04L65/612,G06F13/00;;G06F15/173,709/226;;709/224;;709/225;;711/170;;711/171;;711/172;;711/173,3,1,122-237-481-505-797,10.1016/j.jnca.2009.03.004,"James Broberg et al., ""MetaCDN: Harnessing 'Storage Clouds' for high performance content delivery"", Retrieved on Nov. 3, 2012 from http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.144.7766&rep=rep1&type=pdf, Journal of Network and Computer Applications, Sep. 2009, vol. 32, Issue 5, pp. 1012-1022.;;""Cloud-Web-Hosting-Is-Basically-A-Complete-System"", Retrieved on Nov. 3, 2012 from http://www.pdf-archive.com/2012/09/04/cloud-web-hosting-is-basically-a-complete-system-69-4/cloud-web-hosting-is-basically-a-complete-system-69-4.pdf.;;Al-Mukaddim Khan Pathan et al., ""A Taxonomy and Survey of Content Delivery Networks"", Retrieved on Nov. 3, 2012 from http://www.cloudbus.org/reports/CDN-Taxonomy.pdf.",ACTIVE
245,US,A,US 5411986 A,064-149-768-442-859,1995-05-02,1995,US 3061093 A,1993-03-12,US 3061093 A,1993-03-12,Chemoprotective isothiocyanates,"Sulforaphane has been isolated and identified as a major and very potent phase II enzyme inducer in broccoli (Brassica oleracea italica). Sulforaphane is a monofunctional inducer, inducing phase II enzymes selectively without the induction of aryl hydrocarbon receptor-dependent cytochromes P-450 (phase I enzymes). Analogues differing in the oxidation state of sulfur and the number of methylene groups were synthesized, and their inducer potencies were measured. Sulforaphane is the most potent of these analogues. Other analogues having different substituent groups in place of the methylsulfinyl group of sulforaphane were also synthesized and assessed. Of these, the most potent are 6-isothiocyanato-2-hexanone and exo-2-acetyl-6-isothiocyanatonorbornane.",UNIV JOHNS HOPKINS,CHO CHEON-GYU;;POSNER GARY H;;TALALAY PAUL;;ZHANG YUESHENG,POSNER GARY H (1994-03-28);;ZHANG YUESHENG (1994-03-28);;TALALAY PAUL (1994-03-28);;JOHN HOPKINS UNIVERSITY THE (1993-04-20);;CHO CHEON-GYU (1994-03-28),https://lens.org/064-149-768-442-859,Granted Patent,yes,0,116,3,3,0,A61K31/145;;A61K31/26;;A61K31/66;;C07C331/20;;C07C331/24;;C07C331/26;;C07C331/28;;C07F9/4006;;C07C331/28;;A61K31/145;;A61K31/66;;C07C331/24;;C07C331/26;;C07C331/20;;A61K31/26;;C07F9/4006,A61K31/145;;A61K31/26;;A61K31/66;;C07C331/20;;C07C331/24;;C07C331/26;;C07C331/28;;C07F9/40,514/514;;558/17,18,18,030-354-490-624-015;;006-147-740-404-815;;111-443-882-111-762;;042-084-883-848-720;;002-934-212-223-508;;137-086-531-005-037;;027-813-648-373-407;;120-707-565-476-760;;113-239-263-720-133;;082-398-075-943-271;;006-755-379-756-711;;066-485-501-057-105;;103-595-929-451-880;;067-058-935-935-796;;011-859-930-997-793;;097-556-928-996-785;;055-163-572-183-570;;012-958-037-091-331,10.3891/acta.chem.scand.12-0833;;10.1021/ja01525a057;;10.1007/978-3-7091-7159-2_4;;10.1021/ja01081a057;;10.1016/s0040-4020(01)82133-5;;10.3891/acta.chem.scand.28b-0418;;7059995;;3731391;;10.1093/carcin/7.8.1379;;3382006;;10.1016/0003-2697(88)90292-8;;3409219;;8778762;;10.1006/pmed.1996.0015;;1549602;;pmc48664;;10.1073/pnas.89.6.2394;;10.1093/carcin/8.12.1971;;3677323;;2766468;;10.1093/carcin/10.9.1757;;2009525;;2044181;;10.1093/carcin/12.6.1029;;10.1093/jnci/58.2.395;;401894;;6262554;;10.1093/jnci/66.4.769,"Kjaer, et al., isoThiocyanates XXX. Glucohirsutin, a New Naturally Occurring Glucoside Furnishing ( ) 8 Methylsulphinyl octyl isoThiocyanate on Enzymic Hydrolysis , Acta Chem. Scand. 12(5):833 838 (1958).;;McKay, et al., Bacteriostats. II. The Chemical and Bacteriostatic Properties of Isothiocyanates and their Derivatives, J. Amer. Chem. Soc. 81(16):4328 4335 (1959).;;Kjaer, Naturally Derived isoThiocyanates (Mustard Oils) and Their Parent Glucosides, Progress in the Chemistry of Organic Natural Products, 18:138 176 (1960).;;Mislow, et al., Diastereoisomerism in 9 Dimethylamino 9,10 dihydro 4,5 dimethylphenanthrene J. Amer. Chem. Soc., 87(3):665 666 (1965).;;Balenov , et al., Synthesis of ( ) Sulphoraphene , Tetrahedron, 22:2139 2143 (1966).;;Hansen, et al., Intramolecular Cyclizations of Thioureas Derived From Sulphoraphene: a Case of Asymmetrically Induced Additions to Vinylic Sulphoxides , Acta Chemica Scandinavica B 28:418 424 (1974).;;Lam, et al., Isolation and Identification of Kahweol Palmitate and Cafestol Palmitate as Active Constituents of Green Coffee Beans That Enhance Glutathione S Transferase Activity in the Mouse , Cancer Research, 42:1193 1198 (1982).;;Wattenberg, et al., Inhibitory Effects of 5 (2 pyraziny) 4 methyl 1,2 dithiol 3 thione(Oltipraz) on Carcinogenesis Induced by Benzo a pyrene, Diethylnitrosamine and Uracil Mustard, Carcinogenesis, 7(8):1379 1381 (1986).;;Prochaska, et al., Direct Measurement of NAD(P)H:Quinone Reductase from Cells Cultured in Microtiter Wells: A Screening Assay for Anticarcinogenic Enzyme Inducers , Analytical Biochemistry, 169:328 336 (1988).;;Prochaska, et al., Regulatory Mechanisms of Monofunctional and Bifunctional Anticarcinogenic Enzyme Inducers in Murine Liver , Cancer Research, 48:4776 4782 (1988).;;Wattenberg, et al., Chemoprevention of Cancer , Cancer Research, 45:1 8 (1985).;;Prochaska, Rapid Detection of Inducers of Enzymes That Protect Against Carcinogens , Proc. Natl. Acad. Sci. USA, 89:2394 2398 (1992).;;Wattenberg, et al., Inhibitory Effects of Benzyl Isothiocyanate Administered Shortly Before Diethlnitrosamine or Benzo a pyrene on Pulmonary and Forestomach Neoplasia in A/J Mice, Carcinogenesis, 8(12):1971 1973, 1987.;;Morse, et al., Effects of Alkyl Chain Length on the Inhibition of NNK Induced Lung Neoplasia in A/J Mice by Arylalkyl Isothiocyanates , Carcinogenesis, 10(9):1757 1759, 1989.;;Stoner, et al., Inhibitory Effects of Phenethyl Isothiocyanate on N Nitrosobenzylmethylamine Carcinogenesis in the Rat Esophagus, Cancer Research 51:2063 2068, 1991.;;Doerr O Rourke, et al., Effect of Phenethyl Isothiocyanate on the Metabolism of the Tobacco Specific Nitrosamine 4 (methylnitrosamino) 1 (3 pyridyl) 1 butanone by Cultured Rat Lung Tissue, Carcinogenesis, 12(6):1029 1034, 1991.;;Wattenberg, et al., Inhibition of Carcinogenic Effects of Polycyclic Hydrocarbons by Benzyl Isothiocyanate and Related Compounds, J. Natl Cancer, 48(2):395 398, 1977.;;Sparnins, et al., Enhancement of Glutathione S Transferase Activity of the Mouse Forestomach by Inhibitors of Benzo a pyrene Induced Neoplasia of the Forestomach , Jncl., 66(4):769 771, 1981.",EXPIRED
246,CN,A,CN 115335614 A,099-488-392-906-884,2022-11-11,2022,CN 202180009214 A,2021-01-14,KR 20200006342 A;;KR 2021000569 W,2020-01-17,Brake body and brake device,"Provided is a brake body in which a coating layer containing an iron-based amorphous alloy is formed on a contact surface on which a braking force is generated, the braking force being generated by friction between the brake body that performs a rotational motion and a friction means, the coating layer having a low coefficient of friction and thus generating little dust during braking, and the friction force being generated by the friction means. And has excellent corrosion resistance and wear resistance, and thus has excellent performance and price competitiveness when applied to a brake base material produced using a low budget.",KOLON INC,CHO GEUN-SANG;;KIM CHUNG-NYUN PAUL;;CHOI KWAN-MIN,,https://lens.org/099-488-392-906-884,Patent Application,no,0,0,6,6,0,F16D69/027;;F16D2250/0046;;F16D65/125;;F16D65/127;;B32B15/011;;C22C45/02;;C22C33/003;;C23C4/129;;C23C4/06;;C23C4/067;;C23C30/00;;C23C4/134;;C23C24/04;;C23C24/08;;C23C24/082;;C23C24/10;;F16D69/027;;F16D2250/0046;;F16D65/123;;F16D65/125;;F16D65/127;;F16D69/027;;F16D2200/0008;;F16D2250/0046,F16D69/02,,0,0,,,,PENDING
247,WO,A1,WO 1994/019948 A1,019-744-420-996-468,1994-09-15,1994,US 9402453 W,1994-03-11,US 3061093 A,1993-03-12,CHEMOPROTECTIVE ISOTHIOCYANATES,"Sulforaphane has been isolated and identified as a major and very potent phase II enzyme inducer in broccoli (Brassica oleracea italica). Sulforaphane is a monofunctional inducer, inducing phase II enzymes selectively without the induction of aryl hydrocarbon receptor-dependent cytochromes P-450 (phase I enzymes). Analogues differing in the oxidation state of sulfur and the number of methylene groups were synthesized, and their inducer potencies were measured. Sulforaphane is the most potent of these analogues. Other analogues having different substituent groups in place of the methylsulfinyl group of sulforaphane were also synthesized and assessed. Of these, the most potent are 6-isothiocyanato-2-hexanone and exo-2-acethyl-6-isothiocyanatonorbornane.",CHO CHEON GYU;;POSNER GARY H;;TALALAY PAUL;;ZHANG YUESHENG,CHO CHEON-GYU;;POSNER GARY H;;TALALAY PAUL;;ZHANG YUESHENG,,https://lens.org/019-744-420-996-468,Patent Application,yes,0,74,3,3,0,A61K31/145;;A61K31/26;;A61K31/66;;C07C331/20;;C07C331/24;;C07C331/26;;C07C331/28;;C07F9/4006;;C07C331/28;;A61K31/145;;A61K31/66;;C07C331/24;;C07C331/26;;C07C331/20;;A61K31/26;;C07F9/4006,A61K31/145;;A61K31/26;;A61K31/66;;C07C331/20;;C07C331/24;;C07C331/26;;C07C331/28;;C07F9/40,,2,2,103-595-929-451-880;;011-859-930-997-793,10.1093/carcin/8.12.1971;;3677323;;2009525,"CARCINOGENESIS, Volume 8, No. 12, issued 1987, LEE W. WATTENBERG, ""Inhibitory Effects of Benzyl Isothiocyanate Administered Shortly Before Diethylnitrosamine of BenziÄaÜ Pyrene on Pulmonary and Forestomach Neoplasia in A/J Mice"", pages 1971-1973.;;CANCER RESEARCH, Volume 51, issued 13 April 1991, GARY D. STONER et al., ""Inhibitory Effects of Phenethyl Isothiocyanate on N-Nitrosbenzylmethylamine Carcinogenesis in the Rat Esophagus"", pages 2063-2068.",PENDING
248,US,S,US D0761382 S,007-595-371-385-748,2016-07-12,2016,US 201529527438 F,2015-05-19,US 201529527438 F,2015-05-19,Filter cartridge,,ELECTROLUX HOME PROD INC,CURTIS BRENT AARON;;MCCOLLOUGH THOMAS;;SHRADER BENJAMIN PAUL;;CHO NATHAN,ELECTROLUX HOME PRODUCTS INC (2015-05-12),https://lens.org/007-595-371-385-748,Design Right,no,0,5,2,2,0,,,2301;;D23/209,0,0,,,,ACTIVE
249,US,B2,US 9043437 B2,017-224-716-127-737,2015-05-26,2015,US 201313921893 A,2013-06-19,US 201313921893 A;;US 201213654197 A,2012-10-17,Targeted and dynamic content-object storage based on inter-network performance metrics,"Methods and systems for coordinating provisions of storage service for clients are provided. For each storage provider of a set of storage providers, a service-provider database stores a metric characterizing a property of a service provided by the service provider. The storage providers are independently owned and operated relative to each other. The metrics are repeatedly updated. A selection engine repeatedly selects a service provider from the set of service providers to store a content object of a client of the content delivery system. The selection is based on the repeatedly updated metrics for the set of service providers. For each service provider selected by the selection engine to store the content object of the client, a service manager coordinates with the service provider such that the service provider stores the content object of the client.",LIMELIGHT NETWORKS INC,TSUNODA KOICHI;;ASAVAREUNGCHAI MICHAEL;;CHO PAUL;;ACHARYA SOAM;;THIBEAULT JASON,LIMELIGHT NETWORKS INC (2012-10-08),https://lens.org/017-224-716-127-737,Granted Patent,yes,57,0,3,3,0,H04L67/1097;;H04L65/1073;;H04L65/403;;H04L67/1097;;H04L67/60;;H04L65/612,H04L29/08;;H04L29/06,709/217,4,1,122-237-481-505-797,10.1016/j.jnca.2009.03.004,"Broberg et al., ""MetaCDN: Harnessing 'Storage Clouds' for high performance content delivery"", Retrieved on Nov. 3, 2012 from http://citeseerx. ist.psu.edu/viewdoc/download?doi= 1 0.1.1.144. 7766&rep=rep 1 &type=pdf, Journal of Network and Computer Applications, Sep. 2009, vol. 32, Issue 5, 11 pages.;;""Cloud-Web-Hosting-Is-Basically-A-Complete-System,"" Retrieved on Nov. 3,2012 from http://www.pdf-archive.com/2012/09/04/cloud-web-hosting-is-basically-a-complete-system-69-4/cloud-web-hosting-is-basically-a-complete-D system-69-4 .pdf.;;Al-Mukkadim, Khan Pathan et al., ""A Taxonomy and Survey of Content Delivery Networks"", Retrieved on Nov. 3, 2012 from http://www.cloudbus.org/reports/CDN-Taxonomy.pdf.;;U.S. Appl. No. 13/654,197, filed Oct. 17, 2007, Notice of Allowance mailed May 29, 2013, 36 pages.",INACTIVE
250,KR,A,KR 20230032897 A,070-689-854-005-051,2023-03-07,2023,KR 20220098296 A,2022-08-08,KR 20210114588 A,2021-08-30,METHOD FOR THREAT MODELING USING BLOCKCHAIN TECHNOLOGY,"본 개시의 일 실시예에 따라, 블록체인 네트워크를 구성하는 제 1 노드에 의해 수행되는 위협 모델링 방법으로서, 위협 모델링의 수행에 요구되는 데이터를 포함하는 작업 요청을 상기 블록체인 네트워크를 통해 획득하는 단계; 상기 작업 요청에 응답하여, 상기 데이터에 기초하여 수행된 위협 모델링의 결과물을 생성하는 단계; 및 상기 결과물에 대한 평가 정보 및 상기 평가 정보에 대한 검증 정보가 생성될 수 있도록, 상기 위협 모델링의 결과물을 상기 블록체인 네트워크에 전송하는 단계;를 포함하고, 상기 평가 정보는, 상기 블록체인 네트워크를 구성하는 제 2 노드에서, 사전 결정된 평가 기준에 기초하여 상기 블록체인 네트워크를 통해 획득된 상기 결과물에 대한 평가를 통해 생성되고, 그리고 상기 블록체인 네트워크에 전송되고, 상기 검증 정보는, 상기 블록체인 네트워크를 구성하는 제 3 노드에서, 상기 사전 결정된 평가 기준에 기초하여 상기 블록체인 네트워크를 통해 획득된 상기 평가 정보의 생성의 유효성에 대한 검증을 통해 생성되고, 그리고 상기 블록체인 네트워크에 전송되고, 그리고 상기 평가 정보의 생성에 대한 유효성이 검증된 경우, 상기 블록체인 네트워크 상에 저장된 스마트 컨트랙트(smart contract)에 의해 상기 평가 정보에 대응되는 보상을 상기 제 1 노드에 지급하도록 결정될 수 있다.",UNIV KOREA RES & BUS FOUND,KIM SEUNGJOO;;PARK SHINCHUL;;HONG PAUL;;KIM YEJUN;;CHO KWANGSOO,,https://lens.org/070-689-854-005-051,Patent Application,no,2,0,2,2,0,H04L63/1433;;G06F21/577;;H04L63/1441;;H04L9/50;;H04L2463/102,H04L9/40;;G06F21/57;;H04L9/00,,0,0,,,,ACTIVE
251,US,A1,US 2014/0108598 A1,079-161-172-764-300,2014-04-17,2014,US 201313921893 A,2013-06-19,US 201313921893 A;;US 201213654197 A,2012-10-17,TARGETED AND DYNAMIC CONTENT-OBJECT STORAGE BASED ON INTER-NETWORK PERFORMANCE METRICS,"Methods and systems for coordinating provisions of storage service for clients are provided. For each storage provider of a set of storage providers, a service-provider database stores a metric characterizing a property of a service provided by the service provider. The storage providers are independently owned and operated relative to each other. The metrics are repeatedly updated. A selection engine repeatedly selects a service provider from the set of service providers to store a content object of a client of the content delivery system. The selection is based on the repeatedly updated metrics for the set of service providers. For each service provider selected by the selection engine to store the content object of the client, a service manager coordinates with the service provider such that the service provider stores the content object of the client.",LIMELIGHT NETWORKS INC,TSUNODA KOICHI;;ASAVAREUNGCHAI MICHAEL;;CHO PAUL;;ACHARYA SOAM;;THIBEAULT JASON,LIMELIGHT NETWORKS INC (2012-10-08),https://lens.org/079-161-172-764-300,Patent Application,yes,48,0,3,3,0,H04L67/1097;;H04L65/1073;;H04L65/403;;H04L67/1097;;H04L67/60;;H04L65/612,H04L29/08,709/217,0,0,,,,INACTIVE
252,US,B1,US 6216709 B1,098-250-780-329-55X,2001-04-17,2001,US 18604898 A,1998-11-03,US 18604898 A;;US 9915998 P,1998-09-04,Method for drying a substrate,"A method for drying workpieces in accordance with our invention includes the step of immersing the workpieces in a liquid, holding the workpieces with a first holding mechanism, slowly draining the liquid from the container until a first portion of the workpieces is exposed and dried, holding the workpieces with a second holding means at the first portion, and draining the remainder of the liquid from the container. Because of this, a drying portion of the workpiece is not held by a wet holding mechanism.",KOMAG INC,FUNG ROBERT PUI CHI;;MUSSER DAVID PAUL;;CHO JONATHAN SANGHUN,WD MEDIA LLC (2007-09-05);;KOMAG INCORPORATED (1998-10-08),https://lens.org/098-250-780-329-55X,Granted Patent,yes,13,95,1,10,0,G11B5/8404;;H01L21/67034;;Y10S134/902;;G11B5/8404;;H01L21/67034;;Y10S134/902,G11B5/84;;H01L21/00,134/25.4;;134/2;;134/26;;134/30;;134/32;;134/37;;134/95.2;;134/902,0,0,,,,EXPIRED
253,CN,A,CN 114945769 A,088-249-264-102-382,2022-08-26,2022,CN 202180009336 A,2021-01-14,KR 20200006341 A;;KR 2021000570 W,2020-01-17,Pipe and manufacturing method thereof,"The tube according to the present invention comprises: a hollow tube body through which fluids having different temperatures flow; and a coating layer provided on an outer surface of the hollow tube body and having an alloy including an amorphous phase, the alloy including Fe and including: a first component that is at least one selected from the group consisting of Cr, Mo, and Co, and a second component that is at least one selected from the group consisting of Cr, Mo, and Co; and a second component which is at least one selected from the group consisting of B, C, Si, and Nb.",KOLON INC,CHO GEUN-SANG;;KIM CHUNG-NYUN PAUL;;CHOI KWAN-MIN,,https://lens.org/088-249-264-102-382,Patent Application,no,14,0,7,7,0,C23C4/16;;F16L58/08;;C23C4/067;;C23C24/08;;C23C24/04;;C23C4/129;;C23C4/134;;C23C4/137;;C23C4/18;;C23C4/06;;Y02E20/12;;F16L58/08;;C23C4/067;;C23C4/16;;C23C24/08;;F16L58/08,F16L58/08;;C23C4/067;;C23C4/16,,0,0,,,,PENDING
254,US,S,US D0761383 S,131-387-828-725-802,2016-07-12,2016,US 201529527439 F,2015-05-19,US 201529527439 F,2015-05-19,Filter cartridge,,ELECTROLUX HOME PROD INC,CURTIS BRENT AARON;;MCCOLLOUGH THOMAS;;SHRADER BENJAMIN PAUL;;CHO NATHAN,ELECTROLUX HOME PRODUCTS INC (2015-05-12),https://lens.org/131-387-828-725-802,Design Right,no,0,4,2,2,0,,,2301;;D23/209,0,0,,,,ACTIVE
255,US,E,US RE036784 E,145-167-259-441-319,2000-07-18,2000,US 85038797 A,1997-05-02,US 85038797 A;;US 3061093 A,1993-03-12,Chemoprotective isothiocyanates,"Sulforaphane has been isolated and identified as a major and very potent phase II enzyme inducer in broccoli (Brassica oleracea italica). Sulforaphane is a monofunctional inducer, inducing phase II enzymes selectively without the induction of aryl hydrocarbon receptor-dependent cytochromes P-450 (phase I enzymes). Analogues differing in the oxidation state of sulfur and the number of methylene groups were synthesized, and their inducer potencies were measured. Sulforaphane is the most potent of these analogues. Other analogues having different substituent groups in place of the methylsulfinyl group of sulforaphane were also synthesized and assessed. Of these, the most potent are 6-isothiocyanato-2-hexanone and exo-2-acetyl-6-isothiocyanatonorbornane.",UNIV JOHNS HOPKINS,CHO CHEON-GYU;;POSNER GARY H;;TALALAY PAUL;;ZHANG YUESHENG,,https://lens.org/145-167-259-441-319,Amended Patent,yes,3,71,3,3,0,A61K31/145;;A61K31/26;;A61K31/66;;C07C331/20;;C07C331/24;;C07C331/26;;C07C331/28;;C07F9/4006;;C07C331/28;;A61K31/145;;A61K31/66;;C07C331/24;;C07C331/26;;C07C331/20;;A61K31/26;;C07F9/4006,A61K31/145;;A61K31/26;;A61K31/66;;C07C331/20;;C07C331/24;;C07C331/26;;C07C331/28;;C07F9/40,424/94.1;;426/49;;426/52;;426/547;;426/615;;424/648;;424/655;;514/514;;514/515;;558/17,60,18,103-595-929-451-880;;067-058-935-935-796;;011-859-930-997-793;;097-556-928-996-785;;055-163-572-183-570;;012-958-037-091-331;;030-354-490-624-015;;006-147-740-404-815;;111-443-882-111-762;;042-084-883-848-720;;002-934-212-223-508;;137-086-531-005-037;;027-813-648-373-407;;120-707-565-476-760;;113-239-263-720-133;;082-398-075-943-271;;006-755-379-756-711;;066-485-501-057-105,10.1093/carcin/8.12.1971;;3677323;;2766468;;10.1093/carcin/10.9.1757;;2009525;;2044181;;10.1093/carcin/12.6.1029;;10.1093/jnci/58.2.395;;401894;;6262554;;10.1093/jnci/66.4.769;;10.3891/acta.chem.scand.12-0833;;10.1021/ja01525a057;;10.1007/978-3-7091-7159-2_4;;10.1021/ja01081a057;;10.1016/s0040-4020(01)82133-5;;10.3891/acta.chem.scand.28b-0418;;7059995;;3731391;;10.1093/carcin/7.8.1379;;3382006;;10.1016/0003-2697(88)90292-8;;3409219;;8778762;;10.1006/pmed.1996.0015;;1549602;;pmc48664;;10.1073/pnas.89.6.2394,"Wattenberg, et al., Inhibitory Effects of Benzyl Isothiocyanate Administered Shortly Before Diethlnitrosamine or Benzo pyrene on Pulmonary and Forestomach Neoplasia in A/J Mice, Carcinogenesis , 8(12): 1971 1973, 1987.;;Morse, et al,. Effects of Alkyl Chain Length on the Inhibition of NNK Induced Lung Neoplasia in A/J Mice by Arylalkyl Isothiocyanates, Carcinogenesis , 10(9):1757 1759, 1989.;;Stoner, et al., Inhibitory Effects of Phenethyl Isothiocyanate on N Nitrosobenzylmethylamine Carcinogenesis in the Rat Esophagus, Cancer Research 51:2023 2068, 1991.;;Doerr O Rourke, et al., Effects of Phenethyl Isothiocyanate on the Metabolism of the Tobacco Specific Nitrosamine 4 (methylnitrosamino) 1(3 pyridyl) 1 butanone by Cultured Rat Lung Tissue, Carcinogenesis , 12(6):1029 1034, 1991.;;Wattenberg, et al., Inhibition of Carcinogenic Effects of Polycyclic Hydrocarbons by Benzyl Isothiocyanate and Related Compounds, J. Natl. Cancer , 48(2):395 398, 1977.;;Sparnins, et al., Enhancement of Gluthathione S Transferase Activity of the Mouse Forestomach by Inhibitors of Benzo pyrene Induced Neoplasia of the Forestomach , Jncl. , 66(4):769 771, 1981.;;Kj r, et al., isoThiocyanates XXX. Glucohirsutin, a New Naturally Occurring Glucoside Furnishing ( ) 8 Methylsulphiny octyl isoThiocyanate on Enzymic Hydrolysis , Acta Chem. Scand. 12(5):833 838, (1958).;;McKay, et al., Bacteriostats. II. The Chemical and Bacteriostatic Properties of Isothiocyanates and their Derivatives, J. Amer. Chem. Soc. , 81 (16):4328 4335 (1959).;;Kj r, Naturally Derived isoThiocyanates (Mustard Oils) and Their Parent Glucosides, Progress in the Chemistry of Organic Natural Products , 18:138 176 (1960).;;Mislow, et al., Diastereoisomerism in 9 Dimethylamino 9, 10 dihydro 4,5 dimethylphenanthrene , J. Amer. Chem. Soc. , 87(3):665 666 (1965).;;Balenovi c , et al., Synthesis of ( ) Sulphoraphene , Tetrahedron , 22:2139 2143 (1966).;;Hansen, et al., Intramolecular Cyclizations of Thioureas Derived From Sulphoraphene: a Case of Asymmetrically Induced Additions to Vinylic Sulphoxides , Acta Chemica Scandinavica B , 28:418 424 (1974).;;Lam, et al., Isolation and Identification of Kahweol Palmitate and Cafestol Palmitate as Active Constituents of Green Coffee Beans That Enhance Gluthathione S Transferase Activity in the Mouse , Cancer Research , 42:1193 1198(1982).;;Wattenberg, et al., Inhibiroty Effects of 5 (2 pyraziny) 4 methyl 1,2 dithiol 3 thione(Oltipraz) on Carcinogenesis Induced by Benzo pyrene, Diethylnitrosamine and Uracil Mustare, Carcinogenesis , 7(8):1379 1381 (1986).;;Prochaska, et al., Direct Measurement of NAD(P)H:Quinone Reductase from Cells Cultured in Microtiter Wells: A Screening Assay for Anticarcinogenic Enzyme Inducer , Analytical Biochemistry , 169:328 336(1988).;;Prochaska, et al., Regulatory Mechanisms of Monofunctional and Bifunctional Anticarcinogenic Enzyme Inducers in Murine Liver , Cancer Research , 48:4776 4782 (1988).;;Wattenberg, et al., Chemoprevention of Cancer , Cancer Research , 45:1 8 (1985).;;Prochaska, Rapid Detection of Inducers of Enzymes That Protect Against Carcinogens , Proc. Natl. Acad. Sci. USA , 89:2394 2398(1992).;;The Sproutletter, No. 25, Nov. Dec. 1984.;;The Sproutletter May Jun. 1981, No. 4.;;Roy Bruder, Ph.D., Discovering Natural Foods, (including pp. 203 209), Woodbridge Press, 1982.;;Brian R. Clement, Hippocrates Health Program, (including pp. 7 11), Hipprocrates Publications, 1989.;;Jethro Kloss, The Back to Eden Cookbook, pp. 61 61, Woodbridge Press, 1974.;;Steve Meyerowitz, Sproutmann Kitchen Garden Cookbook, The Sprouthouse, Inc., pp. 178 179, 290, 1994.;;Steve Meyerowitz, Sprout It, One week from Seed to Salad, The Sprouthouse, Inc., (including pp. 84 85, 120 123), Jun. 1994.;;Steve Meyerowitz, The Complete Guide to Sprouting, Sprouts The Miracle Food, Sproutman Publications, (including pp. 121 2), May 1998.;;Esther Munroe, Sprouts to Grow and Eat, (including pp. 2 15). Dec. 1974.;;Jean Hewitt, The New York Times New Natural Foods Cookbook:, Avon Books, pp. 200 203, 1982.;;Martha H. Oliver, Add a Few Sprouts To Ear Better for Less Money, Pivot Original Health Books, (including pp. 52 53, 118 119), 1975.;;James C. Schmidt, Horticulture Facts, Growing Sprouts Indoors , (Rev. 4/81).;;Angnes Toms, The Joy of Eating Natural Foods, The Complete Organic Cookbook, pp. 318 319, Nov. 1971.;;Karen Cross Whyte, The Complete Sprouting Cookbook, Troubador Press, (including pp. 57 59), 1973.;;Ann Wigmore, The Sprouting Book, Avery Publications, (including pp. 29 37), 1986.;;Debra Schwarze, Growing Sprouts, Neb Guide, Jan. 1989.;;John Tobe, Sprouts Elixir of Life, 1970.;;David Ehrlich with George Wolf, Foreward by Peter Albright, M.D., The Bowell Book , Schocken Books, 1981.;;The Good News Sprouts Recipe Book ISGA, Aug. 1992.;;Ann Wigmore, The Hippocrates Diet and Health Program , Avery Publications, 1984.;;Sproutletter, 41, Summer, 1989.;;The Sproutletter, No. 27, Mar. Apr. 1985.;;Steve Meyerowitz, Growing Vegetables Indoors , 1983.;;The Sproutletter, No. 24, Sep. Oct. 1984.;;The Sproutletter, Issue 33, Spring 1987.;;The Sproutletter, No. 28, May Jun. 1985.;;The Sproutletter, No. 26, Jan. Feb. 1985.;;The Sproutletter, No. 29, Jul. Aug. 1985.;;Sproutletter, 40, Spring, 1989.;;Sproutletter, 44, Mar. 1991.;;Sproutletter, 36, Winter, 1988.;;Sproutletter, 39, Fall, 1988.;;Sproutletter, 43, May/Jun. 1990.;;Sproutletterm, 38, Summer, 1988.;;Deirdre Purdy, ed., The Summer Kitchen, A Farmers Market Cookbook, 1981.;;Viktoras Kulvinskas, M.S. Co Director Hippocrates Health Institute, Love Your Body or how to be a live food lover , 1974.;;New Prices New Products, Jul., 1985.;;The Sprout House Newsletter, Issue 15, Aug., 1992.;;Complaint for Patent Infringement (Brassica Protection Products, LLC v. The Sproutman, Inc. dated Sep. 20, 1999.;;Murry Tizer s Answer, Affirmative Defenses and Counterclaims dated Jun. 28, 1999.;;The Sproutman, Inc. s, Answer, Affirmative Defenses and Counterclaims dated Jun. 28, 1999.;;Request for Reexamination of U.S. Patent No. 5,725,895 filed Oct. 11, 1999.",PENDING
256,EP,B1,EP 2725511 B1,071-062-257-518-219,2016-12-21,2016,EP 12189773 A,2012-10-24,EP 12189773 A,2012-10-24,Managing application execution and data access on a device,,BLACKBERRY LTD;;ONTARIO INC 2236008,BENDER CHRISTOPHER LYLE;;CHO JUNG HYUN;;FOY JASON PAUL;;NAGARAJAN SIVAKUMAR,"BLACKBERRY LIMITED (2014-09-10);;2236008 ONTARIO INC. (2014-09-10);;BLACKBERRY LIMITED, WATERLOO, CA (2020-06-29)",https://lens.org/071-062-257-518-219,Granted Patent,yes,2,0,7,7,0,G06F21/53;;G06F21/53,G06F21/53,,0,0,,,,ACTIVE
257,CA,A1,CA 2829805 A1,022-711-993-588-610,2014-04-24,2014,CA 2829805 A,2013-10-10,EP 12189773 A,2012-10-24,MANAGING APPLICATION EXECUTION AND DATA ACCESS ON A DEVICE,"Some aspects of what is described here relate to managing application execution and data access on a mobile device. A request to access data is received from an application associated with a first perimeter on a device. The data is associated with a second, different perimeter on the device and has a data type. It is determined, based on the data type, that a management policy associated with the first perimeter permits the application to access the data independent of a second, different management policy assigned to the second perimeter. Based on the determining, the application is provided access to the data.",BLACKBERRY LTD;;QNX SOFTWARE SYSTEMS LTD,BENDER CHRISTOPHER LYLE;;CHO JUNG HYUN;;FOY JASON PAUL;;NAGARAJAN SIVAKUMAR,,https://lens.org/022-711-993-588-610,Patent Application,no,0,0,7,7,0,G06F21/53;;G06F21/53,H04L9/32;;G06Q10/10;;H04W12/08,,0,0,,,,ACTIVE
258,US,B2,US 11579958 B2,050-887-382-869-880,2023-02-14,2023,US 202117239342 A,2021-04-23,US 202117239342 A,2021-04-23,Detecting system events based on user sentiment in social media messages,Methods and systems are disclosed herein for using anomaly detection in timeseries data of user sentiment to detect incidents in computing systems and identify events within an enterprise. An anomaly detection system may receive social media messages that include a timestamp indicating when each message was published. The system may generate sentiment identifiers for the social media messages. The sentiment identifiers and timestamps associated with the social media messages may be used to generate a timeseries dataset for each type of sentiment identifier. The timeseries datasets may be input into an anomaly detection model to determine whether an anomaly has occurred. The system may retrieve textual data from the social media messages associated with the detected anomaly and may use the text to determine a computing system or event associated with the detected anomaly.,CAPITAL ONE SERVICES LLC,GONZALEZ MACIAS VANNIA;;CHO PAUL;;GUPTA RAHUL;;GARCIA SCOTT;;RAMANATHAN ADITHYA,CAPITAL ONE SERVICES LLC (2021-04-23),https://lens.org/050-887-382-869-880,Granted Patent,yes,7,0,4,4,0,G06F40/30;;G06F40/284;;G06Q50/01;;G06N3/09;;G06N3/084;;G06N3/0455;;G06F11/0781;;H04L12/1827;;G06F11/0781;;G06N20/00;;G06F40/30;;G06F40/289,G06F11/07;;G06F40/289;;G06F40/30;;G06N20/00,,0,0,,,,ACTIVE
259,DE,B2,DE 2729737 B2,061-020-468-170-955,1978-08-17,1978,DE 2729737 A,1977-07-01,US 71075576 A,1976-08-02,DE 2729737 B2,,"DART INDUSTRIES INC., LOS ANGELES, CALIF. (V.ST.A.)","CHO, KAZUNOBU, TOKIO;;BATEMAN, ROBERT FRANCIS, GREENVILLE;;BEAUCHAMP, ROGER PAUL, HARRISVILLE",,https://lens.org/061-020-468-170-955,Patent Application,no,0,0,48,49,0,B65D25/04,B65D25/04;;B65D1/24;;B65D43/08,,0,0,,,,EXPIRED
260,DE,C3,DE 2729737 C3,047-419-735-107-318,1979-04-19,1979,DE 2729737 A,1977-07-01,US 71075576 A,1976-08-02,DE 2729737 C3,,"DART INDUSTRIES INC., LOS ANGELES, CALIF. (V.ST.A.)","CHO, KAZUNOBU, TOKIO;;BATEMAN, ROBERT FRANCIS, GREENVILLE;;BEAUCHAMP, ROGER PAUL, HARRISVILLE",,https://lens.org/047-419-735-107-318,Granted Patent,no,0,0,48,49,0,B65D25/04,B65D25/04;;B65D1/24;;B65D43/08,,0,0,,,,EXPIRED
261,KR,A,KR 20170054244 A,154-759-503-661-002,2017-05-17,2017,KR 20160135174 A,2016-10-18,TW 104134382 A;;TW 105126114 A,2015-10-20,AN ELECTROPLATING MACHINE AND AN ELECTROPLATING METHOD,"Disclosed are an electroplating machine with a plurality of portable workpiece carriers, and an electroplating method thereof. According to the present invention, the electroplating machine (100, 200) comprises: a tank (102, 202) to store electroplating solution; a plurality of carriers (104, 204) capable of moving to the tank (102, 202) to be detachably engaged with each workpiece (205) to be electroplated, wherein each carrier (104, 205) are electrically connected to two power supply units (106a, 106b, 206a, 206b), and are able to be moved at the same time; and at least one power supply unit (106a, 106b, 206a, 206b) of each carrier (104, 204) electrically connected to a common anode (108, 110) or a grounded common conductive body (230).",PROCESS AUTOMATION INT LTD,CHIU YU HIM;;HUI KWAI PUN;;CHENG KWONG CHO;;HENINGTON PAUL,,https://lens.org/154-759-503-661-002,Patent Application,no,4,0,2,8,0,C25D17/06;;C25D17/10;;C25D17/007;;C25D17/28;;C25D17/02;;C25D17/00;;C25D21/10,C25D17/06;;C25D17/00;;C25D17/02;;C25D17/10;;C25D17/28;;C25D21/10,,0,0,,,,ACTIVE
262,US,A1,US 2012/0157801 A1,070-946-423-902-492,2012-06-21,2012,US 201113299119 A,2011-11-17,US 201113299119 A;;US 41517410 P,2010-11-18,Adaptor for On-Body Analyte Monitoring System,"An analyte monitoring system comprising: an on-body housing; an analyte sensor coupled to the housing; an electrical output interface disposed on an outer surface of the housing; and a removable adaptor coupled to the housing. In one embodiment, a portion of the analyte sensor extends from the housing for implantation into a patient's body. The electrical output interface is electrically coupled to the analyte sensor. The removable adaptor is mechanically coupled to the housing and electrically coupled to the electrical output interface. The removable adaptor serves as a data conduit between the analyte sensor and a remote device.",HOSS UDO;;SHARP CRAIG W;;CHO HYUN;;WINKLER TODD;;LEGG PAUL;;ABBOTT DIABETES CARE INC,HOSS UDO;;SHARP CRAIG W;;CHO HYUN;;WINKLER TODD;;LEGG PAUL,ABBOTT DIABETES CARE INC (2012-01-31),https://lens.org/070-946-423-902-492,Patent Application,yes,7,66,3,3,0,A61B5/14503;;A61B5/14503;;A61B5/14532;;A61B5/14532;;A61B2560/0412;;A61B2560/0412,A61B5/145,600/309,0,0,,,,DISCONTINUED
263,US,B1,US 8656016 B1,041-044-596-349-053,2014-02-18,2014,US 201213659527 A,2012-10-24,US 201213659527 A,2012-10-24,Managing application execution and data access on a device,"Some aspects of what is described here relate to managing application execution and data access on a mobile device. A request to access data is received from an application associated with a first perimeter on a device. The data is associated with a second, different perimeter on the device and has a data type. It is determined, based on the data type, that a management policy associated with the first perimeter permits the application to access the data independent of a second, different management policy assigned to the second perimeter. Based on the determining, the application is provided access to the data.",RESEARCH IN MOTION LTD;;QNX SOFTWARE SYSTEMS LTD;;BLACKBERRY LTD,BENDER CHRISTOPHER LYLE;;CHO JUNG HYUN;;FOY JASON PAUL;;NAGARAJAN SIVAKUMAR,BLACKBERRY LIMITED (2012-11-29);;8758271 CANADA INC (2014-04-03);;2236008 ONTARIO INC (2014-04-03);;RESEARCH IN MOTION UK LIMITED (2012-11-20);;RESEARCH IN MOTION CORPORATION (2012-11-30),https://lens.org/041-044-596-349-053,Granted Patent,yes,100,36,3,3,0,G06F9/468;;G06F2221/2105;;G06F2221/2113;;H04L63/0209;;G06F21/6218;;H04W12/086;;G06F21/6245;;H04L63/102;;H04L41/0893;;G06F21/6218;;G06F9/468;;G06F2221/2105;;G06F2221/2113;;H04L63/0209;;H04W12/086;;G06F15/16;;H04L41/50,G06F15/16,709/225;;726/1,98,1,030-818-024-660-177,10.4108/icst.mobiquitous2009.6855,"Extended European Search Report issued in European Application No. 11188696.6 on Apr. 12, 2012; 7 pages.;;Office Action issued in U.S. Appl. No. 13/398,676 on Sep. 5, 2012; 21 pages.;;Extended European Search Report issued in European Application No. 11186802.2 on Jan. 18, 2012; 7 pages.;;Extended European Search Report issued in European Application No. 11186796.6 on Jan. 18, 2012; 8 pages.;;Ferguson et al., U.S. Appl. No. 13/293,743, ""Managing Cross Perimeter Access,"" filed Nov. 10, 2011.;;Google Inc.; Android 2.3.4 User's Guide; May 20, 2011; 384 pages.;;Microsoft Corp.; Microsoft Outlook 2010; Released Jul. 15, 2010; 27 pages.;;Office Action issued in U.S. Appl. No. 13/293,743 on Feb. 14, 2013; 15 pages.;;Office Action issued in U.S. Appl. No. 13/274,913 on Jan. 23, 2013; 22 pages.;;International Search Report and Written Opinion issued in International Application No. PCT/CA2012/050797 on Feb. 5, 2013; 8 pages.;;Office Action issued in U.S. Appl. No. 13/25,097 on Feb. 28, 2013; 18 pages.;;Extended European Search Report issued in European Application No. 12189773.0 on Mar. 7, 2013; 8 pages.;;International Search Report and Written Opinion of the International Searching Authority issued in International Application No. PCT/CA2012/050796 on Feb. 21, 2013; 13 pages.;;Research in Motion, ""BlackBerry Bridge App 2.1 and Blackberry PlayBook Tablet 2.1, Security Technical Overview""; Version: 2.1; Jul. 17, 2012; 43 pages.;;Research in Motion, ""BlackBerry Device Sercvice 6.1 and BlackBerry PlayBook Tablet 2.1, Security Technical Overview""; Version: 6.1; Sep. 17, 2012; 90 pages.;;Office Action issued in U.S. Appl. No. 10/524,353 on Sep. 21, 2012; 16 pages.;;Office Action issued in U.S. Appl. No. 13/098,456 on Sep. 13, 2012; 20 pages.;;International Search Report and Written Opinion issued in International Application No. PCT/CA2011/001058 on Dec. 21, 2011; 9 pages.;;XP002167366; Chen, Zhigun; ""Java Card Technology for Smart Cards: Architecture and Programmer's Guide""; ""Applet Firewall and Object Sharing,"" Internet citation; Jun. 2, 2000; .;;Microsoft Office: Microsoft Outlook 2010 Product Guide; Microsoft Corp. published in 2010; 65 pages.;;Windows 7 Product Guide; Microsoft Corp. published in 2009; 140 pages.;;Extended European Search Report issued in European Application No. 12173030.3 on Nov. 22, 2012; 6 pages.;;View messages with restricted permission sent by using IRM; Support/Outlook/Outlook 2007 Help and How-to. http://office.mircosoft.com/en-us/outlook-help/view-messages-with-restricted-permission-sent-by-using-irm-HA010246115.as . . . , pp. 1-2, retrieved on Feb. 12, 2010.;;Send an e-mail message with restricted permission by using IRM; Support/Outlook/Outlook 2007 Help and How to. http://office.mircosoft.com/en-us/outlook-help/send-an-e-mail-message-with-restricted-permission-by-using-irm-HA01024780 . . . , pp. 1-4, retrieved on Feb. 12, 2010.;;Introduction to using IRM for e-mail messages; Support/Outlook/Outlook 2007 Help and How-to. http://office.microsoft.com/en-us/outlook-help/introduction-to-using-irm-for-e-mail-message-HA010100366.aspx?CTT=5&or . . . , pp. 1-6, retrieved on Feb. 12, 2010.;;EP Application No. 12155659.1, Extended European Search Report dated Jan. 8, 2012.;;Smartphone Security Beyond Lock and Wipe (Jun. 10, 2010): http://www.enterprisemobiletoday.com/article. php/3887006.;;Basic Access Authentication (Jan. 23, 2010): http://en.wikipedia.org/wiki/Basic-access-authentication.;;Digital Access Authentication (Dec. 23, 2009): http://en.wikipedia.org/wiki/Digest-access-authentication.;;Cross-site request forgery (Nov. 30, 2008): http://en.wikipedia.org/wiki/Cross-site-request-forgery.;;Extended European Search Report mailed Jul. 13, 2012, in corresponding European patent application No. 12153439.0.;;""Customizing User Interaction in Smart Phones"", Pervasive Computing, IEEE CS (2006) pp. 81-90 (URL: http://www.idi. ntnu.no/grupperlsu/bibliography/pdf/2006/Korpipaa2006pc.pdf).;;""Supporting Mobile Privacy and Security through Sensor-Based Context Detection"""", Julian Seifert, Second International Workshop on Security and Privacy in Spontaneous Interaction and Mobile Phone Use, May 17, 2010, Finland (U RL: http://www.medien.ifi.Imu.de/iwssi201 0/papers/iwssi-spmu201 O-seifert.pdf)"".;;EagleVision: A Pervasive Mobile Device Protection System, Ka Yang, Nalin Subramanian, Daji Qiao, and Wen sheng Zhang, Iowa State Unviersity (URL: http://www.cs.iastate.edu/-wzhang/papers/eagleVision.pdf), 2009.;;""Using context-profiling to aid access control decisions in mobile devices"""", Gupta et al., Nokia Research Center (URL: http://www.cerias.purdue.edu/assets/symposium/2011-posters1372-C48.pdf) Please refer to the I-page file named 372-C48.pdf"", 2011.;;Owen, Russell N., U.S. Appl. No. 10/524,353, filed Feb. 14, 2005; Title: System and Method for Secure Control of Resources of Wireless Mobile Communication Device.;;International Application No. PCT/CA 03101245, International Search Report dated Dec. 23, 2003.;;International Application No. PCT/CA 03101245, PCT Written Opinion, dated Apr. 23, 2004.;;International Application No. PCT/CA 03101245, PCT Written Opinion, dated Sep. 20, 2004.;;International Application No. PCT/CA 03101245, PCT International Preliminary Examination Report, dated Nov. 29, 2004.;;""Owen, Russell N., U.S. Appl. No. 13/371,093, filed Feb. 10, 2012; Title: System and Method for Secure Control of Resources of Wireless Mobile Communication Devices Secure Control of Resources of Wireless Mobile Communication Device"".;;Int'l Search Report and the Written Opinion of the Int'l Searching Authority, or the Declaration of Appln. Serial No. PCT/CA2004/000250 of 02120/2004-12 pgs., 2004.;;Int'l Search Report or the Declaration of Appln. Serial No. PCT/CA03/01679 of 10131/2003-6 pgs.;;Red Hat: ""Red Hat Linux 7.2-The Official Red Had Linux Reference Guide"" Red Hat Linux Manuals, Online!, Oct. 22, 2001, XP002276029, pp. 145-155.;;Sygate: ""Sygate Personal Firewall Pro User Guide"" Sygate Personal Firewall Pro User Guide version 2.02001, pp. 1-77, XP002248366, 2001.;;Bender, Christopher Lyle; U.S. Appl. No. 13/074,136, filed Mar. 29, 2011; Title: Data Source Based Application Sandboxing.;;""A Technical Overview of the Lucent VPN Firewall"" White Paper Lucent Technologies, XX, XX, Aug. 2002, pp. 1-35, XP002271173, Chapter 1.;;European Search Report of Appln. No. 04256690.1-2412, date of mailing Apr. 6, 2005-9 pgs.;;Fourth Office Action. Chinese Application No. 200380105435.2. Dated: Aug. 3, 2011.;;Patent Certificate. Indian Patent Application No. 1956/DELNP/2005. Dated: Oct. 31, 2003.;;Certificate of Grant of Patent. Singapore Patent No. 112419. Dated: Apr. 30, 2007.;;Certificate of Grant of Patent. Hong Kong Patent No. 1080315. Dated: Apr. 24, 2009.;;Notice of Allowance. Canadian Application No. 2,505,343. Dated: Sep. 15, 2009.;;Extended European Search Report issued in European Application No. 12189805.0 on Apr. 16, 2013; 6 pages.;;Office Action issued in U.S. Appl. No. 11/118,791 on Sep. 25, 2006; 11 pages.;;Office Action issued in U.S. Appl. No. 11/118,791 on Nov. 28, 2007; 12 pages.;;Office Action issued in U.S. Appl. No. 11/118,791 on Mar. 30, 2007; 12 pages.;;Office Action issued in U.S. Appl. No. 11/118,791 on May 20, 2008; 13 pages.;;Office Action issued in U.S. Appl. No. 11/118,791 on Jan. 27, 2009; 16 pages.;;Office Action issued in U.S. Appl. No. 11/118,791 on Apr. 8, 2009; 14 pages.;;Advisory Action issued in U.S. Appl. No. 11/118,791 on Jun. 26, 2009; 8 pages.;;Notice of Allowance issued in U.S. Appl. No. 11/118,791 on Jan. 20, 2010; 4 pages.;;Office Action issued in U.S. Appl. No. 12/795,252 on Aug. 6, 2010; 6 pages.;;Notice of Allowance issued in U.S. Appl. No. 12/795,252 on Dec. 17, 2010; 4 pages.;;Notice of Allowance issued in U.S. Appl. No. 12/795,252 on Apr. 14, 2011; 4 pages.;;Examiner's First Report issued in Australian Application No. 2005239005 on Oct. 15, 2007; 2 pages.;;Examiner's Report No. 2 issued in Australian Application No. 2005239005 on Jul. 15, 2009; 2 pages.;;Examiner's First Report issued in Australian Application No. 2009202857 on Nov. 5, 2010; 3 pages.;;Office Action issued in Canadian Application No. 2,564,914 on May 3, 2010; 4 pages.;;Office Action issued in Canadian Application No. 2,564,914 on Apr. 4, 2011; 2 pages.;;First Office Action issued in Chinese Application No. 200580013730.4 on Mar. 27, 2009; 9 pages.;;Second Office Action issued in Chinese Application No. 200580013730.4 on Dec. 12, 2010; 10 pages.;;Third Office Action issued in Chinese Application No. 200580013730.4 on Mar. 8, 2011; 10 pages.;;Notice of Allowance issued in Chinese Application No. 200580013730.4 on Jul. 28, 2011; 4 pages.;;European Supplementary Search Report issued in European Application No. 05738877.9 on Sep. 13, 2007; 3 pages.;;Communication Pursuant to Article 94(3) EPC issued in European Application No. 05738877.9 on Jan. 15, 2008; 4 pages.;;Communication Pursuant to Article 94(3) EPC issued in European Application No. 05738877.9 on Jul. 15, 2009; 4 pages.;;Communication under Rule 71(3) EPC issued in European Application No. 05738877.9 on Sep. 17, 2010; 41 pages.;;First Examination Report issued in Indian Application No. 6068/DELNP/2006 on Jun. 3, 2010; 2 pages.;;Notice of Reasons for Rejection issued in Japanese Application No. 2007-509840 on Jun. 15, 2009; 5 pages.;;Notice of Allowance issued in Japanese Application No. 2007-509840 on Jan. 25, 2010; 3 pages.;;Notice Requesting Submission of Opinion issued in Korean Application No. 10-2006-7025081 on Nov. 16, 2007; 10 pages.;;Notice of Decision of Final Rejection issued Korean Application No. 10-2006-7025081 on Jun. 18, 2008.;;Trial Decision issued in Korean Application No. 10-2006-7025081 on Jul. 27, 2009; 10 pages.;;Notice of Decision for Patent issued in Korean Application No. 10-2006-7025081 on Aug. 7, 2009; 3 pages.;;International Search Report issued in International Application No. PCT/CA2005/000652 on Aug. 17, 2005; 9 pages.;;International Preliminary Report on Patentability under Chapter I issued in International Application No. PCT/CA2005/000652 on Nov. 9, 2006; 6 pages.;;Office Action issued in U.S. Appl. No. 13/722,213 on May 22, 2013; 8 pages.;;Office Action issued in Canadian Application No. 2,769,646 on Jun. 5, 2012; 3 pages.;;Office Action issued in Canadian Application No. 2,769,646 on Oct. 22, 2012; 2 pages.;;International Search Report and Written Opinion of the International Searching Authority issued in International Application No. PCT/CA2011/050707 on Jan. 18, 2012; 7 pages.;;International Preliminary Report on Patentability issued in International Application No. PCT/CA2011/050707 on May 30, 2013; 4 pages.;;Office Action issued in U.S. Appl. No. 13/25,097 on Sep. 10, 2013; 21 pages.;;Office Action issued in U.S. Appl. No. 13/293,743 on Sep. 20, 2013; 19 pages.;;Office Action issued in U.S. Appl. No. 13/274,913 on Jul. 16, 2013.;;Office Action issued in U.S. Appl. No. 13/098,456 on Apr. 17, 2013; 31 pages.;;Office Action issued in U.S. Appl. No. 13/098,456 on Sep. 27, 2013; 28 pages.;;Communication Pursuant to Article 94(3) EPC issued in European Application No. 11188696.6 on Jul. 9, 2013; 4 pages.",ACTIVE
264,TW,A,TW 201715095 A,065-028-192-228-985,2017-05-01,2017,TW 105126114 A,2016-08-16,TW 104134382 A,2015-10-20,An electroplating machine and an electroplating method,"An electroplating machine (100, 200) is disclosed as including a tank (102, 202) for containing an electroplating solution, a number of carriers (104, 204) each releasably engageable with a respective workpiece (205) to be electroplated and movable relative to the tank (102, 202), each carrier (104, 204) being electrically connected and simultaneously movable with two power supplies (106a, 106b, 206a, 206b), at least one power supply (106a, 106b, 206a, 206b) of each carrier (104, 204) being electrically connected with a common anode (108, 110) or an earthed common conductor (230).",PROCESS AUTOMATION INT LTD,CHIU YU HIM;;HUI KWAI PUN;;CHENG KWONG CHO;;HENINGTON PAUL,,https://lens.org/065-028-192-228-985,Patent of Addition,no,0,0,6,8,0,C25D17/02;;C25D17/007;;C25D21/12,C25D17/00;;C25D5/00,,0,0,,,,ACTIVE
265,TW,A,TW 200608741 A,134-431-787-731-759,2006-03-01,2006,TW 94117106 A,2005-05-25,US 57498904 P;;US 66970205 P,2004-05-26,"System, method, and computer program product for validating an identity claimed by a subject","Embodiments of a system, method, and computer program product for validating an identity claimed by a subject are disclosed. Information for logging under an identity claimed by a subject is obtained from the subject and then submitted in an attempt to login under the claimed identity. The response to the login attempt is then analyzed to determine whether the identity with the site claimed by the subject is valid.",OPINITY INC,CHO WONG-YU TED;;KIM DO-YON;;CHOI JIN-KEUN PAUL,,https://lens.org/134-431-787-731-759,Patent of Addition,no,0,0,1,4,0,,H04L9/32,,0,0,,,,PENDING
266,US,A1,US 2023/0161660 A1,150-029-602-993-088,2023-05-25,2023,US 202318152590 A,2023-01-10,US 202318152590 A;;US 202117239342 A,2021-04-23,DETECTING SYSTEM EVENTS BASED ON USER SENTIMENT IN SOCIAL MEDIA MESSAGES,Methods and systems are disclosed herein for using anomaly detection in timeseries data of user sentiment to detect incidents in computing systems and identify events within an enterprise. An anomaly detection system may receive social media messages that include a timestamp indicating when each message was published. The system may generate sentiment identifiers for the social media messages. The sentiment identifiers and timestamps associated with the social media messages may be used to generate a timeseries dataset for each type of sentiment identifier. The timeseries datasets may be input into an anomaly detection model to determine whether an anomaly has occurred. The system may retrieve textual data from the social media messages associated with the detected anomaly and may use the text to determine a computing system or event associated with the detected anomaly.,CAPITAL ONE SERVICES LLC,GONZALEZ MACIAS VANNIA;;CHO PAUL;;GUPTA RAHUL;;GARCIA SCOTT;;RAMANATHAN ADITHYA,CAPITAL ONE SERVICES LLC (2021-04-23),https://lens.org/150-029-602-993-088,Patent Application,yes,10,0,4,4,0,G06F40/30;;G06F40/284;;G06Q50/01;;G06N3/09;;G06N3/084;;G06N3/0455;;G06F11/0781;;H04L12/1827;;G06F11/0781;;G06N20/00;;G06F40/30;;G06F40/289,G06F11/07;;G06F40/289;;G06F40/30;;G06N20/00,,0,0,,,,ACTIVE
267,US,A1,US 2018/0289295 A1,177-157-033-734-364,2018-10-11,2018,US 201815945636 A,2018-04-04,US 201815945636 A;;US 201113299119 A;;US 41517410 P,2010-11-18,ADAPTOR FOR ON-BODY ANALYTE MONITORING SYSTEM,"An analyte monitoring system comprising: an on-body housing; an analyte sensor coupled to the housing; an electrical output interface disposed on an outer surface of the housing; and a removable adaptor coupled to the housing. In one embodiment, a portion of the analyte sensor extends from the housing for implantation into a patient's body. The electrical output interface is electrically coupled to the analyte sensor. The removable adaptor is mechanically coupled to the housing and electrically coupled to the electrical output interface. The removable adaptor serves as a data conduit between the analyte sensor and a remote device.",ABBOTT DIABETES CARE INC,HOSS UDO;;SHARP CRAIG W;;CHO HYUN;;WINKLER TODD;;LEGG PAUL,ABBOTT DIABETES CARE INC (2012-01-31),https://lens.org/177-157-033-734-364,Patent Application,yes,2,7,3,3,0,A61B5/14503;;A61B5/14503;;A61B5/14532;;A61B5/14532;;A61B2560/0412;;A61B2560/0412,A61B5/145,,0,0,,,,DISCONTINUED
268,CN,A,CN 107012497 A,197-203-546-347-562,2017-08-04,2017,CN 201610862410 A,2016-09-28,TW 104134382 A;;TW 105126114 A,2015-10-20,An electroplating machine and an electroplating method,"An electroplating machine (100, 200) is disclosed as including a tank (102, 202) for containing an electroplating solution, a number of carriers (104, 204) each releasably engageable with a respective workpiece (205) to be electroplated and movable relative to the tank (102, 202), each carrier (104, 204) being electrically connected and simultaneously movable with two power supplies (106a, 106b, 206a, 206b), at least one power supply (106a, 106b, 206a, 206b) of each carrier (104, 204) being electrically connected with a common anode (108, 110) or an earthed common conductor (230).",PROCESS AUTOMATION INTERNATIONAL LTD,KWONG CHO CHENG;;PAUL HENINGTON;;YU HIM CHIU;;KWAI PUN HUI,,https://lens.org/197-203-546-347-562,Patent Application,no,6,0,6,8,0,C25D17/02;;C25D17/007;;C25D21/12,C25D17/02;;C25D21/12,,0,0,,,,ACTIVE
269,US,B2,US 11914462 B2,020-065-877-651-903,2024-02-27,2024,US 202318152590 A,2023-01-10,US 202318152590 A;;US 202117239342 A,2021-04-23,Detecting system events based on user sentiment in social media messages,Methods and systems are disclosed herein for using anomaly detection in timeseries data of user sentiment to detect incidents in computing systems and identify events within an enterprise. An anomaly detection system may receive social media messages that include a timestamp indicating when each message was published. The system may generate sentiment identifiers for the social media messages. The sentiment identifiers and timestamps associated with the social media messages may be used to generate a timeseries dataset for each type of sentiment identifier. The timeseries datasets may be input into an anomaly detection model to determine whether an anomaly has occurred. The system may retrieve textual data from the social media messages associated with the detected anomaly and may use the text to determine a computing system or event associated with the detected anomaly.,CAPITAL ONE SERVICES LLC,GONZALEZ MACIAS VANNIA;;CHO PAUL;;GUPTA RAHUL;;GARCIA SCOTT;;RAMANATHAN ADITHYA,CAPITAL ONE SERVICES LLC (2021-04-23),https://lens.org/020-065-877-651-903,Granted Patent,yes,10,0,4,4,0,G06F40/30;;G06F40/284;;G06Q50/01;;G06N3/09;;G06N3/084;;G06N3/0455;;G06F11/0781;;H04L12/1827;;G06F11/0781;;G06N20/00;;G06F40/30;;G06F40/289,G06F11/07;;G06F40/289;;G06F40/30;;G06N20/00,,0,0,,,,ACTIVE
270,EP,A1,EP 3925416 A1,134-051-111-807-317,2021-12-22,2021,EP 20706089 A,2020-02-12,US 201962804808 P;;US 202016787292 A;;EP 2020025061 W,2019-02-13,LED LIGHTING SIMULATION SYSTEM,,SIGNIFY HOLDING BV,BOUDREAU PAUL A;;JOSHI PARTH;;GROSSE DEBORA YOON;;CHO NAM CHIN,,https://lens.org/134-051-111-807-317,Patent Application,yes,0,0,4,4,0,G06T19/006;;H05B47/00;;H05B47/155;;H05B47/175;;G06T11/00;;G06F30/20;;G06F30/13;;H05B47/115;;H05B47/17;;G06T15/50;;G06T2210/04;;Y02B20/40;;G06F30/13;;G06T19/006;;G06F30/20;;G06T2210/04;;G06T11/00;;G06T17/00;;H05B47/11;;G06T15/506,G06T15/50;;H05B47/155;;G06T19/00;;H05B47/00,,0,0,,,,PENDING
271,US,A1,US 2022/0342745 A1,017-555-509-835-446,2022-10-27,2022,US 202117239342 A,2021-04-23,US 202117239342 A,2021-04-23,DETECTING SYSTEM EVENTS BASED ON USER SENTIMENT IN SOCIAL MEDIA MESSAGES,Methods and systems are disclosed herein for using anomaly detection in timeseries data of user sentiment to detect incidents in computing systems and identify events within an enterprise. An anomaly detection system may receive social media messages that include a timestamp indicating when each message was published. The system may generate sentiment identifiers for the social media messages. The sentiment identifiers and timestamps associated with the social media messages may be used to generate a timeseries dataset for each type of sentiment identifier. The timeseries datasets may be input into an anomaly detection model to determine whether an anomaly has occurred. The system may retrieve textual data from the social media messages associated with the detected anomaly and may use the text to determine a computing system or event associated with the detected anomaly.,CAPITAL ONE SERVICES LLC,GONZALEZ MACIAS VANNIA;;CHO PAUL;;GUPTA RAHUL;;GARCIA SCOTT;;RAMANATHAN ADITHYA,CAPITAL ONE SERVICES LLC (2021-04-23),https://lens.org/017-555-509-835-446,Patent Application,yes,7,2,4,4,0,G06F40/30;;G06F40/284;;G06Q50/01;;G06N3/09;;G06N3/084;;G06N3/0455;;G06F11/0781;;H04L12/1827;;G06F11/0781;;G06N20/00;;G06F40/30;;G06F40/289,G06F11/07;;G06F40/289;;G06F40/30;;G06N20/00,,0,0,,,,ACTIVE
272,US,A1,US 2014/0115158 A1,071-592-050-182-63X,2014-04-24,2014,US 201213722213 A,2012-12-20,US 201213722213 A;;US 201213659527 A,2012-10-24,MANAGING APPLICATION EXECUTION AND DATA ACCESS ON A DEVICE,"Some aspects of what is described here relate to managing application execution and data access on a mobile device. A request to access data is received from an application associated with a first perimeter on a device. The data is associated with a second, different perimeter on the device and has a data type. It is determined, based on the data type, that a management policy associated with the first perimeter permits the application to access the data independent of a second, different management policy assigned to the second perimeter. Based on the determining, the application is provided access to the data.",RESEARCH IN MOTION LTD;;QNX SOFTWARE SYSTEMS LTD,BENDER CHRISTOPHER LYLE;;CHO JUNG HYUN;;FOY JASON PAUL;;NAGARAJAN SIVAKUMAR,BLACKBERRY LIMITED (2012-11-29);;8758271 CANADA INC (2014-04-03);;2236008 ONTARIO INC (2014-04-03);;RESEARCH IN MOTION UK LIMITED (2012-11-20);;QNX SOFTWARE SYSTEMS LIMITED (2012-11-28);;RESEARCH IN MOTION CORPORATION (2012-11-30),https://lens.org/071-592-050-182-63X,Patent Application,yes,0,9,3,3,0,G06F9/468;;G06F2221/2105;;G06F2221/2113;;H04L63/0209;;G06F21/6218;;H04W12/086;;G06F21/6245;;H04L63/102;;H04L41/0893;;G06F21/6218;;G06F9/468;;G06F2221/2105;;G06F2221/2113;;H04L63/0209;;H04W12/086;;G06F15/16;;H04L41/50,H04L12/24,709/225,0,0,,,,ACTIVE
273,US,B2,US 9065771 B2,068-220-184-572-160,2015-06-23,2015,US 201213722213 A,2012-12-20,US 201213722213 A;;US 201213659527 A,2012-10-24,Managing application execution and data access on a device,"Some aspects of what is described here relate to managing application execution and data access on a mobile device. A request to access data is received from an application associated with a first perimeter on a device. The data is associated with a second, different perimeter on the device and has a data type. It is determined, based on the data type, that a management policy associated with the first perimeter permits the application to access the data independent of a second, different management policy assigned to the second perimeter. Based on the determining, the application is provided access to the data.",RESEARCH IN MOTION LTD;;QNX SOFTWARE SYSTEMS LTD;;BLACKBERRY LTD,BENDER CHRISTOPHER LYLE;;CHO JUNG HYUN;;FOY JASON PAUL;;NAGARAJAN SIVAKUMAR,BLACKBERRY LIMITED (2012-11-29);;8758271 CANADA INC (2014-04-03);;2236008 ONTARIO INC (2014-04-03);;RESEARCH IN MOTION UK LIMITED (2012-11-20);;QNX SOFTWARE SYSTEMS LIMITED (2012-11-28);;RESEARCH IN MOTION CORPORATION (2012-11-30),https://lens.org/068-220-184-572-160,Granted Patent,yes,100,4,3,3,0,G06F9/468;;G06F2221/2105;;G06F2221/2113;;H04L63/0209;;G06F21/6218;;H04W12/086;;G06F21/6245;;H04L63/102;;H04L41/0893;;G06F21/6218;;G06F9/468;;G06F2221/2105;;G06F2221/2113;;H04L63/0209;;H04W12/086;;G06F15/16;;H04L41/50,G06F21/00;;G06F9/46;;G06F15/16;;G06F21/62;;H04L12/24;;H04L29/06,,99,1,030-818-024-660-177,10.4108/icst.mobiquitous2009.6855,"Research in Motion, ""BlackBerry Bridge App 2.1 and Blackberry PlayBook Tablet 2.1, Security Technical Overview""; Version: 2.1; Jul. 17, 2012; 43 pages.;;Research in Motion, ""BlackBerry Device Service 6.1 and BlackBerry PlayBook Tablet 2.1, Security Technical Overview"" ; Version: 6.1; Sep. 17, 2012; 90 pages.;;Office Action issued in U.S. Appl. No. 10/524,353 on Sep. 21, 2012; 16 pages (10742-US-PCT).;;Office Action issued in U.S. Appl. No. 13/098,456 on Sep. 13, 2012; 20 pages. (39524-US-PAT).;;International Search Report and Written Opinion issued in International Application No. PCT/CA2011/001058 on Dec. 21, 2011; 9 pages. (39524-WO-PCT).;;XP002167366; Chen, Zhigun; ""Java Card Technology for Smart Cards: Architecture and Programmer's Guide""; ""Applet Firewall and Object Sharing;"" Internet citation; Jun. 2, 2000; .;;Google Inc.; Android 2.3.4 User's Guide; May 20 2011; 384 pages.;;Microsoft Corp.; Microsoft Outlook 2010; Released Jul. 15, 2010; 27 pages.;;Office Action issued in U.S. Appl. No. 13/293,743 on Feb. 14, 2013; 15 pages.;;Office Action issued in U.S. Appl. No. 13/274,913 on Jan. 23, 2013; 22 pages.;;International Search Report and Written Opinion issued in International Application No. PCT/CA2012/050797 on Feb. 5, 2013; 8 pages.;;Office Action issued in U.S. Appl. No. 13/25,097 on Feb. 28, 2013; 18 pages.;;Extended European Search Report issued in European Application No. 12189773.0 on Mar. 7, 2013; 8 pages.;;International Search Report and Written Opinion of the International Searching Authority issued in International Application No. PCT/CA2012/050796 on Feb. 21, 2013; 13 pages.;;Extended European Search Report issued in European Application No. 11188696.6 on Apr. 12, 2012; 7 pages.;;Office Action issued in U.S. Appl. No. 13/398,676 on Sep. 5, 2012; 21 pages.;;Extended European Search Report issued in European Application No. 11186802.2 on Jan. 18, 2012; 7 pages.;;Extended European Search Report issued in European Application No. 11186796.6 on Jan. 18, 2012; 8 pages.;;Ferguson et al., U.S. Appl. No. 13/293,743, ""Managing Cross Perimeter Access,"" filed Nov. 10, 2011.;;Microsoft Office: Microsoft Outlook 2010 Product Guide; Microsoft Corp. published in 2010; 65 pages.;;Windows 7 Product Guide; Microsoft Corp. published in 2009; 140 pages.;;Extended European Search Report issued in European Application No. 12173030.3 on Nov. 22, 2012; 6 pages.;;View messages with restricted permission sent by using IRM; Support/Outlook/Outlook 2007 Help and How-to. http://office.mircosoft.com/en-us/outlook-help/view-messages-with-restricted-permission-sent-by-using-irm-HA010246115.as . . . , pp. 1-2, retrieved on Feb. 12, 2010.;;Send an e-mail message with restricted permission by using IRM; Support/Outlook/Outlook 2007 Help and How to. http://office.mircosoft.com/en-us/outlook-help/send-an-e-mail-message-with-restricted-permission-by-using-irm-HA01024780 . . . , pp. 1-4, retrieved on Feb. 12, 2010.;;Introduction to using IRM for e-mail messages; Support/Outlook/Outlook 2007 Help and How-to. http://office.microsoft.com/en-us/outlook-help/introduction-to-using-irm-for-e-mail-message-HA010100366.aspx?CTT=5&or . . . , pp. 1-6, retrieved on Feb. 12, 2010.;;EP Application No. 12155659.1, Extended European Search Report dated Jan. 8, 2012.;;Smartphone Security Beyond Lock and Wipe (Jun. 10, 2010): http://www.enterprisemobiletoday.com/article. php/3887006.;;Basic Access Authentication (Jan. 23, 2010): http://en.wikipedia.org/wiki/Basic-access-authentication.;;Digital Access Authentication (Dec. 23, 2009): http://en.wikipedia.org/wiki/Digest-access-authentication.;;Cross-site request forgery (Nov. 30, 2008): http://en.wikipedia.org/wiki/Cross-site-request-forgery.;;Extended European Search Report mailed Jul. 13, 2012, in corresponding European patent application No. 12153439.0.;;""Customizing User Interaction in Smart Phones"", Pervasive Computing, IEEE CS (2006) pp. 81-90 (URL: http://www.idi. ntnu.no/grupperlsu/bibliography/pdf/2006/Korpipaa2006pc.pdf).;;""Supporting Mobile Privacy and Security through Sensor-Based Context Detection"", Julian Seifert, Second International Workshop on Security and Privacy in Spontaneous Interaction and Mobile Phone Use, May 17, 2010, Finland (U RL: http://www.medien.ifi.Imu.de/iwssi201 0/papers/iwssi-spmu201 O-seifert.pdf).;;EagleVision: A Pervasive Mobile Device Protection System, Ka Yang, Nalin Subramanian, Daji Qiao, and Wen sheng Zhang, Iowa State Unviersity (URL: http://www.cs.iastate.edu/-wzhang/papers/eagleVision.pdf).;;""Using context-profiling to aid access control decisions in mobile devices"", Gupta et al., Nokia Research Center (URL: http://www.cerias.purdue.edu/assets/symposium/2011-posters1372-C48.pdf) Please refer to the I-page file named 372-C48.pdf.;;Owen, Russell N., U.S. Appl. No. 10/524,353, filed Feb. 14, 2005; Title: System and Method for Secure Control of Resources of Wireless Mobile Communication Device.;;International Application No. PCT/CA 03101245, International Search Report dated Dec. 23, 2003.;;International Application No. PCT/CA 03101245, PCT Written Opinion, dated Apr. 23, 2004.;;International Application No. PCT/CA 03101245, PCT Written Opinion, dated Sep. 20, 2004.;;International Application No. PCT/CA 03101245, PCT International Preliminary Examination Report, dated Nov 29, 2004.;;Owen, Russell N., U.S. Appl. No. 13/371,093, filed Feb. 10, 2012; Title: System and Method for Secure Control of Resources of Wireless Mobile Communication Devices Secure Control of Resources of Wireless Mobile Communication Device.;;Int'l Search Report and the Written Opinion of the Int'l Searching Authority, or the Declaration of Appln. Serial No. PCT/CA2004/000250 of 02120/2004-12 pgs.;;Int'l Search Report or the Declaration of Appln. Serial No. PCT/CA03/01679 of 10131/2003-6 pgs.;;Red Hat: ""Red Hat Linux 7.2-The Official Red Had Linux Reference Guide"" Red Hat Linux Manuals, Online!, Oct. 22, 2001, XP002276029, pp. 145-155.;;Sygate: ""Sygate Personal Firewall PRO User Guide"" Sygate Personal Firewall Pro User Guide version 2.02001, pp. 1-77, XP002248366.;;Bender, Christopher Lyle; U.S. Appl. No. 13/074,136, filed Mar. 29, 2011; Title: Data Source Based Application Sandboxing.;;""A Technical Overview of the Lucent VPN Firewall"" White Paper Lucent Technologies, XX, XX, Aug. 2002, pp. 1-35, XP002271173, Chapter 1.;;European Search Report of Appln. No. 04256690.1-2412, date of mailing Apr. 6, 2005-9 pgs.;;Fourth Office Action. Chinese Application No. 200380105435.2. Dated: Aug. 3, 2011.;;Patent Certificate. Indian Patent Application No. 1956/DELNP/2005. Dated: Oct. 31, 2003.;;Certificate of Grant of Patent. Singapore Patent No. 112419. Dated: Apr. 30, 2007.;;Certificate of Grant of Patent. Hong Kong Patent No. 1080315. Dated: Apr. 24, 2009.;;Notice of Allowance. Canadian Application No. 2,505,343. Dated: Sep. 15, 2009.;;Extended European Search Report issued in European Application No. 12189805.0 on Apr. 16, 2013; 6 pages.;;Office Action issued in U.S. Appl. No. 11/118,791 on Sep. 25, 2006; 11 pages.;;Office Action issued in U.S. Appl. No. 11/118,791 on Nov. 28, 2007; 12 pages.;;Office Action issued in U.S. Appl. No. 11/118,791 on Mar. 30, 2007; 12 pages.;;Office Action issued in U.S. Appl. No. 11/118,791 on May 20, 2008; 13 pages.;;Office Action issued in U.S. Appl. No. 11/118,791 on Jan. 27, 2009; 16 pages.;;Office Action issued in U.S. Appl. No. 11/118,791 on Apr. 8, 2009; 14 pages.;;Advisory Action issued in U.S. Appl. No. 11/118,791 on Jun. 26, 2009; 8 pages.;;Notice of Allowance issued in U.S. Appl. No. 11/118,791 on Jan. 20, 2010; 4 pages.;;Office Action issued in U.S. Appl. No. 12/795,252 on Aug. 6, 2010; 6 pages.;;Notice of Allowance issued in U.S. Appl. No. 12/795,252 on Dec. 17, 2010; 4 pages.;;Notice of Allowance issued in U.S. Appl. No. 12/795,252 on Apr. 14, 2011; 4 pages.;;Examiner's First Report issued in Australian Application No. 2005239005 on Oct. 15, 2007; 2 pages.;;Examiner's Report No. 2 issued in Australian Application No. 2005239005 on Jul. 15, 2009; 2 pages.;;Examiner's First Report issued in Australian Application No. 2009202857 on Nov. 5, 2010; 3 pages.;;Office Action issued in Canadian Application No. 2,564,914 on May 3, 2010; 4 pages.;;Office Action issued in Canadian Application No. 2,564,914 on Apr. 4, 2011; 2 pages.;;First Office Action issued in Chinese Application No. 200580013730.4 on Mar. 27, 2009; 9 pages.;;Second Office Action issued in Chinese Application No. 200580013730.4 on Dec. 12, 2010; 10 pages.;;Third Office Action issued in Chinese Application No. 200580013730.4 on Mar. 8, 2011; 10 pages.;;Notice of Allowance issued in Chinese Application No. 200580013730.4 on Jul. 28, 2011; 4 pages.;;European Supplementary Search Report issued in European Application No. 05738877.9 on Sep. 13, 2007; 3 pages.;;Communication Pursuant to Article 94(3) EPC issued in European Application No. 05738877.9 on Jan. 15, 2008; 4 pages.;;Communication Pursuant to Article 94(3) EPC issued in European Application No. 05738877.9 on Jul. 15, 2009; 4 pages.;;Communication under Rule 71(3) EPC issued in European Application No. 05738877.9 on Sep. 17, 2010; 41 pages.;;First Examination Report issued in Indian Application No. 6068/DELNP/2006 on Jun. 3, 2010; 2 pages.;;Notice of Reasons for Rejection issued in Japanese Application No. 2007-509840 on Jun. 15, 2009; 5 pages.;;Notice of Allowance issued in Japanese Application No. 2007-509840 on Jan. 25, 2010; 3 pages.;;Notice Requesting Submission of Opinion issued in Korean Application No. 10-2006-7025081 on Nov. 16, 2007; 10 pages.;;Notice of Decision of Final Rejection issued Korean Application No. 10-2006-7025081 on Jun. 18, 2008.;;Trial Decision issued in Korean Application No. 10-2006-7025081 on Jul. 27, 2009; 10 pages.;;Notice of Decision for Patent issued in Korean Application No. 10-2006-7025081 on Aug. 7, 2009; 3 pages.;;International Search Report issued in International Application No. PCT/CA2005/000652 on Aug. 17, 2005; 9 pages.;;International Preliminary Report on Patentability under Chapter I issued in International Application No. PCT/CA2005/000652 on Nov. 9, 2006; 6 pages.;;Office Action issued in U.S. Appl. No. 13/659,527 on May 23, 2013; 8 pages.;;Office Action issued in Canadian Application No. 2,769,646 on Jun. 5, 2012; 3 pages.;;Office Action issued in Canadian Application No. 2,769,646 on Oct. 22, 2012; 2 pages.;;International Search Report and Written Opinion of the International Searching Authority issued in International Application No. PCT/CA2011/050707 on Jan. 18, 2012; 7 pages.;;International Preliminary Report on Patentability issued in International Application No. PCT/CA2011/050707 on May 30, 2013; 4 pages.;;Office Action issued in U.S. Appl. No. 13/25,097 on Sep. 10, 2013; 21 pages.;;Office Action issued in U.S. Appl. No. 13/293,743 on Sep. 20, 2013; 19 pages.;;Office Action issued in U.S. Appl. No. 13/274,913 on Jul. 16, 2013; 29 pages.;;Office Action issued in U.S. Appl. No. 13/098,456 on Apr. 17, 2013; 31 pages.;;Office Action issued in U.S. Appl. No. 13/098,456 on Sep. 27, 2013; 28 pages.;;Communication Pursuant to Article 94(3) EPC issued in European Application No. 11188696.6 on Jul. 9, 2013; 4 pages.;;Office Action issued in U.S. Appl. No. 13/529,509, filed Mar. 25, 2014.",ACTIVE
274,TW,B,TW I698554 B,075-301-076-761-085,2020-07-11,2020,TW 105126114 A,2016-08-16,TW 104134382 A,2015-10-20,An electroplating machine and an electroplating method,,PROCESS AUTOMATION INTERNATIONAL LTD,CHIU YU HIM;;HUI KWAI PUN;;CHENG KWONG CHO;;HENINGTON PAUL,,https://lens.org/075-301-076-761-085,Granted Patent,no,2,0,6,8,0,C25D17/02;;C25D17/007;;C25D21/12,,,0,0,,,,ACTIVE
275,US,B1,US 7823098 B1,038-439-812-876-148,2010-10-26,2010,US 59058106 A,2006-10-31,US 59058106 A,2006-10-31,Method of designing a digital circuit by correlating different static timing analyzers,"A method of designing a digital circuit is described, so that it is likely to pass a signoff time test. The method begins with the running of a basic static time test on a partially developed version of the digital circuit, next a signoff time test is run for the partially developed version of the digital system. The differences between the results of the basic static time test and the signoff time test are noted and the prospective basic static time test passing conditions are altered so that if a similar system passes the basic static time test with the altered passing conditions it will be more likely to pass the signoff time test. Then, the partially developed version of the digital system is altered to yield a second partially developed version and the first static time test is run, with the altered passing conditions on the second partially developed version.",TELA INNOVATIONS INC,MOON CHO W;;GUPTA PUNEET;;DONEHUE PAUL J;;KAHNG ANDREW B,BLAZE DFM INC (2006-10-23);;TELA INNOVATIONS INC (2009-03-12);;RPX CORPORATION (2021-06-04),https://lens.org/038-439-812-876-148,Granted Patent,yes,1,4,1,1,0,G06F30/3312;;G06F30/3312,G06F17/50,716/4;;716/1;;716/6,0,0,,,,INACTIVE
276,CN,A,CN 113383614 A,056-395-867-455-712,2021-09-10,2021,CN 202080014204 A,2020-02-12,US 201962804808 P;;US 202016787292 A;;EP 2020025061 W,2019-02-13,LED LIGHTING SIMULATION SYSTEM,"A lighting device simulation system simulates operation of luminaires in a facility according to scene by using location and capability data for the luminaires and mapping it to structural feature data for the facility. In response to receiving a selection of a scene, the system will play the selected scene on a display. The display may be a two-dimensional representation of the facility, or it may be a three-dimensional representation on an augmented reality or mixed reality device.",SIGNIFY HOLDING BV,BOUDREAU PAUL A;;JOSHI PARTH;;GROSSE DEBORA YOON;;CHO NAM-CHIN,,https://lens.org/056-395-867-455-712,Patent Application,no,12,1,4,4,0,G06T19/006;;H05B47/00;;H05B47/155;;H05B47/175;;G06T11/00;;G06F30/20;;G06F30/13;;H05B47/115;;H05B47/17;;G06T15/50;;G06T2210/04;;Y02B20/40;;G06F30/13;;G06T19/006;;G06F30/20;;G06T2210/04;;G06T11/00;;G06T17/00;;H05B47/11;;G06T15/506,H05B47/155;;G06F30/13;;G06T11/00;;G06T15/50;;G06T17/00;;G06T19/00;;H05B47/00;;H05B47/11;;H05B47/115;;H05B47/17,,0,0,,,,DISCONTINUED
277,EP,A1,EP 2725511 A1,071-182-509-561-878,2014-04-30,2014,EP 12189773 A,2012-10-24,EP 12189773 A,2012-10-24,Managing application execution and data access on a device,"A method for managing application execution and data access on a mobile device, wherein a request to access data is received from an application associated with a first perimeter on a device, while the data has a data type and is associated with a second, perimeter on the device, which is different from the first perimeter. It is determined, based on the data type, whether a management policy associated with the first perimeter permits the application to access the data independently of a second, different management policy assigned to the second perimeter. Depending on the results of the determination, the application is provided access to the data.
",BLACKBERRY LTD;;QNX SOFTWARE SYSTEMS,BENDER CHRISTOPHER LYLE;;CHO JUNG HYUN;;FOY JASON PAUL;;NAGARAJAN SIVAKUMAR,"BLACKBERRY LIMITED (2014-09-10);;2236008 ONTARIO INC. (2014-09-10);;BLACKBERRY LIMITED, WATERLOO, CA (2020-06-29)",https://lens.org/071-182-509-561-878,Patent Application,yes,2,4,7,7,0,G06F21/53;;G06F21/53,G06F21/53,,0,0,,,,ACTIVE
278,US,A1,US 2009/0123940 A1,006-460-342-320-123,2009-05-14,2009,US 24985008 A,2008-10-10,US 24985008 A;;US 97960907 P,2007-10-12,MOLECULES INVOLVED IN SYNAPTOGENESIS AND USES THEREFOR,"The present invention is based on the discovery that neuronal pentraxins play a role in the clustering and internalization of AMPA receptors, synaptogenesis, and metabotropic glutamate receptor-mediated long term depression (LTD) of a synapse. Accordingly, there are provided methods of identifying compounds that that modulate mGluR-mediated AMPA receptor internalization and LTD. Further provided are cleavage products of a member of the neuronal pentraxin family, neuronal pentraxin receptor (NPR). Also provided are isolated peptides comprising the Narp association regions 1 and 2 (NAR1 and NAR2, respectively) and the Narp binding motif (NBM) of AMPA receptors. Finally, there are provided antibodies that block binding of neuronal pentraxins to AMPA receptors, in particular, antibodies that bind NAR1, or NAR2, or NBM.",UNIV JOHNS HOPKINS,WORLEY PAUL F;;XU DESHENG;;CHO RICHARD WILLIAM;;REDDY RADHIKA CHINTHAMANI,THE JOHNS HOPKINS UNIVERSITY (2008-10-15),https://lens.org/006-460-342-320-123,Patent Application,yes,0,3,1,1,35,C07K14/70571;;C07K14/70571;;C07K16/28;;C07K16/28;;C07K2317/77;;C07K2317/77;;G01N33/9406;;G01N33/9406;;G01N33/5041;;G01N33/5041;;G01N33/5058;;G01N33/5058;;G01N33/6893;;G01N33/6893;;G01N2800/28;;G01N2800/28,G01N33/53;;C07H21/00;;C07K2/00;;C07K16/28,435/7.2;;530/300;;536/23.1;;530/387.1,0,0,,,,DISCONTINUED
279,JP,A,JP 2018028143 A,020-863-030-286-919,2018-02-22,2018,JP 2017061071 A,2017-03-27,TW 105126114 A;;TW 104134382 A,2015-10-20,ELECTROPLATING MACHINE AND ELECTROPLATING METHOD,"PROBLEM TO BE SOLVED: To provide a method for realizing uniform plating even if workpieces have different electrical resistances.SOLUTION: An electroplating machine 200 includes a tank 202 to contain an electroplating solution, and a large number of carriers 204 each releasably engaged with a corresponding workpiece 205 to be electroplated and movable relative to the tank 202. Each carrier 204 is electrically connected and simultaneously movable with two power supplies 206a, 206b. The power supplies 206a, 206b of the carriers 204 are electrically connected with at least one earthed common conductor 230.SELECTED DRAWING: Figure 3",PROCESS AUTOMATION INT LTD,CHIU YU HIM;;HUI KWAI PUN;;CHENG KWONG CHO;;PAUL HENINGTON,,https://lens.org/020-863-030-286-919,Patent Application,no,6,0,6,8,0,C25D17/02;;C25D17/007;;C25D21/12,C25D21/12;;C25D17/06;;C25D21/00,,0,0,,,,ACTIVE
280,CN,A,CN 103778379 A,115-296-533-200-95X,2014-05-07,2014,CN 201310503089 A,2013-10-23,EP 12189773 A,2012-10-24,Managing application execution and data access on a device,"Some aspects of the described content here relates to managing application execution and data access on a mobile device, wherein a request to access data is received from an application associated with a first perimeter on a device, while the data has a data type and is associated with a second, perimeter on the device, which is different from the first perimeter. It is determined, based on the data type, whether a management policy associated with the first perimeter permits the application to access the data independently of a second, different management policy assigned to the second perimeter. Depending on the results of the determination, the application is provided access to the data.",BLACKBERRY LTD;;QNX SOFTWARE SYSTEMS LTD,BENDER CHRISTOPHER LYLE;;CHO JUNG HYUN;;FOY JASON PAUL;;NAGARAJAN SIVAKUMAR,2236008 ONTARIO INC. (2014-07-25);;8758271 CANADIAN INC. (2014-07-25),https://lens.org/115-296-533-200-95X,Patent Application,no,4,3,7,7,0,G06F21/53;;G06F21/53,G06F21/62,,0,0,,,,ACTIVE
281,CA,C,CA 2829805 C,011-705-784-861-414,2021-09-14,2021,CA 2829805 A,2013-10-10,EP 12189773 A,2012-10-24,MANAGING APPLICATION EXECUTION AND DATA ACCESS ON A DEVICE,"Some aspects of what is described here relate to managing application execution and data access on a mobile device. A request to access data is received from an application associated with a first perimeter on a device. The data is associated with a second, different perimeter on the device and has a data type. It is determined, based on the data type, that a management policy associated with the first perimeter permits the application to access the data independent of a second, different management policy assigned to the second perimeter. Based on the determining, the application is provided access to the data.",QNX SOFTWARE SYSTEMS LTD,BENDER CHRISTOPHER LYLE;;CHO JUNG HYUN;;FOY JASON PAUL;;NAGARAJAN SIVAKUMAR,,https://lens.org/011-705-784-861-414,Granted Patent,no,0,0,7,7,0,G06F21/53;;G06F21/53,H04L9/32;;G06Q10/10;;H04W12/37,,0,0,,,,ACTIVE
282,US,A1,US 2020/0257831 A1,065-706-296-040-442,2020-08-13,2020,US 202016787292 A,2020-02-11,US 202016787292 A;;US 201962804808 P,2019-02-13,LED LIGHTING SIMULATION SYSTEM,"A lighting device simulation system simulates operation of luminaires in a facility according to scene by using location and capability data for the luminaires and mapping it to structural feature data for the facility. In response to receiving a selection of a scene, the system will play the selected scene on a display. The display may be a two-dimensional representation of the facility, or it may be a three-dimensional representation on an augmented reality or mixed reality device.",EATON INTELLIGENT POWER LTD,BOUDREAU PAUL A;;JOSHI PARTH;;GROSSE DEBORA YOON;;CHO NAM CHIN,,https://lens.org/065-706-296-040-442,Patent Application,yes,2,1,4,4,0,G06T19/006;;H05B47/00;;H05B47/155;;H05B47/175;;G06T11/00;;G06F30/20;;G06F30/13;;H05B47/115;;H05B47/17;;G06T15/50;;G06T2210/04;;Y02B20/40;;G06F30/13;;G06T19/006;;G06F30/20;;G06T2210/04;;G06T11/00;;G06T17/00;;H05B47/11;;G06T15/506,G06F30/13;;G06F30/20;;G06T11/00;;G06T15/50;;G06T17/00;;G06T19/00;;H05B47/11,,1,0,,,"Microsoft, What is mixed reality?, May 2022, Microsoft, Pgs. 1-7 (Year: 2022)",PENDING
283,KR,A,KR 20170120830 A,174-639-824-031-377,2017-11-01,2017,KR 20160049191 A,2016-04-22,KR 20160049191 A,2016-04-22,NATURALLY DERIVED COSMETIC COMPOSITION,"The present invention relates to a cosmetic composition derived from natural substances. According to the present invention, the cosmetic composition derived from natural substances maximizes emulsification stability in oil-in-water forms without using synthetic polymers, and also ensures high moisturizing effects and outstanding spreadability without sweating and white turbidity shown in existing cosmetic compositions derived from natural substances, thereby satisfying needs of consumers requiring eco-friendly natural cosmetic products.",AMOREPACIFIC CORP,CHO YOUNG SUK;;PARK SEUNG HAN;;KIM SUN YOUNG;;KANG PAUL,,https://lens.org/174-639-824-031-377,Patent Application,no,0,2,1,1,0,A61K8/37;;A61K8/062;;A61K8/19;;A61K8/25;;A61K8/29;;A61K8/4973;;A61K8/60;;A61K8/92;;A61Q19/00,A61K8/37;;A61K8/06;;A61K8/19;;A61K8/25;;A61K8/29;;A61K8/49;;A61K8/60;;A61K8/92;;A61Q19/00,,0,0,,,,DISCONTINUED
284,WO,A1,WO 2012/068393 A1,177-003-437-551-490,2012-05-24,2012,US 2011/0061228 W,2011-11-17,US 41517410 P,2010-11-18,ADAPTOR FOR ON-BODY ANALYTE MONITORING SYSTEM,"An analyte monitoring system comprising: an on-body housing; an analyte sensor coupled to the housing; an electrical output interface disposed on an outer surface of the housing; and a removable adaptor coupled to the housing. In one embodiment, a portion of the analyte sensor extends from the housing for implantation into a patient's body. The electrical output interface is electrically coupled to the analyte sensor. The removable adaptor is mechanically coupled to the housing and electrically coupled to the electrical output interface. The removable adaptor serves as a data conduit between the analyte sensor and a remote device.",ABBOTT DIABETES CARE INC;;HOSS UDO;;SHARP CRAIG W;;CHO HYUN;;WINKLER TODD;;LEGG PAUL,HOSS UDO;;SHARP CRAIG W;;CHO HYUN;;WINKLER TODD;;LEGG PAUL,,https://lens.org/177-003-437-551-490,Patent Application,yes,4,5,3,3,0,A61B5/14503;;A61B5/14503;;A61B5/14532;;A61B5/14532;;A61B2560/0412;;A61B2560/0412,A61B5/145,,0,0,,,,PENDING
285,US,A1,US 2017/0301910 A1,130-645-799-421-000,2017-10-19,2017,US 201515515573 A,2015-09-29,US 201515515573 A;;US 201462057129 P;;US 2015/0053033 W,2014-09-29,PRE-LITHIATED SILICON ANODES WITH PVDF BINDER,"A pre-lithiated silicon anode comprising a PVDF binder at 5-12 wt. % for use in a Li-ion cell is provided. In particular instances, a conductive additive may be added at less than 5 wt. %. The Si anode with PVDF binder is pre-lithiated prior to cell assembly and following Si anode fabrication. The combination of pre-lithiation and PVDF in the Si anode for use in a rechargeable Li-ion cell shows the unexpected result of extending the cycle life.",A123 SYSTEMS LLC,WANG JUN;;GIONET PAUL;;CHO HUNGOO;;PINNELL LESLIE J;;GRANT ROBERT W,A123 SYSTEMS LLC (2017-02-28),https://lens.org/130-645-799-421-000,Patent Application,yes,3,9,13,13,0,H01M4/134;;H01M4/134;;H01M4/366;;H01M4/386;;H01M4/0404;;H01M4/043;;H01M4/0459;;H01M4/0459;;H01M4/133;;H01M4/134;;H01M4/1395;;H01M4/1395;;H01M4/364;;H01M4/364;;H01M4/366;;H01M4/366;;H01M4/386;;H01M4/386;;H01M4/386;;H01M4/587;;H01M4/587;;H01M4/587;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/625;;H01M4/625;;H01M4/625;;H01M4/661;;H01M4/661;;H01M10/052;;H01M10/052;;H01M10/0525;;H01M10/0525;;H01M10/0525;;H01M2004/027;;H01M2004/027;;Y02E60/10;;Y02E60/10;;Y02P70/50,H01M4/134;;H01M4/02;;H01M4/04;;H01M4/133;;H01M4/36;;H01M4/38;;H01M4/587;;H01M4/62;;H01M4/66;;H01M10/0525,,0,0,,,,DISCONTINUED
286,WO,A1,WO 2019/074892 A1,022-284-774-370-140,2019-04-18,2019,US 2018/0054952 W,2018-10-09,US 201762569834 P,2017-10-09,ANTIBODIES TARGETING GLIOBLASTOMA STEM-LIKE CELLS AND METHODS OF USE THEREOF,The present invention provides antibodies that target glioblastoma stem-like cells and methods and kits for their use.,WISCONSIN ALUMNI RES FOUND,ZORNIAK MICHAEL;;CLARK PAUL;;CHO YONGKU;;UMLAUF BENJAMIN;;SHUSTA ERIC;;HUO JOHN,,https://lens.org/022-284-774-370-140,Patent Application,yes,10,0,5,5,10,C07K16/18;;C07K16/30;;G01N33/57407;;A61K2039/505;;C07K2317/569;;A61P35/00;;A61K49/0058;;A61K2039/505;;C07K16/3053;;C07K2317/565;;C07K2317/622;;C07K2317/92;;G01N33/57407,C07K16/18;;A61K39/00;;A61P35/00;;C07K16/30;;G01N33/53,,88,80,044-139-486-413-246;;013-196-850-300-026;;164-041-763-164-918;;051-449-459-754-069;;065-845-026-596-467;;017-597-089-494-010;;065-067-575-525-372;;019-921-917-139-327;;001-308-283-819-689;;060-800-606-301-88X;;028-862-168-091-90X;;116-058-608-181-929;;112-206-594-779-001;;072-221-669-832-927;;000-087-532-932-840;;077-233-519-852-789;;008-661-986-771-169;;085-656-742-202-556;;035-428-777-329-102;;092-864-235-322-940;;028-981-833-063-784;;105-369-693-995-394;;019-377-086-323-88X;;054-778-738-922-420;;039-376-070-403-51X;;002-091-355-242-789;;030-327-153-441-88X;;063-180-739-005-237;;065-845-026-596-467;;044-139-486-413-246;;051-449-459-754-069;;164-041-763-164-918;;045-857-295-659-908;;024-910-342-741-241;;018-169-670-602-076;;027-628-739-240-883;;035-149-244-661-733;;071-073-635-453-103;;007-750-921-871-271;;042-513-156-090-960;;035-428-777-329-102;;127-278-436-943-010;;010-568-275-556-548;;088-006-869-449-526;;053-301-739-905-628;;094-452-013-519-715;;005-790-218-190-208;;008-387-158-819-578;;054-117-557-242-401;;013-196-850-300-026;;040-091-367-301-676;;050-643-301-507-490;;057-167-704-218-212;;024-348-041-797-510;;001-698-087-702-930;;004-929-207-346-112;;128-333-076-135-348;;071-419-968-226-297;;023-301-536-947-707;;007-057-986-430-201;;072-124-564-678-690;;132-094-885-330-409;;090-855-538-709-694;;044-055-955-198-975;;091-102-566-701-905;;037-370-743-821-194;;066-190-897-568-631;;068-232-562-966-086;;015-998-463-324-164;;002-473-848-957-436;;015-459-933-949-167;;047-143-347-080-307;;192-609-714-372-280;;009-619-262-328-708;;026-824-155-633-618;;011-020-280-584-511;;026-141-621-631-087;;097-006-524-687-437;;044-555-535-916-468;;031-529-904-715-725,20587664;;pmc2944778;;10.1158/1535-7163.mct-09-1059;;24832468;;pmc4085538;;10.1038/cdd.2014.65;;pmc3933790;;23796560;;10.1158/0008-5472.can-12-4556;;10.1016/j.biomaterials.2011.07.048;;21880363;;10.1016/j.neuint.2014.03.005;;pmc4119816;;24657832;;29158489;;10.1038/s41598-017-16066-1;;pmc5696472;;10.1016/j.omtn.2018.04.004;;29858087;;pmc5992475;;26759369;;pmc4743815;;10.1073/pnas.1524155113;;26405231;;pmc4721629;;10.1126/science.aab4077;;pmc5997667;;29895885;;10.1038/s41598-018-27264-w;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;27192568;;pmc4873959;;10.1016/j.immuni.2016.04.017;;pmc2688461;;10.1016/j.bmcl.2009.01.028;;19181522;;10.1021/nn1023363;;21609027;;21839049;;10.1016/j.nano.2011.07.007;;11156394;;10.1007/s11095-007-9379-0;;17619996;;pmc2685177;;20044633;;10.1158/1078-0432.ccr-12-0339;;pmc3597469;;22589395;;10.1056/nejmoa043330;;15758009;;26670971;;10.1001/jama.2015.16669;;10.1001/jama.2014.12146;;17051156;;10.1038/nature05236;;17140455;;pmc1697823;;10.1186/1476-4598-5-67;;pmc3384429;;22745588;;10.1596/neo.12432;;10.1038/nature03128;;15549107;;pmc7227614;;10.1016/j.stem.2009.03.003;;19427293;;20173750;;10.1038/nmeth.1430;;10.1016/j.ccr.2009.12.049;;20385361;;10.1016/j.neuint.2014.03.005;;pmc4119816;;24657832;;20587664;;pmc2944778;;10.1158/1535-7163.mct-09-1059;;10.1016/j.biomaterials.2011.07.048;;21880363;;pmc3933790;;23796560;;10.1158/0008-5472.can-12-4556;;12536217;;10.1038/nbt785;;10.1038/77325;;10888844;;16549400;;10.1093/protein/gzl008;;16099466;;10.1016/j.jim.2005.05.006;;17206151;;pmc2637222;;10.1038/nmeth993;;11075358;;10.1016/s0076-6879(00)28410-3;;pmc1207636;;10.1093/genetics/144.3.967;;8913742;;18000980;;10.1002/dvdy.21381;;10.1158/1078-0432.ccr-12-0339;;pmc3597469;;22589395;;24920661;;pmc4336181;;10.1126/scitranslmed.3007646;;25361488;;10.3171/2014.9.jns132373;;pmc4337891;;27419830;;10.3171/2016.1.jns152077;;pmc5237623;;10.1158/1078-0432.ccr-15-3169;;pmc5627655;;27635088;;19497285;;10.1016/j.stem.2009.03.014;;10.1016/j.jim.2008.11.005;;19041873;;pmc2637942;;10.1021/bp990133s;;10662486;;9702778;;10.1038/nbt0898-773;;24832468;;pmc4085538;;10.1038/cdd.2014.65;;10.1016/j.ccr.2006.03.030;;10.3410/f.30634.375123;;16697959;;16957578;;10.1097/01.jnen.0000235118.75182.94;;16151404;;10.1038/nbt1126;;10.1016/j.chembiol.2007.09.008;;17961829;;10.1002/btpr.174;;19363813;;pmc2837102;;23248284;;10.1073/pnas.1219817110;;pmc3538214;;pmc2999649;;20829328;;10.1158/1078-0432.ccr-10-1564;;10.1227/neu.0000000000000622;;25549194;;pmc4343207;;pmc5014630;;27421304;;10.1021/acs.molpharmaceut.6b00441;;10.2217/cns-2016-0017;;pmc5514628;;27616199;;27572805;;10.1080/14712598.2016.1230195;;10.1517/17425247.2016.1171315;;27020469;;10.1227/neu.0000000000001451;;27861405;;10.1023/a:1007049806660;;10696511;;10.1038/sj.gt.3302445;;15647762;;pmc4664343;;26553993;;10.1073/pnas.1502648112;;10.1158/1535-7163.mct-14-1078;;25931519;;10.1080/2162402x.2015.1008339;;26155413;;pmc4485829;;10.1038/mt.2015.199;;pmc4817815;;26514825;;10.1158/2326-6066.cir-15-0060;;26822025;;9874150;;10.1016/s0165-0270(98)00126-5;;12203386;;10.1002/glia.10094;;14522905;;10.1007/s11095-006-9778-7;;16550469;;10.1021/cb500689g;;25384269;;pmc4340354;;18781684;;10.1002/bit.22019;;10.1128/aem.01466-14;;25015885;;pmc4178591;;22449570;;pmc3405166;;10.1016/j.ymeth.2012.03.010;;10.1158/0008-5472.can-04-1364;;15466194;;pmc3189267;;21814852;;10.1007/s00259-011-1886-x,"X. ZHU ET AL: ""Identification of Internalizing Human Single-Chain Antibodies Targeting Brain Tumor Sphere Cells"", MOLECULAR CANCER THERAPEUTICS, vol. 9, no. 7, 1 July 2010 (2010-07-01), pages 2131 - 2141, XP055178095, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-09-1059;;J K LIU ET AL: ""Phage display discovery of novel molecular targets in glioblastoma-initiating cells"", CELL DEATH AND DIFFERENTIATION., vol. 21, no. 8, 16 May 2014 (2014-05-16), GB, pages 1325 - 1339, XP055544885, ISSN: 1350-9047, DOI: 10.1038/cdd.2014.65;;Y. KIM ET AL: ""Aptamer Identification of Brain Tumor-Initiating Cells"", CANCER RESEARCH, vol. 73, no. 15, 24 June 2013 (2013-06-24), US, pages 4923 - 4936, XP055544884, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-4556;;SAMUEL BECK ET AL: ""Identification of a peptide that interacts with Nestin protein expressed in brain cancer stem cells"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 32, no. 33, 16 July 2011 (2011-07-16), pages 8518 - 8528, XP028295853, ISSN: 0142-9612, [retrieved on 20110801], DOI: 10.1016/J.BIOMATERIALS.2011.07.048;;POINTER KELLI B ET AL: ""Glioblastoma cancer stem cells: Biomarker and therapeutic advances"", NEUROCHEMISTRY INTERNATIONAL, vol. 71, 19 March 2014 (2014-03-19), pages 1 - 7, XP028655023, ISSN: 0197-0186, DOI: 10.1016/J.NEUINT.2014.03.005;;MICHAEL ZORNIAK ET AL: ""Yeast display biopanning identifies human antibodies targeting glioblastoma stem-like cells"", SCIENTIFIC REPORTS, vol. 7, no. 1, 20 November 2017 (2017-11-20), XP055544982, DOI: 10.1038/s41598-017-16066-1;;ARNOLD AMY E ET AL: ""Antibody-Antisense Oligonucleotide Conjugate Downregulates a Key Gene in Glioblastoma Stem Cells."", MOLECULAR THERAPY. NUCLEIC ACIDS 01 JUN 2018, vol. 11, 1 June 2018 (2018-06-01), pages 518 - 527, XP002788205, ISSN: 2162-2531;;RODGERS ET AL.: ""Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies"", PNAS, 12 January 2006 (2006-01-12), pages E459 - E468;;WU ET AL.: ""Remote control of therapeutic T cells through a small molecule-gated chimeric receptor"", SCIENCE, vol. 350, no. 6258, 16 October 2015 (2015-10-16), pages aab4077 - 9, XP055260068, DOI: doi:10.1126/science.aab4077;;VALTON ET AL.: ""A Versatile Safeguard for Chimeric Antigen Receptor T-cell Immunotherapies"", NATURE SCIENTIFIC REPORTS, vol. 8, 2018;;KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2267 - 2268;;ALTSCHUL ET AL., NUCL. ACIDS RES., vol. 25, 1997, pages 3389 - 3402;;ZHANG ET AL.: ""Co-stimulatory and Co-inhibitory Pathways in Autoimmunity"", IMMUNITY, vol. 44, 17 May 2016 (2016-05-17), pages 1034 - 1051, XP029537983, DOI: doi:10.1016/j.immuni.2016.04.017;;GAVRILYUK ET AL.: ""3-Lactam-based Approach for Chemical Programming of Aldolast Antibody 38C2"", BIOORG MED CHEM LETT., vol. 19, no. 5, 1 March 2009 (2009-03-01), pages 1421 - 1424;;B. VAN DE BROEK ET AL., ACS NANO, vol. 5, no. 6, 2011, pages 4319 - 4328;;A. SUKHANOVA ET AL., NANOMEDICINE, vol. 8, 2012, pages 516 - 525;;SUGANO ET AL.: ""Antibody Targeting of Doxorubicin-loaded Liposomes Suppresses the Growth and Metastatic Spread of Established Human Lung Tumor Xenografts in Severe Combined Immunodeficient Mice"", CANCER RESEARCH, vol. 60, 15 December 2000 (2000-12-15), pages 6942 - 6949, XP000980029;;MARTIN ET AL.: ""Nanomaterials in Analytical Chemistry"", ANALYTICAL CHEMISTRY NEWS & FEATURES, 1 May 1998 (1998-05-01), pages 322 A - 327 A;;JONES, A.R.; E.V. SHUSTA: ""Blood-brain barrier transport of therapeutics via receptor-mediation"", PHARMACEUTICAL RESEARCH, vol. 24, no. 9, 2007, pages 1759 - 1771, XP019532601, DOI: doi:10.1007/s11095-007-9379-0;;TERNYNCK; AVRAMEAS: ""Techniques immunoenzymatiques"", 1987;;G.T. HERMANSON: ""Bioconjugate Techniques"", 2010, ACADEMIC PRESS;;WONG: ""Chemistry of protein conjugation and cross-linking"", 1991, CRC PRESS;;""Merck Index"";;""Physicians' Desk Reference"";;""The Pharmacological Basis of Therapeutics"";;MINNITI ET AL.: ""Chemotherapy for Glioblastoma: Current Treatment and Further Perspectives for Cytotoxic and Targeted Agents"", ANTICANCER RESEARCH, vol. 29, no. 12, December 2009 (2009-12-01), pages 5171 - 5184;;ZORNIAK ET AL.: ""Differential Expression of 2'3'-Cyclic-Nucleotide 3'-Phosphodiesterase and Neural Lineage Markers Correlate with Glioblastoma Xenograft Infiltration and Patient Survival"", CLINICAL CANCER RESEARCH, May 2012 (2012-05-01);;STUPP, R. ET AL.: ""Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma"", NENGL J MED, vol. 352, 2005, pages 987 - 996, XP002439490, DOI: doi:10.1056/NEJMoa043330;;STUPP, R. ET AL.: ""Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial"", JAMA : THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 314, 2015, pages 2535 - 2543;;BAO, S. ET AL.: ""Glioma stem cells promote radioresistance by preferential activation of the DNA damage response"", NATURE, vol. 444, 2006, pages 756 - 760, XP055200572, DOI: doi:10.1038/nature05236;;LIU, G. ET AL.: ""Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma"", MOLECULAR CANCER, vol. 5, 2006, pages 67, XP021024382, DOI: doi:10.1186/1476-4598-5-67;;CLARK, P. A. ET AL.: ""Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition"", NEOPLASIA, vol. 14, 2012, pages 420 - 428;;SINGH, S. K. ET AL.: ""Identification of human brain tumour initiating cells"", NATURE, vol. 432, 2004, pages 396 - 401, XP002467853, DOI: doi:10.1038/nature03128;;SON, M. J.; WOOLARD, K.; NAM, D. H.; LEE, J.; FINE, H. A.: ""SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma"", CELL STEM CELL, vol. 4, 2009, pages 440 - 452;;CLEMENT, V. ET AL.: ""Marker-independent identification of glioma-initiating cells"", NATURE METHODS, vol. 7, 2010, pages 224 - 228, XP007914533, DOI: doi:10.1038/nmeth.1430;;CHEN, R. ET AL.: ""A hierarchy of self-renewing tumor-initiating cell types in glioblastoma"", CANCER CELL, vol. 17, 2010, pages 362 - 375, XP055032071, DOI: doi:10.1016/j.ccr.2009.12.049;;POINTER, K. B.; CLARK, P. A.; ZORNIAK, M.; ALRFAEI, B. M.; KUO, J. S.: ""Glioblastoma cancer stem cells: Biomarker and therapeutic advances"", NEUROCHEM INT, vol. 71, 2014, pages 1 - 7, XP028655023, DOI: doi:10.1016/j.neuint.2014.03.005;;ZHU, X. ET AL.: ""Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells"", MOLECULAR CANCER THERAPEUTICS, vol. 9, 2010, pages 2131 - 2141, XP055178095, DOI: doi:10.1158/1535-7163.MCT-09-1059;;BECK, S. ET AL.: ""Identification of a peptide that interacts with Nestin protein expressed in brain cancer stem cells"", BIOMATERIALS, vol. 32, 2011, pages 8518 - 8528, XP028295853, DOI: doi:10.1016/j.biomaterials.2011.07.048;;KIM, Y. ET AL.: ""Aptamer Identification of Brain Tumor-Initiating Cells"", CANCER RESEARCH, vol. 73, 2013, pages 4923 - 4936;;FELDHAUS, M. J. ET AL.: ""Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library"", NATURE BIOTECHNOLOGY, vol. 21, 2003, pages 163 - 170, XP002451748;;SHUSTA, E. V.; HOLLER, P. D.; KIEKE, M. C.; KRANZ, D. M.; WITTRUP, K. D.: ""Directed evolution of a stable scaffold for T-cell receptor engineering"", NATURE BIOTECHNOLOGY, vol. 18, 2000, pages 754 - 759, XP055004062, DOI: doi:10.1038/77325;;RICHMAN, S. A. ET AL.: ""Development of a novel strategy for engineering high-affinity proteins by yeast display"", PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS, vol. 19, 2006, pages 255 - 264;;WANG, X. X.; SHUSTA, E. V.: ""The use of scFv-displaying yeast in mammalian cell surface selections"", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 304, 2005, pages 30 - 42;;WANG, X. X.; CHO, Y. K.; SHUSTA, E. V.: ""Mining a yeast library for brain endothelial cell-binding antibodies"", NATURE METHODS, vol. 4, 2007, pages 143 - 145, XP008086824, DOI: doi:10.1038/nmeth993;;BODER, E. T.; WITTRUP, K. D.: ""Yeast surface display for directed evolution of protein expression, affinity, and stability"", METHODS IN ENZYMOLOGY, vol. 328, 2000, pages 430 - 444, XP009103962, DOI: doi:10.1016/S0076-6879(00)28410-3;;LIU, H.; STYLES, C. A.; FINK, G. R.: ""Saccharomyces cerevisiae S288C has a mutation in FL08, a gene required for filamentous growth"", GENETICS, vol. 144, 1996, pages 967 - 978;;CLARK, P. A.; TREISMAN, D. M.; EBBEN, J.; KUO, J. S.: ""Developmental signaling pathways in brain tumor-derived stem-like cells"", DEV DYN, vol. 236, 2007, pages 3297 - 3308;;ZORNIAK, M. ET AL.: ""Differential expression of 2',3'-cyclic-nucleotide 3'-phosphodiesterase and neural lineage markers correlate with glioblastoma xenograft infiltration and patient survival"", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 18, 2012, pages 3628 - 3636;;WEICHERT, J. P. ET AL.: ""Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy"", SCIENCE TRANSLATIONAL MEDICINE, vol. 6, 2014, pages 240ra275;;ZORNIAK, M.; CLARK, P. A.; KUO, J. S.: ""Myelin-forming cell-specific cadherin-19 is a marker for minimally infiltrative glioblastoma stem-like cells"", J NEUROSURG, vol. 122, 2015, pages 69 - 77;;CLARK, P. A. ET AL.: ""Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration"", J NEUROSURG, 2016, pages 1 - 13;;POINTER, K. B. ET AL.: ""Non-torsadogenic human Ether-a-go-go Related Gene (hERG) inhibitors are associated with better survival for high hERG-expressing glioblastoma patients"", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 2016;;POLLARD, S. M. ET AL.: ""Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens"", CELL STEM CELL, vol. 4, 2009, pages 568 - 580, XP002665238, DOI: doi:10.1016/j.stem.2009.03.014;;CHO, Y. K.; CHEN, I.; WEI, X.; LI, L.; SHUSTA, E. V.: ""A yeast display immunoprecipitation method for efficient isolation and characterization of antigens"", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 341, 2009, pages 117 - 126, XP025913977, DOI: doi:10.1016/j.jim.2008.11.005;;VANANTWERP, J. J.; WITTRUP, K. D.: ""Fine affinity discrimination by yeast surface display and flow cytometry"", BIOTECHNOLOGY PROGRESS, vol. 16, 2000, pages 31 - 37;;SHUSTA, E. V.; RAINES, R. T.; PLUCKTHUN, A.; WITTRUP, K. D.: ""Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments"", NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 773 - 777, XP002138520, DOI: doi:10.1038/nbt0898-773;;LIU, J. K. ET AL.: ""Phage display discovery of novel molecular targets in glioblastoma-initiating cells"", CELL DEATH DIFFER, vol. 21, 2014, pages 1325 - 1339;;LEE, J. ET AL.: ""Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines"", CANCER CELL, vol. 9, 2006, pages 391 - 403, XP002550739, DOI: doi:10.1016/j.ccr.2006.03.030;;HOMMA, T. ET AL.: ""Correlation among pathology, genotype, and patient outcomes in glioblastoma"", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, vol. 65, 2006, pages 846 - 854, XP009132036;;HOOGENBOOM, H. R.: ""Selecting and screening recombinant antibody libraries"", NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 1105 - 1116, XP002348401, DOI: doi:10.1038/nbt1126;;LIPOVSEK, D. ET AL.: ""Selection of horseradish peroxidase variants with enhanced enantioselectivity by yeast surface display"", CHEMISTRY & BIOLOGY, vol. 14, 2007, pages 1176 - 1185, XP009091881, DOI: doi:10.1016/j.chembiol.2007.09.008;;ACKERMAN, M. ET AL.: ""Highly avid magnetic bead capture: an efficient selection method for de novo protein engineering utilizing yeast surface display"", BIOTECHNOLOGY PROGRESS, vol. 25, 2009, pages 774 - 783;;CHOI, B. D. ET AL.: ""Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 110, 2013, pages 270 - 275, XP055156305, DOI: doi:10.1073/pnas.1219817110;;LOCKMAN, P. R. ET AL.: ""Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer"", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 16, 2010, pages 5664 - 5678;;SWANSON, K. I. ET AL.: ""Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection"", NEUROSURGERY, vol. 76, 2015, pages 115 - 123;;CLARK, P. A. ET AL.: ""Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood-Brain Barrier Model"", MOL PHARM, vol. 13, 2016, pages 3341 - 3349;;ZHANG, R. R.; SWANSON, K. I.; HALL, L. T.; WEICHERT, J. P.; KUO, J. S.: ""Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies"", CNS ONCOL, vol. 5, 2016, pages 223 - 231;;PARDRIDGE, W. M.: ""Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies"", EXPERT OPIN BIOL THER, 2016, pages 1 - 14;;PARDRIDGE, W. M.: ""CSF, blood-brain barrier, and brain drug delivery"", EXPERT OPIN DRUG DELIV, vol. 13, 2016, pages 963 - 975;;LIU, H. L. ET AL.: ""Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment"", RADIOLOGY, vol. 281, 2016, pages 99 - 108;;RAPOPORT, S. I.: ""Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications"", CELLULAR AND MOLECULAR NEUROBIOLOGY, vol. 20, 2000, pages 217 - 230;;LIU, R.; MARTUZA, R. L.; RABKIN, S. D.: ""Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain"", GENE THERAPY, vol. 12, 2005, pages 647 - 654;;YANG, Y. ET AL.: ""Targeting CD 146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 112, 2015, pages E6525 - 6534, XP055453695, DOI: doi:10.1073/pnas.1502648112;;HAMBLETT, K. J. ET AL.: ""AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma"", MOLECULAR CANCER THERAPEUTICS, vol. 14, 2015, pages 1614 - 1624;;SURYADEVARA, C. M. ET AL.: ""Are BiTEs the ''missing link'' in cancer therapy?"", ONCOIMMUNOLOGY, vol. 4, 2015, pages el008339;;KRENCIUTE, G. ET AL.: ""Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Ralpha2-positive Glioma"", MOL THER, vol. 24, 2016, pages 354 - 363, XP055462357, DOI: doi:10.1038/mt.2015.199;;SHIINA, S. ET AL.: ""CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains"", CANCER IMMUNOL RES, vol. 4, 2016, pages 259 - 268;;SVENDSEN, C. N. ET AL.: ""A new method for the rapid and long term growth of human neural precursor cells"", JNEUROSCI METHODS, vol. 85, 1998, pages 141 - 152, XP002902582, DOI: doi:10.1016/S0165-0270(98)00126-5;;IGNATOVA, T. N. ET AL.: ""Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro"", GLIA, vol. 39, 2002, pages 193 - 206, XP009044599, DOI: doi:10.1002/glia.10094;;SINGH, S. K. ET AL.: ""Identification of a cancer stem cell in human brain tumors"", CANCER RESEARCH, vol. 63, 2003, pages 5821 - 5828;;HACKEL, B. J.; HUANG, D.; BUBOLZ, J. C.; WANG, X. X.; SHUSTA, E. V.: ""Production of soluble and active transferrin receptor-targeting single-chain antibody using Saccharomyces cerevisiae"", PHARMACEUTICAL RESEARCH, vol. 23, 2006, pages 790 - 797, XP019405238, DOI: doi:10.1007/s11095-006-9778-7;;MARSHALL, C. J. ET AL.: ""An evolved Mxe GyrA intein for enhanced production of fusion proteins"", ACS CHEM BIOL, vol. 10, 2015, pages 527 - 538;;HUANG, D.; GORE, P. R.; SHUSTA, E. V.: ""Increasing yeast secretion of heterologous proteins by regulating expression rates and post-secretory loss"", BIOTECHNOL BIOENG, vol. 101, 2008, pages 1264 - 1275;;BUMS, M. L. ET AL.: ""Directed evolution of brain-derived neurotrophic factor for improved folding and expression in Saccharomyces cerevisiae"", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 80, 2014, pages 5732 - 5742;;TILLOTSON, B. J.; CHO, Y. K.; SHUSTA, E. V.: ""Cells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface display"", METHODS, vol. 60, 2013, pages 27 - 37;;GALLI, R. ET AL.: ""Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma"", CANCER RESEARCH, vol. 64, 2004, pages 7011 - 7021, XP002550845, DOI: doi:10.1158/0008-5472.CAN-04-1364;;YANG, Y. ET AL.: ""In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis"", EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 38, 2011, pages 2066 - 2076, XP019961557, DOI: doi:10.1007/s00259-011-1886-x",PENDING
287,US,B2,US 11304606 B2,105-289-684-116-992,2022-04-19,2022,US 201816182650 A,2018-11-07,US 201816182650 A,2018-11-07,Method and system for enhancing RF energy delivery during thermoacoustic imaging,"A method and system for enhancing radio frequency energy delivery to a tissue region of interest. The method and system direct with a radio frequency (RF) applicator, one or more RF energy pulses into the tissue region of interest, the tissue region of interest comprising an object of interest and at least one reference that are separated by at least one boundary; detect with an acoustic receiver, at least one bipolar acoustic signal generated in the tissue region of interest in response to the RF energy pulses and processing the at least one bipolar acoustic signal to determine a peak-to-peak amplitude thereof; adjust the RF applicator to maximize the peak-to-peak amplitude of bipolar acoustic signals generated in the tissue region of interest in response to RF energy pulses generated by the adjusted RF applicator; and direct with the adjusted RF applicator, one or more RF energy pulses into the region of interest.",ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/105-289-684-116-992,Granted Patent,yes,5,2,6,6,0,A61B5/0093;;A61B5/201;;A61B5/4244;;A61B5/4872;;A61B5/0093;;A61B5/4872;;A61B5/4244;;A61B5/201;;A61B5/02007,A61B5/00;;A61B5/02;;A61B5/20,,4,3,033-786-059-395-583;;013-000-205-460-222;;067-917-708-067-522,10.1109/tbme.2012.2210218;;22851231;;pmc2774978;;19895126;;10.1117/1.3247155;;10.1109/ultsym.2011.0587,"Xiong Wang et al., “Microwave-Induced Thermoacoustic Imaging Model for Potential Breast Cancer Detection”, Oct. 2012, IEEE Transactions on Biomedical Engineering, vol. 59, No. 10, 2782-2791 (Year: 2012).;;Manojit Pramanik et al., “Thermoacoustic and Photoacoustic Sensing of Temperature”, Oct. 2009, Journal of Biomedical Optics, vol. 14(5) (Year: 2009).;;Daniel Bauer et al., “Thermoacoustic Imaging and Spectroscopy for Enhanced Breast Cancer Detection”, 2011 IEEE International Ultrasonics Symposium Proceedings (Year: 2011).;;Shane Thomas; PCT International Search Report and Written Opinion; dated Jan. 27, 2020; 7 pages total; WIPO; Alexandria, VA, United States.",ACTIVE
288,US,S,US D0525123 S,118-963-776-211-085,2006-07-18,2006,US 21842804 F,2004-11-29,US 21842804 F,2004-11-29,Trigger pump package,,SEAQUIST PERFECT DISPENSING FOREIGN INC,WALTERS PETER J;;KSIAZK JASON A;;CHO SEAN H;;HALLMAN PAUL E,WALTERS PETER J (2004-11-29),https://lens.org/118-963-776-211-085,Design Right,no,0,19,1,14,0,B05B11/1057;;B05B11/1059;;B05B11/1059;;B05B11/1057,,0907;;D 9448,0,0,,,,EXPIRED
289,EP,B1,EP 2707311 B1,184-282-301-721-380,2016-12-07,2016,EP 11870539 A,2011-08-11,US 2011/0047440 W,2011-08-11,LOCKABLE DISPENSING PACKAGE AND ACTUATOR,,APTARGROUP INC,CHO SEAN H;;WALTERS PETER J;;MARQUARDT GERALD J;;HALLMAN PAUL E,,https://lens.org/184-282-301-721-380,Granted Patent,yes,6,1,11,11,0,B65D83/206;;B65D83/22;;B65D83/22;;B65D83/206;;B65D83/206;;B65D83/22,B65D83/22;;B65D83/20,,0,0,,,,ACTIVE
290,CN,A,CN 113227391 A,048-246-373-464-150,2021-08-06,2021,CN 201980080544 A,2019-12-19,EP 18214358 A;;EP 2019086173 W,2018-12-20,LASER-INDUCED CELL TRANSFER AND SORTING,"Disclosed herein is a method for transferring objects, preferably biological objects, in particular biological cells, onto a substrate. The method comprises the steps: providing a medium in a reservoir, wherein the medium contains objects; providing the substrate having an acceptor surface, wherein the acceptor surface faces an opening of the reservoir; determining a first target focus point in the medium; and generating a first laser pulse or first laser pulse train focused onto the first target focus point. The method is characterized in that a pulse intensity of the first laser pulse or first laser pulse train at the first target focus point and/or a pulse duration of the first laser pulse or first laser pulse train is/ are chosen such that the first laser pulse or first laser pulse train generates a droplet of the medium that is ejected from the medium to- wards the acceptor surface; a center wavelength of the first laser pulse or first laser pulse train is larger than 500 nm, preferably larger than 650 nm, most preferably between 0.9 micron and 1.35 microns; a position of at least one of the objects in the medium is determined at least in part; and the first target focus point is determined relative to the position of the at least one object.",HOCHSCHULE FUER ANGEWANDTE WSS MUENCHEN;;UNIV REGENSBURG UNIVSKLINIKUM,CHO TAKASHI;;HUBER HEINZ PAUL;;CLAUSEN-SCHAUMANN HAUKE;;SUDHOP STEFANIE;;DOCHEVA DENITSA,,https://lens.org/048-246-373-464-150,Patent Application,no,4,1,5,5,0,G01N33/5005;;B41J2/44;;C12M33/00;;C12Q1/24;;B41J2/44;;C12M33/00;;C12Q1/24,C12Q1/24;;B41J2/44;;C12M1/00;;G01N33/50,,4,0,,,"董晓斌等: ""基于光镊的细胞搬运研究"", 企业技术开发, vol. 37, no. 7, pages 14 - 15;;ZHANG J等: ""Sacrificial-layer free transfer of mammalian cells using near infrared femtosecond laser pulses"", PLOS ONE, vol. 13, no. 5, pages 1 - 3;;TAKAHIRO K等: ""Nondestructive micropatterning of living animal cells using focused femtosecond laser-induced impulsive force"", APPLIED PHYSICS LETTERS, vol. 91, no. 2, pages 1;;冉玲苓等: ""飞秒激光操控细胞的研究"", 黑龙江大学工程学报, vol. 3, no. 4, pages 85 - 89",PENDING
291,EP,A1,EP 3893759 A1,125-255-219-892-785,2021-10-20,2021,EP 19881356 A,2019-11-07,US 201816182650 A;;US 2019/0060293 W,2018-11-07,METHOD AND SYSTEM FOR ENHANCING RF ENERGY DELIVERY DURING THERMOACOUSTIC IMAGING,,ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/125-255-219-892-785,Patent Application,yes,0,0,6,6,0,A61B5/0093;;A61B5/201;;A61B5/4244;;A61B5/4872;;A61B5/0093;;A61B5/4872;;A61B5/4244;;A61B5/201;;A61B5/02007,A61B8/08;;A61B5/00,,0,0,,,,PENDING
292,TW,A,TW 201624819 A,135-916-919-771-990,2016-07-01,2016,TW 104132014 A,2015-09-30,US 201462057129 P,2014-09-29,Li-ion battery and method of preparing a pre-lithiated anode for use in a Li-ion cell,"A Li-ion battery and a method of preparing a pre-lithiated anode for use in a Li-ion cell are provided. The pre-lithiated anode includes a PVDF binder at 5-12 wt. % for use in a Li-ion cell. In particular instances, a conductive additive may be added at less than 5 wt. %. The Si anode with PVDF binder is pre-lithiated prior to cell assembly and following Si anode fabrication. The combination of pre-lithiation and PVDF in the Si anode for use in a rechargeable Li-ion cell shows the unexpected result of extending the cycle life.",A123 SYSTEMS LLC,WANG JUN;;GIONET PAUL;;CHO HUNGOO;;PINNELL LESLIE J;;GRANT ROBERT W,,https://lens.org/135-916-919-771-990,Patent of Addition,no,0,0,13,13,0,H01M4/134;;H01M4/134;;H01M4/366;;H01M4/386;;H01M4/0404;;H01M4/043;;H01M4/0459;;H01M4/0459;;H01M4/133;;H01M4/134;;H01M4/1395;;H01M4/1395;;H01M4/364;;H01M4/364;;H01M4/366;;H01M4/366;;H01M4/386;;H01M4/386;;H01M4/386;;H01M4/587;;H01M4/587;;H01M4/587;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/625;;H01M4/625;;H01M4/625;;H01M4/661;;H01M4/661;;H01M10/052;;H01M10/052;;H01M10/0525;;H01M10/0525;;H01M10/0525;;H01M2004/027;;H01M2004/027;;Y02E60/10;;Y02E60/10;;Y02P70/50,H01M10/42;;C08F14/22;;H01M4/1395;;H01M4/62;;H01M10/052,,0,0,,,,PENDING
293,UA,C2,UA 75635 C2,137-741-095-608-12X,2006-05-15,2006,UA 2003087745 A,2002-02-15,US 31236101 P;;US 26868301 P;;US 0204407 W,2001-02-15,DERIVATIVES OF 3-(4-AMIDOPYROL-2-YLMETHYLIDEN)-2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE,The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceulically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.,SUGEN INC;;UPJOHN CO,TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;HERRINTON PAUL MATTHEW,,https://lens.org/137-741-095-608-12X,Limited Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/416;;A61K31/4178;;A61K31/437;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
294,JP,A,JP 2020074340 A,172-515-911-735-543,2020-05-14,2020,JP 2020019799 A,2020-02-07,US 201462057129 P,2014-09-29,Li ION BATTERY,"To provide a high capacity retention rate after a plurality of cycles to provide a long cell cycle life.SOLUTION: A pre-lithiated silicon anode comprising a PVDF binder at 5-12 wt.% for use in a Li-ion cell is provided. In particular instances, a conductive additive may be added at less than 5 wt.%. The anode with the PVDF binder is pre-lithiated prior to cell assembly and following Si anode fabrication. The combination of pre-lithiation and PVDF in the Si anode for use in a rechargeable Li-ion cell shows an unexpected result of extending a cycle life.SELECTED DRAWING: Figure 3",A123 SYSTEMS LLC,WANG JUN;;PAUL GIONET;;CHO HUNGOO;;LESLIE J PINNELL;;ROBERT W GRANT,,https://lens.org/172-515-911-735-543,Patent Application,no,13,0,13,13,0,H01M4/134;;H01M4/1395;;H01M4/386;;H01M4/623;;H01M10/0525;;H01M4/366;;H01M4/386;;H01M4/587;;H01M4/623;;H01M4/625;;H01M4/661;;H01M10/052;;H01M2004/027;;Y02E60/10;;Y02P70/50;;H01M4/134;;H01M4/623;;H01M4/625;;H01M4/386;;H01M4/366;;H01M4/364;;H01M4/587;;H01M10/0525;;H01M4/1395;;H01M4/0459;;Y02E60/10;;H01M4/366;;H01M4/386;;H01M4/587;;H01M4/623;;H01M4/625;;H01M4/661;;H01M2004/027;;H01M10/052;;H01M4/0404;;H01M4/043;;H01M4/0459;;H01M4/133;;H01M4/134;;H01M4/364;;H01M10/0525,H01M10/052;;H01M4/134;;H01M4/36;;H01M4/587;;H01M4/62;;H01M4/66,,0,0,,,,PENDING
295,BR,A2,BR 112014000900 A2,084-789-552-926-396,2017-02-21,2017,BR 112014000900 A,2011-08-11,US 2011/0047440 W,2011-08-11,embalagem e acionador de dispensação traváveis,"resumo patente de invenção: ""embalagem e acionador de dispensação traváveis"". a presente invenção refere-se a um acionador (18, 18') é fornecido para acionar uma válvula (16) em um recipiente (14) para dispensar um produto fluente. o acionador (18, 18') inclui um alojamento externo (40, 40') e um elemento girável (42, 42'). o elemento girável (42, 42') fica localizado dentro de uma câmara interna (48) do alojamento (40, 40') e inclui uma superfície encaixável (54) localizada em uma janela se estendendo circunferencialmente (50) do alojamento (40, 40') para ser encaixada por um usuário para movimento da superfície encaixável (54) dentro da janela (50) entre uma posição travada em que movimento de um botão acionador (52) de uma posição não acionada para uma posição acionada é impedido e uma posição destravada em que movimento do botão acionador (52) da posição não acionada para a posição acionada é permitido para acionar a válvula (16). 20247042v1",APTARGROUP INC,GERALD J MARQUARDT;;PAUL E HALLMAN;;PETER J WALTERS;;SEAN H CHO,,https://lens.org/084-789-552-926-396,Patent Application,no,0,0,11,11,0,B65D83/206;;B65D83/22;;B65D83/22;;B65D83/206;;B65D83/206;;B65D83/22,B65D83/22,,0,0,,,,ACTIVE
296,CN,A,CN 112969416 A,176-690-671-491-319,2021-06-15,2021,CN 201980073250 A,2019-11-07,US 201816182650 A;;US 2019/0060293 W,2018-11-07,METHOD AND SYSTEM FOR ENHANCING RF ENERGY DELIVERY DURING THERMOACOUSTIC IMAGING,"A method and system for enhancing radio frequency energy delivery to a tissue region of interest. The method and system direct with a radio frequency (RF) applicator, one or more RF energy pulses into the tissue region of interest, the tissue region of interest comprising an object of interest and at least one reference that are separated by at least one boundary; detect with an acoustic receiver, at least one bipolar acoustic signal generated in the tissue region of interest in response to the RF energy pulses and processing the at least one bipolar acoustic signal to determine a peak-to-peak amplitude thereof; adjust the RF applicator to maximize the peak-to-peak amplitude of bipolar acoustic signals generated in the tissue region of interest in response to RF energy pulses generated by the adjusted RF applicator; and direct with the adjusted RF applicator, one or more RF energy pulses into the region of interest.",ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG-HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/176-690-671-491-319,Patent Application,no,0,0,6,6,0,A61B5/0093;;A61B5/201;;A61B5/4244;;A61B5/4872;;A61B5/0093;;A61B5/4872;;A61B5/4244;;A61B5/201;;A61B5/02007,A61B8/08;;A61B5/00,,0,0,,,,PENDING
297,EP,A4,EP 3893759 A4,131-742-119-129-569,2022-11-09,2022,EP 19881356 A,2019-11-07,US 201816182650 A;;US 2019/0060293 W,2018-11-07,METHOD AND SYSTEM FOR ENHANCING RF ENERGY DELIVERY DURING THERMOACOUSTIC IMAGING,,ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/131-742-119-129-569,Search Report,no,8,0,6,6,0,A61B5/0093;;A61B5/201;;A61B5/4244;;A61B5/4872;;A61B5/0093;;A61B5/4872;;A61B5/4244;;A61B5/201;;A61B5/02007,A61B8/08;;A61B5/00,,1,0,,,See also references of WO 2020097351A1,PENDING
298,CN,U,CN 203511580 U,032-221-505-957-984,2014-04-02,2014,CN 201320431604 U,2013-07-19,CN 201320431604 U,2013-07-19,"Cover body of windscreen wiper motor, windscreen wiper motor, rear windscreen wiper and automobile","The utility model relates to a cover body of a windscreen wiper motor. The cover body is provided with a sub-cover body and a gear cover. The cover body further comprises a plurality of welding pins arranged on the gear cover, and after the end portions of the welding pins penetrate through through holes formed in the sub-cover body, the end portions are welded in a fusion mode to fix the sub-cover body on the gear cover. The utility model further provides the windscreen wiper motor with the cover body, a rear windscreen wiper with the windscreen wiper motor and an automobile with the rear windscreen wiper. The cover body of the windscreen wiper motor has the advantages of being flexible in arrangement, stable in connection, low in production cost, low in process cost and the like.",BOSCH AUTOMOTIVE PROD CHANGSHA,KAIKAI XU;;NAIRUI CHENG;;THOMAS HOLZER;;PAUL GEUBEL;;YE GUI;;WOOYEAN CHO,,https://lens.org/032-221-505-957-984,Limited Patent,no,0,0,3,3,0,B60S1/166;;H02K5/04;;H02K7/116,B60S1/04,,0,0,,,,EXPIRED
299,CN,A,CN 103717511 A,133-291-681-398-662,2014-04-09,2014,CN 201180072814 A,2011-08-11,US 2011/0047440 W,2011-08-11,Lockable dispensing package and actuator,"[00104] An actuator (18, 18') is provided for actuating a valve (16) on a container (14) for dispensing a fluent product. The actuator (18, 18') includes an exterior housing (40, 40') and a rotatable member (42, 42'). The rotatable member (42, 42') is located in an interior chamber (48) of the housing (40, 40') and includes an engageable surface (54) located in a circumferentially extending window (50) of the housing (40, 40') to be engaged by a user for movement of the engageable surface (54) within the window (50) between a locked position wherein movement of an actuator button (52) from an un- actuated position to an actuated position is prevented and an unlocked position wherein movement of the actuator button (52) from the un-actuated position to the actuated position is allowed to actuate the valve (16).",APTARGROUP INC,CHO SEAN H;;WALTERS PETER J;;MARQUARDT GERALD J;;HALLMAN PAUL E,,https://lens.org/133-291-681-398-662,Patent Application,no,10,0,11,11,0,B65D83/206;;B65D83/22;;B65D83/22;;B65D83/206;;B65D83/206;;B65D83/22,B65D83/22,,0,0,,,,ACTIVE
300,DE,A1,DE 102014209232 A1,081-821-288-398-675,2015-01-22,2015,DE 102014209232 A,2014-05-15,CN 201320431604 U,2013-07-19,"Deckelkörper eines Scheibenwischermotors, Scheibenwischermotor, hinterer Schei-benwischer und Fahrzeug","Das Gebrauchsmuster betrifft einen Deckelkörper des Scheibenwischermotors, wobei der Deckelkörper einen Teildeckel und einen Getriebedeckel aufweist. Der Deckelkörper weist ferner mehrere am Getriebedeckel angeordnete Schweißstifte auf, wobei durch Schweißen der Enden der Schweißstifte der Teildeckel am Getriebedeckel befestigt wird, nachdem die Enden der Schweißstifte durch die am Teildeckel angeordneten Durchgangslöcher hin gehen. Das Gebrauchsmuster stellt ferner einen mit dem Deckelkörper versehenen Scheibenwischermotor, einen mit dem Scheibenwischermotor versehenen hinteren Scheibenwischer und ein mit dem hinteren Scheibenwischer ausgestattetes Fahrzeug zur Verfügung. Der Deckelkörper des Scheibenwischermotors des vorliegenden Gebrauchsmusters hat viele Vorteile, wie flexible Anordnung, stabile Verbindung, keiner Raumbedarf und gute Bedienbarkeit.",BOSCH AUTOMOTIVE PRODUCTS CHANGSHA CO,HOLZER THOMAS;;CHENG NAIRUI;;GEUBEL PAUL;;CHO WOOYEAN;;GUI YE;;XU KAIKAI,,https://lens.org/081-821-288-398-675,Patent Application,no,0,0,3,3,0,B60S1/166;;H02K5/04;;H02K7/116,H02K5/04;;B60S1/08;;H02K7/116,,0,0,,,,DISCONTINUED
301,EP,A4,EP 2707311 A4,188-037-083-003-482,2015-04-08,2015,EP 11870539 A,2011-08-11,US 2011/0047440 W,2011-08-11,LOCKABLE DISPENSING PACKAGE AND ACTUATOR,,APTARGROUP INC,CHO SEAN H;;WALTERS PETER J;;MARQUARDT GERALD J;;HALLMAN PAUL E,,https://lens.org/188-037-083-003-482,Search Report,no,4,0,11,11,0,B65D83/206;;B65D83/22;;B65D83/22;;B65D83/206;;B65D83/206;;B65D83/22,B65D83/22;;B65D83/20,,1,0,,,See also references of WO 2013022452A1,ACTIVE
302,EP,A1,EP 2707311 A1,067-889-517-596-813,2014-03-19,2014,EP 11870539 A,2011-08-11,US 2011/0047440 W,2011-08-11,LOCKABLE DISPENSING PACKAGE AND ACTUATOR,,APTARGROUP INC,CHO SEAN H;;WALTERS PETER J;;MARQUARDT GERALD J;;HALLMAN PAUL E,,https://lens.org/067-889-517-596-813,Patent Application,yes,0,0,11,11,0,B65D83/206;;B65D83/22;;B65D83/22;;B65D83/206;;B65D83/206;;B65D83/22,B65D83/22;;B65D83/20,,0,0,,,,ACTIVE
303,WO,A1,WO 2013/022452 A1,103-011-613-175-62X,2013-02-14,2013,US 2011/0047440 W,2011-08-11,US 2011/0047440 W,2011-08-11,LOCKABLE DISPENSING PACKAGE AND ACTUATOR,"[00104] An actuator (18, 18') is provided for actuating a valve (16) on a container (14) for dispensing a fluent product. The actuator (18, 18') includes an exterior housing (40, 40') and a rotatable member (42, 42'). The rotatable member (42, 42') is located in an interior chamber (48) of the housing (40, 40') and includes an engageable surface (54) located in a circumferentially extending window (50) of the housing (40, 40') to be engaged by a user for movement of the engageable surface (54) within the window (50) between a locked position wherein movement of an actuator button (52) from an un- actuated position to an actuated position is prevented and an unlocked position wherein movement of the actuator button (52) from the un-actuated position to the actuated position is allowed to actuate the valve (16).",APTARGROUP INC;;CHO SEAN H;;WALTERS PETER J;;MARQUARDT GERALD J;;HALLMAN PAUL E,CHO SEAN H;;WALTERS PETER J;;MARQUARDT GERALD J;;HALLMAN PAUL E,,https://lens.org/103-011-613-175-62X,Patent Application,yes,2,5,11,11,0,B65D83/206;;B65D83/22;;B65D83/206;;B65D83/22;;B65D83/206;;B65D83/22,B65D83/22,,0,0,,,,PENDING
304,BR,B1,BR 112014000900 B1,136-892-426-259-035,2020-06-02,2020,BR 112014000900 A,2011-08-11,US 2011/0047440 W,2011-08-11,acionador para acionar uma válvula em um recipiente para dispensar um produto fluente,"resumo patente de invenção: ""embalagem e acionador de dispensação traváveis"". a presente invenção refere-se a um acionador (18, 18') é fornecido para acionar uma válvula (16) em um recipiente (14) para dispensar um produto fluente. o acionador (18, 18') inclui um alojamento externo (40, 40') e um elemento girável (42, 42'). o elemento girável (42, 42') fica localizado dentro de uma câmara interna (48) do alojamento (40, 40') e inclui uma superfície encaixável (54) localizada em uma janela se estendendo circunferencialmente (50) do alojamento (40, 40') para ser encaixada por um usuário para movimento da superfície encaixável (54) dentro da janela (50) entre uma posição travada em que movimento de um botão acionador (52) de uma posição não acionada para uma posição acionada é impedido e uma posição destravada em que movimento do botão acionador (52) da posição não acionada para a posição acionada é permitido para acionar a válvula (16). 20247042v1",APTARGROUP INC,GERALD J MARQUARDT;;PAUL E HALLMAN;;PETER J WALTERS;;SEAN H CHO,,https://lens.org/136-892-426-259-035,Granted Patent,no,0,0,11,11,0,B65D83/206;;B65D83/22;;B65D83/22;;B65D83/206;;B65D83/206;;B65D83/22,B65D83/22;;B65D83/20,,0,0,,,,ACTIVE
305,CN,A,CN 107004844 A,149-155-695-223-390,2017-08-01,2017,CN 201580053380 A,2015-09-29,US 201462057129 P;;US 2015/0053033 W,2014-09-29,Pre-lithiated silicon anodes with pvdf binder,"A pre-lithiated silicon anode comprising a PVDF binder at 5-12 wt. % for use in a Li-ion cell is provided. In particular instances, a conductive additive may be added at less than 5 wt. %. The Si anode with PVDF binder is pre-lithiated prior to cell assembly and following Si anode fabrication. The combination of pre-lithiation and PVDF in the Si anode for use in a rechargeable Li-ion cell shows the unexpected result of extending the cycle life.",A123 SYSTEMS LLC,WANG JUN;;GIONET PAUL;;CHO HUNGOO;;PINNELL LESLIE J;;GRANT ROBERT W,,https://lens.org/149-155-695-223-390,Patent Application,no,3,4,13,13,0,H01M4/134;;H01M4/134;;H01M4/366;;H01M4/386;;H01M4/0404;;H01M4/043;;H01M4/0459;;H01M4/0459;;H01M4/133;;H01M4/134;;H01M4/1395;;H01M4/1395;;H01M4/364;;H01M4/364;;H01M4/366;;H01M4/366;;H01M4/386;;H01M4/386;;H01M4/386;;H01M4/587;;H01M4/587;;H01M4/587;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/625;;H01M4/625;;H01M4/625;;H01M4/661;;H01M4/661;;H01M10/052;;H01M10/052;;H01M10/0525;;H01M10/0525;;H01M10/0525;;H01M2004/027;;H01M2004/027;;Y02E60/10;;Y02E60/10;;Y02P70/50,H01M4/38;;H01M4/134;;H01M4/1395;;H01M4/62;;H01M10/0525,,0,0,,,,ACTIVE
306,AT,T1,AT E538878 T1,161-229-687-657-897,2012-01-15,2012,AT 06785489 T,2006-06-23,US 17689605 A;;US 26844505 A;;US 2006/0024586 W,2005-07-07,ABGABEVORRICHTUNG MIT SCHLOSS,,APTARGROUP INC,WALTERS PETER;;KSIAZK JASON;;CHO SEAN;;HALLMAN PAUL;;WERNER JONATHAN;;BRAUN CRAIG,,https://lens.org/161-229-687-657-897,Granted Patent,no,0,0,1,14,0,,,,0,0,,,,ACTIVE
307,US,B2,US 8379794 B2,036-682-146-034-789,2013-02-19,2013,US 58422709 A,2009-09-01,US 58422709 A;;US 19134808 P,2008-09-05,"Method to estimate position, motion and trajectory of a target with a single x-ray imager","The present invention provides a method for estimation of retrospective and real-time 3D target position by a single imager. The invention includes imaging a target on at least one 2D plane to determine 2D position and/or position components of the target, and resolving a position and/or position component along at least one imager axis of the target using a spatial probability density. The present invention provides a probability-based method for accurate estimation of the mean position, motion magnitude, motion correlation, and trajectory of a tumor from CBCT projections. The applicability of the method for tumors with periodic respiratory motion and for prostate are provided. Clinical feasibility is demonstrated for a pancreas tumor. The method includes monoscopic tracking of the 3D prostate position utilizing the spatial probability density to estimate the unresolved motion from the resolved motion. The method is applicable to prostate tracking even with a population-based probability density.",UNIV LELAND STANFORD JUNIOR;;POULSEN PER RUGAARD;;CHO BYUNGCHUL;;LANGEN KATJA;;KUPELIAN PATRICK;;KEALL PAUL J,POULSEN PER RUGAARD;;CHO BYUNGCHUL;;LANGEN KATJA;;KUPELIAN PATRICK;;KEALL PAUL J,BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY THE (2010-03-17),https://lens.org/036-682-146-034-789,Granted Patent,yes,8,9,2,2,0,A61B6/12;;A61B6/5288;;A61B6/541;;A61B8/08;;A61N5/1049;;A61N2005/1061;;G06T2207/30081;;G06T2207/30096;;G06T2207/30241;;A61B6/583;;G06T7/77;;G06T7/277;;A61N5/1049;;A61N2005/1061;;A61B6/12;;G06T2207/30081;;G06T2207/30096;;A61B6/541;;G06T2207/30241;;A61B6/5288;;A61B8/08;;A61B6/583;;G06T7/277;;G06T7/77,A61N5/10,378/65;;378/20;;378/62,0,0,,,,ACTIVE
308,US,A1,US 2020/0138298 A1,108-019-258-652-409,2020-05-07,2020,US 201816182650 A,2018-11-07,US 201816182650 A,2018-11-07,METHOD AND SYSTEM FOR ENHANCING RF ENERGY DELIVERY DURING THERMOACOUSTIC IMAGING,"A method and system for enhancing radio frequency energy delivery to a tissue region of interest. The method and system direct with a radio frequency (RF) applicator, one or more RF energy pulses into the tissue region of interest, the tissue region of interest comprising an object of interest and at least one reference that are separated by at least one boundary; detect with an acoustic receiver, at least one bipolar acoustic signal generated in the tissue region of interest in response to the RF energy pulses and processing the at least one bipolar acoustic signal to determine a peak-to-peak amplitude thereof; adjust the RF applicator to maximize the peak-to-peak amplitude of bipolar acoustic signals generated in the tissue region of interest in response to RF energy pulses generated by the adjusted RF applicator; and direct with the adjusted RF applicator, one or more RF energy pulses into the region of interest.",ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/108-019-258-652-409,Patent Application,yes,0,4,6,6,0,A61B5/0093;;A61B5/201;;A61B5/4244;;A61B5/4872;;A61B5/0093;;A61B5/4872;;A61B5/4244;;A61B5/201;;A61B5/02007,A61B5/00;;A61B5/02;;A61B5/20,,0,0,,,,ACTIVE
309,CA,C,CA 2168518 C,160-327-692-059-034,2008-11-18,2008,CA 2168518 A,1996-01-31,US 39397795 A,1995-02-24,COSMETIC COMPOSITIONS FOR REDUCING OR PREVENTING SIGNS OF CELLULITE,"The invention is directed to increasing the strength and firmness of the ski n and reducing the signs of cellulite. The inventive method includes applying to t he skin a composition that includes inositol phosphate, particularly phytic acid and i ts salts, in a cosmetically acceptable carrier.",UNILEVER PLC,ZNAIDEN ALEXANDER PAUL;;CHENEY MICHAEL CHARLES;;SLAVTCHEFF CRAIG STEVEN;;CHO SUK HYUNG,,https://lens.org/160-327-692-059-034,Granted Patent,no,0,0,12,12,0,A61K8/55;;A61Q19/06;;A61Q19/06;;A61K8/55,A61K8/55;;A61K8/00;;A61K8/36;;A61K8/365;;A61K8/49;;A61K8/58;;A61K8/65;;A61Q19/06,,0,0,,,,EXPIRED
310,US,A1,US 2014/0124539 A1,034-488-470-342-917,2014-05-08,2014,US 201114123293 A,2011-08-11,US 2011/0047440 W,2011-08-11,LOCKABLE DISPENSING PACKAGE AND ACTUATOR,"An actuator ( 18, 18 ′) is provided for actuating a valve ( 16 ) on a container ( 14 ) for dispensing a fluent product. The actuator ( 18, 18 ′) includes an exterior housing ( 40, 40 ′) and a rotatable member ( 42, 42 ′). The rotatable member ( 42, 42 ′) is located in an interior chamber ( 48 ) of the housing ( 40, 40 ′) and includes an engageable surface ( 54 ) located in a circumferentially extending window ( 50 ) of the housing ( 40, 40 ′) to be engaged by a user for movement of the engageable surface ( 54 ) within the window ( 50 ) between a locked position wherein movement of an actuator button ( 52 ) from an un-actuated position to an actuated position is prevented and an unlocked position wherein movement of the actuator button ( 52 ) from the un-actuated position to the actuated position is allowed to actuate the valve ( 16 ).",CHO SEAN H;;WALTERS PETER J;;MARQUARDT GERALD J;;HALLMAN PAUL E;;APTARGROUP INC,CHO SEAN H;;WALTERS PETER J;;MARQUARDT GERALD J;;HALLMAN PAUL E,APTARGROUP INC (2011-08-11),https://lens.org/034-488-470-342-917,Patent Application,yes,10,2,11,11,0,B65D83/206;;B65D83/22;;B65D83/22;;B65D83/206;;B65D83/206;;B65D83/22,B67B1/00;;B65D83/00,222/153.11;;222/402.13;;222/402.11,0,0,,,,ACTIVE
311,EP,A4,EP 3201982 A4,071-075-367-346-350,2018-03-21,2018,EP 15848040 A,2015-09-29,US 201462057129 P;;US 2015/0053033 W,2014-09-29,PRE-LITHIATED SILICON ANODES WITH PVDF BINDER,,A123 SYSTEMS LLC,WANG JUN;;GIONET PAUL;;CHO HUNGOO;;PINNELL LESLIE J;;GRANT ROBERT W,,https://lens.org/071-075-367-346-350,Search Report,no,3,0,13,13,0,H01M4/134;;H01M4/134;;H01M4/366;;H01M4/386;;H01M4/0404;;H01M4/043;;H01M4/0459;;H01M4/0459;;H01M4/133;;H01M4/134;;H01M4/1395;;H01M4/1395;;H01M4/364;;H01M4/364;;H01M4/366;;H01M4/366;;H01M4/386;;H01M4/386;;H01M4/386;;H01M4/587;;H01M4/587;;H01M4/587;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/625;;H01M4/625;;H01M4/625;;H01M4/661;;H01M4/661;;H01M10/052;;H01M10/052;;H01M10/0525;;H01M10/0525;;H01M10/0525;;H01M2004/027;;H01M2004/027;;Y02E60/10;;Y02E60/10;;Y02P70/50,H01M10/0525;;H01M4/02;;H01M4/04;;H01M4/133;;H01M4/134;;H01M4/36;;H01M4/38;;H01M4/587;;H01M4/62;;H01M4/66;;H01M10/052;;H01M10/058,,1,0,,,See also references of WO 2016054105A1,ACTIVE
312,US,A1,US 2020/0259164 A1,128-510-900-177-285,2020-08-13,2020,US 202016858487 A,2020-04-24,US 202016858487 A;;US 201715515573 A;;US 2015/0053033 W;;US 201462057129 P,2014-09-29,PRE-LITHIATED SILICON ANODES WITH PVDF BINDER,"A pre-lithiated silicon anode comprising a PVDF binder at 5-12 wt. % for use in a Li-ion cell is provided. In particular instances, a conductive additive may be added at less than 5 wt. %. The Si anode with PVDF binder is pre-lithiated prior to cell assembly and following Si anode fabrication. The combination of pre-lithiation and PVDF in the Si anode for use in a rechargeable Li-ion cell shows the unexpected result of extending the cycle life.",A123 SYSTEMS LLC,WANG JUN;;GIONET PAUL;;CHO HUNGOO;;PINNELL LESLIE J;;GRANT ROBERT W,,https://lens.org/128-510-900-177-285,Patent Application,yes,0,1,13,13,0,H01M4/134;;H01M4/134;;H01M4/366;;H01M4/386;;H01M4/0404;;H01M4/043;;H01M4/0459;;H01M4/0459;;H01M4/133;;H01M4/134;;H01M4/1395;;H01M4/1395;;H01M4/364;;H01M4/364;;H01M4/366;;H01M4/366;;H01M4/386;;H01M4/386;;H01M4/386;;H01M4/587;;H01M4/587;;H01M4/587;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/625;;H01M4/625;;H01M4/625;;H01M4/661;;H01M4/661;;H01M10/052;;H01M10/052;;H01M10/0525;;H01M10/0525;;H01M10/0525;;H01M2004/027;;H01M2004/027;;Y02E60/10;;Y02E60/10;;Y02P70/50,H01M4/134;;H01M4/04;;H01M4/133;;H01M4/36;;H01M4/38;;H01M4/587;;H01M4/62;;H01M4/66;;H01M10/052;;H01M10/0525,,0,0,,,,DISCONTINUED
313,US,A1,US 2010/0172469 A1,174-254-280-968-93X,2010-07-08,2010,US 58422709 A,2009-09-01,US 58422709 A;;US 19134808 P,2008-09-05,"Method to estimate position, motion and trajectory of a target with a single x-ray imager","The present invention provides a method for estimation of retrospective and real-time 3D target position by a single imager. The invention includes imaging a target on at least one 2D plane to determine 2D position and/or position components of the target, and resolving a position and/or position component along at least one imager axis of the target using a spatial probability density. The present invention provides a probability-based method for accurate estimation of the mean position, motion magnitude, motion correlation, and trajectory of a tumor from CBCT projections. The applicability of the method for tumors with periodic respiratory motion and for prostate are provided. Clinical feasibility is demonstrated for a pancreas tumor. The method includes monoscopic tracking of the 3D prostate position utilizing the spatial probability density to estimate the unresolved motion from the resolved motion. The method is applicable to prostate tracking even with a population-based probability density.",POULSEN PER RUGAARD;;CHO BYUNGCHUL;;LANGEN KATJA;;KUPELIAN PATRICK;;KEALL PAUL J,POULSEN PER RUGAARD;;CHO BYUNGCHUL;;LANGEN KATJA;;KUPELIAN PATRICK;;KEALL PAUL J,BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY THE (2010-03-17),https://lens.org/174-254-280-968-93X,Patent Application,yes,7,27,2,2,0,A61B6/12;;A61B6/5288;;A61B6/541;;A61B8/08;;A61N5/1049;;A61N2005/1061;;G06T2207/30081;;G06T2207/30096;;G06T2207/30241;;A61B6/583;;G06T7/77;;G06T7/277;;A61N5/1049;;A61N2005/1061;;A61B6/12;;G06T2207/30081;;G06T2207/30096;;A61B6/541;;G06T2207/30241;;A61B6/5288;;A61B8/08;;A61B6/583;;G06T7/277;;G06T7/77,A61N5/10;;A61B6/12,378/20;;378/65,0,0,,,,ACTIVE
314,CA,A1,CA 2168518 A1,066-152-574-192-329,1996-08-25,1996,CA 2168518 A,1996-01-31,US 39397795 A,1995-02-24,COSMETIC COMPOSITIONS FOR REDUCING OR PREVENTING SIGNS OF CELLULITE,"The invention is directed to increasing the strength and firmness of the skin and reducing the signs of cellulite. The inventive method includes applying to the skin a composition that includes inositol phosphate, particularly phytic acid and its salts, in a cosmetically acceptable carrier.",UNILEVER PLC,ZNAIDEN ALEXANDER PAUL;;CHENEY MICHAEL CHARLES;;SLAVTCHEFF CRAIG STEVEN;;CHO SUK HYUNG,,https://lens.org/066-152-574-192-329,Patent Application,no,0,0,12,12,0,A61K8/55;;A61Q19/06;;A61Q19/06;;A61K8/55,A61K8/00;;A61K8/36;;A61K8/365;;A61K8/49;;A61K8/55;;A61K8/58;;A61K8/65;;A61Q19/06,,0,0,,,,EXPIRED
315,WO,A1,WO 2020/097351 A1,130-554-144-737-502,2020-05-14,2020,US 2019/0060293 W,2019-11-07,US 201816182650 A,2018-11-07,METHOD AND SYSTEM FOR ENHANCING RF ENERGY DELIVERY DURING THERMOACOUSTIC IMAGING,"A method and system for enhancing radio frequency energy delivery to a tissue region of interest. The method and system direct with a radio frequency (RF) applicator, one or more RF energy pulses into the tissue region of interest, the tissue region of interest comprising an object of interest and at least one reference that are separated by at least one boundary; detect with an acoustic receiver, at least one bipolar acoustic signal generated in the tissue region of interest in response to the RF energy pulses and processing the at least one bipolar acoustic signal to determine a peak-to-peak amplitude thereof; adjust the RF applicator to maximize the peak-to-peak amplitude of bipolar acoustic signals generated in the tissue region of interest in response to RF energy pulses generated by the adjusted RF applicator; and direct with the adjusted RF applicator, one or more RF energy pulses into the region of interest.",ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/130-554-144-737-502,Patent Application,yes,12,0,6,6,0,A61B5/0093;;A61B5/201;;A61B5/4244;;A61B5/4872;;A61B5/0093;;A61B5/4872;;A61B5/4244;;A61B5/201;;A61B5/02007,A61B8/08;;A61B5/00,,1,0,,,See also references of EP 3893759A4,PENDING
316,AR,A1,AR 084746 A1,146-927-543-428-854,2013-06-05,2013,AR P110105023 A,2011-12-29,US 2011/0047440 W,2011-08-11,ENVASE DISPENSADOR Y ACTUADOR BLOQUEABLES,"Actuador (18, 18’) para accionar una válvula (16) en un recipiente (14) a fin de dispensar un producto fluyente. El actuador (18, 18’) incluye un alojamiento exterior (40, 40’) y un miembro giratorio (42, 42’) está situado en una cámara interior (48) del alojamiento (40, 40’) e incluye una superficie acoplable (54) situada en una ventana extendida en circunferencia (50) en el alojamiento (40, 40’) para ser acoplada por un usuario a fin de efectuar el movimiento de la superficie acoplable (54) dentro de la ventana (50) entre una posición bloqueada, donde se impide el movimiento de un botón actuador (52) de una posición no accionada a una posición accionada, y una posición desbloqueada donde se admite el movimiento del botón de actuador (52) de la posición no accionada a la posición accionada a fin de accionar la válvula (16).",APTARGROUP INC,MARQUARDT GERALD J;;HALLMAN PAUL E;;CHO SEAN H;;WALTERS PETER J,,https://lens.org/146-927-543-428-854,Patent Application,no,0,0,11,11,0,B65D83/206;;B65D83/22;;B65D83/22;;B65D83/206;;B65D83/206;;B65D83/22,B65D83/14,,0,0,,,,ACTIVE
317,WO,A1,WO 2016/054105 A1,102-492-908-363-883,2016-04-07,2016,US 2015/0053033 W,2015-09-29,US 201462057129 P,2014-09-29,PRE-LITHIATED SILICON ANODES WITH PVDF BINDER,"A pre-lithiated silicon anode comprising a PVDF binder at 5-12 wt. % for use in a Li-ion cell is provided. In particular instances, a conductive additive may be added at less than 5 wt. %. The Si anode with PVDF binder is pre-lithiated prior to cell assembly and following Si anode fabrication. The combination of pre-lithiation and PVDF in the Si anode for use in a rechargeable Li-ion cell shows the unexpected result of extending the cycle life.",A123 SYSTEMS LLC,WANG JUN;;GIONET PAUL;;CHO HUNGOO;;PINNELL LESLIE J;;GRANT ROBERT W,,https://lens.org/102-492-908-363-883,Patent Application,yes,11,4,13,13,0,H01M4/134;;H01M4/134;;H01M4/366;;H01M4/386;;H01M4/0404;;H01M4/043;;H01M4/0459;;H01M4/0459;;H01M4/133;;H01M4/134;;H01M4/1395;;H01M4/1395;;H01M4/364;;H01M4/364;;H01M4/366;;H01M4/366;;H01M4/386;;H01M4/386;;H01M4/386;;H01M4/587;;H01M4/587;;H01M4/587;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/625;;H01M4/625;;H01M4/625;;H01M4/661;;H01M4/661;;H01M10/052;;H01M10/052;;H01M10/0525;;H01M10/0525;;H01M10/0525;;H01M2004/027;;H01M2004/027;;Y02E60/10;;Y02E60/10;;Y02P70/50,H01M10/0525;;H01M4/134;;H01M4/38;;H01M4/62;;H01M10/058,,2,0,,,"See also references of EP 3201982A4;;HOCHGATTERER ET AL., ELECTROCHEMICAL AND SOLID-STATE LETTERS, vol. 11, no. 5, 2008, pages A76 - A80",PENDING
318,EP,B1,EP 3201982 B1,102-841-618-372-709,2020-05-27,2020,EP 15848040 A,2015-09-29,US 201462057129 P;;US 2015/0053033 W,2014-09-29,PRE-LITHIATED SILICON ANODES WITH PVDF BINDER,,A123 SYSTEMS LLC,WANG JUN;;GIONET PAUL;;CHO HUNGOO;;PINNELL LESLIE J;;GRANT ROBERT W,,https://lens.org/102-841-618-372-709,Granted Patent,yes,1,0,13,13,0,H01M4/134;;H01M4/134;;H01M4/366;;H01M4/386;;H01M4/0404;;H01M4/043;;H01M4/0459;;H01M4/0459;;H01M4/133;;H01M4/134;;H01M4/1395;;H01M4/1395;;H01M4/364;;H01M4/364;;H01M4/366;;H01M4/366;;H01M4/386;;H01M4/386;;H01M4/386;;H01M4/587;;H01M4/587;;H01M4/587;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/625;;H01M4/625;;H01M4/625;;H01M4/661;;H01M4/661;;H01M10/052;;H01M10/052;;H01M10/0525;;H01M10/0525;;H01M10/0525;;H01M2004/027;;H01M2004/027;;Y02E60/10;;Y02E60/10;;Y02P70/50,H01M10/0525;;H01M4/02;;H01M4/04;;H01M4/133;;H01M4/134;;H01M4/36;;H01M4/38;;H01M4/587;;H01M4/62;;H01M4/66;;H01M10/052;;H01M10/058,,0,0,,,,ACTIVE
319,KR,A,KR 20170061677 A,190-057-814-407-350,2017-06-05,2017,KR 20177008344 A,2015-09-29,US 201462057129 P;;US 2015/0053033 W,2014-09-29,PVDF - PRE-LITHIATED SILICON ANODES WITH PVDF BINDER,"Li 이온 전지에 사용하기 위한 5-12 중량%의 PVDF 바인더를 포함하는 사전-리튬화된 실리콘 애노드가 제공된다. 특별한 경우에, 전도성 첨가제는 5 중량% 미만으로 첨가될 수 있다. PVDF 바인더를 가지는 Si 애노드는 셀 조립 이전에 사전-리튬화 되고, 이어서 Si 애노드를 제조한다. 재충전가능한 Li-이온 셀에 사용하기 위한 Si 애노드에서의 사전-리튬화 및 PVDF의 조합은 사이클 수명을 연장시키는 예기치 않은 결과를 보여준다.",A123 SYSTEMS LLC,WANG JUN;;GIONET PAUL;;CHO HUNGOO;;PINNELL LESLIE J;;GRANT ROBERT W,,https://lens.org/190-057-814-407-350,Patent Application,no,0,2,13,13,0,H01M4/134;;H01M4/134;;H01M4/366;;H01M4/386;;H01M4/0404;;H01M4/043;;H01M4/0459;;H01M4/0459;;H01M4/133;;H01M4/134;;H01M4/1395;;H01M4/1395;;H01M4/364;;H01M4/364;;H01M4/366;;H01M4/366;;H01M4/386;;H01M4/386;;H01M4/386;;H01M4/587;;H01M4/587;;H01M4/587;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/625;;H01M4/625;;H01M4/625;;H01M4/661;;H01M4/661;;H01M10/052;;H01M10/052;;H01M10/0525;;H01M10/0525;;H01M10/0525;;H01M2004/027;;H01M2004/027;;Y02E60/10;;Y02E60/10;;Y02P70/50,H01M4/134;;H01M4/04;;H01M4/1395;;H01M4/36;;H01M4/38;;H01M4/587;;H01M4/62;;H01M10/0525,,0,0,,,,PENDING
320,US,B2,US 9216852 B2,033-932-763-084-239,2015-12-22,2015,US 201114123293 A,2011-08-11,US 2011/0047440 W,2011-08-11,Lockable dispensing package and actuator,"An actuator ( 18, 18 ′) is provided for actuating a valve ( 16 ) on a container ( 14 ) for dispensing a fluent product. The actuator ( 18, 18 ′) includes an exterior housing ( 40, 40 ′) and a rotatable member ( 42, 42 ′). The rotatable member ( 42, 42 ′) is located in an interior chamber ( 48 ) of the housing ( 40, 40 ′) and includes an engageable surface ( 54 ) located in a circumferentially extending window ( 50 ) of the housing ( 40, 40 ′) to be engaged by a user for movement of the engageable surface ( 54 ) within the window ( 50 ) between a locked position wherein movement of an actuator button ( 52 ) from an un-actuated position to an actuated position is prevented and an unlocked position wherein movement of the actuator button ( 52 ) from the un-actuated position to the actuated position is allowed to actuate the valve ( 16 ).",CHO SEAN H;;WALTERS PETER J;;MARQUARDT GERALD J;;HALLMAN PAUL E;;APTARGROUP INC,CHO SEAN H;;WALTERS PETER J;;MARQUARDT GERALD J;;HALLMAN PAUL E,APTARGROUP INC (2011-08-11),https://lens.org/033-932-763-084-239,Granted Patent,yes,38,4,11,11,0,B65D83/206;;B65D83/22;;B65D83/22;;B65D83/206;;B65D83/206;;B65D83/22,B67B1/00;;B65D83/20;;B65D83/22,,1,0,,,"International Search Report and Written Opinion of the International Searching Authority, or the Declaration dated ""Jan. 13, 2012"" for the International Application No. PCT/US2011/047440 of which the above-captioned instant U.S. patent Application is a U.S. national phase application.",ACTIVE
321,EP,A1,EP 3201982 A1,032-176-098-476-736,2017-08-09,2017,EP 15848040 A,2015-09-29,US 201462057129 P;;US 2015/0053033 W,2014-09-29,PRE-LITHIATED SILICON ANODES WITH PVDF BINDER,,A123 SYSTEMS LLC,WANG JUN;;GIONET PAUL;;CHO HUNGOO;;PINNELL LESLIE J;;GRANT ROBERT W,,https://lens.org/032-176-098-476-736,Patent Application,yes,0,0,13,13,0,H01M4/134;;H01M4/134;;H01M4/366;;H01M4/386;;H01M4/0404;;H01M4/043;;H01M4/0459;;H01M4/0459;;H01M4/133;;H01M4/134;;H01M4/1395;;H01M4/1395;;H01M4/364;;H01M4/364;;H01M4/366;;H01M4/366;;H01M4/386;;H01M4/386;;H01M4/386;;H01M4/587;;H01M4/587;;H01M4/587;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/623;;H01M4/625;;H01M4/625;;H01M4/625;;H01M4/661;;H01M4/661;;H01M10/052;;H01M10/052;;H01M10/0525;;H01M10/0525;;H01M10/0525;;H01M2004/027;;H01M2004/027;;Y02E60/10;;Y02E60/10;;Y02P70/50,H01M10/0525;;H01M4/134;;H01M4/38;;H01M4/62;;H01M10/058,,0,0,,,,ACTIVE
322,ZA,B,ZA 96737 B,133-489-330-673-929,1997-07-31,1997,ZA 96737 A,1996-01-31,US 39397795 A,1995-02-24,Cosmetic compositions for reducing or preventing signs of cullulite,,UNILEVER PLC,CHENEY MICHAEL CHARLES;;ZNAIDEN ALEXANDER PAUL;;CHO SUK HYUNG;;SLAVTCHEFF CRAIG STEVEN,,https://lens.org/133-489-330-673-929,Granted Patent,no,0,0,12,12,0,A61K8/55;;A61Q19/06;;A61Q19/06;;A61K8/55,A61K8/00;;A61K8/36;;A61K8/365;;A61K8/49;;A61K8/55;;A61K8/58;;A61K8/65;;A61Q19/06,,0,0,,,,EXPIRED
323,EP,B1,EP 3084872 B1,018-942-235-986-939,2019-02-20,2019,EP 14870855 A,2014-12-18,US 201361918014 P;;US 201361918859 P;;US 2014/0071214 W,2013-12-19,HYDROGEN/BROMINE FLOW BATTERY IN WHICH HYDROGEN IS FREELY EXCHANGED BETWEEN TWO CELL COMPARTMENTS,,BOSCH GMBH ROBERT;;UNIV CALIFORNIA,ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/018-942-235-986-939,Granted Patent,yes,7,0,6,6,0,H01M8/184;;H01M8/04208;;Y02E60/50;;H01M8/184;;H01M8/04208;;Y02B90/10;;Y02E60/50;;H01M8/04201;;H01M8/188;;H01M8/20;;H01M8/22;;H01M2250/10,H01M8/18,,0,0,,,,ACTIVE
324,IN,A,IN 1441DE2014 A,032-823-823-122-374,2015-06-19,2015,IN 1441DE2014 A,2014-05-30,CN 201320431604 U,2013-07-19,"COVER BODY OF WIPER MOTOR, WIPER MOTOR, REAR WIPER AND AUTOMOBILE","The utility model relates to a cover body of wiper motor, wherein the cover body has a sub cover body and a gear cover. The cover body further comprises a plurality of welding pins provided on the gear cover, and the sub cover body is fixed onto the gear cover by fusion welding ends of the welding pins after passing the ends through the through holes disposed in the sub cover body. The utility model further provides a wiper motor provided with the cover body, a rear wiper arranged with the wiper motor as well as an automobile equipped with the rear wiper. The cover body of wiper motor according to utility model has many advantages such as flexible arrangement, stable connection, low manufacture cost and low process cost, etc.",BOSCH AUTOMOTIVE PROD CHANGSHA,HOLZER THOMAS;;CHENG NAIRUI;;GEUBEL PAUL;;CHO WOOYEAN;;GUI Y E;;XU KAIKAI,,https://lens.org/032-823-823-122-374,Patent Application,no,0,0,3,3,0,B60S1/166;;H02K5/04;;H02K7/116,H02K5/22,,0,0,,,,PENDING
325,WO,A1,WO 2018/064604 A1,171-205-736-116-189,2018-04-05,2018,US 2017/0054558 W,2017-09-29,US 201662402238 P;;US 201662410919 P;;US 201662410922 P;;US 201662414302 P;;US 201662419202 P;;US 201662419247 P,2016-09-30,"PHOSPHORUS-CONTAINING SOLID CATALYSTS AND REACTIONS CATALYZED THEREBY, INCLUDING SYNTHESIS OF P-XYLENE","Methods and phosphorus-containing solid catalysts for catalyzing dehydration of cyclic ethers (e.g., furans, such as 2,5-dimethylfuran) and alcohols (e.g., ethanol and isopropanol). The alcohols and cyclic ethers may be derived from biomass. One example includes a tandem Diels-Alder cycloaddition and dehydration of biomass-derived 2,5-dimethyl-furan and ethylene to renewable p-xylene. The phosphorus-containing solid catalysts are also active and selective for dehydration of alcohols to alkenes.",CHO HONG JE;;FAN WEI;;TSAPATSIS MICHAEL;;DAUENHAUER PAUL;;REN LIMIN;;LOBO RAUL,CHO HONG JE;;FAN WEI;;TSAPATSIS MICHAEL;;DAUENHAUER PAUL;;REN LIMIN;;LOBO RAUL,,https://lens.org/171-205-736-116-189,Patent Application,yes,3,4,6,6,0,B01J37/28;;B01J29/40;;B01J29/7007;;B01J29/82;;B01J29/85;;B01J2229/16;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;Y02P20/582;;Y02P20/52;;B01J29/40;;B01J29/7007;;B01J29/85;;B01J37/28;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;C07C51/42;;C07C2521/04;;C07C2521/06;;C07C2521/08;;C07C2521/10;;C07C2521/12;;C07C2521/18;;C07C2523/10;;C07C2523/20;;C07C2527/167;;C07C2527/18;;C07C2527/188;;C07C2529/08;;B01J37/0201;;C07C2529/85;;C07C2529/82;;B01J2229/186;;B01J2229/18;;B01J2229/183;;B01J35/67;;B01J35/69,B01J37/00;;B01J29/40;;B01J29/85,,0,0,,,,PENDING
326,US,A1,US 2016/0079180 A1,048-168-444-776-784,2016-03-17,2016,US 201514948476 A,2015-11-23,US 201514948476 A;;US 201414243491 A,2014-04-02,OVERLAY MARK DEPENDENT DUMMY FILL TO MITIGATE GATE HEIGHT VARIATION,A method of forming dummy structures and an overlay mark protection zone over an active layer zone based on the shape of an overlay mark and the resulting device are provided. Embodiments include determining a size and a shape of an overlay mark; determining a size and a shape of an overlay mark protection zone based on the shape of the overlay mark; determining a shape of a plurality of dummy structures based on the shape of the overlay mark; determining a size and a shape of an active layer zone based on the size and the shape of the overlay mark and the plurality of dummy structures; forming the active layer zone in an active layer of a semiconductor substrate; forming the overlay mark and the plurality of dummy structures over the active layer zone in a poly layer of the semiconductor substrate; and planarizing the poly layer.,GLOBALFOUNDRIES INC,NING GUOXIANG;;CHO CHAN SEOB;;ACKMANN PAUL;;HSIEH JUNG YU;;KOH HUI PENG,GLOBALFOUNDRIES INC (2014-03-11),https://lens.org/048-168-444-776-784,Patent Application,yes,0,0,4,4,0,G03F7/70633;;G03F7/70683;;H01L2924/0002;;H01L21/3212;;H01L22/12;;H01L27/088;;H01L22/12;;H01L27/088;;G03F7/70633;;G03F7/70683;;H01L2924/0002;;H01L21/3212;;H01L23/544;;H01L29/4916;;H01L2223/54426,H01L23/544;;H01L29/49,,0,0,,,,INACTIVE
327,JP,A,JP 2017055017 A,060-730-822-720-228,2017-03-16,2017,JP 2015179190 A,2015-09-11,JP 2015179190 A,2015-09-11,INVERTED METAMORPHIC MULTI-JUNCTION SOLAR CELL WITH MULTIPLE METAMORPHIC LAYERS,PROBLEM TO BE SOLVED: To provide an advanced solar cell structure.SOLUTION: A multi-junction solar cell has a multi-junction solar cell structure comprising: first solar sub cells (cell A); second solar sub cells (cell B) adjacent to an upper first solar sub cell; a first composition tilted intermediate layer (116) adjacent to the second solar sub cells; and third solar sub cells (cell C) adjacent to the first composition tilted intermediate layer. The third solar sub cells is lattice mismatching to the second solar sub cells. The first composition tilted intermediate layer includes a composition tilted intermediate layer so as to achieve smooth transition of a lattice constant from the second sub cells to the third sub cells in a semiconductor structure.SELECTED DRAWING: Figure 1H,SOLAERO TECH CORP,YONG LIN;;SHARPS PAUL;;CORNFELD ARTHUR;;PRAVIN PATEL;;STAN MARK A;;BENJAMIN CHO,,https://lens.org/060-730-822-720-228,Patent Application,no,6,2,2,2,0,Y02E10/544;;Y02P70/50,H01L31/0725;;H01L31/0735,,0,0,,,,ACTIVE
328,EP,B1,EP 2996162 B1,094-439-171-841-156,2017-12-13,2017,EP 15183022 A,2015-08-28,US 201414485121 A,2014-09-12,INVERTED METAMORPHIC MULTIJUNCTION SOLAR CELL WITH MULTIPLE METAMORPHIC LAYERS,,SOLAERO TECH CORP,LIN YONG;;SHARPS PAUL;;CORNFELD ARTHUR;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN,,https://lens.org/094-439-171-841-156,Granted Patent,yes,1,0,5,111,0,H01L31/03046;;H01L31/06875;;H01L31/1844;;H01L31/1892;;Y02E10/544;;H01L31/078;;Y02P70/50;;H01L31/1844;;H01L31/06875;;H01L31/03046;;H01L31/1892;;Y02E10/544;;H01L31/078;;Y02P70/50;;H01L31/0725;;H01L31/0735,H01L31/0687;;H01L31/0304;;H01L31/078;;H01L31/18,,3,0,,,"KING R R ET AL: ""Solar Cell Generations over 40% Efficiency"", 26TH EUROPEAN INTERNATIONAL CONFERENCE ON PHOTOVOLTAIC SOLAR ENERGY 5-9 SEPT. 2011 HAMBURG, GERMANY,, 7 May 2012 (2012-05-07), pages 1-15, XP007920588, DOI: 10.4229/26THEUPVSEC2011-1AP.1.2 ISBN: 3-936338-27-2;;SCHULTZ J C ET AL: ""High efficiency 1.0 eV GaInAs bottom solar cell for 3-junction monolithic stack"", PROCEEDINGS OF THE PHOTOVOLTAIC SPECIALISTS CONFERENCE 1990 AND CONFERENCE RECORD OF THE TWENTY FIRST IEEE, 21 May 1990 (1990-05-21), pages 148-152, XP010003168,;;C.R. LEWIS ET AL: ""The crystallographic connection of MOCVD-grown monolithic cascade subcells via transparent graded layers"", JOURNAL OF CRYSTAL GROWTH, vol. 69, no. 2-3, November 1984 (1984-11), pages 515-526, XP055115927, ISSN: 0022-0248, DOI: 10.1016/0022-0248(84)90363-4",ACTIVE
329,WO,A1,WO 2015/095555 A1,138-250-051-731-45X,2015-06-25,2015,US 2014/0071214 W,2014-12-18,US 201361918859 P;;US 201361918014 P,2013-12-19,HYDROGEN/BROMINE FLOW BATTERY IN WHICH HYDROGEN IS FREELY EXCHANGED BETWEEN TWO CELI COMPARTMENTS,"A flow battery system includes a first tank including a hydrogen reactant, a second tank including a bromine electrolyte, and at least one cell including a first electrolyte side operably connected to the first tank and a second electrolyte side operably connected to the second tank. The battery system further includes a direct connection line directly connecting the first tank and the second tank and configured such that the hydrogen reactant passes between the first tank and the second tank.",BOSCH GMBH ROBERT;;ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z;;UNIV CALIFORNIA,ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/138-250-051-731-45X,Patent Application,yes,7,2,6,6,0,H01M8/184;;H01M8/04208;;Y02E60/50;;H01M8/184;;H01M8/04208;;Y02B90/10;;Y02E60/50;;H01M8/04201;;H01M8/188;;H01M8/20;;H01M8/22;;H01M2250/10,H01M8/18;;H01M8/02,,1,0,,,See also references of EP 3084872A4,PENDING
330,EP,B1,EP 3095152 B1,009-543-851-418-009,2018-09-26,2018,EP 14873586 A,2014-12-22,US 201361919926 P;;US 2014/0071835 W,2013-12-23,"SYSTEM AND METHOD FOR RETURNING MATERIAL FROM THE BR2 , SIDE OF AN H2/BR2 FLOW BATTERY BACK AFTER CROSSOVER",,BOSCH GMBH ROBERT;;UNIV CALIFORNIA,KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/009-543-851-418-009,Granted Patent,yes,6,0,6,6,0,H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/20;;H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/04007;;H01M8/04097;;H01M8/04216;;H01M8/04283,H01M8/18;;H01M8/20,,0,0,,,,ACTIVE
331,US,B2,US 9252061 B2,086-259-336-206-372,2016-02-02,2016,US 201414243491 A,2014-04-02,US 201414243491 A,2014-04-02,Overlay mark dependent dummy fill to mitigate gate height variation,A method of forming dummy structures and an overlay mark protection zone over an active layer zone based on the shape of an overlay mark and the resulting device are provided. Embodiments include determining a size and a shape of an overlay mark; determining a size and a shape of an overlay mark protection zone based on the shape of the overlay mark; determining a shape of a plurality of dummy structures based on the shape of the overlay mark; determining a size and a shape of an active layer zone based on the size and the shape of the overlay mark and the plurality of dummy structures; forming the active layer zone in an active layer of a semiconductor substrate; forming the overlay mark and the plurality of dummy structures over the active layer zone in a poly layer of the semiconductor substrate; and planarizing the poly layer.,GLOBALFOUNDRIES INC,NING GUOXIANG;;CHO CHAN SEOB;;ACKMANN PAUL;;HSIEH JUNG YU;;KOH HUI PENG,GLOBALFOUNDRIES INC (2014-03-11),https://lens.org/086-259-336-206-372,Granted Patent,yes,2,0,4,4,0,G03F7/70633;;G03F7/70683;;H01L2924/0002;;H01L21/3212;;H01L22/12;;H01L27/088;;H01L22/12;;H01L27/088;;G03F7/70633;;G03F7/70683;;H01L2924/0002;;H01L21/3212;;H01L23/544;;H01L29/4916;;H01L2223/54426,H01L23/544;;H01L21/306;;H01L21/66;;H01L27/088,,0,0,,,,INACTIVE
332,US,A1,US 2016/0322653 A1,080-768-742-605-026,2016-11-03,2016,US 201415105874 A,2014-12-22,US 201415105874 A;;US 201361919926 P;;US 2014/0071835 W,2013-12-23,System and Method for Returning Material from the BR2 Side of an H2/BR2 Flow Battery Back after Crossover,"A flow battery system includes a first tank having a hydrogen reactant, a second tank having a bromine electrolyte, at least one cell including a hydrogen reactant side operably connected to the first tank through an ¾ feed and return system and a bromine electrolyte side operably connected to the second tank, and a crossover return system. The crossover return system includes a vessel operably connected to the ¾ feed and return system and configured to receive an effluent containing a first portion of the hydrogen reactant and a second portion of the bromine electrolyte, the vessel configured to separate the first portion from the second portion. A first return line returns the first portion of the hydrogen reactant to the first tank and a second return line returns the bromine electrolyte to the second tank.",BOSCH GMBH ROBERT;;UNIV CALIFORNIA,KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO TAEK KYU;;WEBER ADAM Z,ROBERT BOSCH GMBH (2016-10-31),https://lens.org/080-768-742-605-026,Patent Application,yes,0,4,6,6,0,H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/20;;H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/04007;;H01M8/04097;;H01M8/04216;;H01M8/04283,H01M8/04089;;H01M8/04007;;H01M8/04082;;H01M8/04276;;H01M8/18;;H01M8/20,,0,0,,,,ACTIVE
333,JP,A,JP H1180913 A,122-745-240-716-885,1999-03-26,1999,JP 24670597 A,1997-09-11,JP 24670597 A,1997-09-11,MANUFACTURE OF ALUMINUM ALLOY SHEET,"PROBLEM TO BE SOLVED: To provide a method of manufacture of an aluminum alloy sheet excellent in shape freezability as well as in stress corrosion cracking resistance. SOLUTION: A continuously cast and rolled sheet of an aluminum alloy containing 3-6 wt.% Mg is subjected to annealing treatment, to strain straightening treatment, and then to heating and holding treatment at a prescribed temp. ranging from 240 to 340 deg.C for >=1 hr and to slow cooling treatment succeeding the heating and holding treatment, by which the aluminum alloy sheet excellent in shape freezability as well as in stress corrosion cracking resistance can be obtained. At this time, slow cooling treatment is carried out at a cooling rate in the range corresponding to the prescribed temp. within the shaded region S of the figure.",NIPPON LIGHT METAL CO;;HONDA MOTOR CO LTD;;ALCAN INT LTD,CHO HISHOKU;;MORIYAMA TAKESHI;;HAYASHI NOBORU;;YASUNAGA KUNIHIRO;;PAUL WYCLIFFE;;DAVID JAMES LLOYD,,https://lens.org/122-745-240-716-885,Patent Application,no,0,2,20,20,0,C22F1/047;;C22F1/047;;C21D1/26;;B21B1/46;;C22F1/047,C22F1/00;;C22C21/06;;C22F1/047,,0,0,,,,EXPIRED
334,US,B1,US 9634172 B1,034-928-623-356-903,2017-04-25,2017,US 201414485121 A,2014-09-12,US 201414485121 A;;US 201213401181 A;;US 27119208 A;;US 2377208 A;;US 86014207 A;;US 86018307 A,2007-09-24,Inverted metamorphic multijunction solar cell with multiple metamorphic layers,The disclosure describes multi-junction solar cell structures that include two or more graded interlayers.,SOLAERO TECH CORP,LIN YONG;;SHARPS PAUL;;CORNFELD ARTHUR;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN,EMCORE SOLAR POWER INC (2014-11-20);;SOLAERO TECHNOLOGIES CORP (2015-11-11),https://lens.org/034-928-623-356-903,Granted Patent,yes,102,0,5,111,0,H01L31/03046;;H01L31/06875;;H01L31/1844;;H01L31/1892;;Y02E10/544;;H01L31/078;;Y02P70/50;;H01L31/1844;;H01L31/06875;;H01L31/03046;;H01L31/1892;;Y02E10/544;;H01L31/078;;Y02P70/50;;H01L31/0725;;H01L31/0735,H01L31/18;;H01L31/0725;;H01L31/0735,,52,28,026-281-940-590-23X;;015-557-396-201-987;;015-557-396-201-987;;002-874-834-532-776;;073-300-069-664-773;;115-973-926-256-941;;083-287-525-840-54X;;084-891-382-112-541;;025-407-739-778-403;;034-023-904-332-047;;164-535-659-415-932;;007-176-082-871-508;;102-210-428-050-695;;106-513-576-934-63X;;076-989-478-838-81X;;015-717-993-971-840;;043-633-301-060-630;;030-787-136-717-28X;;038-574-682-896-969;;052-700-785-133-704;;093-340-948-123-836;;091-028-789-674-438;;020-636-430-481-14X;;026-862-096-577-376;;026-169-360-688-45X;;107-582-530-482-098;;164-535-659-415-932;;106-513-576-934-63X,10.1109/wcpec.2006.279587;;10.1109/pvsc.2010.5614498;;10.1109/pvsc.2010.5614498;;10.1109/wcpec.2006.279835;;10.1109/wcpec.2006.279527;;10.1063/1.2753729;;10.1109/pvsc.2008.4922452;;10.1063/1.335957;;10.1109/pvsc.2002.1190685;;10.1109/77.783715;;10.1016/0022-0248(84)90363-4;;10.1016/0379-6787(88)90047-6;;10.1109/pvsc-vol2.2012.6656717;;10.1109/pvsc.1990.111608;;10.1109/iscs.1998.711543;;10.1002/pip.449;;10.1016/0379-6787(86)90032-3;;10.1016/j.jcrysgro.2009.10.059;;10.1002/pip.642;;10.1109/pvsc.1991.169189;;10.1063/1.106494;;10.1088/0953-8984/16/21/008;;10.1109/pvsc.2005.1488186;;10.1109/wcpec.2006.279559;;10.1063/1.98946;;10.1134/1.1187812;;10.1016/0022-0248(84)90363-4;;10.1109/pvsc.1990.111608,"U.S. Appl. No. 12/708,361, filed Feb. 18, 2010, Cornfeld.;;U.S. Appl. No. 12/716,814, filed Mar. 3, 2010, Cornfeld.;;U.S. Appl. No. 12/730,018, filed Mar. 23, 2010, Cornfeld.;;U.S. Appl. No. 12/756,926, filed Apr. 8, 2010, Cornfeld.;;U.S. Appl. No. 12/813,408, filed Jun. 10, 2010, Patel.;;U.S. Appl. No. 12/844,673, filed Jul. 27, 2010, Stan.;;U.S. Appl. No. 13/547,334, filed Jul. 12, 2012, Cornfeld.;;U.S. Appl. No. 13/554,527, filed Jul. 20, 2012, Tourino.;;U.S. Appl. No. 13/569,794, filed Aug. 8, 2012, Stan.;;Aiken et al., “Consideration of High Bandgap Subcells for Advanced Multijunction Solar Cells,” Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, 2006:838-841.;;Cornfeld et al., “Development of a Large Area Inverted Metamorphic Multi-Junction (IMM) Highly Efficient AM0 Solar Cell,” 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Cornfeld et al., “Development of a Large Area Inverted Metamorphic Multi-junction Highly Efficient AM0 Solar Cell,” Conference paper presented at the 33rd IEEE Photovoltaic Specialists Conference (May 11-16, 2008) on May 12, 2008. San Diego, CA, USA.;;Cornfeld et al., “Advances in the Performance of Inverted Metamorphic Multijunction Solar Cells,” 23rd European Photovoltaic Energy Conference, Aug. 29, 2008, Valencia, Spain.;;Dimroth et al., “Thin 5-Junction Solar Cells with Improved Radiation Hardness,” Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 2006; pp. 1777-1780.;;Extended European Search Report for European Application No. 11010224.1-1528 dated May 15, 2012; 2 pgs.;;Friedman et al., “0.7-eV GaInAs Junction for a GaInP/GaAs/GaInAs(1eV)/GaInAs(0.7eV) Four-Junction Solar Cell,” 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA; 598-602.;;Geisz et al., “High efficiency GaInP/GaAs/InGaAs triple-junction solar cells grown inverted with a metamorphic bottom junction,” Applied Physics Letters, 2007; 91:023502-1-023502-3. Published online Jul. 10, 2007.;;Geisz et al., “Inverted GaInP / (In)GaAs Triple-Junction Solar Cells with Low-Stress Metamorphic Bottom Junctions,” 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Hamaker, H.C., “Computer modeling study of the effects of inhomogeneous doping and/or composition in GaAs solar-cell devices,” J Appl. Phys., Sep. 15, 1985; 58(6):2344-2351.;;King et al., “Next-Generation, High Efficiency III-V Multijunction Solar Cells,” 28th IEEE Photovoltaic Specialists Conference, Sep. 15-22, 2000, Anchorage, AK, USA; pp. 998-1001.;;King et al., “High-Efficiency Space and Terrestrial Multijunction Solar Cells Through Bandgap Control in Cell Structures,” 2002 Photovoltaic Specialists Conference, Conference Record of the 29th IEEE, May 19-24, 2002, New Orleans, LA, USA; pp. 776-781.;;King et al., “Solar Cell Generations Over 40% Efficiency,” 26th European Photovoltaic Solar Energy Conference and Exhibition, Sep. 5, 2011, Hamburg, Germany; 15 pgs.;;Koh et al., “Fabrication of Superconducting Delay Line with GaAs Schottky Diode,” IEEE Transactions on Applied Superconductivity, 1999; 9(2):3224-3227.;;Lewis et al., “The Crystallographic Connection of MOCVD-Grown Monolithic Cascade Subcells Via Transparent Graded Layers,” Journal of Crystal Growth, 1984; 69:515-526.;;Lewis et al., “Recent Developments in Multijunction Solar Cell Research,” Solar Cells, 1988; 24:171-183.;;Li et al., “Unintentional doping and compensation effects of carbon in metal-organic chemical vapor deposition fabricated ZnO thin films”, 2006, pp. 1213-1217.;;Patel et al., “Experimental Results From Performance Improvement and Radiation Hardening of inverted Metamorphic Multi-Junction Solar Cells,” Proceedings of the 37th IEEE PVSC, Seattle, WA, 2011 (Presented at PVSC Jun. 22, 2001).;;Patel et al., “Initial Results of the Monolithically Grown Six-Junction Inverted Metamorphic Multi-junction Solar Cell,” Proceedings of the 38th IEEE PVSC, Austin, TX, 2012 (Presented at PVSC Jun. 7, 2012).;;Schultz et al., “High Efficiency 1.0-eV GaInAs Bottom Solar Cell for 3-Junction Monolithic Stack,” IEEE, 1990:148-152.;;Sexl et al., “MBE Growth of Metamorphic In(Ga)AIAs Buffers,” 1997 IEEE International Symposium on Compound Semiconductors, Sep. 8-11, 1997; pp. 49-52.;;Sharps et al., “Inverting the triple junction improves efficiency and flexibility,” Compound Semiconductor, Oct. 2007; pp. 25-28.;;Sinharoy et al., “Progress in the Development of Metamorphic Multi junction III-V Space Solar Cells,” Progress in Photovoltaics: Research and Applications, Feb. 2002; 10:427-432.;;Soukup et al., “Limitations of Built-in Electric Field Enhancement of Minority Carrier Current Collection in GaAs Backwall Schottky Barrier Solar Cells,” Solar Cells, 1986; 18:139-151.;;Stan et al., “Recent Advances in the Performance of Multi-Junction Space Solar Cells,” 22nd European Photovoltaic Solar Energy Conference, Sep. 3-7, 2007, Milan, Italy; pp. 101-105.;;Stan et al., “Very High Efficiency Triple Junction Solar Cells by MOVPE,” 14th International Conference of Metalorganic Vapor Phase Epitaxy, Jun. 5, 2008, Metz, France.;;Stan et al., “High efficiency quadruple junction solar cells using MOVPE with inverted metamorphic device structures,” Journal of Crystal Growth, 2010; 312:1370-1374.;;Takamoto et al., “Future Development of InGaP/(In)GaAs Based Multijunction Solar Cells,” Proceedings of the 31st IEEE PVSC, Jan. 3-7, 2005, Lake Buena Vista, FL; pp. 519-524.;;Takamoto et al., “InGaP/GaAs-based Multijunction Solar Cells,” Progress in Photovoltaics: Research and Applications, 2005; 13:495-511.;;Venkatasubramanian et al., “An Inverted-Growth Approach to Development of an IR-Transparent, High-Efficiency AlGaAs/GaAs Cascade Solar Cell,” 22nd IEEE Photovoltaic Specialists Conference, Oct. 7-11, 1991, Las Vegas, NV, USA; pp. 93-98.;;Venkatasubramanian et al., “High-quality eutectic-metal-bonded AlGaAs-GaAs thin films on Si substrates,” Appl. Phys. Lett., Feb. 1992; 60(7):886-888.;;Voncken et al., “Strain-accelerated HF etching of AlAs for epitaxial lift-off,” J. Phys.: Condens. Matter, 2004; 16:3585-3596.;;Walters et al., “Space Radiation Effects in Advanced Solar Cell Materials and Devices,” Mat. Res. Soc. Symp. Proc., 2002; 692:569-580.;;Wanlass et al., “Lattice-Mismatched Approaches for High-Performance, III-V Photovoltaic Energy Converters,” Conference Proceedings of the 31st IEEE Photovoltaic Specialists Conference and Exhibition, Lake Buena Vista, FL, USA; Jan. 3-7, 2005;530-535.;;Wanlass et al., “Monolithic, Ultra-Thin GaInP/GaAs/GaInAs Tandem Solar Cells,” 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA; 729-732.;;Warfel, “Basic Structure of Solar Cells,” Physics of Solar Cells: From Basic Principles to Advanced Concepts, Second, Updated and Expanded Edition, 2009; Sections 6.4, 6.5 and 6.8.;;Yablonovitch et al., “Extreme selectivity in the lift-off of epitaxial GaAs films,” Appl. Phys. Lett., 1987; 51(28):2222-2224.;;Yamaguchi, “Physics and Technologies of Superhigh-Efficiency Tandem Solar Cells,” Semiconductors, Sep. 1999; 33(9):961-964.;;Yoon et al., “Progress of Inverted Metamorphic III-V Solar Cell Development at Spectrolab,” 33rd IEEE Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;European Search Report for EP Application No. 15183022.1, Jan. 14, 2016, 10 pages.;;King et al., “Solar Cell Generations Over 40% Efficiency,” 26th European International Conference on Photovoltaic Solar Energy, Sep. 5-9, 2011, Hamburg Germany; 15 pages.;;Lewis et al., “The Crystallographic Connection of MOCVD-grown Monolithic Cascade Subcells Via Transparent Graded Layers,” Journal of Crystal Growth, Nov. 1984; 69(2-3):515-526.;;Schultz et al., “High Efficiency 1.0-eV GaInAs Bottom Solar Cell for 3-Junction Monolithic Stack,” Proceedings of the Photovoltaic Specialists Conference 1990 and Conference Record of the 21st IEEE, May 21, 1990; 148-152.",ACTIVE
335,US,B2,US 7526506 B2,127-922-715-477-192,2009-04-28,2009,US 23400605 A,2005-09-23,US 23400605 A;;US 97060204 A,2004-10-21,Interlinking sports and television program listing metadata,"Matching metadata for sporting events with television program listing data. A global sports format enables the import of sports metadata from various providers. The metadata is interlinked with the television program listing data via configurable match rules or criteria. An enhanced electronic programming guide is created to display, to a user, the interlinked metadata.",MICROSOFT CORP,CHO WEI WEI ADA;;DEEDS PAUL D;;SAN JULE TODD;;CLEMENT SAMUEL D,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-09-21),https://lens.org/127-922-715-477-192,Granted Patent,yes,62,11,2,4,0,H04H60/72;;H04H60/73;;H04N7/17318;;H04N21/4622;;H04N21/4722;;H04N21/8133;;H04N21/84;;H04N21/8586;;H04N7/17318;;H04N21/8133;;H04H60/72;;H04N21/4622;;H04N21/4722;;H04N21/8586;;H04N21/84;;H04H60/73,G06F7/00;;G06F17/30;;H04N7/173,707/104.1;;725/105,4,0,,,"Silverberg E., ""Using the Program Guide in Windows XP Media Center Edition,"" Using Windows XP, Feb. 9, 2004, 8 pages, Microsoft Corporation, U.S.A.;;Unknown, ""Windows XP Media Center Edition 2005 Experience,"" Oct. 12, 2004, 1 page, Microsoft Corporation, U.S.A.;;Unknown, ""Electronic Programme Guide,"" Digital Cable TV, printed Sep. 22, 2005, 1 page, Hathway Datacom Pvt. Ltd., India.;;Unknown, ""Shaw Cable and Satellite: Star Choice Interactive Program Guide,"" Case Studies, printed Sep. 22, 2005, 3 pages, GIST Communications, Inc., U.S.A.",INACTIVE
336,EP,A4,EP 3084872 A4,165-863-013-108-510,2017-11-01,2017,EP 14870855 A,2014-12-18,US 201361918014 P;;US 201361918859 P;;US 2014/0071214 W,2013-12-19,HYDROGEN/BROMINE FLOW BATTERY IN WHICH HYDROGEN IS FREELY EXCHANGED BETWEEN TWO CELI COMPARTMENTS,,BOSCH GMBH ROBERT;;UNIV CALIFORNIA,ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/165-863-013-108-510,Search Report,no,2,0,6,6,0,H01M8/184;;H01M8/04208;;Y02E60/50;;H01M8/184;;H01M8/04208;;Y02B90/10;;Y02E60/50;;H01M8/04201;;H01M8/188;;H01M8/20;;H01M8/22;;H01M2250/10,H01M8/18,,1,0,,,See also references of WO 2015095555A1,ACTIVE
337,US,A1,US 2017/0110612 A1,182-180-464-353-404,2017-04-20,2017,US 201414485121 A,2014-09-12,US 201414485121 A;;US 201213401181 A;;US 27119208 A;;US 2377208 A;;US 86014207 A;;US 86018307 A,2007-09-24,INVERTED METAMORPHIC MULTIJUNCTION SOLAR CELL WITH MULTIPLE METAMORPHIC LAYERS,The disclosure describes multi-junction solar cell structures that include two or more graded interlayers.,SOLAERO TECH CORP,LIN YONG;;SHARPS PAUL;;CORNFELD ARTHUR;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN,EMCORE SOLAR POWER INC (2014-11-20);;SOLAERO TECHNOLOGIES CORP (2015-11-11),https://lens.org/182-180-464-353-404,Patent Application,yes,0,0,5,111,0,H01L31/03046;;H01L31/06875;;H01L31/1844;;H01L31/1892;;Y02E10/544;;H01L31/078;;Y02P70/50;;H01L31/1844;;H01L31/06875;;H01L31/03046;;H01L31/1892;;Y02E10/544;;H01L31/078;;Y02P70/50;;H01L31/0725;;H01L31/0735,H01L31/0725;;H01L31/0735;;H01L31/18,,0,0,,,,ACTIVE
338,US,A1,US 2016/0308237 A1,187-634-435-223-657,2016-10-20,2016,US 201415104161 A,2014-12-18,US 201415104161 A;;US 201361918014 P;;US 201361918859 P;;US 2014/0071214 W,2013-12-19,Hydrogen/Bromine Flow Battery in which Hydrogen is Freely Exchanged between Two Cell Compartments,"A flow battery system includes a first tank including a hydrogen reactant, a second tank including a bromine electrolyte, and at least one cell including a first electrolyte side operably connected to the first tank and a second electrolyte side operably connected to the second tank. The battery system further includes a direct connection line directly connecting the first tank and the second tank and configured such that the hydrogen reactant passes between the first tank and the second tank.",BOSCH GMBH ROBERT;;UNIV CALIFORNIA,ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO TAEK KYU;;WEBER ADAM Z,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2017-02-15);;ROBERT BOSCH GMBH (2016-10-31),https://lens.org/187-634-435-223-657,Patent Application,yes,5,4,6,6,0,H01M8/184;;H01M8/04208;;Y02E60/50;;H01M8/184;;H01M8/04208;;Y02B90/10;;Y02E60/50;;H01M8/04201;;H01M8/188;;H01M8/20;;H01M8/22;;H01M2250/10,H01M8/18;;H01M8/04082;;H01M8/20;;H01M8/22,,0,0,,,,ACTIVE
339,EP,A1,EP 3084872 A1,038-870-199-246-276,2016-10-26,2016,EP 14870855 A,2014-12-18,US 201361918014 P;;US 201361918859 P;;US 2014/0071214 W,2013-12-19,HYDROGEN/BROMINE FLOW BATTERY IN WHICH HYDROGEN IS FREELY EXCHANGED BETWEEN TWO CELL COMPARTMENTS,,BOSCH GMBH ROBERT;;UNIV CALIFORNIA,ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/038-870-199-246-276,Patent Application,yes,0,0,6,6,0,H01M8/184;;H01M8/04208;;Y02E60/50;;H01M8/184;;H01M8/04208;;Y02B90/10;;Y02E60/50;;H01M8/04201;;H01M8/188;;H01M8/20;;H01M8/22;;H01M2250/10,H01M8/18;;H01M8/02,,0,0,,,,ACTIVE
340,EP,A1,EP 3095152 A1,119-583-036-675-660,2016-11-23,2016,EP 14873586 A,2014-12-22,US 201361919926 P;;US 2014/0071835 W,2013-12-23,"SYSTEM AND METHOD FOR RETURNING MATERIAL FROM THE BR2 , SIDE OF AN H2/BR2 FLOW BATTERY BACK AFTER CROSSOVER",,BOSCH GMBH ROBERT;;UNIV CALIFORNIA,KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/119-583-036-675-660,Patent Application,yes,0,0,6,6,0,H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/20;;H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/04007;;H01M8/04097;;H01M8/04216;;H01M8/04283,H01M8/18;;H01M8/20,,0,0,,,,ACTIVE
341,US,B2,US 9368453 B2,183-974-234-069-193,2016-06-14,2016,US 201514948476 A,2015-11-23,US 201514948476 A;;US 201414243491 A,2014-04-02,Overlay mark dependent dummy fill to mitigate gate height variation,A method of forming dummy structures and an overlay mark protection zone over an active layer zone based on the shape of an overlay mark and the resulting device are provided. Embodiments include determining a size and a shape of an overlay mark; determining a size and a shape of an overlay mark protection zone based on the shape of the overlay mark; determining a shape of a plurality of dummy structures based on the shape of the overlay mark; determining a size and a shape of an active layer zone based on the size and the shape of the overlay mark and the plurality of dummy structures; forming the active layer zone in an active layer of a semiconductor substrate; forming the overlay mark and the plurality of dummy structures over the active layer zone in a poly layer of the semiconductor substrate; and planarizing the poly layer.,GLOBALFOUNDRIES INC,NING GUOXIANG;;CHO CHAN SEOB;;ACKMANN PAUL;;HSIEH JUNG YU;;KOH HUI PENG,GLOBALFOUNDRIES INC (2014-03-11),https://lens.org/183-974-234-069-193,Granted Patent,yes,2,1,4,4,0,G03F7/70633;;G03F7/70683;;H01L2924/0002;;H01L21/3212;;H01L22/12;;H01L27/088;;H01L22/12;;H01L27/088;;G03F7/70633;;G03F7/70683;;H01L2924/0002;;H01L21/3212;;H01L23/544;;H01L29/4916;;H01L2223/54426,H01L23/544;;H01L29/49,,0,0,,,,INACTIVE
342,JP,A,JP H1180873 A,035-612-058-346-491,1999-03-26,1999,JP 24670497 A,1997-09-11,JP 24670497 A,1997-09-11,AUTOMOTIVE ALUMINUM ALLOY SHEET EXCELLENT IN CONTINUOUS RESISTANCE SPOT WELDABILITY,"PROBLEM TO BE SOLVED: To provide an automotive aluminum alloy sheet in which the electrode is hard to deform and having stable continuous resistance spot weldability. SOLUTION: This automotive aluminum alloy sheet continuously subjected to resistance spot welding is the one contg., by weight, 2 to 6% Mg, 0.15 to 1.0% Fe and 0.03 to 2.0% Mn, in which the surface layer on the side to be pressed against the electrode in resistance spot welding contains intermetallic compd. grains having >=0.5 μm grain size by 4,000 pieces/mm<2> density, the thickness of the surface layer lies in the range of <=20 μm from the surface, and moreover, the thickness of oxidized coating on the sheet surface on the side to be pressed against the electrode is regulated to 0.04 to 0.2 μm.",NIPPON LIGHT METAL CO;;HONDA MOTOR CO LTD;;ALCAN INT LTD,CHO HISHOKU;;MORIYAMA TAKESHI;;HAYASHI NOBORU;;YASUNAGA KUNIHIRO;;PAUL WYCLIFFE;;DAVID JAMES LLOYD,,https://lens.org/035-612-058-346-491,Patent Application,no,0,2,18,18,0,C22C21/06;;C22C21/06;;C22C21/06,B23K11/18;;C22C21/06,,0,0,,,,EXPIRED
343,US,A1,US 2006/0088276 A1,092-608-067-202-241,2006-04-27,2006,US 23400605 A,2005-09-23,US 23400605 A;;US 97060204 A,2004-10-21,Interlinking sports and television program listing metadata,"Matching metadata for sporting events with television program listing data. A global sports format enables the import of sports metadata from various providers. The metadata is interlinked with the television program listing data via configurable match rules or criteria. An enhanced electronic programming guide is created to display, to a user, the interlinked metadata.",MICROSOFT CORP,CHO WEI WEI A;;DEEDS PAUL D;;SAN JULE TODD;;CLEMENT SAMUEL D,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-09-21),https://lens.org/092-608-067-202-241,Patent Application,yes,32,52,2,4,0,H04H60/72;;H04H60/73;;H04N7/17318;;H04N21/4622;;H04N21/4722;;H04N21/8133;;H04N21/84;;H04N21/8586;;H04N7/17318;;H04N21/8133;;H04H60/72;;H04N21/4622;;H04N21/4722;;H04N21/8586;;H04N21/84;;H04H60/73,H04N5/76;;H04N5/781,386/46;;386/125,0,0,,,,INACTIVE
344,US,B2,US 10326153 B2,155-596-649-969-846,2019-06-18,2019,US 201415105874 A,2014-12-22,US 201415105874 A;;US 201361919926 P;;US 2014/0071835 W,2013-12-23,System and method for returning material from the Br2 side of an H2/Br2 flow battery back after crossover,"A flow battery system includes a first tank having a hydrogen reactant, a second tank having a bromine electrolyte, at least one cell including a hydrogen reactant side operably connected to the first tank through an ¾ feed and return system and a bromine electrolyte side operably connected to the second tank, and a crossover return system. The crossover return system includes a vessel operably connected to the ¾ feed and return system and configured to receive an effluent containing a first portion of the hydrogen reactant and a second portion of the bromine electrolyte, the vessel configured to separate the first portion from the second portion. A first return line returns the first portion of the hydrogen reactant to the first tank and a second return line returns the bromine electrolyte to the second tank.",BOSCH GMBH ROBERT;;UNIV CALIFORNIA,KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,ROBERT BOSCH GMBH (2016-10-31),https://lens.org/155-596-649-969-846,Granted Patent,yes,11,2,6,6,0,H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/20;;H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/04007;;H01M8/04097;;H01M8/04216;;H01M8/04283,H01M8/04007;;H01M8/04082;;H01M8/04089;;H01M8/04276;;H01M8/18;;H01M8/20,,1,0,,,"International Search Report corresponding to PCT Application No. PCT/US2014/071835, dated Apr. 17, 2015 (4 pages).",ACTIVE
345,EP,A1,EP 2996162 A1,027-083-704-316-158,2016-03-16,2016,EP 15183022 A,2015-08-28,US 201414485121 A,2014-09-12,INVERTED METAMORPHIC MULTIJUNCTION SOLAR CELL WITH MULTIPLE METAMORPHIC LAYERS,The disclosure describes multi-junction solar cell structures that include two or more graded interlayers.,SOLAERO TECHNOLOGIES CORP,LIN YONG;;SHARPS PAUL;;CORNFELD ARTHUR;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN,,https://lens.org/027-083-704-316-158,Patent Application,yes,7,0,5,111,0,H01L31/03046;;H01L31/06875;;H01L31/1844;;H01L31/1892;;Y02E10/544;;H01L31/078;;Y02P70/50;;H01L31/1844;;H01L31/06875;;H01L31/03046;;H01L31/1892;;Y02E10/544;;H01L31/078;;Y02P70/50;;H01L31/0725;;H01L31/0735,H01L31/0687;;H01L31/0304;;H01L31/18,,4,2,106-513-576-934-63X;;164-535-659-415-932,10.1109/pvsc.1990.111608;;10.1016/0022-0248(84)90363-4,"KING R R ET AL: ""Solar Cell Generations over 40% Efficiency"", 26TH EUROPEAN INTERNATIONAL CONFERENCE ON PHOTOVOLTAIC SOLAR ENERGY 5-9 SEPT. 2011 HAMBURG, GERMANY,, 7 May 2012 (2012-05-07), pages 1 - 15, XP007920588, ISBN: 3-936338-27-2, DOI: 10.4229/26THEUPVSEC2011-1AP.1.2;;SCHULTZ J C ET AL: ""High efficiency 1.0 eV GaInAs bottom solar cell for 3-junction monolithic stack"", PROCEEDINGS OF THE PHOTOVOLTAIC SPECIALISTS CONFERENCE 1990 AND CONFERENCE RECORD OF THE TWENTY FIRST IEEE, 21 May 1990 (1990-05-21), pages 148 - 152, XP010003168;;C.R. LEWIS ET AL: ""The crystallographic connection of MOCVD-grown monolithic cascade subcells via transparent graded layers"", JOURNAL OF CRYSTAL GROWTH, vol. 69, no. 2-3, November 1984 (1984-11-01), pages 515 - 526, XP055115927, ISSN: 0022-0248, DOI: 10.1016/0022-0248(84)90363-4;;M. W. WANLASS ET AL.: ""V Photovoltaic Energy Converters (Conference Proceedings of the 31.sup.st IEEE Photovoltaic Specialists Conference"", 3 January 2005, IEEE PRESS, article ""Lattice Mismatched Approaches for High Performance""",ACTIVE
346,US,A1,US 2015/0287651 A1,084-942-824-241-293,2015-10-08,2015,US 201414243491 A,2014-04-02,US 201414243491 A,2014-04-02,OVERLAY MARK DEPENDENT DUMMY FILL TO MITIGATE GATE HEIGHT VARIATION,A method of forming dummy structures and an overlay mark protection zone over an active layer zone based on the shape of an overlay mark and the resulting device are provided. Embodiments include determining a size and a shape of an overlay mark; determining a size and a shape of an overlay mark protection zone based on the shape of the overlay mark; determining a shape of a plurality of dummy structures based on the shape of the overlay mark; determining a size and a shape of an active layer zone based on the size and the shape of the overlay mark and the plurality of dummy structures; forming the active layer zone in an active layer of a semiconductor substrate; forming the overlay mark and the plurality of dummy structures over the active layer zone in a poly layer of the semiconductor substrate; and planarizing the poly layer.,GLOBALFOUNDRIES INC,NING GUOXIANG;;CHO CHAN SEOB;;ACKMANN PAUL;;HSIEH JUNG YU;;KOH HUI PENG,GLOBALFOUNDRIES INC (2014-03-11),https://lens.org/084-942-824-241-293,Patent Application,yes,2,4,4,4,0,G03F7/70633;;G03F7/70683;;H01L2924/0002;;H01L21/3212;;H01L22/12;;H01L27/088;;H01L22/12;;H01L27/088;;G03F7/70633;;G03F7/70683;;H01L2924/0002;;H01L21/3212;;H01L23/544;;H01L29/4916;;H01L2223/54426,H01L21/66;;H01L21/306;;H01L23/544;;H01L27/088,,0,0,,,,INACTIVE
347,EP,A4,EP 3095152 A4,179-574-700-063-040,2017-07-26,2017,EP 14873586 A,2014-12-22,US 201361919926 P;;US 2014/0071835 W,2013-12-23,"SYSTEM AND METHOD FOR RETURNING MATERIAL FROM THE BR2 , SIDE OF AN H2/BR2 FLOW BATTERY BACK AFTER CROSSOVER",,BOSCH GMBH ROBERT;;UNIV CALIFORNIA,KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/179-574-700-063-040,Search Report,no,1,0,6,6,0,H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/20;;H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/04007;;H01M8/04097;;H01M8/04216;;H01M8/04283,H01M8/18;;H01M8/20,,0,0,,,,ACTIVE
348,US,B2,US 11594749 B2,012-304-759-128-412,2023-02-28,2023,US 201415104161 A,2014-12-18,US 201415104161 A;;US 201361918014 P;;US 201361918859 P;;US 2014/0071214 W,2013-12-19,Hydrogen/bromine flow battery in which hydrogen is freely exchanged between two cell compartments,"A flow battery system includes a first tank including a hydrogen reactant, a second tank including a bromine electrolyte, and at least one cell including a first electrolyte side operably connected to the first tank and a second electrolyte side operably connected to the second tank. The battery system further includes a direct connection line directly connecting the first tank and the second tank and configured such that the hydrogen reactant passes between the first tank and the second tank.",BOSCH GMBH ROBERT;;UNIV CALIFORNIA;;THE REGENTS OF THE UNIVERISTY OF CALIFORNIA,ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2017-02-15);;ROBERT BOSCH GMBH (2016-10-31),https://lens.org/012-304-759-128-412,Granted Patent,yes,10,0,6,6,0,H01M8/184;;H01M8/04208;;Y02E60/50;;H01M8/184;;H01M8/04208;;Y02B90/10;;Y02E60/50;;H01M8/04201;;H01M8/188;;H01M8/20;;H01M8/22;;H01M2250/10,H01M4/36;;H01M4/58;;H01M6/04;;H01M6/20;;H01M6/24;;H01M8/04082;;H01M8/18;;H01M8/20;;H01M8/22,,4,0,,,"Machine translation of Hamel et al. (WO2013/086100) “Hydrogen bromide flow battery system for distributed scale applications using pressure balanced cells”, pp. 1-40. (Year: 2013).;;International Search Report corresponding to PCT Application No. PCT/US2014/071214, dated Mar. 31, 2015 (4 pages).;;Supplementary Partial European Search Report corresponding to European Patent Application No. 14 87 0855 (13 pages), dated May 2017.;;Supplementary European Search Report corresponding to European Patent Application No. 14 87 0855 (13 pages), dated May 2017.",ACTIVE
349,WO,A1,WO 2015/100216 A1,091-232-852-854-203,2015-07-02,2015,US 2014/0071835 W,2014-12-22,US 201361919926 P,2013-12-23,SYSTEM AND METHOD FOR RETURNING MATERIAL FROM THE BR2 SIDE OF AN H2/BR2 FLOW BATTERY BACK AFTER CROSSOVER,"A flow battery system includes a first tank having a hydrogen reactant, a second tank having a bromine electrolyte, at least one cell including a hydrogen reactant side operably connected to the first tank through an ¾ feed and return system and a bromine electrolyte side operably connected to the second tank, and a crossover return system. The crossover return system includes a vessel operably connected to the ¾ feed and return system and configured to receive an effluent containing a first portion of the hydrogen reactant and a second portion of the bromine electrolyte, the vessel configured to separate the first portion from the second portion. A first return line returns the first portion of the hydrogen reactant to the first tank and a second return line returns the bromine electrolyte to the second tank.",BOSCH GMBH ROBERT;;KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z;;UNIV CALIFORNIA,KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/091-232-852-854-203,Patent Application,yes,6,6,6,6,0,H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/20;;H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/04007;;H01M8/04097;;H01M8/04216;;H01M8/04283,H01M8/20;;H01M8/18,,0,0,,,,PENDING
350,US,A1,US 2016/0190914 A1,043-911-140-294-002,2016-06-30,2016,US 201514981314 A,2015-12-28,KR 20140192915 A,2014-12-30,Power Factor Correction Circuit and Electronic Product Including the Same,"A power factor correction circuit and an electronic product including the same are disclosed. This technology configures a bridgeless circuit with no rectifier diode by using an additional switch, eliminating conduction loss due to the diode and reducing common mode EMI noise of the power factor correction circuit. A power factor correction circuit includes at least one inductor directly connected to an AC input stage, an output capacitor to smooth the output voltage, first switching elements to control current to store magnetic energy in the inductor, and a second switching element to maintain a substantially constant voltage between a ground voltage of an AC input stage and a ground voltage of an output stage.",SAMSUNG ELECTRONICS CO LTD;;UNIV SEOUL NAT R & DB FOUND,KIM JIN-HAN;;SEO HAN SOL;;CHO BO HYUNG;;JANG PAUL;;KANG SANG WOO,SAMSUNG ELECTRONICS CO. LTD (2015-12-17);;SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (2015-12-17),https://lens.org/043-911-140-294-002,Patent Application,yes,6,7,3,3,0,H02M1/4225;;H02M1/44;;Y02B70/10;;H02M1/123;;H02M1/0085;;G05F1/70;;H02M1/4233;;H02M1/12;;H02M1/44;;Y02B70/10;;H02M1/4225;;H02M1/44;;Y02B70/10;;H02M1/123;;H02M1/0085,H02M1/42;;H02M1/44;;H02M7/06,,0,0,,,,INACTIVE
351,US,B2,US 9941785 B2,150-769-786-198-794,2018-04-10,2018,US 201514981314 A,2015-12-28,KR 20140192915 A,2014-12-30,Power factor correction circuit and electronic product including the same,"A power factor correction circuit and an electronic product including the same are disclosed. This technology configures a bridgeless circuit with no rectifier diode by using an additional switch, eliminating conduction loss due to the diode and reducing common mode EMI noise of the power factor correction circuit. A power factor correction circuit includes at least one inductor directly connected to an AC input stage, an output capacitor to smooth the output voltage, first switching elements to control current to store magnetic energy in the inductor, and a second switching element to maintain a substantially constant voltage between a ground voltage of an AC input stage and a ground voltage of an output stage.",SAMSUNG ELECTRONICS CO LTD;;SEOUL NAT UNIV R&DB FOUNDATION,KIM JIN-HAN;;SEO HAN SOL;;CHO BO HYUNG;;JANG PAUL;;KANG SANG WOO,SAMSUNG ELECTRONICS CO. LTD (2015-12-17);;SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (2015-12-17),https://lens.org/150-769-786-198-794,Granted Patent,yes,8,2,3,3,0,H02M1/4225;;H02M1/44;;Y02B70/10;;H02M1/123;;H02M1/0085;;G05F1/70;;H02M1/4233;;H02M1/12;;H02M1/44;;Y02B70/10;;H02M1/4225;;H02M1/44;;Y02B70/10;;H02M1/123;;H02M1/0085,H02M1/42;;H02M1/12;;H02M1/44;;H02M7/217,,0,0,,,,INACTIVE
352,US,A1,US 2016/0112986 A1,034-159-344-170-096,2016-04-21,2016,US 201514883469 A,2015-10-14,US 201514883469 A;;US 201462064904 P;;US 201562109530 P;;US 201562205472 P,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,"In some examples, a method includes generating, at a first device, a paging message including an indication of whether the first device is available for a particular time period during which devices of a data link group of a neighbor aware network (NAN) are configured to operate in an active operating mode. The method also includes sending the message from the first device to one or more devices of the data link group of the NAN.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,QUALCOMM INCORPORATED (2015-12-07),https://lens.org/034-159-344-170-096,Patent Application,yes,18,32,12,36,0,H04W48/16;;H04W84/12;;H04W84/18;;H04W52/0216;;H04W84/18;;H04W48/16;;H04W84/12;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W68/02;;H04W84/18;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W84/18;;Y02D30/70;;H04W68/02;;H04W84/12,H04W68/02,,0,0,,,,INACTIVE
353,BR,A2,BR 112017007804 A2,140-502-674-282-590,2017-12-19,2017,BR 112017007804 A,2015-10-15,US 2015/0055813 W;;US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883469 A,2014-10-16,comunicação entre dispositivos de uma rede ciente de vizinhos,"trata-se de um método que inclui gerar, em um primeiro dispositivo, uma mensagem de paginação que inclui uma indicação da possibilidade de o primeiro dispositivo estar disponível por um período de tempo em particular durante o qual os dispositivos de um grupo de enlace de dados de uma rede ciente de vizinhos (nan) são configurados para operar em um modo operacional ativo. o método também inclui enviar a mensagem a partir do primeiro dispositivo para um ou mais dispositivos do grupo de enlace de dados da nan.",QUALCOMM INC,ABHISHEK PRAMOD PATIL;;ALIREZA RAISSINIA;;GEORGE CHERIAN;;GUIDO FREDERIKS;;JAMES CHO;;SANTOSH PAUL ABRAHAM,,https://lens.org/140-502-674-282-590,Patent Application,no,0,0,12,36,0,H04W48/16;;H04W84/12;;H04W84/18;;H04W52/0216;;H04W84/18;;H04W48/16;;H04W84/12;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W68/02;;H04W84/18;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W84/18;;Y02D30/70;;H04W68/02;;H04W84/12,H04W52/02;;H04W84/18,,0,0,,,,DISCONTINUED
354,US,A1,US 2008/0017249 A1,151-105-408-422-992,2008-01-24,2008,US 55711806 A,2006-11-07,US 55711806 A;;US 80795906 P,2006-07-21,SLURRY DISPENSING SYSTEM,"A slurry dispensing system comprises a first supply station, a second supply station, a first loop, a second loop, a first valve and a second valve. The first loop is selectively connected to the first supply station and the second supply station. The second loop is also selectively connected to the first supply station and the second supply station. The first valve connects the first loop to points of use. The second valve connects the second loop to the points of use. When slurry is supplied to the first loop from the first slurry station, slurry is supplied to the second loop from the second slurry station. When the first valve is opened and the second valve is closed, slurry is supplied to the points of use from the first loop.",TAIWAN SEMICONDUCTOR MFG,HSU MING-TZUNG;;TAN PAUL;;CHEN CHIANG-JEH;;CHEN CHO-CHING;;CHU HUI-MING,TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD (2006-10-13),https://lens.org/151-105-408-422-992,Patent Application,yes,3,7,6,6,0,B24B37/04;;B24B37/04;;B24B57/02;;B24B57/02;;Y10T137/0318;;Y10T137/0318;;Y10T137/4259;;Y10T137/4259;;Y10T137/85954;;Y10T137/85954;;Y10T137/85978;;Y10T137/85978,F16K51/00;;F16K11/00,137/240;;137/563,0,0,,,,INACTIVE
355,BR,A,BR 8907424 A,175-362-740-430-642,1991-05-07,1991,BR 8907424 A,1989-05-04,US 19144688 A;;US 8901898 W,1988-05-09,PROCESSO E APARELHO PARA FIACAO POR FUSAO EM ALTA VELOCIDADE,,NORTH CAROLINA STATE OF UNIVER,CUCULO JOHN;;TUCKER PAUL A;;CHEN CAO-YUAN;;CHO-YIE;;DENTON JEFFREY;;LUNDBERG FERDINAND,,https://lens.org/175-362-740-430-642,Patent Application,no,0,0,16,16,0,D01D5/098;;D01D5/098;;D01D5/098;;D01D5/088;;D01D5/088;;D01F6/62;;D01F6/62,D01D5/088;;D01D5/098;;D01F6/62,,0,0,,,,EXPIRED
356,WO,A1,WO 2016/061405 A1,032-492-390-297-14X,2016-04-21,2016,US 2015/0055820 W,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883523 A,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,"A method includes generating a paging message at a first device of a data link group of a neighbor aware network (NAN). The paging message includes a paged device list. The paged device list identifies a subset of devices of the data link group, the subset of devices scheduled to receive data from the first device during a transmission window. The paging message includes a receiver address field having a particular receiver address value. The method also includes transmitting, during the paging window, the paging message from to at least one device of the data link group other than the first device.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/032-492-390-297-14X,Patent Application,yes,5,0,8,36,0,H04W4/80;;H04W48/12;;H04W84/18;;H04W48/12;;H04W68/005;;H04W74/002;;H04W74/0808;;H04W76/14;;H04W4/80;;H04W84/12;;H04W76/14;;H04W4/80;;H04W84/18;;H04L47/12;;H04W48/12;;H04W68/005;;H04W74/0808;;H04W74/002;;H04W8/005;;H04W68/02;;H04W84/12,H04W84/18;;H04L12/801;;H04W4/80;;H04W8/00;;H04W48/16;;H04W68/02,,1,0,,,See also references of EP 3207759A1,PENDING
357,EP,A1,EP 3207761 A1,152-583-833-683-328,2017-08-23,2017,EP 15797727 A,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883473 A;;US 2015/0055816 W,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,,QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/152-583-833-683-328,Patent Application,yes,0,0,13,36,0,H04W8/005;;H04W8/005;;H04W8/005;;H04W74/04;;H04W4/70;;H04W8/005;;H04W8/24;;H04W8/24;;H04W8/24;;H04W68/025;;H04W68/025;;H04W68/025;;H04W74/04;;H04W74/04;;H04W76/14;;H04W76/14;;H04W84/12;;H04W84/12;;H04W84/18;;H04W84/18;;H04W84/18;;H04W84/18,H04W84/18,,1,0,,,See references of WO 2016061402A1,ACTIVE
358,BR,A2,BR 112017007789 A2,193-286-404-491-287,2018-01-16,2018,BR 112017007789 A,2015-10-15,US 2015/0055816 W;;US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883473 A,2014-10-16,comunicação entre dispositivos de uma rede ciente de vizinhos,"trata-se de um método que inclui receber, em um primeiro dispositivo, informações de disponibilidade a partir de um segundo dispositivo durante uma fase de definição de conexão de comunicação de uma rede ciente de vizinhos (nan) ou durante uma janela de descoberta de nan. a fase de definição de conexão inclui uma troca de informações de capacidade de dispositivo. o método também inclui, com base nas informações de disponibilidade que indicam que o segundo dispositivo está disponível durante uma janela de transmissão de um grupo de enlace de dados da nan para receber dados a partir do primeiro dispositivo, enviar dados a partir do primeiro dispositivo para o segundo dispositivo durante a janela de transmissão sem realizar uma troca de mensagem para determinar uma disponibilidade do segundo dispositivo.",QUALCOMM INC,ABHISHEK PRAMOD PATIL;;ALIREZA RAISSINIA;;GEORGE CHERIAN;;GUIDO FREDERIKS;;JAMES CHO;;SANTOSH PAUL ABRAHAM,,https://lens.org/193-286-404-491-287,Patent Application,no,0,0,13,36,0,H04W8/005;;H04W8/005;;H04W8/005;;H04W74/04;;H04W4/70;;H04W8/005;;H04W8/24;;H04W8/24;;H04W8/24;;H04W68/025;;H04W68/025;;H04W68/025;;H04W74/04;;H04W74/04;;H04W76/14;;H04W76/14;;H04W84/12;;H04W84/12;;H04W84/18;;H04W84/18;;H04W84/18;;H04W84/18,H04W84/18,,0,0,,,,DISCONTINUED
359,US,B2,US 11498062 B2,011-852-514-162-250,2022-11-15,2022,US 201716337603 A,2017-09-29,US 201716337603 A;;US 201662419247 P;;US 201662419202 P;;US 201662414302 P;;US 201662410922 P;;US 201662410919 P;;US 201662402238 P;;US 2017/0054558 W,2016-09-30,"Phosphorus-containing solid catalysts and reactions catalyzed thereby, including synthesis of p-xylene","Methods and phosphorus-containing solid catalysts for catalyzing dehydration of cyclic ethers (e.g., furans, such as 2,5-dimethylfuran) and alcohols (e.g., ethanol and isopropanol). The alcohols and cyclic ethers may be derived from biomass. One example includes a tandem Diels-Alder cycloaddition and dehydration of biomass-derived 2,5-dimethyl-furan and ethylene to renewable p-xylene. The phosphorus-containing solid catalysts are also active and selective for dehydration of alcohols to alkenes.",UNIV MINNESOTA;;UNIV OF MASSACHUSETTS AMHERST;;UNIV DELAWARE,CHO HONG JE;;FAN WEI;;TSAPATSIS MICHAEL;;DAUENHAUER PAUL J;;REN LIMIN;;LOBO RAUL,REGENTS OF THE UNIVERSITY OF MINNESOTA (2019-07-11);;UNIVERSITY OF MASSACHUSETTS (2021-07-15);;UNIVERSITY OF DELAWARE (2021-09-13),https://lens.org/011-852-514-162-250,Granted Patent,yes,37,0,6,6,0,B01J37/28;;B01J29/40;;B01J29/7007;;B01J29/82;;B01J29/85;;B01J2229/16;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;Y02P20/582;;Y02P20/52;;B01J29/40;;B01J29/7007;;B01J29/85;;B01J37/28;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;C07C51/42;;C07C2521/04;;C07C2521/06;;C07C2521/08;;C07C2521/10;;C07C2521/12;;C07C2521/18;;C07C2523/10;;C07C2523/20;;C07C2527/167;;C07C2527/18;;C07C2527/188;;C07C2529/08;;B01J37/0201;;C07C2529/85;;C07C2529/82;;B01J2229/186;;B01J2229/18;;B01J2229/183;;B01J35/67;;B01J35/69,C07C1/24;;B01J29/40;;B01J29/70;;B01J29/85;;B01J35/10;;B01J37/02;;B01J37/28;;C07C2/86;;C07C6/06;;C07C51/42,,57,47,010-163-764-789-347;;010-163-764-789-347;;054-047-423-031-296;;043-993-419-583-188;;045-959-043-779-847;;066-047-071-802-303;;123-469-778-155-344;;001-257-671-378-160;;065-839-296-414-909;;069-809-046-857-553;;009-650-459-799-218;;018-562-220-888-880;;009-606-541-526-069;;013-651-853-825-815;;128-064-484-435-080;;059-567-684-687-120;;098-648-195-061-601;;057-532-463-884-232;;063-943-832-600-738;;063-278-878-784-256;;025-179-354-559-857;;048-231-544-969-259;;077-494-912-953-194;;021-528-524-085-218;;025-239-645-426-589;;022-238-280-831-712;;108-167-629-985-152;;034-091-146-308-770;;050-712-596-776-116;;047-741-444-168-482;;022-876-865-099-869;;004-507-110-607-419;;033-904-593-331-867;;038-038-551-106-059;;150-670-748-404-833;;055-144-252-904-849;;013-079-541-152-354;;065-809-338-900-36X;;014-877-133-100-718;;166-200-406-908-577;;154-604-984-527-106;;025-286-660-523-223;;010-500-246-698-650;;119-503-310-552-186;;036-803-919-357-175;;015-931-084-082-453;;118-564-821-194-969,10.1016/j.apcata.2015.07.011;;10.1016/j.apcata.2015.07.011;;10.1021/acs.energyfuels.8b04485;;10.1016/j.cattod.2005.06.002;;34067754;;10.3390/ma14102609;;pmc8156553;;10.1039/cc9960002365;;10.1039/c5gc02164b;;10.1039/c2ra21381h;;10.1039/c3gc40740c;;10.1021/ja2038358;;21736345;;10.1002/cctc.201601294;;10.1038/nmat1705;;16892049;;10.1038/nature08288;;19741706;;10.1021/cs300265d;;10.1016/j.apcata.2014.12.006;;10.1021/cr00035a007;;10.1007/bf00909833;;10.1021/ja00189a016;;10.1016/0921-3449(90)90018-y;;10.1039/b517510k;;10.1016/j.apcata.2005.10.054;;12405821;;10.1021/ja020947w;;23945710;;pmc3744081;;10.1038/srep02445;;10.1039/c5cy02211h;;10.1021/jp035110h;;21162573;;10.1021/ja107942n;;10.1016/0144-4565(84)90039-8;;16852024;;10.1021/jp0441893;;10.1021/cs100042r;;18179218;;10.1021/ja077711i;;24993100;;10.1039/c4cs00105b;;20136135;;10.1021/ja908382n;;22887922;;10.1002/cssc.201100780;;10.1016/j.catcom.2004.05.006;;10.1021/ja0478734;;15521742;;10.1107/s0021889895014191;;10.1007/bf01083812;;10.1007/bf00907677;;10.1021/ja01170a013;;10.1002/cctc.201600710;;10.1002/cctc.200900278;;10.1002/anie.200705755;;18435514;;10.1016/0144-2449(94)90134-1;;20437452;;10.1002/cssc.200900285;;10.1038/nchembio.580;;21602812;;10.1021/ja065071y;;17044675;;22745424;;10.1126/science.1221111,"Ding et al., “Combined desilication and phosphorus modification for high-silica ZSM-5 zeolite with related study of hydrocarbon cracking”, Applied Catalysis A: General 503, (2015), pp. 147-155.;;Machine Translation, JP 2011225401, Nov. 20, 2011.;;J. Ding et al., Applied Catalysis A: General 503 (2015), pp. 147-155.;;Manrique et al., “Phosphorus-Modified Beta Zeolite and Its Performance in Vacuum Fas Oil Hydrocracking Activity”, Energy & Fuels, 2019, 33, pp. 3483-3491.;;Pitchumani et al., “Tuning of nanostructured SBA-15 silica using phosphoric acid”, Catalysis Today, vol. 105, 3-4, 2005, pp. 618-622.;;Machin et al., “One-Dimensional (1D) Nanostructured Materials for Energy Applications”, Materials, 14, 2021, pp. 1-47.;;Abdelrahman et al., “Biomass-Derived Butadiene by Dehydra-Decyclization of Tetrahydrofuran” ACS Sustain, Chem. Eng., 5:3732-6, Apr. 2017.;;Camblor et al., “Spontaneous nucleation and growth of pure silica zeolite-beta free of connectivity defects,” Chem. Comm., 2365-6, Jul. 1996.;;Chang et al., “Lewis acid zeolites for tandem Diels-Alder cycloaddition and dehydration of biomass-derived dimethylfuran and ethylene to renewable p-xylenem,” Green Chem, 18:1368-76, 2016.;;Chang et al., “Rapid synthesis of Sn-Beta for the isomerization of cellulosic sugars,” RSC Adv., 2(28): 10475-7, Sep. 2012.;;Chang et al., “Ultra-selective cycloaddition of dimethylfuran for renewable p-xylene with H-BEA,” Green Chem., 16:585-88, 2014.;;Chia et al., “Selective Hydrogenolysis of Polyols and Cyclic Ethers over Bifunctional Surface Sites on Rhodium-Rhenium Catalysts” J. Am. Chem. Soc., 133:12675-89, Jul. 2011.;;Cho et al., “Renewable p-Xylene from 2,5-Dinethylfuran and Ethylene Using Phosphorus-Containing Zeolite Catalysts,” ChemCatChem., 9(3):398-402, Feb. 2017.;;Choi et al., “Amphiphilic organosilane-directed synthesis of crystalline zeolite with tunable mesoporosity,” Nat. Mater., 5: 718-23, Sep. 2006.;;Choi et al., “Stable single-unit-cell nanosheets of active and long-lived catalysts,” Nature, 461:246-9, Sep. 2009.;;Choudhary et al.,“ Conversion of Xylose to Furfural Using Lewis and Brønsted Acid Catalysts in Aqueous Media,” ACS Catalysis 2(9):2022-8, Aug. 2012.;;Duan et al., “Efficient production of 1,3-butadiene in the catalytic dehydration of 2,3-butanediol,” Applied Catalysis A: General 491:163-9, Feb. 2015.;;Farneth and Gorte, “Methods for Characterizing Zeolite Acidity,” Chem. Rev., 95(3):615-35, May 1995.;;Freidlin and Sharf, “Two paths for the dehydration of 1,4-butandiol to divinyl with a tricalcium phosphate catalyst,” Bull. Acad. Sci. USSR, Div. Chem. Sci. 9(9):1577-9, Feb. 1960.;;Fyfe et al., “Detailed Investigation of the Lattice Structure of Zeolite ZSM-11 by a Combination of Solid-State NMR and Synchrotron X-ray Diffraction Techniques,” J. Am. Chem. Soc., 111(7):2470-4, Mar. 1989.;;Godawa et al., “Palladium catalyzed hydrogenation of furan: optimization of production conditions for tetrahydrofuran,” Resources, Conservation and Recycling 3(4):201-16, Jun. 1990.;;Gorte, “What do we know about the acidity of solid acids?, Catalysis Letters,” 62(1):1-13, Sep. 1999.;;Groen et al., “Desilication: on the controlled generation of mesoporosity in MFI zeolites,” Mater. Chem., 16:2121-31, Mar. 2006.;;Ichikawa et al., “Catalytic reaction of 1,3-butanediol over solid acids,” J. Mol. Catal. A: Chem. 256(1-2): 106-12, Aug. 2006.;;Igarashi et al., “Dehydration of butanediols over CeO2 catalysts with different particle sizes,” Applied Catalysis A: General 300(l):50-7, Jan. 2006.;;Jeong et al., “Oriented Molecular Sieve Membranes by Heteroepitaxial Growth,” J. Am. Chem. Soc., 124(44):12966-8, Nov. 2002.;;Jiang et al. “Biodegradation-inspired bioproduction of methylacetoin and 2-methyl-2, 3-butanediol” Sci. Rep., 3:1-7, Aug. 2013.;;Jing et al., “Direct Dehydration of 1,3-butanediol into butadiene over aluminosilicate catalysts,” Catal. Sci. Technol., 6(15):5830-40, Feb. 2016.;;Kragten et al., “Structure of the Silica Phase Extracted from Silica/(TPA)OH Solutions Containing Nanoparticles,” J. Phys. Chem. B, 107(3 7): 10006-16, Sep. 2003.;;Lee et al., “Sub-40 nm Zeolite Suspensions via Disassembly of Three-Dimensionally Ordered Mesoporous-Imprinted Silicalite-1,” J. Am. Chem. Soc., 133(3):493-502, Jan. 2011.;;Lejemble et al., “From biomass to furan through decarbonylation of furfural under mild conditions,” Biomass, 4(4):263-74, Jan. 1984.;;Li et al., “Pure-Silica-Zeolite MEL Low-k Films from Nanoparticle Suspensions,” J. Phys. Chem. B., 109(18):8652-8, May 2005.;;Liu et al., Catalytic Behavior of Bronsted Acid Sites in MWW and MFI Zeolites with Dual Meso- and Microporosity ACS Catal., 1(1):7-17, Jan. 2011.;;Maheshwari et al., “Layer Structure Preservation during Swelling, Pillaring, and Exfoliation of a Zeolite Precursor,” J. Am. Chem. Soc., 130(4): 1507-16, Jan. 2008.;;Makshina et al., “Review of old chemistry and new catalytic advances in the on-purpose synthesis of butadiene,” Chem. Soc. Rev., 43(22), 7917-53, Mar. 2014.;;Na et al., “Pillared MFI Zeolite Nanosheets of a single-Unit-Cell Thickness,” J. Am. Chem. Soc., 132(12):4169-77, Mar. 2010.;;Nair et al., “Zeolite-β grown epitaxially on SSZ-31 nanofibers,” Chem. Commun., 10:921-2, Mar. 1999.;;Pace et al., “2-Methyltetrahydrofuran (2-MeTHF): A Biomass-Derived Solvent with Broad Application in Organic Chemistry,” ChemSusChem., 5(8): 1369-79, Aug. 2012.;;PCT International Preliminary Report on Patentability in International Appln. No. PCT/US17/54558 dated Apr. 11, 2019, 9 pages.;;PCT International Search Report and Written Opinion in International Appln. No. PCT/US17/54558 dated Jan. 26, 2018, 18 pages.;;Roth et al., “MCM-36: The first pillared molecular sieve with zeolite properties,” Stud. Surf. Sci. and Catal., 94:301, Jan. 1995.;;Sato et al., “Dehydration of 1,4-butanediol into 3-buten-1-ol catalyzed by ceria,” Catal. Comm., 5(8):397-400, Aug. 2004.;;Sato et al., “Dehydration of diols catalyzed by CeO2,” J. Mol. Catal. A: Chem., 221(1-2):177-83, Nov. 2004.;;Sayari et al., “Simple Synthesis Route to Monodispersed SBA-15 Silica Rods,” J. Am. Chem. Soc., 126(44)14348-9, Oct. 2004.;;Schlenker et al., “Computed X-ray Powder Diffraction Patterns for Ultrasmall Zeolite Crystals,” J. Appl. Cryst., 29(2): 178-85, Apr. 1996.;;Sharf et al., “Production of isoprene from formaldehyde and isobutylene through 3-methylbutanediol-1, 3,” Bull. Acad. Sci. USSR, Div. Chem. Sci., 14(9), 1621-3, Sep. 1965.;;Shuikin and An, “Dehydration of tetrahydropyran over TiO2-A12O3,” Bull. Acad. Sci. USSR, Div. Chem. Sci., 9(8):1400-140, Jan. 1960.;;Smith and Fuzek, “Catalytic Hydrogenation of Furan and Substituted Furans on Platinum,” J. Am. Chem. Soc., 71(2):415-9, Feb. 1949.;;Spanjers et al., “Branched Diol Monomers from the Sequential Hydrogenation of Renewable Carboxylic Acids,” ChemCatChem., 8(19):3031-5, Oct. 2016.;;Tsapatsis et al., “A New, Yet Familiar, Lamellar Zeolite,” ChemCatChem., 2:246-8, Mar. 2010.;;Tsapatsis et al., “Pores by Pillaring: Not Always a Maze,” Angew. Chem. Int. Ed., 47(23):4262-3, May 2008.;;Van Koningsveld et al., “The monoclinic framework structure of zeolite H-ZSM-5. Comparison with the orthorhombic framework of as-synthesized ZSM-5”, Zeolites, 10:235-42, May 1990.;;Yang and Seng, “One-Step Catalytic Transformation of Carbohydrates and Cellulosic Biomass to 2,5-Dimethyltetrahydrofuran for Liquid Fuels,” ChemSusChem., 3(5):597-603, May 2010.;;Yim et al., “Metabolic engineering of Escherichia coli for direct production of 1,4-butanediol,” Nat. Chem. Biol., 7(7):445-52, May 2011.;;Yokoi et al.,“ Periodic Arrangement of Silica Nanospheres Assisted by Amino Acids,” J. Am. Chem. Soc., 128(42) 13664-5, Oct. 2006.;;Zhang et al., “Synthesis of Self-Pillared Zeolite Nanosheets by Repetitive Branching,” Science 336(6089):1684-7, Jun. 2012.;;U.S. Appl. No. 16/337,600, filed Mar. 28, 2019, Omar A. Abdelrahman, Published.",ACTIVE
360,US,A1,US 2019/0344252 A1,018-054-619-368-181,2019-11-14,2019,US 201716337603 A,2017-09-29,US 201716337603 A;;US 201662419247 P;;US 201662419202 P;;US 201662414302 P;;US 201662410922 P;;US 201662410919 P;;US 201662402238 P;;US 2017/0054558 W,2016-09-30,"PHOSPHORUS-CONTAINING SOLID CATALYSTS AND REACTIONS CATALYZED THEREBY, INCLUDING SYNTHESIS OF P-XYLENE","Methods and phosphorus-containing solid catalysts for catalyzing dehydration of cyclic ethers (e.g., furans, such as 2,5-dimethylfuran) and alcohols (e.g., ethanol and isopropanol). The alcohols and cyclic ethers may be derived from biomass. One example includes a tandem Diels-Alder cycloaddition and dehydration of biomass-derived 2,5-dimethyl-furan and ethylene to renewable p-xylene. The phosphorus-containing solid catalysts are also active and selective for dehydration of alcohols to alkenes.",UNIV MINNESOTA;;UNIV OF MASSACHUSETTS AMHERST,CHO HONG JE;;FAN WEI;;TSAPATSIS MICHAEL;;DAUENHAUER PAUL J;;REN LIMIN;;LOBO RAUL,REGENTS OF THE UNIVERSITY OF MINNESOTA (2019-07-11);;UNIVERSITY OF MASSACHUSETTS (2021-07-15);;UNIVERSITY OF DELAWARE (2021-09-13),https://lens.org/018-054-619-368-181,Patent Application,yes,0,5,6,6,0,B01J37/28;;B01J29/40;;B01J29/7007;;B01J29/82;;B01J29/85;;B01J2229/16;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;Y02P20/582;;Y02P20/52;;B01J29/40;;B01J29/7007;;B01J29/85;;B01J37/28;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;C07C51/42;;C07C2521/04;;C07C2521/06;;C07C2521/08;;C07C2521/10;;C07C2521/12;;C07C2521/18;;C07C2523/10;;C07C2523/20;;C07C2527/167;;C07C2527/18;;C07C2527/188;;C07C2529/08;;B01J37/0201;;C07C2529/85;;C07C2529/82;;B01J2229/186;;B01J2229/18;;B01J2229/183;;B01J35/67;;B01J35/69,B01J29/85;;B01J29/40;;B01J29/70;;B01J37/28;;C07C1/24;;C07C2/86;;C07C6/06,,0,0,,,,ACTIVE
361,CN,A,CN 107079241 A,081-199-415-820-756,2017-08-18,2017,CN 201580056018 A,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883473 A;;US 2015/0055816 W,2014-10-16,Communication between devices of a neighbor aware network,"In some examples, a method includes receiving, at a first device, availability information from a second device during a connection set-up phase of communication of a neighbor aware network (NAN) or during a NAN discovery window. The connection set-up phase includes an exchange of device capability information. The method also includes, based on the availability information indicating that the second device is available during a transmission window of a data link group of the NAN to receive data from the first device, sending data from the first device to the second device during the transmission window without performing a message exchange to determine an availability of the second device.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/081-199-415-820-756,Patent Application,no,4,3,13,36,0,H04W8/005;;H04W8/005;;H04W8/005;;H04W74/04;;H04W4/70;;H04W8/005;;H04W8/24;;H04W8/24;;H04W8/24;;H04W68/025;;H04W68/025;;H04W68/025;;H04W74/04;;H04W74/04;;H04W76/14;;H04W76/14;;H04W84/12;;H04W84/12;;H04W84/18;;H04W84/18;;H04W84/18;;H04W84/18,H04W4/00;;H04W8/00;;H04W84/18,,0,0,,,,ACTIVE
362,CN,A,CN 107079390 A,115-260-506-533-930,2017-08-18,2017,CN 201580056047 A,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883469 A;;US 2015/0055813 W,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,"A method includes generating a paging message at a first device of a data link group of a neighbor aware network (NAN). The paging message includes a paged device list. The paged device list identifies a subset of devices of the data link group, the subset of devices scheduled to receive data from the first device during a transmission window. The paging message includes a receiver address field having a particular receiver address value. The method also includes transmitting, during the paging window, the paging message from to at least one device of the data link group other than the first device.",REMY TECH LLC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/115-260-506-533-930,Patent Application,no,3,1,12,36,0,H04W48/16;;H04W84/12;;H04W84/18;;H04W52/0216;;H04W84/18;;H04W48/16;;H04W84/12;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W68/02;;H04W84/18;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W84/18;;Y02D30/70;;H04W68/02;;H04W84/12,H04W48/16;;H04W84/12;;H04W84/18,,0,0,,,,DISCONTINUED
363,US,A1,US 2016/0112984 A1,043-403-255-718-038,2016-04-21,2016,US 201514883518 A,2015-10-14,US 201514883518 A;;US 201462064904 P;;US 201562109530 P;;US 201562205472 P,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,"A method includes generating, at a first device, a paging message. The method includes, during a first transmission window of a data link group of a neighbor aware network (NAN), sending the paging message from the first device to one or more devices of the data link group. The method further includes, during a second transmission window of the data link group and prior to a data window of the second transmission window, sending data traffic to a particular device of the one or more devices without sending a traffic announcement to the particular device during a second paging window of the second transmission window.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,QUALCOMM INCORPORATED (2015-12-07),https://lens.org/043-403-255-718-038,Patent Application,yes,2,27,3,36,0,H04W48/16;;H04W84/12;;H04W52/0216;;Y02D30/70;;H04W48/16;;H04W84/12;;H04W52/0216;;Y02D30/70;;H04W68/005,H04W68/00,,0,0,,,,INACTIVE
364,US,B2,US 7392818 B2,046-959-930-560-450,2008-07-01,2008,US 55711806 A,2006-11-07,US 55711806 A;;US 80795906 P,2006-07-21,Slurry dispensing system,"A slurry dispensing system comprises a first supply station, a second supply station, a first loop, a second loop, a first valve and a second valve. The first loop is selectively connected to the first supply station and the second supply station. The second loop is also selectively connected to the first supply station and the second supply station. The first valve connects the first loop to points of use. The second valve connects the second loop to the points of use. When slurry is supplied to the first loop from the first slurry station, slurry is supplied to the second loop from the second slurry station. When the first valve is opened and the second valve is closed, slurry is supplied to the points of use from the first loop.",TAIWAN SEMICONDUCTOR MFG,HSU MING-TZUNG;;TAN PAUL;;CHEN CHIANG-JEH;;CHEN CHO-CHING;;CHU HUI-MING,TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD (2006-10-13),https://lens.org/046-959-930-560-450,Granted Patent,yes,3,1,6,6,0,B24B37/04;;B24B37/04;;B24B57/02;;B24B57/02;;Y10T137/0318;;Y10T137/0318;;Y10T137/4259;;Y10T137/4259;;Y10T137/85954;;Y10T137/85954;;Y10T137/85978;;Y10T137/85978,F16K51/00;;F16K11/00,137/1;;137/240;;137/563;;137/565.01,0,0,,,,INACTIVE
365,US,A1,US 2017/0162739 A1,048-329-528-258-532,2017-06-08,2017,US 201715433641 A,2017-02-15,US 201715433641 A;;US 201514623883 A;;US 201313956122 A;;US 75839010 A;;US 44579306 A;;US 201213463069 A;;US 40115709 A;;US 201414485121 A;;US 201213401181 A;;US 27119208 A;;US 2377208 A;;US 86014207 A;;US 86018307 A,2006-06-02,INVERTED METAMORPHIC MULTIJUNCTION SOLAR CELL WITH MULTIPLE METAMORPHIC LAYERS,The disclosure describes multi-junction solar cell structures that include two or more graded interlayers.,SOLAERO TECH CORP,LIN YONG;;SHARPS PAUL R;;CORNFELD ARTHUR;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN,,https://lens.org/048-329-528-258-532,Patent Application,yes,5,0,4,111,0,H01L31/078;;H01L31/078;;H01L31/03046;;H01L31/03046;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/0725;;H01L31/0735;;H01L31/1844;;H01L31/1844;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02P70/50;;Y02P70/50,H01L31/078;;H01L31/0687;;H01L31/0725;;H01L31/0735;;H01L31/18,,0,0,,,,ACTIVE
366,EP,B1,EP 3207761 B1,122-564-075-893-067,2021-05-12,2021,EP 15797727 A,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883473 A;;US 2015/0055816 W,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,,QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/122-564-075-893-067,Granted Patent,yes,3,0,13,36,0,H04W4/70;;H04W8/005;;H04W84/18;;H04W84/18;;H04W8/24;;H04W68/025;;H04W74/04;;H04W8/005;;H04W84/12;;H04W76/14;;H04W8/005;;H04W8/24;;H04W68/025;;H04W74/04;;H04W84/18;;H04W8/005;;H04W84/12;;H04W76/14;;H04W68/025;;H04W74/04;;H04W84/18;;H04W8/24,H04W84/18;;H04W8/00;;H04W8/24;;H04W68/02;;H04W74/04;;H04W84/12,,0,0,,,,ACTIVE
367,US,A1,US 2016/0285353 A1,187-863-804-578-381,2016-09-29,2016,US 201514965346 A,2015-12-10,US 201514965346 A;;KR 20150116091 A;;US 201562139141 P,2015-03-27,"SWITCH DRIVING CIRCUIT, AND POWER FACTOR CORRECTION CIRCUIT HAVING THE SAME","The present disclosure relates generally to a switch driving circuit and power factor correction circuit having the same, and more particularly, to a technology to provide a negative offset using Zener diodes to prevent malfunctions in driving a switch. The switch driving circuit to operate a switch implemented with a Field Effect Transistor (FET) includes a first Zener diode connected to a control input end of the switch; a capacitor connected in parallel with the first Zener diode; and second and third Zener diodes for providing a negative offset to fix a voltage applied between the gate and source of the switch to a negative value.",SAMSUNG ELECTRONICS CO LTD;;SNU R&DB FOUNDATION,KIM JIN HAN;;SEO HAN SOL;;CHO BO-HYUNG;;KANG SANG-WOO;;JANG PAUL,SAMSUNG ELECTRONICS CO. LTD (2015-11-17),https://lens.org/187-863-804-578-381,Patent Application,yes,8,13,2,2,0,H03K17/162;;H03K17/302;;H02M1/4225;;H02M1/4208;;Y02B70/10;;H02M1/0085;;H02M1/4208;;H03K17/162;;H03K17/302;;H02M1/4225;;Y02B70/10;;H02M1/0085,H02M1/08;;H02M1/42;;H02M7/06;;H02M7/217;;H03K17/687,,0,0,,,,ACTIVE
368,WO,A1,WO 2016/061404 A1,054-815-921-055-45X,2016-04-21,2016,US 2015/0055818 W,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883518 A,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,"A method includes generating, at a first device, a paging message. The method includes, during a first transmission window of a data link group of a neighbor aware network (NAN), sending the paging message from the first device to one or more devices of the data link group. The method further includes, during a second transmission window of the data link group and prior to a data window of the second transmission window, sending data traffic to a particular device of the one or more devices without sending a traffic announcement to the particular device during a second paging window of the second transmission window.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/054-815-921-055-45X,Patent Application,yes,3,0,3,36,0,H04W48/16;;H04W84/12;;H04W52/0216;;Y02D30/70;;H04W48/16;;H04W84/12;;H04W52/0216;;Y02D30/70;;H04W68/005,H04W48/18,,0,0,,,,PENDING
369,EP,B1,EP 3207760 B1,052-944-150-402-940,2018-07-25,2018,EP 15797726 A,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883469 A;;US 2015/0055813 W,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,,QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/052-944-150-402-940,Granted Patent,yes,3,0,12,36,0,H04W48/16;;H04W84/12;;H04W84/18;;H04W52/0216;;H04W84/18;;H04W48/16;;H04W84/12;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W68/02;;H04W84/18;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W84/18;;Y02D30/70;;H04W68/02;;H04W84/12,H04W84/18;;H04W52/02,,0,0,,,,ACTIVE
370,KR,A,KR 20170070054 A,079-339-787-026-086,2017-06-21,2017,KR 20177010230 A,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883469 A;;US 2015/0055813 W,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,"일부 예들에서, 방법은, 제 1 디바이스에서, NAN(neighbor aware network)의 데이터 링크 그룹의 디바이스들이 활성 동작 모드로 동작하도록 구성되는 특정 시간 기간 동안에 상기 제 1 디바이스가 이용가능한지 여부의 표시를 포함하는 페이징 메시지를 생성하는 단계를 포함한다. 방법은 또한 제 1 디바이스로부터 NAN의 데이터 링크 그룹의 하나 또는 그 초과의 디바이스들에 메시지를 전송하는 단계를 포함한다.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/079-339-787-026-086,Patent Application,no,0,0,12,36,0,H04W48/16;;H04W84/12;;H04W84/18;;H04W52/0216;;H04W84/18;;H04W48/16;;H04W84/12;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W68/02;;H04W84/18;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W84/18;;Y02D30/70;;H04W68/02;;H04W84/12,H04W52/02;;H04W48/16;;H04W68/02;;H04W84/18,,0,0,,,,PENDING
371,EP,A1,EP 3207759 A1,122-603-494-647-142,2017-08-23,2017,EP 15791076 A,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883523 A;;US 2015/0055820 W,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,,QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/122-603-494-647-142,Patent Application,yes,1,0,8,36,0,H04W4/80;;H04W48/12;;H04W84/18;;H04W48/12;;H04W68/005;;H04W74/002;;H04W74/0808;;H04W76/14;;H04W4/80;;H04W84/12;;H04W76/14;;H04W4/80;;H04W84/18;;H04L47/12;;H04W48/12;;H04W68/005;;H04W74/0808;;H04W74/002;;H04W8/005;;H04W68/02;;H04W84/12,H04W84/18;;H04L12/801;;H04W4/80;;H04W8/00;;H04W48/16;;H04W68/02,,0,0,,,,DISCONTINUED
372,CN,A,CN 106852192 A,176-976-842-256-254,2017-06-13,2017,CN 201580055992 A,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883523 A;;US 2015/0055820 W,2014-10-16,Communication between devices of a neighbor aware network,"A method includes generating a paging message at a first device of a data link group of a neighbor aware network (NAN). The paging message includes a paged device list. The paged device list identifies a subset of devices of the data link group, the subset of devices scheduled to receive data from the first device during a transmission window. The paging message includes a receiver address field having a particular receiver address value. The method also includes transmitting, during the paging window, the paging message from to at least one device of the data link group other than the first device.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/176-976-842-256-254,Patent Application,no,6,3,8,36,0,H04W4/80;;H04W48/12;;H04W84/18;;H04W48/12;;H04W68/005;;H04W74/002;;H04W74/0808;;H04W76/14;;H04W4/80;;H04W84/12;;H04W76/14;;H04W4/80;;H04W84/18;;H04L47/12;;H04W48/12;;H04W68/005;;H04W74/0808;;H04W74/002;;H04W8/005;;H04W68/02;;H04W84/12,H04W4/80;;H04W48/12,,0,0,,,,INACTIVE
373,KR,A,KR 20170069226 A,037-547-792-883-755,2017-06-20,2017,KR 20177010229 A,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883473 A;;US 2015/0055816 W,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,"일부 예들에서, 방법은, 제 1 디바이스에서, NAN(neighbor aware network)의 통신의 연결 셋업 단계 동안에 또는 NAN 발견 윈도우 동안에 제 2 디바이스로부터 가용성 정보를 수신하는 단계를 포함한다. 연결 셋업 단계는 디바이스 성능 정보의 교환을 포함한다. 방법은 또한, 제 2 디바이스가 제 1 디바이스로부터 데이터를 수신하기 위해서 NAN의 데이터 링크 그룹의 송신 윈도우 동안에 이용가능하다고 표시하는 가용성 정보에 기반하여, 제 2 디바이스의 가용성을 결정하기 위해서 메시지 교환을 수행하지 않고도 송신 윈도우 동안에 제 1 디바이스로부터 제 2 디바이스에 데이터를 전송하는 단계를 포함한다.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/037-547-792-883-755,Patent Application,no,0,0,13,36,0,H04W8/005;;H04W8/005;;H04W8/005;;H04W74/04;;H04W4/70;;H04W8/005;;H04W8/24;;H04W8/24;;H04W8/24;;H04W68/025;;H04W68/025;;H04W68/025;;H04W74/04;;H04W74/04;;H04W76/14;;H04W76/14;;H04W84/12;;H04W84/12;;H04W84/18;;H04W84/18;;H04W84/18;;H04W84/18,H04W74/04;;H04W8/00;;H04W8/24;;H04W68/02;;H04W84/18,,0,0,,,,ACTIVE
374,MX,A,MX 2017004837 A,060-877-529-463-839,2017-07-20,2017,MX 2017004837 A,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883469 A;;US 2015/0055813 W,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK.,"In some examples, a method includes generating, at a first device, a paging message including an indication of whether the first device is available for a particular time period during which devices of a data link group of a neighbor aware network (NAN) are configured to operate in an active operating mode. The method also includes sending the message from the first device to one or more devices of the data link group of the NAN.",QUALCOMM INC,ALIREZA RAISSINIA;;SANTOSH PAUL ABRAHAM;;GEORGE CHERIAN;;ABHISHEK PRAMOD PATIL;;JAMES CHO;;GUIDO FREDERIKS,,https://lens.org/060-877-529-463-839,Patent Application,no,0,0,12,36,0,H04W48/16;;H04W84/12;;H04W84/18;;H04W52/0216;;H04W84/18;;H04W48/16;;H04W84/12;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W68/02;;H04W84/18;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W84/18;;Y02D30/70;;H04W68/02;;H04W84/12,H04W84/18;;H04W52/02,,0,0,,,,PENDING
375,WO,A1,WO 2016/061402 A1,150-584-220-500-543,2016-04-21,2016,US 2015/0055816 W,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883473 A,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,"In some examples, a method includes receiving, at a first device, availability information from a second device during a connection set-up phase of communication of a neighbor aware network (NAN) or during a NAN discovery window. The connection set-up phase includes an exchange of device capability information. The method also includes, based on the availability information indicating that the second device is available during a transmission window of a data link group of the NAN to receive data from the first device, sending data from the first device to the second device during the transmission window without performing a message exchange to determine an availability of the second device.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/150-584-220-500-543,Patent Application,yes,3,0,13,36,0,H04W4/70;;H04W8/005;;H04W84/18;;H04W84/18;;H04W8/24;;H04W68/025;;H04W74/04;;H04W8/005;;H04W84/12;;H04W76/14;;H04W8/005;;H04W8/24;;H04W68/025;;H04W74/04;;H04W84/18;;H04W8/005;;H04W84/12;;H04W76/14;;H04W68/025;;H04W74/04;;H04W84/18;;H04W8/24,H04W84/18,,0,0,,,,PENDING
376,US,B2,US 9763223 B2,008-185-775-865-152,2017-09-12,2017,US 201514883523 A,2015-10-14,US 201514883523 A;;US 201462064904 P;;US 201562109530 P;;US 201562205472 P,2014-10-16,Communication between devices of a neighbor aware network,"A method includes generating a paging message at a first device of a data link group of a neighbor aware network (NAN). The paging message includes a paged device list. The paged device list identifies a subset of devices of the data link group, the subset of devices scheduled to receive data from the first device during a transmission window. The paging message includes a receiver address field having a particular receiver address value. The method also includes transmitting, during the paging window, the paging message from to at least one device of the data link group other than the first device.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,QUALCOMM INCORPORATED (2015-12-07),https://lens.org/008-185-775-865-152,Granted Patent,yes,32,7,8,36,0,H04W4/80;;H04W48/12;;H04W84/18;;H04W48/12;;H04W68/005;;H04W74/002;;H04W74/0808;;H04W76/14;;H04W4/80;;H04W84/12;;H04W76/14;;H04W4/80;;H04W84/18;;H04L47/12;;H04W48/12;;H04W68/005;;H04W74/0808;;H04W74/002;;H04W8/005;;H04W68/02;;H04W84/12,H04B7/00;;H04L12/801;;H04W4/80;;H04W8/00;;H04W48/12;;H04W68/02;;H04W76/02;;H04W84/12;;H04W84/18,,1,0,,,"International Search Report and Written Opinion for International Application No. PCT/US2015/055820, ISA/EPO, dated Jan. 21, 2016, 11 pgs.",INACTIVE
377,US,A9,US 2018/0351022 A9,159-173-465-703-403,2018-12-06,2018,US 201715433641 A,2017-02-15,US 201715433641 A;;US 201514623883 A;;US 201313956122 A;;US 75839010 A;;US 44579306 A;;US 201213463069 A;;US 40115709 A;;US 201414485121 A;;US 201213401181 A;;US 27119208 A;;US 2377208 A;;US 86014207 A;;US 86018307 A,2006-06-02,INVERTED METAMORPHIC MULTIJUNCTION SOLAR CELL WITH MULTIPLE METAMORPHIC LAYERS,The disclosure describes multi-junction solar cell structures that include two or more graded interlayers.,SOLAERO TECH CORP,LIN YONG;;SHARPS PAUL R;;CORNFELD ARTHUR;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN,SOLAERO TECHNOLOGIES CORP (2017-02-24),https://lens.org/159-173-465-703-403,Amended Application,yes,0,0,4,111,0,H01L31/078;;H01L31/078;;H01L31/03046;;H01L31/03046;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/0725;;H01L31/0735;;H01L31/1844;;H01L31/1844;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02P70/50;;Y02P70/50,H01L31/078;;H01L31/0687;;H01L31/0725;;H01L31/0735;;H01L31/18,,0,0,,,,ACTIVE
378,US,A1,US 2016/0119894 A1,000-263-030-746-650,2016-04-28,2016,US 201514883473 A,2015-10-14,US 201514883473 A;;US 201462064904 P;;US 201562109530 P;;US 201562205472 P,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,"In some examples, a method includes receiving, at a first device, availability information from a second device during a connection set-up phase of communication of a neighbor aware network (NAN) or during a NAN discovery window. The connection set-up phase includes an exchange of device capability information. The method also includes, based on the availability information indicating that the second device is available during a transmission window of a data link group of the NAN to receive data from the first device, sending data from the first device to the second device during the transmission window without performing a message exchange to determine an availability of the second device.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,QUALCOMM INCORPORATED (2015-12-07),https://lens.org/000-263-030-746-650,Patent Application,yes,2,24,13,36,0,H04W8/005;;H04W8/005;;H04W8/005;;H04W74/04;;H04W4/70;;H04W8/005;;H04W8/24;;H04W8/24;;H04W8/24;;H04W68/025;;H04W68/025;;H04W68/025;;H04W74/04;;H04W74/04;;H04W76/14;;H04W76/14;;H04W84/12;;H04W84/12;;H04W84/18;;H04W84/18;;H04W84/18;;H04W84/18,H04W68/02;;H04W8/00;;H04W76/02,,0,0,,,,ACTIVE
379,US,B2,US 10435227 B2,085-034-230-659-716,2019-10-08,2019,US 201313868900 A,2013-04-23,US 201313868900 A;;US 201261637734 P,2012-04-24,Trigger operated aerosol dispenser,"A trigger operated aerosol dispenser is disclosed for dispensing an aerosol product from an aerosol container through an aerosol valve. The trigger operated aerosol dispenser comprises a base secured to the aerosol container with a dispensing head mounted to the base. A nozzle extends through the dispensing head for communicating the aerosol valve with a terminal orifice. A trigger actuator extends from the dispensing head for actuating the aerosol valve upon depression of the trigger actuator to dispense the aerosol product from the terminal orifice. The trigger operated aerosol dispenser may incorporate a lock for inhibiting the trigger from actuating the aerosol valve. In one example, the trigger operated aerosol dispenser may be actuated in an alternate manner upon a depression of the dispensing head. Preferably, the trigger operated aerosol dispenser is formed from a two piece unit.",APTARGROUP INC,ERICKSON GREGORY A;;MARQUARDT GERAID J;;CHO SEAN;;BLUMENSTEIN BERND;;JASPER BERNHARD;;HALLMAN PAUL,APTARGROUP INC (2013-08-13),https://lens.org/085-034-230-659-716,Granted Patent,yes,72,2,13,13,0,B65D83/205;;B65D83/22;;B65D83/22;;B65D83/205;;B65D83/205;;B65D83/206;;B65D83/206;;B65D83/206;;B65D83/22;;B65D83/753,B65D83/22;;B65D83/14;;B65D83/20,,0,0,,,,ACTIVE
380,EP,A1,EP 3207760 A1,094-678-561-306-245,2017-08-23,2017,EP 15797726 A,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883469 A;;US 2015/0055813 W,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,,QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/094-678-561-306-245,Patent Application,yes,0,0,12,36,0,H04W48/16;;H04W84/12;;H04W84/18;;H04W52/0216;;H04W84/18;;H04W48/16;;H04W84/12;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W68/02;;H04W84/18;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W84/18;;Y02D30/70;;H04W68/02;;H04W84/12,H04W84/18;;H04W52/02,,0,0,,,,ACTIVE
381,US,B2,US 9763221 B2,040-974-000-093-11X,2017-09-12,2017,US 201514883518 A,2015-10-14,US 201514883518 A;;US 201462064904 P;;US 201562109530 P;;US 201562205472 P,2014-10-16,Communication between devices of a neighbor aware network,"A method includes generating, at a first device, a paging message. The method includes, during a first transmission window of a data link group of a neighbor aware network (NAN), sending the paging message from the first device to one or more devices of the data link group. The method further includes, during a second transmission window of the data link group and prior to a data window of the second transmission window, sending data traffic to a particular device of the one or more devices without sending a traffic announcement to the particular device during a second paging window of the second transmission window.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,QUALCOMM INCORPORATED (2015-12-07),https://lens.org/040-974-000-093-11X,Granted Patent,yes,34,8,3,36,0,H04W48/16;;H04W84/12;;H04W52/0216;;Y02D30/70;;H04W48/16;;H04W84/12;;H04W52/0216;;Y02D30/70;;H04W68/005,H04B7/00;;H04W48/16;;H04W52/02;;H04W68/00;;H04W84/12,,1,0,,,"International Search Report and Written Opinion for International Application No. PCT/US2015/055818, ISA/EPO, dated Dec. 18, 2015, 13 pgs.",INACTIVE
382,TW,A,TW 200806886 A,061-476-513-779-782,2008-02-01,2008,TW 96103851 A,2007-02-02,US 80795906 P;;US 55711806 A,2006-07-21,Slurry dispensing system and slurry supply method,"A slurry dispensing system comprises a first supply station, a second supply station, a first loop, a second loop, a first valve and a second valve. The first loop is selectively connected to the first supply station and the second supply station. The second loop is also selectively connected to the first supply station and the second supply station. The first valve connects the first loop to points of use. The second valve connects the second loop to the points of use. When slurry is supplied to the first loop from the first slurry station, slurry is supplied to the second loop from the second slurry station. When the first valve is opened and the second valve is closed, slurry is supplied to the points of use from the first loop.",TAIWAN SEMICONDUCTOR MFG,HSU MING-TZUNG;;TAN PAUL;;CHEN CHIANG-JEH;;CHEN CHO-CHING;;CHU HUI-MING,,https://lens.org/061-476-513-779-782,Patent of Addition,no,0,0,6,6,0,B24B37/04;;B24B37/04;;B24B57/02;;B24B57/02;;Y10T137/0318;;Y10T137/0318;;Y10T137/4259;;Y10T137/4259;;Y10T137/85954;;Y10T137/85954;;Y10T137/85978;;Y10T137/85978,F04B15/02,,0,0,,,,INACTIVE
383,US,A1,US 2017/0164327 A1,090-594-725-759-23X,2017-06-08,2017,US 201715417077 A,2017-01-26,US 201715417077 A;;US 201514883469 A;;US 201462064904 P;;US 201562109530 P;;US 201562205472 P,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,"In some examples, a method includes receiving, at a second device of a data link group of a neighbor aware network (NAN), a message including an indication of whether a first device corresponding to a particular service is available during a particular time period during which devices of the data link group are configured to operate in an active operating mode. The method also includes transitioning to a low-power operating mode during one or more transmission windows corresponding to the particular time period in response to determining that the first device is unavailable during the particular time period.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,QUALCOMM INCORPORATED (2015-12-07),https://lens.org/090-594-725-759-23X,Patent Application,yes,18,11,12,36,0,H04W48/16;;H04W84/12;;H04W84/18;;H04W52/0216;;H04W84/18;;H04W48/16;;H04W84/12;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W68/02;;H04W84/18;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W84/18;;Y02D30/70;;H04W68/02;;H04W84/12,H04W68/02;;H04W48/16;;H04W52/02,,0,0,,,,ACTIVE
384,US,A9,US 2018/0102454 A9,147-825-449-651-768,2018-04-12,2018,US 201715433641 A,2017-02-15,US 201715433641 A;;US 201514623883 A;;US 201313956122 A;;US 75839010 A;;US 44579306 A;;US 201213463069 A;;US 40115709 A;;US 201414485121 A;;US 201213401181 A;;US 27119208 A;;US 2377208 A;;US 86014207 A;;US 86018307 A,2006-06-02,INVERTED METAMORPHIC MULTIJUNCTION SOLAR CELL WITH MULTIPLE METAMORPHIC LAYERS,The disclosure describes multi-junction solar cell structures that include two or more graded interlayers.,SOLAERO TECH CORP,LIN YONG;;SHARPS PAUL R;;CORNFELD ARTHUR;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN,,https://lens.org/147-825-449-651-768,Amended Application,yes,0,0,4,111,0,H01L31/078;;H01L31/078;;H01L31/03046;;H01L31/03046;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/0725;;H01L31/0735;;H01L31/1844;;H01L31/1844;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02P70/50;;Y02P70/50,H01L31/078;;H01L31/0687;;H01L31/0725;;H01L31/0735;;H01L31/18,,0,0,,,,ACTIVE
385,TW,B,TW I328645 B,047-562-027-198-513,2010-08-11,2010,TW 96103851 A,2007-02-02,US 80795906 P;;US 55711806 A,2006-07-21,Slurry dispensing system and slurry supply method,,TAIWAN SEMICONDUCTOR MFG,HSU MING TZUNG;;PAUL TAN;;CHEN CHIANG JEH;;CHEN CHO CHING;;CHU HUI MING,,https://lens.org/047-562-027-198-513,Granted Patent,no,0,0,6,6,0,B24B37/04;;B24B37/04;;B24B57/02;;B24B57/02;;Y10T137/0318;;Y10T137/0318;;Y10T137/4259;;Y10T137/4259;;Y10T137/85954;;Y10T137/85954;;Y10T137/85978;;Y10T137/85978,,,0,0,,,,INACTIVE
386,US,B2,US 9961668 B2,067-018-645-413-213,2018-05-01,2018,US 201514883469 A,2015-10-14,US 201514883469 A;;US 201462064904 P;;US 201562109530 P;;US 201562205472 P,2014-10-16,Communication between devices of a neighbor aware network,"In some examples, a method includes generating, at a first device, a paging message including an indication of whether the first device is available for a particular time period during which devices of a data link group of a neighbor aware network (NAN) are configured to operate in an active operating mode. The method also includes sending the message from the first device to one or more devices of the data link group of the NAN.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,QUALCOMM INCORPORATED (2015-12-07),https://lens.org/067-018-645-413-213,Granted Patent,yes,43,5,12,36,0,H04W48/16;;H04W84/12;;H04W84/18;;H04W52/0216;;H04W84/18;;H04W48/16;;H04W84/12;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W68/02;;H04W84/18;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W84/18;;Y02D30/70;;H04W68/02;;H04W84/12,H04M1/00;;H04W48/16;;H04W52/02;;H04W68/02;;H04W84/12;;H04W84/18,,1,0,,,"International Search Report and Written Opinion for International Application No. PCT/US2015/055813, ISA/EPO, dated Jan. 28, 2016, 12 pgs.",INACTIVE
387,WO,A1,WO 2016/061399 A1,068-204-735-419-147,2016-04-21,2016,US 2015/0055813 W,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883469 A,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,"In some examples, a method includes generating, at a first device, a paging message including an indication of whether the first device is available for a particular time period during which devices of a data link group of a neighbor aware network (NAN) are configured to operate in an active operating mode. The method also includes sending the message from the first device to one or more devices of the data link group of the NAN.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,,https://lens.org/068-204-735-419-147,Patent Application,yes,3,4,12,36,0,H04W48/16;;H04W84/12;;H04W84/18;;H04W52/0216;;H04W84/18;;H04W48/16;;H04W84/12;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W68/02;;H04W84/18;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W84/18;;Y02D30/70;;H04W68/02;;H04W84/12,H04W84/18;;H04W52/02,,0,0,,,,PENDING
388,US,B2,US 10381501 B2,090-540-372-993-499,2019-08-13,2019,US 201715433641 A,2017-02-15,US 201715433641 A;;US 201514623883 A;;US 201313956122 A;;US 75839010 A;;US 44579306 A;;US 201213463069 A;;US 40115709 A;;US 201414485121 A;;US 201213401181 A;;US 27119208 A;;US 2377208 A;;US 86014207 A;;US 86018307 A,2006-06-02,Inverted metamorphic multijunction solar cell with multiple metamorphic layers,The disclosure describes multi-junction solar cell structures that include two or more graded interlayers.,SOLAERO TECH CORP,LIN YONG;;SHARPS PAUL R;;CORNFELD ARTHUR;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN,SOLAERO TECHNOLOGIES CORP (2017-02-24),https://lens.org/090-540-372-993-499,Granted Patent,yes,103,0,4,111,0,H01L31/078;;H01L31/078;;H01L31/03046;;H01L31/03046;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/0725;;H01L31/0735;;H01L31/1844;;H01L31/1844;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02P70/50;;Y02P70/50,H01L31/0735;;H01L31/0304;;H01L31/0687;;H01L31/0725;;H01L31/078;;H01L31/18,,48,25,026-281-940-590-23X;;015-557-396-201-987;;002-874-834-532-776;;073-300-069-664-773;;115-973-926-256-941;;083-287-525-840-54X;;084-891-382-112-541;;025-407-739-778-403;;034-023-904-332-047;;164-535-659-415-932;;007-176-082-871-508;;102-210-428-050-695;;106-513-576-934-63X;;076-989-478-838-81X;;015-717-993-971-840;;043-633-301-060-630;;030-787-136-717-28X;;038-574-682-896-969;;052-700-785-133-704;;093-340-948-123-836;;091-028-789-674-438;;020-636-430-481-14X;;026-862-096-577-376;;026-169-360-688-45X;;107-582-530-482-098,10.1109/wcpec.2006.279587;;10.1109/pvsc.2010.5614498;;10.1109/wcpec.2006.279835;;10.1109/wcpec.2006.279527;;10.1063/1.2753729;;10.1109/pvsc.2008.4922452;;10.1063/1.335957;;10.1109/pvsc.2002.1190685;;10.1109/77.783715;;10.1016/0022-0248(84)90363-4;;10.1016/0379-6787(88)90047-6;;10.1109/pvsc-vol2.2012.6656717;;10.1109/pvsc.1990.111608;;10.1109/iscs.1998.711543;;10.1002/pip.449;;10.1016/0379-6787(86)90032-3;;10.1016/j.jcrysgro.2009.10.059;;10.1002/pip.642;;10.1109/pvsc.1991.169189;;10.1063/1.106494;;10.1088/0953-8984/16/21/008;;10.1109/pvsc.2005.1488186;;10.1109/wcpec.2006.279559;;10.1063/1.98946;;10.1134/1.1187812,"U.S. Appl. No. 12/708,361, filed Feb. 18, 2010, Cornfeld.;;U.S. Appl. No. 12/716,814, filed Mar. 3, 2010, Cornfeld.;;U.S. Appl. No. 12/730,018, filed Mar. 23, 2010, Cornfeld.;;U.S. Appl. No. 12/756,926, filed Apr. 8, 2010, Cornfeld.;;U.S. Appl. No. 12/813,408, filed Jun. 10, 2010, Patel.;;U.S. Appl. No. 12/844,673, filed Jul. 27, 2010, Stan.;;U.S. Appl. No. 13/547,334, filed Jul. 12, 2012, Cornfeld.;;U.S. Appl. No. 13/554,527, filed Jul. 20, 2012, Tourino.;;U.S. Appl. No. 13/569,794, filed Aug. 8, 2012, Stan.;;Aiken et al., “Consideration of High Bandgap Subcells for Advanced Multijunction Solar Cells,” Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, 2006:838-841.;;Cornfeld et al., “Development of a Large Area Inverted Metamorphic Multi-Junction (IMM) Highly Efficient AM0 Solar Cell,” Conference paper presented at the 33rd IEEE Photovoltaic Specialists Conference on May 12, 2008, May 11-16, 2008, San Diego, CA, USA.;;Cornfeld et al., “Advances in the Performance of Inverted Metamorphic Multijunction Solar Cells,” 23rd European Photovoltaic Energy Conference, Aug. 29, 2008, Valencia, Spain.;;Dimroth et al., “Thin 5-Junction Solar Cells with Improved Radiation Hardness,” Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 2006; pp. 1777-1780.;;Extended European Search Report for European Application No. 11010224.1-1528 dated May 15, 2012 (2 pages).;;European Search Report for EP Application No. 15183022.1, dated Jan. 14, 2016, (10 pages).;;Friedman et al., “0.7-eV GaInAs Junction for a GaInP/GaAs/GaInAs(1eV)/GaInAs(0.7eV) Four-Junction Solar Cell,” 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA; 598-602.;;Geisz et al., “High efficiency GaInP/GaAs/InGaAs triple junction solar cells grown inverted with a metamorphic bottom junction,” Applied Physics Letters, 2007; 91:023502-1-023502-3. Published online Jul. 10, 2007.;;Geisz et al., “Inverted GaInP / (In)GaAs Triple-Junction Solar Cells with Low-Stress Metamorphic Bottom Junctions,” 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Hamaker, H.C., “Computer modeling study of the effects of inhomogeneous doping and/or composition in GaAs solar-cell devices,” J Appl. Phys., Sep. 15, 1985; 58(6):2344-2351.;;King et al., “Next-Generation, High Efficiency III-V Multijunction Solar Cells,” 28th IEEE Photovoltaic Specialists Conference, Sep. 15-22, 2000, Anchorage, AK, USA; pp. 998-1001.;;King et al., “High-Efficiency Space and Terrestrial Multijunction Solar Cells Through Bandgap Control in Cell Structures,” 2002 Photovoltaic Specialists Conference, Conference Record of the 29th IEEE, May 19-24, 2002, New Orleans, LA, USA; pp. 776-781.;;King et al., “Solar Cell Generations Over 40% Efficiency,” 26th European Photovoltaic Solar Energy Conference and Exhibition, Sep. 5, 2011, Hamburg, Germany; 15 pgs.;;Koh et al., “Fabrication of Superconducting Delay Line with GaAs Schottky Diode,” IEEE Transactions on Applied Superconductivity, 1999; 9(2):3224-3227.;;Lewis et al., “The Crystallographic Connection of MOCVD-Grown Monolithic Cascade Subcells Via Transparent Graded Layers,” Journal of Crystal Growth, 1984; 69:515-526.;;Lewis et al., “Recent Developments in Multijunction Solar Cell Research,” Solar Cells, 1988; 24:171-183.;;Li et al., “Unintentional doping and compensation effects of carbon in metal-organic chemical vapor deposition fabricated ZnO thin films”, 2006, pp. 1213-1217.;;Patel et al., “Experimental Results From Performance Improvement And Radiation Hardening Of inverted Metamorphic Multi-Junction Solar Cells,” Proceedings of the 37th IEEE PVSC, Seattle, WA, 2011 (Presented at PVSC Jun. 22, 2001).;;Patel et al., “Initial Results of the Monolithically Grown Six-Junction Inverted Metamorphic Multi-junction Solar Cell,” Proceedings of the 38th IEEE PVSC, Austin, TX, 2012 (Presented at PVSC Jun. 7, 2012).;;Schultz et al., “High Efficiency 1.0-eV GaInAs Bottom Solar Cell for 3-Junction Monolithic Stack,” Proceedings of the Photovoltaic Specialists Conference Record of the 21st IEEE, May 21, 1990, pp. 148-152.;;Sexl et al., “MBE Growth of Metamorphic In(Ga)AIAs Buffers,” 1997 IEEE International Symposium on Compound Semiconductors, Sep. 8-11, 1997; pp. 49-52.;;Sharps et al., “Inverting the triple junction improves efficiency and flexibility,” Compound Semiconductor, Oct. 2007; pp. 25-28.;;Sinharoy et al., “Progress in the Development of Metamorphic Multi-junction III-V Space Solar Cells,” Progress in Photovoltaics: Research and Applications, Feb. 2002; 10:427-432.;;Soukup et al., “Limitations of Built-in Electric Field Enhancement of Minority Carrier Current Collection in GaAs Backwall Schottky Barrier Solar Cells,” Solar Cells, 1986; 18:139-151.;;Stan et al., “Recent Advances in the Performance of Multi-Junction Space Solar Cells,” 22nd European Photovoltaic Solar Energy Conference, Sep. 3-7, 2007, Milan, Italy; pp. 101-105.;;Stan et al., “Very High Efficiency Triple Junction Solar Cells by MOVPE,” 14th International Conference of Metalorganic Vapor Phase Epitaxy, Jun. 5, 2008, Metz, France.;;Stan et al., “High efficiency quadruple junction solar cells using MOVPE with inverted metamorphic device structures,” Journal of Crystal Growth, 2010; 312:1370-1374.;;Takamoto et al., “Future Development of InGaP/(In)GaAs Based Multijunction Solar Cells,” Proceedings of the 31st IEEE PVSC, Jan. 3-7, 2005, Lake Buena Vista, FL; pp. 519-524.;;Takamoto et al., “InGaP/GaAs-based Multijunction Solar Cells,” Progress in Photovoltaics: Research and Applications, 2005; 13:495-511.;;Venkatasubramanian et al., “An Inverted-Growth Approach to Development of an IR-Transparent, High-Efficiency AlGaAs/GaAs Cascade Solar Cell,” 22nd IEEE Photovoltaic Specialists Conference, Oct. 7-11, 1991, Las Vegas, NV, USA; pp. 93-98.;;Venkatasubramanian et al., “High-quality eutectic-metal-bonded AlGaAs—GaAs thin films on Si substrates,” Appl. Phys. Lett., Feb. 1992; 60(7):886-888.;;Voncken et al., “Strain-accelerated HF etching of AlAs for epitaxial lift-off,” J. Phys.: Condens. Matter, 2004; 16:3585-3596.;;Walters et al., “Space Radiation Effects in Advanced Solar Cell Materials and Devices,” Mat. Res. Soc. Symp. Proc., 2002; 692:569-580.;;Wanlass et al., “Lattice-Mismatched Approaches for High-Performance, III-V Photovoltaic Energy Converters,” Conference Proceedings of the 31st IEEE Photovoltaic Specialists Conference and Exhibition, Lake Buena Vista, FL, USA; Jan. 3-7, 2005;530-535.;;Wanlass et al., “Monolithic, Ultra-Thin GaInP/GaAs/GaInAs Tandem Solar Cells,” 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA; 729-732.;;Wurfel, “Basic Structure of Solar Cells,” Physics of Solar Cells: From Basic Principles to Advanced Concepts, Second, Updated and Expanded Edition, 2009; Sections 6.4, 6.5 and 6.8.;;Yablonovitch et al., “Extreme selectivity in the lift-off of epitaxial GaAs films,” Appl. Phys. Lett., 1987; 51(28):2222-2224.;;Yamaguchi, “Physics and Technologies of Superhigh-Efficiency Tandem Solar Cells,” Semiconductors, Sep. 1999; 33(9):961-964.;;Yoon et al., “Progress of Inverted Metamorphic III-V Solar Cell Development at Spectrolab,” 33rd IEEE Specialists Conference, May 11-16, 2008, San Diego, CA, USA.",ACTIVE
389,MX,A,MX 2017004936 A,118-424-499-012-279,2017-06-22,2017,MX 2017004936 A,2015-10-15,US 201462064904 P;;US 201562109530 P;;US 201562205472 P;;US 201514883473 A;;US 2015/0055816 W,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK.,"In some examples, a method includes receiving, at a first device, availability information from a second device during a connection set-up phase of communication of a neighbor aware network (NAN) or during a NAN discovery window. The connection set-up phase includes an exchange of device capability information. The method also includes, based on the availability information indicating that the second device is available during a transmission window of a data link group of the NAN to receive data from the first device, sending data from the first device to the second device during the transmission window without performing a message exchange to determine an availability of the second device.",QUALCOMM INC,ALIREZA RAISSINIA;;SANTOSH PAUL ABRAHAM;;GEORGE CHERIAN;;ABHISHEK PRAMOD PATIL;;JAMES CHO;;GUIDO FREDERIKS,,https://lens.org/118-424-499-012-279,Patent Application,no,0,0,13,36,0,H04W8/005;;H04W8/005;;H04W8/005;;H04W74/04;;H04W4/70;;H04W8/005;;H04W8/24;;H04W8/24;;H04W8/24;;H04W68/025;;H04W68/025;;H04W68/025;;H04W74/04;;H04W74/04;;H04W76/14;;H04W76/14;;H04W84/12;;H04W84/12;;H04W84/18;;H04W84/18;;H04W84/18;;H04W84/18,H04W84/18,,0,0,,,,PENDING
390,US,B2,US 9762119 B2,174-169-923-959-329,2017-09-12,2017,US 201514965346 A,2015-12-10,US 201514965346 A;;KR 20150116091 A;;US 201562139141 P,2015-03-27,"Switch driving circuit, and power factor correction circuit having the same","The present disclosure relates generally to a switch driving circuit and power factor correction circuit having the same, and more particularly, to a technology to provide a negative offset using Zener diodes to prevent malfunctions in driving a switch. The switch driving circuit to operate a switch implemented with a Field Effect Transistor (FET) includes a first Zener diode connected to a control input end of the switch; a capacitor connected in parallel with the first Zener diode; and second and third Zener diodes for providing a negative offset to fix a voltage applied between the gate and source of the switch to a negative value.",SAMSUNG ELECTRONICS CO LTD;;SNU R&DB FOUNDATION,KIM JIN HAN;;SEO HAN SOL;;CHO BO-HYUNG;;KANG SANG-WOO;;JANG PAUL,SAMSUNG ELECTRONICS CO. LTD (2015-11-17),https://lens.org/174-169-923-959-329,Granted Patent,yes,11,11,2,2,0,H03K17/162;;H03K17/302;;H02M1/4225;;H02M1/4208;;Y02B70/10;;H02M1/0085;;H02M1/4208;;H03K17/162;;H03K17/302;;H02M1/4225;;Y02B70/10;;H02M1/0085,H03K17/687;;H02M1/42;;H03K17/16;;H03K17/30,,0,0,,,,ACTIVE
391,CN,B,CN 101108472 B,069-419-193-548-298,2010-07-21,2010,CN 200710109533 A,2007-06-25,US 80795906 P;;US 55711806 A,2006-07-21,Slurry dispensing system and method thereof,"A slurry dispensing system comprises a first supply station, a second supply station, a first loop, a second loop, a first valve and a second valve. The first loop is selectively connected to the first supply station and the second supply station. The second loop is also selectively connected to the first supply station and the second supply station. The first valve connects the first loop to points of use. The second valve connects the second loop to the points of use. When slurry is supplied to the first loop from the first slurry station, slurry is supplied to the second loop from the second slurry station. When the first valve is opened and the second valve is closed, slurry is supplied to the points of use from the first loop.",TAIWAN SEMICONDUCTOR MFG,HUI-MING CHU;;CHO-CHING CHEN;;PAUL TAN;;CHIANG-JEH CHEN;;MING-TZUNG HSU,,https://lens.org/069-419-193-548-298,Granted Patent,no,0,0,6,6,0,B24B37/04;;B24B37/04;;B24B57/02;;B24B57/02;;Y10T137/0318;;Y10T137/0318;;Y10T137/4259;;Y10T137/4259;;Y10T137/85954;;Y10T137/85954;;Y10T137/85978;;Y10T137/85978,B24B57/02,,0,0,,,,ACTIVE
392,US,A1,US 2016/0112987 A1,167-548-172-512-804,2016-04-21,2016,US 201514883523 A,2015-10-14,US 201514883523 A;;US 201462064904 P;;US 201562109530 P;;US 201562205472 P,2014-10-16,COMMUNICATION BETWEEN DEVICES OF A NEIGHBOR AWARE NETWORK,"A method includes generating a paging message at a first device of a data link group of a neighbor aware network (NAN). The paging message includes a paged device list. The paged device list identifies a subset of devices of the data link group, the subset of devices scheduled to receive data from the first device during a transmission window. The paging message includes a receiver address field having a particular receiver address value. The method also includes transmitting, during the paging window, the paging message from to at least one device of the data link group other than the first device.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,QUALCOMM INCORPORATED (2015-12-07),https://lens.org/167-548-172-512-804,Patent Application,yes,3,39,8,36,0,H04W4/80;;H04W48/12;;H04W84/18;;H04W48/12;;H04W68/005;;H04W74/002;;H04W74/0808;;H04W76/14;;H04W4/80;;H04W84/12;;H04W76/14;;H04W4/80;;H04W84/18;;H04L47/12;;H04W48/12;;H04W68/005;;H04W74/0808;;H04W74/002;;H04W8/005;;H04W68/02;;H04W84/12,H04W68/02;;H04W4/80;;H04W8/00;;H04W76/02,,0,0,,,,INACTIVE
393,US,B2,US 9769645 B2,089-122-426-264-156,2017-09-19,2017,US 201514883473 A,2015-10-14,US 201514883473 A;;US 201462064904 P;;US 201562109530 P;;US 201562205472 P,2014-10-16,Communication between devices of a neighbor aware network,"In some examples, a method includes receiving, at a first device, availability information from a second device during a connection set-up phase of communication of a neighbor aware network (NAN) or during a NAN discovery window. The connection set-up phase includes an exchange of device capability information. The method also includes, based on the availability information indicating that the second device is available during a transmission window of a data link group of the NAN to receive data from the first device, sending data from the first device to the second device during the transmission window without performing a message exchange to determine an availability of the second device.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,QUALCOMM INCORPORATED (2015-12-07),https://lens.org/089-122-426-264-156,Granted Patent,yes,34,9,13,36,0,H04W8/005;;H04W8/005;;H04W8/005;;H04W74/04;;H04W4/70;;H04W8/005;;H04W8/24;;H04W8/24;;H04W8/24;;H04W68/025;;H04W68/025;;H04W68/025;;H04W74/04;;H04W74/04;;H04W76/14;;H04W76/14;;H04W84/12;;H04W84/12;;H04W84/18;;H04W84/18;;H04W84/18;;H04W84/18,H04B7/00;;H04W8/00;;H04W8/24;;H04W68/02;;H04W74/04;;H04W76/02;;H04W84/12;;H04W84/18,,1,0,,,"International Search Report and Written Opinion for International Application No, PCT/US2015/055816, ISA/EPO, dated Jan. 4, 2016, 13 pgs.",ACTIVE
394,US,B2,US 10117222 B2,118-524-332-535-463,2018-10-30,2018,US 201715417077 A,2017-01-26,US 201715417077 A;;US 201514883469 A;;US 201462064904 P;;US 201562109530 P;;US 201562205472 P,2014-10-16,Communication between devices of a neighbor aware network,"In some examples, a method includes receiving, at a second device of a data link group of a neighbor aware network (NAN), a message including an indication of whether a first device corresponding to a particular service is available during a particular time period during which devices of the data link group are configured to operate in an active operating mode. The method also includes transitioning to a low-power operating mode during one or more transmission windows corresponding to the particular time period in response to determining that the first device is unavailable during the particular time period.",QUALCOMM INC,PATIL ABHISHEK PRAMOD;;ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;CHO JAMES;;FREDERIKS GUIDO,QUALCOMM INCORPORATED (2015-12-07),https://lens.org/118-524-332-535-463,Granted Patent,yes,49,3,12,36,0,H04W48/16;;H04W84/12;;H04W84/18;;H04W52/0216;;H04W84/18;;H04W48/16;;H04W84/12;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W68/02;;H04W84/18;;Y02D30/70;;H04W48/16;;H04W52/0216;;H04W84/18;;Y02D30/70;;H04W68/02;;H04W84/12,H04B7/00;;H04W48/16;;H04W52/02;;H04W68/02;;H04W84/12;;H04W84/18,,1,0,,,"International Search Report and Written Opinion—PCT/US2015/055813—ISA/EPO—dated Jan. 28, 2016.",ACTIVE
395,CA,A1,CA 2995242 A1,000-837-753-620-20X,2019-08-15,2019,CA 2995242 A,2018-02-15,CA 2995242 A,2018-02-15,METHOD AND SYSTEM FOR ACTIVITY CLASSIFICATION,"This disclosure is directed to an activity classifier system, for classifying human activities using 2D skeleton data. The system includes a skeleton preprocessor that transforms the 2D skeleton data into transformed skeleton data, the transformed skeleton data comprising scaled, relative joint positions and relative joint velocities. It also includes a gesture classifier comprising a first recurrent neural network that receives the transformed skeleton data, and is trained to identify the most probable of a plurality of gestures. There is also an action classifier comprising a second recurrent neural network that receives information from the first recurrent neural networks and is trained to identify the most probable of a plurality of actions.",WRNCH INC,BROWN COLIN J;;TOLSTIKHIN ANDREY;;PETERS THOMAS D;;CHO DONGWOOK;;ZHANG MAGGIE;;KRUSZEWSKI PAUL A,,https://lens.org/000-837-753-620-20X,Patent Application,no,0,2,7,7,0,G06N3/08;;G06V40/23;;G06V40/28;;G06V10/34;;G06N3/048;;G06N3/044;;G06N3/045;;G06N3/08;;A41D27/20;;A45C13/185;;G06V40/23;;G06V20/647;;A45C1/024;;A45C1/06;;A45C13/18;;A45F5/022;;G06V40/28;;G06N3/045;;G06V10/34,A61B5/103;;A61B5/11;;G06N3/02;;G06N3/08;;G06V10/34,,0,0,,,,PENDING
396,US,B1,US 10591337 B1,062-368-961-351-796,2020-03-17,2020,US 201514714151 A,2015-05-15,US 201514714151 A;;US 201461994724 P,2014-05-16,Dispensing cup for aerosol device,A lockable metering aerosol dispenser is disclosed for dispensing an aerosol product from an aerosol container through an aerosol valve. The lockable metering aerosol dispenser comprises a base secured to the aerosol container with a cup rotationally mounted to the base between a locked rotational position and an unlocked rotational position. A metering cup is secured relative to the base and communicates with the aerosol valve. The cup is capable of actuating the aerosol valve for dispensing the aerosol product into the metering cup when the cup is rotated into the unlocked rotational position. The cup is inhibited from actuating the aerosol valve when the cup is rotated into the locked rotational position.,APTARGROUP INC,NEUHALFEN MARK;;ERICKSON GREGORY A;;VIRGILIO STEPHEN;;HALLMAN PAUL;;MARQUARDT GERALD J;;CHO SEAN HANG,APTAR GROUP INC (2017-06-14),https://lens.org/062-368-961-351-796,Granted Patent,yes,21,1,1,1,0,B05B1/267;;B65D83/206;;B65D83/22;;B65D83/40;;B65D83/40;;B65D83/75;;G01F11/006;;G01F11/263;;G01F11/28;;G01F11/288,G01F11/26;;B65D83/14;;B65D83/40,,0,0,,,,ACTIVE
397,US,B2,US 11593490 B2,115-902-744-446-64X,2023-02-28,2023,US 202117386826 A,2021-07-28,US 202117386826 A,2021-07-28,System and method for maintaining trusted execution in an untrusted computing environment using a secure communication channel,"An Information Handling System (IHS) includes multiple hardware devices, and a baseboard Management Controller (BMC) in communication with the plurality of hardware devices. The BMC includes instructions for executing an assistance application (APP) in an untrusted domain of the BMC. The assistance APP configured to monitor a custom BMC firmware stack executed in the untrusted domain. The instructions are further executed to verify an integrity of the assistance APP from a trusted domain of the BMC by encrypting communications between the trusted and untrusted domains using an encryption key that comprises a function of a time counter value.",DELL PRODUCTS LP,CHO EUGENE DAVID;;SANCHEZ MARIO ALBERTO;;MADDUKURI AKKIAH CHOUDARY;;SAVAGE MARSHAL F;;VANCIL PAUL W,DELL PRODUCTS L.P (2021-07-21),https://lens.org/115-902-744-446-64X,Granted Patent,yes,6,0,2,2,0,H04L9/0891;;H04L9/0872;;G06F21/575;;G06F21/606;;G06F21/51;;G06F21/575;;H04L25/0204;;H04L9/0822;;G06F21/572;;G06F21/52;;G06F21/606,G06F21/57;;G06F21/52;;G06F21/60;;H04L9/08;;H04L25/02,,0,0,,,,ACTIVE
398,CA,A1,CA 2606954 A1,033-640-030-233-52X,2006-11-16,2006,CA 2606954 A,2006-04-26,US 12385905 A;;US 2006/0015703 W,2005-05-06,SELF-HEALING POLYMERS,,UNIV ILLINOIS,ANDERSSON MAGNUS H;;WHITE SCOTT R;;SOTTOS NANCY R;;BRAUN PAUL V;;CHO SOO HYOUN,,https://lens.org/033-640-030-233-52X,Patent Application,no,0,0,8,8,0,B29C73/163;;B29C73/163;;B29C73/22;;B29C73/22;;B29C73/22;;C08K9/10;;C08F8/00;;C08F291/00;;C08F291/00;;C08K7/16,C08F291/00;;B29C73/22;;C08K9/10,,0,0,,,,DISCONTINUED
399,WO,A1,WO 2006/121609 A1,172-019-567-994-059,2006-11-16,2006,US 2006/0015703 W,2006-04-26,US 12385905 A,2005-05-06,SELF-HEALING POLYMERS,"A composite material includes a polymer matrix, a polymerizer, and a plurality of capsules containing a corresponding activator for the polymerizer. The composite material can also include an adhesion promoter, and the polymerizer can be phase separated from the polymer matrix. The composite material can be made by dispersing the polymerizer and capsules into the polymer matrix. These composite materials can exhibit improved environmental stability, and can be used with a wider variety of activators.",UNIV ILLINOIS;;BRAUN PAUL V;;CHO SOO HYOUN;;WHITE SCOTT R;;SOTTOS NANCY R;;ANDERSSON MAGNUS H,BRAUN PAUL V;;CHO SOO HYOUN;;WHITE SCOTT R;;SOTTOS NANCY R;;ANDERSSON MAGNUS H,,https://lens.org/172-019-567-994-059,Patent Application,yes,5,5,8,8,0,B29C73/163;;B29C73/163;;B29C73/22;;B29C73/22;;B29C73/22;;C08K9/10;;C08F8/00;;C08F291/00;;C08F291/00;;C08K7/16,C08F291/00;;B29C73/22;;C08K9/10,,0,0,,,,PENDING
400,US,B2,US 11783183 B2,123-606-943-913-814,2023-10-10,2023,US 202117173978 A,2021-02-11,US 202117173978 A;;CA 2995242 A;;US 201916276493 A,2018-02-15,Method and system for activity classification,"An activity classifier system and method that classifies human activities using 2D skeleton data. The system includes a skeleton preprocessor that transforms the 2D skeleton data into transformed skeleton data, the transformed skeleton data comprising scaled, relative joint positions and relative joint velocities. The system also includes a gesture classifier comprising a first recurrent neural network that receives the transformed skeleton data, and is trained to identify the most probable of a plurality of gestures. The system also has an action classifier comprising a second recurrent neural network that receives information from the first recurrent neural networks and is trained to identify the most probable of a plurality of actions.",HINGE HEALTH INC,BROWN COLIN J;;TOLSTIKHIN ANDREY;;PETERS THOMAS D;;CHO DONGWOOK;;ZHANG MAGGIE;;KRUSZEWSKI PAUL A,WRNCH INC (2018-03-20);;HINGE HEALTH INC (2021-09-15),https://lens.org/123-606-943-913-814,Granted Patent,yes,9,0,7,7,0,G06N3/08;;G06V40/23;;G06V40/28;;G06V10/34;;G06N3/048;;G06N3/044;;G06N3/045;;G06N3/08;;A41D27/20;;A45C13/185;;G06V40/23;;G06V20/647;;A45C1/024;;A45C1/06;;A45C13/18;;A45F5/022;;G06V40/28;;G06N3/045;;G06V10/34,G06V40/20;;A41D27/20;;A45C1/02;;A45C1/06;;A45C13/18;;A45F5/02;;G06N3/04;;G06N3/045;;G06N3/08;;G06V10/34;;G06V20/64,,2,2,084-468-139-209-388;;084-468-139-209-388,31331883;;10.1109/cvpr.2017.143;;10.1109/tpami.2019.2929257;;31331883;;10.1109/cvpr.2017.143;;10.1109/tpami.2019.2929257,"Realtime Multi-Person 2D Pose Estimation using Part Affinity Fields (IEEE 2017) (Year: 2017).;;Cao et al., “Realtime Multi-Person 2D Pose Estimation using Part Affinity Fields”, The Robotics Institute, Canegie Mellon University, 2017 IEEEConference on Computer and Pattern Recognition, Downloaded on Jun. 3, 2020, 9 pages.",ACTIVE
401,US,A1,US 2020/0183922 A1,138-497-261-596-342,2020-06-11,2020,US 202016795516 A,2020-02-19,US 202016795516 A,2020-02-19,NEAREST NEIGHBOR SEARCH LOGIC CIRCUIT WITH REDUCED LATENCY AND POWER CONSUMPTION,An apparatus is described. The apparatus includes a nearest neighbor search circuit to perform a search according to a first stage search and a second stage search. The nearest neighbor search circuit includes a first stage circuit and a second stage circuit. The first stage search circuit includes a hash logic circuit and a content addressable memory. The hash logic circuit is to generate a hash word from a input query vector. The hash word has B bands. The content addressable memory is to store hashes of a random access memory's data items. The hashes each have B bands. The content addressable memory is to compare the hashes against the hash word on a sequential band-by-band basis. The second stage circuit char the random access memory and a compare and sort circuit. The compare and sort circuit is to receive the input query vector. The random access memory has crosswise bit lines coupled to the compare and sort circuit. The compare and sort circuit is to identify k nearest ones of the data items whose hashes were selected by the content addressable memory.,INTEL CORP,LIM WOOTAEK;;CHO MINCHANG;;PAUL SOMNATH;;AUGUSTINE CHARLES;;BANG SUYOUNG;;MAJUMDER TURBO;;KHELLAH MUHAMMAD M,INTEL CORPORATION (2020-04-14),https://lens.org/138-497-261-596-342,Patent Application,yes,3,0,1,1,0,G06F7/20;;G06F7/08;;G11C7/1006;;G11C11/412;;G11C15/04;;G06F16/906;;Y02D10/00;;G06F16/2453;;G11C15/04;;G06F7/20;;G06F7/08,G06F16/2453;;G06F7/08;;G06F7/20;;G11C15/04,,0,0,,,,DISCONTINUED
402,US,A9,US 2022/0240638 A9,023-530-870-731-097,2022-08-04,2022,US 202117173978 A,2021-02-11,US 202117173978 A;;CA 2995242 A;;US 201916276493 A,2018-02-15,METHOD AND SYSTEM FOR ACTIVITY CLASSIFICATION,"An activity classifier system and method that classifies human activities using 2D skeleton data. The system includes a skeleton preprocessor that transforms the 2D skeleton data into transformed skeleton data, the transformed skeleton data comprising scaled, relative joint positions and relative joint velocities. The system also includes a gesture classifier comprising a first recurrent neural network that receives the transformed skeleton data, and is trained to identify the most probable of a plurality of gestures. The system also has an action classifier comprising a second recurrent neural network that receives information from the first recurrent neural networks and is trained to identify the most probable of a plurality of actions.",HINGE HEALTH INC;;WRNCH INC,BROWN COLIN J;;TOLSTIKHIN ANDREY;;PETERS THOMAS D;;CHO DONGWOOK;;ZHANG MAGGIE;;KRUSZEWSKI PAUL A,WRNCH INC (2018-03-20);;HINGE HEALTH INC (2021-09-15),https://lens.org/023-530-870-731-097,Amended Application,yes,9,0,7,7,0,G06N3/08;;G06V40/23;;G06V40/28;;G06V10/34;;G06N3/048;;G06N3/044;;G06N3/045;;G06N3/08;;A41D27/20;;A45C13/185;;G06V40/23;;G06V20/647;;A45C1/024;;A45C1/06;;A45C13/18;;A45F5/022;;G06V40/28;;G06N3/045;;G06V10/34,A45C13/18;;A41D27/20;;A45C1/02;;A45C1/06;;A45F5/02;;G06V10/34,,1,1,084-468-139-209-388,31331883;;10.1109/cvpr.2017.143;;10.1109/tpami.2019.2929257,Realtime Multi-Person 2D Pose Estimation using Part Affinity Fields (IEEE 2017) (Year: 2017),ACTIVE
403,US,A1,US 2019/0251340 A1,072-020-796-349-371,2019-08-15,2019,US 201916276493 A,2019-02-14,CA 2995242 A,2018-02-15,METHOD AND SYSTEM FOR ACTIVITY CLASSIFICATION,"This disclosure is directed to an activity classifier system, for classifying human activities using 2D skeleton data. The system includes a skeleton preprocessor that transforms the 2D skeleton data into transformed skeleton data, the transformed skeleton data comprising scaled, relative joint positions and relative joint velocities. It also includes a gesture classifier comprising a first recurrent neural network that receives the transformed skeleton data, and is trained to identify the most probable of a plurality of gestures. There is also an action classifier comprising a second recurrent neural network that receives information from the first recurrent neural networks and is trained to identify the most probable of a plurality of actions.",WRNCH INC,BROWN COLIN J;;TOLSTIKHIN ANDREY;;PETERS THOMAS D;;CHO DONGWOOK;;ZHAN MAGGIE;;KRUSZEWSKI PAUL A,WRNCH INC (2018-03-20);;HINGE HEALTH INC (2021-09-15),https://lens.org/072-020-796-349-371,Patent Application,yes,9,31,7,7,0,G06N3/08;;G06V40/23;;G06V40/28;;G06V10/34;;G06N3/048;;G06N3/044;;G06N3/045;;G06N3/08;;A41D27/20;;A45C13/185;;G06V40/23;;G06V20/647;;A45C1/024;;A45C1/06;;A45C13/18;;A45F5/022;;G06V40/28;;G06N3/045;;G06V10/34,G06N3/04;;G06N3/08;;G06V10/34,,0,0,,,,ACTIVE
404,EP,A1,EP 4013679 A1,117-976-507-578-803,2022-06-22,2022,EP 20760516 A,2020-08-14,GB 201911773 A;;GB 2020051943 W,2019-08-16,AN AIRCRAFT CABIN,,SAFRAN SEATS GB LTD;;SAFRAN SEATS;;ZODIAC AEROSPACE EQUIPMENT DE MEXICO S DE R L DE C V,WOODINGTON JAMES BYRON;;MADRIGAL JOSE;;BERMUDEZ CRISTINA;;LEUNG CHO KIU HEATHER;;JONES RYAN;;HURSTEL PAUL,,https://lens.org/117-976-507-578-803,Patent Application,yes,0,0,8,8,0,B64D11/0601;;B64D11/0606;;B64D11/0641;;B64D11/0644;;B64D11/0605;;B64D11/0638;;B64D11/0604;;B64D11/0641;;B64D11/0601;;B64D11/0606;;B64D11/064;;B64D11/0641,B64D11/06,,0,0,,,,ACTIVE
405,KR,A,KR 20080035511 A,012-562-851-772-149,2008-04-23,2008,KR 20077028497 A,2007-12-06,US 12385905 A,2005-05-06,SELF-HEALING POLYMERS,"A composite material includes a polymer matrix, a polymerizer, and a plurality of capsules containing a corresponding activator for the polymerizer. The composite material can also include an adhesion promoter, and the polymerizer can be phase separated from the polymer matrix. The composite material can be made by dispersing the polymerizer and capsules into the polymer matrix. These composite materials can exhibit improved environmental stability, and can be used with a wider variety of activators.",UNIV ILLINOIS,BRAUN PAUL V;;CHO SOO HYOUN;;WHITE SCOTT R;;SOTTOS NANCY R;;ANDERSSON H MAGNUS,,https://lens.org/012-562-851-772-149,Patent Application,no,0,8,8,8,0,B29C73/163;;B29C73/163;;B29C73/22;;B29C73/22;;B29C73/22;;C08K9/10;;C08F8/00;;C08F291/00;;C08F291/00;;C08K7/16,B29C73/22;;C08F8/00;;C08K7/16,,0,0,,,,DISCONTINUED
406,US,B2,US 8868185 B2,184-693-177-349-046,2014-10-21,2014,US 201213686359 A,2012-11-27,US 201213686359 A;;US 201161553524 P,2011-10-31,Use of thoracic and extra-thoracic impedance for diagnostic monitoring,"A medical device and associated method for delivery of a cardiac therapy that includes determining a first impedance signal along a thoracic electrode vector extending within a portion of a thoracic cavity, determining a second impedance signal along an extra-thoracic electrode vector extending outside the thoracic cavity, comparing first amplitude measurements corresponding to the first impedance signals and second amplitude measurements corresponding to the second impedance signals, comparing first slope measurements corresponding to the first impedance signals and second slope measurements corresponding to the second impedance signals, and determining delivery of the cardiac therapy in response to the comparing.",MEDTRONIC INC,ZIELINSKI TODD M;;HETTRICK DOUGLAS A;;CHO YONG K;;WARMAN EDUARDO N;;SOBOTKA PAUL A,MEDTRONIC INC (2012-11-13),https://lens.org/184-693-177-349-046,Granted Patent,yes,32,6,2,7,0,A61B5/0537;;A61B5/085;;A61N1/3627;;A61N1/36521;;A61B5/085;;A61B5/0537;;A61N1/36521;;A61N1/3627;;A61M27/00;;A61N1/36507,A61N1/368;;A61M27/00;;A61N1/365,607/17;;607/7,2,1,080-526-133-879-724,19298923;;pmc2699432;;10.1016/j.jacc.2008.12.018,"Khoury DS, et al. ""Ambulatory Monitoring of Congestive Heart Failure by Multiple Bioelectric Impedance Vectors"", JACC, 2009, vol. 53(12).;;P0041250.WOU4 (PCT/US2012/066810) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority.",ACTIVE
407,GB,B,GB 2586273 B,067-233-082-456-587,2023-04-12,2023,GB 201911773 A,2019-08-16,GB 201911773 A,2019-08-16,An aircraft cabin,,SAFRAN SEATS GB LTD;;SAFRAN SEATS;;ZODIAC AEROSPACE EQUIPMENT DE MEXICO,JAMES BYRON WOODINGTON;;JOSE MADRIGAL;;CRISTINA BERMUDEZ;;CHO KIU HEATHER LEUNG;;RYAN JONES;;PAUL HUNSTEL,,https://lens.org/067-233-082-456-587,Granted Patent,no,3,0,8,8,0,B64D11/0601;;B64D11/0606;;B64D11/0641;;B64D11/0644;;B64D11/0605;;B64D11/0638;;B64D11/0604;;B64D11/0641;;B64D11/0601;;B64D11/0606;;B64D11/064;;B64D11/0641,B64D11/06,,0,0,,,,ACTIVE
408,US,A1,US 2009/0014015 A1,152-573-443-710-520,2009-01-15,2009,US 10386408 A,2008-04-16,US 10386408 A;;US 91237107 P,2007-04-17,INTRAOPERATIVE DOSIMETRY FOR PROSTATE BRACHYTHERAPY USING TRANSRECTAL ULTRASOUND AND X-RAY FLUOROSCOPY,"While performing prostate brachytherapy in which radioactive seeds are implanted into the prostate, both X-ray and transrectal ultrasound (TRUS) data are collected. The X-ray data indicate all of the implanted seeds, but not their relative position within the prostate. The TRUS data correspond to both axial and longitudinal ultrasound images. A subset of the implanted seeds can be automatically (or manually) detected in the TRUS data (using longitudinal ultrasound images), and the prostate is indicated in the TRUS data (using axial ultrasound images). Registration is performed between the X-ray and TRUS data, thereby identifying the disposition of all implanted seeds within the prostate, enabling dosimetry to be intraoperatively determined. A medical practitioner can thus determine whether and where to implant additional seeds to achieve a desired optimal dosage and do so before the prostate brachytherapy procedure is concluded.",UNIV WASHINGTON,TUTAR ISMAIL;;CHO PAUL S;;NARAYANAN SREERAM;;PATHAK SAYAN;;GONG LIXIN;;SHANG JUNQING;;KIM YONGMIN,UNIVERSITY OF WASHINGTON (2008-05-13),https://lens.org/152-573-443-710-520,Patent Application,yes,2,24,1,1,0,A61N5/1027;;A61N5/1048;;A61N2005/1058;;A61N2005/1061;;A61N5/1027;;A61N2005/1058;;A61N5/1048;;A61N2005/1061,A61M36/12,128/898;;600/7,1,0,,,"Jain et al., Matching and Reconstruction of Brachytherapy Seeds using the Hungarian Algorithm (MARSHAL), 2005-04-12, SPIE Digital Library, Volume 5744, pages 810-821",DISCONTINUED
409,US,A1,US 2024/0028896 A1,129-709-525-103-499,2024-01-25,2024,US 202318477482 A,2023-09-28,US 202318477482 A;;CA 2995242 A;;US 202117173978 A;;US 201916276493 A,2018-02-15,METHOD AND SYSTEM FOR ACTIVITY CLASSIFICATION,"An activity classifier system and method that classifies human activities using 2D skeleton data. The system includes a skeleton preprocessor that transforms the 2D skeleton data into transformed skeleton data, the transformed skeleton data comprising scaled, relative joint positions and relative joint velocities. The system also includes a gesture classifier comprising a first recurrent neural network that receives the transformed skeleton data, and is trained to identify the most probable of a plurality of gestures. The system also has an action classifier comprising a second recurrent neural network that receives information from the first recurrent neural networks and is trained to identify the most probable of a plurality of actions.",HINGE HEALTH INC,BROWN COLIN J;;TOLSTIKHIN ANDREY;;PETERS THOMAS D;;CHO DONGWOOK;;ZHANG MAGGIE;;KRUSZEWSKI PAUL A,,https://lens.org/129-709-525-103-499,Patent Application,yes,0,0,7,7,0,G06N3/08;;G06V40/23;;G06V40/28;;G06V10/34;;G06N3/048;;G06N3/044;;G06N3/045;;G06N3/08;;A41D27/20;;A45C13/185;;G06V40/23;;G06V20/647;;A45C1/024;;A45C1/06;;A45C13/18;;A45F5/022;;G06V40/28;;G06N3/045;;G06V10/34,G06N3/08;;A41D27/20;;A45C1/02;;A45C1/06;;A45C13/18;;A45F5/02;;G06N3/045;;G06V10/34;;G06V20/64;;G06V40/20,,0,0,,,,PENDING
410,WO,A1,WO 2013/082126 A1,018-008-700-276-551,2013-06-06,2013,US 2012/0066810 W,2012-11-28,US 201161564473 P;;US 201213686308 A;;US 201213686359 A,2011-11-29,USE OF THORACIC AND EXTRA-THORACIC IMPEDANCE FOR DIAGNOSTIC MONITORING,"A medical device and associated method for monitoring a fluid status of a patient that includes determining a first impedance signal along an electrode vector comprising a portion of a thoracic cavity, determining a second impedance signal along an extra-thoracic electrode vector, and determining a fluid status measurement in response to the determined first impedance signal and the determined second impedance signal",MEDTRONIC INC,ZIELINKSI TODD A;;HETTRICK DOUGLAS A;;CHO YONG K;;WARMAN EDUARDO N;;SOBOTKA PAUL A,,https://lens.org/018-008-700-276-551,Patent Application,yes,11,0,1,7,0,A61B5/0537;;A61B5/0538,A61B5/053,,0,0,,,,PENDING
411,WO,A1,WO 2020/041480 A1,030-941-214-298-141,2020-02-27,2020,US 2019/0047518 W,2019-08-21,US 201862720734 P,2018-08-21,HIGH-THROUGHPUT SYSTEM AND METHOD FOR THE TEMPORARY PERMEABILIZATION OF CELLS USING LIPID BILAYERS,"A microfluidic device is disclosed that is used to process cells for the intracellular delivery of molecules or other cargo. The device includes one or more microchannels disposed in a substrate or chip and is fluidically coupled to an inlet configured to receive a solution containing the cells and the molecules or other cargo to be delivered intracellularly to the cells. Each of the one or more microchannels has one or more constriction regions formed therein, wherein the inner surface(s) of the microchannels and the one or more constriction regions have a lipid bilayer disposed thereon. In some embodiments, multiple microfluidic devices operating in parallel are used to process large numbers of cells. The device and method have particularly applicability to delivering gene-editing molecules intracellularly to cells.",UNIV CALIFORNIA;;UNIV NANYANG TECH,BELLING JASON N;;JONAS STEVEN J;;JACKMAN JOSHUA A;;CHO NAM-JOON;;WEISS PAUL S,,https://lens.org/030-941-214-298-141,Patent Application,yes,5,4,2,2,0,C12M23/16;;B01L3/502715;;B01L3/50273;;B01L3/502761;;B01L2200/0647;;B01L2300/16;;C12N15/907,C12M1/42,,0,0,,,,PENDING
412,US,B2,US 11797679 B2,182-913-491-922-145,2023-10-24,2023,US 202117386779 A,2021-07-28,US 202117386779 A,2021-07-28,Trust verification system and method for a baseboard management controller (BMC),"An Information Handling System (IHS) includes multiple hardware devices, and a baseboard Management Controller (BMC) in communication with the plurality of hardware devices. The BMC includes instructions for executing a bootloader to verify an integrity of a first firmware stack, and boot the first firmware stack on a first processor. Once booted, the first firmware stack verifies the integrity of a first code segment on a second processor that is also used to execute a custom BMC firmware stack. The first code segment is executed to verify the integrity of one or more vendor supplied code segments executed on the second processor.",DELL PRODUCTS LP,CHO EUGENE DAVID;;SANCHEZ MARIO ALBERTO;;MADDUKURI AKKIAH CHOUDARY;;SAVAGE MARSHAL F;;VANCIL PAUL W,DELL PRODUCTS L.P (2021-07-21),https://lens.org/182-913-491-922-145,Granted Patent,yes,16,0,2,2,0,G06F11/1417;;G06F21/575;;G06F21/572;;G06F21/572;;G06F21/575;;G06F21/64;;G06F2221/2149;;G06F21/53;;G06F11/0772;;G06F21/602;;G06F9/4401,G06F1/24;;G06F9/4401;;G06F11/07;;G06F21/53;;G06F21/57;;G06F21/60;;G06F21/64,,0,0,,,,ACTIVE
413,US,B2,US 7612152 B2,024-045-077-094-640,2009-11-03,2009,US 12385905 A,2005-05-06,US 12385905 A,2005-05-06,Self-healing polymers,"A composite material includes a polymer matrix, a polymerizer, and a plurality of capsules containing a corresponding activator for the polymerizer. The composite material can also include an adhesion promoter, and the polymerizer can be phase separated from the polymer matrix. The composite material can be made by dispersing the polymerizer and capsules into the polymer matrix. These composite materials can exhibit improved environmental stability, and can be used with a wider variety of activators.",UNIV ILLINOIS,BRAUN PAUL V;;CHO SOO HYOUN;;WHITE SCOTT R;;SOTTOS NANCY R;;ANDERSSON H MAGNUS,THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2005-07-14),https://lens.org/024-045-077-094-640,Granted Patent,yes,96,40,8,8,0,B29C73/163;;B29C73/163;;B29C73/22;;B29C73/22;;B29C73/22;;C08K9/10;;C08F8/00;;C08F291/00;;C08F291/00;;C08K7/16,C08L63/00,525/476;;523/211,60,38,076-798-598-569-712;;082-384-453-424-130;;014-792-882-849-045;;170-610-332-806-274;;093-484-358-134-335;;077-764-439-479-366;;086-894-629-121-172;;009-662-627-686-297;;154-394-767-357-056;;046-200-523-560-505;;069-332-614-378-599;;065-000-446-201-13X;;170-516-225-875-150;;043-116-372-017-853;;116-086-960-052-69X;;002-382-271-095-013;;012-054-779-954-464;;006-768-208-140-560;;155-552-614-776-505;;139-351-452-102-573;;048-708-929-094-081;;042-776-607-112-28X;;116-234-691-305-864;;025-361-036-003-520;;077-348-794-905-566;;002-382-271-095-013;;162-520-781-772-058;;016-049-804-950-318;;004-661-793-312-956;;002-892-432-405-378;;015-788-629-510-755;;131-620-028-146-501;;000-298-832-501-604;;013-490-090-949-021;;083-533-256-589-668;;012-205-744-526-158;;011-897-357-168-534;;186-535-924-711-344,10.1088/0964-1726/5/3/007;;10.1088/0964-1726/3/2/006;;10.1016/0263-8223(96)00033-5;;10.1016/s0040-4020(97)10427-6;;10.1021/ja963136z;;10.1016/0079-6700(93)90012-2;;10.1021/om9708788;;10.1021/ma970292x;;10.1021/ma00125a030;;10.1021/ma00016a003;;10.1016/s1359-8368(98)00034-1;;10.1038/35057232;;11236987;;10.1021/ma010438z;;10.1038/35057412;;11236978;;10.1016/j.corsci.2004.10.018;;10.1002/adma.200501814;;10.1177/0021998305055188;;10.1016/0020-7403(92)90060-t;;10.1016/j.matchemphys.2004.06.043;;10.1016/s0079-6700(02)00010-2;;10.1080/02652040110055243;;11695640;;10.1021/ma012214m;;10.1016/0376-7388(94)00306-j;;10.1002/macp.200290052;;10.1021/la001276n;;10.1002/adma.200501814;;10.1021/ja01665a002;;10.1103/physrevlett.45.569;;10.1016/j.compscitech.2007.07.021;;10.1016/j.solmat.2004.12.008;;10.1002/htj.20138;;10.1039/b411359d;;12411700;;10.1126/science.1074868;;10.1351/pac200476071365;;10.1126/science.1109164;;15845850;;10.1002/app.21438;;2654353;;10.3109/02652048909019898;;10.1002/pi.1125,"International Search Report dated Aug. 1, 2006 for PCT application No. PCT/US2006/015703.;;Stevens, M.P., Polymer Chemistry, p. 184-186, 1999.;;Stevens, M.P. Polymer Chemistry, p. 378-381, 1999.;;Dry, C., et al., ""Three part methylmethacrylate adhesive system as an internal delivery system for smart responsive concrete"", Smart Mater. Struct., 5, p. 297-300, 1996.;;Dry, C. ""Matrix cracking repair and filling using active and passive modes for smart time release of chemicals from fibers into cement matrices"", Smart Mater. Struct., 3, p. 118-123, 1994.;;Dry, C., ""Procedures developed for self-repair of polymer matrix composite materials"", Composite Structures, 35, p. 263-269, 1996.;;Dry, C. et al., ""Passive smart self-repair in polymer matrix composite materials"", SPIE, vol. 1916, p. 438-444, 1993.;;D. Jung, et al., ""Self-healing composites using embedded microspheres"", K. Jacob, N. Katsube and W. Jones, ed., vol. MD-80, The American Society for Mechanical Engineers (ASME), 265-275 (1997).;;Beckwith, et al., ""Resin Transfer Molding: A Decade of Technology Advances"", SAMPE Journal, vol. 34, No. 6, p. 7-19, 1998.;;Grubbs, R.H., et al., ""Recent Advances in Olefin Metathesis and Its Application in Organic Synthesis"", Tetrahedron 54, p. 4413-4450, 1998.;;Dias, E.L., et al., ""Well-Defined Ruthenium Olefin Metathesis Catalyst: Mechanism and Activity"", J. Am. Chem. Soc., 119, p. 3887-3897, 1997.;;Breslow, D.S., ""Metathesis Polymerization"", Prog. Polym. Sci. vol. 18, p. 1141-1195, 1993.;;Dias, E.L., et al., ""Synthesis and Investigation of Homo- and Heterobimetallic Ruthenium Olefin Metathesis Catalysts Exhibiting Increased Activities"", Organometallics, 17, p. 2758-2767, 1998.;;Weck, M., et al., ""Synthesis of Discotic Columnar Side-Chain Liquid Crystalline Polymers by Ring-Opening Metathesis Polymerization (ROMP)"", Macromolecules, 30, p. 6430-6437, 1997.;;Fraser, C., et al., ""Synthesis of Glycopolymers of Controlled Molecular Weight by Ring-Opening Metathesis Polymerization Using Well-Defined Functional Group Tolerant Ruthenium Carbene Catalysts"", Macromolecules, 28, p. 7248-7255, 1995.;;Bazan, G.C., et al., ""Polymerization of Functionalized Norbornenes Employing Mo (CH-t-Bu) (NAr) (O-t-Bu)2 as the Initiator"", Macromolecules, 24, p. 4495-4502, 1991.;;Li, Victor C., et al., ""Feasibility Study of a Passive Smart Self-healing cementitious composite."", Composites Part B, 29B, p. 819-827, 1998.;;International Search Report dated Oct. 4, 2002 for Application No. PCT/US02/04163.;;White, S.R., ""Autonomic healing of polymer composites"", Nature, p. 794-797, 2001.;;Dean, K., ""Near-Infrared and Rheological Investigations of Epoxy-Vinyl Ester Interpenetrating Polymer Networks"", Macromolecules, p. 6623-6630, 2001.;;Wool, Richard P., ""A material fix"", Nature, vol. 409, p. 773-774.;;EPON, Resin 160 Epoxy Novolac Resin, Product Bulletin, p. 1-3, 1998.;;D. Jung, et al., ""Self-healing composites using embedded microspheres"", K. Jacob, N. Katsube and W. Jones, ed., vol. MD-80, in Proceedings of the ASME International Mechanical Engineering Conference and Exposition, 265-275 (1997).;;Cook, D.C., ""Spectroscopic identification of protective and non-protective corrosion coatings on steel structures in marine environments"", Corrosion Science, vol. 47, pp. 2550-2570, (2005).;;Wessling, B., ""Scientific engineering of anti-corrosion coating systems based on organic metals (polyaniline)"", Journal of Corrosion Science and Engineering, vol. 1, paper 15, 19 pages, found at www.jcse.org, ISSN 1466-8858, (1999).;;Cho, S.H., et al., ""Polydimethylsiloxane-based self-healing materials"", Advanced Materials, vol. 18, issue 8, pp. 997-1000, (2006).;;Rzeszutko, A.A. et al., ""Tensile properties of self-healing epoxy"", TAM Techinical Reports-1041: Proceedings of the Fifth Undergraduate Research Conference in Mechanics, pp. 27-33, (2004).;;Sudduth, R.D., ""Analysis of the maximum tensile strength of a composite with spherical particulates"", Journal of Composite Materials, vol. 40, No. 4, pp. 301-331, (2006); published on-line (2005).;;Tvergaard, V., ""Effect of ductile particle debonding during crack bridging in ceramics"", International Journal of Mechanical Sciences, vol. 34, No. 8, pp. 635-649, (1992).;;Zhang, X.X. et al., ""Fabrication and properties of microcapsules and nanocapsules containing n-octadecane"", Materials Chemistry and Physics, vol. 88, pp. 300-307, (2004).;;Asua, J.M., ""Miniemulsion Polymerization"", Prog. Polymer Science, vol. 27, pp. 1283-1346, (2002).;;Schork, F.J., ""Miniemulsion Polymerization"", Adv. Polym. Sci., vol. 175, pp. 129-255, (2005).;;Blaiszik, B.J. et al., ""Nanocapsules for self-healing composites"", Proceedings of the SEM annual meeting on experimental and applied mechanics, Society for Experimental Mechanics, St. Louis, MO, 6 pages, Jun. 4-7, 2006.;;Alexandridou, S. et al., ""Surface characterization of oil-containing polyterephthalamide microcapsules prepared by interfacial polymerization"", J. Microencapsulation, vol. 18, No. 6, pp. 767-781, (2001).;;IUPAC, ""emulsion"", IUPAC Compendium of Chemical Terminology: IUPAC Recommendations, 2nd Edition, compiled by A.D. McNaught and A. Wilkinson, Blackwell, Oxford, 1 page, (1997).;;Lansalot, M. et al., ""RAFT miniemulsion polymerization: Influence of the structure of the RAFT agent"", Macromolecules, vol. 35, No. 20, pp. 7582-7591, (2002).;;Ni, P. et al., ""Effect of operating variables and monomers on the formation of polyurea microcapsules"", Journal of Membrane Science, vol. 103, pp. 51-55, (1995).;;Ramirez, L.P. et al.,""Magnetic polystyrene nanoparticles with a high magnetite content obtained by miniemulsion processes"", Macromolecular Chemistry and Physics, vol. 204, No. 1, pp. 22-31, (2003).;;Tiarks, F. et al., ""Preparation of polymeric nanocapsules by miniemulsion polymerization"", Langmuir, vol. 17, No. 3, pp. 908-918, (2001).;;Holden, G. ""Elastomers, Thermoplastic"" Encyclopedia of Polymer Science and Technology, John Wiley & Sons, 1-25, 2002.;;Cho, S.H., ""Polydimethylsiloxane-Based Self-Healing Materials"", Advanced Materials, vol. 18, Issue 8, 997-100, Apr. 7, 2006.;;International Search Report and Written Opinion dated Oct. 24, 2007 for PCT application No. PCT/US2007/069981.;;International Search Report and Written Opinion dated Feb. 22, 2008 for PCT application No. PCT/US2007/060149.;;Keller, M.W. et al., ""An elastomeric self-healing material"", Proceedings of the 2006 SEM Annual Conference and Exposition on Experimental and Applied Mechanics 2006, vol. 1, pp. 379-382, (2006).;;Pickering, S.U., ""Emulsions"", Journal of the Chemical Society, Transactions, vol. 91, pp. 2001-2021, (1907).;;Finkle, P. et al., ""The theory of emulsification"", Journal of the American Chemical Society, vol. 45, No. 12, pp. 2780-2788, (1923).;;Pieranski, P. ""Two-dimensional interfacial colloidal crystals"", Physical Review Letters, vol. 45, No. 7, pp. 569-572, (1980).;;Gotro, J. et al., ""Thermosets"", Encyclopedia of Polymer Science and Technology, vol. 12, pp. 207-260, John Wiley & Sons, (2004).;;Blaiszik, B.J. et al., ""Nanocapsules for self-healing materials"", Composites Science and Technology, vol. 68, pp. 978-986, (2008).;;Gschwander, S. et al., ""Micro-encapsulated paraffin in phase-change slurries"", Solar Energy Materials & Solar Cells, vol. 89, pp. 307-315, (2005).;;Rao, Y. et al.,""Preparation and thermal properties of microencapsulated phase change material for enhancing fluid flow heat transfer"", Heat Transfer-Asian Research, vol. 36, No. 1, pp. 28-37, (2007), originally published in 2005.;;Wei, L. et al., ""Preparation and characterization of microencapsulated phase change material with low remnant formaldehyde content"", Materials Chemistry and Physics, vol. 106, pp. 437-442, (2007).;;Cayre, O.J. et al., ""Fabrication of novel colloidosome microcapsules with gelled aqueous cores"", Journal of Materials Chemistry, vol. 14, pp. 3351-3355, (2004).;;Dinsmore, A.D. et al., ""Colloidosomes: Selectively permeable capsules composed of colloidal particles"", Science, vol. 298, pp. 1006-1009, (2002).;;Croll, L.M. et al., ""Composite tectocapsules via the self-assembly of functionalized poly(divinylbenzene) microspheres"", Pure Appl. Chemistry, vol. 76, No. 7-8, pp. 1365-1374, (2004).;;Utada, A.S. et al., ""Monodisperse double emulsions generated from a microcapillary device"", Science, vol. 308, pp. 537-541, (2005).;;Shin, Y. et al., ""Development of thermoregulating textile materials with microencapsulated phase change materials (PCM). II. Preparation and application of PCM Microcapsules"", Journal of Applied Polymer Science, vol. 96, pp. 2005-2010, (2005).;;Arshady, R., ""Preparation of microspheres and microcapsules by interfacial polycondensation techniques"", Journal of Microencapsulation, vol. 6, issue 1, pp. 13-28, (1989).;;Mayya, K.S. et al., ""Micro-encapsulation by complex coacervation: influence of surfactant"", Polymer International, vol. 52, pp. 644-647, (2003).;;Karukstis, K.K. et al., ""Chemistry Connections: The chemical basis of everyday phenomena"", Academic Press, second edition, p. 88, (2003), best available copy.",ACTIVE
414,US,A1,US 2022/0281605 A1,071-202-238-447-525,2022-09-08,2022,US 202017635691 A,2020-08-14,GB 201911773 A;;GB 2020051943 W,2019-08-16,AN AIRCRAFT CABIN,"The present invention provides an aircraft cabin comprising an aisle defining an aisle axis, a plurality of aircraft passenger seats arranged in a seat column adjacent the aisle, and accessible from the aisle, each aircraft passenger seat comprising a seat pan and a backrest with a front face defining a seat facing direction and a rear face, and each aircraft passenger seat being convertible between a seat configuration and a bed configuration, wherein each aircraft passenger seat in the seat column is able to be angled away from the aisle such that the seat facing direction is at an angle of at least degrees from the aisle axis and wherein each aircraft passenger seat can be in the bed configuration when at that angle. The invention also provides an aircraft passenger accommodation unit, an aircraft, a kit of parts and a method of providing enhanced passenger access to an aircraft passenger accommodation unit.",SAFRAN SEATS GB LTD;;SAFRAN SEATS;;ZODIAC AEROSPACE EQUIPMENT DE MEXICO S DE R L DE C V,WOODINGTON JAMES BYRON;;MADRIGAL JOSE;;BERMUDEZ CRISTINA;;LEUNG CHO KIU HEATHER;;JONES RYAN;;HURSTEL PAUL,SAFRAN SEATS GB LIMITED (2019-08-16);;ZODIAC AEROSPACE EQUIPMENT DE MEXICO S. DE R.L. DE C.V (2019-08-16),https://lens.org/071-202-238-447-525,Patent Application,yes,0,1,8,8,0,B64D11/0601;;B64D11/0606;;B64D11/0641;;B64D11/0644;;B64D11/0605;;B64D11/0638;;B64D11/0604;;B64D11/0641;;B64D11/0601;;B64D11/0606;;B64D11/064;;B64D11/0641,B64D11/06,,0,0,,,,PENDING
415,EP,B1,EP 4013679 B1,101-674-926-418-797,2024-02-28,2024,EP 20760516 A,2020-08-14,GB 201911773 A;;GB 2020051943 W,2019-08-16,AN AIRCRAFT CABIN,,SAFRAN SEATS GB LTD;;SAFRAN SEATS;;ZODIAC AEROSPACE EQUIPMENT DE MEXICO S DE R L DE C V,WOODINGTON JAMES BYRON;;MADRIGAL JOSE;;BERMUDEZ CRISTINA;;LEUNG CHO KIU HEATHER;;JONES RYAN;;HURSTEL PAUL,,https://lens.org/101-674-926-418-797,Granted Patent,yes,2,0,8,8,0,B64D11/0601;;B64D11/0606;;B64D11/0641;;B64D11/0644;;B64D11/0605;;B64D11/0638;;B64D11/0604;;B64D11/0641;;B64D11/0601;;B64D11/0606;;B64D11/064;;B64D11/0641,B64D11/06,,0,0,,,,ACTIVE
416,US,B2,US 10949658 B2,123-193-066-546-908,2021-03-16,2021,US 201916276493 A,2019-02-14,CA 2995242 A,2018-02-15,Method and system for activity classification,"This disclosure is directed to an activity classifier system, for classifying human activities using 2D skeleton data. The system includes a skeleton preprocessor that transforms the 2D skeleton data into transformed skeleton data, the transformed skeleton data comprising scaled, relative joint positions and relative joint velocities. It also includes a gesture classifier comprising a first recurrent neural network that receives the transformed skeleton data, and is trained to identify the most probable of a plurality of gestures. There is also an action classifier comprising a second recurrent neural network that receives information from the first recurrent neural networks and is trained to identify the most probable of a plurality of actions.",WRNCH INC,BROWN COLIN J;;TOLSTIKHIN ANDREY;;PETERS THOMAS D;;CHO DONGWOOK;;ZHANG MAGGIE;;KRUSZEWSKI PAUL A,WRNCH INC (2018-03-20);;HINGE HEALTH INC (2021-09-15),https://lens.org/123-193-066-546-908,Granted Patent,yes,9,2,7,7,0,G06N3/08;;G06V40/23;;G06V40/28;;G06V10/34;;G06N3/048;;G06N3/044;;G06N3/045;;G06N3/08;;A41D27/20;;A45C13/185;;G06V40/23;;G06V20/647;;A45C1/024;;A45C1/06;;A45C13/18;;A45F5/022;;G06V40/28;;G06N3/045;;G06V10/34,G06N3/04;;G06N3/08;;G06V10/34,,1,1,084-468-139-209-388,31331883;;10.1109/cvpr.2017.143;;10.1109/tpami.2019.2929257,Realtime Multi-Person 2D Pose Estimation using Part Affinity Fields (Year: 2017).,ACTIVE
417,EP,A1,EP 1885762 A1,196-267-533-601-652,2008-02-13,2008,EP 06758596 A,2006-04-26,US 2006/0015703 W;;US 12385905 A,2005-05-06,SELF-HEALING POLYMERS,,UNIV ILLINOIS,BRAUN PAUL V;;CHO SOO HYOUN;;WHITE SCOTT R;;SOTTOS NANCY R;;ANDERSSON H MAGNUS,,https://lens.org/196-267-533-601-652,Patent Application,yes,0,0,8,8,0,B29C73/163;;B29C73/163;;B29C73/22;;B29C73/22;;B29C73/22;;C08K9/10;;C08F8/00;;C08F291/00;;C08F291/00;;C08K7/16,C08F291/00;;B29C73/22;;C08K9/10,,1,0,,,See references of WO 2006121609A1,DISCONTINUED
418,US,S,US D0674371 S,173-978-983-982-217,2013-01-15,2013,US 36645110 F,2010-07-26,US 36645110 F,2010-07-26,Portable audio device,,BOSCH GMBH ROBERT;;CHO ANDREW P;;WEIR J ALAN;;HATCH PAUL;;CEPRESS CARL;;LEE HYUNG SEOK;;CHENG HOWARD,CHO ANDREW P;;WEIR J ALAN;;HATCH PAUL;;CEPRESS CARL;;LEE HYUNG SEOK;;CHENG HOWARD,ROBERT BOSCH TOOL CORPORATION (2010-09-28),https://lens.org/173-978-983-982-217,Design Right,no,0,4,1,1,0,,,1403;;D14/188,0,0,,,,ACTIVE
419,US,A1,US 2008/0141221 A1,037-600-426-415-118,2008-06-12,2008,US 63603606 A,2006-12-08,US 63603606 A,2006-12-08,Using recorder technology to find defects in software applications,"Using recorder technology for finding defects in software applications by capturing software and/or user-driven events in a computing system. In one implementation, recorder technology is employed in a software defect reporting tool for reporting customer feedback related to software defects or bugs. The recorder can be utilized to capture events and defects for reporting such information to application vendors for defect resolution. A record file can be played back to reproduce the software defect and the steps leading up to the defect, and convert the information into a human readable file format. The recorder can also be used to create regressions scripts. When employed in a beta testing client reporting tool, customers are now able to record reproduce steps automatically, and ship the output file to the software vendor for more comprehensive reporting and hence, effective triage of the software defect.",MICROSOFT CORP,BENESOVSKA ANNA;;ANDERSON DOUGLAS A;;KLEMENTIEV DMITRI A;;DONNELLY PAUL H;;SMITH VINCENT;;CHO TENNY,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2011-08-23),https://lens.org/037-600-426-415-118,Patent Application,yes,19,90,1,1,0,G06F9/45512;;G06F11/3688;;G06F9/45512;;G06F11/3688,G06F9/04;;G06F9/44,717/124;;717/128,0,0,,,,DISCONTINUED
420,US,A1,US 2006/0252852 A1,125-134-738-071-726,2006-11-09,2006,US 12385905 A,2005-05-06,US 12385905 A,2005-05-06,Self-healing polymers,"A composite material includes a polymer matrix, a polymerizer, and a plurality of capsules containing a corresponding activator for the polymerizer. The composite material can also include an adhesion promoter, and the polymerizer can be phase separated from the polymer matrix. The composite material can be made by dispersing the polymerizer and capsules into the polymer matrix. These composite materials can exhibit improved environmental stability, and can be used with a wider variety of activators.",BRAUN PAUL V;;CHO SOO H;;WHITE SCOTT R;;SOTTOS NANCY R;;ANDERSSON H M,BRAUN PAUL V;;CHO SOO H;;WHITE SCOTT R;;SOTTOS NANCY R;;ANDERSSON H M,THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2005-07-14),https://lens.org/125-134-738-071-726,Patent Application,yes,68,45,8,8,0,B29C73/163;;B29C73/163;;B29C73/22;;B29C73/22;;B29C73/22;;C08K9/10;;C08F8/00;;C08F291/00;;C08F291/00;;C08K7/16,C08K9/10;;C08F8/00,523/200;;524/80;;525/192,0,0,,,,ACTIVE
421,WO,A1,WO 2021/032954 A1,026-144-776-198-664,2021-02-25,2021,GB 2020051943 W,2020-08-14,GB 201911773 A,2019-08-16,AN AIRCRAFT CABIN,"The present invention provides an aircraft cabin (100) comprising an aisle (102) defining an aisle axis (103), a plurality of aircraft passenger seats (220) arranged in a seat column (104) adjacent the aisle, and accessible from the aisle, each aircraft passenger seat comprising a seat pan (221) and a backrest (222) with a front face (223) defining a seat facing direction (225) and a rear face (224), and each aircraft passenger seat being convertible between a seat configuration and a bed configuration, wherein each aircraft passenger seat in the seat column is able to be angled away from the aisle such that the seat facing direction is at an angle (280) of at least 30 degrees from the aisle axis and wherein each aircraft passenger seat can be in the bed configuration when at that angle. The invention also provides an aircraft passenger accommodation unit (200), an aircraft (1000), a kit of parts and a method of providing enhanced passenger access to an aircraft passenger accommodation unit.",SAFRAN SEATS GB LTD;;SAFRAN SEATS;;ZODIAC AEROSPACE EQUIPMENT DE MEXICO S DE R L DE C V,WOODINGTON JAMES BYRON;;MADRIGAL JOSE;;BERMUDEZ CRISTINA;;LEUNG CHO KIU HEATHER;;JONES RYAN;;HURSTEL PAUL,,https://lens.org/026-144-776-198-664,Patent Application,yes,6,3,8,8,0,B64D11/0601;;B64D11/0606;;B64D11/0641;;B64D11/0644;;B64D11/0605;;B64D11/0638;;B64D11/0604;;B64D11/0641;;B64D11/0601;;B64D11/0606;;B64D11/064;;B64D11/0641,B64D11/06,,0,0,,,,PENDING
422,US,A1,US 2023/0034526 A1,052-253-909-194-794,2023-02-02,2023,US 202117386779 A,2021-07-28,US 202117386779 A,2021-07-28,TRUST VERIFICATION SYSTEM AND METHOD FOR A BASEBOARD MANAGEMENT CONTROLLER (BMC),"An Information Handling System (IHS) includes multiple hardware devices, and a baseboard Management Controller (BMC) in communication with the plurality of hardware devices. The BMC includes instructions for executing a bootloader to verify an integrity of a first firmware stack, and boot the first firmware stack on a first processor. Once booted, the first firmware stack verifies the integrity of a first code segment on a second processor that is also used to execute a custom BMC firmware stack. The first code segment is executed to verify the integrity of one or more vendor supplied code segments executed on the second processor.",DELL PRODUCTS LP,CHO EUGENE DAVID;;SANCHEZ MARIO ALBERTO;;MADDUKURI AKKIAH CHOUDARY;;SAVAGE MARSHAL F;;VANCIL PAUL W,DELL PRODUCTS L.P (2021-07-21),https://lens.org/052-253-909-194-794,Patent Application,yes,16,2,2,2,0,G06F11/1417;;G06F21/575;;G06F21/572;;G06F21/572;;G06F21/575;;G06F21/64;;G06F2221/2149;;G06F21/53;;G06F11/0772;;G06F21/602;;G06F9/4401,G06F11/07;;G06F21/57;;G06F21/53;;G06F21/60;;G06F21/64,,0,0,,,,ACTIVE
423,US,A1,US 2014/0148656 A1,115-369-366-665-235,2014-05-29,2014,US 201213686308 A,2012-11-27,US 201213686308 A,2012-11-27,USE OF THORACIC AND EXTRA-THORACIC IMPEDANCE FOR DIAGNOSTIC MONITORING,"A medical device and associated method for monitoring a fluid status of a patient that includes determining a first impedance signal along an electrode vector comprising a portion of a thoracic cavity, determining a second impedance signal along an extra-thoracic electrode vector, and determining a fluid status measurement in response to the determined first impedance signal and the determined second impedance signal",MEDTRONIC INC,ZIELINSKI TODD M;;HETTRICK DOUGLAS A;;CHO YONG K;;WARMAN EDUARDO N;;SOBOTKA PAUL A,MEDTRONIC INC (2012-11-13),https://lens.org/115-369-366-665-235,Patent Application,yes,2,6,1,7,0,A61B5/0538;;A61N1/36114;;A61N1/3627;;A61B5/0537;;A61B5/1116;;A61M5/1723;;A61B5/0537;;A61B5/1116;;A61B5/4857;;A61M5/1723;;A61N1/36114;;A61B5/0538;;A61N1/3627,A61B5/00;;A61B5/053;;A61B5/11;;A61M5/172,600/301;;600/547;;604/65,0,0,,,,DISCONTINUED
424,US,A1,US 2021/0161266 A1,143-274-733-487-789,2021-06-03,2021,US 202117173978 A,2021-02-11,US 202117173978 A;;CA 2995242 A;;US 201916276493 A,2018-02-15,METHOD AND SYSTEM FOR ACTIVITY CLASSIFICATION,"An activity classifier system and method that classifies human activities using 2D skeleton data. The system includes a skeleton preprocessor that transforms the 2D skeleton data into transformed skeleton data, the transformed skeleton data comprising scaled, relative joint positions and relative joint velocities. The system also includes a gesture classifier comprising a first recurrent neural network that receives the transformed skeleton data, and is trained to identify the most probable of a plurality of gestures. The system also has an action classifier comprising a second recurrent neural network that receives information from the first recurrent neural networks and is trained to identify the most probable of a plurality of actions.",WRNCH INC,BROWN COLIN J;;TOLSTIKHIN ANDREY;;PETERS THOMAS D;;CHO DONGWOOK;;ZHANG MAGGIE;;KRUSZEWSKI PAUL A,WRNCH INC (2018-03-20);;HINGE HEALTH INC (2021-09-15),https://lens.org/143-274-733-487-789,Patent Application,yes,0,0,7,7,0,G06N3/08;;G06V40/23;;G06V40/28;;G06V10/34;;G06N3/048;;G06N3/044;;G06N3/045;;G06N3/08;;A41D27/20;;A45C13/185;;G06V40/23;;G06V20/647;;A45C1/024;;A45C1/06;;A45C13/18;;A45F5/022;;G06V40/28;;G06N3/045;;G06V10/34,A45C13/18;;A41D27/20;;A45C1/02;;A45C1/06;;A45F5/02;;G06V10/34,,0,0,,,,ACTIVE
425,US,A1,US 2023/0030501 A1,177-461-833-993-803,2023-02-02,2023,US 202117386826 A,2021-07-28,US 202117386826 A,2021-07-28,SYSTEM AND METHOD FOR MAINTAINING TRUSTED EXECUTION IN AN UNTRUSTED COMPUTING ENVIRONMENT USING A SECURE COMMUNICATION CHANNEL,"An Information Handling System (IHS) includes multiple hardware devices, and a baseboard Management Controller (BMC) in communication with the plurality of hardware devices. The BMC includes instructions for executing an assistance application (APP) in an untrusted domain of the BMC. The assistance APP configured to monitor a custom BMC firmware stack executed in the untrusted domain. The instructions are further executed to verify an integrity of the assistance APP from a trusted domain of the BMC by encrypting communications between the trusted and untrusted domains using an encryption key that comprises a function of a time counter value.",DELL PRODUCTS LP,CHO EUGENE DAVID;;SANCHEZ MARIO ALBERTO;;MADDUKURI AKKIAH CHOUDARY;;SAVAGE MARSHAL F;;VANCIL PAUL W,DELL PRODUCTS L.P (2021-07-21),https://lens.org/177-461-833-993-803,Patent Application,yes,6,0,2,2,0,H04L9/0891;;H04L9/0872;;G06F21/575;;G06F21/606;;G06F21/51;;G06F21/575;;H04L25/0204;;H04L9/0822;;G06F21/572;;G06F21/52;;G06F21/606,G06F21/57;;H04L9/08;;H04L25/02,,0,0,,,,ACTIVE
426,US,A1,US 2014/0148867 A1,180-329-099-440-576,2014-05-29,2014,US 201213686359 A,2012-11-27,US 201213686359 A;;US 201161553524 P,2011-10-31,USE OF THORACIC AND EXTRA-THORACIC IMPEDANCE FOR DIAGNOSTIC MONITORING,"A medical device and associated method for delivery of a cardiac therapy that includes determining a first impedance signal along a thoracic electrode vector extending within a portion of a thoracic cavity, determining a second impedance signal along an extra-thoracic electrode vector extending outside the thoracic cavity, comparing first amplitude measurements corresponding to the first impedance signals and second amplitude measurements corresponding to the second impedance signals, comparing first slope measurements corresponding to the first impedance signals and second slope measurements corresponding to the second impedance signals, and determining delivery of the cardiac therapy in response to the comparing.",MEDTRONIC INC,ZIELINSKI TODD M;;HETTRICK DOUGLAS A;;CHO YONG K;;WARMAN EDUARDO N;;SOBOTKA PAUL A,MEDTRONIC INC (2012-11-13),https://lens.org/180-329-099-440-576,Patent Application,yes,0,1,2,7,0,A61B5/0537;;A61B5/085;;A61N1/3627;;A61N1/36521;;A61B5/085;;A61B5/0537;;A61N1/36521;;A61N1/3627;;A61M27/00;;A61N1/36507,A61M27/00;;A61N1/365,607/3;;607/26,0,0,,,,ACTIVE
427,US,A1,US 2022/0369937 A1,064-310-136-413-02X,2022-11-24,2022,US 202117246331 A,2021-04-30,US 202117246331 A;;US 202163158189 P,2021-03-08,ACUTE HEALTH EVENT MONITORING,"A system comprises processing circuitry and memory comprising program instructions that, when executed by the processing circuitry, cause the processing circuitry to: apply a first set of rules to first patient parameter data for a first determination of whether sudden cardiac arrest of a patient is detected; determine that a one or more context criteria of the first determination are satisfied; and in response to satisfaction of the context criteria, apply a second set of rules to second patient parameter data for a second determination of whether sudden cardiac arrest of the patient is detected. At least the second set of rules comprises a machine learning model, and the second patient parameter data comprises at least one patient parameter that is not included in the first patient parameter data.",MEDTRONIC INC,CHO YONG K;;WYSZYNSKI RYAN D;;NEITZELL GRANT A;;KRAUSE PAUL G;;OUSDIGIAN KEVIN T;;DEGROOT PAUL J;;SARKAR SHANTANU;;KOCH CHRISTOPHER D,MEDTRONIC INC (2021-05-19),https://lens.org/064-310-136-413-02X,Patent Application,yes,8,0,3,22,0,A61B5/0006;;A61B5/024;;A61B5/02405;;A61B5/283;;A61B5/349;;A61B5/361;;A61B5/686;;A61B5/7264;;A61B5/7267;;A61B5/7282;;A61N1/3925;;G16H50/30;;G16H50/20;;G16H40/63;;G16H40/67;;G16H10/60;;G16H50/70;;G16H20/30;;G16H20/10;;G16H40/20;;A61N1/056;;A61N1/365;;A61N1/3956;;A61N1/3756;;A61B5/318;;A61B5/0031;;A61B5/0059;;A61B5/0205;;A61B5/021;;A61B5/053;;A61B5/0816;;A61B5/1116;;A61B5/1118;;A61B5/686;;A61B5/7221;;A61B5/7264;;A61B5/7275;;A61B7/00,A61B5/0205;;A61B5/00;;A61B5/021;;A61B5/053;;A61B5/08;;A61B5/11;;A61B5/318;;A61B7/00,,0,0,,,,PENDING
428,US,A1,US 2008/0044569 A1,031-508-732-413-604,2008-02-21,2008,US 92568107 A,2007-10-26,US 92568107 A;;US 12775305 A;;US 57017304 P,2004-05-12,METHODS FOR ATOMIC LAYER DEPOSITION OF HAFNIUM-CONTAINING HIGH-K DIELECTRIC MATERIALS,"Embodiments of the invention provide methods for depositing materials on substrates during vapor deposition processes, such as atomic layer deposition (ALD). In one embodiment, a chamber contains a substrate support with a receiving surface and a chamber lid containing an expanding channel formed within a thermally insulating material. The chamber further includes at least one conduit coupled to a gas inlet within the expanding channel and positioned to provide a gas flow through the expanding channel in a circular direction, such as a vortex, a helix, a spiral, or derivatives thereof. The expanding channel may be formed directly within the chamber lid or formed within a funnel liner attached thereon. The chamber may contain a retaining ring, an upper process liner, a lower process liner or a slip valve liner. Liners usually have a polished surface finish and contain a thermally insulating material such as fused quartz or ceramic. In an alternative embodiment, a deposition system contains a catalytic water vapor generator connected to an ALD chamber.",MYO NYI O;;CHO KENRIC;;KHER SHREYAS;;NARWANKAR PRAVIN;;POPPE STEVE;;METZNER CRAIG R;;DEATEN PAUL,MYO NYI O;;CHO KENRIC;;KHER SHREYAS;;NARWANKAR PRAVIN;;POPPE STEVE;;METZNER CRAIG R;;DEATEN PAUL,APPLIED MATERIALS INC (2005-06-14),https://lens.org/031-508-732-413-604,Patent Application,yes,99,48,23,25,0,C23C16/0272;;C23C16/40;;C23C16/401;;C23C16/405;;C23C16/4412;;C23C16/4488;;C23C16/45529;;C23C16/45531;;C23C16/45544;;C23C16/45582;;C23C16/56;;Y10T137/0357;;Y10T137/2087;;Y10T137/0396;;C23C16/00;;Y10T137/0357;;Y10T137/2087;;Y10T137/0396;;C23C16/4488;;C23C16/45531;;C23C16/45582;;C23C16/0272;;C23C16/56;;C23C16/401;;C23C16/40;;C23C16/405;;C23C16/4412;;C23C16/45544;;C23C16/45529;;Y02T50/60,C23C16/00;;C23C16/02;;C23C16/40;;C23C16/44;;C23C16/448;;C23C16/455;;C23C16/56;;F22B1/00,427/248.1,0,0,,,,INACTIVE
429,US,A1,US 2021/0346889 A1,114-992-253-003-858,2021-11-11,2021,US 201917269985 A,2019-08-21,US 201917269985 A;;US 201862720734 P;;US 2019/0047518 W,2018-08-21,HIGH-THROUGHPUT SYSTEM AND METHOD FOR THE TEMPORARY PERMEABILIZATION OF CELLS USING LIPID BILAYERS,"A microfluidic device is disclosed that is used to process cells for the intracellular delivery of molecules or other cargo. The device includes one or more microchannels disposed in a substrate or chip and is fluidically coupled to an inlet configured to receive a solution containing the cells and the molecules or other cargo to be delivered intracellularly to the cells. Each of the one or more microchannels has one or more constriction regions formed therein, wherein the inner surface(s) of the microchannels and the one or more constriction regions have a lipid bilayer disposed thereon. In some embodiments, multiple microfluidic devices operating in parallel are used to process large numbers of cells. The device and method have particularly applicability to delivering gene-editing molecules intracellularly to cells.",UNIV CALIFORNIA;;UNIV NANYANG TECH,BELLING JASON N;;JONAS STEVEN J;;JACKMAN JOSHUA A A;;CHO NAM-JOON;;WEISS PAUL S,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2019-08-21);;NANYANG TECHNOLOGICAL UNIVERSITY (2019-08-07),https://lens.org/114-992-253-003-858,Patent Application,yes,0,1,2,2,0,C12M23/16;;B01L3/502715;;B01L3/50273;;B01L3/502761;;B01L2200/0647;;B01L2300/16;;C12N15/907,B01L3/00;;C12N15/90,,0,0,,,,PENDING
430,US,B2,US 8282992 B2,026-716-824-843-025,2012-10-09,2012,US 92568107 A,2007-10-26,US 92568107 A;;US 12775305 A;;US 57017304 P,2004-05-12,Methods for atomic layer deposition of hafnium-containing high-K dielectric materials,"Embodiments of the invention provide methods for depositing materials on substrates during vapor deposition processes, such as atomic layer deposition (ALD). In one embodiment, a chamber contains a substrate support with a receiving surface and a chamber lid containing an expanding channel formed within a thermally insulating material. The chamber further includes at least one conduit coupled to a gas inlet within the expanding channel and positioned to provide a gas flow through the expanding channel in a circular direction, such as a vortex, a helix, a spiral, or derivatives thereof. The expanding channel may be formed directly within the chamber lid or formed within a funnel liner attached thereon. The chamber may contain a retaining ring, an upper process liner, a lower process liner or a slip valve liner. Liners usually have a polished surface finish and contain a thermally insulating material such as fused quartz or ceramic. In an alternative embodiment, a deposition system contains a catalytic water vapor generator connected to an ALD chamber.",MYO NYI OO;;CHO KENRIC;;KHER SHREYAS;;NARWANKAR PRAVIN;;POPPE STEVE;;METZNER CRAIG R;;DEATEN PAUL;;APPLIED MATERIALS INC,MYO NYI OO;;CHO KENRIC;;KHER SHREYAS;;NARWANKAR PRAVIN;;POPPE STEVE;;METZNER CRAIG R;;DEATEN PAUL,APPLIED MATERIALS INC (2005-06-14),https://lens.org/026-716-824-843-025,Granted Patent,yes,106,255,23,25,0,C23C16/0272;;C23C16/40;;C23C16/401;;C23C16/405;;C23C16/4412;;C23C16/4488;;C23C16/45529;;C23C16/45531;;C23C16/45544;;C23C16/45582;;C23C16/56;;Y10T137/0357;;Y10T137/2087;;Y10T137/0396;;C23C16/00;;Y10T137/0357;;Y10T137/2087;;Y10T137/0396;;C23C16/4488;;C23C16/45531;;C23C16/45582;;C23C16/0272;;C23C16/56;;C23C16/401;;C23C16/40;;C23C16/405;;C23C16/4412;;C23C16/45544;;C23C16/45529;;Y02T50/60,C23C16/00;;C23C16/02;;C23C16/40;;C23C16/44;;C23C16/448;;C23C16/455;;C23C16/56;;F22B1/00,427/248.1,79,49,079-286-334-182-725;;097-229-423-083-878;;005-422-288-487-673;;008-564-208-587-459;;068-591-875-478-360;;014-468-014-130-087;;026-867-397-764-805;;069-112-895-260-030;;107-342-444-407-03X;;130-540-262-599-596;;076-248-612-401-136;;100-169-093-989-005;;003-576-119-288-429;;034-169-994-088-333;;088-813-758-300-906;;062-656-145-434-514;;041-521-931-575-111;;049-952-900-800-035;;005-939-246-660-089;;035-108-718-558-332;;160-692-724-124-693;;115-277-635-900-080;;167-579-137-337-563;;006-744-660-312-481;;026-665-034-368-648;;035-320-296-124-670;;093-128-014-943-453;;052-112-599-619-769;;133-453-964-139-889;;108-881-832-693-006;;038-820-907-355-751;;067-157-949-925-963;;038-033-158-153-251;;036-580-992-917-356;;022-792-088-818-508;;039-726-046-752-629;;059-975-022-383-69X;;045-161-904-556-969;;117-928-983-648-757;;029-044-439-538-489;;035-214-673-129-196;;047-610-787-894-734;;018-145-863-267-837;;145-116-618-583-133;;045-647-045-334-822;;016-248-496-656-206;;057-817-203-415-201;;094-049-296-016-72X;;029-101-465-207-438,10.1016/0040-6090(77)90312-1;;10.1116/1.587179;;10.1021/la9916981;;10.1557/proc-811-d7.5;;10.1021/ic981365b;;11671015;;10.1149/1.2085367;;10.1557/proc-670-k2.2;;10.1557/proc-811-d1.3;;10.1109/iitc.2001.930062;;10.1016/0169-4332(94)90260-7;;10.1016/s0169-4332(00)00205-1;;10.1016/0169-4332(94)90259-3;;10.1021/jp9536763;;10.1063/1.116566;;10.1016/b978-012511221-5/50012-x;;12376699;;10.1126/science.1073552;;10.1063/1.1599976;;10.1063/1.1465532;;10.1063/1.1522826;;10.1126/science.288.5464.321;;10764642;;10.1143/jjap.40.285;;10.1109/iwgi.2003.159180;;10.1116/1.1806442;;10.1142/s0218625x99000433;;10.1002/1521-3862(20020903)8:5<199::aid-cvde199>3.0.co;2-u;;10.1016/s0169-4332(96)00989-0;;10.1016/s0965-9773(98)00003-8;;10.1149/1.1837399;;10.1063/1.115990;;10.1016/s0040-6090(97)00025-4;;10.1557/proc-514-337;;10.1557/proc-564-207;;10.1063/1.124742;;10.1016/s0921-5107(96)01617-0;;10.1016/s0040-6090(02)00705-8;;10.1016/s0022-0248(01)01502-0;;10.1149/1.1385822;;10.1016/0040-6090(93)90557-6;;10764641;;10.1126/science.288.5464.319;;10.1149/1.1838736;;10.1149/1.2050083;;10.1016/0040-6090(94)90168-6;;10.1016/s0169-4332(97)00387-5;;10.1016/0040-6090(93)90172-l;;10.1002/(sici)1521-3862(199901)5:1<7::aid-cvde7>3.0.co;2-j;;10.1016/0040-6090(94)90754-4;;10.1109/iedm.2003.1269176;;10.1016/s0022-0248(02)01854-7;;10.1063/1.1476397,"Argarwal, et al. ""Challenges in Integrating the High-K Gate Dielectric Film to the Conventional CMOS Process Flow,"" Mat. Sec. Soc. Sump. Proc. vol. 670 (2001) pp. K2.1.1-K2.1.11.;;Balog, et al. ""Chemical Vapor Deposition and Characterization of HfO2 Films from Organo-Hafnium Compounds,"" Thin Solid Films, 41 (1977) 247-259.;;Bedair ""Atomic Layer Epitaxy Deposition Processes,"" J. Vac. Sci. Technol. B., vol. 12, No. 1, Jan./Feb. 1994.;;Cameron, et al. ""Atomic Layer Deposition of SiO2 and TiO2 in Alumina Tubular Membranes,"" Langmuir, vol. 16, No. 19, American Chemical Society, 2000 pp. 7435-7444.;;Chatham, Hood; et al. ""Nitridation of Hafnium Silicate Thin Films"", Mat. Res. Soc. Symp. Proc. vol. 811, Apr. 12-16, 2004, D7.5.1.;;Cheon, et al. ""Gas Phase Photoproduction of Diatomic Metal Nitrides During Metal Nitride Laser Chemical Vapor Deposition,"" lnorg. Chem. 1999, 38, 2238-2239.;;Choi, et al. ""Stability of TiB2 as a Diffusion Barrier on Silicon,"" J. Electrochem. Soc., vol. 138, No. 10, Oct. 1991 pp. 3062-3067.;;Choi, et al. ""The Effect of Annealing on Resistivity of Low Pressure Chemical Vapor Deposited Titanium Diboride,"" J. Appl. Phys. 69(11), Jun. 1, 1991 pp. 7853-7861.;;Clark-Phelps, et al. ""Engineered Tantalum Aluminate and Hafnium Aluminate ALD Films for Ultrathin Dielectric Films with Improved Electrical and Thermal Properties,"" Mat. Res. Soc. Symp. Proc. vol. 670 (2001).;;Conley, et al. ""Interval Annealing During Alternating Pulse Deposition"", Mat. Res. Soc. Symp. Proc. vol. 811, Apr. 12-16, 2004, D1.3.1.;;Derbyshire ""Applications of Integrated Processing,"" Solid State Technology, Dec. 1994 pp. 45-48.;;Dey, et al. ""Ruthenium films by digital chemical vapor deposition: Selectivity, nanostructure, and work function,"" Applied Physics Letter, vol. 84, No. 9, Mar. 1, 2004, American Institute of Physics, pp. 1606.;;Eisenbraum, et al. ""Atomic Layer Deposition (ALD) of Tantalum-based materials for zero thickness copper barrier applications,"" Proceedings of the IEEE 2001 International Interconnect Technology Conference (Cat. No. 01EX461) 2001.;;Elers, et al. ""NbCI5 as a Precursor in Atomic Layer Epitaxy,"" Applied Surface Science 82/83 (1994) pp. 468-474.;;European Office Action for PCT/US2005/016603 dated Jun. 3, 2008 for European Application No. 05 748 115.2-1215.;;European Search Report dated Sep. 23, 2005 from European Application No. 03257169.7.;;Ferguson, et al. ""Atomic Layer Deposition of AI2O3 and SiO2 on BN Particles Using Sequential Surface Reactions,"" Applied Surface Science, 162-163, (2000), pp. 280-292.;;George, et al. ""Atomic Layer Controlled Deposition of SiO2 and AI2O3 using ABAB . . . binary reaction sequence chemistry,"" Applied Surface Science 82/83 (1994) 460-467.;;George, et al. ""Surface Chemistry for Atomic Layer Growth,"" J. Phys. Chem. (1996), 100, 13121-13131.;;Goswami, et al. 'Transition Metals Show Promise as Copper Barriers, Semiconductor International, ATMI, San Jose-May 1, 2004.;;Goto, et al. ""Atomic layer controlled deposition of silicon nitride with self-limiting mechanism,"" Applied Physics Letters, American Institute of Physics. New York, US, vol. 68, No. 23, Jun. 3, 1996, pp. 3257-3259.;;Groner, et al. ""High-k Dielectrics Grown by Atomic Layer Deposition: Capacitor and Gate Applications,"" Interlayer Dielectrics for Semiconductor Technologies, Chapter 10, Elsevier Inc., 2003, pp. 327-348.;;Hausmann, et al. ""Rapid Vapor Deposition of Highly Conformal Silica Nanolaminates,"" Science, vol. 298, Oct. 11, 2002, pp. 402-406.;;He, et al. ""Pulsed Deposition of Silicate Films,"" Journal of Applied Physics, vol. 94, No. 5, Sep. 1, 2003, pp. 3657-3659.;;Hendrix, et al. ""Composition Control of Hf1-×SixO2 Films Deposited on Si by Chemical-vapor Deposition Using Amide Precursors,"" Applied Physics Letters, American Institute of Physics, New York, US, vol. 80, No. 13, Apr. 1, 2002, pp. 2362-2364.;;Ho, et al. ""Suppressed crystallization of Hf-based gate dielectrics by controlled addition of Al2O3 using atomic layer deposition"", Applied Physics Letters, American Institute of Physics, New York, US, vol. 81, No. 22, Nov. 25, 2002, pp. 4218-4220.;;Hong, et al. ""Characteristics of PAALD-TaN thin films derived from TAIMATA precursor for copper metallization"", Internconnect Technology Conference, 2004. Proceedings of the IEEE 2004 International, Jun. 7-9, 2004, pp. 9-11.;;Hwang, et al. ""Nanometer-Size alpha-PbO2-type TiO2 in Garnet: A Thermobarometer for Ultrahigh-Pressure Metamorphism,"" Science Vo. 288 (Apr. 14, 2000).;;International Search Report and Written Opinion dated Sep. 12, 2008 for International Application No. PCT/US07/82369.;;International Search Report for International Application No. PCT/US2005/016603 dated Sep. 15, 2005.;;International Search Report for International Application No. PCT/US2005/016606 dated Aug. 22, 2005.;;International Search Report for International Application No. PCT/US2005/016690 dated Aug. 22, 2005.;;Jeong, et al. ""Growth and Characterization of Aluminum Oxide (Al2O3) Thin Films by Plasma-Assisted Atomic Layer Controlled Deposition,"" J. Korean Inst. Met. Mater., vol. 38, No. 10, Oct. 2000 pp. 1395-1399.;;Jeong, et al. ""Plasma-assisted Atomic Layer Growth of High-Quality Aluminum Oxide Thin Films,"" Jpn. J. Appl. Phys. 1, vol. 40, No. 1, Jan. 2001 pp. 285-289.;;Kamiyama, et al. ""Improvement in the uniformity and the thermal stability of Hf-silicate gate dielectric by plasma-nitridation,"" Gate Insulator, 2003. IWGI 2003. Extended Abstracts of International Workshop on Nov. 6-7, 2003, Piscataway, NJ, USA, IEEE, Nov. 6, 2002, pp. 42-46.;;Kang, et al. ""Infrared Spectroscopic Study of Atomic Layer Deposition Mechanism for Hafnium Silicate Thin Films Using HfCI2 [N(SiMe3) 2}2 and H2O,"" J. Vac. Sci. Technol. A 22(6), Nov./Dec. 2004, American Vacuum Society, pp. 2393-2397.;;Kattelus, et al. ""Electrical Properties of Tantalum Based Composite Oxide Films,"" Mat. Res. Soc. Symp. Proc., 284 (1993) 511-516.;;Kawahara, et al. ""Effects of Hf sources, oxidizing agents, and NH3 radicals on properties of HfAlOx films prepared by atomic layer deposition"", IWGI 2003, Tokyo, Nov. 6, 2003, pp. 32-37.;;Kim, et al. ""Substrate dependence on the optical properties of Al2O3 films grown by atomic layer deposition,"" Applied. Phys. Lett. 71 (25), Dec. 22, 1997 (3604-6).;;Klaus, et al. ""Atomic Layer Deposition of SiO2 Using Catalyzed and Uncatalyzed Self-Limiting Surface Reactions,"" Surface Review and Letters, vol. 6, Nos. 3 & 4 (1999) 435-448.;;Kukli, et al. ""Atomic Layer Deposition of Hafnium Dioxide Films from Hafnium Tetrakis(ethylmethylamide) and Water"", Chemical Vapor Deposition, VCH Publishers, Weinheim, DE, vol. 8, No. 5, Sep. 2002, pp. 199-204.;;Kukli, et al. ""Atomic Layer Epitaxy Growth of Tantalum Oxide Thin Films from Ta(OC2H5)5 and H2O,"" Journal of the Electrochemical Society, vol. 142, No. 5, May 1995; p. 1670-5.;;Kukli, et al. ""In situ Study of Atomic Layer Epitaxy Growth of Tantalum Oxide Thin Films From Ta(OC2H5)5 and H2O,"" Applied Surface Science, vol. 112, Mar. 1997, p. 236-42.;;Kukli, et al. ""Properties of {Nb1-xTax}2O5 Solid Solutions and {Nb1-xTax}2O5-ZrO2 Nanolaminates Grown by Atomic Layer Epitaxy,"" 1997; p. 785-93.;;Kukli, et al. ""Properties of Ta2O5-Based Dielectric Nanolaminates Deposited by Atomic Layer Epitaxy,"" Journal of the Electrochemical Society, vol. 144, No. 1, Jan. 1997; p. 300-6.;;Kukli, et al. ""Tailoring the Dielectric Properties of HfO2-Ta2O5 Nanolaminates,"" Applied Physics Letters, vol. 68, No. 26 (Jun. 24, 1996), pp. 3737-3739.;;Lee, et al. ""Cyclic Technique for the Enhancement of Highly Oriented Diamond Film Growth,"" Thin Solid Films 303 (1997) pp. 264-269.;;Martensson, et al. ""Use of Atomic Layer Epitaxy for Fabrication of Si/TiN/Cu Structures,"" J. Vac. Sci. & Tech. B, vol. 17, No. 5, (Sep. 1999) pp. 2122-2128.;;Min, et al. ""Atomic Layer Deposition of TiN Thin Films by Sequential Introduction of Ti Precursor and NH3,"" Mat. Res. Soc. Symp. Proc. vol. 514 (1998).;;Min, et al. ""Chemical Vapor Deposition of Ti-Si-N Films With Alternating Source Supply,"" Mat. Rec. Soc. Symp. Proc. vol. (1999).;;Min, et al. ""Metal-organic Atomic-layer Deposition of Titanium-silicon-nitride Films,"" Applied Physics Letters, vol. 75, No. 11 (Sep. 11, 1999) pp. 1521-1523.;;Niinisto, et al. ""Synthesis of Oxide Thin Films and Overlayers by Atomic Layer Epitaxy for Advanced Applications,"" Materials Science and Engineering B41 (1996) 23-29.;;Ohshita, et al. ""Hf1-xSixO2 deposition by metal organic chemical vapor deposition using the Hf(NEt2)4/SiH(NEt2)3/O2 gas system"", Preparation and Characterization, Elsevier Sequioa, NL, vol. 416, No. 1-2, Sep. 2, 2002, pp. 208-211.;;Ohshita, et al. ""HfO2 Growth by Low-pressure Chemical Vapor Deposition Using the Hf(N(C2H5)2)4/O2 Gas System,"" Journal of Crystal Growth 233 (2001) 292-297.;;Paranjpe, et al. ""Atomic Layer Deposition of AIO3 for Thin Film Head Gap Applications,"" J. Elec. Soc., vol. 148, No. 9 Sep. 2001 pp. G465-G471.;;Park, et al. ""Performance improvement of MOSFET with HfO2-Al2O3 laminate gate dielectric and CVD-TaN metal gate deposited by TAIMATA"", Electron Devices Meeting, 2003. IEDM '03 Techinical Digest. IEEE International Dec. 8-10, 2003, pp. 13.6.1-13.6.4.;;Partial International Search Report for International Application No. PCT/US2005/016694 dated Oct. 13, 2005.;;Proceedings of the ICEEE 1998 International Interconnect Technology Conference-San Francisco, California, Jun. 1-3, 1998.;;Ritala, et al. Ann. Acad. Sci. Fenn. Ser. A II. Chemica 257 (1994) 1-48.;;Ritala, et al. ""Atomic Force Microscopy Study of Titanium Dioxide Thin Films Grown by Atomic Layer Epitaxy,"" Thin Solid Films, vol. 228, No. 1-2 (May 15, 1993), pp. 32-35.;;Ritala, et al. ""Atomic Layer Deposition of Oxide Thin Films with Metal Alkoxides as Oxygen Sources,"" Science vol. 288 Apr. 14, 2000 pp. 319-321.;;Ritala, et al. ""Atomic Layer Epitaxy Growth of TiN Thin Films From Til4 and NH3,"" J. Electrochem. Soc., vol. 145, No. 8 (Aug. 1998) pp. 2914-2920.;;Ritala, et al. ""Atomic Layer Epitaxy Growth of TiN Thin Films,"" J. Electrochem. Soc., vol. 142, No. 8, Aug. 1995.;;Ritala, et al. ""Development of Crystallinity and Morphology in Hafnium Dioxide Thin Films Grown by Atomic Layer Epitaxy,"" Thin Solid Films, vol. 250, No. 1-2, (Oct. 1, 1994), p. 72-80.;;Ritala, et al. ""Effects of Intermediate Zinc Pulses on Properties of TiN and NbN Films by Atomic Layer Epitaxy,"" Applied Surface Science, vol. 120, No. 3-4, (Dec. 1997), pp. 199-212.;;Ritala, et al. ""Growth of Titanium Dioxide Thin Films by Atomic Layer Epitaxy,"" Thin Solid Films, vol. 225, No. 1-2 (Mar. 25, 1993) pp. 288-295.;;Ritala, et al. ""Perfectly Conformal TiN and Al2O3 Films Deposited by Atomic Layer Deposition,"" Chem. Vap. Deposition 1999, 5, No. 1.;;Ritala, et al. ""Surface Roughness Reduction in Atomic Layer Epitaxy Growth of Titanium Dioxide Thin Films,"" Thin Solid-Films, vol. 249, No. 2 (Sep. 15, 1994), pp. 155-162.;;Rossnagel, et al. ""Plasma-enhanced Atomic Layer Deposition of Ta and Ti for Interconnect Diffusion Barriers,"" J. Vacuum Sci. & Tech. B., vol. 18, No. 4 (Jul. 2000), pp. 2016-2020.;;Sekine, et al. ""Nitrogen profile control by plasma nitridation technique for poly-Si gate HfSiON CMOSFET with excellent interface property and ultra-low leakage current,"" International Electron Devices Meeting 2003. IEDM. Technical Digest. Washington, DC, Dec. 8-10, 2003, New York, NY, IEEE, US, Dec. 8, 2003, pp. 103-106.;;Senzaki, et al. ""A Novel Atomic Layer Deposition Process to Deposit Hafnium Silicate Thin Films"", Electrochemical Society Proceedings vol. 2004-01, pp. 264-270.;;Shenai, et al. ""Correlation of vapor pressure equation and film properties with trimethylindium purity for the MOVPE grown III-V compounds,"" Journal of Crystal Growth 248 (2003) pp. 91-98.;;Visokay, et al. ""Application of HfSiON as a gate dielectric material"", Applied Physics Letter, American Institute of Physics, New York, US, vol. 80, No. 17, Apr. 29, 2002, pp. 3183-3185.;;Written Opinion of the International Search Report for International Application No. PCT/US2005/016603 dated Sep. 15, 2005.;;Written Opinion of the International Search Report for International Application No. PCT/US2005/016606 dated Aug. 22, 2005.;;Written Opinion of the International Search Report for International Application No. PCT/US2005/016690 dated Aug. 22, 2005.;;Notification of First Office Action dated Feb. 20, 2009 for Chinese Patent Application No. 2005800084063.;;Notice of Rejection dated Oct. 25, 2011 for Japanese Patent Application No. 2007-513372.;;Notice of Rejection dated Apr. 10, 2012 for Korean Patent Application No. 10-2006-7026129.",INACTIVE
431,DE,T1,DE 944912 T1,081-391-404-403-842,2000-05-04,2000,DE 97950630 T,1997-11-26,US 76647796 A;;US 76647496 A;;US 9721095 W,1996-12-12,SPALTSPRUNGVERFAHREN FÜR ABDICHTUNG EINER STRUKTUR,,CANDESCENT TECH CORP,FAHLEN THEODORE;;LUDWIG PAUL;;SCHMID ANTHONY;;PRESSLEY ROBERT;;CHO STEVEN;;CONTE ALFRED;;COOPER ANTHONY;;POTHOVEN FLOYD,,https://lens.org/081-391-404-403-842,Granted Patent,no,0,0,13,16,0,B23K26/206;;C03B23/24;;H01J9/26;;H01J31/123;;H01J9/261;;H01J9/385,G09F9/00;;G09F9/30;;H01J9/24;;H01J9/26;;H01J31/12,,0,0,,,,EXPIRED
432,US,B2,US 7249692 B2,030-466-762-021-020,2007-07-31,2007,US 26844505 A,2005-11-07,US 26844505 A;;US 17689605 A;;US 21842804 F,2004-11-29,Dispenser with lock,"A dispensing assembly is provided for a container of fluent material. A hand-operable dispenser cartridge is adapted to be mounted to the container. An actuator, which may include a nozzle or spout, is mounted on the cartridge. A locking sleeve is mounted around the cartridge and has an upper abutment edge and a recess. The locking sleeve can be rotated between a first rotated position preventing actuation of the dispensing assembly and a second rotated position permitting actuation of the dispensing assembly.",SEAQUISTPERFECT DISPENSING FOR,WALTERS PETER J;;KSIAZK JASON A;;CHO SEAN H;;HALLMAN PAUL E;;WERNER JONATHAN D;;BRAUN CRAIG,SEQUISTPERFECT DISPENSING FOREIGN INC (2005-11-04),https://lens.org/030-466-762-021-020,Granted Patent,yes,105,53,2,14,0,B65D83/201;;B65D83/22;;B05B11/1014;;B05B11/1057;;B05B11/1059;;B65D83/201;;B65D83/22;;B05B11/1057;;B05B11/1014;;B05B11/1059,B67B5/00;;B67D7/58,222/153.11;;222/153.13;;222/182;;222/321.8;;222/383.1;;222/402.13;;222/402.15,2,0,,,"FIGS. 1-4.;;FIGS. 1A, 2A, 3A, and 4A.",ACTIVE
433,US,A1,US 2020/0246288 A1,043-431-147-116-329,2020-08-06,2020,US 202016853696 A,2020-04-20,US 202016853696 A;;MY PI2015704862 A;;US 201816067130 A;;MY 2016000088 W,2015-12-31,"OIL PALM PHENOLICS COMPOSITION FOR THE PROTECTION OF HUMANS, ORGANS, CELLS AND TISSUES AGAINST THE INJURIOUS EFFECTS OF EXPOSURE TO IONIZING RADIATION","A composition for preventing, treating, reversing, protecting against ameliorating the injuring effect of an ionizing radiation upon living cells, tissues, organs, and organisms, comprising oil palm phenolics (OOP) or vegetation liquor extract obtained from aqueous stream of a palm oil milling effluent is provided.",MALAYSIAN PALM OIL BOARD,SAMBANTHAMURTHI RAVIGADEVI;;TAN YEW AI;;KOLEDOVA VERA VLADIMIROVNA;;WEINBERG ROBERT PAUL;;RHA CHO KYUN;;SINSKEY ANTHONY J,MALAYSIAN PALM OIL BOARD (2018-06-06),https://lens.org/043-431-147-116-329,Patent Application,yes,0,0,10,10,0,A61K36/889;;A61K31/192;;A61K31/702;;A61K31/191;;A61K31/225;;A61K31/192;;A61K31/702;;A61K36/889;;A61K2300/00;;A61K31/192;;A61K31/702;;A61K36/889;;A61K31/191;;A61K31/225;;A61K36/888,A61K31/191;;A61K31/192;;A61K31/225;;A61K31/702;;A61K36/888;;A61K36/889,,2,2,040-624-344-535-727;;063-227-793-507-68X,pmc4179495;;21736792;;10.1017/s0007114511002121;;pmc4179496;;10.1017/s0007114511002133;;21736778,Sambanthamurthi (British Journal of Nutrition Vol. 106 pages 1655-1663 published 2011) (Year: 2011);;Sambanthamurthi (British Journal of Nutrition Vol. 106 pages 1664-1675 published 2011). (Year: 2011),DISCONTINUED
434,US,A1,US 2016/0013348 A1,004-578-426-915-731,2016-01-14,2016,US 201514813745 A,2015-07-30,US 201514813745 A;;EP 11102241 A;;US 201213401181 A;;US 27119208 A;;US 2377208 A;;US 86014207 A;;US 86018307 A,2007-09-24,INVERTED METAMORPHIC MULTIJUNCTION SOLAR CELL WITH METAMORPHIC LAYERS,"A multijunction solar cell having at least four solar subcells includes a first solar subcell having a first band gap, and a first graded interlayer adjacent to the first solar subcell, wherein the first graded interlayer has a second band gap greater than the first band gap and that is constant at 1.5 eV throughout the thickness of the first graded interlayer. A second solar subcell is adjacent to the first graded interlayer, wherein the second solar subcell has a third band gap smaller than the first band gap of the first solar subcell and wherein said second solar subcell is lattice mismatched with respect to the first solar subcell. A second graded interlayer is adjacent to the second solar subcell, wherein the second graded interlayer has a fourth band gap greater than the third band gap of the second solar subcell and that is constant at 1.1 eV throughout the thickness of the second graded interlayer. A third solar subcell is adjacent to the second graded interlayer, wherein the third solar subcell has a fifth band gap smaller than the third band gap of the second solar subcell and wherein the third solar subcell is lattice mismatched with respect to the second solar subcell. Each of the first and second graded interlayers is composed, respectively, of a compositionally step-graded series of (In x Ga 1-x ) y Al 1-y As layers with monotonically changing lattice constant, with x and y having respective values such that the band gap of each interlayer remains constant throughout its thickness, and wherein 0<x<1 and 0<y<1.",SOLAERO TECHNOLOGIES CORP,CORNFELD ARTHUR;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN;;SHARPS PAUL R;;AIKEN DANIEL J;;SPANN JOHN,EMCORE SOLAR POWER INC (2012-02-15);;SOLAERO TECHNOLOGIES CORP (2015-01-08),https://lens.org/004-578-426-915-731,Patent Application,yes,0,2,6,111,0,H01L31/06875;;H01L31/06875;;H01L31/078;;H01L31/078;;H01L31/1844;;H01L31/1844;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02E10/548;;Y02P70/50;;Y02P70/50,H01L31/0687,,0,0,,,,ACTIVE
435,WO,A3,WO 2007/008375 A3,014-562-801-066-521,2007-04-19,2007,US 2006/0024586 W,2006-06-23,US 17689605 A;;US 26844505 A;;US 21842804 F,2004-11-29,DISPENSER WITH LOCK,"A dispensing assembly is provided for a container (22, 222, 222B, 22C) of fluent material. A hand-operable dispenser cartridge (24, 224, 224B, 24C) is adapted to be mounted to the container (22, 222, 222B, 22C). An actuator (42, 242, 242B, 42C), which may include a nozzle or spout (45, 245), is mounted on the cartridge (24, 224, 224B, 24C). A locking sleeve (76, 76A, 276, 276B, 76C) is mounted around the cartridge (24, 224, 224B, 24C) and has an upper abutment edge (81/82; 81A/82A; 281/282; 281B/282B; 81C/82C) and a recess (91/92; 91A/92A; 291/292; 291A/292B; 91C/92C). The locking sleeve (76, 76A, 276, 276B, 76C) can be rotated between a first rotated position preventing actuation of the dispensing assembly and a second rotated position permitting actuation of the dispensing assembly.",SEAQUISTPERFECT DISPENSING FOR,WALTERS PETER J;;KSIAZK JASON A;;CHO SEAN H;;HALLMAN PAUL E;;WERNER JONATHAN D;;BRAUN CRAIG,,https://lens.org/014-562-801-066-521,Search Report,yes,4,0,8,14,0,B65D83/201;;B65D83/22;;B05B11/1014;;B05B11/1057;;B05B11/1059,B67B5/00;;B67D7/58,,0,0,,,,PENDING
436,EP,A2,EP 1917205 A2,144-772-966-047-731,2008-05-07,2008,EP 06785489 A,2006-06-23,US 2006/0024586 W;;US 17689605 A;;US 26844505 A;;US 21842804 F,2004-11-29,DISPENSER WITH LOCK,,SEAQUISTPERFECT DISPENSING FOR,WALTERS PETER J;;KSIAZK JASON A;;CHO SEAN H;;HALLMAN PAUL E;;WERNER JONATHAN D;;BRAUN CRAIG,"APTARGROUP, INC (2011-11-30)",https://lens.org/144-772-966-047-731,Patent Application,yes,0,0,8,14,0,B65D83/201;;B65D83/22;;B05B11/1014;;B05B11/1057;;B05B11/1059,B05B11/00;;B67D7/58,,0,0,,,,ACTIVE
437,EP,A4,EP 1917205 A4,166-836-248-681-250,2010-01-20,2010,EP 06785489 A,2006-06-23,US 2006/0024586 W;;US 17689605 A;;US 26844505 A;;US 21842804 F,2004-11-29,DISPENSER WITH LOCK,,SEAQUISTPERFECT DISPENSING FOR,WALTERS PETER J;;KSIAZK JASON A;;CHO SEAN H;;HALLMAN PAUL E;;WERNER JONATHAN D;;BRAUN CRAIG,"APTARGROUP, INC (2011-11-30)",https://lens.org/166-836-248-681-250,Search Report,no,6,0,8,14,0,B65D83/201;;B65D83/22;;B05B11/1014;;B05B11/1057;;B05B11/1059,B67B5/00;;B67D7/58,,1,0,,,See also references of WO 2007008375A2,ACTIVE
438,GB,B,GB 2562661 B,022-677-193-266-318,2020-12-16,2020,GB 201812351 A,2016-12-30,MY 2016000088 W;;MY PI2015704862 A,2015-12-31,"Oil palm phenolics composition for the protection of human organs, cells and tissues against the injurious effects of exposure to ionizing radiation",,MALAYSIAN PALM OIL BOARD,J SINSKEY ANTHONY;;SAMBANTHAMURTHI RAVIGADEVI;;YEW AI TAN;;VLADIMIROVNA KOLEDOVA VERA;;PAUL WEINBERG ROBERT;;KYUN RHA CHO,,https://lens.org/022-677-193-266-318,Granted Patent,no,3,0,10,10,0,A61K36/889;;A61K31/192;;A61K31/702;;A61K31/191;;A61K31/225;;A61K31/192;;A61K31/702;;A61K36/889;;A61K2300/00;;A61K31/192;;A61K31/702;;A61K36/889;;A61K31/191;;A61K31/225;;A61K36/888,A61K36/889;;A61K31/192;;A61K31/702,,2,1,025-754-619-428-683,10.1016/j.apcbee.2012.06.028,"KRISHNAIAH DUDUKU, ET AL.: ""Phytochemical antioxidants for health and medicine–A move towards nature"", BIOTECHNOLOGY AND MOLECULAR BIOLOGY REVIEWS, vol. 1, no. 4, 1 January 2007 (2007-01-01), pages 97 - 104, XP055396191;;VIJAYARATHNA SOUNDARARAJAN, ET AL.: ""Antioxidant Activity of Elaeis guineensis Leaf Extract: An Alternative Nutraceutical Approach in Impeding Aging"", 3RD INTERNATIONAL CONFERENCE ON BIOTECHNOLOGY AND FOOD SCIENCE (ICBFS 2012) ELSEVIER SCIENCE BV, SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SERIES : APCBEE PROCEDIA (ISSN 2212-6708(PRINT)), ELSEVIER BV, NETHERLANDS, vol. 2, 7 March 2012 (2012-03-07), Netherlands, pages 153 - 159, XP055396185, ISSN: 2212-6708, DOI: 10.1016/j.apcbee.2012.06.028",ACTIVE
439,US,A1,US 2012/0211068 A1,025-388-851-380-429,2012-08-23,2012,US 201213401181 A,2012-02-21,US 201213401181 A;;EP 11102241 A;;US 27119208 A;;US 2377208 A;;US 86018307 A;;US 86014207 A,2007-09-24,INVERTED METAMORPHIC MULTIJUNCTION SOLAR CELL WITH TWO METAMORPHIC LAYERS AND HOMOJUNCTION TOP CELL,"A multijunction solar cell including an upper first solar subcell, and the base-emitter junction of the upper first solar subcell being a homojunction; a second solar subcell adjacent to said first solar subcell; a third solar subcell adjacent to said second solar subcell. A first graded interlayer is provided adjacent to said third solar subcell. A fourth solar subcell is provided adjacent to said first graded interlayer, said fourth subcell is lattice mismatched with respect to said third subcell. A second graded interlayer is provided adjacent to said fourth solar subcell; and a lower fifth solar subcell is provided adjacent to said second graded interlayer, said lower fifth subcell is lattice mismatched with respect to said fourth subcell.",CORNFELD ARTHUR;;SPANN JOHN;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN;;SHARPS PAUL R;;AIKEN DANIEL J;;EMCORE SOLAR POWER INC,CORNFELD ARTHUR;;SPANN JOHN;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN;;SHARPS PAUL R;;AIKEN DANIEL J,EMCORE SOLAR POWER INC (2012-02-15);;SOLAERO TECHNOLOGIES CORP (2015-01-08),https://lens.org/025-388-851-380-429,Patent Application,yes,8,49,6,111,0,H01L31/06875;;H01L31/06875;;H01L31/078;;H01L31/078;;H01L31/1844;;H01L31/1844;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02E10/548;;Y02P70/50;;Y02P70/50,H01L31/0248;;H01L31/0304;;H01L31/04;;H01L31/18,136/255;;438/74;;X257E31054,1,1,191-162-012-535-941,10.1116/1.2167981,"Xiaonan Li, Sally E. Asher, Sukit Limpijumnong, S. B. Zhang, Su-Huai Wei, Teresa M. Barnes, Timothy J. Coutts, and Rommel Noufi, ""Unintentional doping and compensation effects of carbon in metal-organic chemical vapor deposition fabricated ZnO thin films"", 2006, Pages 1213-1217.",ACTIVE
440,US,A1,US 2016/0329454 A1,034-524-214-697-618,2016-11-10,2016,US 201615214315 A,2016-07-19,US 201615214315 A;;EP 11010224 A;;US 201615045641 A;;US 201514813745 A;;US 201213401181 A;;US 27119208 A;;US 2377208 A;;US 86014207 A;;US 86018307 A;;US 81340810 A,2007-09-24,INVERTED METAMORPHIC MULTIJUNCTION SOLAR CELL WITH TWO METAMORPHIC LAYERS AND HOMOJUNCTION TOP CELL,"A multijunction solar cell includes an upper first solar subcell having a first band gap, a second solar subcell having a second band gap smaller than the first band gap, and a first graded interlayer composed of (InxGa1-x)yAl1-yAs adjacent to the second solar subcell. The first graded interlayer has a third band gap greater than the second band gap subject to the constraints of having the in-plane lattice parameter greater or equal to that of the second subcell and less than or equal to that of the third subcell, wherein 0<x<1 and 0<y<1, and x and y are selected such that the band gap of the first graded interlayer remains constant throughout its thickness at 1.5 eV. A third solar subcell is adjacent to the first graded interlayer and has a fourth band gap smaller than the second band gap such that the third subcell is lattice mismatched with respect to the second subcell. A second graded interlayer composed of (InxGa1-x)yAl1-yAs is adjacent to the third solar subcell and has a fifth band gap greater than the fourth band gap subject to the constraints of having the in-plane lattice parameter greater or equal to that of the third subcell and less than or equal to that of the bottom fourth subcell, wherein 0<x<1 and 0<y<1, and x and y are selected such that the band gap of the second graded interlayer remains constant throughout its thickness at 1.1 eV. A lower fourth solar subcell is adjacent to the second graded interlayer and has a sixth band gap smaller than the fourth band gap.",SOLAERO TECH CORP,PATEL PRAVIN;;CORNFELD ARTHUR;;SPANN JOHN;;STAN MARK A;;CHO BENJAMIN;;SHARPS PAUL R;;AIKEN DANIEL J,EMCORE SOLAR POWER INC (2012-02-15);;SOLAERO TECHNOLOGIES CORP (2015-01-08),https://lens.org/034-524-214-697-618,Patent Application,yes,0,1,2,111,0,H01L31/1844;;H01L31/1844;;H01L31/03046;;H01L31/03046;;H01L31/06875;;H01L31/06875;;H01L31/078;;H01L31/078;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02P70/50;;Y02P70/50,H01L31/0725;;H01L31/0304;;H01L31/0735;;H01L31/18,,1,1,000-310-095-058-823,10.1109/50.989001,"Jae-Hyung Jang, Student Member, Gabriel Cueva, William E. Hoke, P. J. Lemonias, Patrick Fay, andIlesanmi Adesida, ""Metamorphic Graded Bandgap InGaAs–InGaAlAs–InAlAs Double Heterojunction P-i-I-N Photodiodes"", JOURNAL OF LIGHTWAVE TECHNOLOGY, VOL. 20, NO. 3, MARCH 2002 507",ACTIVE
441,US,A1,US 2013/0191872 A1,026-702-305-737-397,2013-07-25,2013,US 201113521762 A,2011-01-12,US 201113521762 A;;US 29447610 P;;US 2011/0021030 W,2010-01-12,VIDEO MANAGEMENT AND CONTROL IN HOME MULTIMEDIA NETWORK,"A system may include a video link and a hybrid link that connects a transmitting device to the receiving device, and at least one intermediate hop between the transmitting device and the receiving device. The intermediate hop may be configured to relay video content from the video source to the video sink through the hybrid link using one or more data relay modes. The hybrid link may be configured to perform hybrid link control signaling (HLCS) to manage a physical layer of the hybrid link. The video link between the video source and the video sink may be configured to transmit a video stream the from video source to the video sink over one or more video lanes. A video link training may be implemented for the video link and the hybrid link.",LEE DONGYUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;KIM BYOUNG WOON;;HENINWOLF PAUL;;KIM SANGWAN;;CHO SUKJAE;;SILICON IMAGE INC,LEE DONGYUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;KIM BYOUNG WOON;;HENINWOLF PAUL;;KIM SANGWAN;;CHO SUKJAE,SYNERCHIP CO. LTD (2013-02-04);;LATTICE SEMICONDUCTOR CORPORATION (2015-05-13);;SILICON IMAGE INC (2012-10-08);;UNIVERSAL CONNECTIVITY TECHNOLOGIES INC (2021-11-16),https://lens.org/026-702-305-737-397,Patent Application,yes,26,10,22,22,0,G06F13/4286;;G06F13/4286;;G06F13/4286;;G09G2370/047;;G09G2370/047;;G09G2370/12;;G09G2370/12;;H04N21/43615;;H04N21/43615;;H04L12/2838;;H04L12/2838;;H04L12/2838;;H04L2012/2849;;H04L2012/2849;;H04L2012/2849;;H04N21/43615;;H04N21/43632;;H04N21/43632;;H04N21/43635;;H04N21/43635;;H04N21/63;;H04N21/63,H04N21/63,725/78,0,0,,,,ACTIVE
442,EP,A2,EP 2556631 A2,090-352-333-231-389,2013-02-13,2013,EP 11733338 A,2011-01-12,US 29447610 P;;US 2011/0021030 W,2010-01-12,VIDEO MANAGEMENT AND CONTROL IN HOME MULTIMEDIA NETWORK,,SYNERCHIP USA CORP,LEE DONGYUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANGWAN;;CHO SUKJAE,"SYNERCHIP CO., LTD. (2014-04-16);;SILICON IMAGE, INC. (2014-04-16)",https://lens.org/090-352-333-231-389,Patent Application,yes,0,0,22,22,0,G06F13/4286;;G06F13/4286;;G06F13/4286;;G09G2370/047;;G09G2370/047;;G09G2370/12;;G09G2370/12;;H04N21/43615;;H04N21/43615;;H04L12/2838;;H04L12/2838;;H04L12/2838;;H04L2012/2849;;H04L2012/2849;;H04L2012/2849;;H04N21/43615;;H04N21/43632;;H04N21/43632;;H04N21/43635;;H04N21/43635;;H04N21/63;;H04N21/63,H04N21/436;;G06F13/42;;H04L12/28;;H04N21/63,,0,0,,,,DISCONTINUED
443,CN,A,CN 116940278 A,093-784-940-639-966,2023-10-24,2023,CN 202280019371 A,2022-02-16,US 202163158189 P;;US 2022/0016502 W,2021-03-08,Acute health event monitoring and alerting,"A system includes processing circuitry configured to receive a wirelessly transmitted message from a medical device, the message indicating that the medical device detects an acute health event of a patient. In response to the message, the processing circuitry is configured to determine a position of the patient; determining an alarm area based on the position of the patient; and controlling transmission of an alert of the acute health event of the patient to any one or more computing devices of one or more potential responders within the alert area.",MEDTRONIC INC,STADLER ROBERT W;;DOLAN BECKY L;;CHO YONG K;;KRAUSE PAUL G;;SARKAR SHANTANU;;KOVAL RANDY C,,https://lens.org/093-784-940-639-966,Patent Application,no,0,0,11,22,0,A61B5/0004;;A61B5/0024;;A61B5/0205;;A61B5/1032;;A61B5/14542;;A61B5/681;;A61B5/6898;;A61B5/746;;A61B5/747;;A61B2562/0219;;A61B5/0205;;A61B5/0004;;A61B5/746;;A61B5/747;;A61B2562/0219;;A61B5/1032;;A61B5/6898;;A61B5/681;;A61B5/0024;;A61B5/14542,A61B5/0205,,0,0,,,,PENDING
444,BR,A2,BR PI0614052 A2,193-832-350-836-985,2011-03-09,2011,BR PI0614052 A,2006-06-23,US 17689605 A;;US 26844505 A;;US 2006/0024586 W,2005-07-07,distribuidor com trava,"DISTRIBUIDOR COM TRAVA. A presente invenção refere-se a um conjunto de distribuição é provido para um recipiente (22, 222, 222B, 220) de material fluido. Um car- tucho de distribuidor operável com a mão (24, 224, 224B, 24C) é adaptado para ser montado no recipiente (22, 222, 222B, 220). Um atuador (42, 242, 242B, 420), o qual pode incluir um bocal ou bico (45, 245), é montado no cartucho (24, 224, 224B, 24C). Uma luva de travamento (76, 76A, 276, 276B, 76C) é montada em torno do cartucho (24, 224, 224B, 24C) e tem uma borda superior de confinamento (81/82; 81A182A; 281/282; 281 B/282B; 810/820) e um recesso (91/92; 91A/92A; 291/292; 291A/292B; 91 0/920). A luva de travamento (76, 76A, 276, 276B, 760) pode ser rodada entre uma primeira posição rodada, que impede uma atuação do conjunto de distribuição, e uma segunda posição rodada, que permite uma atuação do conjunto de distribuição.",SEAQUISTPERFECT DISPENSING FOREIGN INC,WALTERS PETER J;;KSIAZK JASON A;;CHO SEAN H;;HALLMAN PAUL E;;WERNER JONATHAN D;;BRAUN CRAIG,"APTARGROUP, INC. (US) (2013-06-04)",https://lens.org/193-832-350-836-985,Patent Application,no,0,0,2,14,0,B65D83/201;;B65D83/22;;B05B11/1014;;B05B11/1059;;B05B11/1057;;B65D83/201;;B65D83/22;;B05B11/1014;;B05B11/1057;;B05B11/1059,B67B5/00;;B67D7/58,,0,0,,,,DISCONTINUED
445,US,A1,US 2013/0191570 A1,025-333-877-581-028,2013-07-25,2013,US 201113521739 A,2011-01-12,US 201113521739 A;;US 29447610 P;;US 2011/0021031 W,2010-01-12,MULTI-MEDIA USB DATA TRANSFER OVER DIGITAL INTERACTION INTERFACE FOR VIDEO AND AUDIO (DiiVA),"A system for delivering USB data over a DiiVA network may include a USB host controller, at least one USB device, a first DiiVA device connected to the USB host controller through an upstream USB port, a second DiiVA device connected to the USB device through a downstream USB port; and a network configured to transfer data between the first DiiVA device and the second DiiVA device according to USB protocol through a DiiVA bi-directional hybrid link in the network. The network is responsive to the USB host controller to deliver contents for the USB protocol through at least one line state information packet and at least one USB data packet transmitted through the hybrid link between the upstream USB port and the downstream USB port.",LEE DONGYUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;KIM BYOUNG WOON;;HENINWOLF PAUL;;KIM SANGWAN;;CHO SUKJAE;;SYNERCHIP CO LTD,LEE DONGYUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;KIM BYOUNG WOON;;HENINWOLF PAUL;;KIM SANGWAN;;CHO SUKJAE,SYNERCHIP CO. LTD (2013-02-04);;LATTICE SEMICONDUCTOR CORPORATION (2015-05-13);;SILICON IMAGE INC (2012-10-08);;UNIVERSAL CONNECTIVITY TECHNOLOGIES INC (2021-11-16),https://lens.org/025-333-877-581-028,Patent Application,yes,7,19,22,22,0,G06F13/4286;;G06F13/4286;;G06F13/4286;;G09G2370/047;;G09G2370/047;;G09G2370/12;;G09G2370/12;;H04N21/43615;;H04N21/43615;;H04L12/2838;;H04L12/2838;;H04L12/2838;;H04L2012/2849;;H04L2012/2849;;H04L2012/2849;;H04N21/43615;;H04N21/43632;;H04N21/43632;;H04N21/43635;;H04N21/43635;;H04N21/63;;H04N21/63,G06F13/42,710/106,0,0,,,,DISCONTINUED
446,EP,A2,EP 2556648 A2,119-880-195-417-07X,2013-02-13,2013,EP 11733339 A,2011-01-12,US 29447610 P;;US 2011/0021031 W,2010-01-12,MULTI-MEDIA USB DATA TRANSFER OVER DIGITAL INTERACTION INTERFACE FOR VIDEO AND AUDIO (DIIVA),,SYNERCHIP USA CORP,LEE DONGYUM;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANGWAN;;CHO SUKJAE,"SILICON IMAGE, INC. (2013-08-28)",https://lens.org/119-880-195-417-07X,Patent Application,yes,0,0,22,22,0,G06F13/4286;;G06F13/4286;;G06F13/4286;;G09G2370/047;;G09G2370/047;;G09G2370/12;;G09G2370/12;;H04N21/43615;;H04N21/43615;;H04L12/2838;;H04L12/2838;;H04L12/2838;;H04L2012/2849;;H04L2012/2849;;H04L2012/2849;;H04N21/43615;;H04N21/43632;;H04N21/43632;;H04N21/43635;;H04N21/43635;;H04N21/63;;H04N21/63,H04N21/436;;G06F13/42;;H04L12/28;;H04N21/63,,0,0,,,,DISCONTINUED
447,WO,A1,WO 2017/116225 A1,036-772-147-404-787,2017-07-06,2017,MY 2016000088 W,2016-12-30,MY PI2015704862 A,2015-12-31,"OIL PALM PHENOLICS COMPOSITION FOR THE PROTECTION OF HUMANS, ORGANS, CELLS AND TISSUES AGAINST THE INJURIOUS EFFECTS OF EXPOSURE TO IONIZING RADIATION","A composition for preventing, treating, reversing, protecting against or ameliorating the injuring effects of an ionizing radiation upon living cells, tissues, organs, and organisms, comprising oil palm phenolics (OPP) or vegetation liquor extract obtained from aqueous stream of a palm oil milling effluent is provided.",MALAYSIAN PALM OIL BOARD,RAVIGADEVI SAMBANTHAMURTHI;;TAN YEW AI;;VERA VLADIMIROVNA KOLEDOVA;;ROBERT PAUL WEINBERG;;CHO KYUN RHA;;ANTHONY J SINSKEY,,https://lens.org/036-772-147-404-787,Patent Application,yes,3,3,10,10,0,A61K36/889;;A61K31/192;;A61K31/702;;A61K31/191;;A61K31/225;;A61K31/192;;A61K31/702;;A61K36/889;;A61K2300/00;;A61K31/192;;A61K31/702;;A61K36/889;;A61K31/191;;A61K31/225;;A61K36/888,A61K36/889;;A61K31/192;;A61K31/702,,2,1,025-754-619-428-683,10.1016/j.apcbee.2012.06.028,"KRISHNAIAH, DUDUKU ET AL.: ""Phytochemical antioxidants for health and medicine - A move towards nature"", BIOTECHNOLOGY AND MOLECULAR BIOLOGY REVIEWS, vol. 1, no. 4, 2007, pages 97 - 104, XP055396191;;SOUNDARARAJAN, VIJAYARATHNA ET AL.: ""Antioxidant activity of Elaeis guineensis leaf extract: An alternative nutraceutical approach in impeding aging"", APCBEE PROCEDIA, vol. 2, 2012, pages 153 - 159, XP055396185",PENDING
448,US,B2,US 9117966 B2,151-112-346-264-68X,2015-08-25,2015,US 201213401181 A,2012-02-21,US 201213401181 A;;EP 11102241 A;;US 27119208 A;;US 2377208 A;;US 86018307 A;;US 86014207 A,2007-09-24,Inverted metamorphic multijunction solar cell with two metamorphic layers and homojunction top cell,"A multijunction solar cell including an upper first solar subcell, and the base-emitter junction of the upper first solar subcell being a homojunction; a second solar subcell adjacent to said first solar subcell; a third solar subcell adjacent to said second solar subcell. A first graded interlayer is provided adjacent to said third solar subcell. A fourth solar subcell is provided adjacent to said first graded interlayer, said fourth subcell is lattice mismatched with respect to said third subcell. A second graded interlayer is provided adjacent to said fourth solar subcell; and a lower fifth solar subcell is provided adjacent to said second graded interlayer, said lower fifth subcell is lattice mismatched with respect to said fourth subcell.",CORNFELD ARTHUR;;SPANN JOHN;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN;;SHARPS PAUL R;;AIKEN DANIEL J;;SOLAERO TECHNOLOGIES CORP,CORNFELD ARTHUR;;SPANN JOHN;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN;;SHARPS PAUL R;;AIKEN DANIEL J,EMCORE SOLAR POWER INC (2012-02-15);;SOLAERO TECHNOLOGIES CORP (2015-01-08),https://lens.org/151-112-346-264-68X,Granted Patent,yes,94,4,6,111,0,H01L31/06875;;H01L31/06875;;H01L31/078;;H01L31/078;;H01L31/1844;;H01L31/1844;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02E10/548;;Y02P70/50;;Y02P70/50,H01L31/0232;;H01L31/042;;H01L31/046;;H01L31/0687;;H01L31/0693;;H01L31/0725;;H01L31/0735;;H01L31/076;;H01L31/078;;H01L31/18,,54,26,191-162-012-535-941;;026-281-940-590-23X;;106-513-576-934-63X;;015-557-396-201-987;;015-557-396-201-987;;002-874-834-532-776;;073-300-069-664-773;;115-973-926-256-941;;083-287-525-840-54X;;084-891-382-112-541;;025-407-739-778-403;;034-023-904-332-047;;102-210-428-050-695;;076-989-478-838-81X;;043-633-301-060-630;;030-787-136-717-28X;;038-574-682-896-969;;052-700-785-133-704;;093-340-948-123-836;;091-028-789-674-438;;020-636-430-481-14X;;026-862-096-577-376;;026-169-360-688-45X;;107-582-530-482-098;;164-535-659-415-932;;007-176-082-871-508,10.1116/1.2167981;;10.1109/wcpec.2006.279587;;10.1109/pvsc.1990.111608;;10.1109/pvsc.2010.5614498;;10.1109/pvsc.2010.5614498;;10.1109/wcpec.2006.279835;;10.1109/wcpec.2006.279527;;10.1063/1.2753729;;10.1109/pvsc.2008.4922452;;10.1063/1.335957;;10.1109/pvsc.2002.1190685;;10.1109/77.783715;;10.1109/pvsc-vol2.2012.6656717;;10.1109/iscs.1998.711543;;10.1016/0379-6787(86)90032-3;;10.1016/j.jcrysgro.2009.10.059;;10.1002/pip.642;;10.1109/pvsc.1991.169189;;10.1063/1.106494;;10.1088/0953-8984/16/21/008;;10.1109/pvsc.2005.1488186;;10.1109/wcpec.2006.279559;;10.1063/1.98946;;10.1134/1.1187812;;10.1016/0022-0248(84)90363-4;;10.1016/0379-6787(88)90047-6,"Xiaonan Li, Sally E. Asher, Sukit Limpijumnong, S. B. Zhang, Su-Huai Wei, Teresa M. Barnes, Timothy J. Coutts, and Rommel Noufi, ""Unintentional doping and compensation effects of carbon in metal-organic chemical vapor deposition fabricated ZnO thin films"", 2006, pp. 1213-1217.;;Aiken et al., ""Consideration of High Bandgap Subcells for Advanced Multijunction Solar Cells,"" Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, 2006:838-841.;;Schultz et al., ""High Efficiency 1.0-eV GaInAs Bottom Solar Cell for 3-Junction Monolithic Stack,"" IEEE, 1990:148-152.;;U.S. Appl. No. 12/708,361, filed Feb. 18, 2010, Cornfeld.;;U.S. Appl. No. 12/716,814, filed Mar. 3, 2010, Cornfeld.;;U.S. Appl. No. 12/730,018, filed Mar. 23, 2010, Cornfeld.;;U.S. Appl. No. 12/756,926, filed Apr. 8, 2010, Cornfeld.;;U.S. Appl. No. 12/813,408, filed Jun. 10, 2010, Patel.;;U.S. Appl. No. 12/844,673, filed Jul. 27, 2010, Stan.;;U.S. Appl. No. 13/104,451, filed May 10, 2011, Hoffman, Jr.;;U.S. Appl. No. 13/465,477, filed May 7, 2012, Cornfeld.;;U.S. Appl. No. 13/491,390, filed Jun. 7, 2012, Patel.;;U.S. Appl. No. 13/535,570, filed Jun. 28, 2012, Tourino.;;U.S. Appl. No. 13/547,334, filed Jul. 12, 2012, Cornfeld.;;U.S. Appl. No. 13/554,527, filed Jul. 20, 2012, Tourino.;;U.S. Appl. No. 13/560,663, filed Jul. 27, 2012, Varghese.;;U.S. Appl. No. 13/569,671, filed Aug. 8, 2012, Villegas.;;U.S. Appl. No. 13/569,794, filed Aug. 8, 2012, Stan.;;Cornfeld et al., ""Development of a Large Area Inverted Metamorphic Multi-Junction (IMM) Highly Efficient AM0 Solar Cell,"" 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Cornfeld et al., ""Development of a Large Area Inverted Metamorphic Multi-junction Highly Efficient AM0 Solar Cell,"" Conference paper presented at the 33rd IEEE Photovoltaic Specialists Conference (May 11-16, 2008) on May 12, 2008. San Diego, CA, USA.;;Cornfeld et al., ""Advances in the Performance of Inverted Metamorphic Multi-junction Solar Cells,"" 23rd European Photovoltaic Energy Conference, Aug. 29, 2008, Valencia, Spain.;;Dimroth et al., ""Thin 5-Junction Solar Cells with Improved Radiation Hardness,"" Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 2006; pp. 1777-1780.;;Extended European Search Report for European Application No. 11010224.1-1528 dated May 15, 2012; 2 pgs.;;Friedman et al., ""0.7-eV GaInAs Junction for a GaInP/GaAs/GaInAs(1eV)/GaInAs(0.7eV) Four-Junction Solar Cell,"" 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA; 598-602.;;Geisz et al., ""High efficiency GaInP/GaAs/InGaAs triple-junction solar cells grown inverted with a metamorphic bottom junction,"" Applied Physics Letters, 2007; 91:023502-1-023502-3. Published online Jul. 10, 2007.;;Geisz et al., ""Inverted GaInP / (In)GaAs Triple-Junction Solar Cells with Low-Stress Metamorphic Bottom Junctions,"" 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Hamaker, H.C., ""Computer modeling study of the effects of inhomogeneous doping and/or composition in GaAs solar-cell devices,"" J. Appl. Phys., Sep. 15, 1985; 58(6):2344-2351.;;King et al., ""Next-Generation, High Efficiency III-V Multijunction Solar Cells,"" 28th IEEE Photovoltaic Specialists Conference, Sep. 15-22, 2000, Anchorage, AK, USA; pp. 998-1001.;;King et al., ""High-Efficiency Space and Terrestrial Multijunction Solar Cells Through Bandgap Control in Cell Structures,"" 2002 Photovoltaic Specialists Conference, Conference Record of the 29th IEEE, May 19-24, 2002, New Orleans, LA, USA; pp. 776-781.;;King et al., ""Solar Cell Generations Over 40% Efficiency,"" 26th European Photovoltaic Solar Energy Conference and Exhibition, Sep. 5, 2011, Hamburg, Germany; 15 pgs.;;Koh et al., ""Fabrication of Superconducting Delay Line with GaAs Schottky Diode,"" IEEE Transactions on Applied Superconductivity, 1999; 9(2):3224-3227.;;Patel et al., ""Experimental Results From Performance Improvement and Radiation Hardening of Inverted Metamorphic Multi-Junction Solar Cells,"" Proceedings of the 37th IEEE PVSC, Seattle, WA, 2011 (Presented at PVSC Jun. 22, 2001).;;Patel et al., ""Initial Results of the Monolithically Grown Six-Junction Inverted Metamorphic Multi-junction Solar Cell,"" Proceedings of the 38th IEEE PVSC, Austin, TX, 2012 (Presented at PVSC Jun. 7, 2012).;;Sexl et al., ""MBE Growth of Metamorphic In(Ga)AlAs Buffers,"" 1997 IEEE International Symposium on Compound Semiconductors, Sep. 8-11, 1997; pp. 49-52.;;Sharps et al., ""Inverting the triple junction improves efficiency and flexibility,"" Compund Semiconductor, Oct. 2007; pp. 25-28.;;Sinharoy et al., ""Progress in the Development of Metamorphic Multi junction III-V Space Solar Cells,"" Progess in Photovoltaics: Research and Applications, Feb. 2002; 10:427-432.;;Soukup et al., ""Limitations of Built-in Electric Field Enhancement of Minority Carrier Current Collection in GaAs Backwall Schottky Barrier Solar Cells,"" Solar Cells, 1996; 18:139-151.;;Stan et al., ""Recent Advances in the Performance of Multi-Junction Space Solar Cells,"" 22nd European Photovoltaic Solar Energy Conference, Sep. 3-7, 2007, Milan, Italy; pp. 101-105.;;Stan et al., ""Very High Efficiency Triple Junction Solar Cells by MOVPE,"" 14th International Conference of Metalorganic Vapor Phase Epitaxy, Jun. 5, 2008, Metz, France.;;Stan et al., ""High efficiency quadruple junction solar cells using OMVPE with inverted metamorphic device structures,"" Journal of Crystal Growth, 2010; 312:1370-1374.;;Takamoto et al., ""Future Development of InGaP/(In)GaAs Based Multijunction Solar Cells,"" Proceedings of the 31st IEEE PVSC, Jan. 3-7, 2005, Lake Buena Vista, FL; pp. 519-524.;;Takamoto et al., ""InGaP/GaAs-based Multijunction Solar Cells,"" Progress in Photovoltaics: Research and Applications, 2005; 13:495-511.;;Venkatasubramanian et al., ""An Inverted-Growth Approach to Development of an IR-Transparent, High-Efficiency AlGaAs/GaAs Cascade Solar Cell,"" 22nd IEEE Photovoltaic Specialists Conference, Oct. 7-11, 1991, Las Vegas, NV, USA; pp. 93-98.;;Venkatasubramanian et al., ""High-quality eutectic-metal-bonded AlGaAs-GaAs thin films on Si substrates,"" Appl. Phys. Lett., Feb. 1992; 60(7):886-888.;;Voncken et al., ""Strain-accelerated HF etching of AlAs for epitaxial lift-off,"" J. Phys.: Condens. Matter, 2004; 16:3585-3596.;;Walters et al., ""Space Radiation Effects in Advanced Solar Cell Materials and Devices,"" Mat. Res. Soc. Symp. Proc., 2002; 692:569-580.;;Wanlass et al., ""Lattice-Mismatched Approaches for High-Performance, III-V Photovoltaic Energy Converters,"" Conference Proceedings of the 31st IEEE Photovoltaic Specialists Conference and Exhibition, Lake Buena Vista, FL, USA; Jan. 3-7, 2005; 530-535.;;Wanlass et al., ""Monolithic, Ultra-Thin GaInP/GaAs/GaInAs Tandem Solar Cells,"" 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA; 729-732.;;Würfel, ""Basic Structure of Solar Cells,"" Physics of Solar Cells: From Basic Principles to Advanced Concepts, Second, Updated and Expanded Edition, 2009; Sections 6.4, 6.5 and 6.8.;;Yablonovitch et al., ""Extreme selectivity in the lift-off of epitaxial GaAs films,"" Appl. Phys. Lett., 1987; 51(28):2222-2224.;;Yamaguchi, ""Physics and Technologies of Superhigh-Efficiency Tandem Solar Cells,"" Semiconductors, Sep. 1999; 33(9):961-964.;;Yoon et al., ""Progress of Inverted Metamorphic III-V Solar Cell Development at Spectrolab,"" 33rd IEEE Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Lewis et al., ""The Crystallographic Connection of MOCVD-Grown Monolithic Cascade Subcells Via Transparent Graded Layers,"" Journal of Crystal Growth, 1984; 69:515-526.;;Lewis et al., ""Recent Developments in Multijunction Solar Cell Research,"" Solar Cells, 1988; 24:171-183.",ACTIVE
449,WO,A1,WO 2022/191962 A1,193-804-120-188-494,2022-09-15,2022,US 2022/0016502 W,2022-02-16,US 202163158189 P,2021-03-08,ACUTE HEALTH EVENT MONITORING AND ALERTING,"A system comprising processing circuitry configured to receive a wirelessly-transmitted message from a medical device, the message indicating that the medical device detected an acute health event of the patient. In response to the message, the processing circuitry is configured to determine a location of the patient, determine an alert area based on the location of the patient, and control transmission of an alert of the acute heath event of the patient to any one or more computing devices of one or more potential responders within the alert area.",MEDTRONIC INC,STADLER ROBERT W;;DOLAN BECKY L;;CHO YONG K;;KRAUSE PAUL G;;SARKAR SHANTANU;;KOWAL ROBERT C,,https://lens.org/193-804-120-188-494,Patent Application,yes,4,0,11,22,0,A61B5/0004;;A61B5/0024;;A61B5/0205;;A61B5/1032;;A61B5/14542;;A61B5/681;;A61B5/6898;;A61B5/746;;A61B5/747;;A61B2562/0219;;A61B5/0205;;A61B5/0004;;A61B5/746;;A61B5/747;;A61B2562/0219;;A61B5/1032;;A61B5/6898;;A61B5/681;;A61B5/0024;;A61B5/14542,A61B5/0205;;G16H80/00,,0,0,,,,PENDING
450,AU,A1,AU 2016/380627 A1,141-485-759-078-876,2018-08-16,2018,AU 2016/380627 A,2016-12-30,MY PI2015704862 A;;MY 2016000088 W,2015-12-31,"Oil palm phenolics composition for the protection of humans, organs, cells and tissues against the injurious effects of exposure to ionizing radiation","A composition for preventing, treating, reversing, protecting against or ameliorating the injuring effects of an ionizing radiation upon living cells, tissues, organs, and organisms, comprising oil palm phenolics (OPP) or vegetation liquor extract obtained from aqueous stream of a palm oil milling effluent is provided.",MALAYSIAN PALM OIL BOARD,RAVIGADEVI SAMBANTHAMURTHI;;TAN YEW AI;;VERA VLADIMIROVNA KOLEDOVA;;ROBERT PAUL WEINBERG;;CHO KYUN RHA;;ANTHONY J SINSKEY,,https://lens.org/141-485-759-078-876,Patent Application,no,0,0,10,10,0,A61K36/889;;A61K31/192;;A61K31/702;;A61K31/191;;A61K31/225;;A61K31/192;;A61K31/702;;A61K36/889;;A61K2300/00;;A61K31/192;;A61K31/702;;A61K36/889;;A61K31/191;;A61K31/225;;A61K36/888,A61K36/889;;A61K31/192;;A61K31/702,,0,0,,,,DISCONTINUED
451,TW,A,TW 201407005 A,090-797-747-461-522,2014-02-16,2014,TW 101133276 A,2012-09-12,CN 201210288848 A,2012-08-14,Electroplating method,"This invention discloses an electroplating method, which comprises: positioning a plurality of printed circuit boards in a tank loaded with an electrolyte solution; and at the same time of intermittently moving and passing the printed circuit boards through the electrolyte solution, the electroplating on the printed circuit boards is performed.",PROCESS AUTOMATION INTERNAT LTD,WONG KWOK WAI;;HENINGTON PAUL;;CHIU YU HIM;;CHENG KWONG CHO;;HUANG JIE-LING;;ZHANG SHI-FENG,,https://lens.org/090-797-747-461-522,Patent of Addition,no,0,0,3,3,0,,C25D5/00;;C25D7/12,,0,0,,,,INACTIVE
452,EP,A4,EP 2556648 A4,109-107-906-725-693,2013-12-11,2013,EP 11733339 A,2011-01-12,US 29447610 P;;US 2011/0021031 W,2010-01-12,MULTI-MEDIA USB DATA TRANSFER OVER DIGITAL INTERACTION INTERFACE FOR VIDEO AND AUDIO (DIIVA),,SILICON IMAGE INC,LEE DONGYUM;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANGWAN;;CHO SUKJAE,"SILICON IMAGE, INC. (2013-08-28)",https://lens.org/109-107-906-725-693,Search Report,no,4,0,22,22,0,H04L12/2838;;H04L2012/2849;;H04N21/43615;;G06F13/4286;;G06F13/4286;;H04L12/2838;;H04N21/43615;;H04N21/43632;;H04N21/43635;;H04N21/63;;H04L2012/2849;;G09G2370/12;;G09G2370/047;;H04N21/43635;;H04N21/43632;;G09G2370/12;;G09G2370/047;;H04L12/2838;;H04L2012/2849;;H04N21/43615;;G06F13/4286;;H04N21/63,H04N21/436;;G06F13/42;;H04L12/28;;H04N21/63,,1,0,,,"HIROFUCHI T ET AL: ""USB/IP - a Peripheral Bus Extension for Device Sharing over IP Network"", PROCEEDINGS OF THE USENIX ANNUAL TECHNICAL CONFERENCE, XX, XX, 1 January 2005 (2005-01-01), pages 47 - 60, XP007901448",DISCONTINUED
453,CN,A,CN 109152807 A,112-374-977-374-477,2019-01-04,2019,CN 201680082316 A,2016-12-30,MY PI2015704862 A;;MY 2016000088 W,2015-12-31,"OIL PALM PHENOLICS COMPOSITION FOR THE PROTECTION OF HUMANS, ORGANS, CELLS AND TISSUES AGAINST THE INJURIOUS EFFECTS OF EXPOSURE TO IONIZING RADIATION","A composition for preventing, treating, reversing, protecting against or ameliorating the injuring effects of an ionizing radiation upon living cells, tissues, organs, and organisms, comprising oil palm phenolics (OPP) or vegetation liquor extract obtained from aqueous stream of a palm oil milling effluent is provided.",MALAYSIAN PALM OIL BOARD,RAVIGADEVI SAMBANTHAMURTHI;;TAN YEW AI;;VERA VLADIMIROVNA KOLEDOVA;;ROBERT PAUL WEINBERG;;CHO KYUN RHA;;ANTHONY J SINSKEY,,https://lens.org/112-374-977-374-477,Patent Application,no,1,1,10,10,0,A61K36/889;;A61K31/192;;A61K31/702;;A61K31/191;;A61K31/225;;A61K31/192;;A61K31/702;;A61K36/889;;A61K2300/00;;A61K31/192;;A61K31/702;;A61K36/889;;A61K31/191;;A61K31/225;;A61K36/888,A61K36/889;;A61K31/192;;A61K31/702,,0,0,,,,DISCONTINUED
454,TW,B,TW I561687 B,139-556-842-740-377,2016-12-11,2016,TW 101133276 A,2012-09-12,CN 201210288848 A,2012-08-14,An electroplating method,,PROCESS AUTOMATION INT LTD,WONG KWOK WAI;;HENINGTON PAUL;;CHIU YU HIM;;CHENG KWONG CHO;;HUANG JIE LING;;ZHANG SHI FENG,,https://lens.org/139-556-842-740-377,Granted Patent,no,2,0,3,3,0,,,,0,0,,,,INACTIVE
455,EP,B1,EP 2610924 B1,168-261-687-519-886,2019-09-11,2019,EP 11010224 A,2011-12-27,EP 11010224 A,2011-12-27,Inverted metamorphic multijunction solar cell with two metamorphic layers and homojunction top cell,,SOLAERO TECH CORP,CORNFELD ARTHUR;;SPANN JOHN;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN;;SHARPS PAUL R;;AIKEN DANIEL J,SOLAERO TECHNOLOGIES CORP. (2015-08-26),https://lens.org/168-261-687-519-886,Granted Patent,yes,2,0,2,111,0,H01L31/06875;;H01L31/03042;;H01L31/03046;;H01L31/0693;;H01L31/1844;;Y02E10/544,H01L31/18;;H01L31/0304;;H01L31/0687;;H01L31/0693,,1,0,,,"KING, R.R. ET AL: ""Band-Gap-Engineered Architectures for High-Efficiency Multijunction Concentrator Solar Cells"", PROCEEDINGS OF THE 24TH EUROPEAN PHOTOVOLTAIC SOLAR ENERGY CONFERENCE, 21 September 2009 (2009-09-21) - 25 September 2009 (2009-09-25), pages 55 - 61, XP040529653, ISBN: 978-3-936338-25-6",ACTIVE
456,US,B2,US 10374112 B2,058-605-124-573-596,2019-08-06,2019,US 201615045641 A,2016-02-17,US 201615045641 A;;EP 11102241 A;;US 201514813745 A;;US 201213401181 A;;US 27119208 A;;US 2377208 A;;US 86014207 A;;US 86018307 A,2007-09-24,Inverted metamorphic multijunction solar cell including a metamorphic layer,"A multijunction solar cell includes an upper first solar subcell, a second solar subcell adjacent to the first solar subcell, a third solar subcell adjacent to the second solar subcell, and a graded interlayer adjacent to the third solar subcell. The graded interlayer has a band gap that is greater than the band gap of the third solar subcell and is composed of a compositionally step-graded series of (In x Ga 1-x ) y Al 1-y As layers with monotonically changing lattice constant, with x and y having respective values such that the band gap of the graded interlayer remains constant throughout its thickness, and wherein 0<x<1 and 0<y<1. A fourth solar subcell is adjacent to the graded interlayer and is lattice mismatched with respect to the third solar subcell. The graded interlayer provides a transition in lattice constant from the third solar subcell to the fourth solar subcell. A lower fifth solar subcell is adjacent to the fourth solar subcell.",SOLAERO TECH CORP,CORNFELD ARTHUR;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN;;SHARPS PAUL R;;AIKEN DANIEL J;;SPANN JOHN,EMCORE SOLAR POWER INC (2012-02-15);;SOLAERO TECHNOLOGIES CORP (2015-01-08),https://lens.org/058-605-124-573-596,Granted Patent,yes,103,0,6,111,0,H01L31/06875;;H01L31/06875;;H01L31/078;;H01L31/078;;H01L31/1844;;H01L31/1844;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02E10/548;;Y02P70/50;;Y02P70/50,H01L31/0687;;H01L31/078;;H01L31/18,,49,27,000-310-095-058-823;;026-281-940-590-23X;;015-557-396-201-987;;015-557-396-201-987;;002-874-834-532-776;;073-300-069-664-773;;115-973-926-256-941;;083-287-525-840-54X;;084-891-382-112-541;;025-407-739-778-403;;034-023-904-332-047;;164-535-659-415-932;;007-176-082-871-508;;102-210-428-050-695;;106-513-576-934-63X;;076-989-478-838-81X;;015-717-993-971-840;;043-633-301-060-630;;030-787-136-717-28X;;038-574-682-896-969;;052-700-785-133-704;;093-340-948-123-836;;091-028-789-674-438;;020-636-430-481-14X;;026-862-096-577-376;;026-169-360-688-45X;;107-582-530-482-098,10.1109/50.989001;;10.1109/wcpec.2006.279587;;10.1109/pvsc.2010.5614498;;10.1109/pvsc.2010.5614498;;10.1109/wcpec.2006.279835;;10.1109/wcpec.2006.279527;;10.1063/1.2753729;;10.1109/pvsc.2008.4922452;;10.1063/1.335957;;10.1109/pvsc.2002.1190685;;10.1109/77.783715;;10.1016/0022-0248(84)90363-4;;10.1016/0379-6787(88)90047-6;;10.1109/pvsc-vol2.2012.6656717;;10.1109/pvsc.1990.111608;;10.1109/iscs.1998.711543;;10.1002/pip.449;;10.1016/0379-6787(86)90032-3;;10.1016/j.jcrysgro.2009.10.059;;10.1002/pip.642;;10.1109/pvsc.1991.169189;;10.1063/1.106494;;10.1088/0953-8984/16/21/008;;10.1109/pvsc.2005.1488186;;10.1109/wcpec.2006.279559;;10.1063/1.98946;;10.1134/1.1187812,"Jae-Hyung Jang, Student Member, Gabriel Cueva, William E. Hoke, P. J. Lemonias, Patrick Fay, and Ilesanmi Adesida, “Metamorphic Graded Bandgap InGaAs—InGaAlAs—InAlAs Double Heterojunction P-i-I-n. Photodiodes”, Journal of Lightwave Technology, vol. 20, No. 3, Mar. 2002 507.;;U.S. Appl. No. 12/708,361, filed Feb. 18, 2010, Cornfeld.;;U.S. Appl. No. 12/716,814, filed Mar. 3, 2010, Cornfeld.;;U.S. Appl. No. 12/730,018, filed Mar. 23, 2010, Cornfeld.;;U.S. Appl. No. 12/756,926, filed Apr. 8, 2010, Cornfeld.;;U.S. Appl. No. 12/813,408, filed Jun. 10, 2010, Patel.;;U.S. Appl. No. 12/844,673, filed Jul. 27, 2010, Stan.;;Aiken et al., “Consideration of High Bandgap Subcells for Advanced Multijunction Solar Cells,” Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, 2006:838-841.;;Cornfeld et al., “Development of a Large Area Inverted Metamorphic Multi-Junction (IMM) Highly Efficient AM0 Solar Cell,” 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Cornfeld et al., “Development of a Large Area Inverted Metamorphic Multi-Junction Highly Efficient AM0 Solar Cell,” Conference paper presented at the 33rd IEEE Photovoltaic Specialists Conference (May 11-16, 2008) on May 12, 2008. San Diego, CA, USA.;;Cornfeld et al., “Advances in the Performance of Inverted Metamorphic Multijunction Solar Cells,” 23rd European Photovoltaic Energy Conference, Aug. 29, 2008, Valencia, Spain.;;U.S. Appl. No. 13/547,334, filed Jul. 12, 2012, Cornfeld.;;U.S. Appl. No. 13/554,527, filed Jul. 20, 2012, Tourino.;;U.S. Appl. No. 13/569,794, filed Aug. 8, 2012, Stan.;;Dimroth et al., “Thin 5-Junction Solar Cells with Improved Radiation Hardness,” Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 2006; pp. 1777-1780.;;Extended European Search Report for European Application No. 11010224.1-1528 dated May 15, 2012; 2 pgs.;;Friedman et al., “0.7-eV GaInAs Junction for a GaInP/GaAs/GaInAs(leV)/GaInAs(0.7eV) Four-Junction Solar Cell,” 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA; 598-602.;;Geisz et al., “High efficiency GaInP/GaAs/InGaAs triple-junction solar cells grown inverted with a metamorphic bottom junction,” Applied Physics Letters, 2007; 91:023502-1-023502-3. Published online Jul. 10, 2007.;;Geisz et al., “Inverted GaInP / (In)GaAs Triple-Junction Solar Cells with Low-Stress Metamorphic Bottom Junctions,” 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Hamaker, H.C., “Computer modeling study of the effects of inhomogeneous doping and/or composition in GaAs solar-cell devices,” J Appl. Phys., Sep. 15, 1985; 58(6):2344-2351.;;King et al., “Next-Generation, High Efficiency III-V Multijunction Solar Cells,” 28th IEEE Photovoltaic Specialists Conference, Sep. 15-22, 2000, Anchorage, AK, USA; pp. 998-1001.;;King et al., “High-Efficiency Space and Terrestrial Multijunction Solar Cells Through Bandgap Control in Cell Structures,” 2002 Photovoltaic Specialists Conference, Conference Record of the 29th IEEE, May 19-24, 2002, New Orleans, LA, USA; pp. 776-781.;;King et al., “Solar Cell Generations Over 40% Efficiency,” 26th European Photovoltaic Solar Energy Conference and Exhibition, Sep. 5, 2011, Hamburg, Germany; 15 pgs.;;Koh et al., “Fabrication of Superconducting Delay Line with GaAs Schottky Diode,” IEEE Transactions on Applied Superconductivity, 1999; 9(2):3224-3227.;;Lewis et al., “The Crystallographic Connection of MOCVD-Grown Monolithic Cascade Subcells Via Transparent Graded Layers,” Journal of Crystal Growth, 1984; 69:515-526.;;Lewis et al., “Recent Developments in Multijunction Solar Cell Research,” Solar Cells, 1988; 24:171-183.;;Li et al., “Unintentional doping and compensation effects of carbon in metal-organic chemical vapor deposition fabricated ZnO thin films”, 2006, pp. 1213-1217.;;Patel et al., “Experimental Results From Performance Improvement and Radiation Hardening of inverted Metamorphic Multi-Junction Solar Cells,” Proceedings of the 37th IEEE PVSC, Seattle, WA, 2011 (Presented at PVSC Jun. 22, 2001).;;Patel et al., “Initial Results of the Monolithically Grown Six-Junction Inverted Metamorphic Multi-junction Solar Cell,” Proceedings of the 38th IEEE PVSC, Austin, TX, 2012 (Presented at PVSC Jun. 7, 2012).;;Schultz et al., “High Efficiency 1.0-eV GaInAs Bottom Solar Cell for 3-Junction Monolithic Stack,” IEEE, 1990:148-152.;;Sexl et al., “MBE Growth of Metamorphic In(Ga)AIAs Buffers,” 1997 IEEE International Symposium on Compound Semiconductors, Sep. 8-11, 1997; pp. 49-52.;;Sharps et al., “Inverting the triple junction improves efficiency and flexibility,” Compound Semiconductor, Oct. 2007; pp. 25-28.;;Sinharoy et al., “Progress in the Development of Metamorphic Multi-junction III-V Space Solar Cells,” Progress in Photovoltaics: Research and Applications, Feb. 2002; 10:427-432.;;Soukup et al., “Limitations of Built-in Electric Field Enhancement of Minority Carrier Current Collection in GaAs Backwall Schottky Barrier Solar Cells,” Solar Cells, 1986; 18:139-151.;;Stan et al., “Recent Advances in the Performance of Multi-Junction Space Solar Cells,” 22nd European Photovoltaic Solar Energy Conference, Sep. 3-7, 2007, Milan, Italy; pp. 101-105.;;Stan et al., “Very High Efficiency Triple Junction Solar Cells by MOVPE,” 14th International Conference of Metalorganic Vapor Phase Epitaxy, Jun. 5, 2008, Metz, France.;;Stan et al., “High efficiency quadruple junction solar cells using MOVPE with inverted metamorphic device structures,” Journal of Crystal Growth, 2010; 312:1370-1374.;;Takamoto et al., “Future Development of InGaP/(In)GaAs Based Multijunction Solar Cells,”Proceedings of the 31st IEEE PVSC, Jan. 3-7, 2005, Lake Buena Vista, FL; pp. 519-524.;;Takamoto et al., “InGaP/GaAs-based Multijunction Solar Cells,” Progress in Photovoltaics: Research and Applications, 2005; 13:495-511.;;Venkatasubramanian et al., “An Inverted-Growth Approach to Development of an IR-Transparent High-Efficiency AlGaAs/GaAs Cascade Solar Cell,” 22nd IEEE Photovoltaic Specialists Conference, Oct. 7-11, 1991, Las Vegas, NV, USA; pp. 93-98.;;Venkatasubramanian et al., “High-quality eutectic-metal-bonded AlGaAs—GaAs thin films on Si substrates,”Appl. Phys. Lett., Feb. 1992; 60(7):886-888.;;Voncken et al., “Strain-accelerated HF etching of AlAs for epitaxial lift-off,” J. Phys.: Condens. Matter, 2004; 16:3585-3596.;;Walters et al., “Space Radiation Effects in Advanced Solar Cell Materials and Devices,” Mat. Res. Soc. Symp. Proc., 2002; 692:569-580.;;Wanlass et al., “Lattice-Mismatched Approaches for High-Performance, III-V Photovoltaic Energy Converters,” Conference Proceedings of the 31st IEEE Photovoltaic Specialists Conference and Exhibition, Lake Buena Vista, FL, USA; Jan. 3-7, 2005;530-535.;;Wanlass et al., “Monolithic, Ultra-Thin GaInP/GaAs/GaInAs Tandem Solar Cells,” 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA; 729-732.;;Wurfel, “Basic Structure of Solar Cells,” Physics of Solar Cells: From Basic Principles to Advanced Concepts, Second, Updated and Expanded Edition, 2009; Sections 6.4, 6.5 and 6.8.;;Yablonovitch et al., “Extreme selectivity in the lift-off of epitaxial GaAs films,” Appl. Phys. Lett., 1987; 51(28):2222-2224.;;Yamaguchi, “Physics and Technologies of Superhigh-Efficiency Tandem Solar Cells,” Semiconductors, Sep. 1999; 33(9):961-964.;;Yoon et al., “Progress of Inverted Metamorphic III-V Solar Cell Development at Spectrolab,” 33rd IEEE Specialists Conference, May 11-16, 2008, San Diego, CA, USA.",ACTIVE
457,WO,A3,WO 2011/088154 A3,022-288-172-093-041,2011-12-01,2011,US 2011/0021031 W,2011-01-12,US 29447610 P,2010-01-12,MULTI-MEDIA USB DATA TRANSFER OVER DIGITAL INTERACTION INTERFACE FOR VIDEO AND AUDIO (DIIVA),"A system for delivering USB data over a DiiVA network may include a USB host controller, at least one USB device, a first DiiVA device connected to the USB host controller through an upstream USB port, a second DiiVA device connected to the USB device through a downstream USB port; and a network configured to transfer data between the first DiiVA device and the second DiiVA device according to USB protocol through a DiiVA bi-directional hybrid link in the network. The network is responsive to the USB host controller to deliver contents for the USB protocol through at least one line state information packet and at least one USB data packet transmitted through the hybrid link between the upstream USB port and the downstream USB port.",SYNERCHIP USA CORP;;LEE DONGYUM;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANGWAN;;CHO SUKJAE,LEE DONGYUM;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANGWAN;;CHO SUKJAE,,https://lens.org/022-288-172-093-041,Search Report,yes,3,0,22,22,0,G06F13/4286;;G06F13/4286;;G06F13/4286;;G09G2370/047;;G09G2370/047;;G09G2370/12;;G09G2370/12;;H04N21/43615;;H04N21/43615;;H04L12/2838;;H04L12/2838;;H04L12/2838;;H04L2012/2849;;H04L2012/2849;;H04L2012/2849;;H04N21/43615;;H04N21/43632;;H04N21/43632;;H04N21/43635;;H04N21/43635;;H04N21/63;;H04N21/63,H04L29/06;;H04L12/56,,1,0,,,See also references of EP 2556648A4,PENDING
458,EP,A1,EP 4304463 A1,073-340-365-728-707,2024-01-17,2024,EP 22767644 A,2022-02-16,US 202163158189 P;;US 2022/0016502 W,2021-03-08,ACUTE HEALTH EVENT MONITORING AND ALERTING,,MEDTRONIC INC,STADLER ROBERT W;;DOLAN BECKY L;;CHO YONG K;;KRAUSE PAUL G;;SARKAR SHANTANU;;KOWAL ROBERT C,,https://lens.org/073-340-365-728-707,Patent Application,yes,0,0,11,22,0,A61B5/0004;;A61B5/0024;;A61B5/0205;;A61B5/1032;;A61B5/14542;;A61B5/681;;A61B5/6898;;A61B5/746;;A61B5/747;;A61B2562/0219;;A61B5/0205;;A61B5/0004;;A61B5/746;;A61B5/747;;A61B2562/0219;;A61B5/1032;;A61B5/6898;;A61B5/681;;A61B5/0024;;A61B5/14542,A61B5/0205;;G16H80/00,,0,0,,,,PENDING
459,WO,A3,WO 2011/088153 A3,083-650-359-475-869,2011-11-24,2011,US 2011/0021030 W,2011-01-12,US 29447610 P,2010-01-12,VIDEO MANAGEMENT AND CONTROL IN HOME MULTIMEDIA NETWORK,"A system may include a video link and a hybrid link that connects a transmitting device to the receiving device, and at least one intermediate hop between the transmitting device and the receiving device. The intermediate hop may be configured to relay video content from the video source to the video sink through the hybrid link using one or more data relay modes. The hybrid link may be configured to perform hybrid link control signaling (HLCS) to manage a physical layer of the hybrid link. The video link between the video source and the video sink may be configured to transmit a video stream the from video source to the video sink over one or more video lanes. A video link training may be implemented for the video link and the hybrid link.",SYNERCHIP USA CORP;;LEE DONGYUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANGWAN;;CHO SUKJAE,LEE DONGYUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANGWAN;;CHO SUKJAE,,https://lens.org/083-650-359-475-869,Search Report,yes,3,0,22,22,0,G06F13/4286;;G06F13/4286;;G06F13/4286;;G09G2370/047;;G09G2370/047;;G09G2370/12;;G09G2370/12;;H04N21/43615;;H04N21/43615;;H04L12/2838;;H04L12/2838;;H04L12/2838;;H04L2012/2849;;H04L2012/2849;;H04L2012/2849;;H04N21/43615;;H04N21/43632;;H04N21/43632;;H04N21/43635;;H04N21/43635;;H04N21/63;;H04N21/63,H04L12/28;;H04L12/56;;H04N21/60,,1,0,,,See also references of EP 2556631A4,PENDING
460,CN,B,CN 101218166 B,124-420-034-236-140,2011-08-17,2011,CN 200680024761 A,2006-06-23,US 2006/0024586 W;;US 17689605 A;;US 26844505 A;;US 21842804 F,2004-11-29,Dispenser with lock,"A dispensing assembly is provided for a container (22, 222, 222B, 22C) of fluent material. A hand-operable dispenser cartridge (24, 224, 224B, 24C) is adapted to be mounted to the container (22, 222, 222B, 22C). An actuator (42, 242, 242B, 42C), which may include a nozzle or spout (45, 245), is mounted on the cartridge (24, 224, 224B, 24C). A locking sleeve (76, 76A, 276, 276B, 76C) is mounted around the cartridge (24, 224, 224B, 24C) and has an upper abutment edge (81/82; 81A/82A; 281/282; 281B/282B; 81C/82C) and a recess (91/92; 91A/92A; 291/292; 291A/292B; 91C/92C). The locking sleeve (76,76A, 276, 276B, 76C) can be rotated between a first rotated position preventing actuation of the dispensing assembly and a second rotated position permitting actuation of the dispensing assembly.",SEAQUIST PERFECT DISPENSING FOREIGN INC,KSIAZK JASON A;;CHO SEAN H;;WERNER JONATHAN D;;HALLMAN PAUL E;;WALTERS PETER J;;CRAIG BRAUN,VANTONE GROUP CO. (2011-11-14),https://lens.org/124-420-034-236-140,Granted Patent,no,0,0,8,14,0,B65D83/201;;B65D83/22;;B05B11/1014;;B05B11/1057;;B05B11/1059,B67B5/00;;B67D7/58,,0,0,,,,INACTIVE
461,AU,A1,AU 2022/232272 A1,121-084-798-147-771,2023-10-26,2023,AU 2022/232272 A,2022-02-16,US 202163158189 P;;US 2022/0016502 W,2021-03-08,ACUTE HEALTH EVENT MONITORING AND ALERTING,"A system comprising processing circuitry configured to receive a wirelessly-transmitted message from a medical device, the message indicating that the medical device detected an acute health event of the patient. In response to the message, the processing circuitry is configured to determine a location of the patient, determine an alert area based on the location of the patient, and control transmission of an alert of the acute heath event of the patient to any one or more computing devices of one or more potential responders within the alert area.",MEDTRONIC INC,STADLER ROBERT W;;DOLAN BECKY L;;CHO YONG K;;KRAUSE PAUL G;;SARKAR SHANTANU;;KOWAL ROBERT C,,https://lens.org/121-084-798-147-771,Patent Application,no,0,0,11,22,0,A61B5/0004;;A61B5/0024;;A61B5/0205;;A61B5/1032;;A61B5/14542;;A61B5/681;;A61B5/6898;;A61B5/746;;A61B5/747;;A61B2562/0219;;A61B5/0205;;A61B5/0004;;A61B5/746;;A61B5/747;;A61B2562/0219;;A61B5/1032;;A61B5/6898;;A61B5/681;;A61B5/0024;;A61B5/14542,A61B5/0205;;G16H80/00,,0,0,,,,PENDING
462,WO,A2,WO 2011/088153 A2,123-303-286-925-824,2011-07-21,2011,US 2011/0021030 W,2011-01-12,US 29447610 P,2010-01-12,VIDEO MANAGEMENT AND CONTROL IN HOME MULTIMEDIA NETWORK,"A system may include a video link and a hybrid link that connects a transmitting device to the receiving device, and at least one intermediate hop between the transmitting device and the receiving device. The intermediate hop may be configured to relay video content from the video source to the video sink through the hybrid link using one or more data relay modes. The hybrid link may be configured to perform hybrid link control signaling (HLCS) to manage a physical layer of the hybrid link. The video link between the video source and the video sink may be configured to transmit a video stream the from video source to the video sink over one or more video lanes. A video link training may be implemented for the video link and the hybrid link.",SYNERCHIP USA CORP;;LEE DONGYUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANGWAN;;CHO SUKJAE,LEE DONGYUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANGWAN;;CHO SUKJAE,,https://lens.org/123-303-286-925-824,Patent Application,yes,0,0,22,22,0,G06F13/4286;;G06F13/4286;;G06F13/4286;;G09G2370/047;;G09G2370/047;;G09G2370/12;;G09G2370/12;;H04N21/43615;;H04N21/43615;;H04L12/2838;;H04L12/2838;;H04L12/2838;;H04L2012/2849;;H04L2012/2849;;H04L2012/2849;;H04N21/43615;;H04N21/43632;;H04N21/43632;;H04N21/43635;;H04N21/43635;;H04N21/63;;H04N21/63,,,1,0,,,See references of EP 2556631A4,PENDING
463,US,B2,US 10381505 B2,017-431-938-746-914,2019-08-13,2019,US 201615214315 A,2016-07-19,US 201615214315 A;;EP 11010224 A;;US 201615045641 A;;US 201514813745 A;;US 201213401181 A;;US 27119208 A;;US 2377208 A;;US 86014207 A;;US 86018307 A;;US 81340810 A,2007-09-24,Inverted metamorphic multijunction solar cells including metamorphic layers,"A multijunction solar cell includes an upper first solar subcell having a first band gap, a second solar subcell having a second band gap smaller than the first band gap, and a first graded interlayer composed of (InxGa1-x)yAl1-yAs adjacent to the second solar subcell. The first graded interlayer has a third band gap greater than the second band gap subject to the constraints of having the in-plane lattice parameter greater or equal to that of the second subcell and less than or equal to that of the third subcell, wherein 0<x<1 and 0<y<1, and x and y are selected such that the band gap of the first graded interlayer remains constant throughout its thickness at 1.5 eV. A third solar subcell is adjacent to the first graded interlayer and has a fourth band gap smaller than the second band gap such that the third subcell is lattice mismatched with respect to the second subcell. A second graded interlayer composed of (InxGa1-x)yAl1-yAs is adjacent to the third solar subcell and has a fifth band gap greater than the fourth band gap subject to the constraints of having the in-plane lattice parameter greater or equal to that of the third subcell and less than or equal to that of the bottom fourth subcell, wherein 0<x<1 and 0<y<1, and x and y are selected such that the band gap of the second graded interlayer remains constant throughout its thickness at 1.1 eV. A lower fourth solar subcell is adjacent to the second graded interlayer and has a sixth band gap smaller than the fourth band gap.",SOLAERO TECH CORP,PATEL PRAVIN;;CORNFELD ARTHUR;;SPANN JOHN;;STAN MARK A;;CHO BENJAMIN;;SHARPS PAUL R;;AIKEN DANIEL J,EMCORE SOLAR POWER INC (2012-02-15);;SOLAERO TECHNOLOGIES CORP (2015-01-08),https://lens.org/017-431-938-746-914,Granted Patent,yes,158,0,2,111,0,H01L31/1844;;H01L31/1844;;H01L31/03046;;H01L31/03046;;H01L31/06875;;H01L31/06875;;H01L31/078;;H01L31/078;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02P70/50;;Y02P70/50,H01L31/0725;;H01L31/0304;;H01L31/0687;;H01L31/0735;;H01L31/078;;H01L31/18,,60,32,000-310-095-058-823;;026-281-940-590-23X;;015-557-396-201-987;;015-557-396-201-987;;002-874-834-532-776;;073-300-069-664-773;;115-973-926-256-941;;083-287-525-840-54X;;084-891-382-112-541;;077-110-077-401-111;;025-407-739-778-403;;034-023-904-332-047;;164-535-659-415-932;;007-176-082-871-508;;128-821-969-271-702;;186-874-529-491-309;;102-210-428-050-695;;052-952-713-470-171;;106-513-576-934-63X;;076-989-478-838-81X;;015-717-993-971-840;;043-633-301-060-630;;030-787-136-717-28X;;038-574-682-896-969;;052-700-785-133-704;;093-340-948-123-836;;091-028-789-674-438;;020-636-430-481-14X;;026-862-096-577-376;;026-169-360-688-45X;;107-582-530-482-098;;081-270-749-802-637,10.1109/50.989001;;10.1109/wcpec.2006.279587;;10.1109/pvsc.2010.5614498;;10.1109/pvsc.2010.5614498;;10.1109/wcpec.2006.279835;;10.1109/wcpec.2006.279527;;10.1063/1.2753729;;10.1109/pvsc.2008.4922452;;10.1063/1.335957;;10.1063/1.1289478;;10.1109/pvsc.2002.1190685;;10.1109/77.783715;;10.1016/0022-0248(84)90363-4;;10.1016/0379-6787(88)90047-6;;10.1016/j.jcrysgro.2004.08.083;;10.1063/1.93537;;10.1109/pvsc-vol2.2012.6656717;;10.1063/1.369467;;10.1109/pvsc.1990.111608;;10.1109/iscs.1998.711543;;10.1002/pip.449;;10.1016/0379-6787(86)90032-3;;10.1016/j.jcrysgro.2009.10.059;;10.1002/pip.642;;10.1109/pvsc.1991.169189;;10.1063/1.106494;;10.1088/0953-8984/16/21/008;;10.1109/pvsc.2005.1488186;;10.1109/wcpec.2006.279559;;10.1063/1.98946;;10.1134/1.1187812;;10.1016/s1386-9477(02)00871-8,"Jae-Hyung Jang, Student Member, Gabriel Cueva, William E. Hoke, P. J. Lemonias, Patrick Fay, and Ilesanmi Adesida, “Metamorphic Graded Bandgap InGaAs—InGaAlAs—InAlAs Double Heterojunction P-i-I-N Photodiodes”, Journal of Lightwave Technology, vol. 20, No. 3, Mar. 2002 507.;;U.S. Appl. No. 12/265,113, filed Nov. 5, 2008, Varghese.;;U.S. Appl. No. 12/708,361, filed Feb. 18, 2010, Cornfeld.;;U.S. Appl. No. 12/716,814, filed Mar. 3, 2010, Cornfeld.;;U.S. Appl. No. 12/730,018, filed Mar. 23, 2010, Cornfeld.;;U.S. Appl. No. 12/756,926, filed Apr. 8, 2010, Cornfeld.;;U.S. Appl. No. 12/813,408, filed Jun. 10, 2010, Patel.;;U.S. Appl. No. 12/844,673, filed Jul. 27, 2010, Stan.;;U.S. Appl. No. 13/547,334, filed Jul. 12, 2012, Cornfeld.;;U.S. Appl. No. 13/554,527, filed Jul. 20, 2012, Tourino.;;U.S. Appl. No. 13/569,794, filed Aug. 8, 2012, Stan.;;U.S. Appl. No. 12/775,946, filed May 7, 2010, Newman.;;Aiken et al., “Consideration of High Bandgap Subcells for Advanced Multijunction Solar Cells,” Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, 2006:838-841.;;Cornfeld et al., “Development of a Large Area Inverted Metamorphic Multi-Junction (IMM) Highly Efficient AM0 Solar Cell,” 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Cornfeld et al., “Development of a Large Area Inverted Metamorphic Multi-junction Highly Efficient AM0 Solar Cell,” Conference paper presented at the 33rd IEEE Photovoltaic Specialists Conference (May 11-16, 2008) on May 12, 2008. San Diego, CA, USA.;;Cornfeld et al., “Advances in the Performance of Inverted Metamorphic Multijunction Solar Cells,” 23rd European Photovoltaic Energy Conference, Aug. 29, 2008, Valencia, Spain.;;Dimroth et al., “Thin 5-Junction Solar Cells with Improved Radiation Hardness,” Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 2006; pp. 1777-1780.;;Extended European Search Report for European Application No. 11010224.1-1528 dated May 15, 2012; 2 pgs.;;Friedman et al., “0.7-eV GaInAs Junction for a GaInP/GaAs/GaInAs(1eV)/GaInAs(0.7eV) Four-Junction Solar Cell,” 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA; 598-602.;;Geisz et al., “High efficiency GaInP/GaAs/InGaAs triple junction solar cells grown inverted with a metamorphic bottom junction,” Applied Physics Letters, 2007; 91:023502-1-023502-3. Published online Jul. 10, 2007.;;Geisz et al., “Inverted GaInP / (In)GaAs Triple-Junction Solar Cells with Low-Stress Metamorphic Bottom Junctions,” 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Hamaker, H.C., “Computer modeling study of the effects of inhomogeneous doping and/or composition in GaAs solar-cell devices,” J Appl. Phys., Sep. 15, 1985; 58(6):2344-2351.;;Jun, S.W., et al., “Bi surfactant control of ordering and surface structure in GaInP grown by organometallic vapor phase epitaxy-” Journal of Applied Physics, vol. 88, No. 7, pp. 4429-4433. Oct. 2000. AIP, Melville, NY.;;King et al., “Next-Generation, High Efficiency III-V Multijunction Solar Cells,” 28th IEEE Photovoltaic Specialists Conference, Sep. 15-22, 2000, Anchorage, AK, USA; pp. 998-1001.;;King et al., “High-Efficiency Space and Terrestrial Multijunction Solar Cells Through Bandgap Control in Cell Structures,” 2002 Photovoltaic Specialists Conference, Conference Record of the 29th IEEE, May 19-24, 2002, New Orleans, LA, USA; pp. 776-781.;;King et al., “Solar Cell Generations Over 40% Efficiency,” 26th European Photovoltaic Solar Energy Conference and Exhibition, Sep. 5, 2011, Hamburg, Germany; 15 pgs.;;Koh et al., “Fabrication of Superconducting Delay Line with GaAs Schottky Diode,” IEEE Transactions on Applied Superconductivity, 1999; 9(2):3224-3227.;;Lewis et al., “The Crystallographic Connection of MOCVD-Grown Monolithic Cascade Subcells via Transparent Graded Layers,” Journal of Crystal Growth, 1984; 69:515-526.;;Lewis et al., “Recent Developments in Multijunction Solar Cell Research,” Solar Cells, 1988; 24:171-183.;;Li et al., “Unintentional doping and compensation effects of carbon in metal-organic chemical vapor deposition fabricated ZnO thin films”, 2006, pp. 1213-1217.;;Newman, F., et al., “Tellurium surfactant effects in the growth of lattice mismatched lnAsxP1-x by metal organic vapor-phase epitaxy.” Journal of Crystal Growth 272 (2004), pp. 650-657. Elsevier, Amsterdam, Netherlands.;;Olego, D., et al., “Compositional dependence of band-gap energy and conduction-band effective mass of lnl.x-yGa,AlyAs lattice matched to lnP.” Applied Physics Letters vol. 41, No. 5, Sep. 1, 1982. pp. 476-478. American Institute of Physics, Melville, NY.;;Patel et al., “Experimental Results From Performance Improvement and Radiation Hardening of inverted Metamorphic Multi-Junction Solar Cells,” Proceedings of the 37th IEEE PVSC, Seattle, WA, 2011 (Presented at PVSC Jun. 22, 2001).;;Patel et al., “Initial Results of the Monolithically Grown Six-Junction Inverted Metamorphic Multi-junction Solar Cell,” Proceedings of the 38th IEEE PVSC, Austin, TX, 2012 (Presented at PVSC Jun. 7, 2012).;;Pillai, M.R., et al., “Growth of lnxGal-xAs/GaAs heterostructures using Bi as a surfactant.” Journal of Vacuum Science and Technology B 18{3), pp. 1232-1236. 2000. American Vacuum Society, New York, NY.;;Romanov et al., “Threading dislocation reduction in strained layers,” Journal of Applied Physics, Jan. 1, 1999; 85(1):182-192.;;Schultz et al., “High Efficiency 1.0-eV GaInAs Bottom Solar Cell for 3-Junction Monolithic Stack,” IEEE, 1990:148-152.;;Sexl et al., “MBE Growth of Metamorphic in(Ga)AIAs Buffers,” 1997 IEEE International Symposium on Compound Semiconductors, Sep. 8-11, 1997; pp. 49-52.;;Sharps et al., “Inverting the triple junction improves efficiency and flexibility,” Compound Semiconductor, Oct. 2007; pp. 25-28.;;Sinharoy et al., “Progress in the Development of Metamorphic Multi junction III-V Space Solar Cells,” Progress in Photovoltaics: Research and Applications, Feb. 2002; 10:427-432.;;Soukup et al., “Limitations of Built-in Electric Field Enhancement of Minority Carrier Current Collection in GaAs Backwall Schottky Barrier Solar Cells,” Solar Cells, 1986; 18:139-151.;;Stan et al., “Recent Advances in the Performance of Multi-Junction Space Solar Cells,” 22nd European Photovoltaic Solar Energy Conference, Sep. 3-7, 2007, Milan, Italy; pp. 101-105.;;Stan et al., “Very High Efficiency Triple Junction Solar Cells by MOVPE,” 14th International Conference of Metalorganic Vapor Phase Epitaxy, Jun. 5, 2008, Metz, France.;;Stan et al., “High efficiency quadruple junction solar cells using MOVPE with inverted metamorphic device structures,” Journal of Crystal Growth, 2010; 312:1370-1374.;;Takamoto et al., “Future Development of InGaP/(In)GaAs Based Multijunction Solar Cells,” Proceedings of the 31st IEEE PVSC, Jan. 3-7, 2005, Lake Buena Vista, FL; pp. 519-524.;;Takamoto et al., “InGaP/GaAs-based Multijunction Solar Cells,” Progress in Photovoltaics: Research and Applications, 2005; 13:495-511.;;Venkatasubramanian et al., “An Inverted-Growth Approach to Development of an IR-Transparent, High-Efficiency AlGaAs/GaAs Cascade Solar Cell,” 22nd IEEE Photovoltaic Specialists Conference, Oct. 7-11, 1991, Las Vegas, NV, USA; pp. 93-98.;;Venkatasubramanian et al., “High-quality eutectic-metal-bonded AlGaAs-GaAs thin films on Si substrates,” Appl. Phys. Lett., Feb. 1992; 60(7):886-888.;;Voncken et al., “Strain-accelerated HF etching of AlAs for epitaxial lift-off,” J. Phys.: Condens. Matter, 2004; 16:3585-3596.;;Walters et al., “Space Radiation Effects in Advanced Solar Cell Materials and Devices,” Mat. Res. Soc. Symp. Proc., 2002; 692:569-580.;;Wanlass et al., “Lattice-Mismatched Approaches for High-Performance, III-V Photovoltaic Energy Converters,” Conference Proceedings of the 31st IEEE Photovoltaic Specialists Conference and Exhibition, Lake Buena Vista, FL, USA; Jan. 3-7, 2005;530-535.;;Wanlass et al., “Monolithic, Ultra-Thin GaInP/GaAs/GaInAs Tandem Solar Cells,” 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA; 729-732.;;Wurfel, “Basic Structure of Solar Cells,” Physics of Solar Cells: From Basic Principles to Advanced Concepts, Second, Updated and Expanded Edition, 2009; Sections 6.4, 6.5 and 6.8.;;Yablonovitch et al., “Extreme selectivity in the lift-off of epitaxial GaAs films,” Appl. Phys. Lett., 1987; 51(28):2222-2224.;;Yamaguchi, “Physics and Technologies of Superhigh-Efficiency Tandem Solar Cells,” Semiconductors, Sep. 1999; 33(9):961-964.;;Yastrubchak et al., “Misfit dislocations and surface morphology of lattice mismatched GaAs/InGaAs heterostructures,” Physica E, 2003; 17:561-563.;;Yoon et al., “Progress of Inverted Metamorphic III-V Solar Cell Development at Spectrolab,” 33rd IEEE Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;USPTO Non-Final Office Action issued in U.S. Appl. No. 12/813,408, dated Aug. 19, 2014 (28 pages).;;USPTO Applicant's Appeal Brief filed in U.S. Appl. No. 12/813,408, dated Nov. 24, 2014 (15 pages).;;USPTO Examiner's Answer issued in U.S. Appl. No. 12/813,408, dated Jan. 20, 2015 (8 pages).",ACTIVE
464,GB,A,GB 2562661 A,013-582-492-001-071,2018-11-21,2018,GB 201812351 A,2016-12-30,MY 2016000088 W;;MY PI2015704862 A,2015-12-31,"Oil palm phenolics composition for the protection of humans, organs, cells and tissues against the injurious effects of exposure to ionizing radiation","A composition for preventing, treating, reversing, protecting against or ameliorating the injuring effects of an ionizing radiation upon living cells, tissues, organs, and organisms, comprising oil palm phenolics (OPP) or vegetation liquor extract obtained from aqueous stream of a palm oil milling effluent is provided.",MALAYSIAN PALM OIL BOARD,SAMBANTHAMURTHI RAVIGADEVI;;YEW AI TAN;;VLADIMIROVNA KOLEDOVA VERA;;PAUL WEINBERG ROBERT;;KYUN RHA CHO;;J SINSKEY ANTHONY,,https://lens.org/013-582-492-001-071,Patent Application,no,3,0,10,10,0,A61K36/889;;A61K31/192;;A61K31/702;;A61K31/191;;A61K31/225;;A61K31/192;;A61K31/702;;A61K36/889;;A61K2300/00;;A61K31/192;;A61K31/702;;A61K36/889;;A61K31/191;;A61K31/225;;A61K36/888,A61K36/889;;A61K31/192;;A61K31/702,,2,1,025-754-619-428-683,10.1016/j.apcbee.2012.06.028,"KRISHNAIAH DUDUKU, ET AL.: ""Phytochemical antioxidants for health and medicine–A move towards nature"", BIOTECHNOLOGY AND MOLECULAR BIOLOGY REVIEWS, vol. 1, no. 4, 1 January 2007 (2007-01-01), pages 97 - 104, XP055396191;;VIJAYARATHNA SOUNDARARAJAN, ET AL.: ""Antioxidant Activity of Elaeis guineensis Leaf Extract: An Alternative Nutraceutical Approach in Impeding Aging"", 3RD INTERNATIONAL CONFERENCE ON BIOTECHNOLOGY AND FOOD SCIENCE (ICBFS 2012) ELSEVIER SCIENCE BV, SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SERIES : APCBEE PROCEDIA (ISSN 2212-6708(PRINT)), ELSEVIER BV, NETHERLANDS, vol. 2, 7 March 2012 (2012-03-07), Netherlands , pages 153 - 159, XP055396185, ISSN: 2212-6708, DOI: 10.1016/j.apcbee.2012.06.028",ACTIVE
465,EP,A4,EP 2556631 A4,095-895-441-133-631,2013-12-18,2013,EP 11733338 A,2011-01-12,US 29447610 P;;US 2011/0021030 W,2010-01-12,VIDEO MANAGEMENT AND CONTROL IN HOME MULTIMEDIA NETWORK,,SYNERCHIP USA CORP,LEE DONGYUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANGWAN;;CHO SUKJAE,"SYNERCHIP CO., LTD. (2014-04-16);;SILICON IMAGE, INC. (2014-04-16)",https://lens.org/095-895-441-133-631,Search Report,no,4,0,22,22,0,G06F13/4286;;G06F13/4286;;G06F13/4286;;G09G2370/047;;G09G2370/047;;G09G2370/12;;G09G2370/12;;H04N21/43615;;H04N21/43615;;H04L12/2838;;H04L12/2838;;H04L12/2838;;H04L2012/2849;;H04L2012/2849;;H04L2012/2849;;H04N21/43615;;H04N21/43632;;H04N21/43632;;H04N21/43635;;H04N21/43635;;H04N21/63;;H04N21/63,H04N21/436;;G06F13/42;;H04L12/28;;H04N21/63,,1,0,,,"ANONYMOUS: ""Super Booster Plus for HDMI 1.3 USER MANUAL"", 24 August 2009 (2009-08-24), pages 1 - 9, XP002715620, Retrieved from the Internet <URL:https://web.archive.org/web/20090824082648/http://www.gefen.com/pdf/EXT-HDMI1.3-141SBP.pdf> [retrieved on 20131028]",DISCONTINUED
466,US,A1,US 2006/0113329 A1,101-596-930-690-637,2006-06-01,2006,US 17689605 A,2005-07-07,US 17689605 A;;US 21842804 F,2004-11-29,Dispenser with lock,"A dispensing assembly is provided for a container of fluent material. A hand-operable dispenser cartridge is adapted to be mounted to the container. An actuator with a lateral projection, which may be a nozzle or spout, is mounted on the cartridge. A locking sleeve is mounted around the cartridge and has an upper abutment edge and a recess. The locking sleeve can be rotated between a first rotated position preventing actuation of the dispenser and a second rotated position permitting actuation of the dispenser.",SEAQUISPERFECT DISPENSING FORE,WALTERS PETER J;;KSIAZK JASON A;;CHO SEAN H;;HALLMAN PAUL E;;WERNER JONATHAN D;;BRAUN CRAIG,SEAQUISTPERFECT DISPENSING FOREIGN INC (2005-06-30),https://lens.org/101-596-930-690-637,Patent Application,yes,99,24,2,14,0,B65D83/201;;B65D83/22;;B05B11/1014;;B05B11/1059;;B05B11/1057;;B65D83/201;;B65D83/22;;B05B11/1014;;B05B11/1057;;B05B11/1059,B67D7/58,222/383.1,0,0,,,,DISCONTINUED
467,WO,A2,WO 2011/088154 A2,122-302-139-276-077,2011-07-21,2011,US 2011/0021031 W,2011-01-12,US 29447610 P,2010-01-12,MULTI-MEDIA USB DATA TRANSFER OVER DIGITAL INTERACTION INTERFACE FOR VIDEO AND AUDIO (DIIVA),"A system for delivering USB data over a DiiVA network may include a USB host controller, at least one USB device, a first DiiVA device connected to the USB host controller through an upstream USB port, a second DiiVA device connected to the USB device through a downstream USB port; and a network configured to transfer data between the first DiiVA device and the second DiiVA device according to USB protocol through a DiiVA bi-directional hybrid link in the network. The network is responsive to the USB host controller to deliver contents for the USB protocol through at least one line state information packet and at least one USB data packet transmitted through the hybrid link between the upstream USB port and the downstream USB port.",SYNERCHIP USA CORP;;LEE DONGYUM;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANGWAN;;CHO SUKJAE,LEE DONGYUM;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANGWAN;;CHO SUKJAE,,https://lens.org/122-302-139-276-077,Patent Application,yes,0,6,22,22,0,H04L12/2838;;H04L2012/2849;;H04N21/43615;;G06F13/4286;;G06F13/4286;;H04L12/2838;;H04N21/43615;;H04N21/43632;;H04N21/43635;;H04N21/63;;H04L2012/2849;;G09G2370/12;;G09G2370/047;;H04N21/43635;;H04N21/43632;;G09G2370/12;;G09G2370/047;;H04L12/2838;;H04L2012/2849;;H04N21/43615;;G06F13/4286;;H04N21/63,,,0,0,,,,PENDING
468,MX,A,MX 2018008211 A,133-388-515-223-059,2019-05-30,2019,MX 2018008211 A,2016-12-30,MY PI2015704862 A;;MY 2016000088 W,2015-12-31,"OIL PALM PHENOLICS COMPOSITION FOR THE PROTECTION OF HUMANS, ORGANS, CELLS AND TISSUES AGAINST THE INJURIOUS EFFECTS OF EXPOSURE TO IONIZING RADIATION.","A composition for preventing, treating, reversing, protecting against or ameliorating the injuring effects of an ionizing radiation upon living cells, tissues, organs, and organisms, comprising oil palm phenolics (OPP) or vegetation liquor extract obtained from aqueous stream of a palm oil milling effluent is provided.",MALAYSIAN PALM OIL BOARD,SAMBANTHAMURTHI RAVIGADEVI;;YEW AI TAN;;VLADIMIROVNA KOLEDOVA VERA;;PAUL WEINBERG ROBERT;;KYUN RHA CHO;;J SINSKEY ANTHONY,,https://lens.org/133-388-515-223-059,Patent Application,no,0,0,10,10,0,A61K36/889;;A61K31/192;;A61K31/702;;A61K31/191;;A61K31/225;;A61K31/192;;A61K31/702;;A61K36/889;;A61K2300/00;;A61K31/192;;A61K31/702;;A61K36/889;;A61K31/191;;A61K31/225;;A61K36/888,A61K36/889;;A61K31/192;;A61K31/702,,0,0,,,,PENDING
469,WO,A2,WO 2007/008375 A2,177-780-539-383-711,2007-01-18,2007,US 2006/0024586 W,2006-06-23,US 17689605 A;;US 26844505 A;;US 21842804 F,2004-11-29,DISPENSER WITH LOCK,"A dispensing assembly is provided for a container (22, 222, 222B, 22C) of fluent material. A hand-operable dispenser cartridge (24, 224, 224B, 24C) is adapted to be mounted to the container (22, 222, 222B, 22C). An actuator (42, 242, 242B, 42C), which may include a nozzle or spout (45, 245), is mounted on the cartridge (24, 224, 224B, 24C). A locking sleeve (76, 76A, 276, 276B, 76C) is mounted around the cartridge (24, 224, 224B, 24C) and has an upper abutment edge (81/82; 81A/82A; 281/282; 281B/282B; 81C/82C) and a recess (91/92; 91A/92A; 291/292; 291A/292B; 91C/92C). The locking sleeve (76, 76A, 276, 276B, 76C) can be rotated between a first rotated position preventing actuation of the dispensing assembly and a second rotated position permitting actuation of the dispensing assembly.",SEAQUISTPERFECT DISPENSING FOR,WALTERS PETER J;;KSIAZK JASON A;;CHO SEAN H;;HALLMAN PAUL E;;WERNER JONATHAN D;;BRAUN CRAIG,,https://lens.org/177-780-539-383-711,Patent Application,yes,1,10,8,14,0,B65D83/201;;B65D83/22;;B05B11/1014;;B05B11/1057;;B05B11/1059,B67D7/58,,0,0,,,,PENDING
470,CN,A,CN 102860030 A,067-648-786-013-711,2013-01-02,2013,CN 201180005909 A,2011-01-12,US 2011/0021030 W;;US 29447610 P,2010-01-12,Video management and control in home multimedia network,"A system may include a video link and a hybrid link that connects a transmitting device to the receiving device, and at least one intermediate hop between the transmitting device and the receiving device. The intermediate hop may be configured to relay video content from the video source to the video sink through the hybrid link using one or more data relay modes. The hybrid link may be configured to perform hybrid link control signaling (HLCS) to manage a physical layer of the hybrid link. The video link between the video source and the video sink may be configured to transmit a video stream the from video source to the video sink over one or more video lanes. A video link training may be implemented for the video link and the hybrid link.",SYNERCHIP USA CORP,LEE DONGYUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANGWAN;;CHO SUKJAE,SILICON IMAGE INC. A. DELAWARE C. (2013-10-30),https://lens.org/067-648-786-013-711,Patent Application,no,5,0,22,22,0,G06F13/4286;;G06F13/4286;;G06F13/4286;;G09G2370/047;;G09G2370/047;;G09G2370/12;;G09G2370/12;;H04N21/43615;;H04N21/43615;;H04L12/2838;;H04L12/2838;;H04L12/2838;;H04L2012/2849;;H04L2012/2849;;H04L2012/2849;;H04N21/43615;;H04N21/43632;;H04N21/43632;;H04N21/43635;;H04N21/43635;;H04N21/63;;H04N21/63,H04N21/436,,0,0,,,,ACTIVE
471,MY,A,MY 197031 A,149-681-860-309-981,2023-05-22,2023,MY PI2015704862 A,2015-12-31,MY PI2015704862 A,2015-12-31,"OIL PALM PHENOLICS COMPOSITION FOR THE PROTECTION OF HUMANS, ORGANS, CELLS AND TISSUES AGAINST THE INJURIOUS EFFECTS OF EXPOSURE TO IONIZING RADIATION","A composition for preventing, treating, reversing, protecting against or ameliorating the injuring effects of an ionizing radiation upon living cells, tissues, organs, and organisms, comprising oil palm phenolics (OPP) or vegetation liquor extract obtained from aqueous stream of a palm oil milling effluent is provided.",MALAYSIAN PALM OIL BOARD,RAVIGADEVI SAMBANTHAMURTHI;;TAN YEW AI;;VERA VLADIMIROVNA KOLEDOVA;;ROBERT PAUL WEINBERG;;CHO KYUN RHA;;ANTHONY J SINSKEY,,https://lens.org/149-681-860-309-981,Granted Patent,no,0,0,10,10,0,A61K36/889;;A61K31/192;;A61K31/702;;A61K31/191;;A61K31/225;;A61K31/192;;A61K31/702;;A61K36/889;;A61K2300/00;;A61K31/192;;A61K31/702;;A61K36/889;;A61K31/191;;A61K31/225;;A61K36/888,A61K31/702;;A61K31/192;;A61K36/889,,0,0,,,,ACTIVE
472,US,A1,US 2016/0190378 A1,151-962-824-112-738,2016-06-30,2016,US 201615045641 A,2016-02-17,US 201615045641 A;;EP 11102241 A;;US 201514813745 A;;US 201213401181 A;;US 27119208 A;;US 2377208 A;;US 86014207 A;;US 86018307 A,2007-09-24,INVERTED METAMORPHIC MULTIJUNCTION SOLAR CELL INCLUDING A METAMORPHIC LAYER,"A multijunction solar cell includes an upper first solar subcell, a second solar subcell adjacent to the first solar subcell, a third solar subcell adjacent to the second solar subcell, and a graded interlayer adjacent to the third solar subcell. The graded interlayer has a band gap that is greater than the band gap of the third solar subcell and is composed of a compositionally step-graded series of (In x Ga 1-x ) y Al 1-y As layers with monotonically changing lattice constant, with x and y having respective values such that the band gap of the graded interlayer remains constant throughout its thickness, and wherein 0<x<1 and 0<y<1. A fourth solar subcell is adjacent to the graded interlayer and is lattice mismatched with respect to the third solar subcell. The graded interlayer provides a transition in lattice constant from the third solar subcell to the fourth solar subcell. A lower fifth solar subcell is adjacent to the fourth solar subcell.",SOLAERO TECHNOLOGIES CORP,CORNFELD ARTHUR;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN;;SHARPS PAUL R;;AIKEN DANIEL J;;SPANN JOHN,EMCORE SOLAR POWER INC (2012-02-15);;SOLAERO TECHNOLOGIES CORP (2015-01-08),https://lens.org/151-962-824-112-738,Patent Application,yes,0,0,6,111,0,H01L31/06875;;H01L31/06875;;H01L31/078;;H01L31/078;;H01L31/1844;;H01L31/1844;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02E10/548;;Y02P70/50;;Y02P70/50,H01L31/0687;;H01L31/078;;H01L31/18,,1,1,000-310-095-058-823,10.1109/50.989001,"Jae-Hyung Jang, Student Member, Gabriel Cueva, William E. Hoke, P. J. Lemonias, Patrick Fay, andIlesanmi Adesida, ""Metamorphic Graded Bandgap InGaAs–InGaAlAs–InAlAs Double Heterojunction P-i-I-N Photodiodes"", JOURNAL OF LIGHTWAVE TECHNOLOGY, VOL. 20, NO. 3, MARCH 2002 507",ACTIVE
473,US,A1,US 2006/0113327 A1,040-897-208-133-663,2006-06-01,2006,US 26844505 A,2005-11-07,US 26844505 A;;US 17689605 A;;US 21842804 F,2004-11-29,Dispenser with lock,"A dispensing assembly is provided for a container of fluent material. A hand-operable dispenser cartridge is adapted to be mounted to the container. An actuator, which may include a nozzle or spout, is mounted on the cartridge. A locking sleeve is mounted around the cartridge and has an upper abutment edge and a recess. The locking sleeve can be rotated between a first rotated position preventing actuation of the dispensing assembly and a second rotated position permitting actuation of the dispensing assembly.",SEAQUISTPERFECT DISPENSING FOR,WALTERS PETER J;;KSIAZK JASON A;;CHO SEAN H;;HALLMAN PAUL E;;WERNER JONATHAN D;;BRAUN CRAIG,SEQUISTPERFECT DISPENSING FOREIGN INC (2005-11-04),https://lens.org/040-897-208-133-663,Patent Application,yes,40,72,2,14,0,B65D83/201;;B65D83/22;;B05B11/1014;;B05B11/1057;;B05B11/1059;;B65D83/201;;B65D83/22;;B05B11/1057;;B05B11/1014;;B05B11/1059,B67B5/00;;B67D7/58,222/153.11,0,0,,,,ACTIVE
474,EP,B1,EP 1917205 B1,071-394-999-071-12X,2011-12-28,2011,EP 06785489 A,2006-06-23,US 2006/0024586 W;;US 17689605 A;;US 26844505 A;;US 21842804 F,2004-11-29,DISPENSER WITH LOCK,,APTARGROUP INC,WALTERS PETER J;;KSIAZK JASON A;;CHO SEAN H;;HALLMAN PAUL E;;WERNER JONATHAN D;;BRAUN CRAIG,"APTARGROUP, INC (2011-11-30)",https://lens.org/071-394-999-071-12X,Granted Patent,yes,10,1,8,14,0,B65D83/201;;B65D83/22;;B05B11/1014;;B05B11/1057;;B05B11/1059,B05B11/00;;B67D7/58,,0,0,,,,ACTIVE
475,AT,T1,AT E440324 T1,028-657-766-345-196,2009-09-15,2009,AT 06751225 T,2006-04-24,US 67443005 P;;US 2006/0015442 W,2005-04-25,SYSTEM UND VERFAHREN ZUR WIEDERHERSTELLUNG VON DATEN AUF ANFORDERUNG ZUR SOFORTIGEN WIEDERHERSTELLUNG EINES DATENTRÄGERS,"A technique is disclosed for restoring data of sparse volumes, where one or more block pointers within the file system structure are marked as ABSENT, and fetching the appropriate data from an alternate location on demand. Client data access requests to the local storage system initiate a restoration of the data from a backing store as required. A demand generator can also be used to restore the data as a background process by walking through the sparse volume and restoring the data of absent blocks. A pump module is also disclosed to regulate the access of the demand generator. Once all the data has been restored, the volume contains all data locally, and is no longer a sparse volume.",NETWORK APPLIANCE INC,LANGO JASON ANSEL;;CHO YONG;;EASTHAM PAUL;;ZHENG LING;;MANLEY STEPHEN;;EDWARDS JOHN;;ENGLISH ROBERT;;ACKAOUY EMMANUEL,,https://lens.org/028-657-766-345-196,Granted Patent,no,0,0,10,14,0,G06F11/1435;;G06F11/1469;;G06F11/1464,,,0,0,,,,INACTIVE
476,US,A1,US 2019/0022041 A1,148-905-398-854-659,2019-01-24,2019,US 201616067130 A,2016-12-30,MY PI2015704862 A;;MY 2016000088 W,2015-12-31,"OIL PALM PHENOLICS COMPOSITION FOR THE PROTECTION OF HUMANS, ORGANS, CELLS AND TISSUES AGAINST THE INJURIOUS EFFECTS OF EXPOSURE TO IONIZING RADIATION‏","A composition for preventing, treating, reversing, protecting against or ameliorating the injuring effects of an ionizing radiation upon living cells, tissues, organs, and organisms, comprising oil palm phenolics (OPP) or vegetation liquor extract obtained from aqueous stream of a palm oil milling effluent is provided.",MALAYSIAN PALM OIL BOARD,SAMBANTHAMURTHI RAVIGADEVI;;YEW AI TAN;;VLADIMIROVNA KOLEDOVA VERA;;PAUL WEINBERG ROBERT;;KYUN RHA CHO;;J SINSKEY ANTHONY,MALAYSIAN PALM OIL BOARD (2018-06-06),https://lens.org/148-905-398-854-659,Patent Application,yes,1,0,10,10,0,A61K36/889;;A61K31/192;;A61K31/702;;A61K31/191;;A61K31/225;;A61K31/192;;A61K31/702;;A61K36/889;;A61K2300/00;;A61K31/192;;A61K31/702;;A61K36/889;;A61K31/191;;A61K31/225;;A61K36/888,A61K31/191;;A61K31/192;;A61K31/225;;A61K36/888,,0,0,,,,DISCONTINUED
477,US,B2,US 9356176 B2,011-499-824-851-081,2016-05-31,2016,US 201514813745 A,2015-07-30,US 201514813745 A;;EP 11102241 A;;US 201213401181 A;;US 27119208 A;;US 2377208 A;;US 86014207 A;;US 86018307 A,2007-09-24,Inverted metamorphic multijunction solar cell with metamorphic layers,"A multijunction solar cell having at least four solar subcells includes a first solar subcell having a first band gap. A first graded interlayer adjacent to the first solar subcell and has a second band gap greater than the first band gap and that is constant at 1.5 eV throughout the thickness of the first graded interlayer. A second solar subcell is adjacent to the first graded interlayer and has a third band gap smaller than the first band gap of the first solar subcell. The second solar subcell is lattice mismatched with respect to the first solar subcell. A second graded interlayer is adjacent to the second solar subcell and has a fourth band gap greater than the third band gap of the second solar subcell and that is constant at 1.1 eV throughout the thickness of the second graded interlayer. A third solar subcell is adjacent to the second graded interlayer and has a fifth band gap smaller than the third band gap of the second solar subcell. The third solar subcell is lattice mismatched with respect to the second solar subcell. Each of the first and second graded interlayers is composed, respectively, of a compositionally step-graded series of (In x Ga 1-x ) y Al 1-y As layers with monotonically changing lattice constant, with x and y having respective values such that the band gap of each interlayer remains constant throughout its thickness, and wherein 0<x<1 and 0<y<1.",SOLAERO TECHNOLOGIES CORP,CORNFELD ARTHUR;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN;;SHARPS PAUL R;;AIKEN DANIEL J;;SPANN JOHN,EMCORE SOLAR POWER INC (2012-02-15);;SOLAERO TECHNOLOGIES CORP (2015-01-08),https://lens.org/011-499-824-851-081,Granted Patent,yes,100,0,6,111,0,H01L31/06875;;H01L31/06875;;H01L31/078;;H01L31/078;;H01L31/1844;;H01L31/1844;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544;;Y02E10/548;;Y02P70/50;;Y02P70/50,H01L31/0687;;H01L31/078;;H01L31/18,,48,25,026-281-940-590-23X;;015-557-396-201-987;;002-874-834-532-776;;073-300-069-664-773;;115-973-926-256-941;;083-287-525-840-54X;;084-891-382-112-541;;025-407-739-778-403;;034-023-904-332-047;;164-535-659-415-932;;007-176-082-871-508;;102-210-428-050-695;;106-513-576-934-63X;;076-989-478-838-81X;;015-717-993-971-840;;043-633-301-060-630;;030-787-136-717-28X;;038-574-682-896-969;;052-700-785-133-704;;093-340-948-123-836;;091-028-789-674-438;;020-636-430-481-14X;;026-862-096-577-376;;026-169-360-688-45X;;107-582-530-482-098,10.1109/wcpec.2006.279587;;10.1109/pvsc.2010.5614498;;10.1109/wcpec.2006.279835;;10.1109/wcpec.2006.279527;;10.1063/1.2753729;;10.1109/pvsc.2008.4922452;;10.1063/1.335957;;10.1109/pvsc.2002.1190685;;10.1109/77.783715;;10.1016/0022-0248(84)90363-4;;10.1016/0379-6787(88)90047-6;;10.1109/pvsc-vol2.2012.6656717;;10.1109/pvsc.1990.111608;;10.1109/iscs.1998.711543;;10.1002/pip.449;;10.1016/0379-6787(86)90032-3;;10.1016/j.jcrysgro.2009.10.059;;10.1002/pip.642;;10.1109/pvsc.1991.169189;;10.1063/1.106494;;10.1088/0953-8984/16/21/008;;10.1109/pvsc.2005.1488186;;10.1109/wcpec.2006.279559;;10.1063/1.98946;;10.1134/1.1187812,"U.S. Appl. No. 12/708,361, filed Feb. 18, 2010, Cornfeld.;;U.S. Appl. No. 12/716,814, filed Mar. 3, 2010, Cornfeld.;;U.S. Appl. No. 12/730,018, filed Mar. 23, 2010, Cornfeld.;;U.S. Appl. No. 12/756,926, filed Apr. 8, 2010, Cornfeld.;;U.S. Appl. No. 12/813,408, filed Jun. 10, 2010, Patel.;;U.S. Appl. No. 12/844,673, filed Jul. 27, 2010, Stan.;;U.S. Appl. No. 13/547,334, filed Jul. 12, 2010, Cornfeld.;;U.S. Appl. No. 13/554,527, filed Jul. 20, 2010, Tourino.;;U.S. Appl. No. 13/569,794, filed Aug. 8, 2010, Stan.;;Aiken et al., ""Consideration of High Bandgap Subcells for Advanced Multijunction Solar Cells,"" Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, 2006:838-841.;;Cornfeld et al., ""Development of a Large Area Inverted Metamorphic Multi-Junction (IMM) Highly Efficient Amo Solar Cell,"" 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Cornfeld et al., ""Development of a Large Area Inverted Metamorphic Multi-junction Highly Efficient AM0 Solar Cell,"" Conference paper presented at the 33rd IEEE Photovoltaic Specialists Conference (May 11-16, 2008) on May 12, 2008. San Diego, CA, USA.;;Cornfeld et al., ""Advances in the Performance of Inverted Metamorphic Multijunction Solar Cells,"" 23rd European Photovoltaic Energy Conference, Aug. 29, 2008, Valencia, Spain.;;Dimroth et al., ""Thin 5-Junction Solar Cells with Improved Radiation Hardness,"" Conference Record of the 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 2006; pp. 1777-1780.;;Extended European Search Report for European Application No. 11010224.1-1528 dated May 15, 2012; 2 pgs.;;Friedman et al., ""0.7-eV GaInAs Junction for a GaInP/GaAs/GaInAs(1eV)/GaInAs(0.7eV) Four-Junction Solar Cell,"" 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA; 598-602.;;Geisz et al., ""High efficiency GaInP/GaAs/InGaAs triple-junction solar cells grown inverted with a metamorphic bottom junction,"" Applied Physics Letters, 2007; 91:023502-1-023502-3. Published online Jul. 10, 2007.;;Geisz et al., ""Inverted GaInP / (In)GaAs Triple-Junction Solar Cells with Low-Stress Metamorphic Bottom Junctions,"" 33rd IEEE Photovoltaic Specialists Conference, May 11-16, 2008, San Diego, CA, USA.;;Hamaker, H.C., ""Computer modeling study of the effects of inhomogeneous doping and/or composition in GaAs solar-cell devices,"" J Appl. Phys., 1985 Sep. 15; 58(6):2344-2351.;;King et al., ""Next-Generation, High Efficiency III-V Multijunction Solar Cells,"" 28th IEEE Photovoltaic Specialists Conference, Sep. 15-22, 2000, Anchorage, AK, USA; pp. 998-1001.;;King et al., ""High-Efficiency Space and Terrestrial Multijunction Solar Cells Through Bandgap Control in Cell Structures,"" 2002 Photovoltaic Specialists Conference, Conference Record of the 29th IEEE, May 19-24, 2002, New Orleans, LA, USA; pp. 776-781.;;King et al., ""Solar Cell Generations Over 40% Efficiency,"" 26th European Photovoltaic Solar Energy Conference and Exhibition, Sep. 5, 2011, Hamburg, Germany; 15 pgs.;;Koh et al., ""Fabrication of Superconducting Delay Line with GaAs Schottky Diode,"" IEEE Transactions on Applied Superconductivity, 1999; 9(2):3224-3227.;;Lewis et al., ""The Crystallographic Connection of MOCVD-Grown Monolithic Cascade Subcells Via Transparent Graded Layers,"" Journal of Crystal Growth, 1984; 69:515-526.;;Lewis et al., ""Recent Developments in Multijunction Solar Cell Research,"" Solar Cells, 1988; 24:171-183.;;Li et al., ""Unintentional doping and compensation effects of carbon in metal-organic chemical vapor deposition fabricated ZnO thin films"", 2006, pp. 1213-1217.;;Patel et al., ""Experimental Results From Performance Improvement and Radiation Hardening of inverted Metamorphic Multi-Junction Solar Cells,"" Proceedings of the 37th IEEE PVSC, Seattle, WA, 2011 (Presented at PVSC Jun. 22, 2001).;;Patel et al., ""Initial Results of the Monolithically Grown Six-Junction Inverted Metamorphic Multi-junction Solar Cell,"" Proceedings of the 38th IEEE PVSC, Austin, TX, 2012 (Presented at PVSC Jun. 7, 2012).;;Schultz et al., ""High Efficiency 1.0-eV GaInAs Bottom Solar Cell for 3-Junction Monolithic Stack,"" IEEE, 1990:148-152.;;Sexl et al., ""MBE Growth of Metamorphic In(Ga)AIAs Buffers,"" 1997 IEEE International Symposium on Compound Semiconductors, Sep. 8-11, 1997; pp. 49-52.;;Sharps et al., ""Inverting the triple junction improves efficiency and flexibility,"" Compound Semiconductor, Oct. 2007; pp. 25-28.;;Sinharoy et al., ""Progress in the Development of Metamorphic Multi junction III-V Space Solar Cells,"" Progress in Photovoltaics: Research and Applications, Feb. 2002; 10:427-432.;;Soukup et al., ""Limitations of Built-in Electric Field Enhancement of Minority Carrier Current Collection in GaAs Backwall Schottky Barrier Solar Cells,"" Solar Cells, 1986; 18:139-151.;;Stan et al., ""Recent Advances in the Performance of Multi-Junction Space Solar Cells,"" 22nd European Photovoltaic Solar Energy Conference, Sep. 3-7, 2007, Milan, Italy; pp. 101-105.;;Stan et al., ""Very High Efficiency Triple Junction Solar Cells by MOVPE,"" 14th International Conference of Metalorganic Vapor Phase Epitaxy, Jun. 5, 2008, Metz, France.;;Stan et al., ""High efficiency quadruple junction solar cells using MOVPE with inverted metamorphic device structures,"" Journal of Crystal Growth, 2010; 312:1370-1374.;;Takamoto et al., ""Future Development of InGaP/(In)GaAs Based Multijunction Solar Cells,"" Proceedings of the 31st IEEE PVSC, 2005 Jan. 3-7, Lake Buena Vista, FL; pp. 519-524.;;Takamoto et al., ""InGaP/GaAs-based Multijunction Solar Cells,"" Progress in Photovoltaics: Research and Applications, 2005; 13:495-511.;;Venkatasubramanian et al., ""An Inverted-Growth Approach to Development of an Ir-Transparent, High-Efficiency A1GaAs/GaAs Cascade Solar Cell,"" 22nd IEEE Photovoltaic Specialists Conference, Oct. 7-11, 1991, Las Vegas, NV, USA; pp. 93-98.;;Venkatasubramanian et al., ""High-quality eutectic-metal-bonded A1GaAs-GaAs thin films on Si substrates,"" Appl. Phys. Lett., Feb. 1992; 60(7):886-888.;;Voncken et al., ""Strain-accelerated HF etching of AlAs for epitaxial lift-off,"" J. Phys.: Condens. Matter, 2004; 16:3585-3596.;;Walters et al., ""Space Radiation Effects in Advanced Solar Cell Materials and Devices,"" Mat. Res. Soc. Symp. Proc., 2002; 692:569-580.;;Wanlass et al., ""Lattice-Mismatched Approaches for High-Performance, III-V Photovoltaic Energy Converters,"" Conference Proceedings of the 31st IEEE Photovoltaic Specialists Conference and Exhibition, Lake Buena Vista, FL, USA; Jan. 3-7, 2005;530-535.;;Wanlass et al., ""Monolithic, Ultra-Thin GaInP/GaAs/GaInAs Tandem Solar Cells,"" 2006 IEEE 4th World Conference on Photovoltaic Energy Conversion, May 7-12, 2006, Waikoloa, Hawaii, USA; 729-732.;;Warfel, ""Basic Structure of Solar Cells,"" Physics of Solar Cells: From Basic Principles to Advanced Concepts, Second, Updated and Expanded Edition, 2009; Sections 6.4, 6.5 and 6.8.;;Yablonovitch et al., ""Extreme selectivity in the lift-off of epitaxial GaAs films,"" Appl. Phys. Lett., 1987; 51(28):2222-2224.;;Yamaguchi, ""Physics and Technologies of Superhigh-Efficiency Tandem Solar Cells,"" Semiconductors, 1999 Sep.; 33(9):961-964.;;Yoon et al., ""Progress of Inverted Metamorphic III-V Solar Cell Development at Spectrolab,"" 33rd IEEE Specialists Conference, May 11-16, 2008, San Diego, CA, USA.",ACTIVE
478,EP,A1,EP 2610924 A1,187-883-713-388-29X,2013-07-03,2013,EP 11010224 A,2011-12-27,EP 11010224 A,2011-12-27,Inverted metamorphic multijunction solar cell with two metamorphic layers and homojunction top cell,"A multijunction solar cell including an upper first solar subcell having a first band gap, and the base-emitter junction of the upper first solar subcell being a homojunction; a second solar subcell adjacent to said first solar subcell and having a second band gap smaller than said first band gap; a third solar subcell adjacent to said second solar subcell and having a third band gap smaller than said second band gap. A first graded interlayer is provided adjacent to said third solar subcell; said first graded interlayer having a fourth band gap greater than said third band gap. A fourth solar subcell is provided adjacent to said first graded interlayer, said fourth subcell having a fifth band gap smaller than said third band gap such that said fourth subcell is lattice mismatched with respect to said third subcell. A second graded interlayer is provided adjacent to said fourth solar subcell; said second graded interlayer having a sixth band gap greater than said fifth band gap; and a lower fifth solar subcell is provided adjacent to said second graded interlayer, said lower fifth subcell having a seventh band gap smaller than said fifth band gap such that said fifth subcell is lattice mismatched with respect to said fourth subcell.
",EMCORE SOLAR POWER INC,CORNFELD ARTHUR;;SPANN JOHN;;PATEL PRAVIN;;STAN MARK A;;CHO BENJAMIN;;SHARPS PAUL R;;AIKEN DANIEL J,SOLAERO TECHNOLOGIES CORP. (2015-08-26),https://lens.org/187-883-713-388-29X,Patent Application,yes,11,12,2,111,0,H01L31/06875;;H01L31/03042;;H01L31/03046;;H01L31/0693;;H01L31/1844;;Y02E10/544,H01L31/18;;H01L31/0304;;H01L31/0687;;H01L31/0693,,5,2,002-874-834-532-776;;056-691-073-941-491,10.1109/wcpec.2006.279835;;10.1016/s0022-0248(96)00779-8,"R.R. KING ET AL: ""Solar Cell Generations over 40% Efficiency"", PROCEEDINGS OF THE 26TH EUROPEAN PHOTOVOLTAIC SOLAR ENERGY CONFERENCE AND EXHIBITION, 5 September 2011 (2011-09-05) - 9 September 2011 (2011-09-09), Hamburg/GERMANY, pages 1 - 15, XP007920588, ISBN: 3-936338-27-2, DOI: 10.4229/26thEUPVSEC2011-1AP.1.2;;DIMROTH F ET AL: ""Thin 5-Junction Solar Cells with Improved Radiation Hardness"", CONFERENCE RECORD OF THE 2006 IEEE 4TH WORLD CONFERENCE ON PHOTOVOLTAIC ENERGY CONVERSION (IEEE CAT. NO.06CH37747),, 1 May 2006 (2006-05-01), pages 1777 - 1780, XP031007672, ISBN: 978-1-4244-0016-4;;M.W. WANLASS ET AL.: ""Conference Proceedings of the 31st IEEE Photovoltaic Specialists Conference"", 3 January 2005, IEEE PRESS, article ""Lattice Mismatched Approaches for High Performance, Ill-V Photovoltaic Energy Converters"";;V.A. ELYUKHIN; E.L. PORTNOI; E.A. AVRUTIN; J.H. MARSH, J. CRYSTAL GROWTH, vol. 173, 1997, pages 69 - 72;;G.B. STRINGFELLOW: ""Organometallic Vapor-Phase Epitaxy"", 1989, ACADEMIC PRESS",ACTIVE
479,US,A1,US 2024/0018263 A1,023-655-415-831-757,2024-01-18,2024,US 202318463154 A,2023-09-07,US 202318463154 A;;US 202016754677 A;;US 2018/0054952 W;;US 201762569834 P,2017-10-09,ANTIBODIES TARGETING GLIOBLASTOMA STEM-LIKE CELLS AND METHODS OF USE THEREOF,The present invention provides antibodies that target glioblastoma stem-like cells and methods and kits for their use.,WISCONSIN ALUMNI RES FOUND,ZORNIAK MICHAEL;;CLARK PAUL A;;CHO YONGKU PETER;;UMLAUF BENJAMIN J;;SHUSTA ERIC V;;KUO JOHN SHU-SHIN,WISCONSIN ALUMNI RESEARCH FOUNDATION (2018-03-20),https://lens.org/023-655-415-831-757,Patent Application,yes,0,0,5,5,0,C07K16/18;;C07K16/30;;G01N33/57407;;A61K2039/505;;C07K2317/569;;A61P35/00;;A61K49/0058;;A61K2039/505;;C07K16/3053;;C07K2317/565;;C07K2317/622;;C07K2317/92;;G01N33/57407,C07K16/30;;A61K49/00;;G01N33/574,,0,0,,,,PENDING
480,BR,A2,BR 112020000413 A2,028-038-860-262-650,2020-07-21,2020,BR 112020000413 A,2018-07-03,IB 2018054926 W;;US 201762531227 P;;US 201862682044 P,2017-07-11,composições imunogênicas compreendendo cea muc1 e tert,"a presente invenção fornece: (a) polipeptídeos de cea imunogênicos isolados; (b) moléculas de ácido nucleico isoladas que codificam (i) um polipeptídeo de cea imunogênico, (ii) um polipeptídeo de cea imunogênico e um polipeptídeo de muc1 imunogênico, (iii) um polipeptídeo de cea imunogênico e um polipeptídeo de tert imunogênico ou (iv) um polipeptídeo de cea imunogênico, um polipeptídeo de muc1 imunogênico e um polipeptídeo de tert imunogênico; (c) composições compreendendo uma molécula de ácido nucleico isolada; e (d) métodos relacionados às utilizações dos polipeptídeos de cea imunogênicos, moléculas de ácido nucleico e composições.",PFIZER,DEREK JOHN FALCONER;;HELEN KIM CHO;;JOSEPH JOHN BINDER;;MARIANNE MARCELA ANDREA MARTINIC;;PAUL JASON COCKLE;;SIRADANAHALLI GURU,,https://lens.org/028-038-860-262-650,Patent Application,no,0,0,19,20,0,A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/70;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/55555;;C12N2710/10343;;A61K38/00;;C12N9/1276;;C12Y207/07049;;C12N9/1276;;A61K38/00;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/55555;;A61K2039/70;;A61K2300/00;;C12Y207/07049;;C12N2710/10343;;A61K2039/53;;A61K2039/545;;A61K2039/54;;A61K2039/55555;;A61K39/00117;;C12N2710/10343;;A61K39/001182;;A61K2039/70;;A61K39/001157;;A61K2039/5256;;A61K38/00;;C07K14/705;;C12N9/1276;;C12Y207/07049,C12N7/00;;A61K39/00,,0,0,,,,DISCONTINUED
481,CA,A1,CA 3069363 A1,055-645-780-167-569,2019-01-17,2019,CA 3069363 A,2018-07-03,US 201762531227 P;;US 201862682044 P;;IB 2018054926 W,2017-07-11,IMMUNOGENIC COMPOSITIONS COMPRISING CEA MUC1 AND TERT,"The present disclosure provides: (a) isolated immunogenic CEA polypeptides; (b) isolated nucleic acid molecules encoding (i) an immunogenic CEA polypeptide, (ii) an immunogenic CEA polypeptide and an immunogenic MUC1 polypeptide, (iii) an immunogenic CEA polypeptide and an immunogenic TERT polypeptide, or (iv) an immunogenic CEA polypeptide, an immunogenic MUC1 polypeptide, and an immunogenic TERT polypeptide; (c) compositions comprising an isolated nucleic acid molecule; and (d) methods relating to uses of the immunogenic CEA polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;MARTINIC MARIANNE MARCELA ANDREA,,https://lens.org/055-645-780-167-569,Patent Application,no,0,0,19,20,93,A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/70;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/55555;;C12N2710/10343;;A61K38/00;;C12N9/1276;;C12Y207/07049;;C12N9/1276;;A61K38/00;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/55555;;A61K2039/70;;A61K2300/00;;C12Y207/07049;;C12N2710/10343;;A61K2039/53;;A61K2039/545;;A61K2039/54;;A61K2039/55555;;A61K39/00117;;C12N2710/10343;;A61K39/001182;;A61K2039/70;;A61K39/001157;;A61K2039/5256;;A61K38/00;;C07K14/705;;C12N9/1276;;C12Y207/07049,A61K39/00;;C12N7/00,,0,0,,,,DISCONTINUED
482,SG,A,SG 11202000197P A,066-338-354-933-418,2020-02-27,2020,SG 11202000197P A,2018-07-03,US 201762531227 P;;US 201862682044 P;;IB 2018054926 W,2017-07-11,IMMUNOGENIC COMPOSITIONS COMPRISING CEA MUC1 AND TERT,,PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;MARTINIC MARIANNE MARCELA ANDREA,,https://lens.org/066-338-354-933-418,Unknown,no,0,0,19,20,0,A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/70;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/55555;;C12N2710/10343;;A61K38/00;;C12N9/1276;;C12Y207/07049;;C12N9/1276;;A61K38/00;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/55555;;A61K2039/70;;A61K2300/00;;C12Y207/07049;;C12N2710/10343;;A61K2039/53;;A61K2039/545;;A61K2039/54;;A61K2039/55555;;A61K39/00117;;C12N2710/10343;;A61K39/001182;;A61K2039/70;;A61K39/001157;;A61K2039/5256;;A61K38/00;;C07K14/705;;C12N9/1276;;C12Y207/07049,A61K39/00;;C12N7/00,,0,0,,,,PENDING
483,US,B2,US 11780932 B2,011-928-803-035-213,2023-10-10,2023,US 201816754677 A,2018-10-09,US 201816754677 A;;US 201762569834 P;;US 2018/0054952 W,2017-10-09,Antibodies targeting glioblastoma stem-like cells and methods of use thereof,The present invention provides antibodies that target glioblastoma stem-like cells and methods and kits for their use.,WISCONSIN ALUMNI RES FOUND,ZORNIAK MICHAEL;;CLARK PAUL A;;CHO YONGKU PETER;;UMLAUF BENJAMIN J;;SHUSTA ERIC V;;KUO JOHN SHU-SHIN,WISCONSIN ALUMNI RESEARCH FOUNDATION (2018-03-20),https://lens.org/011-928-803-035-213,Granted Patent,yes,10,0,5,5,10,C07K16/18;;C07K16/30;;G01N33/57407;;A61K2039/505;;C07K2317/569;;A61P35/00;;A61K49/0058;;A61K2039/505;;C07K16/3053;;C07K2317/565;;C07K2317/622;;C07K2317/92;;G01N33/57407,A61K39/00;;A61K49/00;;C07K16/30;;G01N33/574,,112,99,044-139-486-413-246;;051-208-529-712-079;;015-947-199-986-598;;005-930-919-665-693;;001-698-087-702-930;;028-862-168-091-90X;;065-067-575-525-372;;051-449-459-754-069;;153-697-003-263-81X;;071-073-635-453-103;;026-141-621-631-087;;063-180-739-005-237;;053-264-448-501-818;;005-790-218-190-208;;004-929-207-346-112;;054-778-738-922-420;;023-301-536-947-707;;042-513-156-090-960;;088-006-869-449-526;;030-327-153-441-88X;;059-320-156-771-738;;047-454-384-106-762;;045-857-295-659-908;;029-746-705-323-760;;044-555-535-916-468;;112-206-594-779-001;;034-848-842-872-836;;009-619-262-328-708;;066-190-897-568-631;;038-244-738-912-920;;058-632-935-364-855;;050-643-301-507-490;;057-167-704-218-212;;011-020-280-584-511;;094-820-214-854-807;;047-143-347-080-307;;008-661-986-771-169;;013-181-635-285-001;;063-209-365-397-876;;164-041-763-164-918;;021-881-534-669-724;;033-217-728-394-888;;015-998-463-324-164;;040-091-367-301-676;;086-535-063-875-025;;024-348-041-797-510;;019-377-086-323-88X;;007-750-921-871-271;;090-855-538-709-694;;013-196-850-300-026;;091-102-566-701-905;;010-568-275-556-548;;105-369-693-995-394;;128-333-076-135-348;;007-047-414-654-825;;026-824-155-633-618;;085-656-742-202-556;;000-434-645-753-842;;043-543-422-125-112;;132-094-885-330-409;;072-124-564-678-690;;067-510-130-720-34X;;053-301-739-905-628;;065-845-026-596-467;;094-452-013-519-715;;044-055-955-198-975;;018-169-670-602-076;;019-921-917-139-327;;002-473-848-957-436;;024-910-342-741-241;;054-117-557-242-401;;192-609-714-372-280;;039-376-070-403-51X;;002-091-355-242-789;;028-981-833-063-784;;092-864-235-322-940;;077-233-519-852-789;;000-087-532-932-840;;068-232-562-966-086;;015-459-933-949-167;;071-419-968-226-297;;028-250-965-567-256;;097-006-524-687-437;;060-800-606-301-88X;;072-221-669-832-927;;008-387-158-819-578;;035-149-244-661-733;;027-628-739-240-883;;127-278-436-943-010;;037-020-438-620-935;;001-308-283-819-689;;037-370-743-821-194;;031-529-904-715-725;;007-057-986-430-201;;116-058-608-181-929;;123-207-792-815-679;;044-139-486-413-246;;017-597-089-494-010;;035-428-777-329-102,20587664;;pmc2944778;;10.1158/1535-7163.mct-09-1059;;17981654;;10.2741/2786;;16051357;;10.1016/j.dci.2005.06.010;;10.1093/jb/mvn009;;18216066;;10.1002/btpr.174;;19363813;;pmc2837102;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1016/j.omtn.2018.04.004;;29858087;;pmc5992475;;10.1016/j.biomaterials.2011.07.048;;21880363;;10.1038/nbt0697-553;;9181578;;11075358;;10.1016/s0076-6879(00)28410-3;;10.1128/aem.01466-14;;25015885;;pmc4178591;;10.1016/j.ccr.2009.12.049;;20385361;;19838178;;pmc2783566;;10.1038/nn.2410;;10.1016/j.jim.2008.11.005;;19041873;;pmc2637942;;23248284;;10.1073/pnas.1219817110;;pmc3538214;;pmc3384429;;22745588;;10.1596/neo.12432;;pmc5014630;;27421304;;10.1021/acs.molpharmaceut.6b00441;;18000980;;10.1002/dvdy.21381;;27419830;;10.3171/2016.1.jns152077;;pmc5237623;;20173750;;10.1038/nmeth.1430;;10.1016/j.wneu.2010.12.055;;21986423;;pmc3278994;;20426697;;pmc3657606;;10.1517/14712598.2010.485186;;12536217;;10.1038/nbt785;;10.1242/dev.010454;;18184726;;10.1158/0008-5472.can-04-1364;;15466194;;pmc2688461;;10.1016/j.bmcl.2009.01.028;;19181522;;pmc3406803;;22753465;;10.1073/pnas.1120068109;;10.1007/s11095-006-9778-7;;16550469;;10.1158/1535-7163.mct-14-1078;;25931519;;10.1056/nejmoa043331;;15758010;;pmc3389128;;10.1158/1078-0432.ccr-12-1456;;22711710;;16957578;;10.1097/01.jnen.0000235118.75182.94;;16151404;;10.1038/nbt1126;;18781684;;10.1002/bit.22019;;10.1038/nrc2818;;20414201;;12203386;;10.1002/glia.10094;;10.1007/s11095-007-9379-0;;17619996;;pmc2685177;;10.1073/pnas.87.6.2264;;2315319;;pmc53667;;21385897;;10.1158/0008-5472.can-10-4117;;pmc3085663;;pmc3933790;;23796560;;10.1158/0008-5472.can-12-4556;;11474661;;10.1056/nejm200107263450402;;10.1200/jco.2011.38.1756;;22355053;;pmc3383181;;10.1038/mt.2015.199;;pmc4817815;;26514825;;10.1016/j.ccr.2006.03.030;;10.3410/f.30634.375123;;16697959;;10.1016/j.neuroscience.2009.10.032;;19850111;;10.1016/j.chembiol.2007.09.008;;17961829;;17140455;;pmc1697823;;10.1186/1476-4598-5-67;;pmc1207636;;10.1093/genetics/144.3.967;;8913742;;10.1227/neu.0000000000001451;;27861405;;24832468;;pmc4085538;;10.1038/cdd.2014.65;;10.1038/sj.gt.3302445;;15647762;;25361488;;10.3171/2014.9.jns132373;;pmc4337891;;17051156;;10.1038/nature05236;;pmc2999649;;20829328;;10.1158/1078-0432.ccr-10-1564;;18066039;;10.1038/nbt1363;;pmc7097443;;10.1021/cb500689g;;25384269;;pmc4340354;;20044633;;22393399;;pmc3290555;;10.1371/journal.pone.0032336;;10.1038/nature02580;;15190345;;10.1517/17425247.2016.1171315;;27020469;;27572805;;10.1080/14712598.2016.1230195;;10.2174/138620708783744516;;pmc2681324;;18336206;;10.1158/1078-0432.ccr-15-3169;;pmc5627655;;27635088;;10.1016/j.neuint.2014.03.005;;pmc4119816;;24657832;;19497285;;10.1016/j.stem.2009.03.014;;10.1023/a:1007049806660;;10696511;;16549400;;10.1093/protein/gzl008;;26759369;;pmc4743815;;10.1073/pnas.1524155113;;10.1158/2326-6066.cir-15-0060;;26822025;;10.1038/77325;;10888844;;9702778;;10.1038/nbt0898-773;;14522905;;10.1038/nature03128;;15549107;;pmc7227614;;10.1016/j.stem.2009.03.003;;19427293;;26670971;;10.1001/jama.2015.16669;;10.1001/jama.2014.12146;;10.1056/nejmoa043330;;15758009;;11156394;;21839049;;10.1016/j.nano.2011.07.007;;10.1080/2162402x.2015.1008339;;26155413;;pmc4485829;;9874150;;10.1016/s0165-0270(98)00126-5;;10.1227/neu.0000000000000622;;25549194;;pmc4343207;;10.1002/dvdy.20209;;15580626;;22449570;;pmc3405166;;10.1016/j.ymeth.2012.03.010;;pmc5997667;;29895885;;10.1038/s41598-018-27264-w;;10.1021/nn1023363;;21609027;;10.1021/bp990133s;;10662486;;17206151;;pmc2637222;;10.1038/nmeth993;;16099466;;10.1016/j.jim.2005.05.006;;24920661;;pmc4336181;;10.1126/scitranslmed.3007646;;12356358;;pmc1920665;;10.1093/neuonc/4.4.278;;10.1215/15228517-4-4-278;;10.1215/s152285170200011x;;26405231;;pmc4721629;;10.1126/science.aab4077;;pmc4664343;;26553993;;10.1073/pnas.1502648112;;pmc3189267;;21814852;;10.1007/s00259-011-1886-x;;10.2217/cns-2016-0017;;pmc5514628;;27616199;;27192568;;pmc4873959;;10.1016/j.immuni.2016.04.017;;pmc2855245;;10.1016/j.neuron.2010.02.018;;20223198;;20587664;;pmc2944778;;10.1158/1535-7163.mct-09-1059;;29158489;;10.1038/s41598-017-16066-1;;pmc5696472;;10.1158/1078-0432.ccr-12-0339;;pmc3597469;;22589395,"Zhu et al. (Molecular Cancer Therapeutics, vol. 9, No. 7, Jul. 2010, pp. 2131-2141) (Year: 2010).;;Almagro & Fransson, Frontiers in Bioscience 2008; 13:1619-33 (Year: 2008).;;De Genst et al., Dev Comp Immunol 2006; 30:187-98 (Year: 2006).;;Yoshinaga et al., J. Biochem 2008; 143:593-601 (Year: 2008).;;Ackerman, M. et al. Highly avid magnetic bead capture: an efficient selection method for de novo protein engineering utilizing yeast surface display. Biotechnology progress 25, 774-783, doi:10.1002/btpr.174 (2009).;;Altschul, SF et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.” Nucleic Acids Res. 25 (1997): 3389-3402.;;Arnold, A. E., et al. “Antibody-antisense oligonucleotide conjugate downregulates a key gene in glioblastoma stem cells.” Molecular Therapy-Nucleic Acids 11 (2018): 518-527.;;Beck, S., et al. “Identification of a peptide that interacts with Nestin protein expressed in brain cancer stem cells.” Biomaterials 32.33 (2011): 8518-8528.;;Boder, E. T., et al. “Yeast surface display for screening combinatorial polypeptide libraries.” Nature biotechnology 15.6 (1997): 553-557.;;Boder, E. T., et al. Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods in enzymology 328, 430-444 (2000).;;Burns ML, et al. Directed evolution of brain-derived neurotrophic factor for improved folding and expression in Saccharomyces cerevisiae. Applied and environmental microbiology. 2014;80:5732-5742. doi: 10.1128/AEM.01466-14.;;Chen, R. et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer cell 17, 362-375, doi:10.1016/j.ccr.2009.12.049 (2010).;;Chen, Y, et al. “The oligodendrocyte-specific G protein-coupled receptor GPR17 is a cell-intrinsic timer of myelination.” Nature neuroscience 12.11 (2009): 1398-1406.;;Cho YK, et al. A yeast display immunoprecipitation method for efficient isolation and characterization of antigens. Journal of immunological methods. 2009;341:117-126. doi: 10.1016/j.jim.2008.11.005.;;Choi BD, et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:270-275. doi: 10.1073/pnas.1219817110.;;Clark PA, et al. “SC-003. Identification of Glioblastoma Cancer Stem-Like Cell-Binding Human Antibodies Via Yeast Expression Library Biopanning.” Neuro-oncology 15.suppl_3 (2013).;;Clark PA, et al. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Neoplasia 14, 420-428 (2012).;;Clark PA, et al. Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood-Brain Barrier Model. Mol Pharm 13, 3341-3349, doi:10.1021/acs.molpharmaceut.6b00441 (2016).;;Clark PA, et al. Developmental signaling pathways in brain tumor-derived stem-like cells. Dev Dyn 236, 3297-3308, doi:10.1002/dvdy.21381 (2007).;;Clark PA, et al. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration. J Neurosurg, 1-13, doi:10.3171/2016.1.JNS152077 (2016).;;Clement V, et al. Marker independent identification of glioma initiating cells. Nature methods. 2010;7:224-228. doi: 10.1038/nmeth.1430.;;Cross, R. Controlling CAR-T: How scientists plan to make the engineered T cell therapy safer, and work for more cancers. Chemical & Engineering News, vol. 96, Issue 19. 2018.;;Ebben, J. D., et al. “Introduction to induced pluripotent stem cells: advancing the potential for personalized medicine.” World neurosurgery 76.3-4 (2011): 270-275.;;Ebben, J. D., et al. “The cancer stem cell paradigm: a new understanding of tumor development and treatment.” Expert opinion on therapeutic targets 14.6 (2010): 621-632.;;Feldhaus MJ, et al. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nature biotechnology. 2003;21:163-170. doi: 10.1038/nbt785.;;Finzsch, M., et al. “Sox9 and Sox10 influence survival and migration of oligodendrocyte precursors in the spinal cord by regulating PDGF receptor a expression.” Development 135.4 (2008): 637-646.;;Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer research 64, 7011-7021, doi:64/19/7011 (2004).;;Gavrilyuk, JI et al. ß-Lactam-based Approach for Chemical Programming of Aldolast Antibody 38C2, Bioorg Med Chem Lett. Mar. 1, 2009; 19(5):1421-1424.;;Gurney, A., et al. “Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.” Proceedings of the National Academy of Sciences 109.29 (2012): 11717-11722.;;Hackel BJ, et al. Production of soluble and active transferrin receptor-targeting single-chain antibody using Saccharomyces cerevisiae. Pharmaceutical research. 2006;23:790-797. doi: 10.1007/s11095-006-9778-7.;;Hamblett KJ, et al. AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Molecular cancer therapeutics. 2015;14:1614-1624. doi: 10.1158/1535-7163. MCT-14-1078.;;Hegi, M. E., et al. “MGMT gene silencing and benefit from temozolomide in glioblastoma.” New England Journal of Medicine 352.10 (2005): 997-1003.;;Hjelmeland, A. B. et al. “The quest for self-identity: not all cancer stem cells are the same.” Clinical Cancer Research 18.13 (2012): 3495-3498.;;Homma T, et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. Journal of neuropathology and experimental neurology. 2006;65:846-854. doi: 10.1097/01.jnen.0000235118.75182.94.;;Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nature biotechnology. 2005;23:1105-1116. doi: 10.1038/nbt1126.;;Huang, D., et al. Increasing yeast secretion of heterologous proteins by regulating expression rates and post-secretory loss. Biotechnol Bioeng 101, 1264-1275, doi:10.1002/bit.22019 (2008).;;Huse, J. T. et al. “Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma.” Nature reviews cancer 10.5 (2010): 319-331.;;Ignatova TN, et al. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 2002;39:193-206. doi: 10.1002/glia.10094.;;International Searching Authority, International Search Report and Written Opinion for application PCT/US2018/054952, dated Feb. 4, 2019.;;Jones, A.R. et al, Blood-brain barrier transport of therapeutics via receptor-mediation. Pharmaceutical Research, 2007. 24(9): p. 1759-1771.;;Karlin, S. et al. “Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes.” Proceedings of the National Academy of Sciences 87.6 (1990): 2264-2268.;;Kim, T-M, et al. “A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs.” Cancer research 71.9 (2011): 3387-3399.;;Kim, Y, et al. “Aptamer identification of brain tumor-initiating cells.” Cancer research 73.15 (2013): 4923-4936.;;Kreitman, R. J., et al. “Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.” New England Journal of Medicine 345.4 (2001): 241-247.;;Kreitman, R. J., et al. “Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.” Journal of Clinical Oncology 30.15 (2012): 1822.;;Krenciute G, et al. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Ralpha2-positive Glioma. Mol Ther. 2016;24:354-363. doi: 10.1038/mt.2015.199.;;Lee, J. et al. “Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.” Cancer cell 9.5 (2006): 391-403.;;Lin, J., et al. “Cadherin-19 expression is restricted to myelin-forming cells in the chicken embryo.” Neuroscience 165.1 (2010): 168-178.;;Lipovsek D, et al. Selection of horseradish peroxidase variants with enhanced enantioselectivity by yeast surface display. Chemistry & biology. 2007;14:1176-1185. doi: 10.1016/j.chembiol.2007.09.008.;;Liu, G. et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Molecular cancer. 2006;5:67. doi: 10.1186/1476-4598-5-67.;;Liu, H. et al. Saccharomyces cerevisiae S288C has a mutation in FLO8, a gene required for filamentous growth. Genetics 144, 967-978 (1996).;;Liu, HL et al. Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment. Radiology. 2016;281:99-108. doi: 10.1148/radiol.2016152444.;;Liu, JK et al. “Phage display discovery of novel molecular targets in glioblastoma-initiating cells.” Cell Death & Differentiation 21.8 (2014): 1325-1339.;;Liu, R. et al. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene therapy. 2005;12:647-654. doi: 10.1038/sj.gt.3302445.;;Zorniak, M. et al. Mining a Yeast Antibody Library for Glioblastoma Cancer Stem Cell-Specific Surface Markers. Poster presented at 2009 AACR conference. Denver, CO. 2009.;;Zorniak, M. et al. Myelin-forming cell-specific cadherin-19 is a marker for minimally infiltrative glioblastoma stem-like cells. J Neurosurg 122, 69-77, doi:10.3171/2014.9.JNS132373 (2015).;;Zorniak, M. et al. scFv-Based Detection and Isolation of Invasive Glioblastoma Cancer Stem-Like Cells from a Yeast Antibody Library. Presented at PEGS Conference 2013. Boston, MA.;;Zorniak, M. Identifying Biomarkers and Antibodies for Brain Cancer and their Stem-Like Cells. Campus Stem Cell Lab Meeting. Mar. 20, 2012.;;Zorniak, M. Membrance Proteomics of Human Glioblastoma Stem-Like Cells. Dissertation. University of Wisconsin-Madison. 2013.;;Zorniak, M. Membrane Proteomics of Human Glioblastoma Stem-Like Cells. Presentation at 2013 Neurosurgery Research Day. Oct. 15, 2013. University of Wisconsin-Madison.;;Zorniak, M. Strategies for Precision Medicine in Brain Cancer. Presentation at Hostage Brain Conference. Lake Forest College. Dec. 8, 2012.;;Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760, doi:10.1038/nature05236 (2006).;;Lockman PR, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010;16:5664-5678. doi: 10.1158/1078-0432.CCR-10-1564.;;Marasco, W.A., et al., 2007. The growth and potential of human antiviral monoclonal antibody therapeutics. Nature biotechnology 25, 1421-1434.;;Marshall CJ, et al. An evolved Mxe GyrA intein for enhanced production of fusion proteins. ACS Chem Biol. 2015;10:527-538. doi: 10.1021/cb500689g.;;Martin, CR, et al., Nanomaterials in Analytical Chemistry, Analytical Chemistry News & Features, May 1, 1998; pp. 322 A-327 A.;;Minniti, G., et al. “Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.” Anticancer Research 29.12 (2009): 5171-5184.;;Myllykoski, M., et al. “Myelin 2′, 3′-cyclic nucleotide 3′-phosphodiesterase: active-site ligand binding and molecular conformation.” PloS one 7.2 (2012): e32336.;;Oh, P., et al. “Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy.” Nature 429.6992 (2004): 629-635.;;Pardridge W.M. CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv. 2016;13:963-975. doi: 10.1517/17425247.2016.1171315.;;Ardridge W.M. Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies. Expert Opin Biol Ther, 1-14, 10.1080/14712598.2016.1230195 (2016).;;Pepper, LR, et al. “A decade of yeast surface display technology: where are we now?.” Combinatorial chemistry & high throughput screening 11.2 (2008): 127-134.;;Pointer, KB, et al. Administration of non-torsadogenic human Ether-a-go-go Related Gene (hERG) inhibitors are associated with better survival for high hERG-expressing glioblastoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research, doi:10.1158/1078-0432.CCR-15-3169 (2016).;;Pointer, KB, et al. Glioblastoma cancer stem cells: Biomarker and therapeutic advances. Neurochem Int. 2014;71:1-7.;;Pollard, S. M. et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens Cell stem cell 4, 568-580, doi:S1934-5909(09)00149-0 (2009).;;Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cellular and molecular neurobiology. 2000;20:217-230. doi: 10.1023/A:1007049806660.;;Richman SA, et al. Development of a novel strategy for engineering high-affinity proteins by yeast display. Protein engineering, design & selection: PEDS. 2006;19:255-264. doi: 10.1093/protein/gzl008.;;Rodgers, D. T., et al. “Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.” Proceedings of the National Academy of Sciences 113.4 (2016):E459-E468.;;Shiina S, et al. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. Cancer Immunol Res. 2016;4:259-268. doi: 10.1158/2326-6066.CIR-15-0060.;;Shusta E. V., et al. Directed evolution of a stable scaffold for T-cell receptor engineering. Nature biotechnology 18, 754-759, doi:10.1038/77325 (2000).;;Shusta, E. V., et al. Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments. Nature biotechnology 16, 773-777, doi:10.1038/nbt0898-773 (1998).;;Singh SK, et al. Identification of a cancer stem cell in human brain tumors. Cancer research. 2003;63:5821-5828.;;Singh SK, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401. doi: 10.1038/nature03128.;;Son MJ, et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell stem cell. 2009;4:440-452. doi: 10.1016/j.stem.2009.03.003.;;Stupp R, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA: the journal of the American Medical Association. 2015;314:2535-2543. doi: 10.1001/jama.2015.16669.;;Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996, doi:352/10/987 (2005).;;Sugano, M, et al., Antibody Targeting of Doxorubicin-loaded Liposomes Suppresses the Growth and Metastatic Spread of Established Human Lung Tumor Xenografts in Severe Combined Immunodeficient Mice, Cancer Research 60, 6942-6949, Dec. 15, 2000.;;Sukhanova, A, et al. “Oriented conjugates of single-domain antibodies and quantum dots: toward a new generation of ultrasmall diagnostic nanoprobes.” Nanomedicine: nanotechnology, biology and medicine 8.4 (2012): 516-525.;;Suryadevara CM, et al. Are BiTEs the “missing link” in cancer therapy? Oncoimmunology. 2015;4:e1008339.;;Svendsen, C. N. et al. A new method for the rapid and long term growth of human neural precursor cells. J Neurosci Methods 85, 141-152, doi:S0165-0270(98)00126-5 (1998).;;Swanson, K. I. et al. Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection. Neurosurgery 76, 115-123, discussion 123-114, doi:10.1227/NEU.0000000000000622 (2015).;;Takahashi, M, et al. “Identification of a novel type II classical cadherin: rat cadherin19 is expressed in the cranial ganglia and Schwann cell precursors during development.” Developmental dynamics: an official publication of the American Association of Anatomists 232.1 (2005): 200-208.;;Tillotson BJ, et al. Cells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface display. Methods. 2013;60:27-37. doi: 10.1016/j.ymeth 2012.03.010.;;Valton, J. et al. “A Versatile Safeguard for Chimeric Antigen Receptor T-cell Immunotherapies” Nature Scientific Reports 8, Article No. 8972 (2018).;;Van De Broek, B., et al. “Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy.” ACS nano 5.6 (2011): 4319-4328.;;Vanantwerp JJ, et al. Fine affinity discrimination by yeast surface display and flow cytometry. Biotechnology progress. 2000;16:31-37. doi: 10.1021/bp990133s.;;Wang XX, et al. Mining a yeast library for brain endothelial cell-binding antibodies. Nature methods. 2007;4:143-145. doi: 10.1038/nmeth993.;;Wang XX, et al. The use of scFv-displaying yeast in mammalian cell surface selections. Journal of immunological nethods. 2005;304:30-42. doi: 10.1016/j.jim.2005.05.006.;;Weichert JP, et al. Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Science translational medicine. 2014;6:240ra275. doi: 10.1126/scitranslmed.3007646.;;Wrensch, M., et al. “Epidemiology of primary brain tumors: current concepts and review of the literature.” Neuro-oncology 4.4 (2002): 278-299.;;Wu, C-Y, et al. “Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.” Science 350.6258 (2015).;;Yang Y, et al. Targeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas. Proceedings of the National Academy of Sciences of the United States of America. 2015;112.E6525-6534. doi: 10.1073/pnas.1502648112.;;Yang Y, et al. In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis. European journal of nuclear medicine and molecular imaging. 2011;38:2066-2076. doi: 10.1007/s00259-011-1886-x.;;Zhang RR, et al. Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies. CNS Oncol. 2016;5:223-231. doi: 10.2217/cns-2016-0017.;;Zhang, Q., et al. (2016). Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunity, 44(5), 1034-1051.;;Zhao, X, et al. “MicroRNA-mediated control of oligodendrocyte differentiation.” Neuron 65.5 (2010). 612-626.;;Zhu, X, et al. “Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells.” Molecular cancer therapeutics 9.7 (2010): 2131-2141.;;Zorniak, M. et al. “Yeast display biopanning identifies human antibodies targeting glioblastoma stem-like cells.” Scientific reports 7.1 (2017): 1-12.;;Zorniak, M. et al. Differential expression of 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and neural lineage markers correlate with glioblastoma xenograft infiltration and patient survival. Clinical cancer research. 2012;18:3628-3636.;;Zorniak, M. et al. Identification of Glioblastoma Cancer Stem-Like Cell-Binding Human Antibodies via Yeast Expression Library Biopanning. Poster at PEGS Conference 2013. Boston, MA.;;Zorniak, M. et al. Identifying and Targeting Oligodendrocyte-Like Glioma Initiating Cells (GICs). Presentation at NTF Monday Night Seminar on Feb. 7, 2011.;;Zorniak, M. et al. Membrane Proteomics of Human Glioblastoma Cancer Stem-Like Cells. NIH National Graduate Student Research Conference Poster. 2012.",ACTIVE
484,WO,A1,WO 2018/031750 A1,129-270-663-499-649,2018-02-15,2018,US 2017/0046259 W,2017-08-10,US 201662373897 P;;US 201662404736 P;;US 201715673281 A,2016-08-11,ADDING AUTHENTICATABLE SIGNATURES TO ACKNOWLEDGEMENTS,"A method for wireless communication may include receiving a communication and determining an acknowledgement signature for an acknowledgment in response to the communication. The acknowledgment signature may allow for authentication with the transmitting wireless device. The acknowledgment signature may be based on a key shared with the wireless device. An acknowledgement frame ( e.g. , acknowledging reception of the communication) may then be sent to the transmitting wireless device. The content of the acknowledgement may be based on the acknowledgement signature. For example, the signature may be included in a frame control, duration, or address field. Determining the acknowledgement signature may include determining a unique signature based on information from the received communication ( e.g. , a cyclic redundancy check (CRC)), the shared key, and/or a hash function. In some cases, the acknowledgement frame may include an encryption header, and a message integrity check may be included as the acknowledgement signature.",QUALCOMM INC,ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;PATIL ABHISHEK PRAMOD;;KAKANI NAVEEN KUMAR;;CHO JAMES SIMON;;MALINEN JOUNI,,https://lens.org/129-270-663-499-649,Patent Application,yes,4,2,2,2,0,H04L9/3242;;H04L63/126;;H04L1/1671;;H04L9/3247;;H04W84/12;;H04W12/63;;H04W12/104;;H04W12/106;;H04W12/069;;H04L63/126;;H04L9/3242;;H04L1/16;;H04L1/1671;;H04W12/069;;H04W12/106;;H04W12/63;;H04W12/104;;G06F11/1004;;H03M13/29;;H04L1/1812;;H04L9/3247;;H04L63/0428;;H04L63/06;;H04L63/083,H04L9/32;;H04L1/16;;H04L29/06;;H04W12/06,,0,0,,,,PENDING
485,EP,A1,EP 3694875 A1,098-476-685-840-837,2020-08-19,2020,EP 18803799 A,2018-10-09,US 201762569834 P;;US 2018/0054952 W,2017-10-09,ANTIBODIES TARGETING GLIOBLASTOMA STEM-LIKE CELLS AND METHODS OF USE THEREOF,,WISCONSIN ALUMNI RES FOUND,ZORNIAK MICHAEL;;CLARK PAUL A;;CHO YONGKU PETER;;UMLAUF BENJAMIN J;;SHUSTA ERIC V;;KUO JOHN SHU-SHIN,,https://lens.org/098-476-685-840-837,Patent Application,yes,0,0,5,5,0,C07K16/18;;C07K16/30;;G01N33/57407;;A61K2039/505;;C07K2317/569;;A61P35/00;;A61K49/0058;;A61K2039/505;;C07K16/3053;;C07K2317/565;;C07K2317/622;;C07K2317/92;;G01N33/57407,C07K16/18;;A61K39/00;;A61P35/00;;C07K16/30;;G01N33/53,,0,0,,,,PENDING
486,US,A,US 6109994 A,114-424-470-473-746,2000-08-29,2000,US 76647796 A,1996-12-12,US 76647796 A,1996-12-12,"Gap jumping to seal structure, typically using combination of vacuum and non-vacuum environments","Portions (40 and 44) of a structure, such as a flat-panel device, are sealed together by a gap-jumping technique in which a sealing area (40S) of one portion is positioned near a matching sealing area (44S) of another portion such that a gap (48) at least partially separates the two sealing areas. The gap typically has an average height of 25 .mu.m or more. With the two portions of the structure so positioned, energy is initially transferred locally to material of a specified one of the portions along part of the gap while the two portions are in a non-vacuum environment to cause material of the two portions to bridge that part of the gap and partially seal the two portions together along the sealing areas. Energy is subsequently transferred locally to material of the specified portion of the structure along the remainder (48A) of the gap while the two portions are in a vacuum environment to cause material of the two portions to bridge the remainder of the gap and complete sealing of the two portions together along the gap. A laser (56) is typically employed in performing at least one of the gap-jumping steps.",CANDESCENT TECH CORP,CHO STEVEN T;;CONTE ALFRED S;;LUDWIG PAUL N;;SCHMID ANTHONY P;;FAHLEN THEODORE S;;PRESSLEY ROBERT J,CANDESCENT TECHNOLOGIES CORPORATION (1997-04-29);;CANDESCENT INTELLECTUAL PROPERTY SERVICES INC (2000-12-05);;CANON KABUSHIKI KAISHA (2006-08-01),https://lens.org/114-424-470-473-746,Granted Patent,yes,13,82,2,16,0,H01J9/261;;H01J9/261;;H01J2329/00;;H01J2329/00,H01J9/26,445/25,5,0,,,"Zimmerman et al, Glass Panel Alignment and Sealing for Flat Panel Displays, Viewgraph Presentation, NCAICM Workshop, Contract No. F33615 94 C 1415, Nov. 30 Dec. 2, 1994, 29 viewgraphs.;;Zimmerman et al, Glass Panel Alignment and Sealing for Flat Panel Displays, Contract Summary, ARPA High Def. Systs. Info. Exch. Conf., Apr. 30 May 3, 1995, 2 pp.;;Branst et al, The Challenge of Flat Panel Display Sealing, Semiconductor Int l , Jan. 1996, pp. 109 112.;;Jellison et al, Laser Materials Processing at Sandia National Labatories, Applications of Lasers and Electrooptics, Conference, Oct. 17 20, 1994, sponsored by Dept. of Energy, 10 pps.;;Tannas, Flat Panel Displays and CRTs (Van Nostrand Reinhold), Section 7.9, 1985, pp. 217 221.",EXPIRED
487,CO,A2,CO 2020000231 A2,186-187-265-327-606,2020-01-17,2020,CO 2020000231 A,2020-01-10,IB 2018054926 W;;US 201762531227 P;;US 201862682044 P,2017-07-11,Composiciones inmunogénicas que comprenden cea muc1 y tert,"La presente descripción proporciona: (a) polipéptidos de CEA inmunogénicos aislados; (b) moléculas de ácidos nucleicos aisladas que codifican (i) un polipéptido de CEA inmunogénico, (ii) un polipéptido de CEA inmunogénico y un polipéptido de MUC1 inmunogénico, (iii) un polipéptido de CEA inmunogénico y un polipéptido de TERT inmunogénico o (iv) un polipéptido de CEA inmunogénico, un polipéptido de MUC1 inmunogénico y un polipéptido de TERT inmunogénico; (c) composiciones que comprenden una molécula de ácidos nucleicos aislada; y (d) métodos relacionados con usos de los polipéptidos de CEA inmunogénicos, moléculas de ácidos nucleicos y composiciones.",PFIZER,CHO HELEN KIM;;BINDER JOSEPH JOHN;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;MARTINIC MARIANNE MARCELA ANDREA,,https://lens.org/186-187-265-327-606,Patent Application,no,0,0,19,20,0,A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/70;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/55555;;C12N2710/10343;;A61K38/00;;C12N9/1276;;C12Y207/07049;;C12N9/1276;;A61K38/00;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/55555;;A61K2039/70;;A61K2300/00;;C12Y207/07049;;C12N2710/10343;;A61K2039/53;;A61K2039/545;;A61K2039/54;;A61K2039/55555;;A61K39/00117;;C12N2710/10343;;A61K39/001182;;A61K2039/70;;A61K39/001157;;A61K2039/5256;;A61K38/00;;C07K14/705;;C12N9/1276;;C12Y207/07049,A61K39/00;;C12N7/00,,0,0,,,,PENDING
488,EP,A3,EP 0415786 A3,181-286-725-787-489,1993-04-21,1993,EP 90309556 A,1990-08-31,US 40114689 A,1989-08-31,INFORMATION STORAGE AND PROCESSING,"Data and directories are separated and stored on separate parts of an optical disk. Directories are on the inner tracks and data are on the outer tracks, in a first format. Data and directories are written from magnetic disk storage in a different second specific format that is determined by a particular operating system used by an information processor. A medical information processing system is provided with an external magnetic disk storage and the optical disk.  ",THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;;HITACHI MAXELL LTD.,"HUANG, HAN K.;;MORIOKA, CRAIG A.;;RATIB, OSMAN;;CHO, PAUL N.S.;;HO, BRUCE K.T.;;SONOBE, TAKEO;;SHINAGAWA, TORU",,https://lens.org/181-286-725-787-489,Search Report,yes,4,0,9,9,0,G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20;;G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20,G06F3/08;;G06F12/00;;G06F17/30;;G11B27/32;;G16H30/20,,1,0,,,"IBM TECHNICAL DISCLOSURE BULLETIN. vol. 15, no. 2, July 1972, NEW YORK US page 693 R.H. VAN BILDERBEEK ET AL : 'Device-Independent conversion program'",EXPIRED
489,WO,A1,WO 2019/012371 A1,001-555-381-590-257,2019-01-17,2019,IB 2018054926 W,2018-07-03,US 201762531227 P;;US 201862682044 P,2017-07-11,IMMUNOGENIC COMPOSITIONS COMPRISING CEA MUC1 AND TERT,"The present disclosure provides: (a) isolated immunogenic CEA polypeptides; (b) isolated nucleic acid molecules encoding (i) an immunogenic CEA polypeptide, (ii) an immunogenic CEA polypeptide and an immunogenic MUC1 polypeptide, (iii) an immunogenic CEA polypeptide and an immunogenic TERT polypeptide, or (iv) an immunogenic CEA polypeptide, an immunogenic MUC1 polypeptide, and an immunogenic TERT polypeptide; (c) compositions comprising an isolated nucleic acid molecule; and (d) methods relating to uses of the immunogenic CEA polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;MARTINIC MARIANNE MARCELA ANDREA,,https://lens.org/001-555-381-590-257,Patent Application,yes,30,3,19,20,93,A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/70;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/55555;;C12N2710/10343;;A61K38/00;;C12N9/1276;;C12Y207/07049;;C12N9/1276;;A61K38/00;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/55555;;A61K2039/70;;A61K2300/00;;C12Y207/07049;;C12N2710/10343;;A61K2039/53;;A61K2039/545;;A61K2039/54;;A61K2039/55555;;A61K39/00117;;C12N2710/10343;;A61K39/001182;;A61K2039/70;;A61K39/001157;;A61K2039/5256;;A61K38/00;;C07K14/705;;C12N9/1276;;C12Y207/07049,A61K39/00;;C12N7/00,,26,22,017-025-699-040-442;;038-162-800-298-708;;114-677-982-144-79X;;036-458-467-729-438;;135-122-897-849-384;;019-016-461-231-773;;009-620-944-399-00X;;018-052-579-451-52X;;042-579-622-138-602;;135-020-829-679-590;;019-947-283-191-566;;019-016-461-231-773;;068-584-249-522-736;;043-492-354-471-517;;001-927-557-674-695;;035-004-930-426-63X;;084-398-389-111-34X;;124-505-688-379-135;;067-767-763-896-859;;013-528-468-895-549;;001-477-109-701-519;;164-409-638-350-634,26374823;;10.18632/oncotarget.5181;;pmc4741610;;10.1038/mt.2010.289;;pmc3098631;;21189474;;18483372;;10.1158/1078-0432.ccr-08-0126;;pmc2673097;;10.1097/qai.0b013e3181651b9d;;18209683;;10.1089/vim.2010.0056;;pmc3034638;;21319978;;10.1517/14712598.5.5.627;;15934839;;16380176;;10.1016/j.tibtech.2005.12.006;;10.1099/vir.0.83428-0;;pmc2885027;;18343847;;10.1089/hum.2008.188;;19419274;;21602908;;pmc3084703;;10.1371/journal.pone.0018556;;10.1038/sj.mt.6300142;;17375065;;10.1517/14712598.5.5.627;;15934839;;pmc165450;;10.1093/nar/gkg003;;12520041;;10.2144/000112243;;16989088;;215915;;10.1038/277108a0;;2558526;;10.1007/978-1-4757-2046-4_22;;1985215;;pmc240552;;10.1128/jvi.65.1.532-536.1991;;17606980;;10.1093/intimm/dxm057;;17640779;;10.1016/j.vaccine.2007.06.009;;15985318;;10.1016/j.vaccine.2005.05.026;;pmc6383519;;10.1007/s00262-013-1494-7;;24233342;;10.1097/cji.0b013e3181aee1b6;;19561534,"GABITZSCH ELIZABETH S ET AL: ""The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic"", ONCOTARGET, IMPACT JOURNALS LLC, UNITED STATES, vol. 6, no. 31, 13 October 2015 (2015-10-13), pages 31344 - 31359, XP002763347, ISSN: 1949-2553;;RITTIG SUSANNE M ET AL: ""Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients."", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY MAY 2011, vol. 19, no. 5, May 2011 (2011-05-01), pages 990 - 999, XP002787196, ISSN: 1525-0024;;ANONYMOUS: ""Archive History for NCT03169764"", 19 June 2017 (2017-06-19), XP055531392, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03169764?V_3=View#StudyPageTop> [retrieved on 20181207];;GULLEY JAMES L ET AL: ""Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma"", CLINICAL CANCER RESE, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, no. 10, 15 May 2008 (2008-05-15), pages 3060 - 3069, XP009104603, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-08-0126;;HUANG, Y.; Z. CHEN ET AL.: ""Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant"", J ACQUIR IMMUNE DEFIC SYNDR, vol. 47, no. 4, 2008, pages 403 - 411;;XU, K.; Z. Y. LING ET AL.: ""Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus"", VIRAL IMMUNOL, vol. 24, no. 1, 2011, pages 45 - 56;;SZYMCZAK, A. L.; D. A. VIGNALI: ""Development of 2A peptide-based strategies in the design of multicistronic vectors"", EXPERT OPIN BIOL THER, vol. 5, no. 5, 2005, pages 627 - 638, XP055378453, DOI: doi:10.1517/14712598.5.5.627;;DE FELIPE, P.; G. A. LUKE ET AL.: ""E unum pluribus: multiple proteins from a self-processing polyprotein"", TRENDS BIOTECHNOL, vol. 24, no. 2, 2006, pages 68 - 75, XP025052212, DOI: doi:10.1016/j.tibtech.2005.12.006;;LUKE, G. A.; P. DE FELIPE ET AL.: ""Occurrence, function and evolutionary origins of '2A-like' sequences in virus genomes"", J GEN VIROL, vol. 89, 2008, pages 1036 - 1042, XP002552736, DOI: doi:10.1099/vir.0.83428-0;;IBRAHIMI, A.; G. VANDE VELDE ET AL.: ""Highly efficient multicistronic lentiviral vectors with peptide 2A sequences"", HUM GENE THER, vol. 20, no. 8, 2009, pages 845 - 860, XP055162441, DOI: doi:10.1089/hum.2008.188;;KIM, J. H.; S. R. LEE ET AL.: ""High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice"", PLOS ONE, vol. 6, no. 4, 2011, pages e18556, XP055175691, DOI: doi:10.1371/journal.pone.0018556;;FANG, J.; S. YI ET AL.: ""An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo"", MOL THER, vol. 15, no. 6, 2007, pages 1153 - 1159, XP002560535, DOI: doi:10.1038/SJ.MT.6300142;;ANDREA L. SZYMCZAK; DARRIO AA VIGNALI: ""Development of 2A peptide-based strategies in the design of multicistronic vectors"", EXPERT OPINION BIOL. THER., vol. 5, no. 5, 2005, pages 627 - 638, XP055378453, DOI: doi:10.1517/14712598.5.5.627;;BONNAL, S.; C. BOUTONNET ET AL.: ""IRESdb: the Internal Ribosome Entry Site database"", NUCLEIC ACIDS RES, vol. 31, no. 1, 2003, pages 427 - 428;;BOCHKOV, Y. A.; A. C. PALMENBERG: ""Translational efficiency of EMCV IRES in bicistronic vectors is dependent upon IRES sequence and gene location"", BIOTECHNIQUES, vol. 41, no. 3, 2006, pages 283 - 284,286,288, XP001536676, DOI: doi:10.2144/000112243;;MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108 - 114;;KIT, ADV. EXP. MED. BIOL., vol. 215, 1989, pages 219 - 236;;POZNANSKY, J. VIROL., vol. 65, 1991, pages 532 - 536;;""Liposomes: A Practical Approach,"", 1990, IRL PRESS;;OKAZAKI T ET AL., INTERNATIONAL IMMUNOLOGY, vol. 19, no. 7, 2007, pages 813 - 824;;SUNSHINE J ET AL., CURR OPIN PHARMACOL., vol. 23, August 2015 (2015-08-01), pages 32 - 8;;""Genbank"", Database accession no. AC_000011.1;;SHARPE, M. ET AL.: ""P. Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery"", VACCINE, vol. 25, no. 34, 2007, pages 6392 - 98, XP022169852, DOI: doi:10.1016/j.vaccine.2007.06.009;;ROBERTS LK ET AL.: ""Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device"", VACCINE, vol. 23, no. 40, 2005, pages 4867 - 78, XP005063270, DOI: doi:10.1016/j.vaccine.2005.05.026;;JOCHEMS C ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 63, 2014, pages 161 - 174;;CONFORTI A ET AL., J IMMUNOTHER, vol. 32, 2009, pages 744 - 754",PENDING
490,CN,A,CN 111065408 A,050-315-025-711-379,2020-04-24,2020,CN 201880057887 A,2018-07-03,US 201762531227 P;;US 201862682044 P;;IB 2018054926 W,2017-07-11,IMMUNOGENIC COMPOSITIONS COMPRISING CEA MUC1 AND TERT,"The present disclosure provides: (a) isolated immunogenic CEA polypeptides; (b) isolated nucleic acid molecules encoding (i) an immunogenic CEA polypeptide, (ii) an immunogenic CEA polypeptide and animmunogenic MUC1 polypeptide, (iii) an immunogenic CEA polypeptide and an immunogenic TERT polypeptide, or (iv) an immunogenic CEA polypeptide, an immunogenic MUC1 polypeptide, and an immunogenic TERTpolypeptide; (c) compositions comprising an isolated nucleic acid molecule; and (d) methods relating to uses of the immunogenic CEA polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;MARTINIC MARIANNE MARCELA ANDREA,,https://lens.org/050-315-025-711-379,Patent Application,no,7,0,19,20,0,A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/70;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/55555;;C12N2710/10343;;A61K38/00;;C12N9/1276;;C12Y207/07049;;C12N9/1276;;A61K38/00;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/55555;;A61K2039/70;;A61K2300/00;;C12Y207/07049;;C12N2710/10343;;A61K2039/53;;A61K2039/545;;A61K2039/54;;A61K2039/55555;;A61K39/00117;;C12N2710/10343;;A61K39/001182;;A61K2039/70;;A61K39/001157;;A61K2039/5256;;A61K38/00;;C07K14/705;;C12N9/1276;;C12Y207/07049,A61K39/00;;C12N7/00,,3,0,,,"ELIZABETH S. GABITZSCH等: ""The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic"";;JAMES L. GULLEY等: ""Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma"";;SUSANNE M RITTIG等: ""Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients""",DISCONTINUED
491,US,B2,US 8849373 B2,091-266-473-388-72X,2014-09-30,2014,US 11946408 A,2008-05-12,US 11946408 A;;US 91763707 P,2007-05-11,Method and apparatus for real-time 3D target position estimation by combining single x-ray imaging and external respiratory signals,A method and system are disclosed for estimating internal position information of a target in real-time based on a single gantry-mounted x-ray imager and a respiratory signal. The x-ray imaging is done periodically to limit radiation dosage. Initial parameters for the estimation model are determined in a pre-treatment session using four dimensional computed tomography (4D CT) in combination with a respiratory signal acquired from the patient. The model parameters are updated during treatment based on the periodic x-ray image data and the respiratory signal.,KEALL PAUL J;;SAWANT AMIT;;MAXIM PETER;;SUH YELIN;;XING LEI;;LOO JR BILLY W;;CHO BYUNG CHUL;;UNIV STANFORD,KEALL PAUL J;;SAWANT AMIT;;MAXIM PETER;;SUH YELIN;;XING LEI;;LOO JR BILLY W;;CHO BYUNG CHUL,,https://lens.org/091-266-473-388-72X,Granted Patent,yes,7,7,2,2,0,A61B6/032;;A61B6/032;;A61B5/08;;A61B5/08;;A61B6/06;;A61B6/06;;A61B6/12;;A61B6/12;;A61B6/541;;A61B6/541,A61B5/00;;A61B5/08;;A61B6/00;;A61B6/03;;A61B6/06;;A61B6/12,600/424;;600/425;;600/426;;600/427;;600/428,0,0,,,,ACTIVE
492,PH,A1,PH 12020500087 A1,128-832-818-032-281,2020-09-14,2020,PH 12020500087 A,2020-01-10,US 201762531227 P;;US 201862682044 P;;IB 2018054926 W,2017-07-11,IMMUNOGENIC COMPOSITIONS COMPRISING CEA MUC1 AND TERT,"The present disclosure provides: (a) isolated immunogenic CEA polypeptides; (b) isolated nucleic acid molecules encoding (i) an immunogenic CEA polypeptide, (ii) an immunogenic CEA polypeptide and an immunogenic MUC1 polypeptide, (iii) an immunogenic CEA polypeptide and an immunogenic TERT polypeptide, or (iv) an immunogenic CEA polypeptide, an immunogenic MUC1 polypeptide, and an immunogenic TERT polypeptide; (c) compositions comprising an isolated nucleic acid molecule; and (d) methods relating to uses of the immunogenic CEA polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;MARTINIC MARIANNE MARCELA ANDREA,,https://lens.org/128-832-818-032-281,Patent Application,no,0,0,19,20,0,A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/70;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/55555;;C12N2710/10343;;A61K38/00;;C12N9/1276;;C12Y207/07049;;C12N9/1276;;A61K38/00;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/55555;;A61K2039/70;;A61K2300/00;;C12Y207/07049;;C12N2710/10343;;A61K2039/53;;A61K2039/545;;A61K2039/54;;A61K2039/55555;;A61K39/00117;;C12N2710/10343;;A61K39/001182;;A61K2039/70;;A61K39/001157;;A61K2039/5256;;A61K38/00;;C07K14/705;;C12N9/1276;;C12Y207/07049,A61K39/00;;C12N7/00,,0,0,,,,PENDING
493,PE,A1,PE 20200613 A1,199-863-998-826-739,2020-03-11,2020,PE 2020000050 A,2018-07-03,US 201762531227 P;;US 201862682044 P;;IB 2018054926 W,2017-07-11,COMPOSICIONES INMUNOGENICAS,"La presente descripcion proporciona: (a) polipeptidos de CEA inmunogenicos aislados; (b) moleculas de acidos nucleicos aisladas que codifican (i) un polipeptido de CEA inmunogenico, (ii) un polipeptido de CEA inmunogenico y un polipeptido de MUC1 inmunogenico, (iii) un polipeptido de CEA inmunogenico y un polipeptido de TERT inmunogenico o (iv) un polipeptido de CEA inmunogenico, un polipeptido de MUC1 inmunogenico y un polipeptido de TERT inmunogenico; (c) composiciones que comprenden una molecula de acidos nucleicos aislada; y (d) metodos relacionados con usos de los polipeptidos de CEA inmunogenicos, moleculas de acidos nucleicos y composiciones",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;MARTINIC MARIANNE MARCELA ANDREA,,https://lens.org/199-863-998-826-739,Patent Application,no,0,0,19,20,0,A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/70;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/55555;;C12N2710/10343;;A61K38/00;;C12N9/1276;;C12Y207/07049;;C12N9/1276;;A61K38/00;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/55555;;A61K2039/70;;A61K2300/00;;C12Y207/07049;;C12N2710/10343;;A61K2039/53;;A61K2039/545;;A61K2039/54;;A61K2039/55555;;A61K39/00117;;C12N2710/10343;;A61K39/001182;;A61K2039/70;;A61K39/001157;;A61K2039/5256;;A61K38/00;;C07K14/705;;C12N9/1276;;C12Y207/07049,A61K39/00;;C12N7/00,,0,0,,,,PENDING
494,EP,A1,EP 3651792 A1,132-159-409-588-331,2020-05-20,2020,EP 18780215 A,2018-07-03,US 201762531227 P;;US 201862682044 P;;IB 2018054926 W,2017-07-11,IMMUNOGENIC COMPOSITIONS COMPRISING CEA MUC1 AND TERT,,PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;MARTINIC MARIANNE MARCELA ANDREA,,https://lens.org/132-159-409-588-331,Patent Application,yes,0,0,19,20,0,A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/70;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/55555;;C12N2710/10343;;A61K38/00;;C12N9/1276;;C12Y207/07049;;C12N9/1276;;A61K38/00;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/55555;;A61K2039/70;;A61K2300/00;;C12Y207/07049;;C12N2710/10343;;A61K2039/53;;A61K2039/545;;A61K2039/54;;A61K2039/55555;;A61K39/00117;;C12N2710/10343;;A61K39/001182;;A61K2039/70;;A61K39/001157;;A61K2039/5256;;A61K38/00;;C07K14/705;;C12N9/1276;;C12Y207/07049,A61K39/00;;C12N7/00,,0,0,,,,DISCONTINUED
495,CN,A,CN 101605501 A,147-597-042-946-052,2009-12-16,2009,CN 200780047507 A,2007-12-21,IB 2007004061 W;;FR 0611198 A,2006-12-21,Vertebral support device,"A vertebral support device ( 1 ) is disclosed, which in various embodiments comprises at least two osseous anchoring implants ( 2 ), each designed to be anchored to a vertebra, and at least one linking element ( 3 ) fixed to the osseous anchoring implants ( 2 ) by fasteners ( 20 ) that maintain a fixed angle between the longitudinal axis (L) of the linking element ( 3 ) passing through rigid elements ( 34 ) of the linking element ( 3 ) and the insertion axis (DV) of the implants ( 2 ). The linking element ( 3 ) includes at least one elastic dampening element ( 31 ) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element ( 31 ) accommodates the stresses imposed on the linking element ( 3 ) during movement of the vertebrae and tends to return the support device ( 1 ) to its normal configuration.",LDR MEDICAL,HERVE CHATAIGNER;;HUGO SANTOS BENITEZ;;DANIEL BRADLEY WILLIAM;;HENRY CHO PAUL;;JAMES DAVIS REGINALD;;ZHONGQIANG CHEN;;ALEXANDRE JODAITIS,,https://lens.org/147-597-042-946-052,Patent Application,no,0,2,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,0,0,,,,INACTIVE
496,US,A1,US 2008/0281192 A1,095-670-817-314-629,2008-11-13,2008,US 11946408 A,2008-05-12,US 11946408 A;;US 91763707 P,2007-05-11,METHOD AND APPARATUS FOR REAL-TIME TARGET POSITION ESTIMATION BY COMBINING X-RAY AND EXTERNAL RESPIRATORY SIGNALS,A method and system are disclosed for estimating internal position information of a target in real-time based on a single gantry-mounted x-ray imager and a respiratory signal. The x-ray imaging is done periodically to limit radiation dosage. Initial parameters for the estimation model are determined in a pre-treatment session using four dimensional computed tomography (4D CT) in combination with a respiratory signal acquired from the patient. The model parameters are updated during treatment based on the periodic x-ray image data and the respiratory signal.,KEALL PAUL J;;SAWANT AMIT;;MAXIM PETER;;SUH YELIN;;XING LEI;;LOO JR BILLY W;;CHO BYUNG CHUL,KEALL PAUL J;;SAWANT AMIT;;MAXIM PETER;;SUH YELIN;;XING LEI;;LOO JR BILLY W;;CHO BYUNG CHUL,,https://lens.org/095-670-817-314-629,Patent Application,yes,7,18,2,2,0,A61B6/032;;A61B6/032;;A61B5/08;;A61B5/08;;A61B6/06;;A61B6/06;;A61B6/12;;A61B6/12;;A61B6/541;;A61B6/541,A61B6/00,600/426;;378/20,0,0,,,,ACTIVE
497,US,A1,US 2019/0016775 A1,102-016-990-768-371,2019-01-17,2019,US 201816029878 A,2018-07-09,US 201816029878 A;;US 201762531227 P;;US 201862682044 P,2017-07-11,Immunogenic Compositions,"The present disclosure provides: (a) isolated immunogenic CEA polypeptides; (b) isolated nucleic acid molecules encoding (i) an immunogenic CEA polypeptide, (ii) an immunogenic CEA polypeptide and an immunogenic MUC1 polypeptide, (iii) an immunogenic CEA polypeptide and an immunogenic TERT polypeptide, or (iv) an immunogenic CEA polypeptide, an immunogenic MUC1 polypeptide, and an immunogenic TERT polypeptide; (c) compositions comprising an isolated nucleic acid molecule; and (d) methods relating to uses of the immunogenic CEA polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;MARTINIC MARIANNE MARCELA ANDREA,,https://lens.org/102-016-990-768-371,Patent Application,yes,0,0,19,20,93,A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/70;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/55555;;C12N2710/10343;;A61K38/00;;C12N9/1276;;C12Y207/07049;;C12N9/1276;;A61K38/00;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/55555;;A61K2039/70;;A61K2300/00;;C12Y207/07049;;C12N2710/10343;;A61K2039/53;;A61K2039/545;;A61K2039/54;;A61K2039/55555;;A61K39/00117;;C12N2710/10343;;A61K39/001182;;A61K2039/70;;A61K39/001157;;A61K2039/5256;;A61K38/00;;C07K14/705;;C12N9/1276;;C12Y207/07049,C07K14/705;;C12N9/12,,0,0,,,,DISCONTINUED
498,TN,A1,TN SN03055 A1,103-673-631-673-465,2005-12-23,2005,TN SN03055 A,2003-07-08,US 26868301 P;;US 31236101 P,2001-02-15,3-(4-AMIDOPYRROL -2-YLMETHLIDENE)-2- INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,THE PRESENT INVENTION RELATES TO PYRROLE SUBSTITUTED 2- INDOLINONE COMPOUNDS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS WHICH MODULATE THE ACTIVITY OF PROTEIN KINASES AND THEREFORE ARE EXPECTED TO BE USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER.,SUGEN INC;;UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;CHAEL A;;VOJKOVSKY THOMAS;;JIN QINGWU;;HERRINGTON PAUL MATTHEW,,https://lens.org/103-673-631-673-465,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4166;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,PENDING
499,AU,A1,AU 2018/300295 A1,015-198-549-859-72X,2020-01-23,2020,AU 2018/300295 A,2018-07-03,US 201762531227 P;;US 201862682044 P;;IB 2018054926 W,2017-07-11,Immunogenic compositions comprising CEA MUC1 and TERT,"The present disclosure provides: (a) isolated immunogenic CEA polypeptides; (b) isolated nucleic acid molecules encoding (i) an immunogenic CEA polypeptide, (ii) an immunogenic CEA polypeptide and an immunogenic MUC1 polypeptide, (iii) an immunogenic CEA polypeptide and an immunogenic TERT polypeptide, or (iv) an immunogenic CEA polypeptide, an immunogenic MUC1 polypeptide, and an immunogenic TERT polypeptide; (c) compositions comprising an isolated nucleic acid molecule; and (d) methods relating to uses of the immunogenic CEA polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;MARTINIC MARIANNE MARCELA ANDREA,,https://lens.org/015-198-549-859-72X,Patent Application,no,0,0,19,20,0,A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/70;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/55555;;C12N2710/10343;;A61K38/00;;C12N9/1276;;C12Y207/07049;;C12N9/1276;;A61K38/00;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/55555;;A61K2039/70;;A61K2300/00;;C12Y207/07049;;C12N2710/10343;;A61K2039/53;;A61K2039/545;;A61K2039/54;;A61K2039/55555;;A61K39/00117;;C12N2710/10343;;A61K39/001182;;A61K2039/70;;A61K39/001157;;A61K2039/5256;;A61K38/00;;C07K14/705;;C12N9/1276;;C12Y207/07049,A61K39/00;;C12N7/00,,0,0,,,,DISCONTINUED
500,TW,A,TW 201920674 A,021-293-949-350-87X,2019-06-01,2019,TW 107123509 A,2018-07-06,US 201762531227 P;;US 201862682044 P,2017-07-11,Immunogenic compositions,"The present disclosure provides: (a) isolated immunogenic CEA polypeptides; (b) isolated nucleic acid molecules encoding (i) an immunogenic CEA polypeptide, (ii) an immunogenic CEA polypeptide and an immunogenic MUC1 polypeptide, (iii) an immunogenic CEA polypeptide and an immunogenic TERT polypeptide, or (iv) an immunogenic CEA polypeptide, an immunogenic MUC1 polypeptide, and an immunogenic TERT polypeptide; (c) compositions comprising an isolated nucleic acid molecule; and (d) methods relating to uses of the immunogenic CEA polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;MARTINIC MARIANNE MARCELA ANDREA,,https://lens.org/021-293-949-350-87X,Patent of Addition,no,0,0,19,20,0,A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/70;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/55555;;C12N2710/10343;;A61K38/00;;C12N9/1276;;C12Y207/07049;;C12N9/1276;;A61K38/00;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/55555;;A61K2039/70;;A61K2300/00;;C12Y207/07049;;C12N2710/10343;;A61K2039/53;;A61K2039/545;;A61K2039/54;;A61K2039/55555;;A61K39/00117;;C12N2710/10343;;A61K39/001182;;A61K2039/70;;A61K39/001157;;A61K2039/5256;;A61K38/00;;C07K14/705;;C12N9/1276;;C12Y207/07049,C12N15/13;;A61K39/395;;A61P35/00;;C07H21/04;;C07K16/32;;C12N15/64,,0,0,,,,PENDING
501,US,B1,US 6416375 B1,084-761-611-156-148,2002-07-09,2002,US 63237200 A,2000-08-03,US 63237200 A;;US 76647796 A,1996-12-12,Sealing of plate structures,"
    A pair of plate structures (  40  and  44  ), such as a baseplate structure and a faceplate structure of a flat-panel display, are sealed to each other by first attaching the plate structures to each other, typically at multiple attachment locations, in a non-vacuum environment. The plate structures are then hermetically sealed to each other, typically through an outer wall (  44  ) or/and typically by gap jumping, in a vacuum environment. 
",CANDESCENT TECH CORP;;CANDESCENT INTELLECTUAL PROP,CHO STEVEN T;;CONTE ALFRED S;;LUDWIG PAUL N;;SCHMID ANTHONY P;;FAHLEN THEODORE S;;PRESSLEY ROBERT J,CANDESCENT INTELLECTUAL PROPERTY SERVICES INC (2000-08-03);;CANON KABUSHIKI KAISHA (2006-08-01),https://lens.org/084-761-611-156-148,Granted Patent,yes,15,37,2,16,0,H01J9/261;;H01J9/261;;H01J2329/00;;H01J2329/00,H01J9/26,445/25,5,0,,,"Branst et al, ""The Challenge of Flat Panel Display Sealing,"" Semiconductor Int'l, Jan. 1996, pp. 109-112.;;Jellison et al, ""Laser Materials Processing at Sandia National Labatories,"" Applications of Lasers and Electrooptics, Conference, Oct. 17-20, 1994, sponsored by Dept. of Energy, 10 pps.;;Tannas, Flat-Panel Displays and CRTs (Van Nostrand Reinhold), Section 7.9, 1985, pp. 217-221.;;Zimmerman et al, ""Glass Panel Alignment and Sealing for Flat-Panel Displays,"" Viewgraph Presentation, NCAICM Workshop, Contract No. F33615-94-C-1415, Nov. 30-Dec. 2, 1994, 29 viewgraphs.;;Zimmerman et al, ""Glass Panel Alignment and Sealing for Flat-Panel Displays,"" Contract Summary, ARPA High Def. Systs. Info. Exch. Conf., Apr. 30-May 3, 1995, 2 pp.",EXPIRED
502,US,B2,US 9398329 B2,067-713-319-611-657,2016-07-19,2016,US 201113521762 A,2011-01-12,US 201113521762 A;;US 29447610 P;;US 2011/0021030 W,2010-01-12,Video management and control in home multimedia network,"A system may include a video link and a hybrid link that connects a transmitting device to the receiving device, and at least one intermediate hop between the transmitting device and the receiving device. The intermediate hop may be configured to relay video content from the video source to the video sink through the hybrid link using one or more data relay modes. The hybrid link may be configured to perform hybrid link control signaling (HLCS) to manage a physical layer of the hybrid link. The video link between the video source and the video sink may be configured to transmit a video stream the from video source to the video sink over one or more video lanes. A video link training may be implemented for the video link and the hybrid link.",LEE DONGYUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;KIM BYOUNG WOON;;HENINWOLF PAUL DANIEL;;KIM SANGWAN;;CHO SUKJAE;;LATTICE SEMICONDUCTOR CORP,LEE DONGYUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;KIM BYOUNG WOON;;HENINWOLF PAUL DANIEL;;KIM SANGWAN;;CHO SUKJAE,SYNERCHIP CO. LTD (2013-02-04);;LATTICE SEMICONDUCTOR CORPORATION (2015-05-13);;SILICON IMAGE INC (2012-10-08);;UNIVERSAL CONNECTIVITY TECHNOLOGIES INC (2021-11-16),https://lens.org/067-713-319-611-657,Granted Patent,yes,95,1,22,22,0,G06F13/4286;;G06F13/4286;;G06F13/4286;;G09G2370/047;;G09G2370/047;;G09G2370/12;;G09G2370/12;;H04N21/43615;;H04N21/43615;;H04L12/2838;;H04L12/2838;;H04L12/2838;;H04L2012/2849;;H04L2012/2849;;H04L2012/2849;;H04N21/43615;;H04N21/43632;;H04N21/43632;;H04N21/43635;;H04N21/43635;;H04N21/63;;H04N21/63,H04N21/436;;G06F13/42;;H04L12/28;;H04N21/4363;;H04N21/63,,39,0,,,"Hirofuchi T. et al., ""USB/IP-a Peripheral Bus Extension for Device Sharing over IP Network,"" Proceedings of the Usenix Annual Technical Conference, Jan. 1, 2005, pp. 47-60, XP007901448.;;Supplementary European Search Report completed Nov. 4, 2013, in European Patent Application No. EP11733339, 9 pages.;;Universal Serial Bus 3.0 Specification (including errata and ECNs through May 1, 2011), Revision 1.0, Hewlett Packard Company et al., Jun. 6, 2011, 531 pages.;;Universal Serial Bus Specification, Revision 2.0, Compaq Computer Corporation et al., Apr. 27, 2000, 650 pages.;;""Super Booster Plus for HDMI 1.3 User Manual,"" www.gefen.com, Aug. 24, 2009, pp. 1-9, XP002715620, retrieved from the Internet: URL:https://web.archive.org/web/20090824082648/http://www.gefen.com/pdf/EXT-HDMI1.3-141SBP.pdf [retrieved on Oct. 28, 2013].;;Extended European Search Report dated Oct. 29, 2013, in European Patent Application No. 11733338.5, 14 pages.;;""Electrical Transient Immunity for Power-Over-Ethernet,"" Application Report, SLVA233A, Texas Instruments, Apr. 2006, Revised Aug. 2006, 20 pages.;;""Introduction to DiiVA Designed Specifically for Home Entertainment Networking,"" DiiVA Licensing LLC, 2010, 4 pages.;;Decision on Rejection dated Feb. 5, 2013 (+ English translation), in Chinese Patent Application No. 200980100976.3, 16 pages.;;Digital Visual Interface DVI Revision 1.0, Digital Display Working Group, Apr. 2, 1999, 76 pages.;;DiiVA Specification 1.1 Draft A, DiiVA Promoters Group, distribution date Jan. 7, 2010, 188 pages.;;DisplayPort Ver. 1.2 Overview, DisplayPort Developer Conference, Taipei, Dec. 6, 2010, 33 pages.;;High-Definition Multimedia Interface Specification Version 1.3, HDMI Licensing, LLC, Jun. 22, 2006, 237 pages.;;International Search Report and Written Opinion in International Patent Application No. PCT/US2009/038077.;;International Search Report and Written Opinion of the International Searching Authority dated Jun. 29, 2010, in International Patent Application No. PCT/US2009/067744, 10 pages.;;International Search Report and Written Opinion of the International Searching Authority dated Sep. 27, 2011, in International Patent Application No. PCT/US11/21031.;;International Search Report and Written Opinion of the International Searching Authority dated Sep. 28, 2011, in International Patent Application No. PCT/US2011/021030.;;Microprocessor and Microcomputer Standards Committee of the IEEE Computer Society, ""IEEE P1394r Draft 1 Draft Standard for High Performance Serial Bus"", 2007.;;Office Action dated Jan. 31, 2012 (+ English translation), in Chinese Patent Application No. 200980100976.3, 21 pages.;;Office Action dated Jul. 24, 2013 (+ English translation), in Taiwan Patent Application No. 098142426, 12 pages.;;Office Action dated Jul. 31, 2012 (+ English translation), in Taiwan Patent Application No. 098110096, 35 pages.;;Office Action dated Mar. 30, 2012 (+ English translation), in Chinese Patent Application No. 200980105447.2, 16 pages.;;Office Action dated Nov. 29, 2012 (+ English translation), in Chinese Patent Application No. 200980105447.2, 8 pages.;;Office Action dated Sep. 13, 2012 (+ English translation), in Chinese Patent Application No. 200980100976.3, 21 pages.;;Office Action for Patent Application No. 2011-501975 (Jul. 22, 2013).;;Office Action mailed Feb. 1, 2013, in U.S. Appl. No. 12/636,063, 9 pages.;;Chinese First Office Action, Chinese Application No. 201180005935.3, Aug. 27, 2014, 14 pages.;;Japanese Office Action, Japanese Application No. 2012-549056, Jul. 8, 2014, 5 pages (with English Summary).;;Japanese Office Action, Japanese Application No. 2012-549055, Oct. 7, 2014, 6 pages (with English Summary).;;Chinese First Office Action, Chinese Application No. 201180005909.0, Dec. 17, 2014, 19 pages.;;Chinese Second Office Action, Chinese Application No. 201180005935.3, May 5, 2015, 17 pages.;;European Examination Report, European Application No. 11733339.3, Feb. 11, 2015, 5 pages.;;Anonymous: ""HDMI 1.4: HDMI Ethernet Channel,"" Nov. 26, 2009, pp. 1-3, [Online] [Retrieved on Jan. 30, 2015] Retrieved from the Internet<URL:https://web.archive.org/web/20091126015121/http://www.hdmi.org/manufacturer/hdmi-1-4/hec.aspx>.;;European Summons to Attend Oral Proceedings Pursuant to Rule 115(1) EPC, European Application No. 11733339.3, Dec. 3, 2015, 5 pages.;;""Differential Signaling,"" Wikipedia, Last Modified Sep. 29, 2014, [Online] [Retrieved on Oct. 8, 2014] Retrieved from the Internet.;;""High-Pass Filter,"" Wikipedia, Last Modified Jun. 4, 2014, [Online] [Retrieved on Oct. 8, 2014] Retrieved from the Internet .;;Chinese Second Office Action, Chinese Application No. 201180005909.0, Oct. 29, 2015, 19 pages.;;Chinese Third Office Action, Chinese Application No. 201180005935.3, Nov. 18, 2015, 10 pages.;;Chinese Third Office Action, Chinese Application No. 201180005909.0, May 6, 2016, 9 pages (with concise explanation of relevance).",ACTIVE
503,US,A1,US 2020/0354472 A1,120-477-951-134-514,2020-11-12,2020,US 201816754677 A,2018-10-09,US 201816754677 A;;US 201762569834 P;;US 2018/0054952 W,2017-10-09,ANTIBODIES TARGETING GLIOBLASTOMA STEM-LIKE CELLS AND METHODS OF USE THEREOF,The present invention provides antibodies that target glioblastoma stem-like cells and methods and kits for their use.,WISCONSIN ALUMNI RES FOUND,ZORNIAK MICHAEL;;CLARK PAUL A;;CHO YONGKU PETER;;UMLAUF BENJAMIN J;;SHUSTA ERIC V;;KUO JOHN SHU-SHIN,WISCONSIN ALUMNI RESEARCH FOUNDATION (2018-03-20),https://lens.org/120-477-951-134-514,Patent Application,yes,0,1,5,5,10,C07K16/18;;C07K16/30;;G01N33/57407;;A61K2039/505;;C07K2317/569;;A61P35/00;;A61K49/0058;;A61K2039/505;;C07K16/3053;;C07K2317/565;;C07K2317/622;;C07K2317/92;;G01N33/57407,C07K16/30;;A61K49/00;;G01N33/574,,4,4,044-139-486-413-246;;051-208-529-712-079;;015-947-199-986-598;;005-930-919-665-693,20587664;;pmc2944778;;10.1158/1535-7163.mct-09-1059;;17981654;;10.2741/2786;;16051357;;10.1016/j.dci.2005.06.010;;10.1093/jb/mvn009;;18216066,"Zhu et al. (Molecular Cancer Therapeutics, Vol. 9, No. 7, July 2010, pgs. 2131-2141) (Year: 2010);;Almagro & Fransson, Frontiers in Bioscience 2008; 13:1619-33 (Year: 2008);;De Genst et al., Dev Comp Immunol 2006; 30:187-98 (Year: 2006);;Yoshinaga et al., J. Biochem 2008; 143:593-601 (Year: 2008)",ACTIVE
504,US,A1,US 2018/0049027 A1,116-722-917-759-23X,2018-02-15,2018,US 201715673281 A,2017-08-09,US 201715673281 A;;US 201662373897 P;;US 201662404736 P,2016-08-11,ADDING AUTHENTICATABLE SIGNATURES TO ACKNOWLEDGEMENTS,"A method for wireless communication may include receiving a communication and determining an acknowledgement signature for an acknowledgment in response to the communication. The acknowledgment signature may allow for authentication with the transmitting wireless device. The acknowledgment signature may be based on a key shared with the wireless device. An acknowledgement frame (e.g., acknowledging reception of the communication) may then be sent to the transmitting wireless device. The content of the acknowledgement may be based on the acknowledgement signature. For example, the signature may be included in a frame control, duration, or address field. Determining the acknowledgement signature may include determining a unique signature based on information from the received communication (e.g., a cyclic redundancy check (CRC)), the shared key, and/or a hash function. In some cases, the acknowledgement frame may include an encryption header, and a message integrity check may be included as the acknowledgement signature.",QUALCOMM INC,ABRAHAM SANTOSH PAUL;;CHERIAN GEORGE;;RAISSINIA ALIREZA;;PATIL ABHISHEK PRAMOD;;KAKANI NAVEEN KUMAR;;CHO JAMES SIMON;;MALINEN JOUNI,QUALCOMM INCORPORATED (2017-10-19),https://lens.org/116-722-917-759-23X,Patent Application,yes,18,6,2,2,0,H04L9/3242;;H04L63/126;;H04L1/1671;;H04L9/3247;;H04W84/12;;H04W12/63;;H04W12/104;;H04W12/106;;H04W12/069;;H04L63/126;;H04L9/3242;;H04L1/16;;H04L1/1671;;H04W12/069;;H04W12/106;;H04W12/63;;H04W12/104;;G06F11/1004;;H03M13/29;;H04L1/1812;;H04L9/3247;;H04L63/0428;;H04L63/06;;H04L63/083,H04W12/06;;G06F11/10;;H03M13/29;;H04L1/18;;H04L9/32;;H04L29/06;;H04W12/04,,0,0,,,,DISCONTINUED
505,KR,A,KR 20200027551 A,099-990-866-855-841,2020-03-12,2020,KR 20207003864 A,2018-07-03,US 201762531227 P;;US 201862682044 P;;IB 2018054926 W,2017-07-11,CEA MUC1 및 TERT를 포함하는 면역원성 조성물,"본 개시내용은 (a) 단리된 면역원성 CEA 폴리펩티드; (b) (i) 면역원성 CEA 폴리펩티드, (ii) 면역원성 CEA 폴리펩티드 및 면역원성 MUC1 폴리펩티드, (iii) 면역원성 CEA 폴리펩티드 및 면역원성 TERT 폴리펩티드, 또는 (iv) 면역원성 CEA 폴리펩티드, 면역원성 MUC1 폴리펩티드 및 면역원성 TERT 폴리펩티드를 코딩하는 단리된 핵산 분자; (c) 단리된 핵산 분자를 포함하는 조성물; 및 (d) 면역원성 CEA 폴리펩티드, 핵산 분자 및 조성물의 용도와 관련된 방법을 제공한다.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;MARTINIC MARIANNE MARCELA ANDREA,,https://lens.org/099-990-866-855-841,Patent Application,no,0,0,19,20,186,A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/70;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/55555;;C12N2710/10343;;A61K38/00;;C12N9/1276;;C12Y207/07049;;C12N9/1276;;A61K38/00;;A61K39/001157;;A61K39/00117;;A61K39/001182;;A61K2039/5256;;A61K2039/53;;A61K2039/54;;A61K2039/545;;A61K2039/55555;;A61K2039/70;;A61K2300/00;;C12Y207/07049;;C12N2710/10343;;A61K2039/53;;A61K2039/545;;A61K2039/54;;A61K2039/55555;;A61K39/00117;;C12N2710/10343;;A61K39/001182;;A61K2039/70;;A61K39/001157;;A61K2039/5256;;A61K38/00;;C07K14/705;;C12N9/1276;;C12Y207/07049,C12N9/12;;A61K38/00;;A61K39/00,,0,0,,,,DISCONTINUED
506,KR,A,KR 20220095066 A,085-706-258-628-62X,2022-07-06,2022,KR 20210045869 A,2021-04-08,KR 20200185788 A,2020-12-29,3 manufacturing method of 3D brain blood barrier structure of 3D brain blood barrier organ-on-a-chip using reverse rapid liquid printing and 3D brain blood barrier organ-on-a-chip comprising the same,"The present invention relates to a blood-brain barrier organ-on-a-chip using backward rapid liquid printing. A method for manufacturing a blood-brain barrier organ-on-a-chip using backward rapid liquid printing according to the present invention can simulate a real 3-dimensional blood-brain barrier, and a blood-brain barrier organ-on-a-chip manufactured thereby can be used as an artificial organ model that can be substituted for animal experiments.",MICROFIT CO LTD,OH HYUN JIK;;CHO JIN HUI;;LEE MIN YOUNG;;CHOI NAK WON;;KANG MIN JIN;;JOHN PAUL FRAMTON IV,,https://lens.org/085-706-258-628-62X,Patent Application,no,3,0,2,3,0,C12M25/14;;C12N5/0062;;C12N5/0622;;C12N5/0634;;B33Y30/00;;B33Y10/00;;B33Y80/00;;B33Y70/00,C12M1/12;;B33Y10/00;;B33Y30/00;;B33Y70/00;;B33Y80/00;;C12N5/00;;C12N5/078;;C12N5/079,,1,0,,,"McCormack 등. 3D printing in suspension baths: keeping the promises of bioprinting afloat. Trends in Biotechnology. 2020.6. vol.38, no.6, pp.584-593 1부.*",ACTIVE
507,WO,A1,WO 2023/146160 A1,109-298-062-019-186,2023-08-03,2023,KR 2023000371 W,2023-01-09,US 202217585340 A,2022-01-26,SYSTEMS AND METHODS FOR REAL-TIME ADAPTIVE AIR QUALITY AND POLLUTION CONTROL IN FOOD PROCESSING AND OTHER THERMAL PROCESSING ENVIRONMENTS,"In one embodiment, a method for controlling air quality in an unenclosed environment by a ventilation system includes determining an environmental state of the environment based on sensor data from sensors associated with the ventilation system, determining a current air quality of the environment based on the sensor data, determining adjustments for system-boundaries or air-manipulating devices associated with the ventilation system based on the current air quality and the environmental state, wherein the adjustments are configured to facilitate a target air quality of the environment; and adjusting the system-boundaries or air-manipulating devices associated with the ventilation system based on the determined adjustments.",SAMSUNG ELECTRONICS CO LTD,SANTOS JOSE MARCEL C;;ANDRONESCU TIBERIU A;;BRENNER THOMAS;;CHO JUN YEON;;HSIAO PAUL;;MAHARRAMOV MUSA;;PATTON BRIAN R,,https://lens.org/109-298-062-019-186,Patent Application,yes,5,0,2,2,0,Y02B30/70;;F24C15/2021;;F24C15/2092;;F24C15/2085;;F24C15/2021;;G05B15/02;;F24C15/2092;;F24C15/2085,F24C15/20;;F24F7/06;;F24F11/70;;F24F110/50;;F24F120/20;;H04N7/18,,0,0,,,,PENDING
508,WO,A1,WO 2022/145743 A1,119-512-742-492-310,2022-07-07,2022,KR 2021017785 W,2021-11-29,KR 20200185788 A;;KR 20210045869 A,2020-12-29,"METHOD FOR PRODUCING THREE-DIMENSIONAL BLOOD-BRAIN BARRIER STRUCTURE OF BLOOD-BRAIN BARRIER ORGAN-ON-A-CHIP USING REVERSE RAPID LIQUID PRINTING, AND BLOOD-BRAIN BARRIER ORGAN-ON-A-CHIP COMPRISING SAME","The present invention relates to a blood-brain barrier organ-on-a-chip using reverse rapid liquid printing. A method for producing a blood-brain barrier organ-on-a-chip using reverse rapid liquid printing, according to the present invention, enables the mimicking of an actual three-dimensional blood-brain barrier, and a blood-brain barrier organ-on-a-chip produced thereby can be used as an artificial organ model which can be an alternative to animal testing.",MICROFIT CO LTD,OH HYUN-JIK;;CHO JIN-HUI;;LEE MIN-YOUNG;;CHOI NAK-WON;;KANG MIN-JIN;;FRAMTON IV JOHN PAUL,,https://lens.org/119-512-742-492-310,Patent Application,yes,5,0,1,3,0,B33Y10/00;;B33Y30/00;;B33Y70/00;;B33Y80/00;;C12M1/12;;C12N5/00;;C12N5/06,C12M1/12;;B33Y10/00;;B33Y30/00;;B33Y70/00;;B33Y80/00;;C12N5/00;;C12N5/078;;C12N5/079,,0,0,,,,PENDING
509,AT,T1,AT E139532 T1,078-593-755-069-249,1996-07-15,1996,AT 92908147 T,1992-04-09,EP 91106105 A,1991-04-17,"NEUE DNA-GYRASE INHIBITOREN, VERFAHREN ZU IHRER HERSTELLUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN","Compounds of the formula <IMAGE> II in which P is hydroxy and T is the group -X2-CR7aR7b-CHR8-OH or T is hydrogen and P is the group O-CHR8-CR7aR7b-X2-OH and, wherein X1, X2, R1, R2, R3, R4, R5, R6, R7a, R7b, and R8 are as defined in the specification, or a reactive derivative thereof. These compounds are useful in the preparation of DNA gyrase inhibitors.",HOFFMANN LA ROCHE,ARISAWA MIKIO;;GOETSCHI ERWIN;;KAMIYAMA TSUTOMU;;CHO SAKAE-KU;;MASCIADRI RAFFAELLO;;SHIMADA HISAO;;WATANABE JUNKO;;HEBEISEN PAUL;;LINK HELMUT,,https://lens.org/078-593-755-069-249,Granted Patent,no,0,0,11,11,0,A61K38/00;;C07D291/08;;C07D419/04;;C07K5/0202;;C07K5/06139;;C07K5/0821;;C07K5/1008;;C07K7/06;;Y10S435/886;;A61P31/04;;C07D419/04;;C07K5/1008;;C07K5/0202;;A61K38/00;;C07D291/08;;C07K5/06139;;C07K7/06;;C07K5/0821,A61K31/395;;A61K31/42;;A61K31/425;;A61K38/00;;A61P31/04;;C07C317/24;;C07C317/28;;C07C317/46;;C07C317/48;;C07C323/56;;C07C323/58;;C07C323/64;;C07D291/08;;C07D413/04;;C07D413/14;;C07D417/04;;C07D417/14;;C07D419/04;;C07D419/12;;C07K5/02;;C07K5/078;;C07K5/097;;C07K5/103;;C07K7/06,,0,0,,,,DISCONTINUED
510,US,A1,US 2023/0235893 A1,037-603-984-207-595,2023-07-27,2023,US 202217585340 A,2022-01-26,US 202217585340 A,2022-01-26,Systems and Methods for Real-time Adaptive Air Quality and Pollution Control in Food Processing and Other Thermal Processing Environments,"In one embodiment, a method for controlling air quality in an unenclosed kitchen environment by a ventilation system includes determining an environmental state of the kitchen environment based on sensor data from sensors associated with the ventilation system, determining a current air quality of the kitchen environment based on the sensor data, determining adjustments for system-boundaries or air-manipulating devices associated with the ventilation system based on the current air quality and the environmental state, wherein the adjustments are configured to facilitate a target air quality of the kitchen environment; and adjusting the system-boundaries or air-manipulating devices associated with the ventilation system based on the determined adjustments.",SAMSUNG ELECTRONICS CO LTD,SANTOS JOSE MARCEL C;;ANDRONESCU TIBERIU A;;BRENNER THOMAS;;CHO JUN YEON;;HSIAO PAUL;;MAHARRAMOV MUSA;;PATTON BRIAN R,SAMSUNG ELECTRONICS COMPANY LTD (2022-01-18),https://lens.org/037-603-984-207-595,Patent Application,yes,6,1,2,2,0,Y02B30/70;;F24C15/2021;;F24C15/2092;;F24C15/2085;;F24C15/2021;;G05B15/02;;F24C15/2092;;F24C15/2085,F24C15/20;;G05B15/02,,0,0,,,,PENDING
511,DE,D1,DE 69032904 D1,128-268-529-112-475,1999-03-04,1999,DE 69032904 T,1990-08-31,US 40114689 A,1989-08-31,Informationsspeicherung und Verarbeitung,"Data and directories are separated and stored on separate parts of an optical disk. Directories are on the inner tracks and data are on the outer tracks, in a first format. Data and directories are written from magnetic disk storage in a different second specific format that is determined by a particular operating system used by an information processor. A medical information processing system is provided with an external magnetic disk storage and the optical disk.",UNIV CALIFORNIA;;HITACHI MAXELL,HUANG HAN K;;MORIOKA CRAIG A;;RATIB OSMAN;;CHO PAUL N S;;HO BRUCE K T;;SONOBE TAKEO;;SHINAGAWA TORU,,https://lens.org/128-268-529-112-475,Granted Patent,no,0,0,9,9,0,G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20;;G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20,G06F3/08;;G06F12/00;;G06F17/30;;G11B27/32;;G16H30/20,,0,0,,,,EXPIRED
512,KR,A,KR 20120135231 A,194-198-155-065-370,2012-12-12,2012,KR 20127021114 A,2011-01-12,US 29447610 P;;US 2011/0021031 W,2010-01-12,MULTI-MEDIA USB DATA TRANSFER OVER DIGITAL INTERACTION INTERFACE FOR VIDEO AND AUDIO (DIIVA),,SYNERCHIP USA CORP,LEE DONG YUN;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG WOON;;KIM SANG WAN;;CHO SUK JAE,,https://lens.org/194-198-155-065-370,Patent Application,no,0,1,22,22,0,G06F13/4286;;G06F13/4286;;G06F13/4286;;G09G2370/047;;G09G2370/047;;G09G2370/12;;G09G2370/12;;H04N21/43615;;H04N21/43615;;H04L12/2838;;H04L12/2838;;H04L12/2838;;H04L2012/2849;;H04L2012/2849;;H04L2012/2849;;H04N21/43615;;H04N21/43632;;H04N21/43632;;H04N21/43635;;H04N21/43635;;H04N21/63;;H04N21/63,H04L12/56,,0,0,,,,DISCONTINUED
513,PL,A1,PL 364176 A1,017-518-367-288-797,2004-12-13,2004,PL 36417602 A,2002-02-15,US 0204407 W;;US 26868301 P;;US 31236101 P,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,,SUGEN;;UPJOHN CO,LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW,,https://lens.org/017-518-367-288-797,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
514,EP,B1,EP 0415786 B1,064-269-660-806-813,1999-01-20,1999,EP 90309556 A,1990-08-31,US 40114689 A,1989-08-31,Information storage and processing,"Data and directories are separated and stored on separate parts of an optical disk. Directories are on the inner tracks and data are on the outer tracks, in a first format. Data and directories are written from magnetic disk storage in a different second specific format that is determined by a particular operating system used by an information processor. A medical information processing system is provided with an external magnetic disk storage and the optical disk.",UNIV CALIFORNIA;;HITACHI MAXELL,HUANG HAN K;;MORIOKA CRAIG A;;RATIB OSMAN;;CHO PAUL N S;;HO BRUCE K T;;SONOBE TAKEO;;SHINAGAWA TORU,,https://lens.org/064-269-660-806-813,Granted Patent,yes,4,0,9,9,0,G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20;;G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20,G06F3/08;;G06F12/00;;G06F17/30;;G11B27/32;;G16H30/20,,1,0,,,"IBM TECHNICAL DISCLOSURE BULLETIN. vol. 15, no. 2, July 1972, NEW YORK US page 693 R.H. VAN BILDERBEEK ET AL : 'Device-Independent conversion program'",EXPIRED
515,DE,D1,DE 69306439 D1,020-399-987-645-977,1997-01-23,1997,DE 69306439 T,1993-02-17,US 84426492 A,1992-03-02,P.i.n-Fotodioden mit transparenten leitfähigen Kontakten,,AT & T CORP,BERGER PAUL RAYMOND;;CHO ALFRED YI;;DUTTA NILOY KUMAR;;LOPATA JOHN;;O'BRYAN HENRY MILES;;SIVCO DEBORAH LEE;;ZYDZIK GEORGE JOHN,,https://lens.org/020-399-987-645-977,Granted Patent,no,0,0,12,12,0,H01L31/022466;;H01L31/022466;;H01L31/10;;H01L31/02161;;H01L31/02161;;H01L31/105;;H01L31/105,H01L31/10;;H01L31/0216;;H01L31/0224;;H01L31/105,,0,0,,,,EXPIRED
516,CN,A,CN 117255645 A,121-195-068-139-464,2023-12-19,2023,CN 202280030961 A,2022-02-17,US 202163182482 P;;US 2022/0016679 W,2021-04-30,Response of robotic device to acute health event reported by medical device,"An apparatus, the apparatus comprising a computer readable medium having executable instructions stored thereon, the executable instructions configured to be executable by processing circuitry for causing the processing circuitry to: determine that a patient is experiencing or has experienced an acute health event; causing a motor to move a robotic device to a position adjacent to the patient; causing a sensor of the robotic device to acquire physiological data from the patient; confirming, based on the physiological data, that the patient is experiencing or has experienced the acute health event; and generating an output in response to confirming that the patient is experiencing or has experienced the acute health event.",MEDTRONIC INC,NEITZEL GARY A;;SARKAR SHANTANU;;KRAUSE PAUL G;;CHO YONG K;;OSTIGIAN KEVIN T;;WISZYNSKI RAYMOND D;;KOCH CRAIG D,,https://lens.org/121-195-068-139-464,Patent Application,no,0,0,3,3,0,G16H50/20;;G16H50/70;;G16H80/00;;G16H40/67;;G16H40/63;;G16H10/60;;G16H10/20;;G16H20/17;;A61B5/746;;A61B5/7221;;A61B5/7282;;A61B5/4836;;A61B5/01;;A61B5/02455;;A61B5/0816;;A61B5/02405;;A61B5/686;;A61B5/33;;A61B5/021;;A61B5/14542;;A61B5/4812;;A61B5/7267;;A61B5/747,A61B5/0205,,0,0,,,,PENDING
517,EP,A1,EP 4329596 A1,039-826-091-538-996,2024-03-06,2024,EP 22796313 A,2022-02-17,US 202163182482 P;;US 2022/0016679 W,2021-04-30,RESPONSE BY ROBOTIC DEVICE TO AN ACUTE HEALTH EVENT REPORTED BY MEDICAL DEVICE,,MEDTRONIC INC,NEITZELL GRANT A;;SARKAR SHANTANU;;KRAUSE PAUL G;;CHO YONG K;;OUSDIGIAN KEVIN T;;WYSZYNSKI RYAN D;;KOCH CHRISTOPHER D,,https://lens.org/039-826-091-538-996,Patent Application,yes,0,0,3,3,0,G16H50/20;;G16H50/70;;G16H80/00;;G16H40/67;;G16H40/63;;G16H10/60;;G16H10/20;;G16H20/17;;A61B5/746;;A61B5/7221;;A61B5/7282;;A61B5/4836;;A61B5/01;;A61B5/02455;;A61B5/0816;;A61B5/02405;;A61B5/686;;A61B5/33;;A61B5/021;;A61B5/14542;;A61B5/4812;;A61B5/7267;;A61B5/747,A61B5/0205;;G16H50/20;;G16H50/70;;G16H80/00,,0,0,,,,PENDING
518,DE,T2,DE 69306439 T2,092-894-290-663-622,1997-06-26,1997,DE 69306439 T,1993-02-17,US 84426492 A,1992-03-02,P.i.n-Fotodioden mit transparenten leitfähigen Kontakten,,AT & T CORP,BERGER PAUL RAYMOND;;CHO ALFRED YI;;DUTTA NILOY KUMAR;;LOPATA JOHN;;O'BRYAN HENRY MILES;;SIVCO DEBORAH LEE;;ZYDZIK GEORGE JOHN,,https://lens.org/092-894-290-663-622,Granted Patent,no,0,0,12,12,0,H01L31/022466;;H01L31/022466;;H01L31/10;;H01L31/02161;;H01L31/02161;;H01L31/105;;H01L31/105,H01L31/10;;H01L31/0216;;H01L31/0224;;H01L31/105,,0,0,,,,EXPIRED
519,HU,A2,HU P0303146 A2,127-197-160-066-04X,2003-12-29,2003,HU P0303146 A,2002-02-15,US 0204407 W;;US 26868301 P;;US 31236101 P,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM,"A jelen találmány tárgya (I) általános képletű pirollal helyettesített2-indolinon-származékok és gyógyászatilag elfogadható sóik, amelyekmódosítják protein kináz enzimek aktivitását, és ezért várhatóanalkalmazhatók protein kinázzal összefüggő celluláris rendellenességek,mint például rák, gyógyító és megelőző kezelésénél hatásosgyógyszerkészítmények előállításánál. A találmány kiterjed avegyületeket tartalmazó gyógyszerkészítményekre is. Az I. általánosképletben: R1 jelentése hidrogénatom, halogénatom, alkil-,halogénatommal helyettesített alkiloxi-, ciklolalkilcsoport, hetero-aliciklusos csoport, hidroxil-, alkiloxicsoport, -C(O)R8, -NR9R10 vagy-C(O)NR12R13 képletű csoport; R2 jelentése hidrogénatom, halogénatom,alkil-, trihalo-metil-, hidroxil-, alkiloxi-, cianocsoport, -NR9R10, -NR9C(O)R10, -C(O)R8, -S(O)2NR9R10 vagy -SO2R14 képletű csoport (amelyképletben R14 jelentése alkil-, aril-, aralkil-, heteroaril- vagyheteroaralkil-csoport); R3, R4 és R5 jelentése egymástól függetlenülhidrogénatom vagy alkilcsoport; Z jelentése aril-, heteroarilcsoport,heterogyűrűs csoport vagy -NR15R16 képletű csoport, ahol R15 és R16jelentése egymástól függetlenül hidrogénatom vagy alkilcsoport; vagyR15 és R16 azzal a nitrogénatommal együtt, amelyikhez kapcsolódnak,heterociklo-aminocsoportot alkotnak; R6 jelentése hidrogénatom vagyalkilcsoport; R7 jelentése hidrogénatom, alkil-, aril-,heteroarilcsoport vagy -C(O)R17 képletű csoport; R8 jelentésehidroxil-, alkiloxi- vagy ariloxicsoport; R9 és R10 jelentéseegymástól fiüggetlenül hidrogénatom, alkil-, ciano-alkil-,cikloalkil-, aril- vagy heteroarilcsoport; vagy R9 és R10 együttheterociklo-aminocsoportot alkotnak; R12 és R13 jelentése egymástólfüggetlenül hidrogénatom, alkil-, hidroxi-alkil- vagy arilcsoport;vagy R12 és R13 azzal a nitrogénatommal, amelyikhez kapcsolódnak,heterociklo-aminocsoportot alkotnak; R17 jelentése hidroxil-, alkil-,cikloalkil-, aril- vagy heteroarilcsoport. Ó",UPJOHN CO;;SUGEN,HERRINTON PAUL MATTHEW;;JIN QINGWU;;LIANG CONGXIN;;MAURAGIS MICHAEL A;;SUN LI;;TANG PENG CHO;;VOJKOVSKY TOMAS;;WEI CHUNG CHEN,,https://lens.org/127-197-160-066-04X,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,DISCONTINUED
520,YU,A,YU 71703 A,068-938-244-036-953,2006-05-25,2006,YU P71703 A,2002-02-15,US 26868301 P;;US 31236101 P,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.,GUAN HUIPING,LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW,,https://lens.org/068-938-244-036-953,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
521,DE,T2,DE 69032904 T2,059-693-790-448-876,1999-06-02,1999,DE 69032904 T,1990-08-31,US 40114689 A,1989-08-31,Informationsspeicherung und Verarbeitung,"Data and directories are separated and stored on separate parts of an optical disk. Directories are on the inner tracks and data are on the outer tracks, in a first format. Data and directories are written from magnetic disk storage in a different second specific format that is determined by a particular operating system used by an information processor. A medical information processing system is provided with an external magnetic disk storage and the optical disk.",UNIV CALIFORNIA;;HITACHI MAXELL,HUANG HAN K;;MORIOKA CRAIG A;;RATIB OSMAN;;CHO PAUL N S;;HO BRUCE K T;;SONOBE TAKEO;;SHINAGAWA TORU,,https://lens.org/059-693-790-448-876,Granted Patent,no,0,0,9,9,0,G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20;;G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20,G06F3/08;;G06F12/00;;G06F17/30;;G11B27/32;;G16H30/20,,0,0,,,,EXPIRED
522,US,A,US 5471606 A,055-434-289-901-305,1995-11-28,1995,US 21206694 A,1994-03-14,US 21206694 A;;US 96755892 A;;US 40114689 A,1989-08-31,Information storage and processing,"Data and directories are separated and stored on separate parts of an optical disk. Directories are on the inner tracks and data are on the outer tracks, in a first format. Data and directories are written from magnetic disk storage in a different second specific format that is determined by a particular operating system used by an information processor. A medical information processing system is provided with an external magnetic disk storage and the optical disk.",UNIV CALIFORNIA;;HITACHI MAXELL,HUANG HAN K;;MORIOKA CRAIG A;;RATIB OSMAN;;CHO PAUL N S;;HO BRUCE K T;;SONOBE TAKEO;;SHINAGAWA TORU,,https://lens.org/055-434-289-901-305,Granted Patent,yes,25,19,9,9,0,G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20;;G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20,G06F12/00;;G06F17/30;;G11B27/32;;G06F3/08;;G16H30/20,395/500;;X364DIG 2;;364/952.31;;364/952.6;;364/963.5;;369/44.26;;369/275.1,3,1,031-470-140-633-186,3347715;;10.1148/radiology.167.1.3347715,"Mankovich et al., RSNA Annual Meeting UCLA (1986), Operational Radiologic Image Archive on Digital Optical Disks .;;Huang et al., Medical Imaging Technology 4:2 (1986) PACS at UCLA I A Status Report .;;R. H. van Bilderbeek et al. IBM Technical Disclosure Bulletin, 12(2):683, Jul. 1972, Device Independent Conversion Program .",EXPIRED
523,AT,T1,AT E176065 T1,095-461-701-456-616,1999-02-15,1999,AT 90309556 T,1990-08-31,US 40114689 A,1989-08-31,INFORMATIONSSPEICHERUNG UND VERARBEITUNG,"Data and directories are separated and stored on separate parts of an optical disk. Directories are on the inner tracks and data are on the outer tracks, in a first format. Data and directories are written from magnetic disk storage in a different second specific format that is determined by a particular operating system used by an information processor. A medical information processing system is provided with an external magnetic disk storage and the optical disk.",UNIV CALIFORNIA;;HITACHI MAXELL,HUANG HAN K;;MORIOKA CRAIG A;;RATIB OSMAN;;CHO PAUL N S;;HO BRUCE K T;;SONOBE TAKEO;;SHINAGAWA TORU,,https://lens.org/095-461-701-456-616,Granted Patent,no,0,0,9,9,0,G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20;;G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20,G06F3/08;;G06F12/00;;G06F17/30;;G11B27/32,,0,0,,,,DISCONTINUED
524,CN,A,CN 102835091 A,129-224-515-209-761,2012-12-19,2012,CN 201180005935 A,2011-01-12,US 2011/0021031 W;;US 29447610 P,2010-01-12,Multi-media USB data transfer over digital interaction interface for video and audio (DIIVA),"A system for delivering USB data over a DiiVA network may include a USB host controller, at least one USB device, a first DiiVA device connected to the USB host controller through an upstream USB port, a second DiiVA device connected to the USB device through a downstream USB port; and a network configured to transfer data between the first DiiVA device and the second DiiVA device according to USB protocol through a DiiVA bi-directional hybrid link in the network. The network is responsive to the USB host controller to deliver contents for the USB protocol through at least one line state information packet and at least one USB data packet transmitted through the hybrid link between the upstream USB port and the downstream USB port.",SYNERCHIP USA CORP,LEE DONG-YUM;;PAK EDWARD;;HAHN JOHN;;GUPTA MAYANK;;HENINWOLF PAUL;;KIM BYOUNG-WOON;;KIM SANG-WAN;;CHO SUK-JAE,SILICON IMAGE INC. A. DELAWARE C. (2013-02-21),https://lens.org/129-224-515-209-761,Patent Application,no,4,4,22,22,0,G06F13/4286;;G06F13/4286;;G06F13/4286;;G09G2370/047;;G09G2370/047;;G09G2370/12;;G09G2370/12;;H04N21/43615;;H04N21/43615;;H04L12/2838;;H04L12/2838;;H04L12/2838;;H04L2012/2849;;H04L2012/2849;;H04L2012/2849;;H04N21/43615;;H04N21/43632;;H04N21/43632;;H04N21/43635;;H04N21/43635;;H04N21/63;;H04N21/63,H04L29/06,,0,0,,,,ACTIVE
525,US,A,US 5410676 A,143-224-680-823-746,1995-04-25,1995,US 96755892 A,1992-10-27,US 96755892 A;;US 40114689 A,1989-08-31,Information system using designating areas for retrieving/converting data and directories of different formats storing in optical and magnetic storage,"Data and directories are separated and stored on separate parts of an optical disk. Data and directories are written from magnetic disk storage in a first specific format that is determined by a particular operating system used by an information processor. Directories are on the inner tracks and data are on the outer tracks, in a second format on the optical disk. A medical information processing system is provided with an external magnetic disk storage and the optical disk.",UNIV CALIFORNIA,HUANG HAN K;;MORIOKA CRAIG A;;RATIB OSMAN;;CHO PAUL N S;;HO BRUCE K T;;SONOBE TAKEO;;SHINAGAWA TORU,,https://lens.org/143-224-680-823-746,Granted Patent,yes,22,97,9,9,0,G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20;;G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20,G06F12/00;;G06F17/30;;G06F3/08;;G11B27/32;;G16H30/20,395/500;;364/260.81;;364/952.31;;364/952.4;;364/963;;382/64;;382/65;;369/13,3,1,031-470-140-633-186,3347715;;10.1148/radiology.167.1.3347715,"R. H. van Bilderbeek and L. A. Valkenburgh, Device Independent Conversion Program , IBM Technical Disclosure Bulletin, 15(2):683, Jul. 1972.;;Mankovich et al., RSNA Annual Meeting UCLA (1986), Operational Radiologic Image Archive on Digital Optical Disks .;;Huang et al., Medical Imaging Technology 4:2 (1986) PACS at UCLA I A Status Report .",EXPIRED
526,WO,A1,WO 2022/231678 A1,064-308-539-636-022,2022-11-03,2022,US 2022/0016679 W,2022-02-17,US 202163182482 P,2021-04-30,RESPONSE BY ROBOTIC DEVICE TO AN ACUTE HEALTH EVENT REPORTED BY MEDICAL DEVICE,"A device comprising a computer-readable medium having executable instructions stored thereon, configured to be executable by processing circuitry for causing the processing circuitry to: determine that a patient is experiencing or has experienced an acute health event; cause a motor to move a robotic device to a location proximate the patient; cause a sensor of the robotic device to gather physiological data from the patient; confirm that the patient is experiencing or has experienced the acute health event based on the physiological data; and generate an output in response to confirming that the patient is experiencing or has experienced the acute health event.",MEDTRONIC INC,NEITZELL GRANT A;;SARKAR SHANTANU;;KRAUSE PAUL G;;CHO YONG K;;OUSDIGIAN KEVIN T;;WYSZYNSKI RYAN D;;KOCH CHRISTOPHER D,,https://lens.org/064-308-539-636-022,Patent Application,yes,4,0,3,3,0,G16H50/20;;G16H50/70;;G16H80/00;;G16H40/67;;G16H40/63;;G16H10/60;;G16H10/20;;G16H20/17;;A61B5/746;;A61B5/7221;;A61B5/7282;;A61B5/4836;;A61B5/01;;A61B5/02455;;A61B5/0816;;A61B5/02405;;A61B5/686;;A61B5/33;;A61B5/021;;A61B5/14542;;A61B5/4812;;A61B5/7267;;A61B5/747,A61B5/0205;;G16H50/20;;G16H50/70;;G16H80/00,,0,0,,,,PENDING
527,EP,A2,EP 0415786 A2,001-275-486-481-106,1991-03-06,1991,EP 90309556 A,1990-08-31,US 40114689 A,1989-08-31,Information storage and processing.,"Data and directories are separated and stored on separate parts of an optical disk. Directories are on the inner tracks and data are on the outer tracks, in a first format. Data and directories are written from magnetic disk storage in a different second specific format that is determined by a particular operating system used by an information processor. A medical information processing system is provided with an external magnetic disk storage and the optical disk.  ",UNIV CALIFORNIA;;HITACHI MAXELL,HUANG HAN K;;MORIOKA CRAIG A;;RATIB OSMAN;;CHO PAUL N S;;HO BRUCE K T;;SONOBE TAKEO;;SHINAGAWA TORU,,https://lens.org/001-275-486-481-106,Patent Application,yes,0,5,9,9,0,G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20;;G11B27/329;;G11B2220/2537;;G06F16/258;;G16H30/20,G06F3/08;;G06F12/00;;G06F17/30;;G11B27/32;;G16H30/20,,0,0,,,,EXPIRED
528,US,A,US 5212395 A,133-384-717-665-017,1993-05-18,1993,US 84426492 A,1992-03-02,US 84426492 A,1992-03-02,P-I-N photodiodes with transparent conductive contacts,"This invention pertains to a p-i-n In.sub.0.53 Ga.sub.0.47 As photodiode having an optically transparent composite top electrode consisting of a thin semitransparent metal layer from 10 to 40 nm thick and a transparent cadmium tin oxide (CTO) layer from 90 to 600 nm thick. The metal layer makes a non-alloyed ohmic contact to the semiconductor surface, acts as a barrier between the semiconductor and the CTO preventing oxidation of the semiconductor from the O.sub.2 in the plasma during reactive magnetron sputtering of the CTO layer, and prevents formation of a p-n junction between the semiconductor and CTO. The CTO functions as the n or p contact, an optical window and an anti-reflection coating. The top electrode also avoids shadowing of the active layer by the top electrode, thus allowing greater collection of incident light. Since the top electrode is non-alloyed, inter-diffusion into the i-region is not relevant, which avoids an increased dark current.",AT & T BELL LAB,BERGER PAUL R;;CHO ALFRED Y;;DUTTA NILOY K;;LOPATA JOHN;;O'BRYAN JR HENRY M;;SIVCO DEBORAH L;;ZYDZIK GEORGE J,AMERICAN TELEPHONE AND TELEGRAPH COMPANY (1992-02-27),https://lens.org/133-384-717-665-017,Granted Patent,yes,6,25,12,12,0,H01L31/022466;;H01L31/022466;;H01L31/10;;H01L31/02161;;H01L31/02161;;H01L31/105;;H01L31/105,H01L31/10;;H01L31/0216;;H01L31/0224;;H01L31/105,H1K KEBCX         EBCX,3,3,017-656-896-125-219;;011-505-970-072-834;;107-554-158-104-286,10.1063/1.101170;;10.1063/1.103913;;10.1016/0042-207x(86)90278-2,"Zirngibl et al., Characterization of a Top Illuminated P I N Diode with an Indium Tin Oxide Contact , Appl. Phys. Lett. 54(21), 22 May 89, 2076 2078.;;Golan et al., Novel Indium Oxide/N GaAs Diodes , Appl. Phys. Lett. 57(21), Nov. 19, 1990, pp. 2205 2207.;;Lewin et al., Transparent Conducting Oxides of Metals and Alloys Made by Reactive Magnetron Sputtering from Elemental Targets , Vacuum, vol. 36, No s 1 3, 1986, pp. 95 98.",EXPIRED
529,EP,B1,EP 0559347 B1,029-631-102-714-877,1996-12-11,1996,EP 93301121 A,1993-02-17,US 84426492 A,1992-03-02,p-i-n Photodiodes with transparent conductive contacts,,AT & T CORP,BERGER PAUL RAYMOND;;CHO ALFRED YI;;DUTTA NILOY KUMAR;;LOPATA JOHN;;O'BRYAN HENRY MILES JR;;SIVCO DEBORAH LEE;;ZYDZIK GEORGE JOHN,AT&T CORP. (1994-06-22),https://lens.org/029-631-102-714-877,Granted Patent,yes,2,1,12,12,0,H01L31/022466;;H01L31/022466;;H01L31/10;;H01L31/02161;;H01L31/02161;;H01L31/105;;H01L31/105,H01L31/10;;H01L31/0216;;H01L31/0224;;H01L31/105,,2,0,,,"APPLIED PHYSICS LETTERS. vol. 54, no. 21, 22 May 1989, NEW YORK US pages 2076 - 2078 ZIRNGIBL ET AL. 'CHARACTERIZATION OF A TOP-ILLUMINATED p-i-n DIODE WITH AN INDIUM TIN OXIDE CONTACT';;APPLIED PHYSICS LETTERS. vol. 61, no. 14, 5 October 1992, NEW YORK US pages 1673 - 1675 BERGER ET AL. 'In(0.53)Ga(0.47)As p-i-n PHOTODIODES WITH TRANSPARENT CADMIUM TIN OXIDE CONTACTS'",EXPIRED
530,CA,A1,CA 2087356 A1,104-190-425-604-362,1993-09-03,1993,CA 2087356 A,1993-01-15,US 84426492 A,1992-03-02,P-I-N PHOTODIODES WITH TRANSPARENT CONDUCTIVE CONTACTS,,AMERICAN TELEPHONE & TELEGRAPH,BERGER PAUL R;;CHO ALFRED Y;;DUTTA NILOY K;;ZYDZIK GEORGE J;;LOPATA JOHN;;O'BRYAN HENRY M JR;;SIVCO DEBORAH L,,https://lens.org/104-190-425-604-362,Patent Application,no,0,0,12,12,0,H01L31/022466;;H01L31/022466;;H01L31/10;;H01L31/02161;;H01L31/02161;;H01L31/105;;H01L31/105,H01L31/10;;H01L31/0216;;H01L31/0224;;H01L31/105,,0,0,,,,EXPIRED
531,NO,B1,NO 326604 B1,171-202-914-910-227,2009-01-19,2009,NO 20033608 A,2003-08-14,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,"3-(4-amidopyrrol-2-ylmetliden)-2-indolinonderivater, fremstilling av slike, farmasoytiske preparater inneholdende slike, metode for a modulere den katalytiske aktiviteten til en proteinkinase in vitro med slike forbindelser samt anvendelse av slike forbindelser for fremstilling av medikament for behandling av sykdommer hos pattedyr",,SUGEN INC,TANG PENG CHO;;SUN LI;;WEI CHUNG CHEN;;LIANG CONGXIN;;VOJKOVSKY THOMAS;;GUAN HUIPING;;MAURAGIS MICHAEL A;;QINGWU JIN;;HERRINGTON PAUL,,https://lens.org/171-202-914-910-227,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D403/06;;A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
532,NO,D0,NO 20033608 D0,172-846-581-915-168,2003-08-14,2003,NO 20033608 A,2003-08-14,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-amidopyrrol-2-ylmetliden)-2-indolinonderivater som protein kinase inhibitorer,,UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY THOMAS;;QINGWU JIN;;HERRINGTON PAUL,,https://lens.org/172-846-581-915-168,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
533,KR,B1,KR 100271833 B1,172-386-639-992-605,2000-11-15,2000,KR 930002885 A,1993-02-27,US 84426492 A,1992-03-02,PIN DIODE,"본 발명은 10∼40nm 두께의 얇은 반투명 금속층과 90∼60nm 두께의 투명카드뮴 주석 산화물(CTO) 층으로 구성된 광학적으로 투명한 화합물 상부 전극을 가지는 핀 InGaAs 광다이오드에 관한 것이다. 상기 금속층은 반도체 표면에 대해 비합금 오믹 접촉을 이루며, CTO 층을 반응성 마그네트론 스퍼터링하는 동안 반도체와 CTO 사이에서 플라즈마내의 O로 인한 반도체의 산화를 방지하는 장벽 역할을 하고, 반도체와 CTO 사이에 p-n 접합이 형성되는 것을 방지한다. 상기 CTO는 n 또는 p 접점, 광학적 개구부, 반사 방지막의 기능을 수행한다. 상기 상부 전극은 또한 활성층이 그늘지게 하지 않으므로 입사광이 더 많이 수집될 수 있다. 상부 전극은 비합금이므로 i-영역으로의 확산이 일어나지 않아 암전류가 증가하지 않는다.",AT & T CORP,BERGER PAUL RAYMOND;;CHO ALFRED YI;;DUTTA NILOY KUMAR;;LOPATA JOHN;;O'BRYAN HENRY MILES JR;;SIVCO DEBORAH LEE;;ZYDZIK GEORGE JOHN,,https://lens.org/172-386-639-992-605,Granted Patent,no,0,1,12,12,0,H01L31/022466;;H01L31/022466;;H01L31/10;;H01L31/02161;;H01L31/02161;;H01L31/105;;H01L31/105,H01L31/10;;H01L31/0216;;H01L31/0224;;H01L31/105,,0,0,,,,EXPIRED
534,EP,A1,EP 0559347 A1,146-096-919-324-726,1993-09-08,1993,EP 93301121 A,1993-02-17,US 84426492 A,1992-03-02,p-i-n Photodiodes with transparent conductive contacts.,"This invention pertains to a p-i-n In 0.53 Ga 0.47 As photodiode having an optically transparent composite top electrode consisting of a thin semitransparent metal layer (24) from 10 to 40 nm thick and a transparent cadmium tin oxide (CTO) layer (25) from 90 to 600 nm thick. The metal layer makes a non-alloyed ohmic contact to the semiconductor surface, acts as a barrier between the semiconductor and the CTO preventing oxidation of the semiconductor from the O₂ in the plasma during reactive magnetron sputtering of the CTO layer, and prevents formation of a p-n junction between the semiconductor and CTO. The CTO functions as the n or p contact, an optical window and an anti-reflection coating. The top electrode also avoids shadowing of the active layer by the top electrode, thus allowing greater collection of incident light. Since the top electrode is non-alloyed, inter-diffusion into the i-region is not relevant, which avoids an increased dark current.",AMERICAN TELEPHONE & TELEGRAPH,BERGER PAUL RAYMOND;;CHO ALFRED YI;;DUTTA NILOY KUMAR;;LOPATA JOHN;;O'BRYAN HENRY MILES JR;;SIVCO DEBORAH LEE;;ZYDZIK GEORGE JOHN,AT&T CORP. (1994-06-22),https://lens.org/146-096-919-324-726,Patent Application,yes,2,12,12,12,0,H01L31/022466;;H01L31/022466;;H01L31/10;;H01L31/02161;;H01L31/02161;;H01L31/105;;H01L31/105,H01L31/10;;H01L31/0216;;H01L31/0224;;H01L31/105,,2,2,017-656-896-125-219;;097-201-333-107-587,10.1063/1.101170;;10.1063/1.108447,"APPLIED PHYSICS LETTERS. vol. 54, no. 21, 22 May 1989, NEW YORK US pages 2076 - 2078 ZIRNGIBL ET AL. 'CHARACTERIZATION OF A TOP-ILLUMINATED p-i-n DIODE WITH AN INDIUM TIN OXIDE CONTACT';;APPLIED PHYSICS LETTERS. vol. 61, no. 14, 5 October 1992, NEW YORK US pages 1673 - 1675 BERGER ET AL. 'In(0.53)Ga(0.47)As p-i-n PHOTODIODES WITH TRANSPARENT CADMIUM TIN OXIDE CONTACTS'",EXPIRED
535,EC,A,EC SP034734 A,150-524-281-400-760,2003-10-28,2003,EC SP034734 A,2003-08-15,US 26868301 P,2001-02-15,DERIVADOS DE 3-(4-AMIDOPIRROL-2-ILMETILIDENO)-2-INDOLINONA COMO INHIBIDORES DE PROTEINA CINASA,"La presente invención se relaciona con compuestos de indolinona sustituidos con 2-pirrol y sus sales aceptables para el uso farmacéutico que modulan la actividad de protein quinasas y así, se espera que sean útiles en a prevención y el tratamiento de afecciones celulares relacionadas tales como el cáncer.",SUGEN INC,WEI CHUNG-CHEN;;TANG PENG CHO;;LIANG CONGXIN;;VOJKOVSKY THOMAS;;GUAN HUIPING;;SUN CONNIE LI;;HERRINTON PAUL M;;MAURAGIS MICHAEL A,,https://lens.org/150-524-281-400-760,Patent Application,no,0,0,1,65,0,,A61K/;;A61K31/405;;A61P/;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D471/04,,0,0,,,,PENDING
536,US,S,US D0841730 S,032-618-165-653-006,2019-02-26,2019,US 201729609439 F,2017-06-30,US 201729609439 F,2017-06-30,Toner cartridge,,LEXMARK INT INC,ANDERSON JR JAMES DANIEL;;CHO MASAHITO;;HALE JASON PAUL;;MARTIN KYLE BRADLEY;;MCALPINE ROBERT WATSON;;PAYNE JEREMY KEITH;;ROGERS MATTHEW LEE,LEXMARK INTERNATIONAL INC (2017-06-23),https://lens.org/032-618-165-653-006,Design Right,no,35,1,1,6,0,,,1603;;D18/43,5,0,,,"Amazon. <URL: https://www.amazon.com/LINKYO-Replacement-Toner-Cartridges-2-Pack/dp/B06Y42ZZPG/ref=pd_day0_229_4?_encoding=UTF8&pd_rd_i=B06Y42ZZPG&pd_rd_r=0VFE28T5AST33K86VWBS&pd_rd_w=lsLkS&pd_rd_wg=pOzbE&psc=1&refRID=0VFE28T5AST33K86VWBS.> Apr. 7, 2017. LINKYO Replacement Toner Cartridges.;;Design U.S. Appl. No. 29/609,432, filed Jun. 30, 2017 (Anderson et al.).;;Design U.S. Appl. No. 29/609,435, filed Jun. 30, 2017 (Anderson et al.).;;Rejection dated Jun. 19, 2018 for Brazilian Registered Design Application No. BR3020170055168.;;Machine translation of rejection dated Jun. 19, 2018 for Brazilian Registered Design Application No. BR3020170055168.",ACTIVE
537,CA,C,CA 2087356 C,006-238-780-164-004,1996-03-12,1996,CA 2087356 A,1993-01-15,US 84426492 A,1992-03-02,P-I-N PHOTODIODES WITH TRANSPARENT CONDUCTIVE CONTACTS,"This invention pertains to a p-i-n In0.53 Ga0.47 As photodiode having an optically transparent composite top electrode consisting of a thin semitransparent metal layer from 10 to 40 nm thick and a transparent cadmium tin oxide (CTO) layer from 90 to 600 nm thick. The metal layer makes a non-alloyed ohmic contact to the semiconductor surface, acts as a barrier between the semiconductor and the CTO preventing oxidation of the semiconductor from the O2 in the plasma during reactive magnetron sputtering of the CTO layer, and prevents formation of a p-n junction between the semiconductor and CTO. The CTO functions as the n or p contact, an optical window and an anti-reflection coating. The top electrode also avoids shadowing of the active layer by the top electrode, thus allowing greater collection of incident light. Since the top electrode is non-alloyed, inter diffusion into the iregion is not relevant, which avoids an increased dark current.",AMERICAN TELEPHONE & TELEGRAPH,BERGER PAUL RAYMOND;;CHO ALFRED YI;;DUTTA NILOY KUMAR;;ZYDZIK GEORGE JOHN;;LOPATA JOHN;;O'BRYAN HENRY MILES JR;;SIVCO DEBORAH LEE,,https://lens.org/006-238-780-164-004,Granted Patent,no,0,0,12,12,0,H01L31/022466;;H01L31/022466;;H01L31/10;;H01L31/02161;;H01L31/02161;;H01L31/105;;H01L31/105,H01L31/10;;H01L31/0216;;H01L31/0224;;H01L31/105,,0,0,,,,EXPIRED
538,HK,A,HK 45597 A,021-131-154-144-034,1997-04-18,1997,HK 45597 A,1997-04-10,US 84426492 A,1992-03-02,P-I-N photodiodes with transparent conductive contacts,,AT & T CORP,BERGER PAUL RAYMOND;;CHO ALFRED YI;;DUTTA NILOY KUMAR;;LOPATA JOHN;;O'BRYAN HENRY MILES JR;;SIVCO DEBORAH LEE;;ZYDZIK GEORGE JOHN,,https://lens.org/021-131-154-144-034,Granted Patent,no,0,0,12,12,0,H01L31/022466;;H01L31/022466;;H01L31/10;;H01L31/02161;;H01L31/02161;;H01L31/105;;H01L31/105,H01L31/10;;H01L31/0216;;H01L31/0224;;H01L31/105,,0,0,,,,EXPIRED
539,US,A1,US 2011/0182107 A1,171-615-057-169-133,2011-07-28,2011,US 200813119932 A,2008-12-12,US 2008/0086667 W,2008-12-12,MEMRISTIVE DEVICE,"A memristive routing device ( 200 ) includes a memristive matrix ( 240 ), mobile dopants ( 255 ) moving with the memristive matrix ( 240 ) in response to programming electrical fields and remaining stable within the memristive matrix ( 240 ) in the absence of the programming electrical fields; and at least three electrodes ( 210, 220, 230 ) surrounding the memristive matrix ( 240 ). A method for tuning electrical circuits with a memristive device ( 900 ) includes measuring a circuit characteristic ( 805 ) and applying a programming voltage to the memristive device ( 900 ) which causes motion of dopants within the memristive device ( 900 ) to alter the circuit characteristic ( 805 ). A method for increasing a switching speed of a memristive device ( 1300 ) includes drawing dopants from two geometrically separated locations into close proximity to form two conductive regions ( 1380, 1390 ) and then switching the memristive device ( 1300 ) to a conductive state by applying a programming voltage which rapidly merges the two conductive regions ( 1380, 1390 ) to form a conductive pathway between a source electrode ( 1310 ) and a drain electrode ( 1320 ).",HEWLETT PACKARD DEVELOPMENT CO,WU WEI;;STRACHEN JOHN PAUL;;WILLIAMS R STANELY;;FLORENTINO MARCO;;WANG SHIH-YUAN;;CHO HANS S;;BORGHETTI JULIEN;;MATHAI SAGI VARGHESE,HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2015-10-27);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2008-12-03),https://lens.org/171-615-057-169-133,Patent Application,yes,7,24,3,3,0,H10B63/82;;H10N70/24;;H10N70/253;;H10N70/823;;H10N70/881;;H10N70/8833;;H10N70/883;;H10N70/8836;;H10B63/82;;H10N70/883;;H10N70/24;;H10N70/253;;H10N70/823;;H10N70/881;;H10N70/8833;;H10N70/8836,G11C11/00;;H01L45/00,365/148;;257/5;;X257E45002,0,0,,,,INACTIVE
540,DE,D1,DE 602006008605 D1,037-077-373-384-405,2009-10-01,2009,DE 602006008605 T,2006-04-24,US 67443005 P;;US 2006/0015442 W,2005-04-25,SYSTEM UND VERFAHREN ZUR WIEDERHERSTELLUNG VON DATEN AUF ANFORDERUNG ZUR SOFORTIGEN WIEDERHERSTELLUNG EINES DATENTRÄGERS,"A technique is disclosed for restoring data of sparse volumes, where one or more block pointers within the file system structure are marked as ABSENT, and fetching the appropriate data from an alternate location on demand. Client data access requests to the local storage system initiate a restoration of the data from a backing store as required. A demand generator can also be used to restore the data as a background process by walking through the sparse volume and restoring the data of absent blocks. A pump module is also disclosed to regulate the access of the demand generator. Once all the data has been restored, the volume contains all data locally, and is no longer a sparse volume.",NETWORK APPLIANCE INC,LANGO JASON;;CHO YONG EUN;;EASTHAM PAUL CHRISTOPER;;ZHENG LING;;MANLEY STEPHEN L;;EDWARDS JOHN W;;ENGLISH ROBERT M;;ACKAOUY EMMANUEL,,https://lens.org/037-077-373-384-405,Granted Patent,no,0,0,10,14,0,G06F11/1435;;G06F11/1469;;G06F11/1464,G06F11/14;;G06F11/20,,0,0,,,,ACTIVE
541,NO,L,NO 20033608 L,054-273-252-340-865,2003-10-14,2003,NO 20033608 A,2003-08-14,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-amidopyrrol-2-ylmetliden)-2-indolinonderivater som protein kinase inhibitorer,,UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY THOMAS;;QINGWU JIN;;HERRINGTON PAUL,,https://lens.org/054-273-252-340-865,Abstract,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
542,WO,A1,WO 2002/066463 A1,044-336-014-158-139,2002-08-29,2002,US 0204407 W,2002-02-15,US 26868301 P;;US 31236101 P,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW,,https://lens.org/044-336-014-158-139,Patent Application,yes,3,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,1,1,008-976-852-428-425,10.1021/jm980123i;;9651163,"SUN ET AL: ""Synthesis and Biological Evaluation of 3-Substituted Indolin-2-ones: A novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particualr Receptor Tyrosine Kinases"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 14, July 1998 (1998-07-01), pages 2588 - 2603, XP002122185, ISSN: 0022-2623",PATENTED
543,SK,A3,SK 11332003 A3,156-903-221-495-073,2004-04-06,2004,SK 11332003 A,2002-02-15,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-Amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors,,SUGEN INC;;UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN OINGWU;;HERRINGTON PAUL MATTHEW,,https://lens.org/156-903-221-495-073,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,DISCONTINUED
544,US,B2,US 6653308 B2,019-432-526-752-143,2003-11-25,2003,US 7614002 A,2002-02-15,US 7614002 A;;US 26868301 P;;US 31236101 P,2001-02-15,3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors,"
    The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer. 
",SUGEN INC;;UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL M;;MAURAGIS MICHAEL A,PHARMACIA & UPJOHN COMPANY (2002-05-16);;SUGEN INC (2002-05-16),https://lens.org/019-432-526-752-143,Granted Patent,yes,99,70,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,514/235.2;;514/414;;544/58.2;;544/144;;546/177;;548/253;;548/255;;548/259;;548/261;;548/312.1;;548/468,99,79,008-976-852-428-425;;054-823-629-511-93X;;022-399-048-324-641;;176-879-479-576-661;;094-652-412-929-005;;067-272-607-027-112;;025-114-183-199-748;;018-048-709-473-304;;004-963-545-993-258;;000-955-818-332-098;;000-955-818-332-098;;009-185-209-152-939;;009-068-402-575-690;;049-540-021-873-405;;035-321-998-935-819;;002-840-884-592-149;;129-714-176-445-277;;042-517-545-674-669;;062-253-139-686-620;;030-880-199-478-403;;171-875-161-435-498;;068-347-002-933-411;;016-739-947-546-505;;130-779-644-212-195;;032-953-229-558-330;;078-578-887-209-471;;049-954-263-824-454;;060-092-756-707-151;;004-911-006-929-420;;102-148-719-482-24X;;099-279-971-758-096;;028-531-800-105-513;;016-333-429-871-463;;156-756-886-926-846;;037-134-997-566-90X;;037-465-890-679-37X;;104-815-369-514-254;;077-040-152-841-627;;122-261-121-873-625;;025-669-944-920-763;;043-489-715-583-833;;029-380-708-151-243;;120-787-793-242-483;;005-766-513-612-952;;081-381-735-516-869;;008-322-661-908-298;;025-209-481-691-070;;096-452-077-440-080;;013-790-909-287-914;;103-663-433-342-64X;;077-363-946-748-009;;128-267-202-156-519;;065-028-064-758-359;;009-954-017-681-952;;052-588-751-234-497;;010-830-508-694-564;;085-471-281-279-890;;000-260-545-266-425;;075-875-793-946-595;;020-017-567-104-545;;135-106-372-968-479;;029-871-534-065-762;;097-695-479-613-215;;045-890-249-073-273;;120-399-346-691-880;;049-676-058-590-911;;062-693-709-183-494;;079-734-101-870-347;;053-570-456-410-225;;102-943-963-373-742;;002-691-796-474-031;;094-207-501-631-352;;055-925-799-631-516;;027-603-408-160-490;;013-804-957-513-749;;106-753-778-592-300;;167-734-194-581-033;;011-265-567-519-296;;030-094-646-061-709,10.1021/jm980123i;;9651163;;10.1039/jr9540001697;;1331337;;10.1016/0022-510x(92)90060-x;;9042225;;10.1016/s0223-5234(97)82778-x;;9706372;;10.1172/jci114315;;2553774;;pmc304004;;7935391;;10.1128/mcb.14.10.6715-6726.1994;;10.1128/mcb.14.10.6715;;pmc359202;;10.1016/0040-4020(67)85040-3;;5793178;;5793179;;10.1021/jm00304a052;;10.1021/jm00304a050;;5793177;;10.1021/jm00304a051;;5793178;;5793179;;10.1021/jm00304a052;;10.1021/jm00304a050;;5793177;;10.1021/jm00304a051;;10.1039/j39660001028;;10.1080/00397919308011169;;10.1016/0092-8674(94)90023-x;;8001140;;7812953;;10.1080/00397918608057203;;10.1039/p29730001660;;10.1096/fasebj.6.15.1281458;;1281458;;8336932;;10.1128/mcb.5.6.1400-1407.1985;;pmc366870;;2993863;;10.1128/mcb.5.6.1400;;10.1002/jlac.19375320112;;8343210;;8099900;;10.1002/ijc.2910540409;;10.1002/jhet.5570220609;;9025911;;10.1006/abio.1996.9854;;10.1016/0092-8674(92)90068-n;;1547509;;10.1039/p29730000469;;9434891;;10.1021/jo00987a009;;8199353;;10.1016/0955-2235(94)90016-7;;10.1039/p29840000615;;pmc358831;;8007963;;10.1128/mcb.14.7.4588-4595.1994;;10.1128/mcb.14.7.4588;;10.1016/s0021-9673(00)86069-0;;10.1016/0006-2952(94)90152-x;;7945409;;1973827;;10.1021/jm00267a020;;4583274;;1312256;;10.1126/science.1312256;;3192948;;10.1016/0022-1759(88)90310-9;;10.1016/0040-4020(96)00695-3;;1360236;;10.1007/978-1-4615-3500-3_13;;10.1021/jo01031a502;;10.1016/0092-8674(92)90444-h;;1374684;;1689212;;2735925;;10.1016/0006-291x(89)92678-8;;8468926;;10.1038/ki.1993.55;;8441232;;10.1016/s0021-9258(19)49853-0;;1375931;;10.1056/nejm197111182852108;;4938153;;10.1093/jnci/82.1.4;;1688381;;5039962;;10.1111/1523-1747.ep12625746;;10.1021/jm00110a022;;1676428;;1802112;;3386259;;10.1016/0022-4731(88)90113-6;;8387483;;10.1016/s0021-9258(18)98327-4;;10.1021/op970037c;;10.1039/p19880001305;;10.1016/0040-4039(95)01202-s;;10.1139/v68-357;;3499230;;10.1016/0092-8674(87)90147-4;;10.1016/s0021-9258(18)35712-0;;1464614;;10.1016/0223-5234(92)90112-e;;10.1128/mcb.12.3.981;;10.1128/mcb.12.3.981-990.1992;;pmc369530;;1372091;;10.1021/bi00200a028;;7520755;;10.1091/mbc.4.1.49;;8443409;;pmc300899;;pmc556586;;1314164;;10.1002/j.1460-2075.1992.tb05182.x;;8376494;;10.1016/0378-4347(93)80472-g;;10.1002/jhet.5570250503;;7688466;;pmc47050;;10.1073/pnas.90.15.6939;;8248162;;10.1073/pnas.90.22.10705;;pmc47846;;10.1016/s0040-4020(01)92520-7;;7683111;;10.1038/362841a0;;1370939;;10.1016/0014-4827(92)90461-g;;10.1016/0960-9822(93)90073-w;;15335866;;925872;;10.1248/yakushi1947.97.9_1033;;10.1126/science.1708916;;1708916;;1172191;;10.1038/256495a0;;7689722;;pmc443180;;1401070;;10.1172/jci116001;;10.1016/0022-1759(83)90438-6;;6300286;;6199426,"Sun, Li et al., ""Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases,"" J. Med. Chem. 41:2588-2603, 1998, American Chemical Society, USA.;;Abramovitch and Hey, ""Internuclear cyclisation. Part VIII. Naphth[3:2:1-cd]oxindoles,"" J. Chem. Soc. 1697-1703 (1954), Strand, London.;;Abramovitch et al., ""A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement,"" Chemistry and Industry 44:1871 (1967) (C)Laporte Industries Limited, Lancashire.;;Beilstein Reg. No. 236050, Beilstein Reference No 4-21-00-06355.;;Akbasak and Sunar-Akbasak, ""Oncogenes: cause or consequence in the development of glial tumors,"" J. Neurol. Sci. 111:119-133 (1992) (C)Elsevier Science Publishers.;;Andreani et al., ""Potential Antitumor Agents, 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3Indolymethylene)1,3-Dihydroindol-2-Ones,"" Anticancer Research 16:3585-3588 (C) Elsevier, Paris.;;Andreani et al., ""Synthesis and cardiotonic activity of 2-indolinones,"" Eur. J. Med. Chem, 25:187-190 (1990).;;Andreani et al., ""Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups,"" Eur. J. Med. Chem. 28:653-657 (1993) (C)Elsevier, Paris.;;Andreani et al., ""Synthesis and cardiotonic activity of 2-indolinones,"" Chemical Abstracts, vol. 113, abstract no. 78106 (1990).;;Andreani et al., ""Synthesis and carditonic activity of pyridylmethylene-2-indolinones, ""Eur. J. Med. Chem. 27:167-170 (1992) (C)Elsevier, Paris.;;Andreani et al., ""Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones, ""Eur. J. Med. Chem. 32:919-924 (1997)(C)Elsevier, Paris.;;Andreani et al., ""Synthesis of lactams with potential cardiotonic activity,"" Eur. J. Med. Chem. 28:825-829 (1993).;;Andreani et al., ""In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones,"" Arzneimittel-Forschung Drug Research 48:727-729 (1998)(C).;;Arteaga et al., ""Blockade of the Type Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice,"" J. Clin. Invest. 84:1418-1423 (1989) copyright The American Society for Clinical investigation, Inc.;;Arvidsson et al., ""Tyr-716 in the Platelet-Derived Growth Factor beta-Receptor Kinase Insert in Involved in GRB2 Binding and Ras Activation,"" Molecular and Cellular Biology 14:6715-6726 (1994)(C) The American Society for Microbiology.;;Autrey and Tahk, ""The Synthesis and Sterochemistry of Some Isatylideneacetic Acid Derivatives,"" Tetrahedron 23:901-914 (1967) (C)Pergamon Press.;;Bahner and Brotherton, ""6-Dimethylaminochrysene and Other Analogs of 4-(4-Dimethylamino)stilbene,"" J. Med. Chem. 12:722-723 (1969).;;Bahner et al., ""Benzylideneindens with Oxygen Attached to the Indene Ring,"" J. Med. Chem. 12:721-722 (1969).;;Bamfield et al., ""Diels-Alder Reactions of Oxindolyideneacetone,"" J. Chem. Soc. (C) 1028-1030 (1966) (C).;;Barbier, et al., ""Synthesis of Isobrassilexin, A Biologically Active Isomer of Brassilexin, a Cruciferae Phytoalexin,"" Synthetic Communications23(22):3109-3117 (1993) (C)Marcel Dekker, Inc.;;Baserga, ""Oncogenes and the Strategy of Growth Factors,"" Cell 79:927-930 (1994)(C)Cell Press.;;Baserga, ""The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?"" Cancer Research 55:249-252 (1995).;;Beilstein Reg. No. 233511 (1997).;;Beilstein Reg. No. 235647 (1997).;;Beilstein Reg. No. 252929 (1998).;;Benzies, et al., ""2-Formyl-3-Methoxymethylindole, 3-Ethoxymethyl-2-Formylindoline and 2-Formyl-3-Methylindole,"" Synthetic Communications: 16(14), 1799-1807 (1986) (C)Mercel Dekker, Inc.;;Blake and Jaques, ""Anistrophic Effects in alpha-Substituted Methoxystilbenes,"" J. Chem. Soc. Perkin II: 1660-1663 (1973) (C)Pergamon, Oxford.;;Bolen et al., ""The Src family of tyrosine protein kinase in hemopoietic signal transduction,"" Faseb J. 6:3403-3409 (1992).;;Bolen, ""Nonreceptor tyrosine protein kinases,""Oncogene 8:2025-2031 (1993) copyright MacMillan Press Ltd.;;Bonner et al., ""Structure and Biological Activity of Human Homologs of the raf/mil Oncogene,"" Molecular and Cellular Biology 5:1400-1407 (1985)(C)The American Society for Microbiology.;;Borsche et al., ""Über vielkernige kondensierte Systeme mit heterocyclischen Ringen. XIII.,"" Liebigs Ann. Chem., 550:160-174 (1941).;;Buzzetti et al., ""Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases,"" Farmaco 48:615-636 (1993).;;Cance et al., ""Novel Protein Kinases Expressed In Human Breast Cancer,"" Int. J. Cancer 54:571-577 (1993) (C)Wiley-Liss, Inc.;;Canoira and Rodriguez, ""Synthesis of Oxindole Derivatives from N-Alkenyl-o-Chloroanilides with Zero-Valent Nickel Complex,"" J. Heterocyclic Chem. 22:1511-1518 (1985).;;Carpenedo et al., ""Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs,"" Analytical Biochemistry 244:74-79 (1997) (C)Academic Press, Inc.;;Chao, ""Growth Factor Signaling: Where Is the Specificity?""Cell 68:995-997 (1992) copyright Cell Press.;;Chatten et al., ""Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted trans-3-Benzylideneindol-2(3H)-ones,"" J. Org. Chem., 38:4002-4004 (C)The American Chemical Society.;;Chen et al., ""Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on gamma-Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron,"" Chinese Journal of Physiology40:149-156 (1997).;;Chatterjee et al., ""Acylation of Indoles by Duff Reaction and Vilsmeier-Haack Formylation and Conformation of N-Formylindoles,"" J. Org. Chem., 38:4002-4004 (C)The American Chemical Society.;;Claesson-Welsh, ""Signal Transduction by the PDGF Receptors,"" Progress in Growth Factor Research 5:37-54 (1994) (C)Elsevier Science Ltd.;;Coda et al., ""(Z)-and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies,""J. Chem.Soc.Perkin Trans. II: 615-619 (1984).;;Coda et al., ""3-(4-methylbenzilidene)-1,3-dihydroindol-2-one,"" Journal of the Chemical Society, Perkin Transactions 2 4:615-620 (1984) DATABASE CROSSFIRE, Beilstein Reference No. 6-21.;;Coppola et al., ""A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor,"" Molecular and Cellular Biology 14:4588-4595 (1994) (C)The American Society for Microbiology.;;Daisley and Walker, ""Thin-layer chromatographic separation of some substituted 3-benzylidene-indol-2(3H)-ones,""J. Chromatography 100:240-242 (1974)(C) Elsevier Scientific Publishing Company.;;Damiani et al., ""Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals,"" Biochemical Pharmacology 48:1155-1161 (1994) copyright Elsevier Science Ltd.;;Dati et al., ""Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells,"" Oncogens 5:1001-1006 (1990).;;Davis et al., ""Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds,""Journal of Medicinal Chemistry 16:1043-1045 (1973) (C)American Chemical Society.;;De Vries et al., ""The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor ,"" Science 255:989-991 (1992).;;Decker and Lohmann-Matthes, ""A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity,"" J. Immunol. Methods 15:61-69 (1988) copyright Elsevier.;;Decodts et al., ""Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams,"" Eur. J. Med. Chem , 18: 107-111 (1983).;;Desimoni et al., ""Catalysis with Inorganic Cations. V<1 >Intramolecular Hetero Diels-Alder versus Ene Reactions: Effect of Magnesium perchlorate on Chemoselectivity, ""Tetrahedron 52(36) 12009-12018 (1196) (C)Pergamon.;;Dickson et al., ""13. Tyrosine kinase receptor -nuclear protooncogene interactions in breast cancer,"" Cancer Treatment Res. 61:249-273 (1992) (C) Kluwer Acacemic Publishers.;;Elliott and Rivers, ""Reduction of Some Oxinodolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride,"" J. Med. Chem. 29:2438-2440 (1964).;;Elliott et al., ""1-methyl-2-(3-oxindolidenmethyl)-pyridinium, ""Journal of Organic Chemistry 29:2438-2440 (1964) DATABASE CROSSFIRE, Beilstein Reference No. 5-24.;;Fantl et al., ""Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules that Mediate Different Signaling Pathways,"" Cell 69:413-423 (1992) (C)Cell Press.;;Fendly et al., Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor of HER2/neu Gene Product, Cancer Research 50:1550-1558 (1990); @ American Association for Cancer Research.;;Ferrara and Henzel, ""Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells, "" Biochemical and Biophysical Research Communications 161:851-858 (1989)(C) Academic Press, Inc.;;Fingl and Woodbury, ""Chapter 1-General Principles, ""in The Pharmacological Basis of Therapeutics 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975) (C)MacMillan Publishing Co. Inc.;;Floege et al., ""Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo,"" Kidney International 43:S47-S54 (1993) (C)International Society of Nephrology.;;Floege et al., ""Heparin suppresses mesangial cell proliferation and matrix expansion in experimental masangiproliferative glomerulonephritis,"" Kidney International 43:369-380 (1993) (C)International Society of Nephrology.;;Folkman and Shing, ""Angiogenesis,""J. Biol. Chem. 267:10931-10934 (1992) (C)American Society for Biochemistry and Molecular Biology.;;Folkman, ""Ch. 24. Angiogenesis, ""Congress of Thrombosis and Haemostasis (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987).;;Folkman, ""Tumor Angiogenesis: Therapeutic Implications,""New England J. Medicine 285:1182-1186 (1971).;;Folkman ""What is the Evidence that Tumors are Angiogenesis Dependent?"" Journal of the National Cancer Institute 82:4-6 (1990).;;Folkman, ""Angiogenesis in Psoriasis: Therapeutic Implications,""J. Invest. Dermatol. 59:40-43 (1973) copyright The Williams & Wilkins Co.;;Gazit et al., ""Tyrphostins. 2. Heterocyclic and ⊕-Substituted Benzylidenemalinonitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases,""J. Med. Chem. 34:1896-1907 (1991) copyright Am. Clem. Soc.;;Gennaro (editor), Remington's Pharmaceutical Sciences (1990) (Table of Contents Only);;Goldring and Goldring, ""Cytokines and Cell Growth Control,"" Critical Reviews in Eukaryotic Gene Expression 1:301-326 (1991).;;Gottardis et al., ""Estradiol-Stimulated Growth of MC7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen,"" J. Steroid Biochem. 30:311-314 (1988) (C)Pergamon Press.;;Grazian et al., ""Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger,"" The Journal of Biochemical Chemistry 268:9165-9168 (1993) (C)American Society for Biochemistry and Molecular Biology.;;Hayler et al., Development of Large-Scale Synthesis of Ropinirole in the Pursuit if a Manufacturing Process, Organic Process Research & Development 2(1) 3-9 (1998) (C)The American Chemical Society and Royal Society of Chemistry.;;Hewgill and Stewart, ""Phenanthrene-4,5-quinones: a Synthesis of Morphenol,"" J. Chem. Soc. Perkin Trans. I:1305-1311 (1988).;;Hirao et al., ""Rhodium-Catalyzed Carbonylation of 2-Alkynylaniline: Synthesis of 1,3-Dihydroindol-2-ones,"" Tetrahedron Letters 36(35) 1995 (C)Pergamon.;;Hodges et al., ""Chemical and biological properties of some oxindolidyl-3-methines, "" Canadian J. Chemistry 46:2189-2194 (1968).;;Honegger et al., ""Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing, ""Cell 51:199-209 (1987) (C)Cell Press.;;Houck et al., ""Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms, "" J. Biol. Chem. 267:26031-26037 (1992)(C)American Society for Biochemistry and Molecular Biology, Inc.;;Howard, Harry R., ""Lactam Derivatives, ""U.S. Provisional Patent Application Number 60/015134.;;Howard et al., ""Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone-and oxindole-1-acetic acids,"" Eur. J. Med. Chem. 27:779-789 (1992) (C)Elsevier, Paris.;;Hu et al., ""Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors,"" Molecular and Cellular Biology 12:981-990 (1992) copyright Am. Soc. Microbiol.;;Ijaz et al., ""The Conversion of o,beta-Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones,"" J. Chem. Res. (S): 116 (1990).;;Jellinek et al., ""Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor,"" Biochemistry 33:10450-10456 (1994) (C) American Chemical Society.;;Kashishian and Cooper, ""Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cgamma1, "" Molecular Biology of the Cell 4:49-57 (1993) (C)The American Society for Cell Biology.;;Kashishian, ""Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and P13 kinase in vivo, ""The EMBO Journal 11:1373-1382 (1992).;;Kato et al., ""Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High Performance Liquid Chromatagraphy,"" Journal of Chromatography 616:67-71 (1993) (C)Elsevier Science.;;Katritzky et al., ""Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues,"" J. Heterocyclic Chem. 25:1287-1292 (1988).;;Kazlauskas et al., ""The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphates Syp,"" Proc. Natl. Acad. Sci. USA . 90:6939-6942 (1993).;;Kendall and Thomas, ""Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor,"" Proc. Natl. Acad. Sci. USA 90:10705-10709 (1993).;;Khalil and Abdel-Rahman, ""Synthesis of New Mero-and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes,"" J. Indian Chem. Soc. 54:904-907 (1977) (C)The Indian Chemical Society.;;Kikumoto et al., ""The Reactions of Oxindoles and Isatin with Nitrobenzyl Chlorides,"" Tetrahedron 22:3337-3343 (1966) (C)Pergamon Press Ltd.;;Kim et al., ""Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, "" Nature 362:841-844 (1993).;;Kinsella et al., ""Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel,"" Exp. Cell Research 199:56-62 (1992) (C)Academic Press, Inc.;;Klagsbrun and Soker, ""VEGF/VPF: the andiogenesis factor found?"" Current Biology 3:699-702 (1993) (C)Current Biology.;;Kobayashi et al., ""Anti-tumor Activity of Indole Derivatives,"" Yakugaku Zasshi, 97:1033-1039 (1977).;;Koch et al., ""SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins,"" Science 252:668-674 (1991).;;Kohler and Milstein, ""Continuous cultures of fused cells secreting antibody of predefined specificity,"" Nature 256: 495-497 (1975).;;Komada and Kitamura, ""The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor,"" Oncogene 8:2381-2390 (1993).;;Korc et al., ""Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha,"" J. Clin. Invest. 90: 1352-1360 (1992) copyright The American Society for Clinical Investigation, Inc.;;Korzeniewski and Callewaert, ""An Enzyme-Release Assay for Natural Cytotoxicity,"" J. Immunol. Methods 64:313-320 (1983) (C) Elsevier Science Publishers.;;Kovac and Stetinova, ""Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoxindoles,"" Chem.rvesu 30:484-492 (1976).",EXPIRED
545,TW,A,TW 201630376 A,027-748-295-496-082,2016-08-16,2016,TW 104143443 A,2015-12-23,US 201462096168 P;;US 201562183176 P;;US 201562190239 P;;US 201562201516 P;;US 201514978039 A,2014-12-23,Shortened block acknowledgement with fragmentation acknowledgement signaling,"Certain aspects of the present disclosure provide methods and apparatus for using a shortened block acknowledgement (BlockAck) frame capable of acknowledging fragments. Such a shortened BlockAck frame may include a bitmap field having a shorter length than that of a basic BlockAck frame in the IEEE 802.11 standard (i.e., < 128 octets). One example method for wireless communications generally includes receiving a plurality of protocol data units (PDUs) (e.g., media access control (MAC) protocol data units (MPDUs)); determining whether each of the PDUs was successfully received and whether each of the PDUs is associated with a non-fragmented service data unit (SDU) (e.g., MAC service data unit (MSDU)) or a fragmented SDU; and outputting for transmission a shortened BlockAck frame comprising a bitmap field indicating a receive status for the non-fragmented and fragmented SDUs based on the determination.",QUALCOMM INC,ASTERJADHI ALFRED;;MERLIN SIMONE;;CHERIAN GEORGE;;ABRAHAM SANTOSH PAUL;;BARRIAC GWENDOLYN DENISE;;MALIK RAHUL;;DING GANG;;FREDERIKS GUIDO ROBERT;;CHO JAMES SIMON,,https://lens.org/027-748-295-496-082,Patent of Addition,no,0,1,11,11,0,H04L1/1614;;H04L1/1685;;H04L1/1685;;H04L1/1614;;H04L1/1614;;H04L1/1685;;H04L5/0055;;H04W72/04;;H04L5/0055;;H04L1/1614;;H04W72/04;;H04L1/1685,H04L5/02;;H04L12/70;;H04L29/02,,0,0,,,,PENDING
546,EE,A,EE 200300385 A,040-158-150-198-27X,2004-02-16,2004,EE P200300385 A,2002-02-15,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-amidopürrool-2-üülmetülideen)-2-indolinooni derivaadid kui proteiini kinaasi inhibiitorid,,SUGEN INC;;UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINGTON PAUL MATTHEW,,https://lens.org/040-158-150-198-27X,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,PENDING
547,CN,A,CN 107113111 A,101-715-148-692-770,2017-08-29,2017,CN 201580070209 A,2015-12-23,US 201462096168 P;;US 201562183176 P;;US 201562190239 P;;US 201562201516 P;;US 201514978039 A;;US 2015/0000267 W,2014-12-23,Shortened block acknowledgement with fragmentation acknowledgement signaling,"Certain aspects of the present disclosure provide methods and apparatus for using a shortened block acknowledgement (BlockAck) frame capable of acknowledging fragments. Such a shortened BlockAck frame may include a bitmap field having a shorter length than that of a basic BlockAck frame in the IEEE 802.11 standard (i.e.,<128 octets). One example method for wireless communications generally includes receiving a plurality of protocol data units (PDUs) (e.g., media access control (MAC) protocol data units (MPDUs)); determining whether each of the PDUs was successfully received and whether each of the PDUs is associated with a non-fragmented service data unit (SDU) (e.g., MAC service data unit (MSDU)) or a fragmented SDU; and outputting for transmission a shortened BlockAck frame comprising a bitmap field indicating a receive status for the non-fragmented and fragmented SDUs based on the determination.",QUALCOMM INC,ASTERJADHI ALFRED;;MERLIN SIMONE;;CHERIAN GEORGE;;ABRAHAM SANTOSH PAUL;;BARRIAC GWENDOLYN DENISE;;MALIK RAHUL;;DING GANG;;FREDERIKS GUIDO ROBERT;;CHO JAMES SIMON,,https://lens.org/101-715-148-692-770,Patent Application,no,6,3,11,11,0,H04L1/1614;;H04L1/1685;;H04L1/1685;;H04L1/1614;;H04L1/1614;;H04L1/1685;;H04L5/0055;;H04W72/04;;H04L5/0055;;H04L1/1614;;H04W72/04;;H04L1/1685,H04L1/16,,0,0,,,,DISCONTINUED
548,US,S,US D0762812 S,026-739-136-874-460,2016-08-02,2016,US 201529527411 F,2015-05-19,US 201529527411 F,2015-05-19,Filter cartridge,,3M INNOVATIVE PROPERTIES CO;;ELECTROLUX HOME PRODUCTS,BRANSCOMB MATT R;;MAKI JEFFREY M;;SCHMOLL JEREMY A;;KRAGNESS JON P;;CURTIS BRENT AARON;;MCCOLLOUGH THOMAS;;SHRADER BENJAMIN PAUL;;CHO NATHAN,SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (2024-02-01);;3M INNOVATIVE PROPERTIES COMPANY (2015-06-02);;ELECTROLUX HOME PRODUCTS (2016-05-02),https://lens.org/026-739-136-874-460,Design Right,no,0,22,1,1,0,,,2301;;D23/209,0,0,,,,ACTIVE
549,HR,A2,HR P20030657 A2,002-380-333-882-305,2005-10-31,2005,HR P20030657 A,2003-08-14,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,,SUGEN PHARMACIA & UPJOHN COMPA,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG-CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JUN QUINGWU;;HERRINGTON PAUL MATTHEW,,https://lens.org/002-380-333-882-305,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
550,MA,A1,MA 26997 A1,047-948-993-633-445,2004-12-20,2004,MA 27282 A,2003-08-15,US 26868301 P;;US 31236101 P,2001-02-15,DERIVES DE 3-(4-AMIDOPYRROLE-2-YLMETHYLIDENE)-2-INDOLINONE UTILISABLES COMME INHIBITEURS DE PROTEINE-KINASES,"DEPOSANT Sociétés dites : SUGEN, INC. PHARMACIA & UPJOHN COMPANY REVENDICATION DE PRIORITES US 15 Février 2001 60/268,683 US 15 Août 2001 60/312,361 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de 3-(4-amidopyrrole-2-ylméthylidène) 2-indolinone utilisables comme inhibiteurs de protéine-kinases La présente invention concerne des dérivés de 2-indolinone à substituant pyrrole et leurs sels pharmaceutiquement acceptables qui modulent l'activité de protéine-kinases et pour lesquels il est donc prévu une utilité dans la prévention et le traitement de troubles cellulaires en rapport avec des protéine-kinases, tels que le cancer.",SUGEN INC;;UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW,,https://lens.org/047-948-993-633-445,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
551,OA,A,OA 12834 A,055-145-397-136-048,2006-09-15,2006,OA 1200300211 A,2002-02-15,US 26868301 P;;US 31236101 P,2001-02-15,3-(4-Amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitiors.,,UPJOHN CO;;SUGEN INC,GUAN HUIPING;;HERRINGTON PAUL MATTHEW;;JIN QINGWU;;LIANG CONGXIN;;MAURAGIS MICHAEL A;;SUN LI;;TANG PENG CHO;;VOJKOVSKY THOMAS;;WEI CHUNG CHEN,,https://lens.org/055-145-397-136-048,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D403/06;;A61K31/404;;A61K31/4166;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P35/00;;C07D/;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
552,BR,A2,BR 112017013360 A2,030-776-557-502-240,2018-03-06,2018,BR 112017013360 A,2015-12-23,US 2015/0000267 W;;US 201462096168 P;;US 201562183176 P;;US 201562190239 P;;US 201562201516 P;;US 201514978039 A,2014-12-23,confirmação de bloco encurtado com sinalização de fragmentação de confirmação,"certos aspectos da presente divulgação proveem métodos e aparelhos para a utilização de um quadro de confirmação de bloco encurtado (blockack) capaz de confirmar fragmentos. tal quadro de blockack encurtado pode incluir um campo de mapa de bits tendo um comprimento mais curto do que o de um quadro de blockack básico na norma ieee 802.11 (isto é, < 128 octetos). um exemplo de método para comunicações sem fio inclui, geralmente, receber uma pluralidade de unidades de dados de protocolo (pdus) (por exemplo, unidades de dados de protocolo de controle de acesso ao meio (mac) (mpdus)); determinar se cada uma das pdus foi recebida com sucesso e se cada uma das pdus está associada com uma unidade de dados de serviço não fragmentado (sdu) (por exemplo, unidade de dados de serviço de mac (msdu)) ou uma sdu fragmentada; e emitir para a transmissão de um quadro de blockack encurtado que compreende um campo de mapa de bits, indicando um status de recepção para as sdus não fragmentadas e fragmentadas com base na determinação.",QUALCOMM INC,ALFRED ASTERJADHI;;GANG DING;;GEORGE CHERIAN;;GUIDO ROBERT FREDERIKS;;GWENDOLYN DENISE BARRIAC;;JAMES SIMON CHO;;RAHUL MALIK;;SANTOSH PAUL ABRAHAM;;SIMONE MERLIN,,https://lens.org/030-776-557-502-240,Patent Application,no,0,0,11,11,0,H04L1/1614;;H04L1/1685;;H04L1/1685;;H04L1/1614;;H04L1/1614;;H04L1/1685;;H04L5/0055;;H04W72/04;;H04L5/0055;;H04L1/1614;;H04W72/04;;H04L1/1685,H04L1/16,,0,0,,,,DISCONTINUED
553,AP,A,AP 1718 A,064-379-274-822-273,2007-01-30,2007,AP 2003002836 A,2002-02-15,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors,The invention provides compounds and their use having a generic structure.,SUGEN INC;;UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINGTON PAUL MATTHEW,,https://lens.org/064-379-274-822-273,Granted Patent,no,2,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,1,0,,,"JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 14, July 1998 (1998-07), pages 2588-2603",EXPIRED
554,AU,B2,AU 2002/247133 B2,097-288-177-716-704,2007-08-30,2007,AU 2002/247133 A,2002-02-15,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors,,PHARMACIA & UPJOHN CO LLC;;SUGEN INC,TANG PENG CHO;;JIN QINGWU;;SUN LI;;VOJKOVSKY TOMAS;;GUAN HUIPING;;MAURAGIS MICHAEL A;;WEI CHUNG CHEN;;HERRINTON PAUL MATTHEW;;LIANG CONGXIN,"SUGEN, INC.; PHARMACIA & UPJOHN COMPANY LLC (2007-10-18)",https://lens.org/097-288-177-716-704,Granted Patent,no,3,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D403/06;;A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/14;;C07D413/14;;C07D471/04,,1,1,008-976-852-428-425,10.1021/jm980123i;;9651163,"Sun, Li., et al. J. Med. Chem. 1998 41 2588-2603",EXPIRED
555,US,B2,US 7809693 B2,105-831-639-471-116,2010-10-05,2010,US 40962606 A,2006-04-24,US 40962606 A;;US 36130303 A;;US 67443005 P,2003-02-10,System and method for restoring data on demand for instant volume restoration,"A technique is disclosed for restoring data of sparse volumes, where one or more block pointers within the file system structure are marked as ABSENT, and fetching the appropriate data from an alternate location on demand. Client data access requests to the local storage system initiate a restoration of the data from a backing store as required. A demand generator can also be used to restore the data as a background process by walking through the sparse volume and restoring the data of absent blocks. A pump module is also disclosed to regulate the access of the demand generator. Once all the data has been restored, the volume contains all data locally, and is no longer a sparse volume.",NETAPP INC,LANGO JASON ANSEL;;CHO YONG EUN;;EASTHAM PAUL CHRISTOPHER;;ZHENG LING;;MANLEY STEPHEN L;;EDWARDS JOHN K;;ENGLISH ROBERT M;;ACKAOUY EMMANUEL,NETAPP INC (2006-08-14),https://lens.org/105-831-639-471-116,Granted Patent,yes,91,38,3,14,0,G06F16/10;;G06F16/10,G06F15/16;;G06F17/30,707/679;;707/686,95,28,003-830-560-393-677;;185-822-237-193-923;;187-552-317-537-20X;;070-852-624-143-237;;034-082-828-628-654;;138-384-758-933-032;;115-653-650-342-968;;073-803-873-780-366;;118-803-795-491-26X;;046-401-738-237-255;;005-596-589-846-940;;145-076-466-874-682;;062-220-644-824-624;;024-408-381-267-024;;034-503-924-328-160;;110-333-611-078-805;;111-691-277-637-654;;003-969-461-063-513;;106-800-948-100-241;;065-644-162-769-886;;144-144-484-946-50X;;147-109-563-054-804;;072-680-043-192-49X;;063-676-340-028-09X;;053-030-476-168-790;;150-234-170-607-309;;035-297-134-619-360;;042-984-932-165-592,10.1145/38807.38819;;10.1145/272682.272717;;10.1145/98460.98509;;10.1147/sj.283.0407;;10.1145/76372.76378;;10.1016/b978-0-932376-22-0.50013-2;;10.1145/93605.98744;;10.1145/320521.320540;;10.1145/323627.323634;;10.1145/121132.286600;;10.1002/spe.4380211203;;10.1007/978-1-4615-2221-8;;10.1145/146941.146943;;10.1145/323647.323633;;10.1146/annurev.cs.04.060190.000445;;10.1109/wwos.1989.109279;;10.1109/12.54838;;10.1109/2.53351;;10.21236/ada611544;;10.21236/ada197007;;10.1145/356842.356847;;10.1145/319996.320002;;10.1109/32.4635;;10.1145/146941.146942;;10.1147/sj.422.0322;;10.21236/ada604306;;10.1109/mass.1993.289764;;10.1145/50202.50214,"Azagury et al., Point-in-Time Copy: Yesterday, Today and Tomorrow, IBM 2002.;;Caplinger, ""An Information System Based on Distributed Objects"", 1987, ACM.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration. Apr. 24, 2006. PCT/US 2006/015442.;;Administration Guide found at http://www.openafs.org/pages/doc/AdminGuide/auagd010.htm, visited on Mar. 2, 2005.;;Basilico, et al., Error Correction System Using ""Shadow Memory,"" IBM Technical Disclosure Bulletin, May 1984, pp. 5792-5793.;;Bitton, Dina, Disk Shadowing, Proceedings of the 14th VLDB Conference, LA, CA (1988).;;Blasgen, M.W. et al., System R:An architectural Overview, Reprinted from IBM Systems Journal vol. 20, No. 1, 1981 © 1981, 1999.;;Borenstein, Nathaniel S., CMU's Andrew project a retrospective, Communications of ACM, (39)12, Dec. 1996.;;Brown, Mark R. et al., The Alpine file system, ACM Transactions on Computing Systems, 3(4):261-293, Nov. 1985.;;Chen, Peter M., et al., An Evaluation of Redundant Arrays of Disks Using an Amdahl 5890 Performance Evaluation, pp. 74-85, 1990.;;Chutani, Sailesh, et al., The Episode file system, In Proceedings of the USENIX Winter 1992.;;Clark, B.E., et al., Application System /400 Performance Characteristics, IBM Systems Journal, 28(3): 407-423, 1989.;;Data Sheet for the Check Point Software Technologies product Flood-Gate-1 (1997).;;Dibble, Peter C., et al., Beyond Striping: The Bridge Multiprocessor File System, Computer Science Department, University of Rochester, Aug. 11, 1989.;;Douglis, Fred, et al., A comparison of two distributed systems: Amoeba and Sprite-Computing Systems, 4(4), Fall 1991, pp. 353-385 ?(copy of article I have has no date or cite).;;Gait, Jason, Phoenix: A Safe In-Memory File System. Communications of the ACM, 33(1):81-86, Jan. 1990.;;Hartman, John H. et al., Performance Measurements of a Multiprocessor Sprite Kernel, Proceedings of the USENIX Conference, 1990.;;Hitz, Dave et al., File System Design for an NFS File Server Appliance, Technical Report 3002, Rev. C395, presented Jan. 19, 1994.;;Howard, John H, et al. Scale and Performance in a Distributed File System, Carnegie Mellon University, CMU-ITC-87-068, Aug. 5, 1987.;;Howard, John, H. et al., Scale and performance in a distributed file system, ACM Trans. Computer. System., 6(1), Feb. 1988 pp. 51-81.;;Howard, John H., An Overview of the Andrew File System, Carnegie Mellon University, CMU-ITC-88-062.;;The IBM System/38, Chapter 8, pp. 137-15.;;Isomaki, Markus, Differentiated Service for the Internet, Department of Technical Physics and Mathematics, May 9, 1998.;;Kazar, Michael L., et al., Decorum File System Architectural Overview, USENIX Summer Conference, Anaheim, California, 1990.;;Lango, Jason, et al., Architecture for Supporting Sparse Volumes, USPTO U.S. Appl. No. 60/674,641. Apr. 25, 2005.;;Lango, Jason, et al., Architecture for Supporting Sparse Volumes, USPTO U.S. Appl. No. 11/409,624. Apr. 24, 2006.;;Lango, Jason, et al., System and Method for Restoring Data on Demand for Instant Volume Restoration,, USPTO U.S. Appl. No. 60/674,430. Apr. 25, 2005.;;Lango, Jason, et al., System and Method for Sparse Volumes, USPTO U.S. Appl. No. 11/409,887. Apr. 24, 2006.;;Lango, Jason., System and Method for Sparse Volumes, USPTO U.S. Appl. No. 60/674,611. Apr. 25, 2005.;;Lomet, David., et al., The performance of a multiversion access method, ACM SIGMOD International Conference on Management of Data, 19:353-363.;;Lorie, Raymond, A, Physical integrity in a large segmented database, ACM Trans. Database Systems, (2)1:91-104, Mar. 1977.;;Lorie, Ra, Shadow Page Mechanism, IBM Technical Disclosure Bulletin, Jun. 1986, pp. 340-342.;;McKusick, Marshall Kirk, et al., A Fast File System for UNIX, Computer Science Division, Department of Electrical Engineering and Computer Sciences, Univ. of CA, Berkley, Feb. 18, 1994.;;Moons, Herman et al., Location-Independent Object Invocation in Open Distributed Systems, Autumn 1991 EurOpen Technical Conference and Exhibition, pp. 287-300 (Sep. 16-20, 1991).;;Morris, James H., et al, Andrew: A Distributed Personal Computing Environment, Comm. of the ACM, vol. 29, Mar. 1986, pp. 184-201.;;Mullender, Sape J., et al., A distributed file service based on optimistic concurrency control, ACM Symposium on Operating System Principles (Orcas Island, Washington). Published as Operating Systems Review, 19(5):51-62, Dec. 1985.;;Muller, Keith, et al., A High Performance Multi-Structured File System Design, In Proceedings of the 13th ACM Symposium on Operating Systems Principles, Oct. 1991, pp. 56-67.;;Ousterhout, John K. et al., The Sprite Network Operating System, Computer Science Division, Department of Electrical Engineering and Computer Sciences, Univ. of CA, Berkley, Nov. 19, 1987.;;Ousterhout, John et al., Beating the I/O Bottleneck: A Case for Log-Structured File Systems, Technical Report, Computer Science Division, Electrical Engineering and Computer Sciences, University of California at Berkeley, Oct. 30, 1988.;;Ousterhout, John, Why Aren't Operating Systems Getting Faster as Fast as Hardware?, Digital WRL Technical Note TN-11, Oct. 1989.;;Ousterhout, John, A Brief Retrospective On The Sprite Network Operating System, found at http://www.cs.berkeley.edu/projects/sprite/retrospective.html,visited on Mar. 11, 2005.;;Patterson, D., et al., A Case for Redundant Arrays of Inexpensive Disks (Raid), Technical Report, CSD-87-391, Computer Science Division, Electrical Engineering and Computer Sciences, University of California at Berkeley (1987).;;Peterson, Zachary Nathaniel Joseph, Data Placement for Copy-on-Write Using Virtual Contiguity, University of CA, Santa Cruz, Master of Science in Computer Science Thesis, Sep. 2002.;;Quinlan, Sean, A Cached WORM File System, Software-Practice and Experience, 21(12):1289-1299 (1991).;;Redundant Array of Independent Disks, from Wikipedia, the free encyclopedia, found at http://en.wikipedia.org/wiki/RAID, visited on Mar. 9, 2005.;;Rosenberg, J., et al., Stability in a Persistent Store Based on a Large Virtual Memory, In Security and Persistence, Rosenber, J. & Keedy, J.L. (ed), Springer-Verlag (1990) pp. 229-245.;;Rosenblum, Mendel, et al., The LFS Storage Manager, Computer Science Division, Electrical Engin. And Computer Sciences, Univ. of CA, presented at Summer '90 USENIX Technical Conference, Anaheim, CA Jun. 1990.;;Rosenblum, Mendel, et al, The Design and Implementation of a Log-Structured File System Jul. 24, 1991 pp. 1-15.;;Rosenblum, Mendel, et al., The Design and Implementation of a Log-Structured File System, , In Proceedings of ACM Transactions on Computer Systems, (10)1:26-52, Feb. 1992.;;Sandberg, Russel et al., Design and implementation of the Sun Network Filesystem. In Proc. Summer 1985 USENIX Conf., pp. 119-130, Portland OR (USA), Jun. 1985.;;Santry, Douglas S., et al., Deciding When to Forget in the Elephant File System, Operating Systems Review, 34(5), (Dec. 1999) pp. 110-123.;;Satyanarayanan, M., et al., The ITC Distributed File System: Principles and Design, In Proceedings of the 10th ACM Symposium on Operating Systems Principles, (19)5:56-67, Dec. 1985.;;Satyanarayanan,.M.. A survey of distributed file-systems. Annual Review of Computing Science, 4(73-104), 1989.;;Satyanarayanan, M., et al, Coda: A highly available file system for a distributed workstation environment Carnegie Mellon University, CMU-ITC.;;Satyanarayanan, M., et al, Coda: A highly available file system for a distributed workstation environment. IEEE Transactions on Computers, 39(4):447-459, 1990.;;Satyanarayanan, Mahadev, Scalable, Secure, and Highly Available Distributed File Access, Computer May 1990:9-21.;;Sidebotham, Bob, Volumes: The Andrew File System Data Structuring Primitive, EEUG Conference Proceedings, Manchester, UK, Autumn 1986.;;User Guide found at http://www.openafs.org/pages/doc/UserGuide/auusg004.htm, visited on Mar. 2, 2005.;;Welch, Brent B., et al., Pseudo Devices: User-Level Extensions to the Sprite File System, Computer Science Division, Department of Electrical Engineering and Computer Sciences, Univ. of CA, Berkley, Apr. 1988.;;Welch, Brent B., et al., Pseudo-File-Systems, Computer Science Division, Department of Electrical Engineering and Computer Sciences, Univ. of CA, Berkley, Oct. 1989.;;Wittle, Mark, et al, LADDIS: The next generation in NFS file server benchmarking, USENIX Association Conference Proceedings, Apr. 1993.;;Cramer et al. ""System and Method for Associating a Network Address with a Storage Device"", U.S. Appl. No. 10/138,918, filed May 3, 2002, 35 pages.;;Common Internet File System (CIFS) Version: CIFS-Spec 0.9, Storage Networking Industry Association (SNIA), Draft SNIA CIFS Documentation Work Group Work-in-Progress, Revision Date: Mar. 26, 2001.;;Fielding et al. (1999) Request for Comments (RFC) 2616, HTTP/1.1.;;Black, David L. ""Scheduling and Resource Management Techniques for Multiprocessors"", Jul. 1990, CMU-CS-90-152.;;Akyurek, Sedat. ""Placing Replicated Data to Reduce Seek Delays"", Department of Computer Science, University of Maryland, UMIACS-TR-91-121, CS-TR-2746, Aug. 1991.;;Chaudhuri, Surajit, et al., Self-Tuning Technology in Microsoft SQL Server, Data Engineering Journal 22, 2 1999 pp. 20-27.;;Coyne, Robert A., et al., Storage Systems for National Information Assets, Proc. Supercomputing 92, Minneapolis, Nov. 1992, pp. 626-633.;;Finlayson, Ross S., et al., Log Files: An Extended File Service Exploiting Write-Once Storage Department of Computer Science, Stanford University, Report No. STAN-CS-87-1177, Sep. 1987.;;Gray, Jim, et al., The Recovery Manager of the System R Database Manager, ACM Computing Surveys, (13)2:223-242 1981.;;Hecht, Matthew S., et al. Shadowed Management of Free Disk Pages with a Linked List, ACM Transactions on Database Systems, 8/4, Dec. 1983, pp. 503-514.;;Kazar, Michael Leon, Synchronization and Caching Issues in the Andrew File System, Carnegie Mellon University, CMU-ITC-88-063.;;Kemper, Alfons, et al., Performance Tuning for SAP R/3, Data Engineering Journal 22, 2 1999 pp. 33-40.;;Kent, Jack et al., Optimizing Shadow Recovery Algorithms, IEEE Transactions on Software Engineering, 14( 2): 155-168 , Feb. 1988.;;Kistler, et al., Disconnected Operation in the Coda File System, ACM Transactions on Computer Systems, vol. 10, No. 1, Feb. 1992, pp. 3-25.;;Schiefer, Berni, et al., DB2 Universal Database Performance Tuning, Data Engineering Journal 22, 2 1999 pp. 12-19.;;Seltzer, Margo I., et al., Journaling Versus Soft Updates: Asynchronous Meta-Data Protection in File Systems, Proceedings of 200 USENIX Annual Technical Conference, Jun. 18-23, 2000.;;Shasha, Dennis, Tuning Time Series Queries in Finance: Case Studies and Recommendations, Data Engineering Journal 22, 2 1999 pp. 41-47.;;Subramanian, Muralidhar, et al., Performance Challenges in Object-Relational DBMSs, Data Engineering Journal 22, 2 1999 pp. 28-32.;;Weikum, Gerhard, et al., Towards Self-Tuning Memory Management for Data Servers, Data Engineering Journal 22, 2 1999 pp. 3-11.;;West, Michael, et al. The ITC Distributed File System: Prototype and Experience, Carnegie-Mellon University, Technical Report CMU-ITC-040, Mar. 1985.;;Zayas, Edward R., AFS-3 Programmer's Reference: Architectural Overview, Transarc Corporation, Pittsburgh, PA, 1.0 edition 1991.;;""Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration"", PCT/US2006/015242, mailed Apr. 24, 2006.;;Kaczmarski et al. ""Beyond Backup Toward Storage Management"", IBM Systems Journal, vol. 42, No. 2, 2003.;;Wilhelm-Olson et al. ""Data Protection Strategies for Network Appliance Storage Systems"", Apr. 25, 2003.;;Burns et al., Storage Virtualization-Definition Why, What, Where, and How?, Nov. 1, 2004.;;Kang et al. ""Improving Storage System Flexibility Through Virtual Allocation"", Department of Electrical Engineering, Texas A&M University, College Station, Texas.;;Lango, Jason, System and Method for Caching Network File Systems, U.S. Appl. No. 60/674,609, filed Apr. 25, 2005, 52 pages.;;Rosenblum, Mendel, The Design and Implementation of a Log-Structured File System, 1992, pp. 1-93.;;Godbole, Rajesh, An Introduction to FlexCache Volumes / Implementing File Caching on Filers, Network Appliance, Inc., May 2005, pp. 1-14, TR3399.;;""Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration"", mailed Apr. 24, 2006, International Application No. PCT/US2006/015279, 7 pages.;;Kim et al., Exploiting Metadata of Absent Objects for Proxy Cache Consistency, IEICE Transactions on Communications, vol. E-84B, No. 5, May 2001, pp. 1406-1412.;;Miller, Ethan L., et al., RAMA: A File System for Massively Parallel Computers, 12.sup.th IEEE Symposium on Mass Storage Systems, Monterey CA, Apr. 1993, pp. 163-168.;;Patterson, D., et al., A Case for Redundant Arrays of Inexpensive Disks (RAID), SIGMOD International Conference on Management of Data, Chicago, IL, USA, Jun. 1-3, 1988, SIGMOD Record (17):3:109-16 (Sep. 1988).;;Invitation to Pay Additional Fees. PCT/US2006/015442. Apr. 24, 2006.",EXPIRED
556,EP,A1,EP 3860855 A1,165-841-312-979-693,2021-08-11,2021,EP 19869873 A,2019-10-04,US 201816153238 A;;US 2019/0054746 W,2018-10-05,APPARATUS AND METHODS FOR ADDITIVELY MANUFACTURED STRUCTURES WITH AUGMENTED ENERGY ABSORPTION PROPERTIES,,DIVERGENT TECH INC,CHO YONG-BAE;;MARTINEZ ANTONIO BERNERD;;GUNNER JON PAUL;;TENG ALEXANDER PAI-CHUNG;;TENHOUTEN BROC WILLIAM;;LAKSHMAN NARENDER SHANKAR;;HOYLE RICHARD WINSTON,,https://lens.org/165-841-312-979-693,Patent Application,yes,0,0,10,10,0,B60R19/02;;B29C64/20;;B29C64/153;;B33Y30/00;;B60R2019/186;;B60R19/18;;B60R19/03;;B60R19/023;;B60R2019/1853;;B33Y80/00;;B22F2999/00;;C22C49/06;;C22C49/14;;C22C47/16;;C23C24/08;;C23C24/082;;C23C24/087;;F16F7/003;;F16F2226/00;;B29C45/14795;;B29C45/0001;;B29K2105/04;;B29L2031/3044;;B29C45/14631;;Y02P10/25;;B60R19/34;;B62D21/152;;F16F7/003;;B60R19/03;;B60R19/18;;B33Y10/00;;B33Y80/00;;B29L2031/3044;;B29C45/14;;F16F2226/00;;F16F2224/0241;;F16F2224/0208;;B60R2019/186;;B29K2105/04;;B29C64/10,B33Y50/02;;B29C64/386;;B29C64/393;;B33Y50/00,,0,0,,,,PENDING
557,NZ,A,NZ 527572 A,173-797-269-927-226,2005-07-29,2005,NZ 52757202 A,2002-02-15,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors,"Disclosed are compounds of formula (I), wherein: R1 is H, halo, alkyl, haloalkyl, cycloalkyl, heteroalicyclic, hydroxy, alkoxy, -C(O)R8, -NR9R10 or -C(O)NR12R13, R2 is H, halo, alkyl, trihalomethyl, hydroxy, alkoxy, cyano, -NR9R10, -NR9C(O)R10, -C(O)R8, -S(O)2NR9R10 or - SO2R14, R3, R4 and R5 are independently H or alkylo, Z is aryl, heteroaryl, heterocycle, or -NR15R16 wherein R15 and R16 are independently H or alkyl, or R15 and R16 together form a heterocycloamino group, R6 is H or alkyl, R7 is H, alkyl, aryl, heteroaryl, or -C(O)R17, and the remaining substituents are defined herein. The compounds are used in the manufacture of medicaments for the modulation of the catalytic activity of a protein kinase.",SUGEN INC,LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;ERRINTON PAUL MATTHEW;;GUAN HUIPING,,https://lens.org/173-797-269-927-226,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,PENDING
558,ZA,B,ZA 200306335 B,084-301-441-139-603,2005-01-26,2005,ZA 200306335 A,2003-08-14,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,,SUGEN INC;;PHARMCIA & UPJOHN COMPANY,PENG CHO TANG;;CHUNG CHEN WEI;;CONGXIN LIANG;;LI SUN;;TOMAS VOJKOVSKY;;HUIPING GUAN;;PAUL MATTHEW HERRINTON;;MICHAEL A MAURAGIS;;QINGWU JIN,,https://lens.org/084-301-441-139-603,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D/;;A61K/;;A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P/;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
559,CA,A1,CA 2438314 A1,085-757-289-341-680,2002-08-29,2002,CA 2438314 A,2002-02-15,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention an d treatment of protein kinase related cellular disorders such as cancer.</SDOA B>,SUGEN INC;;UPJOHN CO,JIN QINGWU;;VOJKOVSKY TOMAS;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;HERRINTON PAUL MATTHEW;;TANG PENG CHO;;SUN LI;;LIANG CONGXIN;;GUAN HUIPING,,https://lens.org/085-757-289-341-680,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
560,US,B2,US 9929847 B2,111-987-198-479-400,2018-03-27,2018,US 201514978039 A,2015-12-22,US 201514978039 A;;US 201562201516 P;;US 201562190239 P;;US 201562183176 P;;US 201462096168 P,2014-12-23,Shortened block acknowledgement with fragmentation acknowledgement signaling,"Certain aspects of the present disclosure provide methods and apparatus for using a shortened block acknowledgement (BlockAck) frame capable of acknowledging fragments. Such a shortened BlockAck frame may include a bitmap field having a shorter length than that of a basic BlockAck frame in the IEEE 802.11 standard (i.e., <128 octets). One example method for wireless communications generally includes receiving a plurality of protocol data units (PDUs) (e.g., media access control (MAC) protocol data units (MPDUs)); determining whether each of the PDUs was successfully received and whether each of the PDUs is associated with a non-fragmented service data unit (SDU) (e.g., MAC service data unit (MSDU)) or a fragmented SDU; and outputting for transmission a shortened BlockAck frame comprising a bitmap field indicating a receive status for the non-fragmented and fragmented SDUs based on the determination.",QUALCOMM INC,ASTERJADHI ALFRED;;MERLIN SIMONE;;CHERIAN GEORGE;;ABRAHAM SANTOSH PAUL;;BARRIAC GWENDOLYN DENISE;;MALIK RAHUL;;DING GANG;;FREDERIKS GUIDO ROBERT;;CHO JAMES SIMON,QUALCOMM INCORPORATED (2016-03-14),https://lens.org/111-987-198-479-400,Granted Patent,yes,15,3,11,11,0,H04L1/1614;;H04L1/1685;;H04L1/1685;;H04L1/1614;;H04L1/1614;;H04L1/1685;;H04L5/0055;;H04W72/04;;H04L5/0055;;H04L1/1614;;H04W72/04;;H04L1/1685,H04W4/00;;H04L1/16;;H04L5/00;;H04W72/04,,1,0,,,"International Search Report and Written Opinion—PCT/US2015/000267—ISA/EPO—Mar. 29, 2016.",ACTIVE
561,AT,T1,AT E307128 T1,151-020-002-598-442,2005-11-15,2005,AT 02714897 T,2002-02-15,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINON- DERIVATIVE ALS PROTEIN-KINASE INHIBITOREN,,PHARMACIA & UPJOHN CO LLC;;SUGEN INC,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW,,https://lens.org/151-020-002-598-442,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
562,WO,A1,WO 2016/105515 A1,132-601-088-117-377,2016-06-30,2016,US 2015/0000267 W,2015-12-23,US 201462096168 P;;US 201562183176 P;;US 201562190239 P;;US 201562201516 P;;US 201514978039 A,2014-12-23,SHORTENED BLOCK ACKNOWLEDGEMENT WITH FRAGMENTATION ACKNOWLEDGEMENT SIGNALING,"Certain aspects of the present disclosure provide methods and apparatus for using a shortened block acknowledgement (BlockAck) frame capable of acknowledging fragments. Such a shortened BlockAck frame may include a bitmap field having a shorter length than that of a basic BlockAck frame in the IEEE 802.11 standard (i.e., < 128 octets). One example method for wireless communications generally includes receiving a plurality of protocol data units (PDUs) (e.g., media access control (MAC) protocol data units (MPDUs)); determining whether each of the PDUs was successfully received and whether each of the PDUs is associated with a non-fragmented service data unit (SDU) (e.g., MAC service data unit (MSDU)) or a fragmented SDU; and outputting for transmission a shortened BlockAck frame comprising a bitmap field indicating a receive status for the non-fragmented and fragmented SDUs based on the determination.",QUALCOMM INC,ASTERJADHI ALFRED;;MERLIN SIMONE;;CHERIAN GEORGE;;ABRAHAM SANTOSH PAUL;;BARRIAC GWENDOLYN DENISE;;MALIK RAHUL;;DING GANG;;FREDERIKS GUIDO ROBERT;;CHO JAMES SIMON,,https://lens.org/132-601-088-117-377,Patent Application,yes,3,19,11,11,0,H04L1/1614;;H04L1/1685;;H04L1/1685;;H04L1/1614;;H04L1/1614;;H04L1/1685;;H04L5/0055;;H04W72/04;;H04L5/0055;;H04L1/1614;;H04W72/04;;H04L1/1685,H04L1/16,,0,0,,,,PENDING
563,EP,A4,EP 3860855 A4,144-014-510-144-645,2022-06-22,2022,EP 19869873 A,2019-10-04,US 201816153238 A;;US 2019/0054746 W,2018-10-05,APPARATUS AND METHODS FOR ADDITIVELY MANUFACTURED STRUCTURES WITH AUGMENTED ENERGY ABSORPTION PROPERTIES,,DIVERGENT TECH INC,CHO YONG-BAE;;MARTINEZ ANTONIO BERNERD;;GUNNER JON PAUL;;TENG ALEXANDER PAI-CHUNG;;TENHOUTEN BROC WILLIAM;;LAKSHMAN NARENDER SHANKAR;;HOYLE RICHARD WINSTON,,https://lens.org/144-014-510-144-645,Search Report,no,5,0,10,10,0,B60R19/02;;B29C64/20;;B29C64/153;;B33Y30/00;;B60R2019/186;;B60R19/18;;B60R19/03;;B60R19/023;;B60R2019/1853;;B33Y80/00;;B22F2999/00;;C22C49/06;;C22C49/14;;C22C47/16;;C23C24/08;;C23C24/082;;C23C24/087;;F16F7/003;;F16F2226/00;;B29C45/14795;;B29C45/0001;;B29K2105/04;;B29L2031/3044;;B29C45/14631;;Y02P10/25;;B60R19/34;;B62D21/152;;F16F7/003;;B60R19/03;;B60R19/18;;B33Y10/00;;B33Y80/00;;B29L2031/3044;;B29C45/14;;F16F2226/00;;F16F2224/0241;;F16F2224/0208;;B60R2019/186;;B29K2105/04;;B29C64/10,B33Y50/02;;B29C64/386;;B29C64/393;;B33Y50/00;;B60R19/34,,0,0,,,,PENDING
564,GE,B,GE P20053600 B,191-433-257-520-109,2005-08-10,2005,GE AP2002005287 A,2002-02-15,US 26868301 P;;US 31236101 P,2001-02-15,3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors,". Technical Result Increase in treatment efficiency. 2. Essence A compound of the formula (1) (values of R1, R2, R3, R4, R5, R6, R7 and Z are provided in specification) or their pharmaceutically acceptable salt, pharmaceutical composition comprising it and use thereof for treatment and prevention of protein kinase related disorders. 3. Field of Application Medicine.",SUGEN INC;;UPJOHN CO,LIANG CONGXIN;;JIN QINGWU;;SUN LI;;TANG CHO PENG;;HERRINTON PAUL MATTHEW;;VOJKOVSKY CZ TOMAS;;MARGARIS MICHAEL;;WEI CHEN CHUNG;;GUAN HUIPING,,https://lens.org/191-433-257-520-109,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D403/06;;A61K31/404;;A61K31/4166;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P35/00;;C07D/;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
565,US,A1,US 2020/0108870 A1,026-409-694-647-594,2020-04-09,2020,US 201816153238 A,2018-10-05,US 201816153238 A,2018-10-05,APPARATUS AND METHODS FOR ADDITIVELY MANUFACTURED STRUCTURES WITH AUGMENTED ENERGY ABSORPTION PROPERTIES,"Apparatus and methods for additively manufactured structures with augmented energy absorption properties are presented herein. Three dimensional (3D) additive manufacturing structures may be constructed with spatially dependent features to create crash components. When used in the construction of a transport vehicle, the crash components with spatially dependent additively manufactured features may enhance and augment crash energy absorption. This in turn absorbs and re-distributes more crash energy away from the vehicle's occupant(s), thereby improving the occupants' safety.",DIVERGENT TECH INC,CHO YONG-BAE;;MARTINEZ ANTONIO BERNERD;;GUNNER JON PAUL;;TENG ALEXANDER PAI-CHUNG;;TENHOUTEN BROC WILLIAM;;LAKSHMAN NARENDER SHANKAR;;HOYLE RICHARD WINSTON,DIVERGENT TECHNOLOGIES INC (2019-06-12),https://lens.org/026-409-694-647-594,Patent Application,yes,0,7,10,10,0,B60R19/02;;B29C64/20;;B29C64/153;;B33Y30/00;;B60R2019/186;;B60R19/18;;B60R19/03;;B60R19/023;;B60R2019/1853;;B33Y80/00;;B22F2999/00;;C22C49/06;;C22C49/14;;C22C47/16;;C23C24/08;;C23C24/082;;C23C24/087;;F16F7/003;;F16F2226/00;;B29C45/14795;;B29C45/0001;;B29K2105/04;;B29L2031/3044;;B29C45/14631;;Y02P10/25;;B60R19/34;;B62D21/152;;F16F7/003;;B60R19/03;;B60R19/18;;B33Y10/00;;B33Y80/00;;B29L2031/3044;;B29C45/14;;F16F2226/00;;F16F2224/0241;;F16F2224/0208;;B60R2019/186;;B29K2105/04;;B29C64/10,B62D21/15;;B29C45/14;;B29C64/10;;B33Y10/00;;B33Y80/00;;B60R19/03;;B60R19/18;;F16F7/00,,0,0,,,,ACTIVE
566,WO,A3,WO 2012/121834 A3,051-755-947-827-621,2013-01-03,2013,US 2012/0024857 W,2012-02-13,US 201113041017 A,2011-03-04,APPARATUS AND METHODS FOR REAL-TIME THREE-DIMENSIONAL SEM IMAGING AND VIEWING OF SEMICONDUCTOR WAFERS,"One embodiment relates to a method of real-time three-dimensional electron beam imaging of a substrate surface. A primary electron beam is scanned over the substrate surface causing electrons to be emitted therefrom. The emitted electrons are simultaneously detection using a plurality of at least two off-axis sensors so as to generate a plurality of image data frames, each image data frame being due to electrons emitted from the substrate surface at a different view angle. The plurality of image data frames are automatically processed to generate a three-dimensional representation of the substrate surface. Multiple views of the three-dimensional representation are then displayed. Other embodiments, aspects and features are also disclosed.",KLA TENCOR CORP;;CHEN CHIEN-HUEI;;MACDONALD PAUL D;;KUPPA RAJASEKHAR;;TADA TAKUJI;;ABBOTT GORDON;;TEH CHO;;YANG HEDONG;;LANG STEPHEN;;NEIL MARK;;SAIDIN ZAIN,CHEN CHIEN-HUEI;;MACDONALD PAUL D;;KUPPA RAJASEKHAR;;TADA TAKUJI;;ABBOTT GORDON;;TEH CHO;;YANG HEDONG;;LANG STEPHEN;;NEIL MARK;;SAIDIN ZAIN,,https://lens.org/051-755-947-827-621,Search Report,yes,4,0,8,8,0,G01B21/20;;G01N23/2251;;G01N23/2251;;G01N23/225,G01N23/225;;G01B21/20,,0,0,,,,PENDING
567,EP,A1,EP 3238357 A1,116-398-290-823-59X,2017-11-01,2017,EP 15828404 A,2015-12-23,US 201462096168 P;;US 201562183176 P;;US 201562190239 P;;US 201562201516 P;;US 201514978039 A;;US 2015/0000267 W,2014-12-23,SHORTENED BLOCK ACKNOWLEDGEMENT WITH FRAGMENTATION ACKNOWLEDGEMENT SIGNALING,,QUALCOMM INC,ASTERJADHI ALFRED;;MERLIN SIMONE;;CHERIAN GEORGE;;ABRAHAM SANTOSH PAUL;;BARRIAC GWENDOLYN DENISE;;MALIK RAHUL;;DING GANG;;FREDERIKS GUIDO ROBERT;;CHO JAMES SIMON,,https://lens.org/116-398-290-823-59X,Patent Application,yes,0,0,11,11,0,H04L1/1614;;H04L1/1685;;H04L1/1685;;H04L1/1614;;H04L1/1614;;H04L1/1685;;H04L5/0055;;H04W72/04;;H04L5/0055;;H04L1/1614;;H04W72/04;;H04L1/1685,H04L1/16,,0,0,,,,PENDING
568,US,A1,US 2018/0191480 A1,142-420-278-780-479,2018-07-05,2018,US 201815910716 A,2018-03-02,US 201815910716 A;;US 201514978039 A;;US 201562201516 P;;US 201562190239 P;;US 201562183176 P;;US 201462096168 P,2014-12-23,BLOCK ACKNOWLEDGEMENT WITH FRAGMENTATION ACKNOWLEDGEMENT SIGNALING,"Certain aspects of the present disclosure provide methods and apparatus for using a block acknowledgement (BlockAck) frame capable of acknowledging fragments. One example method for wireless communications generally includes receiving a plurality of protocol data units (PDUs) (e.g., media access control (MAC) protocol data units (MPDUs)); determining whether each of the PDUs was successfully received and whether each of the PDUs is associated with a non-fragmented service data unit (SDU) (e.g., MAC service data unit (MSDU)) or a fragmented SDU; and outputting for transmission a BlockAck frame comprising a bitmap field indicating a receive status for the non-fragmented and fragmented SDUs based on the determination.",QUALCOMM INC,ASTERJADHI ALFRED;;MERLIN SIMONE;;CHERIAN GEORGE;;ABRAHAM SANTOSH PAUL;;BARRIAC GWENDOLYN DENISE;;MALIK RAHUL;;DING GANG;;FREDERIKS GUIDO ROBERT;;CHO JAMES SIMON,QUALCOMM INCORPORATED (2016-03-14),https://lens.org/142-420-278-780-479,Patent Application,yes,0,1,11,11,0,H04L1/1614;;H04L1/1685;;H04L1/1685;;H04L1/1614;;H04L1/1614;;H04L1/1685;;H04L5/0055;;H04W72/04;;H04L5/0055;;H04L1/1614;;H04W72/04;;H04L1/1685,H04L1/16;;H04L5/00;;H04W72/04,,0,0,,,,DISCONTINUED
569,BR,A,BR 0207494 A,179-447-144-108-92X,2004-04-27,2004,BR 0207494 A,2002-02-15,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,Derivados de 3-(4-amidopirrol-2-ilmetilideno)-2-indolinona como inibidores de proteìna quinase,"""DERIVADOS DE 3-(4-AMIDOPIRROL-2-ILMETILIDENO)-2-INDOLINONA COMO INIBIDORES DE PROTEìNA QUINASE"". A presente invenção refere-se aos composto de 2-indolinona substituída por pirrol e seus sais farmaceuticamente aceitáveis que modulam a atividade de quinases de proteína e portanto espera-se que sejam úteis na prevenção e tratamento de distúrbios celulares relacionados a proteína quinase tal como câncer.",SUGEN INC;;PHARMACIA & UP JOHN COMPANY,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW,,https://lens.org/179-447-144-108-92X,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,DISCONTINUED
570,US,A1,US 2021/0339802 A1,059-118-598-471-864,2021-11-04,2021,US 202117374702 A,2021-07-13,US 202117374702 A;;US 201816153238 A,2018-10-05,APPARATUS AND METHODS FOR ADDITIVELY MANUFACTURED STRUCTURES WITH AUGMENTED ENERGY ABSORPTION PROPERTIES,"Apparatus and methods for additively manufactured structures with augmented energy absorption properties are presented herein. Three dimensional (3D) additive manufacturing structures may be constructed with spatially dependent features to create crash components. When used in the construction of a transport vehicle, the crash components with spatially dependent additively manufactured features may enhance and augment crash energy absorption. This in turn absorbs and re-distributes more crash energy away from the vehicle's occupant(s), thereby improving the occupants' safety.",DIVERGENT TECH INC,CHO YONG-BAE;;MARTINEZ ANTONIO BERNERD;;GUNNER JON PAUL;;TENG ALEXANDER PAI-CHUNG;;TENHOUTEN BROC WILLIAM;;LAKSHMAN NARENDER SHANKAR;;HOYLE RICHARD WINSTON,DIVERGENT TECHNOLOGIES INC (2019-06-12),https://lens.org/059-118-598-471-864,Patent Application,yes,0,0,10,10,0,B60R19/02;;B29C64/20;;B29C64/153;;B33Y30/00;;B60R2019/186;;B60R19/18;;B60R19/03;;B60R19/023;;B60R2019/1853;;B33Y80/00;;B22F2999/00;;C22C49/06;;C22C49/14;;C22C47/16;;C23C24/08;;C23C24/082;;C23C24/087;;F16F7/003;;F16F2226/00;;B29C45/14795;;B29C45/0001;;B29K2105/04;;B29L2031/3044;;B29C45/14631;;Y02P10/25;;B60R19/34;;B62D21/152;;F16F7/003;;B60R19/03;;B60R19/18;;B33Y10/00;;B33Y80/00;;B29L2031/3044;;B29C45/14;;F16F2226/00;;F16F2224/0241;;F16F2224/0208;;B60R2019/186;;B29K2105/04;;B29C64/10,B62D21/15;;B29C45/14;;B29C64/10;;B33Y10/00;;B33Y80/00;;B60R19/03;;B60R19/18;;F16F7/00,,0,0,,,,PENDING
571,US,B2,US 7582756 B2,097-691-802-989-637,2009-09-01,2009,US 77980707 A,2007-07-18,US 77980707 A;;US 51198106 A;;US 65690703 A;;US 7614002 A;;US 31236101 P;;US 26868301 P,2001-02-15,3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors,The present invention provides a method to make a pyrrole substituted 2-indolinone compound of the formula,SUGEN INC;;UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL M;;MAURAGIS MICHAEL A,,https://lens.org/097-691-802-989-637,Granted Patent,yes,100,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D413/14;;A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D471/04,544/144,99,79,054-823-629-511-93X;;022-399-048-324-641;;176-879-479-576-661;;078-854-286-923-547;;094-652-412-929-005;;067-272-607-027-112;;025-114-183-199-748;;018-048-709-473-304;;004-963-545-993-258;;000-955-818-332-098;;000-955-818-332-098;;009-185-209-152-939;;009-068-402-575-690;;049-540-021-873-405;;035-321-998-935-819;;002-840-884-592-149;;129-714-176-445-277;;042-517-545-674-669;;062-253-139-686-620;;030-880-199-478-403;;171-875-161-435-498;;068-347-002-933-411;;016-739-947-546-505;;130-779-644-212-195;;032-953-229-558-330;;078-578-887-209-471;;049-954-263-824-454;;060-092-756-707-151;;102-148-719-482-24X;;099-279-971-758-096;;028-531-800-105-513;;016-333-429-871-463;;156-756-886-926-846;;037-134-997-566-90X;;037-465-890-679-37X;;104-815-369-514-254;;077-040-152-841-627;;122-261-121-873-625;;025-669-944-920-763;;043-489-715-583-833;;029-380-708-151-243;;120-787-793-242-483;;005-766-513-612-952;;081-381-735-516-869;;008-322-661-908-298;;025-209-481-691-070;;096-452-077-440-080;;013-790-909-287-914;;103-663-433-342-64X;;077-363-946-748-009;;128-267-202-156-519;;065-028-064-758-359;;009-954-017-681-952;;052-588-751-234-497;;010-830-508-694-564;;085-471-281-279-890;;000-260-545-266-425;;075-875-793-946-595;;020-017-567-104-545;;029-871-534-065-762;;097-695-479-613-215;;045-890-249-073-273;;120-399-346-691-880;;049-676-058-590-911;;062-693-709-183-494;;079-734-101-870-347;;053-570-456-410-225;;102-943-963-373-742;;002-691-796-474-031;;094-207-501-631-352;;055-925-799-631-516;;027-603-408-160-490;;013-804-957-513-749;;106-753-778-592-300;;167-734-194-581-033;;011-265-567-519-296;;030-094-646-061-709;;009-809-672-105-539;;092-445-513-957-983,10.1039/jr9540001697;;1331337;;10.1016/0022-510x(92)90060-x;;9042225;;10.1016/0223-5234(92)90106-b;;10.1016/s0223-5234(97)82778-x;;9706372;;10.1172/jci114315;;2553774;;pmc304004;;7935391;;10.1128/mcb.14.10.6715-6726.1994;;10.1128/mcb.14.10.6715;;pmc359202;;10.1016/0040-4020(67)85040-3;;5793178;;5793179;;10.1021/jm00304a052;;10.1021/jm00304a050;;5793177;;10.1021/jm00304a051;;5793178;;5793179;;10.1021/jm00304a052;;10.1021/jm00304a050;;5793177;;10.1021/jm00304a051;;10.1039/j39660001028;;10.1080/00397919308011169;;10.1016/0092-8674(94)90023-x;;8001140;;7812953;;10.1080/00397918608057203;;10.1039/p29730001660;;10.1096/fasebj.6.15.1281458;;1281458;;8336932;;10.1128/mcb.5.6.1400-1407.1985;;pmc366870;;2993863;;10.1128/mcb.5.6.1400;;10.1002/jlac.19375320112;;8343210;;8099900;;10.1002/ijc.2910540409;;10.1002/jhet.5570220609;;9025911;;10.1006/abio.1996.9854;;10.1016/0092-8674(92)90068-n;;1547509;;10.1039/p29730000469;;9434891;;8199353;;10.1016/0955-2235(94)90016-7;;10.1039/p29840000615;;pmc358831;;8007963;;10.1128/mcb.14.7.4588-4595.1994;;10.1128/mcb.14.7.4588;;10.1016/s0021-9673(00)86069-0;;10.1016/0006-2952(94)90152-x;;7945409;;1973827;;10.1021/jm00267a020;;4583274;;1312256;;10.1126/science.1312256;;3192948;;10.1016/0022-1759(88)90310-9;;10.1016/0040-4020(96)00695-3;;1360236;;10.1007/978-1-4615-3500-3_13;;10.1021/jo01031a502;;10.1016/0092-8674(92)90444-h;;1374684;;1689212;;2735925;;10.1016/0006-291x(89)92678-8;;8468926;;10.1038/ki.1993.55;;8441232;;10.1016/s0021-9258(19)49853-0;;1375931;;10.1056/nejm197111182852108;;4938153;;10.1093/jnci/82.1.4;;1688381;;5039962;;10.1111/1523-1747.ep12625746;;10.1021/jm00110a022;;1676428;;1802112;;3386259;;10.1016/0022-4731(88)90113-6;;8387483;;10.1016/s0021-9258(18)98327-4;;10.1021/op970037c;;10.1039/p19880001305;;10.1016/0040-4039(95)01202-s;;10.1139/v68-357;;3499230;;10.1016/0092-8674(87)90147-4;;10.1016/s0021-9258(18)35712-0;;1464614;;10.1128/mcb.12.3.981;;10.1128/mcb.12.3.981-990.1992;;pmc369530;;1372091;;10.1021/bi00200a028;;7520755;;10.1091/mbc.4.1.49;;8443409;;pmc300899;;pmc556586;;1314164;;10.1002/j.1460-2075.1992.tb05182.x;;8376494;;10.1016/0378-4347(93)80472-g;;10.1002/jhet.5570250503;;7688466;;pmc47050;;10.1073/pnas.90.15.6939;;8248162;;10.1073/pnas.90.22.10705;;pmc47846;;10.1016/s0040-4020(01)92520-7;;7683111;;10.1038/362841a0;;1370939;;10.1016/0014-4827(92)90461-g;;10.1016/0960-9822(93)90073-w;;15335866;;925872;;10.1248/yakushi1947.97.9_1033;;10.1126/science.1708916;;1708916;;1172191;;10.1038/256495a0;;7689722;;pmc443180;;1401070;;10.1172/jci116001;;10.1016/0022-1759(83)90438-6;;6300286;;6199426;;pmc49721;;1323835;;10.1073/pnas.89.16.7417;;1314366,"Abramovitch and Hey, ""Internuclear cyclisation. Part VIII. Naphth[3:2:1-cd]oxindoles,"" J. Chem. Soc. 1697-1703 (1954), Strand, London.;;Abramovitch et al., ""A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement,"" Chemistry and Industry 44:1871 (1967) 8Laporte Industries Limited, Lancashire.;;Akbasak and Sunar-Akbasak, ""Oncogenes: cause or consequence in the development of glial tumors,"" J. Neurol. Sci. 111:119-133 (1992)8 Elsevier Science Publishers.;;Andreani et al., ""Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolymethylene)1,3-Dihydroindol-2-Ones,"" Anticancer Research 16:3585-3588 (1996) 8 Elsevier, Paris.;;Andreani et al., ""Synthesis and cardiotonic activity of 2-indolinones,"" Eur. J. Med. Chem. 25:187-190 (1990).;;Andreani et al., ""Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups,"" Eur. J. Med. Chem. 28:653-657 (1993) 8 Elsevier, Paris.;;Andreani et al., ""Synthesis and cardiotonic activity of 2-indolinones,"" Chemical Abstracts, vol. 113, abstract No. 78106 (1990).;;Andreani et al., ""Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones,"" Eur. J. Med. Chem. 27:167-170 (1992) 8 Elsevier, Paris.;;Andreani et al., ""Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones,"" Eur. J. Med. Chem. 32:919-924 (1997)8 Elsevier, Paris.;;Andreani et al., ""Synthesis of lactams with potential cardiotonic activity,"" Eur. J. Med. Chem. 28:825-829 (1993).;;Andreani et al., ""In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones,"" Arzneimittel-Forschung Drug Research 48:727-729 (1998) 8.;;Arteaga et al., ""Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice,"" J. Clin. Invest. 84:1418-1423 (1989) copyright The American Society for Clinical investigation, Inc.;;Arvidsson et al., ""Tyr-716 in the Platelet-Derived Growth Factor beta-Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation,"" Molecular and Cellular Biology 14:6715-6726 (1994) 8 The American Society for Microbiology.;;Autrey and Tahk, ""The Synthesis and Sterochemistry of Some Isatylideneacetic Acid Derivatives,"" Tetrahedron 23:901-917 (1967) 8Pergamon Press.;;Bahner and Brotherton, ""6-Dimethylaminochrysene and Other Analogs of 4-(4-Dimethylamino)stilbene,"" J. Med. Chem. 12:722-723 (1969).;;Bahner et al., ""Benzylideneindenes with Oxygen Attached to the Indene Ring,"" J. Med. Chem. 12:721-722 (1969).;;Bamfield et al., ""Diels-Alder Reactions of Oxindolylideneacetone,"" J. Chem. Soc. (C) 1028-1030 (1966) 8.;;Barbier, et al., ""Synthesis of Isobrassilexin, A Biologically Active Isomer of Brassilexin, a Curciferae Phytoalexin,"" Synthetic Communications 23(22):3109-3117 (1993) 8 Marcel Dekker, Inc.;;Baserga, ""Oncogenes and the Strategy of Growth Factors,"" Cell 79:927-930 (1994) 8 Cell Press.;;Baserga, ""The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?"" Cancer Research 55:249-252 (1995).;;Beilstein Reg. No. 233511 (1997).;;Beilstein Reg. No. 235647 (1997).;;Beilstein Reg. No. 252929 (1998).;;Benzies, et al., ""2-Formyl-3-Methoxymethylindole, 3-Ethoxymethyl-2-Formylindoline and 2-Formyl-3-Methylindole,"" Synthetic Communications: 16(14), 1799-1807 (1986) 8 Marcel Dekker, Inc.;;Blake and Jaques, ""Anisotropic Effects in alpha-Substituted Methoxystilbenes,"" J. Chem. Soc. Perkin II: 1660-1663 (1973) 8 Pergamon, Oxford.;;Bolen et al., ""The Src family of tyrosine protein kinases in hemopoietic signal transduction,"" FASEB J. 6:3403-3409 (1992).;;Bolen, ""Nonreceptor tyrosine protein kinases,"" Oncogene 8:2025-2031 (1993) copyright MacMillan Press Ltd.;;Bonner et al., ""Structure and Biological Activity of Human Homologs of the raf/mil Oncogene,"" Molecular and Cellular Biology 5:1400-1407 (1985) 8 The American Society of Microbiology.;;Borsche et al., ""Über vielkernige kondensierte Systeme mit herterocyclischen Ringen. XIII., "" Liebigs Ann. Chem. 550:160-174 (1941).;;Buzzetti et al., ""Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases,"" II Farmaco 48:615-636 (1993).;;Cance et al., ""Novel Protein Kinases Expressed in Human Breast Cancer,"" Int. J. Cancer 54:571-577 (1993) 8 Wiley-Liss, Inc.;;Canoira and Rodriguez, ""Synthesis of Oxindole Derivatives from N-Alkenyl-o-Chloroanilides with Zero-Valent Nickel Complex,"" J. Heterocyclic Chem. 22:1511-1518 (1985).;;Carpenedo et al., ""Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs,"" Analytical Biochemistry 244:74-79 (1997) 8 Academic Press, Inc.;;Chao, ""Growth Factor Signaling: Where Is the Specificity?"" Cell 68:995-997 (1992) copyright Cell Press.;;Chatten et al., ""Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted trans-3-Benzylideneindol-2(3H)-ones,"" J. Chem. Soc. Perkin II: 469-473 (1973).;;Chen et al., ""Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on gamma-Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron,"" Chinese Journal of Physiology 40:149-156 (1997).;;Claesson-Welsh, ""Signal Transduction by the PDGF Receptors,"" Progress in Growth Factor Research 5:37-54 (1994) 8 Elsevier Science Ltd.;;Coda et al., ""(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies,"" J. Chem. Soc. Perkin Trans. II: 615-619 (1984).;;Coda et al., ""3-(4-methylbenzilidene)-1,3-dihydroindol-2-one,"" Journal of the Chemical Society, Perkin Transactions 2 4:615-620 (1984) Database Crossfire, Beilstein Reference No. 6-21.;;Coppola et al., ""A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor,"" Molecular and Cellular Biology 14:4588-4595 (1994) 8 The American Society for Microbiology.;;Daisley and Walker, ""Thin-layer chromatographic separation of some substituted 3-benzylidine-indol-2(3H)-ones,"" J. Chromatography 100:240-242 (1974) 8 Elsevier Scientific Publishing Company.;;Damiani et al., ""Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals,"" Biochemical Pharmacology 48:1155-1161 (1994) copyright Elsevier Science Ltd.;;Dati et al., ""Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells,"" Oncogene 5:1001-1006 (1990).;;Davis et al., ""Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds,"" Journal of Medicinal Chemistry 16:1043-1045 (1973) 8American Chemical Society.;;De Vries et al., ""The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor,"" Science 255:989-991 (1992).;;Decker and Lohmann-Matthes, ""A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity,"" J. Immunol. Methods 15:61-69 (1988) copyright Elsevier.;;Decodts et al., ""Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams,"" Eur. J. Med. Chem 18: 107-111 (1983).;;Desimoni et al., ""Catalysis with Inorganic Cations. V1 Intramolecular Hetero Diels-Alder versus Ene Reactions: Effect of Magnesium perchlorate on Chemoselectivity,"" Tetrahedron 52(36) 12009-12018 (1196) 8 Pergamon.;;Dickson et al., ""13. Tyrosine kinase receptor-nuclear protooncogene interactions in breast cancer,"" Cancer Treatment Res. 61:249-273 (1992) 8 Kluwer Academic Publishers.;;Elliott and Rivers, ""Reduction of Some Oxindolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride,"" J. Med. Chem. 29:2438-2440 (1964).;;Elliott et al., ""1-methyl-2-(3-oxindolidenmethyl)-pyridinium,"" Journal of Organic Chemistry 29:2438-2440 (1964) Database Crossfire, Beilstein Reference No. 5-24.;;Fantl et al., ""Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways,"" Cell 69:413-423 (1992) 8 Cell Press.;;Fendly et al., Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product, Cancer Research 50:1550-1558 (1990); @ American Association for Cancer Research.;;Ferrara and Henzel, ""Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells,"" Biochemical and Biophysical Research Communications 161:851-858 (1989) 8 Academic Press, Inc.;;Fingl and Woodbury, ""Chapter 1-General Principles,"" in The Pharmacological Basis of Therapeutics 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975) 8 MacMillan Publishing Co. Inc.;;Floege et al., ""Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo,"" Kidney International 43:S47-S54 (1993) 8 International Society of Nephrology.;;Floege et al., ""Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis,"" Kidney International 43:369-380 (1993) 8 International Society of Nephrology.;;Folkman and Shing, ""Angiogenesis,"" J. Biol. Chem. 267:10931-10934 (1992) 8 The American Society for Biochemistry and Molecular Biology.;;Folkman, ""Ch. 24. Angiogenesis,"" Congress of Thrombosis and Haemostasis (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987).;;Folkman, ""Tumor Angiogenesis: Therapeutic Implications,"" New England J. Medicine 285:1182-1186 (1971).;;Folkman, ""What is the Evidence that Tumors are Angiogenesis Dependent?"" Journal of the National Cancer Institute 82:4-6 (1990).;;Folkman, ""Angiogenesis in Psoriasis: Therapeutic Implications,"" J. Invest. Dermatol. 59:40-43 (1973) copyright The Williams & Wilkins Co.;;Gazit et al., ""Tyrphostins. 2. Heterocyclic and alpha-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases,"" J. Med. Chem. 34:1896-1907 (1991) copyright Am. Chem. Soc.;;Gennaro (editor), Remington's Pharmaceutical Sciences (1990) (Table of Contents Only).;;Goldring and Goldring, ""Cytokines and Cell Growth Control,"" Critical Reviews in Eukaryotic Gene Expression 1:301-326 (1991).;;Gottardis et al., ""Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study to Tumoristatic Action of Tamoxifen,"" J. Steroid Biochem. 30:311-314 (1988) 8 Pergamon Press.;;Graziani et al., ""Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger,"" The Journal of Biological Chemistry 268:9165-9168 (1993) 8American Society for Biochemistry and Molecular Biology.;;Hayler et al., Development of Large-Scale Syntheses of Ropinirole in the Pursuit if a Manufacturing Process, Organic Process Research & Development 2(1) 3-9 (1998) 8The American Chemical Society and Royal Society of Chemistry.;;Hewgill and Stewart, ""Phenanthrene-4,5-quinones: a Synthesis of Morphenol,"" J. Chem. Soc. Perkin Trans. I:1305-1311 (1988).;;Hirao et al., ""Rhodium-Catalyzed Carbonylation of 2-Alkynylaniline: Syntheses of 1,3-Dihydroindol-2-ones,"" Tetrahedron Letters 36(35) 1995 8Pergamon.;;Hodges et al., ""Chemical and biological properties of some oxindolidyl-3-methines,"" Canadian J. Chemistry 46:2189-2194 (1968).;;Honegger et al., ""Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Acivity and Alters Cellular Routing,"" Cell 51:199-209 (1987) 8 Cell Press.;;Houck et al., ""Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms,"" J. Biol. Chem. 267:26031-26037 (1992)8 American Society for Biochemistry and Molecular Biology, Inc.;;Howard, Harry R., ""Lactam Derivatives,"" U.S. Appl. No. 60/015,134.;;Howard et al., ""Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxidole-1-acetic acids,"" Eur. J. Med. Chem. 27:779-789 (1992) 8 Elsevier, Paris.;;Hu et al., ""Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors,"" Molecular and Cellular Biology 12:981-990 (1992) copyright Am. Soc. Microbiol.;;Ijaz et al., ""The Conversion of o,beta-Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones,"" J. Chem. Res. (S): 116 (1990).;;Jellinek et al., ""Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor,"" Biochemistry 33:10450-10456 (1994) 8 American Chemical Society.;;Kashishian and Cooper, ""Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cgamma1,"" Molecular Biology of the Cell 4:49-57 (1993) 8 The American Society for Cell Biology.;;Kashishian et al., ""Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo,"" The EMBO Journal 11:1373-1382 (1992).;;Kato et al., ""Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography,"" Journal of Chromatography 616:67-71 (1993) 8Elsevier Science.;;Katritzky et al., ""Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues,"" J. Heterocyclic Chem. 25:1287-1292 (1988).;;Kazlauskas et al., ""The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp,"" Proc. Natl. Acad. Sci. USA 90:6939-6942 (1993).;;Kendall and Thomas, ""Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor,"" Proc. Natl. Acad. Sci. USA 90:10705-10709 (1993).;;Khalil and Abdel-Rahman, ""Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes,"" J. Indian Chem. Soc. 54:904-907 (1977) 8The Indian Chemical Society.;;Kikumoto et al., ""The Reactions of Oxindoles and Isatin with Nitrobenzyl Chlorides,"" Tetrahedron 22: 3337-3343 (1996) 8Pergamon Press Ltd.;;Kim et al., ""Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo,"" Nature 362:841-844 (1993).;;Kinsella et al., ""Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel,"" Exp. Cell Research 199:56-62 (1992) 8 Academic Press, Inc.;;Klagsbrun and Soker, ""VEGF/VPF: the angiogenesis factor found?"" Current Biology 3:699-702 (1993) 8Current Biology.;;Kobayashi et al., ""Anti-tumor Activity of Indole Derivatives,"" Yakugaku Zasshi 97:1033-1039 (1977).;;Koch et al., ""SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins,"" Science 252:668-674 (1991).;;Kohler and Milstein, ""Continuous cultures of fused cells secreting antibody of predefined specificity,"" Nature 256:495-497 (1975).;;Komada and Kitamura, ""The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor,"" Oncogene 8:2381-2390 (1993).;;Korc et al., ""Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer Is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha,"" J. Clin. Invest. 90:1352-1360 (1992) copyright The American Society for Clinical Investigation, Inc.;;Korzeniewski and Callewaert, ""An Enzyme-Release Assay for Natural Cytotoxicity,"" J. Immunol. Methods 64:313-320 (1983) 8 Elsevier Science Publishers.;;Kovac and Stetinova, ""Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoxindoles,"" Chem. rvesu 30:484-492 (1976).;;Krueger and Saito, ""A human transmembrane protein-tyrosine-phosphatase, PTPb, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases,"" Proc. Natl. Acad. Sci. USA 89:7417-7421 (1992).;;Kumabe et al., ""Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin,"" Oncogene 7:627-633 (1992).;;Lal et al., ""Novel Diuretic Agents: Syntheses of Substituted Isatylidenes & 3-Alkyl or 3-Arylalkyl-2-oxindoles,"" Indian Journal of Chemistry 13: 898-903 (1975).",EXPIRED
572,US,B2,US 11072371 B2,098-115-941-327-677,2021-07-27,2021,US 201816153238 A,2018-10-05,US 201816153238 A,2018-10-05,Apparatus and methods for additively manufactured structures with augmented energy absorption properties,"Apparatus and methods for additively manufactured structures with augmented energy absorption properties are presented herein. Three dimensional (3D) additive manufacturing structures may be constructed with spatially dependent features to create crash components. When used in the construction of a transport vehicle, the crash components with spatially dependent additively manufactured features may enhance and augment crash energy absorption. This in turn absorbs and re-distributes more crash energy away from the vehicle's occupant(s), thereby improving the occupants' safety.",DIVERGENT TECH INC,CHO YONG-BAE;;MARTINEZ ANTONIO BERNERD;;GUNNER JON PAUL;;TENG ALEXANDER PAI-CHUNG;;TENHOUTEN BROC WILLIAM;;LAKSHMAN NARENDER SHANKAR;;HOYLE RICHARD WINSTON,DIVERGENT TECHNOLOGIES INC (2019-06-12),https://lens.org/098-115-941-327-677,Granted Patent,yes,393,0,10,10,0,B60R19/02;;B29C64/20;;B29C64/153;;B33Y30/00;;B60R2019/186;;B60R19/18;;B60R19/03;;B60R19/023;;B60R2019/1853;;B33Y80/00;;B22F2999/00;;C22C49/06;;C22C49/14;;C22C47/16;;C23C24/08;;C23C24/082;;C23C24/087;;F16F7/003;;F16F2226/00;;B29C45/14795;;B29C45/0001;;B29K2105/04;;B29L2031/3044;;B29C45/14631;;Y02P10/25;;B60R19/34;;B62D21/152;;F16F7/003;;B60R19/03;;B60R19/18;;B33Y10/00;;B33Y80/00;;B29L2031/3044;;B29C45/14;;F16F2226/00;;F16F2224/0241;;F16F2224/0208;;B60R2019/186;;B29K2105/04;;B29C64/10,B60R19/18;;B29C45/14;;B29C64/10;;B29K105/04;;B29L31/30;;B33Y10/00;;B33Y80/00;;B60R19/03;;B62D21/15;;F16F7/00,,5,0,,,"US 9,202,136 B2, 12/2015, Schmidt et al. (withdrawn);;US 9,809,265 B2, 11/2017, Kinjo (withdrawn);;US 10,449,880 B2, 10/2019, Mizobata et al. (withdrawn);;Invitation to Pay Additional Fees received in PCT/US2019/054746 dated Nov. 27, 2019.;;International Search Report & Written Opinion received in PCT/US2019/054746 dated Feb. 3, 2020.",ACTIVE
573,CA,C,CA 2438314 C,164-367-040-728-601,2012-08-07,2012,CA 2438314 A,2002-02-15,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,"The present invention relates to pyrrole substituted 2-indolinone compounds: (see formula I) wherein R1, R2, R3, R4, R5, R6, R7 and Z are as defined herein, and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention or treatment of protein kinase related cellular disorders such as cancer.",SUGEN INC;;UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW,,https://lens.org/164-367-040-728-601,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D403/06;;A61K31/404;;A61K31/4166;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
574,HK,A1,HK 1059621 A1,018-162-116-703-214,2004-07-09,2004,HK 04102229 A,2004-03-25,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-Amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors,,PHARMACIA & UPJOHN CO LLC;;SUGEN INC,GUAN HUIPING;;SUN LI;;TANG PENG CHO;;CHUNG CHEN WEI;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINGTON PAUL MATTHEW;;LIANG CONGXIN,,https://lens.org/018-162-116-703-214,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,DISCONTINUED
575,RS,B,RS 51026 B,045-429-407-577-085,2010-10-31,2010,YU P71703 A,2002-02-15,US 26868301 P;;US 31236101 P,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,"Jedinjenje Formule (I):gde:R1 je odabran iz grupe koju čine vodonik, halo, C1-C10 alkil, C1-C4 haloalkoksi, C3-C8 monocikličan cikloalkil, $5,6]- ili $6,6]-kondenzovan bicikličan cikloalkil, adamantil, 5-9-člana heteroaliciklična grupa sa 1 ili 2 heteroatoma odabrana od N, O ili -S(O)n gde n = 0-2, hidroksi, C1-C10 alkoksi, nesupstituisan C3-C8 cikloalkoksi, -C(O)-R8, -NR9R10 i-C(O)NR12R13;R2 je odabran iz grupe koju čine vodonik, halo, C1-C10 alkil, trihalometil, hidroksi, C1-C10 alkoksi, nesupstituisan C3-C8 cikloalkoksi, cijano, -NR9R10, -NR9C(O)R10, -C(O)R8,-S(O)2NR9R10 i -SO2R14 (gde R14 is C1-C10 alkil, C6-C12 aril, C1-C4 alkil supstituisan C6-C12 arilom, 5-12 člani heteroaril sa 1-4 prstenastih heteroatoma odabranih od N, O ili S, i C1-C4 alkil supstituisan sa 5-12 članim heteroarilom sa 1-4 heteroatoma u prstenu, odabrana od N, O ili S);R3, R4 i R5 su nezavisno vodonik ili C1-C10 alkil;Z je C6-C12 aril, 5-12 člani heteroaril sa 1-4 heteroatoma u prstenu, odabrana od N, O ili S, 3-8 člani zasićen heterociklil sa 1 ili 2 heteroatoma u prstenu odabrana od N, O, ili S(O)n gde n = 0-2, i -NR15R16 gde R15 i R16 su nezavisno vodonik ili C1-C10 alkil; ili R15 i R16 zajedno sar atomom azota za koji su vezani formiraju 3-8 članu heterocikloamino grupu po izboru sa 1 ili 2 dodatna heteroatoma u prstenu odabrana od N, O, ili S(O)n gde n = 0-2;R6 je odabran iz grupe koju čine vodonik ili C1-C10 alkil;R7 je odabran iz grupe koju čine vodonik, C1-C10 alkil, C6-C12 aril, 5-12-člani heteroaril sa 1-4 heteroatoma u prstenu odabrana od N, O ili S, i -C(O)R17 kao što je definisano u daljem tekstu;R8 je odabran iz grupe koju čine hidroksi, C1-C10 alkoksi, nesupstituisan C3-C8 cikloalkoksi, C6-C12 ariloksi, i 5-12 -člani heteroariloksi having 1-4 heteroatoma u prstenu odabrana od N, O ili S;R9 i R10 su nezavisno odabrani iz grupe koju čine vodonik, C1-C10 alkil, C1-C10 cijanoalkil,C3-C8 monocikličan cikloalkil, $5,6]- ili $6,6]-kondenzovan bicikličan cikloalkil, adamantil,C6-C12 aril i 5-12 -člani heteroaril sa 1-4 heteroatoma u prstenu odabrana od N, O ili S; ili R9 i R10 zajedno formiraju 3-8 članu heterocikloamino grupu po izboru sa 1 ili 2 dodatnaheteroatoma u prstenu odabrana od N, O, ili S(O)n gde n = 0-2;R12 i R13 su nezavisno odabrani iz grupe koju čine vodonik, C1-C10 alkil, C1-C10 hidroksialkil, i C6-C12 aril; ili R12 i R13 zajedno sa atomom azota za koji su vezani formiraju 3-8 članu heterocikloamino grupu po izboru sa 1 ili 2 dodatna heteroatoma u prstenu odabrana od N, O, ili S(O)n gde n = 0-2;R17 je odabran iz grupe koju čine C1-C10 alkil, C3-C8 monocikličan cikloalkil, $5,6]- ili $6,6]-kondenzovan bicikličan cikloalkil, adamantil, C6-C12 aril, hidroksi i 5-12 člani heteroaril sa 1-4 heteroatoma u prstenu odabrana od N, O ili S;Ili njegova farma",SUGEN INC;;UPJOHN CO,LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTEW;;GUAN HUIPING,,https://lens.org/045-429-407-577-085,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D403/06;;A61K31/404;;A61K31/4166;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61K35/00;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
576,US,A1,US 2008/0045709 A1,098-306-667-476-355,2008-02-21,2008,US 77980707 A,2007-07-18,US 77980707 A;;US 51198106 A;;US 65690703 A;;US 7614002 A;;US 31236101 P;;US 26868301 P,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,The present invention provides a method to make a pyrrole substituted 2-indolinone compound of the formula,UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG C;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL M;;MAURAGIS MICHAEL A,,https://lens.org/098-306-667-476-355,Patent Application,yes,81,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D413/14;;A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D471/04,544/144,0,0,,,,EXPIRED
577,EP,A1,EP 1370554 A1,106-880-267-745-020,2003-12-17,2003,EP 02714897 A,2002-02-15,US 0204407 W;;US 26868301 P;;US 31236101 P,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,,UPJOHN CO;;SUGEN INC,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW,"PHARMACIA & UPJOHN COMPANY LLC (2005-06-01);;SUGEN, INC. (2005-06-01)",https://lens.org/106-880-267-745-020,Patent Application,yes,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
578,HR,B1,HR P20030657 B1,163-032-584-641-490,2006-10-31,2006,HR P20030657 A,2003-08-14,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,"Spoj formule (I): naznačen time da je: R1 je odabran iz skupine koju čine vodik, halogen, C1-C10 alkil, C1-C4 haloalkoksi, C3-C8 monociklički cikloalkil, [5,6]- ili [6,6]-kondenzirani biciklički cikloalkil, adamantil, 5-9-člana heteroaliciklička grupa s 1 ili 2 heteroatoma izabrana između N, O ili S(O)n gdje je n =0-2, hidroksi, C1-C10 alkoksi, nesupstituirani C3-C8 cikloalkoksi, -C(O)R8, -NR9R10i -C(O)NR12R13; R2 je odabran iz skupine koju čine vodik, halogen, C1-C10 alkil, trihalometil, hidroksi, C1-C10 alkoksi, nesupstituirani C3-C8 cikloalkoksi, cijano, -NR9R10, - NR9C(O)R10, -C(O)R8, -S(O)2NR9R10 i -SO2R14 (pri čemu je R14 C1-C10 alkil, C6-C12 aril, C1-C4 alkil supstituiran C6-C12 arilom, 5-12-člani heteroaril s 1-4 heteroatoma u prstenu, izabrana između N, O ili S, te C1-C4 alkil supstituiran 5-12-članim heteroarilom s 1-4 heteroatoma u prstenu, izabrana između N, O ili S); R3, R4 i R5 su neovisno vodik ili C1-C10 alkil; Z je C6-C12 aril, 5-12-člani heteroaril s 1-4 heteroatomau prtstenu, izabrana između N, O ili S, 3-8-članizasićeni heterociklil s 1 ili 2 heteroatoma u prstenu izabrana između N, O ili S(O)n pri čemu je n = 0-2, i -NR15R16 pri čemu su R15 i R16 neovisno vodik ili C1-C10 alkil; ili R15 i R16 zajedno s atomom dušika na kojeg su spojeni tvore 3-8-članu heterocikloamino skupinu koja još po želji može imati1 ili 2 dodatna heteroatoma u prstenu, izabrana između N, O ili S(O)n pri čemu je n = 0-2; R6 je odabran iz skupine koju čine vodik ili C1-C10 alkil;R7 je odabran iz skupine koju čine vodik, C1-C10 alkil, C6-C12 aril, 5-12-člani heteroaril s 1-4 heteroatoma u prstenu, izabrana između N, O ili S, te -C(O)R17 kao što je definirano u nastavku; R8 jeodabran iz skupine koju čine hidroksi, C1-C10 alkoksi, nesupstituirani C3-C8 cikloalkoksi, C6-C12 ariloksi i 5-12-člani heteroariloksi s 1-4 heteroatoma u prstenu, izabrana između N, O ili S; R9 i R10 su neovisno odabrani iz skupine koju čine vodik,C1-C10 alkil, C1-C10 cijanoalkil, C3-C8 monociklički cikloalkil, [5,6]- ili [6,6]-kondenzirani biciklički cikloalkil, adamantil, C6-C12 aril i 5-12-člani heteroaril s 1-4 heteroatoma u prstenu, izabrana između N, O ili S; ili R9 i R10 zajedno tvore 3-8-članu heterocikloamino skupinu, koja po želji može imati 1 ili 2 dodatna heteroatoma u prstenu, izabrana između N, O ili S(O)n pri čemu je n = 0-2; R12 i R13 su neovisno odabrani iz skupine koju čine vodik, C1-C10 alkil, C1-C10 hidroksialkil, te C6-C12 aril; ili R12 i R13 zajedno s atomom dušikana kojeg su spojeni tvore 3-8-članu heterocikloamino skupinu, koja po želji može imati 1 ili 2 dodatna heteroatoma u prstenu, izabrana između N, O ili S(O)n pri čemu je n = 0-2; R17 je odabran iz skupine koju čine C1-C10 alkil, C3-C8 monociklički cikloalkil, [5,6]- ili [6,6]-kondenzirani bicikličkicikloalkil, adamantil, C6-C12 aril, hidroksi i 5-12-člani heteroaril s 1-4 heteroatoma u prstenu, izabrana između N, O ili S; ili njegova farmaceutski prihvatljiva sol; uz uvjet da spoj nijei gdje C1-C10 alkil",SUGEN;;UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG-CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JUN QUINGWU;;HERRINGTON PAUL MATTHEW,,https://lens.org/163-032-584-641-490,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D403/06;;A61K31/404;;A61K31/4166;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
579,WO,A2,WO 2012/121834 A2,019-976-607-779-079,2012-09-13,2012,US 2012/0024857 W,2012-02-13,US 201113041017 A,2011-03-04,APPARATUS AND METHODS FOR REAL-TIME THREE-DIMENSIONAL SEM IMAGING AND VIEWING OF SEMICONDUCTOR WAFERS,"One embodiment relates to a method of real-time three-dimensional electron beam imaging of a substrate surface. A primary electron beam is scanned over the substrate surface causing electrons to be emitted therefrom. The emitted electrons are simultaneously detection using a plurality of at least two off-axis sensors so as to generate a plurality of image data frames, each image data frame being due to electrons emitted from the substrate surface at a different view angle. The plurality of image data frames are automatically processed to generate a three-dimensional representation of the substrate surface. Multiple views of the three-dimensional representation are then displayed. Other embodiments, aspects and features are also disclosed.",KLA TENCOR CORP;;CHEN CHIEN-HUEI;;MACDONALD PAUL D;;KUPPA RAJASEKHAR;;TADA TAKUJI;;ABBOTT GORDON;;TEH CHO;;YANG HEDONG;;LANG STEPHEN;;NEIL MARK;;SAIDIN ZAIN,CHEN CHIEN-HUEI;;MACDONALD PAUL D;;KUPPA RAJASEKHAR;;TADA TAKUJI;;ABBOTT GORDON;;TEH CHO;;YANG HEDONG;;LANG STEPHEN;;NEIL MARK;;SAIDIN ZAIN,,https://lens.org/019-976-607-779-079,Patent Application,yes,0,0,8,8,0,G01B21/20;;G01N23/2251;;G01N23/2251;;G01N23/225,G01N23/225;;G01B21/20,,0,0,,,,PENDING
580,AU,A1,AU 2015/371324 A1,168-031-559-162-399,2017-06-08,2017,AU 2015/371324 A,2015-12-23,US 201514978039 A;;US 201562190239 P;;US 201562201516 P;;US 201462096168 P;;US 201562183176 P;;US 2015/0000267 W,2014-12-23,Shortened block acknowledgement with fragmentation acknowledgement signaling,"Certain aspects of the present disclosure provide methods and apparatus for using a shortened block acknowledgement (BlockAck) frame capable of acknowledging fragments. Such a shortened BlockAck frame may include a bitmap field having a shorter length than that of a basic BlockAck frame in the IEEE 802.11 standard (i.e., < 128 octets). One example method for wireless communications generally includes receiving a plurality of protocol data units (PDUs) (e.g., media access control (MAC) protocol data units (MPDUs)); determining whether each of the PDUs was successfully received and whether each of the PDUs is associated with a non-fragmented service data unit (SDU) (e.g., MAC service data unit (MSDU)) or a fragmented SDU; and outputting for transmission a shortened BlockAck frame comprising a bitmap field indicating a receive status for the non-fragmented and fragmented SDUs based on the determination.",QUALCOMM INC,ASTERJADHI ALFRED;;MERLIN SIMONE;;CHERIAN GEORGE;;ABRAHAM SANTOSH PAUL;;BARRIAC GWENDOLYN DENISE;;MALIK RAHUL;;DING GANG;;FREDERIKS GUIDO ROBERT;;CHO JAMES SIMON,,https://lens.org/168-031-559-162-399,Patent Application,no,0,0,11,11,0,H04L1/1614;;H04L1/1685;;H04L1/1685;;H04L1/1614;;H04L1/1614;;H04L1/1685;;H04L5/0055;;H04W72/04;;H04L5/0055;;H04L1/1614;;H04W72/04;;H04L1/1685,H04L1/16,,0,0,,,,DISCONTINUED
581,CN,U,CN 212047240 U,189-889-948-215-377,2020-12-01,2020,CN 201921669779 U,2019-10-08,US 201816153238 A,2018-10-05,Energy absorbing structure,"Apparatus and methods for additive manufacturing of structures having increased energy absorption characteristics are provided herein. A three-dimensional (3D) additive manufacturing structure may beconstructed with spatially dependent features to form an impact component. When used in the construction of transportation vehicles, impact components having spatially dependent additive manufacturingfeatures may reinforce and increase impact energy absorption. This in turn absorbs and redistributes more collision energy away from the occupant (door) of the vehicle, thereby increasing the safetyof the occupant.",DIVERGENT TECH INC,CHO YONG-BAE;;MARTINEZ ANTONIO BERNERD;;GUNNER JON PAUL;;TENG ALEXANDER PAI-CHUNG;;TENHOUTEN BROC WILLIAM;;LAKSHMAN NARENDER SHANKAR;;HOYLE RICHARD WINSTON,,https://lens.org/189-889-948-215-377,Limited Patent,no,0,1,10,10,0,B60R19/02;;B29C64/20;;B29C64/153;;B33Y30/00;;B60R2019/186;;B60R19/18;;B60R19/03;;B60R19/023;;B60R2019/1853;;B33Y80/00;;B22F2999/00;;C22C49/06;;C22C49/14;;C22C47/16;;C23C24/08;;C23C24/082;;C23C24/087;;F16F7/003;;F16F2226/00;;B29C45/14795;;B29C45/0001;;B29K2105/04;;B29L2031/3044;;B29C45/14631;;Y02P10/25;;B60R19/34;;B62D21/152;;F16F7/003;;B60R19/03;;B60R19/18;;B33Y10/00;;B33Y80/00;;B29L2031/3044;;B29C45/14;;F16F2226/00;;F16F2224/0241;;F16F2224/0208;;B60R2019/186;;B29K2105/04;;B29C64/10,B60R19/02;;B29C64/153;;B29C64/20;;B33Y30/00,,0,0,,,,ACTIVE
582,IS,A,IS 6913 A,038-850-572-783-064,2003-08-14,2003,IS 6913 A,2003-08-14,US 0204407 W;;US 26868301 P;;US 31236101 P,2001-02-15,3-(4-amídópýrról-2-ýlmetlíden)-2-indólínon afleiður sem prótein kínasa hindrar,,SUGEN INC;;UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINGTON PAUL MATTHEW,,https://lens.org/038-850-572-783-064,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
583,WO,A1,WO 2020/072934 A1,078-182-163-837-578,2020-04-09,2020,US 2019/0054746 W,2019-10-04,US 201816153238 A,2018-10-05,APPARATUS AND METHODS FOR ADDITIVELY MANUFACTURED STRUCTURES WITH AUGMENTED ENERGY ABSORPTION PROPERTIES,"Apparatus and methods for additively manufactured structures with augmented energy absorption properties are presented herein. Three dimensional (3D) additive manufacturing structures may be constructed with spatially dependent features to create crash components. When used in the construction of a transport vehicle, the crash components with spatially dependent additively manufactured features may enhance and augment crash energy absorption. This in turn absorbs and re-distributes more crash energy away from the vehicle's occupant(s), thereby improving the occupants' safety.",DIVERGENT TECH INC,CHO YONG-BAE;;MARTINEZ ANTONIO BERNERD;;GUNNER JON PAUL;;TENG ALEXANDER PAI-CHUNG;;TENHOUTEN BROC WILLIAM;;LAKSHMAN NARENDER SHANKAR;;HOYLE RICHARD WINSTON,,https://lens.org/078-182-163-837-578,Patent Application,yes,4,0,10,10,0,B60R19/02;;B29C64/20;;B29C64/153;;B33Y30/00;;B60R2019/186;;B60R19/18;;B60R19/03;;B60R19/023;;B60R2019/1853;;B33Y80/00;;B22F2999/00;;C22C49/06;;C22C49/14;;C22C47/16;;C23C24/08;;C23C24/082;;C23C24/087;;F16F7/003;;F16F2226/00;;B29C45/14795;;B29C45/0001;;B29K2105/04;;B29L2031/3044;;B29C45/14631;;Y02P10/25;;B60R19/34;;B62D21/152;;F16F7/003;;B60R19/03;;B60R19/18;;B33Y10/00;;B33Y80/00;;B29L2031/3044;;B29C45/14;;F16F2226/00;;F16F2224/0241;;F16F2224/0208;;B60R2019/186;;B29K2105/04;;B29C64/10,B29C64/386;;B33Y50/02;;B29C64/393;;B33Y50/00,,0,0,,,,PENDING
584,TW,A,TW 201241425 A,109-749-383-451-850,2012-10-16,2012,TW 101107218 A,2012-03-03,US 201113041017 A,2011-03-04,Apparatus and methods for real-time three-dimensional SEM imaging and viewing of semiconductor wafers,"One embodiment relates to a method of real-time three-dimensional electron beam imaging of a substrate surface. A primary electron beam is scanned over the substrate surface causing electrons to be emitted therefrom. The emitted electrons are simultaneously detection using a plurality of at least two off-axis sensors so as to generate a plurality of image data frames, each image data frame being due to electrons emitted from the substrate surface at a different view angle. The plurality of image data frames are automatically processed to generate a three-dimensional representation of the substrate surface. Multiple views of the three-dimensional representation are then displayed. Other embodiments, aspects and features are also disclosed.",KLA TENCOR CORP,CHEN CHIEN-HUEI;;MACDONALD PAUL D;;KUPPA RAJASEKHAR;;TADA TAKUJI;;ABBOTT GORDON;;TEH CHO;;YANG HEDONG;;LANG STEPHEN;;NEIL MARK;;SAIDIN ZAIN,,https://lens.org/109-749-383-451-850,Patent of Addition,no,0,0,8,8,0,G01B21/20;;G01N23/2251;;G01N23/2251;;G01N23/225,G01N21/88;;H01L21/66,,0,0,,,,PENDING
585,US,A,US 5952574 A,188-687-669-104-12X,1999-09-14,1999,US 84122497 A,1997-04-29,US 84122497 A,1997-04-29,Trenches to reduce charging effects and to control out-of-plane sensitivities in tuning fork gyroscopes and other sensors,"Trenches which reduce or eliminate force and sensitivity associated with proof mass motion normal to the substrate as a result of voltage transients is disclosed. The trenches provide increased separation between interleaved comb electrodes and the substrate, and thereby also reduce the comb lift to drive ratio. The trenches are typically formed directly below the interleaved comb electrodes, but may also be formed below other suspended portions. Trench depth is from 6-10 microns and provides a comb electrode to substrate separation of approximately 8.5-12.5 microns.",DRAPER LAB CHARLES S,WEINBERG MARC S;;CHO STEVEN T;;HOPKINS III RALPH E;;NILES LANCE C;;KOUREPENIS ANTHONY S;;HILDEBRANT ERIC M;;WARD PAUL A,CHARLES STARK DRAPER LABORATORY INC. THE (1997-04-18),https://lens.org/188-687-669-104-12X,Granted Patent,yes,100,27,1,1,0,G01C19/5719;;G01C19/5719,G01C19/5719,73/504.16;;73/504.12;;438/50,15,9,037-455-049-951-303;;052-143-863-429-158;;044-884-280-439-651;;041-776-625-742-06X;;019-387-765-162-474;;172-006-575-019-146;;068-952-764-422-031;;153-448-008-964-431;;091-344-136-390-934,10.1109/solsen.1988.26427;;10.2514/6.1989-3438;;10.1016/0924-4247(90)85053-7;;10.2514/6.1988-4177;;10.1109/6.58424;;10.1007/bf00839185;;10.1109/t-ed.1982.20653;;10.1109/proc.1982.12331;;10.1109/6.278394,"Barth, P.W. et al., A Monolithic Silicon Accelerometer With Integral Air Damping and Overrange Protection , 1988 IEEE, pp. 35 38.;;Boxenhorn, B., et al., An Electrostatically Rebalanced Micromechanical Acceleratometer, AIAA Guidance, Navigation and Control Conference, Boston, Aug. 14 16, 1989, pp. 118 122.;;Boxenhorn, B., et al., Micromechanical Inertial Guidance System and its Application , Fourteenth Biennial Guidance Test Symposium, vol. 1, Oct. 3 5, 1989, pp. 113 131.;;Boxenhorn, B., et al., Monolithic Silicon Accelerometer , Transducer 89, Jun. 25 30, 1989, pp. 273 277.;;Boxenhorn, B., et al., A Vibratory Micromechanical Gyroscope , AIAA Guidance, Navigation and Control Conference, Minneapolis, Aug. 15 17, 1988, pp. 1033 1040.;;Howe, R., et al., Silicon Micromechanics: Sensors and Actuators on a Chip , IEEE Spectrum, Jul. 1990, pp. 29 35.;;Moskalik, L., Tensometric Accelerometers with Overload Protection , Meas. Tech. ( USA ), vol. 22, No. 12, Dec. 1979 (publ. May 1980), pp. 1469 1471.;;Nakamura, M., et al., Novel Electrochemical Micro Machining and Its Application for Semiconductor Acceleration Sensor IC , Digest of Technical Papers (1987), Insitute of Electrical Engineers of Japan, pp. 112 115.;;Petersen, K.E., Micromechanical Accelerometer Integrated with MOS Detection Circuitry , IEEE, vol. ED 29 No. 1 (Jan. 1982), pp. 23 27.;;Petersen, Kurt E., et al., Silicon as a Mechanical Material , Proceedings of the IEEE, vol. 70, No. 5, May 1982 pp. 420 457.;;Quartz Rate Sensor Replaces Gyros , Defense Electronics, Nov. 1984, p. 177.;;Rosen, Jerome, Machining In the Micro Domain , Mechanical Engineering, Mar. 1989, pp. 40 46.;;Teknekron Sensor Development Corporation, article entitled Micro Vibratory Rate Sensor , 1080 Marsh Road, Menlo Park, CA 94025, 2 pages, undated.;;Bryzek, Janusz et al., Micromachines on the March , IEEE Spectrum, May 1994, pp. 20 31.;;IEEE Robotics & Automation Soc, in coop. w/ASME Dynamic Systems & Control Div., Micro Electro Mechanical Systems, An Investigation of Micro Structures, Sensors, Actuators, Machines and Systems , IEEE Cat. 93CH3265 6, Library of Congress 92 56273, Ft. Lauderdale, Fl. 2/7 10/93.",EXPIRED
586,US,A1,US 2016/0182205 A1,012-841-071-400-223,2016-06-23,2016,US 201514978039 A,2015-12-22,US 201514978039 A;;US 201562201516 P;;US 201562190239 P;;US 201562183176 P;;US 201462096168 P,2014-12-23,SHORTENED BLOCK ACKNOWLEDGEMENT WITH FRAGMENTATION ACKNOWLEDGEMENT SIGNALING,"Certain aspects of the present disclosure provide methods and apparatus for using a shortened block acknowledgement (BlockAck) frame capable of acknowledging fragments. Such a shortened BlockAck frame may include a bitmap field having a shorter length than that of a basic BlockAck frame in the IEEE 802.11 standard (i.e., <128 octets). One example method for wireless communications generally includes receiving a plurality of protocol data units (PDUs) (e.g., media access control (MAC) protocol data units (MPDUs)); determining whether each of the PDUs was successfully received and whether each of the PDUs is associated with a non-fragmented service data unit (SDU) (e.g., MAC service data unit (MSDU)) or a fragmented SDU; and outputting for transmission a shortened BlockAck frame comprising a bitmap field indicating a receive status for the non-fragmented and fragmented SDUs based on the determination.",QUALCOMM INC,ASTERJADHI ALFRED;;MERLIN SIMONE;;CHERIAN GEORGE;;ABRAHAM SANTOSH PAUL;;BARRIAC GWENDOLYN DENISE;;MALIK RAHUL;;DING GANG;;FREDERIKS GUIDO ROBERT;;CHO JAMES SIMON,QUALCOMM INCORPORATED (2016-03-14),https://lens.org/012-841-071-400-223,Patent Application,yes,0,39,11,11,0,H04L1/1614;;H04L1/1685;;H04L1/1685;;H04L1/1614;;H04L1/1614;;H04L1/1685;;H04L5/0055;;H04W72/04;;H04L5/0055;;H04L1/1614;;H04W72/04;;H04L1/1685,H04L1/16;;H04L5/00;;H04W72/04,,0,0,,,,ACTIVE
587,EA,B1,EA 007186 B1,016-483-857-891-843,2006-08-25,2006,EA 200300793 A,2002-02-15,US 26868301 P;;US 31236101 P;;US 0204407 W,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.,SUGEN INK;;UPJOHN CO,LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW;;GUAN HUIPING,,https://lens.org/016-483-857-891-843,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D403/06;;A61K31/404;;A61K31/4166;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
588,MY,A,MY 126235 A,093-427-846-635-189,2006-09-29,2006,MY PI20020528 A,2002-02-15,US 26868301 P;;US 31236101 P,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHYLIDENE) -2- INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS.,THE PRESENT INVENTION RELATES TO PYRROLE SUBSTITUTED 2-INDOLINONE COMPOUNDS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS WHICH MODULATE THE ACTIVITY OF PROTEIN KINASES AND THEREFORE ARE EXPECTED TO BE USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER.,SUGEN INC;;UPJOHN CO,GUAN HUIPING;;SUN LI;;LIANG CONGXIN;;TANG PENG CHO;;WEI CHUNG CHEN;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINGTON PAUL MATTHEW;;MAURAGIS MICHAEL A,,https://lens.org/093-427-846-635-189,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
589,US,A1,US 2010/0325377 A1,106-501-928-733-092,2010-12-23,2010,US 87032410 A,2010-08-27,US 87032410 A;;US 40962606 A;;US 36130303 A;;US 67443005 P,2003-02-10,SYSTEM AND METHOD FOR RESTORING DATA ON DEMAND FOR INSTANT VOLUME RESTORATION,"A technique is disclosed for restoring data of sparse volumes, where one or more block pointers within the file system structure are marked as ABSENT, and fetching the appropriate data from an alternate location on demand. Client data access requests to the local storage system initiate a restoration of the data from a backing store as required. A demand generator can also be used to restore the data as a background process by walking through the sparse volume and restoring the data of absent blocks. A pump module is also disclosed to regulate the access of the demand generator. Once all the data has been restored, the volume contains all data locally, and is no longer a sparse volume.",LANGO JASON ANSEL;;CHO YONG EUN;;EASTHAM PAUL CHRISTOPHER;;ZHENG LING;;MANLEY STEPHEN L;;EDWARDS JOHN K;;ENGLISH ROBERT M;;ACKAOUY EMMANUEL,LANGO JASON ANSEL;;CHO YONG EUN;;EASTHAM PAUL CHRISTOPHER;;ZHENG LING;;MANLEY STEPHEN L;;EDWARDS JOHN K;;ENGLISH ROBERT M;;ACKAOUY EMMANUEL,,https://lens.org/106-501-928-733-092,Patent Application,yes,89,44,3,14,0,G06F16/10;;G06F16/10,G06F12/16,711/162;;X711E12103,0,0,,,,DISCONTINUED
590,TW,B,TW I324155 B,106-723-630-889-477,2010-05-01,2010,TW 91102595 A,2002-02-15,US 31236101 P;;US 26868301 P,2001-02-15,3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors,,SUGEN INC;;UPJOHN CO,GUAN HUIPING;;SUN LI;;LIANG CONGXIN;;TANG PENG CHO;;WEI CHUNG CHEN;;TOMAS VOJKOVSKY;;QINGWU JIN;;PAUL MATTHEW HERRINTON;;MICHAEL A MAURAGIS,,https://lens.org/106-723-630-889-477,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/4178;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;C07D/;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
591,CN,A,CN 111002932 A,147-085-275-604-783,2020-04-14,2020,CN 201910950077 A,2019-10-08,US 201816153238 A,2018-10-05,APPARATUS AND METHODS FOR ADDITIVELY MANUFACTURED STRUCTURES WITH AUGMENTED ENERGY ABSORPTION PROPERTIES,"Apparatus and methods for additively manufactured structures with augmented energy absorption properties are presented herein. Three dimensional (3D) additive manufacturing structures may be constructed with spatially dependent features to create crash components. When used in the construction of a transport vehicle, the crash components with spatially dependent additively manufactured features may enhance and augment crash energy absorption. This in turn absorbs and re-distributes more crash energy away from the vehicle's occupant(s), thereby improving the occupants' safety.",DIVERGENT TECH INC,CHO YONG-BAE;;MARTINEZ ANTONIO BERNERD;;GUNNER JON PAUL;;TENG ALEXANDER PAI-CHUNG;;TENHOUTEN BROC WILLIAM;;LAKSHMAN NARENDER SHANKAR;;HOYLE RICHARD WINSTON,,https://lens.org/147-085-275-604-783,Patent Application,no,9,0,10,10,0,B60R19/02;;B29C64/20;;B29C64/153;;B33Y30/00;;B60R2019/186;;B60R19/18;;B60R19/03;;B60R19/023;;B60R2019/1853;;B33Y80/00;;B22F2999/00;;C22C49/06;;C22C49/14;;C22C47/16;;C23C24/08;;C23C24/082;;C23C24/087;;F16F7/003;;F16F2226/00;;B29C45/14795;;B29C45/0001;;B29K2105/04;;B29L2031/3044;;B29C45/14631;;Y02P10/25;;B60R19/34;;B62D21/152;;F16F7/003;;B60R19/03;;B60R19/18;;B33Y10/00;;B33Y80/00;;B29L2031/3044;;B29C45/14;;F16F2226/00;;F16F2224/0241;;F16F2224/0208;;B60R2019/186;;B29K2105/04;;B29C64/10,B60R19/02;;B29C64/153;;B29C64/20;;B33Y30/00,,0,0,,,,ACTIVE
592,CR,A,CR 7056 A,047-355-088-357-299,2004-02-02,2004,CR 7056 A,2003-08-14,US 26868301 P;;US 31236101 P,2001-02-15,DERIVADOS DE 3-(4-AMIDOPIRROL-2-ILMETILDEN)-2-INDOLINONA COMO INHIBIDORES DE LA PROTEIN QUINASA,"La presente invencion se relaciona con compuestos de indolinona sustituidos con 2-pirrol y sus sales aceptables para el uso farmaceutico que modulan la actividad de protein quinasas y asi, se espera que sean utiles en la prevencion y el tratamiento de afecciones celulares realcionadas tales como el cancer.",SUGEN INC;;UPJOHN CO,CONGXIN LIANG;;LI SUN;;PENG CHO TANG;;CHUNG CHEN WEI;;MICHAEL A MAURAGIS;;TOMAS VOJKOVSKY;;QUINGWU JIN;;PAUL MATTHEW HERRINGTON;;HUIPING GUAN,,https://lens.org/047-355-088-357-299,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,PENDING
593,EP,B1,EP 1370554 B1,054-075-548-403-32X,2005-10-19,2005,EP 02714897 A,2002-02-15,US 0204407 W;;US 26868301 P;;US 31236101 P,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,,PHARMACIA & UPJOHN CO LLC;;SUGEN INC,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW,"PHARMACIA & UPJOHN COMPANY LLC (2005-06-01);;SUGEN, INC. (2005-06-01)",https://lens.org/054-075-548-403-32X,Granted Patent,yes,3,1,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,1,0,,,"SUN ET AL: ""Synthesis and Biological Evaluation of 3-Substituted Indolin-2-ones: A novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particualr Receptor Tyrosine Kinases"" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 14, July 1998 (1998-07), pages 2588-2603, XP002122185 ISSN: 0022-2623",EXPIRED
594,PE,A1,PE 20021006 A1,048-773-490-527-346,2002-11-08,2002,PE 2002000134 A,2002-02-15,US 26868301 P;;US 31236101 P,2001-02-15,DERIVADOS DE 3-(4-AMIDOPIRROL-2-ILMETILIDEN)-2-INDOLINONA COMO INHIBIDORES DE LA PROTEINQUINASA,"SE REFIERE A DERIVADOS DE 3-(4-AMIDOPIRROL-2-ILMETILIDEN)-2-INDOLINONA DE FORMULA I DONDE R1 ES H, HALO, ALQUILO, HALOALCOXILO, CICLOALQUILO, HETEROALICICLICO, HIDROXILO, ENTRE OTROS; R2 ES H, HALO, HALOALQUILO, TRIHALOMETILO, HIDROXILO, ALCOXILO, CIANO, ENTRE OTROS; R3, R4 Y R5 SON H, ALQUILO; Z ES ARILO, HETEROARILO, HETEROCICLO, ENTRE OTROS; R6 ES H, ALQUILO; R7 ES H, ALQUILO, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS ACIDO 5-(5-FLUORO-2-OXO-1,2-DIHIDRO-INDOL-3-ILIDENMETIL)-2,4-DIMETIL-1H-PIRROL-3-CARBOXILICO, (3-DIETILAMINO-2-HIDROXI-PROPIL)-AMIDA, ACIDO 5-[5-FLUORO-2-OXO-1,2-DIHIDRO-INDOL-(3)-ILIDENMETIL]-2,4-DIMETIL-1H-PIRROL-3-CARBOXILICO, (2-HIDROXI-3-MORFOLIN-4-IL-PROPIL)-AMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LA PROTEINQUINASA Y SON UTILES PARA EL TRATAMIENTO DEL CANCER",SUGEN INC;;UPJOHN CO,GUAN HUIPING;;SUN LI;;LIANG CONGXIN;;TANG PENG CHO;;WEI CHUNG CHEN;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW;;MAURAGIS MICHAEL A,,https://lens.org/048-773-490-527-346,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/08;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
595,US,A1,US 2003/0092917 A1,059-625-237-269-288,2003-05-15,2003,US 7614002 A,2002-02-15,US 7614002 A;;US 26868301 P;;US 31236101 P,2001-02-15,3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors,"
   The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer. 
",SUGEN INC,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL M;;MAURAGIS MICHAEL A,PHARMACIA & UPJOHN COMPANY (2002-05-16);;SUGEN INC (2002-05-16),https://lens.org/059-625-237-269-288,Patent Application,yes,0,5,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,548/468,0,0,,,,EXPIRED
596,US,A1,US 2007/0124341 A1,103-923-751-662-962,2007-05-31,2007,US 40962606 A,2006-04-24,US 40962606 A;;US 36130303 A;;US 67443005 P,2003-02-10,System and method for restoring data on demand for instant volume restoration,"A technique is disclosed for restoring data of sparse volumes, where one or more block pointers within the file system structure are marked as ABSENT, and fetching the appropriate data from an alternate location on demand. Client data access requests to the local storage system initiate a restoration of the data from a backing store as required. A demand generator can also be used to restore the data as a background process by walking through the sparse volume and restoring the data of absent blocks. A pump module is also disclosed to regulate the access of the demand generator. Once all the data has been restored, the volume contains all data locally, and is no longer a sparse volume.",LANGO JASON A;;CHO YONG E;;EASTHAM PAUL C;;ZHENG LING;;MANLEY STEPHEN L;;EDWARDS JOHN K;;ENGLISH ROBERT M;;ACKAOUY EMMANUEL,LANGO JASON A;;CHO YONG E;;EASTHAM PAUL C;;ZHENG LING;;MANLEY STEPHEN L;;EDWARDS JOHN K;;ENGLISH ROBERT M;;ACKAOUY EMMANUEL,NETAPP INC (2006-08-14),https://lens.org/103-923-751-662-962,Patent Application,yes,89,66,3,14,0,G06F16/10;;G06F16/10,G06F17/30,707/202,0,0,,,,EXPIRED
597,CN,A,CN 116215427 A,143-983-443-090-646,2023-06-06,2023,CN 202310246509 A,2019-10-08,US 201816153238 A;;CN 201910950077 A,2018-10-05,Additively manufactured energy absorbing structure,"Apparatuses and methods for additive manufacturing of structures having increased energy absorption characteristics are provided herein. Three-dimensional (3D) additive manufactured structures may be configured with spatially dependent features to form impact components. When used in a construction of a transport vehicle, a crash component with spatially dependent additive manufactured features may enhance and increase crash energy absorption. This in turn absorbs and redistributes more collision energy away from the occupant (s) of the vehicle, thereby improving the safety of the occupant.",DIVERGENT TECH INC,CHO YONG-BAE;;MARTINEZ ANTONIO BERNERD;;JON PAUL GUNNER;;TENG ALEXANDER PAI-CHUNG;;TENHOUTEN BROC WILLIAM;;LAKSHMAN NARENDER SHANKAR;;HOYLE RICHARD WINSTON,,https://lens.org/143-983-443-090-646,Patent Application,no,0,0,10,10,0,B60R19/02;;B29C64/20;;B29C64/153;;B33Y30/00;;B60R2019/186;;B60R19/18;;B60R19/03;;B60R19/023;;B60R2019/1853;;B33Y80/00;;B22F2999/00;;C22C49/06;;C22C49/14;;C22C47/16;;C23C24/08;;C23C24/082;;C23C24/087;;F16F7/003;;F16F2226/00;;B29C45/14795;;B29C45/0001;;B29K2105/04;;B29L2031/3044;;B29C45/14631;;Y02P10/25;;B60R19/34;;B62D21/152;;F16F7/003;;B60R19/03;;B60R19/18;;B33Y10/00;;B33Y80/00;;B29L2031/3044;;B29C45/14;;F16F2226/00;;F16F2224/0241;;F16F2224/0208;;B60R2019/186;;B29K2105/04;;B29C64/10,B60R19/02;;B29C64/153;;B29C64/20;;B33Y30/00,,0,0,,,,PENDING
598,CZ,A3,CZ 20032414 A3,165-249-394-741-255,2004-04-14,2004,CZ 20032414 A,2002-02-15,US 26868301 P;;US 31236101 P,2001-02-15,Derivatives of 3-(4-aminopyrrol-2-ylmethylidene-2-indolinone functioning as protein kinase inhibitors,,SUGEN;;UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN OINGWU;;HERRINGTON PAUL MATTHEW,,https://lens.org/165-249-394-741-255,Patent Application,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,PENDING
599,SI,T1,SI 1370554 T1,181-925-674-174-129,2006-04-30,2006,SI 200230238 T,2002-02-15,US 26868301 P;;US 31236101 P;;US 0204407 W;;EP 02714897 A,2001-02-15,3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS,,PHARMACIA & UPJOHN CO LLC;;SUGEN INC,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW,,https://lens.org/181-925-674-174-129,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D403/00;;A61K31/00;;A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/00;;C07D471/04,,0,0,,,,EXPIRED
600,KR,A,KR 20140010136 A,011-148-420-767-444,2014-01-23,2014,KR 20137026297 A,2012-02-13,US 201113041017 A;;US 2012/0024857 W,2011-03-04,APPARATUS AND METHODS FOR REAL-TIME THREE-DIMENSIONAL SEM IMAGING AND VIEWING OF SEMICONDUCTOR WAFERS,,KLA TENCOR CORP,CHEN CHIEN HUEI;;MACDONALD PAUL D;;KUPPA RAJASEKHAR;;TADA TAKUJI;;ABBOTT GORDON;;TEH CHO;;YANG HEDONG;;LANG STEPHEN;;NEIL MARK;;SAIDIN ZAIN,,https://lens.org/011-148-420-767-444,Patent Application,no,0,0,8,8,0,G01B21/20;;G01N23/2251;;G01N23/2251;;G01N23/225,G01N23/225;;G01B21/20,,0,0,,,,ACTIVE
601,IS,B,IS 2411 B,049-463-107-261-171,2008-10-15,2008,IS 6913 A,2003-08-14,US 0204407 W;;US 26868301 P;;US 31236101 P,2001-02-15,3-(4-amídópýrról-2-ýlmetýlíden)-2-indólínon afleiður sem prótein kínasa hindrar,,SUGEN INC;;UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL MATTHEW,,https://lens.org/049-463-107-261-171,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
602,KR,A,KR 20170097654 A,075-032-437-813-758,2017-08-28,2017,KR 20177016455 A,2015-12-23,US 201462096168 P;;US 201562183176 P;;US 201562190239 P;;US 201562201516 P;;US 201514978039 A;;US 2015/0000267 W,2014-12-23,SHORTENED BLOCK ACKNOWLEDGEMENT WITH FRAGMENTATION ACKNOWLEDGEMENT SIGNALING,"본 개시의 특정 양상들은 프래그먼트들을 확인응답할 수 있는 단축된 BlockAck(block acknowledgement) 프레임을 사용하기 위한 방법들 및 장치를 제공한다. 그러한 단축된 BlockAck 프레임은 IEEE 802.11 표준에서 기본 BlockAck 프레임의 것보다 더 짧은 길이(즉, < 128 옥텟들)를 갖는 비트맵 필드를 포함할 수 있다. 하나의 예시적인 무선 통신 방법은 일반적으로 복수의 PDU들(protocol data units)(예를 들면, MPDU들(MAC(media access control) protocol data units))을 수신하는 단계; PDU들 각각이 성공적으로 수신되었는지 및 PDU들 각각이 비-단편화된 SDU(service data unit)(예를 들면, MSDU(MAC service data unit))와 연관되는지 또는 단편화된 SDU와 연관되는지를 결정하는 단계; 및 그 결정에 기초하여 비-단편화 및 단편화된 SDU들에 대한 수신 상태를 표시하는 비트맵 필드를 포함하는 단축된 BlockAck 프레임을 송신을 위해 출력하는 단계를 포함한다.",QUALCOMM INC,ASTERJADHI ALFRED;;MERLIN SIMONE;;CHERIAN GEORGE;;ABRAHAM SANTOSH PAUL;;BARRIAC GWENDOLYN DENISE;;MALIK RAHUL;;DING GANG;;FREDERIKS GUIDO ROBERT;;CHO JAMES SIMON,,https://lens.org/075-032-437-813-758,Patent Application,no,0,0,11,11,0,H04L1/1614;;H04L1/1685;;H04L1/1685;;H04L1/1614;;H04L1/1614;;H04L1/1685;;H04L5/0055;;H04W72/04;;H04L5/0055;;H04L1/1614;;H04W72/04;;H04L1/1685,H04L5/00;;H04L1/16;;H04W72/04,,0,0,,,,PENDING
603,DK,T3,DK 1370554 T3,164-255-972-409-807,2006-02-06,2006,DK 02714897 T,2002-02-15,US 26868301 P;;US 31236101 P,2001-02-15,3-(4-Amidopyrrol-2-ylmethyliden)-2-indolinon-derivater som proteinkinaseinhibitorer,,PHARMACIA & UPJOHN CO LLC;;SUGEN INC,LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;VOJKOVSKY TOMAS;;GUAN HUIPING;;MAURAGIS MICHAEL A;;JIN QINGWU;;HERRINTON PAUL MATTHEW,,https://lens.org/164-255-972-409-807,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D403/06;;A61K31/404;;A61K31/4166;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
604,CN,A,CN 117083016 A,034-995-942-379-520,2023-11-17,2023,CN 202280019901 A,2022-02-10,US 202117246331 A;;US 2022/0016000 W,2021-04-30,Acute health event monitoring,"A system includes processing circuitry and memory including program instructions that, when executed by the processing circuitry, cause the processing circuitry to: apply a first set of rules to first patient parameter data for a first determination of whether cardiac arrest of a patient is detected; determining one or more context criteria that satisfy the first determination; and in response to the contextual criteria being met, applying a second set of rules to second patient parameter data for a second determination of whether cardiac arrest of the patient is detected. At least the second set of rules includes a machine learning model and the second patient parameter data includes at least one patient parameter not included in the first patient parameter data.",MEDTRONIC INC,CHO YONG K;;WISZYNSKI RAYMOND D;;NEITZEL GARY A;;KRAUSE PAUL G;;OSTIGIAN KEVIN T;;DEGROOT PAUL J;;SARKAR SHANTANU;;KOCH CRAIG D;;JAYURKAR ASHOK P;;PHILIPPSEN LAURA JANE;;SIEGFRIED DANIEL I,,https://lens.org/034-995-942-379-520,Patent Application,no,0,0,1,22,0,,A61B5/00,,0,0,,,,PENDING
605,WO,A1,WO 2022/191949 A1,106-349-544-669-024,2022-09-15,2022,US 2022/0016000 W,2022-02-10,US 202117246331 A;;US 202163158189 P,2021-03-08,ACUTE HEALTH EVENT MONITORING,"A system comprises processing circuitry and memory comprising program instructions that, when executed by the processing circuitry, cause the processing circuitry to: apply a first set of rules to first patient parameter data for a first determination of whether sudden cardiac arrest of a patient is detected; determine that a one or more context criteria of the first determination are satisfied; and m response to satisfaction of the context criteria, apply a second set of rides to second patient parameter data for a second determination of whether sudden cardiac arrest of the patient is detected. At least the second set of rules comprises a machine learning model, and the second patient parameter data comprises at least one patient parameter that is not included m the first patient parameter data.",MEDTRONIC INC,CHO YONG K;;WYSZYNSKI RYAN D;;NEITZELL GRANT A;;KRAUSE PAUL G;;OUSDIGIAN KEVIN T;;DEGROOT PAUL J;;SARKAR SHANTANU;;KOCH CHRISTOPHER D;;JEJURKAR ABHIJIT P;;PHILIPPSEN LAURA J;;SIEGFRIED DAVID I,,https://lens.org/106-349-544-669-024,Patent Application,yes,7,0,3,22,0,A61B5/0006;;A61B5/024;;A61B5/02405;;A61B5/283;;A61B5/349;;A61B5/361;;A61B5/686;;A61B5/7264;;A61B5/7267;;A61B5/7282;;A61N1/3925;;G16H50/30;;G16H50/20;;G16H40/63;;G16H40/67;;G16H10/60;;G16H50/70;;G16H20/30;;G16H20/10;;G16H40/20;;A61N1/056;;A61N1/365;;A61N1/3956;;A61N1/3756;;A61B5/318;;A61B5/0031;;A61B5/0059;;A61B5/0205;;A61B5/021;;A61B5/053;;A61B5/0816;;A61B5/1116;;A61B5/1118;;A61B5/686;;A61B5/7221;;A61B5/7264;;A61B5/7275;;A61B7/00,A61B5/00;;A61B5/024;;A61B5/349;;A61B5/361;;A61B8/08;;A61N1/39;;G16H50/30,,0,0,,,,PENDING
606,EP,A1,EP 4304452 A1,027-552-430-620-548,2024-01-17,2024,EP 22705696 A,2022-02-10,US 202163158189 P;;US 202117246331 A;;US 2022/0016000 W,2021-03-08,ACUTE HEALTH EVENT MONITORING,,MEDTRONIC INC,CHO YONG K;;WYSZYNSKI RYAN D;;NEITZELL GRANT A;;KRAUSE PAUL G;;OUSDIGIAN KEVIN T;;DEGROOT PAUL J;;SARKAR SHANTANU;;KOCH CHRISTOPHER D;;JEJURKAR ABHIJIT P;;PHILIPPSEN LAURA J;;SIEGFRIED DAVID I,,https://lens.org/027-552-430-620-548,Patent Application,yes,0,0,3,22,0,A61B5/0006;;A61B5/024;;A61B5/02405;;A61B5/283;;A61B5/349;;A61B5/361;;A61B5/686;;A61B5/7264;;A61B5/7267;;A61B5/7282;;A61N1/3925;;G16H50/30;;G16H50/20;;G16H40/63;;G16H40/67;;G16H10/60;;G16H50/70;;G16H20/30;;G16H20/10;;G16H40/20;;A61N1/056;;A61N1/365;;A61N1/3956;;A61N1/3756;;A61B5/318;;A61B5/0031;;A61B5/0059;;A61B5/0205;;A61B5/021;;A61B5/053;;A61B5/0816;;A61B5/1116;;A61B5/1118;;A61B5/686;;A61B5/7221;;A61B5/7264;;A61B5/7275;;A61B7/00,A61B5/00;;A61B5/024;;A61B5/349;;A61B5/361;;A61B8/08;;A61N1/39;;G16H50/30,,0,0,,,,PENDING
607,TW,B,TW I538913 B,002-489-078-513-412,2016-06-21,2016,TW 103140297 A,2014-11-20,US 201361907322 P,2013-11-21,Purine derivatives,,PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON THEODORE OTTO JR;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/002-489-078-513-412,Granted Patent,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,,,0,0,,,,ACTIVE
608,CL,A1,CL 2016001151 A1,057-999-731-853-686,2017-01-06,2017,CL 2016001151 A,2016-05-13,US 201361907322 P,2013-11-21,"Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.","COMPUESTOS DERIVADOS DE PURINA 2,6-SUSTITUIDOS; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; Y SU USO PARA EL TRATAMIENTO DEL CANCER Y PARA TRATAR EL CRECIMIENTO CELULAR ANORMAL EN UN MAMIFERO.",PFIZER,CHENG HENGMIAO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL;;BEHENNA DOUGLAS CARL;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO,,https://lens.org/057-999-731-853-686,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/52;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,PENDING
609,US,A1,US 2019/0091159 A1,078-718-383-744-149,2019-03-28,2019,US 201816141070 A,2018-09-25,US 201816141070 A;;US 201762563562 P,2017-09-26,ORALLY AVAILABLE ARTICLES CONTAINING AT LEAST ONE STABILIZED SUPPLEMENT THEREIN,"The present disclosure relates to orally available stabilized supplement-containing articles (e.g., softgels). The stabilized supplement may be a probiotic, and may contain a stabilizing component derived from chocolate. The present disclosure also relates to methods of making such stabilized articles.",CAPTEK SOFTGEL INT,CHIPRICH TIMOTHY BRIAN;;MELENDEZ ARGELIA SINAY;;GEORGE BIBU PHILIP;;WOOD DAVID;;PARK JANGSOON;;CHO JUNG KU;;TRAN LILYAN HONG;;HWANG PAUL;;BAYLESS RONNIE,CAPTEK SOFTGEL INTERNATIONAL (2017-10-03),https://lens.org/078-718-383-744-149,Patent Application,yes,10,3,2,2,0,A23K20/10;;A23L33/105;;A61K9/0056;;A61K9/4858;;A23K10/18;;A23K20/174;;A23K50/20;;A23K50/70;;A23K50/30;;A23K50/40;;A23K50/50;;A23L33/135;;A23P10/30;;A61K9/5057;;A23L33/135;;A61K9/4808;;A61K9/4833;;A61K47/36;;A61K9/4891;;A23L29/206;;A61K31/715;;A23P10/30;;A23G1/00;;A23K50/20;;A23K20/10;;A23L33/105;;A61K9/0056;;A23K20/174;;A23K50/30;;A61K9/4858;;A23K50/50;;A23K50/70;;A23K50/40;;A23K10/18,A61K9/50;;A23L33/135;;A23P10/30;;A61K9/48,,1,0,,,JP2013533313A machine translation (Year: 2013),ACTIVE
610,CN,A,CN 107004767 A,111-247-388-354-787,2017-08-01,2017,CN 201480082126 A,2014-09-29,US 2014/0058100 W,2014-09-29,Flexible display device with reduced bend stress wires,A conductive trace design is described that minimizes the possibility of crack initiation and propagation in conductive traces during bending. The conductive trace design has a winding trace pattern that is more resistant to the formation of cracks at high stress points in the conductive traces. The conductive trace design includes a cap that helps ensure electrical connection of the conductive trace even though one or more cracks may begin to form in the conductive portion of the conductive trace.,LG DISPLAY CO LTD,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,,https://lens.org/111-247-388-354-787,Patent Application,no,5,9,9,9,0,Y02E10/549;;G06F3/0412;;G06F2203/04102;;G06F2203/04103;;G06F3/04164;;H04M1/0269;;H04M1/0268;;H10K59/1315;;H10K59/179;;H10K59/1795;;H10K59/131;;H10K77/111;;H10K2102/311;;G06F3/0412;;G06F3/04164;;G06F1/1652;;G09F9/301;;G06F2203/04102;;G06F2203/04103;;Y02E10/549;;H10K77/111;;H04M1/0269;;H10K59/1315;;H10K59/1795;;Y02E10/549;;G06F3/0412;;G06F2203/04103;;G06F2203/04102;;G06F3/04164;;H04M1/0269;;H10K59/131;;H10K59/179;;H10K77/111;;H10K59/1315;;H10K59/1795;;H10K71/00;;H10K2102/311;;G06F1/1652;;G09F9/301;;H04M1/0268,H01L51/00,,0,0,,,,ACTIVE
611,CN,A,CN 113164074 A,130-861-422-527-821,2021-07-23,2021,CN 201980082399 A,2019-12-20,US 201862783728 P;;US 2019/0067884 W,2018-12-21,ACUTE HEART FAILURE MONITORING AND TREATMENT,"Systems and methods include differential diagnosis for acute heart failure to provide treatment to a patient including determining whether the patient has cardiac volume overload, determining whether the patient has decreased abdominal venous system volume, and providing the appropriate treatment in response to the determinations. A multi-sensor system may be used to determine cardiac volume and abdominal venous system volume. Fluid redistribution treatment may be provided when cardiac volume overload is accompanied by a decrease in abdominal venous system volume. Fluid accumulation treatment may be provided when cardiac volume overload is not accompanied by a decrease in abdominal venous system volume.",MEDTRONIC INC,CHO YONG K;;BENNETT TOMMY D;;HETTRICK DOUGLAS A;;SPERLING CHARLES P;;SOBOTKA PAUL A;;SHARMA VINOD;;WARMAN EDUARDO N;;ZIELINSKI TODD M,,https://lens.org/130-861-422-527-821,Patent Application,no,1,0,5,5,0,A61B5/686;;A61B5/0537;;A61B5/02028;;A61B5/029;;A61B5/6869;;A61B5/6876;;A61B5/6823;;A61B5/14551;;A61B5/0538;;A61N1/36521;;A61N1/36585;;A61B5/4836;;A61B5/4839;;A61N1/3956;;A61B5/029;;A61B5/1073;;A61B5/686;;A61B5/6869;;A61B5/6876,A61B5/02;;A61B5/029;;A61B5/0538;;A61B5/1455;;A61N1/365,,0,0,,,,PENDING
612,CA,C,CA 2931034 C,071-898-337-045-546,2019-01-08,2019,CA 2931034 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS","The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON THEODORE OTTO JR;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/071-898-337-045-546,Granted Patent,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
613,JP,A,JP 2017214390 A,100-167-095-007-168,2017-12-07,2017,JP 2017122759 A,2017-06-23,US 201361907322 P,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN TREATMENT OF PROLIFERATIVE DISORDERS","PROBLEM TO BE SOLVED: To provide novel compounds that inhibit an epidermal growth factor receptor (EGFR) mutant sub-population with reduced response to existing EGFR inhibitors such as erlotinib or gefitinib due to mutations occurring in the EGFR in carcinoma such as lung adenocarcinoma, and particularly, EGFR T790M, which is a second mutation (T790M) occurring at the gatekeeper threonine residue of the EGFR.SOLUTION: The invention provides 9-alkyl-6-substituted amino-9H-purine derivatives represented by formula (Ic), or acceptable salts thereof.SELECTED DRAWING: None",PFIZER,DOUGLAS CARL BEHENNA;;CHENG HENGMIAO;;SUJIN CHO-SCHULTZ;;THEODORE OTTO JOHNSON JR;;JOHN CHARLES KATH;;NAGATA ASAKO;;SAJIV KRISHNAN NAIR;;SIMON PAUL PLANKEN,,https://lens.org/100-167-095-007-168,Patent Application,no,5,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61K31/52;;C07D473/16;;A61K45/00;;A61P35/00;;A61P43/00;;C07D473/18;;C07D473/34,,0,0,,,,PENDING
614,AU,B2,AU 2014/351433 B2,181-577-333-958-20X,2017-08-24,2017,AU 2014/351433 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-substituted purine derivatives and their use in the treatment of proliferative disorders","The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/181-577-333-958-20X,Granted Patent,no,1,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
615,KR,A,KR 20170039730 A,038-988-991-709-442,2017-04-11,2017,KR 20177006260 A,2014-09-29,US 2014/0058086 W,2014-09-29,FLEXIBLE DISPLAY DEVICE WITH REDUCED BEND STRESS WIRES,"벤딩 동안 도전성 트레이스에서의 크랙의 발생 및 전파를 최소화하는 도전성 트레이스의 설계가 설명된다. 도전성 트레이스의 설계는 도전성 트레이스 내부에서 높은 스트레스 포인트에서 크랙이들의 형성에 대항하여, 보다 저항력이 강한 굴곡진 트레이스 패턴을 포함한다. 도전성 트레이스의 설계는 하나 이상의 크랙이 도전성 트레이스의 도전 영역에서 형성되기 시작하더라도 전기적인 연결이 확실히 되도록 하는 캡을 포함한다.",LG DISPLAY CO LTD,KWON SEYEOUL;;YANG HEESEOK;;LEE CHANWOO;;YOUN SANGCHEON;;CHO YOONDONG;;LEE SAEMLEENURI;;JO SOYOUNG;;KIM DONGYOON;;HA ANNA;;ZHANG ZHEN;;DRZAIC PAUL STEPHEN,,https://lens.org/038-988-991-709-442,Patent Application,no,9,1,12,12,0,G06F1/1652;;H05K1/028;;H05K1/0283;;H05K2201/09263;;H05K2201/09727;;H05K2201/10128;;G09F9/301;;H04M1/0268;;H10K59/131;;H10K77/111;;H10K2102/311;;G02F1/13452;;H05K1/028;;H05K1/0283;;H10K59/131;;G09F9/301;;G06F1/1652;;H05K1/0283;;H05K1/028;;H05K2201/10128;;H05K2201/09727;;H05K2201/09263;;H10K71/00;;H10K59/131;;H10K77/111;;H10K2102/311;;H04M1/0268,H01L27/32;;G02F1/1345;;H05K1/02,,0,0,,,,ACTIVE
616,US,A1,US 2004/0102510 A1,090-376-433-990-506,2004-05-27,2004,US 65690703 A,2003-09-08,US 65690703 A;;US 7614002 A;;US 26868301 P;;US 31236101 P,2001-02-15,3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors,"
   The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer. 
",SUGEN INC;;UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN CONNIE LI;;TANG PENG CHO;;WEI CHUNG CHEN;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL M;;MAURAGIS MICHAEL A,,https://lens.org/090-376-433-990-506,Patent Application,yes,0,1,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,514/414;;548/465,0,0,,,,EXPIRED
617,KR,A,KR 20160077217 A,145-495-853-571-020,2016-07-01,2016,KR 20167016053 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS","본 발명은 하기 화학식 I의 화합물 또는 그의 제약상 허용되는 염에 관한 것이다. <화학식 I>상기 식에서 Q, G, 고리 A, 고리 B, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, 및 m은 본원에 정의되어 있다. 신규 퓨린 유도체는 포유동물에서 비정상적 세포 성장, 예컨대 암의 치료에 유용하다. 추가 실시양태는 상기 화합물을 함유하는 제약 조성물 및 포유동물에서의 비정상적 세포 성장의 치료에서 상기 화합물 및 조성물을 사용하는 방법에 관한 것이다.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/145-495-853-571-020,Patent Application,no,5,1,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/18,,0,0,,,,ACTIVE
618,CR,A,CR 20160236 A,042-492-457-422-551,2016-07-22,2016,CR 20160236 A,2016-05-20,US 201361907322 P;;IB 2014065935 W,2013-11-21,"DERIVADOS DE PURINA 2,6- SUSTITUIDOS Y SU USO EN EL TRATAMIENTO DE DESORDENES PROLIFERATIVOS","La presente invención se refiere a compuestos de la Fórmula (I). o sales de aquellos aceptables desde el punto de vista farmacéutico, en donde Q, G, anillo A, anillo B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 y m son como se definen en la presente. Los derivados de purina novedosos son útiles para tratar el crecimiento celular anormal, tal como el cáncer, en mamíferos. Otras formas de realización se refieren a composiciones farmacéuticas que contienen los compuestos y a métodos para usar los compuestos y las composiciones en el tratamiento del crecimiento celular anormal en mamíferos.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/042-492-457-422-551,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,PENDING
619,WO,A1,WO 2020/132460 A1,125-139-775-140-615,2020-06-25,2020,US 2019/0067884 W,2019-12-20,US 201862783728 P,2018-12-21,ACUTE HEART FAILURE MONITORING AND TREATMENT,"Systems and methods include differential diagnosis for acute heart failure to provide treatment to a patient including determining whether the patient has cardiac volume overload, determining whether the patient has decreased abdominal venous system volume, and providing the appropriate treatment in response to the determinations. A multi-sensor system may be used to determine cardiac volume and abdominal venous system volume. Fluid redistribution treatment may be provided when cardiac volume overload is accompanied by a decrease in abdominal venous system volume. Fluid accumulation treatment may be provided when cardiac volume overload is not accompanied by a decrease in abdominal venous system volume.",MEDTRONIC INC,CHO YONG K;;BENNETT TOM D;;HETTRICK DOUGLAS A;;SPERLING CHARLES P;;SOBOTKA PAUL A;;SHARMA VINOD;;WARMAN EDUARDO N;;ZIELINSKI TODD M,,https://lens.org/125-139-775-140-615,Patent Application,yes,6,5,5,5,0,A61B5/686;;A61B5/0537;;A61B5/02028;;A61B5/029;;A61B5/6869;;A61B5/6876;;A61B5/6823;;A61B5/14551;;A61B5/0538;;A61N1/36521;;A61N1/36585;;A61B5/4836;;A61B5/4839;;A61N1/3956;;A61B5/029;;A61B5/1073;;A61B5/686;;A61B5/6869;;A61B5/6876,A61B5/02;;A61B5/029;;A61B5/053;;A61B5/1455;;A61N1/365,,1,1,001-010-573-736-281,10.3904/kjim.2017.355;;29627971;;pmc5943665,"PIETER MARTENS ET AL: ""How to tackle congestion in acute heart failure"", KOREAN JOURNAL OF INTERNAL MEDICINE KOREA (SOUTH), vol. 33, no. 3, 11 April 2018 (2018-04-11), pages 462 - 473, XP055680108, ISSN: 1226-3303, DOI: 10.3904/kjim.2017.355",PENDING
620,KR,A,KR 20180129993 A,199-376-227-187-176,2018-12-05,2018,KR 20187034390 A,2014-09-29,US 2014/0058086 W,2014-09-29,FLEXIBLE DISPLAY DEVICE WITH REDUCED BEND STRESS WIRES,"벤딩 동안 도전성 트레이스에서의 크랙의 발생 및 전파를 최소화하는 도전성 트레이스의 설계가 설명된다. 도전성 트레이스의 설계는 도전성 트레이스 내부에서 높은 스트레스 포인트에서 크랙이들의 형성에 대항하여, 보다 저항력이 강한 굴곡진 트레이스 패턴을 포함한다. 도전성 트레이스의 설계는 하나 이상의 크랙이 도전성 트레이스의 도전 영역에서 형성되기 시작하더라도 전기적인 연결이 확실히 되도록 하는 캡을 포함한다.",LG DISPLAY CO LTD,SEYEOUL KWON;;HEESEOK YANG;;CHANWOO LEE;;SANGCHEON YOUN;;YOONDONG CHO;;SAEMLEENURI LEE;;SOYOUNG JO;;DONGYOON KIM;;ANNA HA;;ZHANG ZHEN;;DRZAIC PAUL STEPHEN,,https://lens.org/199-376-227-187-176,Patent Application,no,5,0,12,12,0,G06F1/1652;;H05K1/028;;H05K1/0283;;H05K2201/09263;;H05K2201/09727;;H05K2201/10128;;G09F9/301;;H04M1/0268;;H10K59/131;;H10K77/111;;H10K2102/311;;G02F1/13452;;H05K1/028;;H05K1/0283;;H10K59/131;;G09F9/301;;G06F1/1652;;H05K1/0283;;H05K1/028;;H05K2201/10128;;H05K2201/09727;;H05K2201/09263;;H10K71/00;;H10K59/131;;H10K77/111;;H10K2102/311;;H04M1/0268,H01L27/32;;G02F1/1345;;H05K1/02,,0,0,,,,ACTIVE
621,EP,B1,EP 3201964 B1,009-145-621-057-128,2020-11-18,2020,EP 14903089 A,2014-09-29,US 2014/0058086 W,2014-09-29,FLEXIBLE DISPLAY DEVICE WITH REDUCED BEND STRESS WIRES,,LG DISPLAY CO LTD,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,,https://lens.org/009-145-621-057-128,Granted Patent,yes,11,0,12,12,0,G06F1/1652;;H05K1/028;;H05K1/0283;;H05K2201/09263;;H05K2201/09727;;H05K2201/10128;;G09F9/301;;H04M1/0268;;H10K59/131;;H10K77/111;;H10K2102/311;;G02F1/13452;;H05K1/028;;H05K1/0283;;H10K59/131;;G09F9/301;;G06F1/1652;;H05K1/0283;;H05K1/028;;H05K2201/10128;;H05K2201/09727;;H05K2201/09263;;H10K71/00;;H10K59/131;;H10K77/111;;H10K2102/311;;H04M1/0268,G06F1/16;;H01L51/56;;G09F9/30;;H01L27/32;;H01L51/00;;H04M1/02;;H05K1/02,,0,0,,,,ACTIVE
622,US,A1,US 2017/0301266 A1,014-951-250-240-501,2017-10-19,2017,US 201415509837 A,2014-09-29,US 2014/0058100 W,2014-09-29,FLEXIBLE DISPLAY DEVICE WITH REDUCED BEND STRESS WIRES,A conductive trace design is described that minimizes the possibility of crack initiation and propagation in conductive traces during bending. The conductive trace design has a winding trace pattern that is more resistant to the formation of cracks at high stress points in the conductive traces. The conductive trace design includes a cap that helps ensure electrical connection of the conductive trace even though one or more cracks may begin to form in the conductive portion of the conductive trace.,LG DISPLAY CO LTD,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,LG DISPLAY CO. LTD (2014-10-16);;APPLE INC (2014-10-16),https://lens.org/014-951-250-240-501,Patent Application,yes,2,24,9,9,0,Y02E10/549;;G06F3/0412;;G06F2203/04102;;G06F2203/04103;;G06F3/04164;;H04M1/0269;;H04M1/0268;;H10K59/1315;;H10K59/179;;H10K59/1795;;H10K59/131;;H10K77/111;;H10K2102/311;;G06F3/0412;;G06F3/04164;;G06F1/1652;;G09F9/301;;G06F2203/04102;;G06F2203/04103;;Y02E10/549;;H10K77/111;;H04M1/0269;;H10K59/1315;;H10K59/1795;;Y02E10/549;;G06F3/0412;;G06F2203/04103;;G06F2203/04102;;G06F3/04164;;H04M1/0269;;H10K59/131;;H10K59/179;;H10K77/111;;H10K59/1315;;H10K59/1795;;H10K71/00;;H10K2102/311;;G06F1/1652;;G09F9/301;;H04M1/0268,G09F9/30;;G06F1/16;;H01L51/00;;H01L51/56;;H04M1/02,,0,0,,,,ACTIVE
623,PT,T,PT 3071570 T,083-829-399-335-641,2018-08-01,2018,PT 14806447 T,2014-11-10,US 201361907322 P,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS",,PFIZER,DOUGLAS CARL BEHENNA;;HENGMIAO CHENG;;SUJIN CHO-SCHULTZ;;THEODORE OTTO JOHNSON JR;;JOHN CHARLES KATH;;ASAKO NAGATA;;SAJIV KRISHNAN NAIR;;SIMON PAUL PLANKEN,,https://lens.org/083-829-399-335-641,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,PENDING
624,US,B2,US 10074294 B2,155-410-757-921-77X,2018-09-11,2018,US 201415509837 A,2014-09-29,US 2014/0058100 W,2014-09-29,Flexible display device with reduced bend stress wires,A conductive trace design is described that minimizes the possibility of crack initiation and propagation in conductive traces during bending. The conductive trace design has a winding trace pattern that is more resistant to the formation of cracks at high stress points in the conductive traces. The conductive trace design includes a cap that helps ensure electrical connection of the conductive trace even though one or more cracks may begin to form in the conductive portion of the conductive trace.,LG DISPLAY CO LTD,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,LG DISPLAY CO. LTD (2014-10-16);;APPLE INC (2014-10-16),https://lens.org/155-410-757-921-77X,Granted Patent,yes,16,0,9,9,0,Y02E10/549;;G06F3/0412;;G06F2203/04102;;G06F2203/04103;;G06F3/04164;;H04M1/0269;;H04M1/0268;;H10K59/1315;;H10K59/179;;H10K59/1795;;H10K59/131;;H10K77/111;;H10K2102/311;;G06F3/0412;;G06F3/04164;;G06F1/1652;;G09F9/301;;G06F2203/04102;;G06F2203/04103;;Y02E10/549;;H10K77/111;;H04M1/0269;;H10K59/1315;;H10K59/1795;;Y02E10/549;;G06F3/0412;;G06F2203/04103;;G06F2203/04102;;G06F3/04164;;H04M1/0269;;H10K59/131;;H10K59/179;;H10K77/111;;H10K59/1315;;H10K59/1795;;H10K71/00;;H10K2102/311;;G06F1/1652;;G09F9/301;;H04M1/0268,H01L23/528;;G06F1/16;;G09F9/30;;H01L51/00;;H01L51/56;;H04M1/02,,3,0,,,"Office Action for Korean Patent Application No. KR 10-2017-7006262, dated Jan. 8, 2018, 8 Pages, (With Concise Explanation of Relevance).;;PCT International Search Report, PCT/US2014/058100, dated Dec. 19, 2014, 2 Pages.;;PCT Written Opinion, PCT/US2014/058100, dated Dec. 19, 2014, 3 Pages.",ACTIVE
625,HU,T2,HU E039858 T2,019-920-719-486-657,2019-02-28,2019,HU E14806447 A,2014-11-10,US 201361907322 P,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS",,PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/019-920-719-486-657,Amended Patent,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61P35/00,,0,0,,,,PENDING
626,IL,A0,IL 245698 A0,033-414-735-100-094,2016-08-02,2016,IL 24569816 A,2016-05-18,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-substituted purine derivatives and their use in the treatment of proliferative disorders",,PFIZER;;THEODORE OTTO JOHNSON JR;;HENGMIAO CHENG;;SAJIV KRISHNAN NAIR;;SIMON PAUL PLANKEN;;JOHN CHARLES KATH;;DOUGLAS CARL BEHENNA;;SUJIN CHO-SCHULTZ;;ASAKO NAGATA,THEODORE OTTO JOHNSON JR;;HENGMIAO CHENG;;SAJIV KRISHNAN NAIR;;SIMON PAUL PLANKEN;;JOHN CHARLES KATH;;DOUGLAS CARL BEHENNA;;SUJIN CHO-SCHULTZ;;ASAKO NAGATA,,https://lens.org/033-414-735-100-094,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,,,0,0,,,,ACTIVE
627,NI,A,NI 201600072 A,041-846-614-202-034,2016-08-09,2016,NI 201600072 A,2016-05-20,US 201361907322 P,2013-11-21,"DERIVADOS DE PURINA 2, 6-SUSTITUIDOS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS","La presente invención se refiere a compuestos de la Fórmula (I) o sales de aquellos aceptables desde el punto de vista farmacéutico, en donde Q, G, anillo A, anillo B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 y m son como se definen en la presente. Los derivados de purina novedosos son útiles para tratar el crecimiento celular anormal, tal como el cáncer, en mamíferos. Otras formas de realización se refieren a composiciones farmacéuticas que contienen los compuestos y a métodos para usar los compuestos y las composiciones en el tratamiento del crecimiento celular anormal en mamíferos.",PFIZER,DOUGLAS CARL BEHENNA;;HENGMIAO CHENG;;SUJIN CHO-SCHULTZ;;THEODORE OTTO JOHNSON JR;;JOHN CHARLES KATH;;ASAKO NAGATA;;SAJIV KRISHNAN NAIR;;SIMON PAUL PLANKEN,,https://lens.org/041-846-614-202-034,Granted Patent,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
628,CN,A,CN 105916853 A,052-483-264-388-826,2016-08-31,2016,CN 201480073530 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-substituted purine derivatives and their use in the treatment of proliferative disorders","The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/052-483-264-388-826,Patent Application,no,0,1,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
629,EP,A4,EP 3201964 A4,054-471-050-542-490,2018-01-24,2018,EP 14903089 A,2014-09-29,US 2014/0058086 W,2014-09-29,FLEXIBLE DISPLAY DEVICE WITH REDUCED BEND STRESS WIRES,,LG DISPLAY CO LTD,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,,https://lens.org/054-471-050-542-490,Search Report,no,3,0,12,12,0,G06F1/1652;;H05K1/028;;H05K1/0283;;H05K2201/09263;;H05K2201/09727;;H05K2201/10128;;G09F9/301;;H04M1/0268;;H10K59/131;;H10K77/111;;H10K2102/311;;G02F1/13452;;H05K1/028;;H05K1/0283;;H10K59/131;;G09F9/301;;G06F1/1652;;H05K1/0283;;H05K1/028;;H05K2201/10128;;H05K2201/09727;;H05K2201/09263;;H10K71/00;;H10K59/131;;H10K77/111;;H10K2102/311;;H04M1/0268,H01L51/56,,1,0,,,See also references of WO 2016053246A1,ACTIVE
630,SI,T1,SI 3071570 T1,095-834-704-755-717,2018-12-31,2018,SI 201430806 T,2014-11-10,US 201361907322 P;;IB 2014065935 W;;EP 14806447 A,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS",,PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/095-834-704-755-717,Granted Patent,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/00;;A61K31/00;;A61P35/00;;C07D519/00,,0,0,,,,ACTIVE
631,UY,A,UY 35845 A,128-518-989-152-16X,2015-06-30,2015,UY 35845 A,2014-11-19,US 201361907322 P,2013-11-21,?DERIVADOS DE PURINA?.,"La presente invención se refiere a compuestos de la Fórmula (I)o sales de aquellos aceptables desde el punto de vista farmacéutico, en donde Q, G, anillo A, anillo B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14,R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 y m son como se definen en la presente.Los derivados de purina novedosos son útiles para tratar el crecimiento celular anormal, tal como el cáncer, en mamíferos. Otras formas de realización se refieren a composiciones farmacéuticas que contienen los compuestos y a métodos para usar los compuestos y las composiciones en el tratamiento del crecimiento celular anormal en mamíferos.",PFIZER,CARL BEHENNA DOUGLAS;;SUJIN CHO-SCHULTZ;;HENGMIAO CHENG;;CHARLES KATH JOHN;;ASAKO NAGATA;;KRISHNAN NAIR SAJIV;;PAUL PLANKEN SIMON;;OTTO JOHNSON JR THEODORE,,https://lens.org/128-518-989-152-16X,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61P35/00;;A61K31/52;;C07D473/02;;C07D473/16;;C07D473/18;;C07D473/24,,0,0,,,,DISCONTINUED
632,EP,B1,EP 1882223 B1,166-782-056-941-133,2009-08-19,2009,EP 06751225 A,2006-04-24,US 2006/0015442 W;;US 67443005 P,2005-04-25,SYSTEM AND METHOD FOR RESTORING DATA ON DEMAND FOR INSTANT VOLUME RESTORATION,"A technique is disclosed for restoring data of sparse volumes, where one or more block pointers within the file system structure are marked as ABSENT, and fetching the appropriate data from an alternate location on demand. Client data access requests to the local storage system initiate a restoration of the data from a backing store as required. A demand generator can also be used to restore the data as a background process by walking through the sparse volume and restoring the data of absent blocks. A pump module is also disclosed to regulate the access of the demand generator. Once all the data has been restored, the volume contains all data locally, and is no longer a sparse volume.",NETWORK APPLIANCE INC,LANGO JASON ANSEL;;CHO YONG EUN;;EASTHAM PAUL CHRISTOPER;;ZHENG LING;;MANLEY STEPHEN L;;EDWARDS JOHN W JR;;ENGLISH ROBERT M;;ACKAOUY EMMANUEL,"NETAPP, INC., US (2015-04-03);;NETAPP, INC. (N.D.GES.D. STAATES DELAWARE), SU, US (2014-11-17)",https://lens.org/166-782-056-941-133,Granted Patent,yes,3,0,10,14,0,G06F11/1435;;G06F11/1469;;G06F11/1464,G06F11/14;;G06F11/20,,0,0,,,,ACTIVE
633,KR,A,KR 20170041815 A,182-914-749-337-870,2017-04-17,2017,KR 20177006262 A,2014-09-29,US 2014/0058100 W,2014-09-29,FLEXIBLE DISPLAY DEVICE WITH REDUCED BEND STRESS WIRES,"벤딩 동안 도전성 트레이스에서의 크랙의 발생 및 전파를 최소화하는 도전성 트레이스의 설계가 설명된다. 도전성 트레이스의 설계는 도전성 트레이스 내부에서 높은 스트레스 포인트에서 크랙이들의 형성에 대항하여, 보다 저항력이 강한 굴곡진 트레이스 패턴을 포함한다. 도전성 트레이스의 설계는 하나 이상의 크랙이 도전성 트레이스의 도전 영역에서 형성되기 시작하더라도 전기적인 연결이 확실히 되도록 하는 캡을 포함한다.",LG DISPLAY CO LTD,YANG HEESEOK;;LEE CHANWOO;;YOUN SANGCHEON;;CHO YOONDONG;;KWON SEYEOUL;;LEE SAEMLEENURI;;JO SOYOUNG;;KIM DONGYOON;;HA ANNA;;ZHANG ZHEN;;DRZAIC PAUL STEPHEN,,https://lens.org/182-914-749-337-870,Patent Application,no,0,0,9,9,0,Y02E10/549;;G06F3/0412;;G06F2203/04102;;G06F2203/04103;;G06F3/04164;;H04M1/0269;;H04M1/0268;;H10K59/1315;;H10K59/179;;H10K59/1795;;H10K59/131;;H10K77/111;;H10K2102/311;;G06F3/0412;;G06F3/04164;;G06F1/1652;;G09F9/301;;G06F2203/04102;;G06F2203/04103;;Y02E10/549;;H10K77/111;;H04M1/0269;;H10K59/1315;;H10K59/1795;;Y02E10/549;;G06F3/0412;;G06F2203/04103;;G06F2203/04102;;G06F3/04164;;H04M1/0269;;H10K59/131;;H10K59/179;;H10K77/111;;H10K59/1315;;H10K59/1795;;H10K71/00;;H10K2102/311;;G06F1/1652;;G09F9/301;;H04M1/0268,G06F3/041;;H01L27/32,,0,0,,,,DISCONTINUED
634,UY,A,UY 35848 A,119-958-225-713-513,2015-06-30,2015,UY 35848 A,2014-11-19,EP 13193665 A;;EP 14174731 A,2013-11-20,TIENOPIRIMIDINAS,"Compuestos de tienopirimidina sustituidos de la fórmula general (I) que se describen y definen en la presente,métodos de preparación de dichos compuestos, compuestos intermediarios de utilidad para preparar dichos compuestos,composiciones y combinaciones farmacéuticas que comprenden dichos compuestos y el uso de dichos compuestos en la elaboración de una composición farmacéutica para el tratamien to o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o de angiogénesis, como agente único o en combinación con otros ingredientes activos.",BAYER PHARMA AG,CARL BEHENNA DOUGLAS;;SUJIN CHO-SCHULTZ;;HENGMIAO CHENG;;CHARLES KATH JOHN;;ASAKO NAGATA;;KRISHNAN NAIR SAJIV;;PAUL PLANKEN SIMON;;OTTO JOHNSON JR THEODORE,,https://lens.org/119-958-225-713-513,Patent Application,no,0,0,22,25,0,C07D495/04;;C07D519/00;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K45/06;;C07D231/56;;C07D495/04;;A61K2300/00;;C07D495/04;;A61K31/519;;A61K31/5377;;A61K31/655;;A61K45/06;;C07D519/00,C07D231/56;;A61K31/416;;A61K31/42;;A61K31/519;;A61P35/00;;C07D239/00;;C07D265/30;;C07D495/04;;C07D519/00,,0,0,,,,DISCONTINUED
635,MX,A,MX 2016006397 A,143-657-286-207-48X,2016-08-01,2016,MX 2016006397 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS.","The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.",PFIZER,HENGMIAO CHENG;;THEODORE OTTO JOHNSON JR;;JOHN CHARLES KATH;;ASAKO NAGATA;;SAJIV KRISHNAN NAIR;;SIMON PAUL PLANKEN;;DOUGLAS CARL BEHENNA;;SUJIN CHO-SCHULTZ,,https://lens.org/143-657-286-207-48X,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61K31/522;;C07D473/16;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,PENDING
636,MA,A1,MA 39043 A1,013-181-560-308-116,2018-01-31,2018,MA 39043 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs","L'invention concerne des composés de formule (i) ou leur sels pharmaceutiquement acceptables, formule dans laquelle q, g, le cycle a, le cycle b, r1, r2, r3, r4, r5, r5a, r6, r7, r8, r9, r10, r11, r12, r13, r14, r15, r16, r17, r18, r19, r20, r21, r22, r23, r24 et m sont tels que définis dans la description. Ces nouveaux dérivés de purine sont utiles dans le traitement d'une croissance cellulaire anormale, telle que le cancer, chez les mammifères. D'autres modes de réalisation concernent des compositions pharmaceutiques contenant ces composés, ainsi que des procédés d'utilisation de ces composés et compositions dans le traitement d'une croissance cellulaire anormale chez les mammifères.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/013-181-560-308-116,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61K31/522;;A61P35/00;;C07D473/16;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
637,US,A1,US 2007/0027149 A1,016-088-421-209-866,2007-02-01,2007,US 51198106 A,2006-08-28,US 51198106 A;;US 65690703 A;;US 7614002 A;;US 31236101 P;;US 26868301 P,2001-02-15,3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors,The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.,UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN CONNIE L;;TANG PENG CHO;;WEI CHUNG CHEN;;VOJKOVSKY TOMAS;;JIN QINGWU;;HERRINTON PAUL M;;MAURAGIS MICHAEL A,,https://lens.org/016-088-421-209-866,Patent Application,yes,81,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/5377;;A61K31/404;;A61K31/405;;A61K31/4178;;A61K31/4192;;A61K31/437;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,514/232.8;;544/144;;548/465;;548/255;;514/359;;514/414,0,0,,,,EXPIRED
638,EP,B1,EP 3071570 B1,059-349-816-656-516,2018-06-20,2018,EP 14806447 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS",,PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/059-349-816-656-516,Granted Patent,yes,2,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
639,WO,A3,WO 2006/116293 A3,083-800-005-791-865,2007-02-22,2007,US 2006/0015442 W,2006-04-24,US 67443005 P,2005-04-25,SYSTEM AND METHOD FOR RESTORING DATA ON DEMAND FOR INSTANT VOLUME RESTORATION,"A technique is disclosed for restoring data of sparse volumes, where one or more block pointers within the file system structure are marked as ABSENT, and fetching the appropriate data from an alternate location on demand. Client data access requests to the local storage system initiate a restoration of the data from a backing store as required. A demand generator can also be used to restore the data as a background process by walking through the sparse volume and restoring the data of absent blocks. A pump module is also disclosed to regulate the access of the demand generator. Once all the data has been restored, the volume contains all data locally, and is no longer a sparse volume.",NETWORK APPLIANCE INC,LANGO JASON ANSEL;;CHO YONG EUN;;EASTHAM PAUL CHRISTOPER;;ZHENG LING;;MANLEY STEPHEN L;;EDWARDS JOHN W JR;;ENGLISH ROBERT M;;ACKAOUY EMMANUEL,,https://lens.org/083-800-005-791-865,Search Report,yes,3,0,10,14,0,G06F11/1435;;G06F11/1469;;G06F11/1464,G06F11/14;;G06F11/20,,0,0,,,,PENDING
640,LT,T,LT 3071570 T,106-647-972-381-997,2018-08-10,2018,LT 14806447 T,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS",,PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/106-647-972-381-997,Unknown,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,PENDING
641,EP,A1,EP 3201958 A1,011-912-033-954-718,2017-08-09,2017,EP 14903117 A,2014-09-29,US 2014/0058100 W,2014-09-29,FLEXIBLE DISPLAY DEVICE WITH REDUCED BEND STRESS WIRES,,LG DISPLAY CO LTD,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,,https://lens.org/011-912-033-954-718,Patent Application,yes,0,0,9,9,0,Y02E10/549;;G06F3/0412;;G06F2203/04102;;G06F2203/04103;;G06F3/04164;;H04M1/0269;;H04M1/0268;;H10K59/1315;;H10K59/179;;H10K59/1795;;H10K59/131;;H10K77/111;;H10K2102/311;;G06F3/0412;;G06F3/04164;;G06F1/1652;;G09F9/301;;G06F2203/04102;;G06F2203/04103;;Y02E10/549;;H10K77/111;;H04M1/0269;;H10K59/1315;;H10K59/1795;;Y02E10/549;;G06F3/0412;;G06F2203/04103;;G06F2203/04102;;G06F3/04164;;H04M1/0269;;H10K59/131;;H10K59/179;;H10K77/111;;H10K59/1315;;H10K59/1795;;H10K71/00;;H10K2102/311;;G06F1/1652;;G09F9/301;;H04M1/0268,H01L51/00,,0,0,,,,ACTIVE
642,IL,A,IL 186952 A,014-504-756-855-170,2012-04-30,2012,IL 18695207 A,2007-10-25,US 67443005 P;;US 2006/0015442 W,2005-04-25,SYSTEM AND METHOD FOR RESTORING DATA ON DEMAND FOR INSTANT VOLUME RESTORATION,"A technique is disclosed for restoring data of sparse volumes, where one or more block pointers within the file system structure are marked as ABSENT, and fetching the appropriate data from an alternate location on demand. Client data access requests to the local storage system initiate a restoration of the data from a backing store as required. A demand generator can also be used to restore the data as a background process by walking through the sparse volume and restoring the data of absent blocks. A pump module is also disclosed to regulate the access of the demand generator. Once all the data has been restored, the volume contains all data locally, and is no longer a sparse volume.",NETWORK APPLIANCE INC;;ENGLISH ROBERT M;;EASTHAM PAUL CHRISTOPER;;LANGO JASON ANSEL;;CHO YONG EUN;;ZHENG LING;;MANLEY STEPHEN L;;JR JOHN W EDWARDS;;ACKAOUY EMMANUEL,ENGLISH ROBERT M;;EASTHAM PAUL CHRISTOPER;;LANGO JASON ANSEL;;CHO YONG EUN;;ZHENG LING;;MANLEY STEPHEN L;;JR JOHN W EDWARDS;;ACKAOUY EMMANUEL,,https://lens.org/014-504-756-855-170,Patent Application,no,0,0,10,14,0,G06F11/1435;;G06F11/1469;;G06F11/1464,,,0,0,,,,INACTIVE
643,WO,A2,WO 2006/116293 A2,030-963-153-906-250,2006-11-02,2006,US 2006/0015442 W,2006-04-24,US 67443005 P,2005-04-25,SYSTEM AND METHOD FOR RESTORING DATA ON DEMAND FOR INSTANT VOLUME RESTORATION,"A technique is disclosed for restoring data of sparse volumes, where one or more block pointers within the file system structure are marked as ABSENT, and fetching the appropriate data from an alternate location on demand. Client data access requests to the local storage system initiate a restoration of the data from a backing store as required. A demand generator can also be used to restore the data as a background process by walking through the sparse volume and restoring the data of absent blocks. A pump module is also disclosed to regulate the access of the demand generator. Once all the data has been restored, the volume contains all data locally, and is no longer a sparse volume.",NETWORK APPLIANCE INC,LANGO JASON ANSEL;;CHO YONG EUN;;EASTHAM PAUL CHRISTOPER;;ZHENG LING;;MANLEY STEPHEN L;;EDWARDS JOHN W JR;;ENGLISH ROBERT M;;ACKAOUY EMMANUEL,,https://lens.org/030-963-153-906-250,Patent Application,yes,0,5,10,14,0,G06F11/1435;;G06F11/1469;;G06F11/1464,G06F11/14;;G06F11/20,,0,0,,,,PENDING
644,CN,A,CN 106796999 A,040-257-062-431-565,2017-05-31,2017,CN 201480082121 A,2014-09-29,US 2014/0058086 W,2014-09-29,Flexible display device with reduced bend stress wires,A conductive trace design is described that minimizes the possibility of crack initiation and propagation in conductive traces during bending. The conductive trace design has a winding trace pattern that is more resistant to the formation of cracks at high stress points in the conductive traces. The conductive trace design includes a cap that helps ensure electrical connection of the conductive trace even though one or more cracks may begin to form in the conductive portion of the conductive trace.,LG DISPLAY CO LTD,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,,https://lens.org/040-257-062-431-565,Patent Application,no,7,12,12,12,0,G06F1/1652;;H05K1/028;;H05K1/0283;;H05K2201/09263;;H05K2201/09727;;H05K2201/10128;;G09F9/301;;H04M1/0268;;H10K59/131;;H10K77/111;;H10K2102/311;;G02F1/13452;;H05K1/028;;H05K1/0283;;H10K59/131;;G09F9/301;;G06F1/1652;;H05K1/0283;;H05K1/028;;H05K2201/10128;;H05K2201/09727;;H05K2201/09263;;H10K71/00;;H10K59/131;;H10K77/111;;H10K2102/311;;H04M1/0268,H01L51/56,,0,0,,,,ACTIVE
645,MD,A2,MD 20160053 A2,096-459-081-364-043,2016-10-31,2016,MD 20160053 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-Substituted purine derivatives and their use in the treatment of proliferative disorders","The present invention relates to compounds of formula (I)or pharmaceutically acceptable salts thereof, wherein Q, ring A, ring B, R1, R2, R3, R4, R5, R6, R7, R8, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds (I) and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/096-459-081-364-043,Unknown,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,DISCONTINUED
646,PL,T3,PL 3071570 T3,119-186-771-951-247,2018-10-31,2018,PL 14806447 T,2014-11-10,US 201361907322 P;;EP 14806447 A;;IB 2014065935 W,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS",,PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/119-186-771-951-247,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,PENDING
647,US,B2,US 11547360 B2,138-604-969-545-939,2023-01-10,2023,US 201916723828 A,2019-12-20,US 201916723828 A;;US 201862783728 P,2018-12-21,Acute heart failure monitoring and treatment,"Systems and methods include differential diagnosis for acute heart failure to provide treatment to a patient including determining whether the patient has cardiac volume overload, determining whether the patient has decreased abdominal venous system volume, and providing the appropriate treatment in response to the determinations. A multi-sensor system may be used to determine cardiac volume and abdominal venous system volume. Fluid redistribution treatment may be provided when cardiac volume overload is accompanied by a decrease in abdominal venous system volume. Fluid accumulation treatment may be provided when cardiac volume overload is not accompanied by a decrease in abdominal venous system volume.",MEDTRONIC INC,CHO YONG K;;BENNETT TOM D;;HETTRICK DOUGLAS A;;SPERLING CHARLES P;;SOBOTKA PAUL A;;SHARMA VINOD;;WARMAN EDUARDO N;;ZIELINSKI TODD M,MEDTRONIC INC (2019-12-12),https://lens.org/138-604-969-545-939,Granted Patent,yes,13,0,5,5,0,A61B5/686;;A61B5/0537;;A61B5/02028;;A61B5/029;;A61B5/6869;;A61B5/6876;;A61B5/6823;;A61B5/14551;;A61B5/0538;;A61N1/36521;;A61N1/36585;;A61B5/4836;;A61B5/4839;;A61N1/3956;;A61B5/029;;A61B5/1073;;A61B5/686;;A61B5/6869;;A61B5/6876,A61B5/00;;A61B5/029;;A61B5/107,,7,5,001-010-573-736-281;;096-387-737-740-479;;079-731-512-577-037;;011-362-222-199-009;;081-918-670-623-301,10.3904/kjim.2017.355;;29627971;;pmc5943665;;18279771;;10.1016/j.ejheart.2008.01.007;;10.1161/circheartfailure.111.961789;;21934091;;10.1113/jphysiol.1974.sp010482;;pmc1350884;;4825450;;6361810;;10.1152/physrev.1983.63.4.1281,"International Preliminary Report on Patentability from PCT Application No. PCT/US2019/067884 dated Jul. 1, 2021, 9 pages.;;Martens et al., “How to tackle congesting in acute heart failure”, Korean Journal of Internal Medicine, vol. 33, No. 3, Apr. 2018, pp. 462-473.;;International Search Report and Written Opinion from PCT Application No. PCT/US2019/067884 dated April 9, 2020, 15 pages.;;Cotter et al., “Fluid overload in acute heart failure—re-distribution and other mechanisms beyond fluid accumulation,” Feb. 2008, Eur J Heart Fail., 10:165-169.;;Fallick et al., “Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation,” 2011, Circulation Heart Failure, 4:669-675.;;Greenway et al., “Capacitance effects and blood reservoir function in the splanchnic vascular bed during non-hypotensive haemorrhage and blood volume expansion in anaesthetized cats,” Mar. 1974, Journal of Physiology, 237:279-294.;;Rothe, “Reflex control of veins and vascular capacitance,” Oct. 1983, Physiological Reviews, 63:1281-1342.",ACTIVE
648,TN,A1,TN 2016000188 A1,151-579-283-763-519,2017-10-06,2017,TN 2016000188 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"DERIVES DE PURINES 2,6-SUBSTITUES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES PROLIFERATIFS.","La présente invention concerne des composés de formule<br /> ( I) ou  leurs sel pharmaceutiquement acceptables , formule dans laquelle Q,G,le noyau A , le noyau B, R<sup>1 ,</sup> R<sup>2,</sup> R<sup>3,</sup> R<sup>4,</sup> R<sup>5,</sup> R<sup>6,</sup> R<sup>7,</sup> R<sup>8,</sup> R<sup>9,</sup> R<sup>10,</sup> R<sup>11,</sup> R<sup>12,</sup> R<sup>13,</sup> R<sup>14,</sup> R<sup>15,</sup>  R<sup>16,</sup> R<sup>17,</sup> R<sup>18,</sup> R<sup>19,</sup> R<sup>20,</sup> R<sup>21,</sup> R<sup>22,</sup> R<sup>23,</sup> R<sup>24  </sup>et m répondent aux définitions figurant dans le présent mémoire. Les dérivés de purine nouveaux sont utiles dans le traitement d'une croissance cellulaire anormale , telle que le cancer , chez des mammifères . Des formes de réalisations  supplémentaires concernant  des compositions pharmaceutiques contenant les composés  et des procédés d'utilisation des composés et compositions dans le traitement d'une croissance cellulaire anormale chez les mammifères",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/151-579-283-763-519,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61K31/522;;A61P35/00;;C07D473/16;;C07D473/18,,0,0,,,,PENDING
649,PE,A1,PE 20160885 A1,170-332-813-277-804,2016-09-11,2016,PE 2016000650 A,2014-11-10,US 201361907322 P,2013-11-21,"DERIVADOS DE PURINA 2,6 SUSTITUIDOS EN EL TRATAMIENTO DE TRANSTORNOS PROLIFERATIVOS","Se refiere a derivados de purina de formula (I) o sales farmaceuticamente aceptables de los mismos, en los cuales R1 es H, alquilo C1C6, alquenilo C2C6, cicloalquilo C3C6, heteroarilo de 4 a 6 miembros, entre otros; el anillo A es arilo C6C10 o heteroarilo de 5 a 12 miembros; R2 y R5 independientemente estan ausentes o son H, halogeno, CN, CHF2, CF3, alquilo C1C6, cicloalquilo C3C6, entre otros; R3 esta ausente o es H, halogeno, alquilo C1C6, alcoxi C1C6, cicloalquilo C3C6, entre otros; R4 esta ausente o es H, halogeno, alquilo C1C6 o cicloalquilo C3C6; Q esta ausente o es O, S o NH, entre otros; el anillo B esta ausente o es cicloalquilo C3C10, arilo C6C10 o heteroarilo de 5 a 12 miembros, entre otros; R6 y R8 independientemente estan ausentes o son H, halogeno, CN, OH, alquilo C1C3, alcoxi C1C3, entre otros; R7 es GC(O)CH=CH2, GSO2CH=CH2, GC(O)CH2Cl, GC(O)CH2CN, entre otros; G esta ausente cuando el punto de union a B es un atomo de N, o es NR18 cuando el punto de union a B es un atomo de C, donde R18 es H o alquilo C1C3; y m es 0, 1 o 2, con la condicion que m sea 2 cuando el anillo B este ausente. Tambien se refiere a composiciones farmaceuticas que comprenden dichos derivados de purina. Los derivados de purina de formula (I) son utiles para tratar el crecimiento celular anormal en mamiferos, como el cancer.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;PLANKEN SIMON PAUL;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;JOHNSON JR THEODORE OTTO,,https://lens.org/170-332-813-277-804,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61K31/522;;A61P35/00;;C07D473/16;;C07D473/18;;C07D519/00,,0,0,,,,PENDING
650,EP,A1,EP 3201964 A1,196-806-521-834-205,2017-08-09,2017,EP 14903089 A,2014-09-29,US 2014/0058086 W,2014-09-29,FLEXIBLE DISPLAY DEVICE WITH REDUCED BEND STRESS WIRES,,LG DISPLAY CO LTD,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,,https://lens.org/196-806-521-834-205,Patent Application,yes,0,0,12,12,0,G06F1/1652;;H05K1/028;;H05K1/0283;;H05K2201/09263;;H05K2201/09727;;H05K2201/10128;;G09F9/301;;H04M1/0268;;H10K59/131;;H10K77/111;;H10K2102/311;;G02F1/13452;;H05K1/028;;H05K1/0283;;H10K59/131;;G09F9/301;;G06F1/1652;;H05K1/0283;;H05K1/028;;H05K2201/10128;;H05K2201/09727;;H05K2201/09263;;H10K71/00;;H10K59/131;;H10K77/111;;H10K2102/311;;H04M1/0268,H01L51/56,,0,0,,,,ACTIVE
651,EP,A1,EP 3897364 A1,026-352-563-569-288,2021-10-27,2021,EP 19845642 A,2019-12-20,US 201862783728 P;;US 2019/0067884 W,2018-12-21,ACUTE HEART FAILURE MONITORING AND TREATMENT,,MEDTRONIC INC,CHO YONG K;;BENNETT TOM D;;HETTRICK DOUGLAS A;;SPERLING CHARLES P;;SOBOTKA PAUL A;;SHARMA VINOD;;WARMAN EDUARDO N;;ZIELINSKI TODD M,,https://lens.org/026-352-563-569-288,Patent Application,yes,0,0,5,5,0,A61B5/686;;A61B5/0537;;A61B5/02028;;A61B5/029;;A61B5/6869;;A61B5/6876;;A61B5/6823;;A61B5/14551;;A61B5/0538;;A61N1/36521;;A61N1/36585;;A61B5/4836;;A61B5/4839;;A61N1/3956;;A61B5/029;;A61B5/1073;;A61B5/686;;A61B5/6869;;A61B5/6876,A61B5/02;;A61B5/029;;A61B5/053;;A61B5/1455;;A61N1/365,,0,0,,,,PENDING
652,EP,A2,EP 1882223 A2,027-176-856-939-058,2008-01-30,2008,EP 06751225 A,2006-04-24,US 2006/0015442 W;;US 67443005 P,2005-04-25,SYSTEM AND METHOD FOR RESTORING DATA ON DEMAND FOR INSTANT VOLUME RESTORATION,"A technique is disclosed for restoring data of sparse volumes, where one or more block pointers within the file system structure are marked as ABSENT, and fetching the appropriate data from an alternate location on demand. Client data access requests to the local storage system initiate a restoration of the data from a backing store as required. A demand generator can also be used to restore the data as a background process by walking through the sparse volume and restoring the data of absent blocks. A pump module is also disclosed to regulate the access of the demand generator. Once all the data has been restored, the volume contains all data locally, and is no longer a sparse volume.",NETWORK APPLIANCE INC,LANGO JASON ANSEL;;CHO YONG EUN;;EASTHAM PAUL CHRISTOPER;;ZHENG LING;;MANLEY STEPHEN L;;EDWARDS JOHN W JR;;ENGLISH ROBERT M;;ACKAOUY EMMANUEL,"NETAPP, INC., US (2015-04-03);;NETAPP, INC. (N.D.GES.D. STAATES DELAWARE), SU, US (2014-11-17)",https://lens.org/027-176-856-939-058,Patent Application,yes,0,3,10,14,0,G06F11/1435;;G06F11/1469;;G06F11/1464,G06F11/14;;G06F11/20,,0,0,,,,ACTIVE
653,US,A1,US 2020/0196948 A1,115-138-076-522-14X,2020-06-25,2020,US 201916723828 A,2019-12-20,US 201916723828 A;;US 201862783728 P,2018-12-21,ACUTE HEART FAILURE MONITORING AND TREATMENT,"Systems and methods include differential diagnosis for acute heart failure to provide treatment to a patient including determining whether the patient has cardiac volume overload, determining whether the patient has decreased abdominal venous system volume, and providing the appropriate treatment in response to the determinations. A multi-sensor system may be used to determine cardiac volume and abdominal venous system volume. Fluid redistribution treatment may be provided when cardiac volume overload is accompanied by a decrease in abdominal venous system volume. Fluid accumulation treatment may be provided when cardiac volume overload is not accompanied by a decrease in abdominal venous system volume.",MEDTRONIC INC,CHO YONG K;;BENNETT TOM D;;HETTRICK DOUGLAS A;;SPERLING CHARLES P;;SOBOTKA PAUL A;;SHARMA VINOD;;WARMAN EDUARDO N;;ZIELINSKI TODD M,MEDTRONIC INC (2019-12-12),https://lens.org/115-138-076-522-14X,Patent Application,yes,0,6,5,5,0,A61B5/686;;A61B5/0537;;A61B5/02028;;A61B5/029;;A61B5/6869;;A61B5/6876;;A61B5/6823;;A61B5/14551;;A61B5/0538;;A61N1/36521;;A61N1/36585;;A61B5/4836;;A61B5/4839;;A61N1/3956;;A61B5/029;;A61B5/1073;;A61B5/686;;A61B5/6869;;A61B5/6876,A61B5/00;;A61B5/029;;A61B5/107,,0,0,,,,ACTIVE
654,DO,A,DO P2016000115 A,149-038-530-331-913,2016-07-15,2016,DO 2016000115 A,2016-05-19,US 201361907322 P,2013-11-21,DERIVADOS DE PURINA,"LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE LA FÓRMULA (I) O SALES DE AQUELLOS ACEPTABLES DESDE EL PUNTO DE VISTA FARMACÉUTICO, EN DONDE Q, G, ANILLO A, ANILLO B, R1, R2, R3, R4, R5, R5A, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 Y M SON COMO SE DEFINEN EN LA PRESENTE. LOS DERIVADOS DE PURINA NOVEDOSOS SON ÚTILES PARA TRATAR EL CRECIMIENTO CELULAR ANORMAL, TAL COMO EL CÁNCER, EN MAMÍFEROS. OTRAS FORMAS DE REALIZACIÓN SE REFIEREN A COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS COMPUESTOS Y A MÉTODOS PARA USAR LOS COMPUESTOS Y LAS COMPOSICIONES EN EL TRATAMIENTO DEL CRECIMIENTO CELULAR ANORMAL EN MAMÍFEROS.",PFIZER,JR THEODORE OTTO JOHNSON;;KATH JOHN CHARLES;;CHENG HENGMIAO;;NAIR SAJIV KRISHNAN;;BEHENNA DOUGLAS CARL;;CHO-SCHULTZ SUJIN;;NAGATA ASAKO;;PLANKEN SIMON PAUL,,https://lens.org/149-038-530-331-913,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61P35/00;;A61K31/522;;C07D473/14;;C07D473/18;;C07D519/00,,0,0,,,,PENDING
655,MA,B1,MA 39043 B1,159-826-109-852-15X,2018-09-28,2018,MA 39043 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs","L'invention concerne des composés de formule (i) ou leur sels pharmaceutiquement acceptables, formule dans laquelle q, g, le cycle a, le cycle b, r1, r2, r3, r4, r5, r5a, r6, r7, r8, r9, r10, r11, r12, r13, r14, r15, r16, r17, r18, r19, r20, r21, r22, r23, r24 et m sont tels que définis dans la description. Ces nouveaux dérivés de purine sont utiles dans le traitement d'une croissance cellulaire anormale, telle que le cancer, chez les mammifères. D'autres modes de réalisation concernent des compositions pharmaceutiques contenant ces composés, ainsi que des procédés d'utilisation de ces composés et compositions dans le traitement d'une croissance cellulaire anormale chez les mammifères.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/159-826-109-852-15X,Granted Patent,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61K31/522;;A61P35/00;;C07D473/16;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
656,WO,A1,WO 2016/053252 A1,182-917-512-088-515,2016-04-07,2016,US 2014/0058100 W,2014-09-29,US 2014/0058100 W,2014-09-29,FLEXIBLE DISPLAY DEVICE WITH REDUCED BEND STRESS WIRES,A conductive trace design is described that minimizes the possibility of crack initiation and propagation in conductive traces during bending. The conductive trace design has a winding trace pattern that is more resistant to the formation of cracks at high stress points in the conductive traces. The conductive trace design includes a cap that helps ensure electrical connection of the conductive trace even though one or more cracks may begin to form in the conductive portion of the conductive trace.,LG DISPLAY CO LTD;;ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,,https://lens.org/182-917-512-088-515,Patent Application,yes,5,3,9,9,0,Y02E10/549;;G06F3/0412;;G06F2203/04102;;G06F2203/04103;;G06F3/04164;;H04M1/0269;;H04M1/0268;;H10K59/1315;;H10K59/179;;H10K59/1795;;H10K59/131;;H10K77/111;;H10K2102/311;;G06F3/0412;;G06F3/04164;;G06F1/1652;;G09F9/301;;G06F2203/04102;;G06F2203/04103;;Y02E10/549;;H10K77/111;;H04M1/0269;;H10K59/1315;;H10K59/1795;;Y02E10/549;;G06F3/0412;;G06F2203/04103;;G06F2203/04102;;G06F3/04164;;H04M1/0269;;H10K59/131;;H10K59/179;;H10K77/111;;H10K59/1315;;H10K59/1795;;H10K71/00;;H10K2102/311;;G06F1/1652;;G09F9/301;;H04M1/0268,H01L51/00,,0,0,,,,PENDING
657,US,A1,US 2012/0223227 A1,070-309-838-798-197,2012-09-06,2012,US 201113041017 A,2011-03-04,US 201113041017 A,2011-03-04,APPARATUS AND METHODS FOR REAL-TIME THREE-DIMENSIONAL SEM IMAGING AND VIEWING OF SEMICONDUCTOR WAFERS,"One embodiment relates to a method of real-time three-dimensional electron beam imaging of a substrate surface. A primary electron beam is scanned over the substrate surface causing electrons to be emitted therefrom. The emitted electrons are simultaneously detection using a plurality of at least two off-axis sensors so as to generate a plurality of image data frames, each image data frame being due to electrons emitted from the substrate surface at a different view angle. The plurality of image data frames are automatically processed to generate a three-dimensional representation of the substrate surface. Multiple views of the three-dimensional representation are then displayed. Other embodiments, aspects and features are also disclosed.",CHEN CHIEN-HUEI;;MACDONALD PAUL D;;KUPPA RAJASEKHAR;;TADA TAKUJI;;ABBOTT GORDON;;TEH CHO;;YANG HEDONG;;LANG STEPHEN;;NEIL MARK A;;SAIDIN ZAIN,CHEN CHIEN-HUEI;;MACDONALD PAUL D;;KUPPA RAJASEKHAR;;TADA TAKUJI;;ABBOTT GORDON;;TEH CHO;;YANG HEDONG;;LANG STEPHEN;;NEIL MARK A;;SAIDIN ZAIN,KLA-TENCOR CORPORATION (2011-02-10),https://lens.org/070-309-838-798-197,Patent Application,yes,25,10,8,8,0,G01B21/20;;G01N23/2251;;G01N23/2251;;G01N23/225,G01N23/04,250/307;;250/310,0,0,,,,DISCONTINUED
658,AU,A1,AU 2014/351433 A1,103-747-310-360-782,2016-06-02,2016,AU 2014/351433 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-substituted purine derivatives and their use in the treatment of proliferative disorders","The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/103-747-310-360-782,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
659,WO,A1,WO 2016/053246 A1,116-602-769-636-10X,2016-04-07,2016,US 2014/0058086 W,2014-09-29,US 2014/0058086 W,2014-09-29,FLEXIBLE DISPLAY DEVICE WITH REDUCED BEND STRESS WIRES,A conductive trace design is described that minimizes the possibility of crack initiation and propagation in conductive traces during bending. The conductive trace design has a winding trace pattern that is more resistant to the formation of cracks at high stress points in the conductive traces. The conductive trace design includes a cap that helps ensure electrical connection of the conductive trace even though one or more cracks may begin to form in the conductive portion of the conductive trace.,LG DISPLAY CO LTD;;ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,,https://lens.org/116-602-769-636-10X,Patent Application,yes,8,10,12,12,0,G06F1/1652;;H05K1/028;;H05K1/0283;;H05K2201/09263;;H05K2201/09727;;H05K2201/10128;;G09F9/301;;H04M1/0268;;H10K59/131;;H10K77/111;;H10K2102/311;;G02F1/13452;;H05K1/028;;H05K1/0283;;H10K59/131;;G09F9/301;;G06F1/1652;;H05K1/0283;;H05K1/028;;H05K2201/10128;;H05K2201/09727;;H05K2201/09263;;H10K71/00;;H10K59/131;;H10K77/111;;H10K2102/311;;H04M1/0268,H01L51/56,,1,0,,,See also references of EP 3201964A4,PENDING
660,US,B2,US 7179910 B2,157-827-917-202-210,2007-02-20,2007,US 65690703 A,2003-09-08,US 65690703 A;;US 7614002 A;;US 26868301 P;;US 31236101 P,2001-02-15,3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors,The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.,AGOURON PHARMA,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;VOJKOVSKY TOMAS;;JIN QINGWU ALAN;;HERRINTON PAUL M;;MAURAGIS MICHAEL A,,https://lens.org/157-827-917-202-210,Granted Patent,yes,99,10,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,C07D279/12;;A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D209/34;;C07D249/02;;C07D257/04;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,544/58.2;;544/144;;546/117;;548/468;;548/255;;548/253;;548/312.1,99,80,054-823-629-511-93X;;022-399-048-324-641;;176-879-479-576-661;;078-854-286-923-547;;094-652-412-929-005;;067-272-607-027-112;;025-114-183-199-748;;018-048-709-473-304;;004-963-545-993-258;;000-955-818-332-098;;000-955-818-332-098;;009-185-209-152-939;;009-068-402-575-690;;049-540-021-873-405;;035-321-998-935-819;;002-840-884-592-149;;129-714-176-445-277;;042-517-545-674-669;;062-253-139-686-620;;030-880-199-478-403;;171-875-161-435-498;;068-347-002-933-411;;016-739-947-546-505;;130-779-644-212-195;;032-953-229-558-330;;078-578-887-209-471;;049-954-263-824-454;;060-092-756-707-151;;102-148-719-482-24X;;099-279-971-758-096;;028-531-800-105-513;;016-333-429-871-463;;156-756-886-926-846;;037-134-997-566-90X;;037-465-890-679-37X;;104-815-369-514-254;;077-040-152-841-627;;122-261-121-873-625;;025-669-944-920-763;;043-489-715-583-833;;029-380-708-151-243;;120-787-793-242-483;;005-766-513-612-952;;081-381-735-516-869;;008-322-661-908-298;;025-209-481-691-070;;096-452-077-440-080;;013-790-909-287-914;;103-663-433-342-64X;;077-363-946-748-009;;128-267-202-156-519;;065-028-064-758-359;;009-954-017-681-952;;052-588-751-234-497;;010-830-508-694-564;;085-471-281-279-890;;000-260-545-266-425;;075-875-793-946-595;;020-017-567-104-545;;135-106-372-968-479;;029-871-534-065-762;;097-695-479-613-215;;045-890-249-073-273;;120-399-346-691-880;;049-676-058-590-911;;062-693-709-183-494;;079-734-101-870-347;;053-570-456-410-225;;102-943-963-373-742;;002-691-796-474-031;;094-207-501-631-352;;055-925-799-631-516;;027-603-408-160-490;;013-804-957-513-749;;106-753-778-592-300;;167-734-194-581-033;;011-265-567-519-296;;030-094-646-061-709;;009-809-672-105-539;;092-445-513-957-983,10.1039/jr9540001697;;1331337;;10.1016/0022-510x(92)90060-x;;9042225;;10.1016/0223-5234(92)90106-b;;10.1016/s0223-5234(97)82778-x;;9706372;;10.1172/jci114315;;2553774;;pmc304004;;7935391;;10.1128/mcb.14.10.6715-6726.1994;;10.1128/mcb.14.10.6715;;pmc359202;;10.1016/0040-4020(67)85040-3;;5793178;;5793179;;10.1021/jm00304a052;;10.1021/jm00304a050;;5793177;;10.1021/jm00304a051;;5793178;;5793179;;10.1021/jm00304a052;;10.1021/jm00304a050;;5793177;;10.1021/jm00304a051;;10.1039/j39660001028;;10.1080/00397919308011169;;10.1016/0092-8674(94)90023-x;;8001140;;7812953;;10.1080/00397918608057203;;10.1039/p29730001660;;10.1096/fasebj.6.15.1281458;;1281458;;8336932;;10.1128/mcb.5.6.1400-1407.1985;;pmc366870;;2993863;;10.1128/mcb.5.6.1400;;10.1002/jlac.19375320112;;8343210;;8099900;;10.1002/ijc.2910540409;;10.1002/jhet.5570220609;;9025911;;10.1006/abio.1996.9854;;10.1016/0092-8674(92)90068-n;;1547509;;10.1039/p29730000469;;9434891;;8199353;;10.1016/0955-2235(94)90016-7;;10.1039/p29840000615;;pmc358831;;8007963;;10.1128/mcb.14.7.4588-4595.1994;;10.1128/mcb.14.7.4588;;10.1016/s0021-9673(00)86069-0;;10.1016/0006-2952(94)90152-x;;7945409;;1973827;;10.1021/jm00267a020;;4583274;;1312256;;10.1126/science.1312256;;3192948;;10.1016/0022-1759(88)90310-9;;10.1016/0040-4020(96)00695-3;;1360236;;10.1007/978-1-4615-3500-3_13;;10.1021/jo01031a502;;10.1016/0092-8674(92)90444-h;;1374684;;1689212;;2735925;;10.1016/0006-291x(89)92678-8;;8468926;;10.1038/ki.1993.55;;8441232;;10.1016/s0021-9258(19)49853-0;;1375931;;10.1056/nejm197111182852108;;4938153;;10.1093/jnci/82.1.4;;1688381;;5039962;;10.1111/1523-1747.ep12625746;;10.1021/jm00110a022;;1676428;;1802112;;3386259;;10.1016/0022-4731(88)90113-6;;8387483;;10.1016/s0021-9258(18)98327-4;;10.1021/op970037c;;10.1039/p19880001305;;10.1016/0040-4039(95)01202-s;;10.1139/v68-357;;3499230;;10.1016/0092-8674(87)90147-4;;10.1016/s0021-9258(18)35712-0;;1464614;;10.1016/0223-5234(92)90112-e;;10.1128/mcb.12.3.981;;10.1128/mcb.12.3.981-990.1992;;pmc369530;;1372091;;10.1021/bi00200a028;;7520755;;10.1091/mbc.4.1.49;;8443409;;pmc300899;;pmc556586;;1314164;;10.1002/j.1460-2075.1992.tb05182.x;;8376494;;10.1016/0378-4347(93)80472-g;;10.1002/jhet.5570250503;;7688466;;pmc47050;;10.1073/pnas.90.15.6939;;8248162;;10.1073/pnas.90.22.10705;;pmc47846;;10.1016/s0040-4020(01)92520-7;;7683111;;10.1038/362841a0;;1370939;;10.1016/0014-4827(92)90461-g;;10.1016/0960-9822(93)90073-w;;15335866;;925872;;10.1248/yakushi1947.97.9_1033;;10.1126/science.1708916;;1708916;;1172191;;10.1038/256495a0;;7689722;;pmc443180;;1401070;;10.1172/jci116001;;10.1016/0022-1759(83)90438-6;;6300286;;6199426;;pmc49721;;1323835;;10.1073/pnas.89.16.7417;;1314366,"Abramovitch and Hey, ""Internuclear cyclisation. Part VIII. Naphth[3:2:1-cd]oxindoles,"" J. Chem. Soc. 1697-1703 (1954), Strand, London.;;Abramovitch et al., ""A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement,"" Chemistry and Industry 44:1871 (1967) 8Laporte Industries Limited, Lancashire.;;Akbasak and Sunar-Akbasak, ""Oncogenes: cause or consequence in the development of glial tumors,"" J. Neurol. Sci. 111:119-133 (1992)8 Elsevier Science Publishers.;;Andreani et al., ""Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolymethylene)1,3-Dihydroindol-2-Ones,"" Anticancer Research 16:3585-3588 (1996) 8 Elsevier, Paris.;;Andreani et al., ""Synthesis and cardiotonic activity of 2-indolinones,"" Eur. J. Med. Chem. 25:187-190 (1990).;;Andreani et al., ""Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups,"" Eur. J. Med. Chem. 28:653-657 (1993) 8 Elsevier, Paris.;;Andreani et al., ""Synthesis and cardiotonic activity of 2-indolinones,"" Chemical Abstracts. vol. 113, abstract No. 78106 (1990).;;Andreani et al., ""Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones,"" Eur. J. Med. Chem. 27:167-170 (1992) 8 Elsevier, Paris.;;Andreani et al., ""Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones,"" Eur. J. Med. Chem. 32:919-924 (1997)8 Elsevier, Paris.;;Andreani et al., ""Synthesis of lactams with potential cardiotonic activity,"" Eur. J. Med. Chem. 28:825-829 (1993).;;Andreani et al., ""In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones,"" Arzneimittel-Forschung Drug Research 48:727-729 (1998) 8.;;Arteaga et al., ""Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice,"" J. Clin. Invest. 84:1418-1423 (1989) copyright The American Society for Clinical investigation, Inc.;;Arvidsson et al., ""Tyr-716 in the Platelet-Derived Growth Factor beta-Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation,"" Molecular and Cellular Biology 14:6715-6726 (1994) 8 The American Society for Microbiology.;;Autrey and Tahk, ""The Synthesis and Sterochemistry of Some Isatylideneacetic Acid Derivatives,"" Tetrahedron 23:901-917 (1967) 8Pergamon Press.;;Bahner and Brotherton, ""6-Dimethylaminochrysene and Other Analogs of 4-(4-Dimethylamino)stilbene,"" J. Med. Chem. 12:722-723 (1969).;;Bahner et al., ""Benzylideneindenes with Oxygen Attached to the Indene Ring,"" J. Med. Chem. 12:721-722 (1969).;;Bamfield et al., ""Diels-Alder Reactions of Oxindolylideneacetone,"" J. Chem. Soc. (C) 1028-1030 (1966) 8.;;Barbier, et al., ""Synthesis of Isobrassilexin, A Biologically Active Isomer of Brassilexin, a Cruciferae Phytoalexin,"" Synthetic Communications 23(22):3109-3117 (1993) 8 Marcel Dekker, Inc.;;Baserga, ""Oncogenes and the Strategy of Growth Factors,"" Cell 79:927-930 (1994) 8 Cell Press.;;Baserga, ""The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?"" Cancer Research 55:249-252 (1995).;;Beilstein Reg. No. 233511 (1997).;;Beilstein Reg. No. 235647 (1997).;;Beilstein Reg. No. 252929 (1998).;;Benzies, et al., ""2-Formyl-3-Methoxymethylindole, 3-Ethoxymethyl-2-Formylindoline and 2-Formyl-3-Methylindole,"" Synthetic Communications: 16(14), 1799-1807 (1986) 8 Mercel Dekker, Inc.;;Blake and Jaques, ""Anisotropic Effects in alpha-Substituted Methoxystilbenes,"" J. Chem. Soc. Perkin II: 1660-1663 (1973) 8 Pergamon, Oxford.;;Bolen et al., ""The Src family of tyrosine protein kinases in hemopoietic signal transduction,"" FASEB J. 6:3403-3409 (1992).;;Bolen, ""Nonreceptor tyrosine protein kinases,"" Oncogene 8:2025-2031 (1993) copyright MacMillan Press Ltd.;;Bonner et al., ""Structure and Biological Activity of Human Homologs of the raf/mil Oncogene,"" Molecular and Cellular Biology 5:1400-1407 (1985) 8 The American Society for Microbiology.;;Borsche et al., ""Über vielkernige kondensierte Systeme mit heterocyclischen Ringen. XIII.,"" Liebigs Ann. Chem. 550:160-174 (1941).;;Buzzetti et al., ""Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases,"" II Farmaco 48:615-636 (1993).;;Cance et al., ""Novel Protein Kinases Expressed in Human Breast Cancer,"" Int. J. Cancer 54:571-577 (1993) 8 Wiley-Liss, Inc.;;Canoira and Rodriguez, ""Synthesis of Oxindole Derivatives from N-Alkenyl-o-Chloroanilides with Zero-Valent Nickel Complex,"" J. Heterocyclic Chem. 22:1511-1518 (1985).;;Carpenedo et al., ""Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs,"" Analytical Biochemistry 244:74-79 (1997) 8 Academic Press, Inc.;;Chao, ""Growth Factor Signaling: Where Is the Specificity?"" Cell 68:995-997 (1992) copyright Cell Press.;;Chatten et al., ""Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted trans-3-Benzylideneindol-2(3H)-ones,"" J. Chem. Soc. Perkin II: 469-473 (1973).;;Chen et al., ""Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on gamma-Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron,"" Chinese Journal of Physiology 40:149-156 (1997).;;Claesson-Welsh, ""Signal Transduction by the PDGF Receptors,"" Progress in Growth Factor Research 5:37-54 (1994) 8 Elsevier Science Ltd.;;Coda et al., ""(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies,"" J. Chem. Soc. Perkin Trans. II: 615-619 (1984).;;Coda et al., ""3-(4-methylbenzilidene)-1,3-dihydroindol-2-one,"" Journal of the Chemical Society, Perkin Transactions 2 4:615-620 (1984) Database Crossfire, Beilstein Referenece No. 6-21.;;Coppola et al., ""A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor,"" Molecular and Cellular Biology 14:4588-4595 (1994) 8 The American Society for Microbiology.;;Daisley and Walker, ""Thin-layer chromatographic separation of some substituted 3-benzylidine-indol-2(3H)-ones,"" J. Chromatography 100:240-242 (1974) 8 Elsevier Scientific Publishing Company.;;Damiani et al., ""Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals,"" Biochemical Pharmacology 48:1155-1161 (1994) copyright Elsevier Science Ltd.;;Dati et al., ""Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells,"" Oncogene 5:1001-1006 (1990).;;Davis et al., ""Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds,"" Journal of Medicinal Chemistry 16:1043-1045 (1973) 8American Chemical Society.;;De Vries et al., ""The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor,"" Science 255:989-991 (1992).;;Decker and Lohmann-Matthes, ""A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity,"" J. Immunol. Methods 15:61-69 (1988) copyright Elsevier.;;Decodts et al., ""Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams,"" Eur. J. Med. Chem 18: 107-111 (1983).;;Desimoni et al., ""Catalysis with Inorganic Cations. V<SUP>1 </SUP>Intramolecular Hetero Diels-Alder versus Ene Reactions: Effect of Magnesium perchlorate on Chemoselectivity,""Tetrahedron 52(36) 12009-12018 (1996) 8 Pergamon.;;Dickson et al., ""13. Tyrosine kinase receptor-nuclear protooncogene interactions in breast cancer,"" Cancer Treatment Res. 61:249-273 (1992) 8 Kluwer Academic Publishers.;;Elliott and Rivers, ""Reduction of Some Oxinodolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride,"" J. Med. Chem. 29:2438-2440 (1964).;;Elliott et al., ""1-methyl-2-(3-oxindolidenmethyl)-pyridinium,"" Journal of Organic Chemistry 29:2438-2440 (1964) Database Crossfire, Beilstein Reference No. 5-24.;;Fantl et al., ""Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways,"" Cell 69:413-423 (1992) 8 Cell Press.;;Fendly et al., Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product, Cancer Research 50:1550-1558 (1990); @ American Association for Cancer Research.;;Ferrara and Henzel, ""Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells,"" Biochemical and Biophysical Research Communications 161:851-858 (1989) 8 Academic Press, Inc.;;Fingl and Woodbury, ""Chapter 1-General Principles,"" in The Pharmacological Basis of Therapeutics 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York , pp. 1-46 (1975) 8 MacMillan Publishing Co. Inc.;;Floege et al., ""Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo,"" Kidney International 43:S47-S54 (1993) 8 International Society of Nephrology.;;Floege et al., ""Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis,"" Kidney International 43:369-380 (1993) 8 International Society of Nephrology.;;Folkman and Shing, ""Angiogenesis,"" J. Biol. Chem. 267:10931-10934 (1992) 8 The American Society for Biochemistry and Molecular Biology.;;Folkman, ""Ch. 24. Angiogenesis,"" Congress of Thrombosis and Haemostasis (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987).;;Folkman, ""Tumor Angiogenesis: Therapeutic Implications,"" New England J. Medicine 285:1182-1186 (1971).;;Folkman, ""What is the Evidence that Tumors are Angiogenesis Dependent?"" Journal of the National Cancer Institute 82:4-6 (1990).;;Folkman, ""Angiogenesis in Psoriasis: Therapeutic Implications,"" J. Invest. Dermatol. 59:40-43 (1973) copyright The Williams & Wilkins Co.;;Gazit et al., ""Tyrphostins. 2. Heterocyclic and alpha-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases,"" J. Med. Chem. 34:1896-1907 (1991) copyright Am. Clem. Soc.;;Gennaro (editor), Remington's Pharmaceutical Sciences (1990) (Table of Contents Only).;;Goldring and Goldring, ""Cytokines and Cell Growth Control,"" Critical Reviews in Eukaryotic Gene Expression 1:301-326 (1991).;;Gottardis et al., ""Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen,"" J. Steroid Biochem. 30:311-314 (1988) 8 Pergamon Press.;;Graziani et al., ""Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger,"" The Journal of Biological Chemistry 268:9165-9168 (1993) 8American Society for Biochemistry and Molecular Biology.;;Hayler et al., Development of Large-Scale Syntheses of Ropinirole in the Pursuit if a Manufacturing Process, Organic Process Research & Development 2(1) 3-9 (1998) 8The American Chemical Society and Royal Society of Chemistry.;;Hewgill and Stewart, ""Phenanthrene-4,5-quinones: a Synthesis of Morphenol,"" J. Chem. Soc. Perkin Trans. I:1305-1311 (1988).;;Hirao et al., ""Rhodium-Catalyzed Carbonylation of 2-Alkynylaniline: Syntheses of 1,3-Dihydroindol-2-ones,"" Tetrahedron Letters 36(35) 1995 8Pergamon.;;Hodges et al., ""Chemical and biological properties of some oxindolidyl-3-methines,"" Canadian J. Chemistry 46:2189-2194 (1968).;;Honegger et al., ""Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing,"" Cell 51:199-209 (1987) 8 Cell Press.;;Houck et al., ""Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms,"" J. Biol. Chem. 267:26031-26037 (1992)8 American Society for Biochemistry and Molecular Biology, Inc.;;Howard, Harry R., ""Lactam Derivatives,"" U.S. Appl. No. 60/015,134, (Mar. 29, 1996).;;Howard et al., ""Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids,"" Eur. J. Med. Chem. 27:779-789 (1992) 8 Elsevier, Paris.;;Hu et al., ""Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors,"" Molecular and Cellular Biology 12:981-990 (1992) copyright Am. Soc. Microbiol.;;Ijaz et al., ""The Conversion of o,beta-Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones,"" J. Chem. Res. (S): 116 (1990).;;Jellinek et al., ""Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor,"" Biochemistry 33:10450-10456 (1994) 8 American Chemical Society.;;Kashishian and Cooper, ""Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cgamma1,"" Molecular Biology of the Cell 4:49-57 (1993) 8 The American Society for Cell Biology.;;Kashishian et al., ""Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo,"" The EMBO Journal 11:1373-1382 (1992).;;Kato et al., ""Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography,"" Journal of Chromatography 616:67-71 (1993) 8Elsevier Science.;;Katritzky et al., ""Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues,"" J. Heterocyclic Chem. 25:1287-1292 (1988).;;Kazlauskas et al., ""The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp,"" Proc. Natl. Acad. Sci. USA 90:6939-6942 (1993).;;Kendall and Thomas, ""Inhibiton of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor,"" Proc. Natl. Acad. Sci. USA 90:10705-10709 (1993).;;Khalil and Abdel-Rahman, ""Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes,"" J. Indian Chem. Soc. 54:904-907 (1977) 8The Indian Chemical Society.;;Kikumoto et al., ""The Reactions of Oxindoles and Isatin with Nitrobenzyl Chlorides,"" Tetrahedron 22: 3337-3343 (1966) 8Pergamon Press Ltd.;;Kim et al., ""Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo,"" Nature 362:841-844 (1993).;;Kinsella et al., ""Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel,"" Exp. Cell Research 199:56-62 (1992) 8 Academic Press, Inc.;;Klagsbrun and Soker, ""VEGF/VPF: the angiogenesis factor found?"" Current Biology 3:699-702 (1993) 8Current Biology.;;Kobayashi et al., ""Anti-tumor Activity of Indole Derivatives,"" Yakugaku Zasshi 97:1033-1039 (1977).;;Koch et al., ""SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins,"" Science 252:668-674 (1991).;;Kohler and Milstein, ""Continuous cultures of fused cells secreting antibody of predefined specificity,"" Nature 256:495-497 (1975).;;Komada and Kitamura, ""The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor,"" Oncogene 8:2381-2390 (1993).;;Korc et al., ""Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer Is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha,"" J. Clin. Invest. 90:1352-1360 (1992) copyright The American Society for Clinical Investigation, Inc.;;Korzeniewski and Callewaert, ""An Enzyme-Release Assay for Natural Cytotoxicity,"" J. Immunol. Methods 64:313-320 (1983) 8 Elsevier Science Publishers.;;Kovac and Stetinova, ""Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoxindoles,"" Chem. rvesu 30:484-492 (1976).;;Krueger and Saito, ""A human transmembrane protein-tyrosine-phosphatase, PTPb, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases,"" Proc. Natl. Acad. Sci. USA 89:7417-7421 (1992).;;Kumabe et al., ""Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin,"" Oncogene 7:627-633 (1992).;;Lal et al., ""Novel Diuretic Agents: Syntheses of Substituted Isatylidenes & 3-Alkyl or 3-Arylalkyl-2-oxindoles,"" Indian Journal of Chemistry 13: 898-903 (1975).",EXPIRED
661,US,B2,US 7256189 B2,158-782-639-554-370,2007-08-14,2007,US 51198106 A,2006-08-28,US 51198106 A;;US 65690703 A;;US 7614002 A;;US 31236101 P;;US 26868301 P,2001-02-15,3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors,The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.,UPJOHN CO,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;VOJKOVSKY TOMAS;;JIN QINGWU ALAN;;HERRINTON PAUL M;;MAURAGIS MICHAEL A,,https://lens.org/158-782-639-554-370,Granted Patent,yes,100,4,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/5377;;A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,514/235.2;;544/144,99,80,054-823-629-511-93X;;022-399-048-324-641;;176-879-479-576-661;;078-854-286-923-547;;094-652-412-929-005;;067-272-607-027-112;;025-114-183-199-748;;018-048-709-473-304;;004-963-545-993-258;;000-955-818-332-098;;000-955-818-332-098;;009-185-209-152-939;;009-068-402-575-690;;049-540-021-873-405;;035-321-998-935-819;;002-840-884-592-149;;129-714-176-445-277;;042-517-545-674-669;;062-253-139-686-620;;030-880-199-478-403;;171-875-161-435-498;;068-347-002-933-411;;016-739-947-546-505;;130-779-644-212-195;;032-953-229-558-330;;078-578-887-209-471;;049-954-263-824-454;;060-092-756-707-151;;102-148-719-482-24X;;099-279-971-758-096;;028-531-800-105-513;;016-333-429-871-463;;156-756-886-926-846;;037-134-997-566-90X;;037-465-890-679-37X;;104-815-369-514-254;;077-040-152-841-627;;122-261-121-873-625;;025-669-944-920-763;;043-489-715-583-833;;029-380-708-151-243;;120-787-793-242-483;;005-766-513-612-952;;081-381-735-516-869;;008-322-661-908-298;;025-209-481-691-070;;096-452-077-440-080;;013-790-909-287-914;;103-663-433-342-64X;;077-363-946-748-009;;128-267-202-156-519;;065-028-064-758-359;;009-954-017-681-952;;052-588-751-234-497;;010-830-508-694-564;;085-471-281-279-890;;000-260-545-266-425;;075-875-793-946-595;;020-017-567-104-545;;135-106-372-968-479;;029-871-534-065-762;;097-695-479-613-215;;045-890-249-073-273;;120-399-346-691-880;;049-676-058-590-911;;062-693-709-183-494;;079-734-101-870-347;;053-570-456-410-225;;102-943-963-373-742;;002-691-796-474-031;;094-207-501-631-352;;055-925-799-631-516;;027-603-408-160-490;;013-804-957-513-749;;106-753-778-592-300;;167-734-194-581-033;;011-265-567-519-296;;030-094-646-061-709;;009-809-672-105-539;;092-445-513-957-983,10.1039/jr9540001697;;1331337;;10.1016/0022-510x(92)90060-x;;9042225;;10.1016/0223-5234(92)90106-b;;10.1016/s0223-5234(97)82778-x;;9706372;;10.1172/jci114315;;2553774;;pmc304004;;7935391;;10.1128/mcb.14.10.6715-6726.1994;;10.1128/mcb.14.10.6715;;pmc359202;;10.1016/0040-4020(67)85040-3;;5793178;;5793179;;10.1021/jm00304a052;;10.1021/jm00304a050;;5793177;;10.1021/jm00304a051;;5793178;;5793179;;10.1021/jm00304a052;;10.1021/jm00304a050;;5793177;;10.1021/jm00304a051;;10.1039/j39660001028;;10.1080/00397919308011169;;10.1016/0092-8674(94)90023-x;;8001140;;7812953;;10.1080/00397918608057203;;10.1039/p29730001660;;10.1096/fasebj.6.15.1281458;;1281458;;8336932;;10.1128/mcb.5.6.1400-1407.1985;;pmc366870;;2993863;;10.1128/mcb.5.6.1400;;10.1002/jlac.19375320112;;8343210;;8099900;;10.1002/ijc.2910540409;;10.1002/jhet.5570220609;;9025911;;10.1006/abio.1996.9854;;10.1016/0092-8674(92)90068-n;;1547509;;10.1039/p29730000469;;9434891;;8199353;;10.1016/0955-2235(94)90016-7;;10.1039/p29840000615;;pmc358831;;8007963;;10.1128/mcb.14.7.4588-4595.1994;;10.1128/mcb.14.7.4588;;10.1016/s0021-9673(00)86069-0;;10.1016/0006-2952(94)90152-x;;7945409;;1973827;;10.1021/jm00267a020;;4583274;;1312256;;10.1126/science.1312256;;3192948;;10.1016/0022-1759(88)90310-9;;10.1016/0040-4020(96)00695-3;;1360236;;10.1007/978-1-4615-3500-3_13;;10.1021/jo01031a502;;10.1016/0092-8674(92)90444-h;;1374684;;1689212;;2735925;;10.1016/0006-291x(89)92678-8;;8468926;;10.1038/ki.1993.55;;8441232;;10.1016/s0021-9258(19)49853-0;;1375931;;10.1056/nejm197111182852108;;4938153;;10.1093/jnci/82.1.4;;1688381;;5039962;;10.1111/1523-1747.ep12625746;;10.1021/jm00110a022;;1676428;;1802112;;3386259;;10.1016/0022-4731(88)90113-6;;8387483;;10.1016/s0021-9258(18)98327-4;;10.1021/op970037c;;10.1039/p19880001305;;10.1016/0040-4039(95)01202-s;;10.1139/v68-357;;3499230;;10.1016/0092-8674(87)90147-4;;10.1016/s0021-9258(18)35712-0;;1464614;;10.1016/0223-5234(92)90112-e;;10.1128/mcb.12.3.981;;10.1128/mcb.12.3.981-990.1992;;pmc369530;;1372091;;10.1021/bi00200a028;;7520755;;10.1091/mbc.4.1.49;;8443409;;pmc300899;;pmc556586;;1314164;;10.1002/j.1460-2075.1992.tb05182.x;;8376494;;10.1016/0378-4347(93)80472-g;;10.1002/jhet.5570250503;;7688466;;pmc47050;;10.1073/pnas.90.15.6939;;8248162;;10.1073/pnas.90.22.10705;;pmc47846;;10.1016/s0040-4020(01)92520-7;;7683111;;10.1038/362841a0;;1370939;;10.1016/0014-4827(92)90461-g;;10.1016/0960-9822(93)90073-w;;15335866;;925872;;10.1248/yakushi1947.97.9_1033;;10.1126/science.1708916;;1708916;;1172191;;10.1038/256495a0;;7689722;;pmc443180;;1401070;;10.1172/jci116001;;10.1016/0022-1759(83)90438-6;;6300286;;6199426;;pmc49721;;1323835;;10.1073/pnas.89.16.7417;;1314366,"Abramovitch and Hey, ""Internuclear cyclisation. Part VIII. Naphth[3:2:1-cd]oxindoles,"" J. Chem. Soc. 1697-1703 (1954), Strand, London.;;Abramovitch et al., ""A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement,"" Chemistry and Industry 44:1871 (1967) 8Laporte Industries Limited, Lancashire.;;Akbasak and Sunar-Akbasak, ""Oncogenes: cause or consequence in the development of gilal tumors,"" J. Neurol. Sci. 111:119-133 (1992)8 Elsevier Science Publishers.;;Andreani et al., ""Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolymethylene)1,3-Dihydroindol-2-Ones,"" Anticancer Research 18:3585-3588 (1996) 8 Elsevier, Paris.;;Andreani et al., ""Synthesis and cardiotonic activity of 2-indolinones,"" Eur. J. Med. Chem. 25:187-190 (1990).;;Andreani et al., ""Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups,"" Eur. J. Med. Chem. 28:653-657 (1993) 8 Elsevier, Paris.;;Andreani et al., ""Synthesis and cardiotonic activity of 2-indolinones,"" Chemical Abstracts, vol. 113, abstract No. 78106 (1990).;;Andreani et al., ""Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones,"" Eur. J. Med. Chem. 27:167-170 (1992) 8 Elsevier, Paris.;;Andreani et al., ""Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones,"" Eur. J. Med. Chem. 32:919-924 (1997)8 Elsevier, Paris.;;Andreani et al., ""Synthesis of lactams with potential cardiotonic activity,"" Eur. J. Med. Chem. 28:825-829 (1993).;;Andreani et al., ""In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones,"" Arzneimittel-Forschung Drug Research 48:727-729 (1998) 8.;;Arteaga et al., ""Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells In Athymic Mice,"" J. Clin. Invest. 84:1418-1423 (1989) copyright The American Society for Clinical Investigation, Inc.;;Arvidsson et al., ""Tyr-716 in the Platelet-Derived Growth Factor beta-Receptor Kinase Insert is Involved In GRB2 Binding and Ras Activation,"" Molecular and Cellular Biology 14:6715-6726 (1994) 8 The American Society for Microbiology.;;Autrey and Tahk, ""The Synthesis and Sterochemistry of Some Isatylidenetic Acid Derivatives,"" Tetrahedron 23:901-917 (1967) 8Pergamon Press.;;Bahner and Brotherton, ""6-Dimethylaminochrysene and Other Analogs of 4-(4-Dimethylamino)stilbene,"" J. Med. Chem. 12:722-723 (1969).;;Bahner et al., ""Benzylideneindenes with Oxygen Attached to the Indene Ring,"" J. Med. Chem. 12:721-722 (1969).;;Bamfield et al., ""Diels-Alder Reactions of Oxindolylideneacetone,"" J. Chem. Soc. (C) 1028-1030 (1966) 8.;;Barbier, et al., ""Synthesis of Isobrassllexin, A Biologically Active Isomer of Brassilexin, a Cruciferae Phytoalexin,"" Synthetic Communications 23(22):3109-3117 (1993) 8 Marcel Dekker, Inc.;;Baserga, ""Oncogenes and the Strategy of Growth Factors,"" Cell 79:927-930 (1994) 8 Cell Press.;;Baserga, ""The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?"" Cancer Research 55:249-252 (1995).;;Beilstein Reg. No. 233511 (1997).;;Beilstein Reg. No. 235647 (1997).;;Beilstein Reg. No. 252929 (1998).;;Benzies, et al., ""2-Formyl-3-Methoxymethylindole, 3-Ethoxymethyl-2-Formylindoline and 2-Formyl-3-Methylindole,"" Synthetic Communications: 16(14), 1799-1807 (1986) 8 Mercel Dekker, Inc.;;Blake and Jaques, ""Anisotropic Effects in alpha-Substituted Methoxystilberies,"" J. Chem. Soc. Perkin II: 1660-1663 (1973) 8 Pergamon, Oxford.;;Bolen et al., ""The Src family of tyrosine protein kinases in hemopoietic signal transduction,"" FASEB J. 6:3403-3409 (1992).;;Bolen, ""Nonreceptor tyrosine protein kinases,"" Oncogene 8:2025-2031 (1993) copyright MacMillan Press Ltd.;;Bonner et al., ""Structure and Biological Activity of Human Homologs of the raf/mil Oncogene,"" Molecular and Cellular Biology 5:1400-1407 (1985) 8 The American Society for Microbiology.;;Borsche et al., ""Über vielkernige kondensierte Systeme mit heterocyclischen Ringen. XIII.,"" Liebigs Ann. Chem. 550:160-174 (1941).;;Buzzetti et al., ""Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases,"" Il Farmaco 48:615-636 (1993).;;Cance et al., ""Novel Protein Kinases Expressed in Human Breast Cancer,"" Int. J. Cancer 54:571-577 (1993) 8 Wiley-Liss, Inc.;;Canoira and Rodriguez, ""Synthesis of Oxindole Derivatives from N-Alkenyl-o-Chloroanilides with Zero-Valent Nickel Complex,"" J. Heterocyclic Chem. 22:1511-1518 (1985).;;Carpenedo et al., ""Identification and Measurement of Oxindole (2-Indolinone) In the Mammalian Brain and Other Rat Organs,"" Analytical Biochemistry 244:74-79 (1997) 8 Academic Press, Inc.;;Chao, ""Growth Factor Signaling: Where Is the Specificity?"" Cell 68:995-997 (1992) copyright Cell Press.;;Chatten et al., ""Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted trans-3-Benzylideneindol-2(3H)-ones,"" J. Chem. Soc. Perkin II: 469-473 (1973).;;Chen et al., ""Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on gamma-Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron,"" Chinese Journal of Physiology 40:149-158 (1997).;;Claesson-Welsh, ""Signal Transduction by the PDGF Receptors,"" Progress In Growth Factor Research 5:37-54 (1994) 8 Elsevier Science Ltd.;;Coda et al., ""(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies,"" J. Chem. Soc. Perkin Trans. II: 615-619 (1984).;;Coda et al., ""3-(4-methylbenzilidene)-1,3-dihydroindol-2-one,"" Journal of the Chemical Society, Perkin Transactions 2 4:615-620 (1984) Database Crossfire, Beilstein Reference No. 6-21.;;Coppola et al., ""A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activitles of the Epidermal Growth Factor Receptor,"" Molecular and Cellular Biology 14:4588-4595 (1994) 8 The American Society for Microbiology.;;Daisley and Walker, ""Thin-layer chromatographic separation of some substituted 3-benzylidine-Indol-2(3H)-ones,"" J. Chromatography 100:240-242 (1974) 8 Elsevier Scientific Publishing Company.;;Damiani et al., ""Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals,"" Biochemical Pharmacology 48:1155-1161 (1994) copyright Elsevier Science Ltd.;;Dati et al., ""Inhibition of c-arbB-2 oncogene expression by estrogens in human breast cancer cells,"" Oncogene 5:1001-1006 (1990).;;Davis et al., ""Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds,"" Journal of Medicinal Chemistry 16:1043-1045 (1973) 8American Chemical Society.;;De Vries et al., ""The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor,"" Science 255:989-991 (1992).;;Decker and Lohmann-Matthes, ""A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity,"" J. Immunol. Methods 15:61-89 (1988) copyright Elsevier.;;Decodts et al., ""Suicide Inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams,"" Eur. J. Med. Chem 18: 107-111 (1983).;;Desimoni et al., ""Catalysis with Inorganic Cations. V<SUP>1 </SUP>Intramolecular Hetero Diets-Alder versus Ene Reactions: Effect of Magnesium perchlorate on Chemoselectivity,""Tetrahedron 52(36) 12009-12018 (1196) 8 Pergamon.;;Dickson et al., ""13. Tyrosine kinase receptor-nuclear protooncogene interactions in breast cancer,"" Cancer Treatment Res. 61:249-273 (1992) 8 Kluwar Publishers.;;Elliott and Rivers, ""Reduction of Some Oxindolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride,"" J. Med. Chem. 29:2438-2440 (1964).;;Elliott et al., ""1-methyl-2-(3-oxindolidenmethyl)-pyridinium,"" Journal of Organic Chemistry 29:2438-2440 (1964) Database Crossfire, Beilstein Reference No. 5-24.;;Fantl et al., ""Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways,"" Cell 69:413-423 (1992) 8 Cell Press.;;Fendly et al., Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product, Cancer Research 50:1550-1558 (1990); @ American Association for Cancer Research.;;Ferrara and Henzel, ""Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells,"" Biochemical and Biophysical Research Communications 161:851-858 (1989) 8 Academic Press, Inc.;;Fingl and Woodbury, ""Chapter 1-General Principles,"" In The Pharmacological Basis of Therapeutics 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975) 8 MacMillan Publishing Co. Inc.;;Floege et al., ""Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo,"" Kidney International 43:S47-S54 (1993) 8 International Society of Nephrology.;;Floege et al., ""Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis,"" Kidney International 43:369-380 (1993) 8 International Society of Nephrology.;;Folkman and Shing, ""Angiogenesis,"" J. Biol. Chem. 267:10931-10934 (1992) 8 The American Society for Biochemistry and Molecular Biology.;;Folkman, ""Ch. 24. Angiogenesis,"" Congress of Thrombosis and Haemostasis (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987).;;Folkman, ""Tumor Angiogenesis: Therapeutic Implications,"" New England J. Medicine 285:1182-1186 (1971).;;Folkman, ""What is the Evidence that Tumors are Angiogenesis Dependent?"" Journal of the National Cancer Institute 82:4-6 (1990).;;Folkman, ""Angiogenesis in Psoriasis: Therapeutic Implications,"" J. Invest. Dermatol. 59:40-43 (1973) copyright The Williams & Wilkins Co.;;Gazit et al., ""Tyrphostins. 2. Heterocyclic and alpha-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and Erb82/neu Tyrosine Kinases,"" J. Med. Chem. 34:1896-1907 (1991) copyright Am. Clem. Soc.;;Gennaro (editor), Remington's Pharmaceutical Sciences (1990) (Table of Contents Only).;;Goldring and Goldring, ""Cytokines and Cell Growth Control,"" Critical Reviews in Eukaryotic Gene Expression 1:301-326 (1991).;;Gottardis et al., ""Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen,"" J. Steroid Biochem. 30:311-314 (1988) 8 Pergamon Press.;;Graziani et al., ""Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger,"" The Journal of Biological Chemistry 268:9165-9168 (1993) 8American Society for Biochemistry and Molecular Biology.;;Hayler et al., Development of Large-Scale Syntheses of Ropinirole in the Pursuit if a Manufacturing Process, Organic Process Research & Development 2(1) 3-9 (1998) 8The American Chemical Society and Royal Society of Chemistry.;;Hewgill and Stewart, ""Phenanthrene-4,5-quinones: a Synthesis of Morphenol,"" J. Chem. Soc. Perkin Trans. l:1305-1311 (1988).;;Hirao et al., ""Rhodium-Catalyzed Carbonylation of 2-Alkynylaniline: Synthesis of 1,3-Dihydroindol-2-ones,"" Tetrahedron Letters 36(35) 1995 8Pergamon.;;Hodges et al., ""Chemical and biological properties of some oxindolidyl-3-methines,"" Canadian J. Chemistry 46:2189-2194 (1968).;;Honegger et al., ""Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing,"" Cell 51:199-209 (1987) 8 Cell Press.;;Houck et al., ""Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms,"" J. Biol. Chem. 267:26031-26037 (1992)8 American Society for Biochemistry and Molecular Biology, Inc.;;Howard, Harry R., ""Lactam Derivatives,"" U.S. Appl. No. 60/015134.;;Howard et al., ""Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids,"" Eur. J. Med. Chem. 27:779-789 (1992) 8 Elsevier, Paris.;;Hu et al., ""Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors,"" Molecular and Cellular Biology 12:981-990 (1992) copyright Am. Soc. Microbiol.;;Ijaz et al., ""The Conversion of o,beta-Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones,"" J. Chem. Res. (S): 116 (1990).;;Jellinek et al., ""Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor,"" Biochemistry 33:10450-10456 (1994) 8 American Chemical Society.;;Kashishian and Cooper, ""Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cy1,"" Molecular Biology of the Cell 4:49-57 (1993) 8 The American Society for Cell Biology.;;Kashishian et al., ""Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo,"" The EMBO Journal 11:1373-1382 (1992).;;Kato et al., ""Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography,"" Journal of Chromatography 616:67-71 (1993) 8Elsevier Science.;;Katritzky et al., ""Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues,"" J. Heterocyclic Chem. 25:1287-1292 (1988).;;Kazlauskas et al., ""The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp,"" Proc. Natl. Acad. Sci. USA 90:6939-6942 (1993).;;Kendall and Thomas, ""Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor,"" Proc. Natl. Acad. Sci. USA 90:10705-10709 (1993).;;Khalil and Abdel-Rahman, ""Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes,"" J. Indian Chem. Soc. 54:904-907 (1977) 8The Indian Chemical Society.;;Kikumoto et al., ""The Reactions of Oxindoles and Isatin with Nitrobenzyl Chlorides,"" Tetrahedron 22: 3337-3343 (1966) 8Pergamon Press Ltd.;;Kim et al., ""Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo,"" Nature 362:841-844 (1993).;;Kinsella et al., ""Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel,"" Exp. Cell Research 199:56-62 (1992) 8 Academic Press, Inc.;;Klagsbrun and Soker, ""VEGF/VPF: the angiogenesis factor found?"" Current Biology 3:699-702 (1993) 8Current Biology.;;Kobayashi et al., ""Anti-tumor Activity of Indole Derivatives,"" Yakugaku Zasshi 97:1033-1039 (1977).;;Koch et al., ""SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins,"" Science 252:668-674 (1991).;;Kohler and Milstein, ""Continuous cultures of fused cells secreting antibody of predefined specificity,"" Nature 256:495-497 (1975).;;Komada and Kitamura, ""The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor,"" Oncogene 8:2381-2390 (1993).;;Korc et al., ""Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha,"" J. Clin. Invest. 90:1352-1360 (1992) copyright The American Society for Clinical Investigation, Inc.;;Korzeniewski and Callewaert, ""An Enzyme-Release Assay for Natural Cytotoxicity,"" J. Immunol. Methods 64:313-320 (1983) 8 Elsevier Science Publishers.;;Kovac and Stetinova, ""Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoxindoles,"" Chem. rvesu 30:484-492 (1976).;;Krueger and Saito, ""A human transmembrane protein-tyrosine-phosphatase, PTPb, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases,"" Proc. Natl. Acad. Sci. USA 89:7417-7421 (1992).;;Kumabe et al., ""Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin,"" Oncogane 7:627-633 (1992).;;Lal et al., ""Novel Diuretic Agents: Synthesis of Substituted Isatylidenes & 3-Alkyl or 3-Arylalkyl-2-oxindoles,"" Indian Journal of Chemistry 13: 898-903 (1975).",EXPIRED
662,EP,A1,EP 3071570 A1,183-511-034-821-984,2016-09-28,2016,EP 14806447 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS",,PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/183-511-034-821-984,Patent Application,yes,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
663,TW,A,TW 201524979 A,188-675-246-169-070,2015-07-01,2015,TW 103140297 A,2014-11-20,US 201361907322 P,2013-11-21,Purine derivatives,"The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R<SP>5a</SP>, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON THEODORE OTTO JR;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/188-675-246-169-070,Patent of Addition,no,0,1,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/32;;A61K31/52;;A61P35/00,,0,0,,,,ACTIVE
664,CU,B1,CU 24402 B1,194-108-652-809-56X,2019-05-03,2019,CU 20160073 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6 PURINAS DI-SUSTITUIDAS ÚTILES EN EL TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS TALES COMO CÁNCER","<p>La presente invención se refiere a compuestos de Ia Fórmula (I)</p> <p> </p> <p>ESPACIO PARA FÓRMULA</p> <p> </p> <p>en donde Q, G, anillo A, anillo B, R¹, R<sup>2</sup> , R<sup>3</sup> , R<sup>4</sup>, R<sup>5</sup> , R<sup>5a</sup> , R<sup>6</sup>, R<sup>7</sup> , R<sup>8</sup> , R<sup>9</sup> , R<sup>10</sup> , R<sup>11</sup> , R<sup>12</sup> , R<sup>13</sup> , R<sup>14</sup> , R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, R<sup>24 </sup>y m son como se definen en Ia presente. Los derivados de purina novedosos son útiles para tratar el crecimiento celular anormal, tal como el cáncer, en mamíferos.</p>",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/194-108-652-809-56X,Unknown,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61K31/522;;A61P35/00;;C07D473/16;;C07D473/18;;C07D519/00,,0,0,,,,PENDING
665,EA,B1,EA 029842 B1,004-381-033-059-779,2018-05-31,2018,EA 201600337 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS","The present invention relates to compounds of formula (Ia)or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, Rand n, p are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/004-381-033-059-779,Granted Patent,no,2,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
666,EP,B1,EP 3201958 B1,035-320-827-330-95X,2020-08-26,2020,EP 14903117 A,2014-09-29,US 2014/0058100 W,2014-09-29,FLEXIBLE DISPLAY DEVICE WITH REDUCED BEND STRESS WIRES,,LG DISPLAY CO LTD,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,,https://lens.org/035-320-827-330-95X,Granted Patent,yes,10,0,9,9,0,Y02E10/549;;G06F3/0412;;G06F2203/04102;;G06F2203/04103;;G06F3/04164;;H04M1/0269;;H04M1/0268;;H10K59/1315;;H10K59/179;;H10K59/1795;;H10K59/131;;H10K77/111;;H10K2102/311;;G06F3/0412;;G06F3/04164;;G06F1/1652;;G09F9/301;;G06F2203/04102;;G06F2203/04103;;Y02E10/549;;H10K77/111;;H04M1/0269;;H10K59/1315;;H10K59/1795;;Y02E10/549;;G06F3/0412;;G06F2203/04103;;G06F2203/04102;;G06F3/04164;;H04M1/0269;;H10K59/131;;H10K59/179;;H10K77/111;;H10K59/1315;;H10K59/1795;;H10K71/00;;H10K2102/311;;G06F1/1652;;G09F9/301;;H04M1/0268,H01L51/00;;G06F3/041;;H01L27/32,,0,0,,,,ACTIVE
667,US,A1,US 2023/0315766 A1,060-887-181-254-831,2023-10-05,2023,US 202217710009 A,2022-03-31,US 202217710009 A,2022-03-31,"METHODS, MEDIUMS, AND SYSTEMS FOR REUSABLE INTELLIGENT SEARCH WORKFLOWS","Exemplary embodiments provide methods, mediums, and systems for performing a reusable, intelligent semantic search across a potentially large number of records. Embodiments may be particularly useful for responding to requests for information from regulatory agencies. In one embodiment, an embedding model is trained to embed queries in an embedding space. When a new query is received, the new query is embedded with the embedding model. A set of documents (e.g., previous responses to regulatory inquiries) may be searched using the embedded query and an indexing model that allows for efficient searches of embedding spaces. A number of results may be returned from the document store, and the results may be ranked by a ranking model. User feedback about the quality of the results may be received, and the ranking model may be retrained based on the feedback.",CAPITAL ONE SERVICES LLC,CHO PAUL;;WILLIAMS GARY B;;BUSSAN ALEXANDER;;CAMPBELL ERIC;;COBLE PIPER ALEXANDRA;;LOZANO RALPH;;MANIKANTAN MUKUND;;WALSH TALYNE DERDERIAN;;KOC TALHA;;BHATTARAI PRARTHANA,CAPITAL ONE SERVICES LLC (2022-03-08),https://lens.org/060-887-181-254-831,Patent Application,yes,3,0,1,1,0,G06F16/3326;;G06F16/3338;;G06F16/338;;G06F16/3338;;G06F16/3326;;G06F16/338,G06F16/33;;G06F16/332;;G06F16/338,,0,0,,,,PENDING
668,AR,A1,AR 098492 A1,058-214-586-768-277,2016-06-01,2016,AR P140104368 A,2014-11-20,US 201361907322 P,2013-11-21,DERIVADOS DE PURINA,"Compuestos o sales aceptables desde el punto de vista farmacéutico útiles para tratar el crecimiento celular anormal, tal como el cáncer, en mamíferos. Otras formas de realización se refieren a composiciones farmacéuticas que contienen los compuestos y a métodos para usar los compuestos y las composiciones en el tratamiento del crecimiento celular anormal en mamíferos. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) en donde R¹ es hidrógeno, C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₃₋₆ cicloalquilo, heterocicloalquilo de 4 - 6 miembros, o heteroarilo de 4 - 6 miembros, en donde el C₁₋₆ alquilo se sustituye opcionalmente con 1, 2 ó 3 sustituyentes seleccionados del grupo que consiste en halógeno, hidroxi, y C₁₋₃ alcoxi, en donde además el C₃₋₆ cicloalquilo, el heterocicloalquilo de 4 - 6 miembros y el heteroarilo de 4 - 6 miembros se sustituyen cada uno, de manera independiente y opcional, con 1, 2 ó 3 sustituyentes seleccionados del grupo que consiste en C₁₋₃ alquilo, hidroxi y C₁₋₃ alcoxi; el anillo A es C₆₋₁₀ arilo o heteroarilo de 5 - 12 miembros; R² y R⁵ cada uno, independientemente, está ausente, es hidrógeno, halógeno, ciano, difluorometilo, trifluorometilo, C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ alcoxi, -N(R¹⁰)(R¹¹), C₃₋₅ cicloalquilo o heterocicloalquilo de 4 - 6 miembros, en donde el C₁₋₆ alquilo se sustituye opcionalmente con 1, 2 ó 3 sustituyentes seleccionados del grupo que consiste en halógeno, hidroxi, C₁₋₆ alcoxi y N(R¹²)(R¹³); R³ está ausente o es hidrógeno, halógeno, C₁₋₆ alquilo, C₂₋₆ alquinilo, C₁₋₆ alcoxi, C₃₋₇ cicloalquilo o heterocicloalquilo de 3 - 7 miembros, en donde C₁₋₆ alquilo y C₁₋₆ alcoxi se sustituyen cada uno, opcionalmente, con 1, 2 ó 3 grupos R¹⁴, y en donde además el C₃₋₇ cicloalquilo y el heterocicloalquilo de 3 - 7 miembros se sustituyen cada uno, opcionalmente, con 1, 2 ó 3 grupos R¹⁵; R⁴ está ausente o es hidrógeno, halógeno, C₁₋₆ alquilo o C₃₋₆ cicloalquilo, en donde R² y R³ o R³ y R⁴ se pueden combinar para formar un anillo C₅₋₇ cicloalquilo o un anillo de heterocicloalquilo de 5 - 7 miembros, en donde además el anillo C₅₋₇ cicloalquilo y el anillo de heterocicloalquilo de 5 - 7 miembros se sustituyen cada uno, de manera independiente y opcional, con 1, 2 ó 3 grupos R¹⁴; Q está ausente o es O, S o NR⁹; el anillo B está ausente o es C₃₋₁₀ cicloalquilo, heterocicloalquilo de 3 - 10 miembros, C₆₋₁₀ arilo o heteroarilo de 5 - 12 miembros; R⁶ y R⁸ cada uno, independientemente, está ausente o es hidrógeno, halógeno, ciano, hidroxi, difluorometilo, trifluorometilo, C₁₋₃ alquilo, C₁₋₃ alcoxi o C₃₋₅ cicloalquilo, en donde C₁₋₃ alquilo se sustituye opcionalmente con hidroxi, difluorometilo, trifluorometilo, C₁₋₃ alcoxi o C₃₋₅ cicloalquilo; R⁷ es un compuesto seleccionado del grupo de fórmulas (2); G está ausente cuando el punto de unión de R⁷ en el anillo B es un átomo de nitrógeno, y G es -NR¹⁸- cuando el anillo B está ausente o cuando el punto de unión de R⁷ en el anillo B es un átomo de carbono; R⁹, R¹² y R¹³ son cada uno, independientemente, hidrógeno o C₁₋₃ alquilo; R¹⁰ y R¹¹ son cada uno, independientemente, hidrógeno o C₁₋₃ alquilo; o R¹⁰ y R¹¹, junto con el nitrógeno al que están unidos, se pueden combinar para formar un anillo de heterocicloalquilo de 4 - 7 miembros, en donde R¹⁰ y R¹¹ son cada uno C₁₋₃ alquilo, en donde el anillo de heterocicloalquilo de 4 - 7 miembros formado se sustituye opcionalmente con 1, 2, 3 ó 4 grupos R¹⁵; cada R¹⁴ es, independientemente, halógeno, ciano, C₁₋₃ alquilo, hidroxi, C₁₋₆ alcoxi, -N(R¹⁹)(R²⁰), -CON(R²¹)(R²²) o heterocicloalquilo de 3 - 7 miembros, en donde el heterocicloalquilo de 3 - 7 miembros se sustituye opcionalmente con 1, 2, 3 ó 4 grupos R¹⁵; cada R¹⁵ es, independientemente, halógeno, C₁₋₃ alquilo, hidroxi, C₁₋₆ alcoxi, NH₂, -NHCH₃ o -N(CH₃)₂; R¹⁶ y R¹⁷ son cada uno, independientemente, hidrógeno o C₁₋₆ alquilo, en donde el C₁₋₆ alquilo se sustituye opcionalmente con -N(R²³)(R²⁴), siempre que R¹⁶ y R¹⁷ puedan formar un anillo C₃₋₅ cicloalquilo; R¹⁸ es hidrógeno o C₁₋₃ alquilo; cada R¹⁹, R²⁰, R²¹, R²², R²³ y R²⁴ es, independientemente, hidrógeno o C₁₋₃ alquilo; y m es 0, 1 ó 2, siempre que cuando el anillo B esté ausente, m sea 2; o una sal de aquel aceptable desde el punto de vista farmacéutico. Reivindicación 23: Un compuesto, caracterizado porque es de fórmula (3), o una sal de aquel aceptable desde el punto de vista farmacéutico.",PFIZER,SAJIV KRISHNAN NAIR;;HENGMIAO CHENG;;THEODORE OTTO JOHNSON JR;;JOHN CHARLES KATH;;SUJIN CHO-SCHULTZ;;DOUGLAS CARL BEHENNA;;ASAKO NAGATA;;SIMON PAUL PLANKEN,,https://lens.org/058-214-586-768-277,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/52;;A61P35/00;;C07D473/18;;C07D473/34;;C07D519/00,,0,0,,,,PENDING
669,BR,A,BR 0011249 A,119-601-345-740-303,2002-10-22,2002,BR 0011249 A,2000-06-01,US 13706599 P;;US 19160100 P;;US 0015306 W,1999-06-02,Métodos e composições para isolamento de dna de elevado peso molecular a partir de amostras naturais,"""MéTODOS E COMPOSIçõES PARA ISOLAMENTO DE DNA DE ELEVADO PESO MOLECULAR A PARTIR DE AMOSTRAS NATURAIS"". São divulgados métodos e composições para isolamento e propagação de DNA de elevado peso molecular. Grandes segmentos de DNA isolado de amostras obtidas diretamente de fontes naturais tal como o solo, amostras submarinas, água doce e salgada, ar e outras fontes podem ser usados para examinar agrupamentos genéticos inteiros e isolar produtos de expressão de organismos anteriormente desconhecidos e não caracterizados ou mesmo extintos. O isolamento e manipulação de grandes segmentos de DNA que não era possível anteriormente é ensinado aqui.",AVENTIS PHARMA INC,MCNEIL IAM;;LYNCH BERKLEY A;;LOIACONO KARA A;;TIONG CHO LAI;;MINOR CHARLES A;;OSBURNE MARCIA S;;GROSSMAN TRUDY H;;AUGUST PAUL R,,https://lens.org/119-601-345-740-303,Patent Application,no,0,0,14,15,0,C07D209/14;;C12N15/1003;;C12N15/1093;;C12P17/165;;C12Q1/6806;;C12Q1/68,C07D209/14;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/10;;C12N15/09;;C12P17/16;;C12P17/18;;C12Q1/00;;C12Q1/68,,0,0,,,,DISCONTINUED
670,HR,T1,HR P20181036 T1,108-365-078-284-006,2018-08-24,2018,HR P20181036 T,2018-07-05,US 201361907322 P;;EP 14806447 A;;IB 2014065935 W,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS",,PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON THEODORE OTTO JR;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/108-365-078-284-006,Granted Patent,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
671,UA,C2,UA 115388 C2,114-481-542-327-539,2017-10-25,2017,UA A201605505 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS","The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals. EMBED ISISServer , (I)",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/114-481-542-327-539,Limited Patent,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
672,US,B2,US 11896720 B2,155-524-420-025-57X,2024-02-13,2024,US 201816141070 A,2018-09-25,US 201816141070 A;;US 201762563562 P,2017-09-26,Orally available articles containing at least one stabilized supplement therein,"The present disclosure relates to orally available stabilized supplement-containing articles (e.g., softgels). The stabilized supplement may be a probiotic, and may contain a stabilizing component derived from chocolate. The present disclosure also relates to methods of making such stabilized articles.",CAPTEK SOFTGEL INT,CHIPRICH TIMOTHY BRIAN;;MELENDEZ ARGELIA SINAY;;GEORGE BIBU PHILIP;;WOOD DAVID;;PARK JANGSOON;;CHO JUNG KU;;TRAN LILYAN HONG;;HWANG PAUL;;BAYLESS RONNIE,,https://lens.org/155-524-420-025-57X,Granted Patent,yes,16,0,2,2,0,A23K20/10;;A23L33/105;;A61K9/0056;;A61K9/4858;;A23K10/18;;A23K20/174;;A23K50/20;;A23K50/70;;A23K50/30;;A23K50/40;;A23K50/50;;A23L33/135;;A23P10/30;;A61K9/5057;;A23L33/135;;A61K9/4808;;A61K9/4833;;A61K47/36;;A61K9/4891;;A23L29/206;;A61K31/715;;A23P10/30;;A23G1/00;;A23K50/20;;A23K20/10;;A23L33/105;;A61K9/0056;;A23K20/174;;A23K50/30;;A61K9/4858;;A23K50/50;;A23K50/70;;A23K50/40;;A23K10/18,A61K9/50;;A23G1/00;;A23K10/18;;A23K20/10;;A23K20/174;;A23K50/20;;A23K50/30;;A23K50/40;;A23K50/50;;A23K50/70;;A23L29/206;;A23L33/105;;A23L33/135;;A23P10/30;;A61K9/00;;A61K9/48;;A61K31/715;;A61K47/36,,9,0,,,"JP2013533313A machine translation (Year: 2013).;;FDA, “Chocolate, As defined by FDA Food & Beverages”, Oct. 15, 2015.;;FDA, “Requirements for Specific Standardized Cacao Products”, FDA CFR Title 21 Subpart B, Part 163, Aug. 15, 2017.;;Possemiers et al., “Bacteria and chocolate: successful combination for probiotic delivery”, International Journal of Food Microbiology, vol. 141, 2010, pp. 97-103.;;Miscellaneous Document, Beijing Kunyou Pharmatech Co., Ltd. (2016), Beijing, CN; Retrieved Jul. 1, 2020: http://www.softgelencapsulationmachine.com/; 12 pages.;;“Premium Probiotics for dark chocolate products”, Danisco A/S, (2007). Technical Memorandum. Retrieved Jul. 1, 2020: https://www.dupontnutritionandbiosciences.com/product-range/probiotics/howaru-premium-probiotics.html; 4 pages.;;“Micro-Nano encapsulation”, Southwest Research Institute San Antonio, TX., (2015). Retrieved Jul. 1, 2020: https://www.swri.org/sites/default/files/brochures/micro-nano-encapsulation_0.pdf; 12 pages.;;Excerpts from Frank D. Gunstone, “Vegetable Oils in Food Technology”, Blackwell Publishing (2002). ISBN 1-84127-331-7 (pp. 68-70, 90, 170-172, 180-185, 192-193).;;NIIR Board of Consultants & Engineers, The Complete Technology Book of Cocoa, Chocolate, Ice Cream and other Milk Products, Jun. 12, 2005, p. 134, National Institute of Industrial Research, Delhi, India.",ACTIVE
673,GT,A,GT 201600091 A,178-196-321-135-92X,2017-11-09,2017,GT 201600091 A,2016-05-20,US 201361907322 P,2013-11-21,"DERIVADOS DE PURINA 2, 6-SUSTITUIDOS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS","LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE LA FÓRMULA (I) O SALES DE AQUELLOS ACEPTABLES DESDE EL PUNTO DE VISTA FARMACÉUTICO, EN DONDE Q, G, ANILLO A, ANILLO B, R1 AL R24 INCLUYENDO EL R5A Y M SON COMO SE DEFINEN EN LA PRESENTE. LOS DERIVADOS DE PURINA NOVEDOSOS SON ÚTILES PARA TRATAR EL CRECIMIENTO CELULAR ANORMAL, TAL COMO EL CÁNCER, EN MAMÍFEROS. OTRAS FORMAS DE REALIZACIÓN SE REFIEREN A COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS COMPUESTOS Y A MÉTODOS PARA USAR LOS COMPUESTOS Y LAS COMPOSICIONES EN EL TRATAMIENTO DEL CRECIMIENTO CELULAR ANORMAL EN MAMÍFEROS.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/178-196-321-135-92X,Amended Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D519/00,,0,0,,,,PENDING
674,IL,B,IL 245698 B,044-855-170-651-886,2019-11-28,2019,IL 24569816 A,2016-05-18,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-substituted purine derivatives and their use in the treatment of proliferative disorders",,PFIZER;;THEODORE OTTO JOHNSON JR;;HENGMIAO CHENG;;SAJIV KRISHNAN NAIR;;SIMON PAUL PLANKEN;;JOHN CHARLES KATH;;DOUGLAS CARL BEHENNA;;SUJIN CHO SCHULTZ;;ASAKO NAGATA,THEODORE OTTO JOHNSON JR;;HENGMIAO CHENG;;SAJIV KRISHNAN NAIR;;SIMON PAUL PLANKEN;;JOHN CHARLES KATH;;DOUGLAS CARL BEHENNA;;SUJIN CHO-SCHULTZ;;ASAKO NAGATA,,https://lens.org/044-855-170-651-886,Unknown,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,,,0,0,,,,ACTIVE
675,EP,A4,EP 3201958 A4,042-286-002-482-948,2017-10-18,2017,EP 14903117 A,2014-09-29,US 2014/0058100 W,2014-09-29,FLEXIBLE DISPLAY DEVICE WITH REDUCED BEND STRESS WIRES,,LG DISPLAY CO LTD,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,,https://lens.org/042-286-002-482-948,Search Report,no,5,0,9,9,0,Y02E10/549;;G06F3/0412;;G06F2203/04102;;G06F2203/04103;;G06F3/04164;;H04M1/0269;;H04M1/0268;;H10K59/1315;;H10K59/179;;H10K59/1795;;H10K59/131;;H10K77/111;;H10K2102/311;;G06F3/0412;;G06F3/04164;;G06F1/1652;;G09F9/301;;G06F2203/04102;;G06F2203/04103;;Y02E10/549;;H10K77/111;;H04M1/0269;;H10K59/1315;;H10K59/1795;;Y02E10/549;;G06F3/0412;;G06F2203/04103;;G06F2203/04102;;G06F3/04164;;H04M1/0269;;H10K59/131;;H10K59/179;;H10K77/111;;H10K59/1315;;H10K59/1795;;H10K71/00;;H10K2102/311;;G06F1/1652;;G09F9/301;;H04M1/0268,H01L51/00;;G06F3/041;;H01L27/32,,0,0,,,,ACTIVE
676,MY,A,MY 184433 A,081-463-717-515-44X,2021-04-01,2021,MY PI2016701796 A,2014-11-10,IB 2014065935 W;;US 201361907322 P,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS","The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2 , R3, R4, R5, R5a, R6, R7, R8, R9, R1o, R11, R12, R13, R14, R15, R16, R17, R18, R19, R2o, R21,R 22 , R23, R24, and mare defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/081-463-717-515-44X,Granted Patent,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,,,0,0,,,,ACTIVE
677,US,B1,US 9235862 B1,127-414-875-108-854,2016-01-12,2016,US 42629006 A,2006-06-23,US 42629006 A,2006-06-23,Corporate board management system,Methods and systems for providing financial and/or board member information in a secured manner to members of boards of directors of companies and others through a publicly-available widely disseminated network.,RADNER GREGORY;;PRUSSMAN ERIC C;;STEVENS MICHAEL W;;DANG DANH;;BAHLIN NICOLE;;KHURANA REBECCA CHO;;JAIN NEERAJ;;CORAN ROBERT;;PAUL JERON;;ZINNI CARMINE;;THOMSON REUTERS GLO RESOURCES,RADNER GREGORY;;PRUSSMAN ERIC C;;STEVENS MICHAEL W;;DANG DANH;;BAHLIN NICOLE;;KHURANA REBECCA CHO;;JAIN NEERAJ;;CORAN ROBERT;;PAUL JERON;;ZINNI CARMINE,THOMSON REUTERS (MARKETS) LLC (2009-03-22);;THOMSON REUTERS GLOBAL RESOURCES UNLIMITED COMPANY (2016-11-21);;REFINITIV US ORGANIZATION LLC (2018-11-26),https://lens.org/127-414-875-108-854,Granted Patent,yes,22,5,1,1,0,G06Q50/01;;G06Q50/01,G06Q30/02;;G06Q10/06;;G06Q10/08;;G06Q10/10;;G06Q30/06;;G06Q50/00,,1,0,,,"Ahmed et al. ""A Meeting Scheduling System for Global Events on the Internet,"" ISOC, Geneva Switzerland, Jul. 1998.",ACTIVE
678,PH,A1,PH 12016500911 A1,148-773-993-348-222,2016-06-20,2016,PH 12016500911 A,2016-05-17,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS","The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.",PFIZER,CARL BEHENNA DOUGLAS;;HENGMIAO CHENG;;SUJIN CHO-SCHULTZ;;OTTO JOHNSON JR THEODORE;;CHARLES KATH JOHN;;ASAKO NAGATA;;KRISHNAN NAIR SAJIV;;PAUL PLANKEN SIMON,,https://lens.org/148-773-993-348-222,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61P35/00;;A61K31/522;;C07D473/16;;C07D473/18;;C07D519/00,,0,0,,,,PENDING
679,DK,T3,DK 3071570 T3,008-970-623-388-768,2018-08-13,2018,DK 14806447 T,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-substituerede purinderivater og anvendelse deraf i behandlingen af proliferative sygdomme",,PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/008-970-623-388-768,Granted Patent,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
680,US,B2,US 9290496 B2,075-893-270-115-193,2016-03-22,2016,US 201414548749 A,2014-11-20,US 201414548749 A;;US 201361907322 P,2013-11-21,Purine derivatives,"The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R 1 , R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/075-893-270-115-193,Granted Patent,yes,64,1,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61P35/00;;C07D473/16;;C07D473/18;;C07D487/04;;C07D498/10;;C07D519/00,,4,2,041-703-940-947-068;;029-742-983-481-795,9544425;;10.1023/a:1005960822365;;10.1126/science.286.5439.531;;10521349,"Cancer [online], [retrieved on Jun. 6, 2007] Retrieved from the Internet, URL: http://www.nlm.nih.gov/medlineplus/cancer.html.;;Lala et al., Role of nitric oxide in tumor progression: Lessons from experimental tumors, Cancer and Metastasis Reviews (1998), 17, 91-106.;;Golub et al., Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, Science (1999), vol. 286, 531-537.;;International Search Report for International Appln. No. PCT/IB2014/065935 issued Jan. 21, 2015.",ACTIVE
681,CA,A1,CA 2931034 A1,075-702-286-882-149,2015-05-28,2015,CA 2931034 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS","The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON THEODORE OTTO JR;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/075-702-286-882-149,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
682,RS,B1,RS 57537 B1,078-562-896-830-87X,2018-10-31,2018,RS P20180909 A,2014-11-10,US 201361907322 P;;IB 2014065935 W;;EP 14806447 A,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS",,PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/078-562-896-830-87X,Granted Patent,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
683,WO,A1,WO 2015/075598 A1,088-281-440-817-011,2015-05-28,2015,IB 2014065935 W,2014-11-10,US 201361907322 P,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS","The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R 1 , R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/088-281-440-817-011,Patent Application,yes,77,7,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,11,0,,,"PAEZ ET AL., SCIENCE, 2004;;LYNCH ET AL., NEJM, 2004;;PAO ET AL., PNAS, 2004;;SHIGEMATSU ET AL., JNCI, 2005;;FUKUOKA ET AL., JCO, 2003;;KRIS ET AL., JAMA, 2003;;SHEPHERD ET AL., NEJM, 2004;;KOSAKA ET AL., CCR, 2006;;BALAK ET AL., CCR, 2006;;ENGELMAN ET AL., SCIENCE, 2007;;STAHL; WERMUTH: ""Properties, Selection, and Use"", 2002, WILEY-VCH",PENDING
684,AP,A0,AP 2016009219 A0,075-252-837-412-675,2016-05-31,2016,AP 2016009219 A,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS",,PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON THEODORE OTTO JR;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/075-252-837-412-675,Patent Application,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,A61P35/00;;A61K31/522;;C07D473/16;;C07D473/18;;C07D519/00,,0,0,,,,PENDING
685,US,A1,US 2015/0141402 A1,087-714-497-499-944,2015-05-21,2015,US 201414548749 A,2014-11-20,US 201414548749 A;;US 201361907322 P,2013-11-21,PURINE DERIVATIVES,"The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R 1 , R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/087-714-497-499-944,Patent Application,yes,1,8,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16,514/210.21;;544/277;;514/252.16;;514/263.2;;514/263.22,3,2,041-703-940-947-068;;029-742-983-481-795,9544425;;10.1023/a:1005960822365;;10.1126/science.286.5439.531;;10521349,"Cancer [online], [retrieved on 2007-07-06] Retrieved from the Intemet, URL: http://www.nlm.nih.gov/medlineplus/cancer.html;;Lala et al., Role of nitric oxide in tumor progression: Lessons from experimental tumors, Cancer and Metastasis Reviews (1998), 17, 91-106;;Golub et al., Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, Science (1999), Vol. 286, 531-537",ACTIVE
686,US,A1,US 2017/0302772 A1,104-076-725-975-385,2017-10-19,2017,US 201415509835 A,2014-09-29,US 2014/0058086 W,2014-09-29,FLEXIBLE DISPLAY DEVICE WITH REDUCED BEND STRESS WIRES,A conductive trace design is described that minimizes the possibility of crack initiation and propagation in conductive traces during bending. The conductive trace design has a winding trace pattern that is more resistant to the formation of cracks at high stress points in the conductive traces. The conductive trace design includes a cap that helps ensure electrical connection of the conductive trace even though one or more cracks may begin to form in the conductive portion of the conductive trace.,LG DISPLAY CO LTD,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,LG DISPLAY CO. LTD (2014-10-16);;APPLE INC (2014-10-16),https://lens.org/104-076-725-975-385,Patent Application,yes,0,20,12,12,0,G06F1/1652;;H05K1/028;;H05K1/0283;;H05K2201/09263;;H05K2201/09727;;H05K2201/10128;;G09F9/301;;H04M1/0268;;H10K59/131;;H10K77/111;;H10K2102/311;;G02F1/13452;;H05K1/028;;H05K1/0283;;H10K59/131;;G09F9/301;;G06F1/1652;;H05K1/0283;;H05K1/028;;H05K2201/10128;;H05K2201/09727;;H05K2201/09263;;H10K71/00;;H10K59/131;;H10K77/111;;H10K2102/311;;H04M1/0268,H04M1/02;;G06F1/16;;G09F9/30;;H01L51/56,,0,0,,,,ACTIVE
687,CY,T1,CY 1120478 T1,132-758-168-438-766,2019-07-10,2019,CY 181100779 T,2018-07-25,US 201361907322 P;;IB 2014065935 W,2013-11-21,"ΠΑΡΑΓΩΓΑ 2,6-ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ ΠΟΥΡΙΝΗΣ ΚΑΙ Η ΧΡΗΣΗ ΑΥΤΩΝ ΣΤΗΝ ΑΓΩΓΗ ΥΠΕΡΠΛΑΣΤΙΚΩΝ ΔΙΑΤΑΡΑΧΩΝ","Η παρούσα εφεύρεση σχετίζεται με ενώσεις του χημικού τύπου (I) ή φαρμακευτικώς αποδεκτά άλατα εξ' αυτών, όπου τα Q, G, δακτύλιος Α, δακτύλιος Β, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, και m καθορίζονται εις το παρόν. Τα καινοφανή παράγωγα πουρίνης είναι χρήσιμα στην αγωγή μη-φυσιολογικής αύξησης κυττάρων, όπως είναι ο καρκίνος, σε θηλαστικά. Επιπρόσθετες ενσωματώσεις σχετίζονται με φαρμακευτικές συνθέσεις περιέχοντας τις ενώσεις και με μεθόδους χρήσης των ενώσεων και συνθέσεων στην αγωγή μη-φυσιολογικής αύξησης κυττάρων σε θηλαστικά.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/132-758-168-438-766,Granted Patent,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
688,US,B2,US 10075573 B2,144-893-239-529-559,2018-09-11,2018,US 201415509835 A,2014-09-29,US 2014/0058086 W,2014-09-29,Flexible display device with reduced bend stress wires,A conductive trace design is described that minimizes the possibility of crack initiation and propagation in conductive traces during bending. The conductive trace design has a winding trace pattern that is more resistant to the formation of cracks at high stress points in the conductive traces. The conductive trace design includes a cap that helps ensure electrical connection of the conductive trace even though one or more cracks may begin to form in the conductive portion of the conductive trace.,LG DISPLAY CO LTD,ZHANG ZHEN;;DRZAIC PAUL STEPHEN;;KWON SEYEOUL;;YOUN SANGCHEON;;YANG HEESEOK;;LEE CHANWOO;;JO SOYOUNG;;HA ANNA;;KIM DONGYOON;;LEE SAEMLEENURI;;CHO YOONDONG,LG DISPLAY CO. LTD (2014-10-16);;APPLE INC (2014-10-16),https://lens.org/144-893-239-529-559,Granted Patent,yes,12,4,12,12,0,G06F1/1652;;H05K1/028;;H05K1/0283;;H05K2201/09263;;H05K2201/09727;;H05K2201/10128;;G09F9/301;;H04M1/0268;;H10K59/131;;H10K77/111;;H10K2102/311;;G02F1/13452;;H05K1/028;;H05K1/0283;;H10K59/131;;G09F9/301;;G06F1/1652;;H05K1/0283;;H05K1/028;;H05K2201/10128;;H05K2201/09727;;H05K2201/09263;;H10K71/00;;H10K59/131;;H10K77/111;;H10K2102/311;;H04M1/0268,H01L23/52;;G06F1/16;;G09F9/30;;H01L51/56;;H04M1/02,,3,0,,,"PCT International Search Report, PCT/US2014/058086, dated Dec. 16, 2014, 2 Pages.;;PCT Written Opinion, PCT/US2014/058086, dated Dec. 16, 2014, 5 Pages.;;Extended European Search Report for European Patent Application No. EP 14903089.2, dated Jan. 3, 2018, 9 Pages.",ACTIVE
689,ES,T3,ES 2681799 T3,179-588-819-927-675,2018-09-17,2018,ES 14806447 T,2014-11-10,US 201361907322 P;;IB 2014065935 W,2013-11-21,"Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastornos proliferativos","Un compuesto de fórmula (la): **(Ver fórmula)** en la que R1 es alquilo C1-6, alquenilo C2-C6, alquinilo C2-5 C6, cicloalquilo C3-C6, heterocicloalquilo de 4-6 miembros, o heteroarilo de 4-6 miembros, en la que el alquilo C1-C6 está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados entre el grupo que consiste en halógeno, hidroxi, y alcoxi C1-C3, además en la que el cicloalquilo C3-C6, el heterocicloalquilo de 4-6 miembros, y el heteroarilo de 4-6 miembros están, cada uno de ellos, independiente y opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados entre el grupo que consiste en alquilo C1-C3, hidroxi, y alcoxi C1-C3; el anillo A es arilo C6-C10 o heteroarilo de 5-12 miembros; cada uno de R2 y R5 independientemente está ausente o es, hidrógeno, halógeno, ciano, difluorometilo, trifluorometilo, alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, alcoxi C1-C6, -N(R10)(R11), cicloalquilo C3-C5, o heterocicloalquilo de 4-6 miembros, en la que el alquilo C1-C6 está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados entre el grupo que consiste en halógeno, hidroxi, alcoxi C1-C6, y -N(R12)(R13); R3 está ausente o es, hidrógeno, halógeno, alquilo C1-C6, alquinilo C2-C6, alcoxi C1-C6, cicloalquilo C3-C7, o heterocicloalquilo de 3-7 miembros, en la que el alquilo C1-C6 y el alcoxi C1-C6 están, cada uno de ellos, opcionalmente sustituido con uno, dos o tres grupos R14, y además en la que el cicloalquilo C3-C7 y el heterocicloalquilo de 3-7 miembros están, cada uno de ellos, opcionalmente sustituido con uno, dos o tres grupos R15; R4 está ausente o es, hidrógeno, halógeno, alquilo C1-C6, o cicloalquilo C3-C6, en la que R2 y R3 o R3 y R4 se pueden combinar para formar un anillo de cicloalquilo C5-C7 o un anillo de heterocicloalquilo de 5-7 miembros, además, en la que el anillo de cicloalquilo C5-C7 y el anillo de heterocicloalquilo de 5-7 miembros están, cada uno de ellos, independiente y opcionalmente sustituido con uno, dos o tres grupos R14; cada uno de R6 y R8 independientemente es hidrógeno, halógeno, ciano, hidroxi, difluorometilo, trifluorometilo, alquilo C1-C3, alcoxi C1-C3, o cicloalquilo C3-C5, en la que el alquilo C1-C3 está opcionalmente sustituido con hidroxi, difluorometilo, trifluorometilo, alcoxi C1-C3, o cicloalquilo C3-C5; R7 es **(Ver fórmula)** G es -NR18-; R12 y R13 son, cada uno de ellos independientemente, hidrógeno o alquilo C1-C3; R10 y R11 son, cada uno de ellos independientemente, hidrógeno o alquilo C1-C6; o R10 y R11 junto con el átomo de nitrógeno al que están unidos, se pueden combinar para formar un anillo de heterocicloalquilo de 4-7 miembros, cuando R10 y R11 son, cada uno de ellos, alquilo C1-C3, en la que el anillo de heterocicloalquilo de 4-7 miembros formado está opcionalmente sustituido con uno, dos, tres o cuatro grupos R15; cada R14 es independientemente halógeno, ciano, alquilo C1-C3, hidroxi, alcoxi C1-C6, -N(R19)(R20), - CON(R21)(R22), o heterocicloalquilo de 3-7 miembros, en la que el heterocicloalquilo de 3-7 miembros está opcionalmente sustituido con uno, dos, tres o cuatro grupos R15; cada R15 es independientemente halógeno, alquilo C1-C3, hidroxi, alcoxi C1-C6, -NH2,-NHCH3, o -N(CH3)2; cada uno de R16 y R17 son, independientemente hidrógeno o alquilo C1-C6, en la que el alquilo C1-C6 está opcionalmente sustituido con -N(R23)(R24), con la condición de que R16 y R17 pueden formar un anillo de cicloalquilo C3-C5; R18 es hidrógeno o alquilo C1-C3; cada R19, R20, R21, R22, R23, y R24 es independientemente hidrógeno o alquilo C1-C3; n es 0, 1 o 2; y p es 0, 1 o 2; o una sal farmacéuticamente aceptable del mismo.",PFIZER,BEHENNA DOUGLAS CARL;;CHENG HENGMIAO;;CHO-SCHULTZ SUJIN;;JOHNSON JR THEODORE OTTO;;KATH JOHN CHARLES;;NAGATA ASAKO;;NAIR SAJIV KRISHNAN;;PLANKEN SIMON PAUL,,https://lens.org/179-588-819-927-675,Granted Patent,no,0,0,52,52,0,C07D473/18;;C07D519/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;A61P35/00;;A61P43/00;;A61K31/519;;A61K31/52;;A61K31/5377;;A61K31/5386;;A61K45/06;;C07D403/14;;C07D473/16;;C07D473/18;;A61K2300/00;;C07D473/16;;A61K31/519;;A61K31/5377;;A61K31/52;;A61K31/5386;;C07D473/18;;C07D519/00,C07D473/16;;A61K31/522;;A61P35/00;;C07D473/18;;C07D519/00,,0,0,,,,ACTIVE
690,WO,A1,WO 2023/164297 A1,014-691-344-472-823,2023-08-31,2023,US 2023/0014147 W,2023-02-28,US 202263315046 P,2022-02-28,PROTEIN DESIGN WITH SEGMENT PRESERVATION,"A method for segment preserving protein design includes determining, within a protein structure having a first sequence of residues, one or more fixed segments and adjustable segments. The protein structure may be identified as having a desired property. A protein design computational model may be used to generate a second sequence of residues comprising at least one of a corruption and a length change to the first adjustable segment. The protein design computational model may be further used to generate a modified protein structure having the second sequence of residues. The second sequence of residues forming the modified protein structure includes the fixed segments present in the first sequence of residues. Structural and/or functional analysis may be performed to determine whether the modified protein structure also exhibits the same desired property as the protein structure. Related systems and computer program products are also provided.",GENENTECH INC;;GLIGORIJEVIC VLADIMIR;;KELOW SIMON PAUL;;LEE JAE HYEON;;PARK JI WON;;RA STEPHEN ROBERT;;WATKINS ANDREW MARTIN;;BERENBERG DANIEL;;BONNEAU RICHARD A;;CHO KYUNGHYUN,GLIGORIJEVIC VLADIMIR;;KELOW SIMON PAUL;;LEE JAE HYEON;;PARK JI WON;;RA STEPHEN ROBERT;;WATKINS ANDREW MARTIN;;BERENBERG DANIEL;;BONNEAU RICHARD A;;CHO KYUNGHYUN,,https://lens.org/014-691-344-472-823,Patent Application,yes,2,0,1,1,0,G16B40/20;;G16B15/00;;G16B30/00,G16B30/00;;G16B15/00;;G16B40/20,,1,0,,,"GLIGORIJEVIC VLADIMIR ET AL: ""Function-guided protein design by deep manifold sampling"", BIORXIV, 23 December 2021 (2021-12-23), XP093055296, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.12.22.473759v1.full.pdf> [retrieved on 20230619], DOI: 10.1101/2021.12.22.473759",PENDING
691,EP,B1,EP 1826800 B1,031-888-986-071-920,2012-03-28,2012,EP 07008029 A,1997-11-26,EP 97950630 A;;US 76647796 A;;US 76647496 A,1996-12-12,Gap jumping to seal structure,,CANON KK,FAHLEN THEODORE S;;LUDWIG PAUL N;;SCHMID ANTHONY P;;PRESSLEY ROBERT J;;CHO STEVEN T;;CONTE ALFRED S;;COOPER ANTHONY J;;POTHOVEN FLOYD R,,https://lens.org/031-888-986-071-920,Granted Patent,yes,6,1,13,16,0,B23K26/206;;C03B23/24;;H01J9/26;;H01J31/123;;H01J9/261;;H01J9/385,H01J9/26;;B23K26/32;;C03B23/24;;G09F9/00;;G09F9/30;;H01J9/24;;H01J9/385;;H01J31/12,,0,0,,,,EXPIRED
692,TW,B,TW I709647 B,084-877-913-273-328,2020-11-11,2020,TW 108100405 A,2017-01-16,US 201662280636 P;;US 201662419190 P,2016-01-19,Cancer vaccines,,PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/084-877-913-273-328,Granted Patent,no,3,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,,,0,0,,,,INACTIVE
693,US,A1,US 2017/0202938 A1,135-797-652-993-009,2017-07-20,2017,US 201715407890 A,2017-01-17,US 201715407890 A;;US 201662419190 P;;US 201662280636 P,2016-01-19,Cancer Vaccines,"The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON;;CHO HELEN KIM,,https://lens.org/135-797-652-993-009,Patent Application,yes,3,2,41,42,621,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,INACTIVE
694,MX,A,MX 2018008797 A,021-100-555-767-695,2018-11-29,2018,MX 2018008797 A,2017-01-16,US 201662280636 P;;US 201662419190 P;;IB 2017050229 W,2016-01-19,CANCER VACCINES.,"The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (b) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (c) vaccine compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,KARIN UTE JOOSS;;HELEN KIM CHO;;JOSEPH JOHN BINDER;;PAUL JASON COCKLE;;DEREK JOHN FALCONER;;SIRADANAHALLI GURU;;MARIANNE MARCELA ANDREA MARTINIC;;KENNETH NELSON WILLS,,https://lens.org/021-100-555-767-695,Patent Application,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,PENDING
695,EP,A2,EP 1826800 A2,051-505-879-249-206,2007-08-29,2007,EP 07008029 A,1997-11-26,EP 97950630 A;;US 76647796 A;;US 76647496 A,1996-12-12,Gap jumping to seal structure,"A method comprising the steps of: 
positioning a sealing area of one body near a matching sealing area of another body such that a gap at least partially separates the two sealing areas; 
initially transferring energy locally to material of a specified one of the bodies along part of the gap while the bodies are in a non-vacuum environment to cause material of the bodies to bridge that part of the gap and partially seal the bodies together along the sealing areas; and 
subsequently transferring energy locally to material of the specified body along the remainder of the gap while the bodies are in a vacuum environment to cause material of the bodies to bridge the remainder of the gap and complete sealing of the bodies together along the sealing areas.
",CANON KK,FAHLEN THEODORE S;;LUDWIG PAUL N;;SCHMID ANTHONY P;;PRESSLEY ROBERT J;;CHO STEVEN T;;CONTE ALFRED S;;COOPER ANTHONY J;;POTHOVEN FLOYD R,,https://lens.org/051-505-879-249-206,Patent Application,yes,0,2,13,16,0,B23K26/206;;C03B23/24;;H01J9/261;;H01J9/385;;H01J31/123;;H01J9/26,H01J9/26;;B23K26/32;;C03B23/24;;G09F9/00;;G09F9/30;;H01J9/24;;H01J9/385;;H01J31/12,,0,0,,,,EXPIRED
696,CA,A1,CA 2954892 A1,061-693-425-135-814,2017-07-19,2017,CA 2954892 A,2017-01-16,US 201662280636 P;;US 201662419190 P,2016-01-19,IMMUNOGENS DERIVED FROM TUMOR-ASSOCIATED ANTIGENS OR NUCLEIC ACID MOLECULES ENCODING THE IMMUNOGENS,"The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides); (b) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides; (c) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide; and (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/061-693-425-135-814,Patent Application,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,C12N15/62;;A61K39/00;;A61P35/00;;A61P37/04;;C07K14/705;;C07K19/00;;C12N9/12;;C12N15/12;;C12N15/54;;C12N15/85,,0,0,,,,PENDING
697,KR,A,KR 20210011847 A,076-544-161-207-866,2021-02-02,2021,KR 20190089236 A,2019-07-23,KR 20190089236 A,2019-07-23,CARTOMIZER AND AEROSOL GENERATING APPARATUS COMPRISING THEREOF,"A vaporizer used in an aerosol generating apparatus comprises: a heater for heating aerosol generating substances; and a liquid storage unit for storing the aerosol generating substances. As the amount of the aerosol generating substances decrease below a threshold value, temperature of the heater reaches first temperature that is above temperature at which flavoring agents in the aerosol generating substances are vaporized. When the temperature of the heater reaches the first temperature, the flavoring agents are vaporized to inform a user of replacement time of the aerosol generating substances.",KT & G CORP,LIM HUN IL;;SUNWOO PAUL JOON;;YOON SUNG WOOK;;LEE SANG CHEOL;;LEE WON KYEONG;;LEE JU HWAN;;CHO BYUNG SUNG;;HAN DAE NAM,,https://lens.org/076-544-161-207-866,Patent Application,no,4,1,2,2,0,A24F40/10;;A24B15/167;;A24B15/28;;A24F40/50;;B05B1/02,A24F47/00;;H05B1/02,,0,0,,,,ACTIVE
698,DK,T3,DK 3405212 T3,013-190-615-281-841,2020-08-24,2020,DK 17702951 T,2017-01-16,US 201662280636 P;;US 201662419190 P;;IB 2017050229 W,2016-01-19,Cancervacciner,,PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/013-190-615-281-841,Granted Patent,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,ACTIVE
699,US,A1,US 2022/0323558 A1,076-727-461-808-665,2022-10-13,2022,US 202117319395 A,2021-05-13,US 202117319395 A;;US 201916252239 A;;US 201715407890 A;;US 201662419190 P;;US 201662280636 P,2016-01-19,CANCER VACCINES,"The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON;;CHO HELEN KIM,,https://lens.org/076-727-461-808-665,Patent Application,yes,0,0,41,42,621,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00;;A61K48/00,,0,0,,,,PENDING
700,WO,A1,WO 2017/125844 A1,110-959-770-140-332,2017-07-27,2017,IB 2017050229 W,2017-01-16,US 201662280636 P;;US 201662419190 P,2016-01-19,CANCER VACCINES,"The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (b) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (c) vaccine compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/110-959-770-140-332,Patent Application,yes,54,0,41,42,621,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,26,23,049-945-652-843-70X;;035-795-780-485-784;;045-015-312-466-69X;;036-458-467-729-438;;135-122-897-849-384;;019-016-461-231-773;;009-620-944-399-00X;;018-052-579-451-52X;;042-579-622-138-602;;135-020-829-679-590;;019-947-283-191-566;;068-584-249-522-736;;043-492-354-471-517;;130-241-123-998-300;;041-520-949-838-43X;;073-748-251-847-360;;001-927-557-674-695;;035-004-930-426-63X;;084-398-389-111-34X;;124-505-688-379-135;;067-767-763-896-859;;013-528-468-895-549;;001-477-109-701-519,10.3892/ijo.2014.2717;;25354268;;10.1158/1538-7445.am2015-2512;;10.1073/pnas.93.1.136;;pmc40193;;8552591;;10.1097/qai.0b013e3181651b9d;;18209683;;10.1089/vim.2010.0056;;pmc3034638;;21319978;;10.1517/14712598.5.5.627;;15934839;;16380176;;10.1016/j.tibtech.2005.12.006;;10.1099/vir.0.83428-0;;pmc2885027;;18343847;;10.1089/hum.2008.188;;19419274;;21602908;;pmc3084703;;10.1371/journal.pone.0018556;;10.1038/sj.mt.6300142;;17375065;;pmc165450;;10.1093/nar/gkg003;;12520041;;10.2144/000112243;;16989088;;2911575;;10.1073/pnas.86.1.317;;pmc286455;;2698098;;10.1111/j.1749-6632.1989.tb27360.x;;2316280;;10.1016/0264-410x(90)90171-h;;215915;;10.1038/277108a0;;2558526;;10.1007/978-1-4757-2046-4_22;;1985215;;pmc240552;;10.1128/jvi.65.1.532-536.1991;;17606980;;10.1093/intimm/dxm057;;17640779;;10.1016/j.vaccine.2007.06.009;;15985318;;10.1016/j.vaccine.2005.05.026;;pmc6383519;;10.1007/s00262-013-1494-7;;24233342,"TANIDA TSUKASA ET AL: ""Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express alpha-gal epitopes, targets pancreatic cancer stem cells"", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 46, no. 1, January 2015 (2015-01-01), pages 78 - 90, XP002769243, ISSN: 1019-6439;;FURUKAWA KENTA ET AL: ""Abstract 2512: Novel immunotherapy using a tumor lysate vaccine with alpha-gal epitopes against pancreatic cancer"", CANCER RESEARCH, vol. 75, no. Suppl. 15, August 2015 (2015-08-01), & 106TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); PHILADELPHIA, PA, USA; APRIL 18 -22, 2015, XP002769244, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2015-2512;;CHANG ET AL., PROC NATL ACAD SCI USA, vol. 93, 1996, pages 136 - 40;;HUANG, Y.; Z. CHEN ET AL.: ""Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant"", J ACQUIR IMMUNE DEFIC SYNDR, vol. 47, no. 4, 2008, pages 403 - 411;;XU, K.; Z. Y. LING ET AL.: ""Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus"", VIRAL IMMUNOL, vol. 24, no. 1, 2011, pages 45 - 56;;SZYMCZAK, A. L.; D. A. VIGNALI: ""Development of 2A peptide-based strategies in the design of multicistronic vectors"", EXPERT OPIN BIOL THER, vol. 5, no. 5, 2005, pages 627 - 638, XP009062400, DOI: doi:10.1517/14712598.5.5.627;;DE FELIPE, P.; G. A. LUKE ET AL.: ""E unum pluribus: multiple proteins from a self-processing polyprotein"", TRENDS BIOTECHNOL, vol. 24, no. 2, 2006, pages 68 - 75, XP025052212, DOI: doi:10.1016/j.tibtech.2005.12.006;;LUKE, G. A.; P. DE FELIPE ET AL.: ""Occurrence, function and evolutionary origins of '2A-like' sequences in virus genomes"", J GEN VIROL, vol. 89, 2008, pages 1036 - 1042, XP002552736, DOI: doi:10.1099/vir.0.83428-0;;IBRAHIMI, A.; G. VANDE VELDE ET AL.: ""Highly efficient multicistronic lentiviral vectors with peptide 2A sequences"", HUM GENE THER, vol. 20, no. 8, 2009, pages 845 - 860, XP055162441, DOI: doi:10.1089/hum.2008.188;;KIM, J. H.; S. R. LEE ET AL.: ""High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice"", PLOS ONE, vol. 6, no. 4, 2011, pages E18556;;FANG, J.; S. YI ET AL.: ""An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo"", MOL THER, vol. 15, no. 6, 2007, pages 1153 - 1159, XP002560535, DOI: doi:10.1038/SJ.MT.6300142;;BONNAL, S.; C. BOUTONNET ET AL.: ""IRESdb: the Internal Ribosome Entry Site database"", NUCLEIC ACIDS RES, vol. 31, no. 1, 2003, pages 427 - 428;;BOCHKOV, Y. A.; A. C. PALMENBERG: ""Translational efficiency of EMCV IRES in bicistronic vectors is dependent upon IRES sequence and gene location"", BIOTECHNIQUES, vol. 41, no. 3, 2006, pages 283 - 284,286,288, XP001536676, DOI: doi:10.2144/000112243;;FISHER-HOCH ET AL., PNAS, vol. 86, 1989, pages 317 - 321;;FLEXNER ET AL., ANN. N.Y. ACAD. SCI., vol. 569, 1989, pages 86 - 103;;FLEXNER ET AL., VACCINE, vol. 8, 1990, pages 17 - 21;;MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108 - 114;;KIT, ADV. EXP. MED. BIOL., vol. 215, 1989, pages 219 - 236;;POZNANSKY, J. VIROL, vol. 65, 1991, pages 532 - 536;;""Liposomes: A Practical Approach"", 1990, IRL PRESS;;POWELL & NEWMAN: ""Vaccine design: the subunit and adjuvant approach"", 1995, PLENUM PRESS, article ""Chapter 10"";;OKAZAKI T ET AL., INTERNATIONAL IMMUNOLOGY, vol. 19, no. 7, 2007, pages 813 - 824;;SUNSHINE J ET AL., CURR OPIN PHARMACOL., vol. 23, August 2015 (2015-08-01), pages 32 - 8;;SHARPE, M. ET AL.: ""P. Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery"", VACCINE, vol. 25, no. 34, 2007, pages 6392 - 98, XP022169852, DOI: doi:10.1016/j.vaccine.2007.06.009;;ROBERTS LK ET AL.: ""Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device"", VACCINE, vol. 23, no. 40, 2005, pages 4867 - 78, XP005063270, DOI: doi:10.1016/j.vaccine.2005.05.026;;JOCHEMS C, CANCER IMMUNOL IMMUNOTHER, vol. 63, 2014, pages 161 - 174",PENDING
701,ES,T3,ES 2811523 T3,121-667-081-629-92X,2021-03-12,2021,ES 17702951 T,2017-01-16,US 201662280636 P;;US 201662419190 P;;IB 2017050229 W,2016-01-19,Vacunas contra el cáncer,"Un constructo de múltiples antígenos, que comprende una molécula de ácido nucleico comprendiendo: (i) al menos una secuencia de nucleótidos que codifica un polipéptido de MSLN inmunogénico; (ii) al menos una secuencia de nucleótidos que codifica un polipéptido de MUC1 inmunogénico; y (iii) al menos una secuencia de nucleótidos que codifica un polipéptido de TERT inmunogénico; en el que: (i) el polipéptido de MUC1 inmunogénico comprende la secuencia de aminoácidos seleccionada del grupo que consiste en: (1) la secuencia de aminoácidos de la SEQ ID NÚM.: 8; (2) una secuencia de aminoácidos que comprende los aminoácidos 4-537 de la SEQ ID NÚM.: 8 y (3) una secuencia de aminoácidos que comprende los aminoácidos 24-537 de la SEQ ID NÚM.: 8; (ii) el polipéptido de MSLN inmunogénico comprende (1) la secuencia de aminoácidos de la SEQ ID NÚM.: 6; o (2) una secuencia de aminoácidos que comprende los aminoácidos 4-564 de la secuencia de aminoácidos de la SEQ ID NÚM.: 6; y (iii) el polipéptido de TERT inmunogénico comprende: (1) la secuencia de aminoácidos de la SEQ ID NÚM.: 10; o (2) una secuencia de aminoácidos que comprende los aminoácidos 2-892 de la SEQ ID NÚM.: 10.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/121-667-081-629-92X,Granted Patent,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,ACTIVE
702,WO,A1,WO 1998/026440 A1,147-636-824-067-414,1998-06-18,1998,US 9721095 W,1997-11-26,US 76647796 A;;US 76647496 A,1996-12-12,GAP JUMPING TO SEAL STRUCTURE,"Portions (40 and 44) of a structure, such as a flat-panel display, are positioned such that a sealing area (40S) of one portion is at least partially separated from a corresponding sealing area (44S) of another portion such that a gap (48) at least partially separates the two sealing areas, typically by height of 25 microns or more. Energy is applied in a 'gap jumping technique' to locally heat material of at least one portion along the sealing area such that the material bridges the gap and seals the portions (40 and 44) together. A laser is typically employed to locally melt and draw the material into the gap by a combination of factors such as surface tension. A first part of the gap jumping technique may be performed in a non-vacuum environment to tack the portions together, but the gap jumping technique is typically completed in a vacuum to form an evacuated panel.",CANDESCENT TECH CORP,FAHLEN THEODORE S;;LUDWIG PAUL N;;SCHMID ANTHONY P;;PRESSLEY ROBERT J;;CHO STEVEN T;;CONTE ALFRED S;;COOPER ANTHONY J;;POTHOVEN FLOYD R,,https://lens.org/147-636-824-067-414,Patent Application,yes,4,24,13,16,0,B23K26/206;;C03B23/24;;H01J9/26;;H01J31/123;;H01J9/261;;H01J9/385,G09F9/00;;G09F9/30;;H01J9/24;;H01J9/26;;H01J31/12,,1,0,,,See also references of EP 0944912A4,PATENTED
703,US,B2,US 10251944 B2,174-891-154-387-132,2019-04-09,2019,US 201715407890 A,2017-01-17,US 201715407890 A;;US 201662419190 P;;US 201662280636 P,2016-01-19,Cancer vaccines,"The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON;;CHO HELEN KIM,,https://lens.org/174-891-154-387-132,Granted Patent,yes,51,0,41,42,638,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00;;A61K31/711;;A61K48/00;;C12N15/12;;C12N15/62,,14,13,116-350-693-343-141;;043-492-354-471-517;;068-584-249-522-736;;009-620-944-399-00X;;019-947-283-191-566;;036-458-467-729-438;;042-579-622-138-602;;135-020-829-679-590;;018-052-579-451-52X;;019-016-461-231-773;;135-122-897-849-384;;035-795-780-485-784;;049-945-652-843-70X,10815887;;10.2144/000112243;;16989088;;pmc165450;;10.1093/nar/gkg003;;12520041;;16380176;;10.1016/j.tibtech.2005.12.006;;10.1038/sj.mt.6300142;;17375065;;10.1097/qai.0b013e3181651b9d;;18209683;;10.1089/hum.2008.188;;19419274;;21602908;;pmc3084703;;10.1371/journal.pone.0018556;;10.1099/vir.0.83428-0;;pmc2885027;;18343847;;10.1517/14712598.5.5.627;;15934839;;10.1089/vim.2010.0056;;pmc3034638;;21319978;;10.1158/1538-7445.am2015-2512;;10.3892/ijo.2014.2717;;25354268,"Teresa Gilewski et al. Vaccination of high-risk Breast Cancer Patients with Mucin-1 (MUC1) Keyhole Limpet Hemocyanin Conjugate plus QS-21. Clinical Cancer Research, vol. 6, 1693-1701 (May 2000).;;International Search Report, PCT/IB2017/050229, dated Jan. 16, 2017.;;Bochkov, Y. A., et al., “Translational efficiency of EMCV IRES in bicistronic vectors is dependent upon IRES sequence and gene location,” Biotechniques, 2006, 283-292, 41(3).;;Bonnal, S., et al., “IRESdb: the Internal Ribosome Entry Site database,” Nucleic Acids Res, 2003, 427-428, 31(1).;;De Felipe, P., et al., “E unum pluribus: multiple proteins from a self-processing polyprotein,” Trends Biotechnol, 2006, 68-75, 24(2).;;Fang, J., et al., “An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo,” Mol Ther, 2007, 1153-1159, 15(6).;;Huang, Y., et al., “Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B′ recombinant,” J Acquired Immune Deficiency Syndrome, 2008, 403-411, 47(4).;;Ibrahimi, A., et al., “Highly efficient multicistronic lentiviral vectors with peptide 2A sequences,” Hum Gene Ther, 2009, 845-860, 20(8).;;Kim, J. H., et al., “High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice,” PLoS One, 2011, 6(4): e18556.;;Luke, G., et al., “Occurrence, function and evolutionary origins of ‘2A-like’ sequences in virus genomes,” J Gen Virol, 2008,1036-1042, 89(Pt 4).;;Szymczak, A. L., et al., “Development of 2A peptide-based strategies in the design of multicistronic vectors,” Expert Opin Biol Ther, 2005, 627-638, 5(5).;;Xu, K., et al., “Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus,” Viral Immunol, 2011, 45-56, 24(1).;;Furukawa, K., et al., “Abstract 2512: Novel immunotherapy using a tumor lysate vaccine with a-gal epitopes against pancreatic cancer”, AACR 106th Annual Meeting, 2015, Suppl 2512. vol. 75, Issue 15.;;Tanida, T., et al., “Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express a-gal epitopes, targets pancreatic cancer stem cells”, International Journal of Oncology, 2015, pp. 78-90, vol. 46.",INACTIVE
704,KR,A,KR 20210015529 A,194-268-303-255-573,2021-02-10,2021,KR 20190094535 A,2019-08-02,KR 20190094535 A,2019-08-02,Aerosol generating device,"The present invention relates to an aerosol generating device capable of improving the convenience of replacing a cartridge. The aerosol generating device according to an embodiment comprises: a cartridge generating aerosol from an aerosol generating material; a main body extending in one direction and including an accommodating space for accommodating the cartridge; and a support unit disposed in the accommodating space to support the cartridge, wherein the support unit is movable between the accommodating position in which the cartridge is accommodated in the accommodating space of the main body and the discharging position in which the cartridge is discharged from the accommodating space.",KT & G CORP,YOON SUNG WOOK;;SUNWOO PAUL JOON;;LEE SANG CHEOL;;LEE WON KYEONG;;LEE JU HWAN;;LIM HUN IL;;CHO BYUNG SUNG;;HAN DAE NAM,,https://lens.org/194-268-303-255-573,Patent Application,no,6,0,2,2,0,A24F40/40;;A24F40/42,A24F47/00,,0,0,,,,ACTIVE
705,KR,A,KR 20180101537 A,089-466-809-972-896,2018-09-12,2018,KR 20187023390 A,2017-01-16,US 201662280636 P;;US 201662419190 P;;IB 2017050229 W,2016-01-19,암 백신,"본 개시내용은 (a) 단리된 면역원성 TAA 폴리펩티드 (즉, 면역원성 MUC1 폴리펩티드, 면역원성 MSLN 폴리펩티드, 및 면역원성 TERT 폴리펩티드), (b) 1종 이상의 면역원성 TAA 폴리펩티드를 코딩하는 단리된 핵산 분자, (c) 면역원성 TAA 폴리펩티드 또는 면역원성 TAA 폴리펩티드를 코딩하는 단리된 핵산 분자를 포함하는 백신 조성물, 및 (d) 폴리펩티드, 핵산 분자, 및 조성물의 용도에 관련된 방법을 제공한다.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/089-466-809-972-896,Patent Application,no,1,0,41,42,1242,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00;;A61K45/06;;A61P35/00;;C07K14/47,,0,0,,,,ACTIVE
706,PL,T3,PL 3405212 T3,113-413-433-736-826,2020-11-16,2020,PL 17702951 T,2017-01-16,US 201662280636 P;;US 201662419190 P;;EP 17702951 A;;IB 2017050229 W,2016-01-19,CANCER VACCINES,,PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/113-413-433-736-826,Patent Application,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,PENDING
707,WO,A1,WO 2010/068221 A1,168-275-337-467-665,2010-06-17,2010,US 2008/0086667 W,2008-12-12,US 2008/0086667 W,2008-12-12,MEMRISTIVE DEVICE,"A memristive routing device (200) includes a memristive matrix (240), mobile dopants (255) moving with the memristive matrix (240) in response to programming electrical fields and remaining stable within the memristive matrix (240) in the absence of the programming electrical fields; and at least three electrodes (210, 220, 230) surrounding the memristive matrix (240). A method for tuning electrical circuits with a memristive device (900) includes measuring a circuit characteristic (805) and applying a programming voltage to the memristive device (900) which causes motion of dopants within the memristive device (900) to alter the circuit characteristic (805). A method for increasing a switching speed of a memristive device (1300) includes drawing dopants from two geometrically separated locations into close proximity to form two conductive regions (1380, 1390) and then switching the memristive device (1300) to a conductive state by applying a programming voltage which rapidly merges the two conductive regions (1380, 1390) to form a conductive pathway between a source electrode (1310) and a drain electrode (1320).",HEWLETT PACKARD DEVELOPMENT CO;;WU WEI;;STRACHAN JOHN PAUL;;WILLIAMS R STANLEY;;FIORENTINO MARCO;;WANG SHIH-YUAN;;QUITORIANO NATHANIEL J;;CHO HANS S;;BORGHETTI JULIEN;;MATHAI SAGI VARGHESE,WU WEI;;STRACHAN JOHN PAUL;;WILLIAMS R STANLEY;;FIORENTINO MARCO;;WANG SHIH-YUAN;;QUITORIANO NATHANIEL J;;CHO HANS S;;BORGHETTI JULIEN;;MATHAI SAGI VARGHESE,,https://lens.org/168-275-337-467-665,Patent Application,yes,3,35,3,3,0,H10B63/82;;H10N70/24;;H10N70/253;;H10N70/823;;H10N70/881;;H10N70/8833;;H10N70/883;;H10N70/8836;;H10B63/82;;H10N70/883;;H10N70/24;;H10N70/253;;H10N70/823;;H10N70/881;;H10N70/8833;;H10N70/8836,G11C16/00;;H01L21/265;;G11C16/02,,0,0,,,,PENDING
708,EP,B1,EP 3405212 B1,012-755-680-211-494,2020-07-08,2020,EP 17702951 A,2017-01-16,US 201662280636 P;;US 201662419190 P;;IB 2017050229 W,2016-01-19,CANCER VACCINES,,PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/012-755-680-211-494,Granted Patent,yes,1,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,2,0,,,"TANIDA TSUKASA ET AL: ""Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express alpha-gal epitopes, targets pancreatic cancer stem cells"", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 46, no. 1, January 2015 (2015-01), pages 78-90, XP002769243, ISSN: 1019-6439;;FURUKAWA KENTA ET AL: ""Abstract 2512: Novel immunotherapy using a tumor lysate vaccine with alpha-gal epitopes against pancreatic cancer"", CANCER RESEARCH, vol. 75, no. Suppl. 15, August 2015 (2015-08), XP002769244, & 106TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); PHILADELPHIA, PA, USA; APRIL 18 -22, 2015 ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2015-2512",ACTIVE
709,SG,A,SG 11201805621S A,075-041-489-983-681,2018-08-30,2018,SG 11201805621S A,2017-01-16,US 201662280636 P;;US 201662419190 P;;IB 2017050229 W,2016-01-19,CANCER VACCINES,,PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/075-041-489-983-681,Unknown,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,PENDING
710,JP,A,JP 2021061851 A,135-639-890-922-878,2021-04-22,2021,JP 2021000428 A,2021-01-05,US 201662280636 P;;US 201662419190 P,2016-01-19,CANCER VACCINES,"To provide (a) isolated immunogenic TAA polypeptides (i.e., immunogenic MUC1 polypeptides, immunogenic MSLN polypeptides, and immunogenic TERT polypeptides), (b) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (c) vaccine compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (d) the polypeptides, nucleic acid molecules and compositions, for use in cancer immunotherapy.SOLUTION: A multi-antigen construct comprises two sequences selected from: at least one nucleotide sequence encoding an immunogenic MUC1 polypeptide; at least one nucleotide sequence encoding an immunogenic TERT polypeptide; and at least one nucleotide sequence encoding an immunogenic MSLN polypeptide.SELECTED DRAWING: None",PFIZER,JOSEPH JOHN BINDER;;HELEN KIM CHO;;PAUL JASON COCKLE;;DEREK JOHN FALCONER;;SIRADANAHALLI GURU;;KARIN UTE JOOSS;;MARIANNE MARCELA ANDREA MARTINIC;;KENNETH NELSON WILLS,,https://lens.org/135-639-890-922-878,Patent Application,no,3,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,C12N15/12;;A61K38/02;;A61K39/00;;A61K48/00;;A61P35/00;;A61P37/04;;A61P43/00,,0,0,,,,PENDING
711,KR,A,KR 20000057499 A,176-833-986-778-045,2000-09-15,2000,KR 19997005179 A,1999-06-10,US 76647796 A;;US 76647496 A,1996-12-12,GAP JUMPING TO SEAL STRUCTURE,"PURPOSE: A technique for sealing portions of a structure is provided to readily achieve a reduced pressure state, typically a high vacuum level, without the necessity for providing the structure with an awkward pressure-reduction device, such as pump-out tubulation, that protrudes substantially beyond the remainder of the sealed structure. CONSTITUTION: Portions(40,44) of a structure, such as a flat-panel display, are positioned such that a sealing area(40S) of one portion is at least partially separated from a corresponding sealing area(44S) of another portion such that a gap(48) at least partially separates the two sealing areas, typically by height of 25 microns or more. Energy is applied in a ""gap jumping technique"" to locally heat material of at least one portion along the sealing area such that the material bridges the gap and seals the portions(40 ,44) together. A laser is typically employed to locally melt and draw the material into the gap by a combination of factors such as surface tension and capillary action. A first part of the gap jumping technique may be performed in a non-vacuum environment to tack the portions together, but the gap jumping technique is typically completed in a vacuum to form an evacuated panel",CANDESCENT TECH CORP,FAHLEN THEODORE S;;PRESSLEY ROBERT J;;LUDWIG PAUL N;;CHO STEVEN T;;CONTE ALFRED S;;COOPER ANTHONY J;;POTHOVEN FLOYD R;;SCHMID ANTHONY P,,https://lens.org/176-833-986-778-045,Patent Application,no,0,0,13,16,0,B23K26/206;;C03B23/24;;H01J9/26;;H01J31/123;;H01J9/261;;H01J9/385,G09F9/00;;G09F9/30;;H01J9/24;;H01J9/26;;H01J31/12,,0,0,,,,EXPIRED
712,CO,A2,CO 2018007442 A2,068-422-880-201-473,2018-07-31,2018,CO 2018007442 A,2018-07-16,IB 2017050229 W;;US 201662280636 P;;US 201662419190 P,2016-01-19,Vacunas contra el cáncer,"La presente divulgación proporciona (a) polipéptidos aislados de TAA inmunogénico (es decir, un polipéptido de MUC1 inmunogénico, un polipéptido de MSLN inmunogénico, y un polipéptido de TERT inmunogénico), (b) moléculas aisladas de ácido nucleico que codifican uno o más polipéptidos de TAA inmunogénico, (c) composiciones de vacuna que comprenden un polipéptido de TAA inmunogénico o una molécula aislada de ácido nucleico que codifica un polipéptido de TAA inmunogénico, y (d) métodos relacionados con los usos de los polipéptidos, moléculas de ácido nucleico y composiciones.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/068-422-880-201-473,Patent Application,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,PENDING
713,EP,A3,EP 1826800 A3,117-251-343-512-884,2009-05-13,2009,EP 07008029 A,1997-11-26,EP 97950630 A;;US 76647796 A;;US 76647496 A,1996-12-12,Gap jumping to seal structure,"A method comprising the steps of: 
positioning a sealing area of one body near a matching sealing area of another body such that a gap at least partially separates the two sealing areas; 
initially transferring energy locally to material of a specified one of the bodies along part of the gap while the bodies are in a non-vacuum environment to cause material of the bodies to bridge that part of the gap and partially seal the bodies together along the sealing areas; and 
subsequently transferring energy locally to material of the specified body along the remainder of the gap while the bodies are in a vacuum environment to cause material of the bodies to bridge the remainder of the gap and complete sealing of the bodies together along the sealing areas.
",CANON KK,FAHLEN THEODORE S;;LUDWIG PAUL N;;SCHMID ANTHONY P;;PRESSLEY ROBERT J;;CHO STEVEN T;;CONTE ALFRED S;;COOPER ANTHONY J;;POTHOVEN FLOYD R,,https://lens.org/117-251-343-512-884,Search Report,yes,6,0,13,16,0,B23K26/206;;C03B23/24;;H01J9/261;;H01J9/385;;H01J31/123;;H01J9/26,H01J9/26;;G09F9/00;;G09F9/30;;H01J9/24;;H01J31/12,,0,0,,,,EXPIRED
714,EP,A1,EP 3405212 A1,151-022-787-816-84X,2018-11-28,2018,EP 17702951 A,2017-01-16,US 201662280636 P;;US 201662419190 P;;IB 2017050229 W,2016-01-19,CANCER VACCINES,,PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/151-022-787-816-84X,Patent Application,yes,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,ACTIVE
715,HU,T2,HU E051722 T2,034-773-332-036-033,2021-03-29,2021,HU E17702951 A,2017-01-16,US 201662280636 P;;US 201662419190 P,2016-01-19,CANCER VACCINES,,PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/034-773-332-036-033,Amended Patent,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,PENDING
716,US,A1,US 2019/0142918 A1,099-885-221-204-940,2019-05-16,2019,US 201916252239 A,2019-01-18,US 201916252239 A;;US 201715407890 A;;US 201662419190 P;;US 201662280636 P,2016-01-19,CANCER VACCINES,"The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON;;CHO HELEN KIM,,https://lens.org/099-885-221-204-940,Patent Application,yes,0,0,41,42,621,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00;;A61K48/00,,0,0,,,,ACTIVE
717,SI,T1,SI 3405212 T1,004-276-766-883-023,2020-09-30,2020,SI 201730373 T,2017-01-16,US 201662280636 P;;US 201662419190 P;;IB 2017050229 W;;EP 17702951 A,2016-01-19,CANCER VACCINES,,PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/004-276-766-883-023,Granted Patent,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,ACTIVE
718,US,B2,US 8547727 B2,018-969-322-115-306,2013-10-01,2013,US 200813119932 A,2008-12-12,US 2008/0086667 W,2008-12-12,Memristive device,"A memristive routing device includes a memristive matrix, mobile dopants moving with the memristive matrix in response to programming electrical fields and remaining stable within the memristive matrix in the absence of the programming electrical fields; and at least three electrodes surrounding the memristive matrix. A method for tuning electrical circuits with a memristive device includes measuring a circuit characteristic and applying a programming voltage to the memristive device which causes motion of dopants within the memristive device to alter the circuit characteristic. A method for increasing a switching speed of a memristive device includes drawing dopants from two geometrically separated locations into close proximity to form two conductive regions and then switching the memristive device to a conductive state by applying a programming voltage which rapidly merges the two conductive regions to form a conductive pathway between a source electrode and a drain electrode.",WU WEI;;STRACHAN JOHN PAUL;;WILLIAMS R STANLEY;;FLORENTINO MARCO;;WANG SHIH-YUAN;;QUITORIANO NATHANIEL J;;CHO HANS S;;BORGHETTI JULIEN;;MATHAI SAGI VARGHESE;;HEWLETT PACKARD DEVELOPMENT CO,WU WEI;;STRACHAN JOHN PAUL;;WILLIAMS R STANLEY;;FLORENTINO MARCO;;WANG SHIH-YUAN;;QUITORIANO NATHANIEL J;;CHO HANS S;;BORGHETTI JULIEN;;MATHAI SAGI VARGHESE,HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2015-10-27);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2008-12-03),https://lens.org/018-969-322-115-306,Granted Patent,yes,7,8,3,3,0,H10B63/82;;H10N70/24;;H10N70/253;;H10N70/823;;H10N70/881;;H10N70/8833;;H10N70/883;;H10N70/8836;;H10B63/82;;H10N70/883;;H10N70/24;;H10N70/253;;H10N70/823;;H10N70/881;;H10N70/8833;;H10N70/8836,G11C11/00,365/148,2,1,178-087-288-945-345,10.1109/iedm.2005.1609383,"Sakamoto, Toshitsugu et al.; ""Three Terminal Solid-Electrolyte Nanometer Switch""; Electron Devices Meeting, 2005. IEDM Technical Digest. IEEE International; Dec. 2005; 475-478: IEEE; USA.;;Sakamoto, Toshitsugu et al.; ""NanoBridge Technology for Reconfigurable LSI"", NEC Technical Journal; 2007; 72-75; vol. 2; No. 1.",INACTIVE
719,PH,A1,PH 12018501532 A1,063-654-893-503-455,2019-05-15,2019,PH 12018501532 A,2018-07-18,US 201662280636 P;;US 201662419190 P;;IB 2017050229 W,2016-01-19,CANCER VACCINES,"The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (b) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (c) vaccine compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/063-654-893-503-455,Patent Application,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,PENDING
720,EP,B1,EP 0944912 B1,105-881-033-260-897,2009-12-16,2009,EP 97950630 A,1997-11-26,US 9721095 W;;US 76647796 A;;US 76647496 A,1996-12-12,GAP JUMPING METHOD OF SEALING PLATE STRUCTURES,,CANON KK,FAHLEN THEODORE S;;LUDWIG PAUL N;;SCHMID ANTHONY P;;PRESSLEY ROBERT J;;CHO STEVEN T;;CONTE ALFRED S;;COOPER ANTHONY J;;POTHOVEN FLOYD R,"CANON KABUSHIKI KAISHA (2007-04-25);;CANDESCENT INTELLECTUAL PROPERTY SERVICES, INC. (2002-01-16)",https://lens.org/105-881-033-260-897,Granted Patent,yes,1,0,13,16,0,B23K26/206;;C03B23/24;;H01J9/26;;H01J31/123;;H01J9/261;;H01J9/385,H01J9/26;;G09F9/00;;G09F9/30;;H01J9/24;;H01J31/12,,0,0,,,,EXPIRED
721,TW,A,TW 202111125 A,163-693-356-681-368,2021-03-16,2021,TW 109135756 A,2017-01-16,US 201662280636 P;;US 201662419190 P,2016-01-19,Cancer vaccines,"The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (b) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (c) vaccine compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/163-693-356-681-368,Patent of Addition,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,C12N15/12;;A61K39/00;;A61P35/00,,0,0,,,,PENDING
722,EP,A1,EP 3733201 A1,168-335-685-886-93X,2020-11-04,2020,EP 20175571 A,2017-01-16,US 201662280636 P;;US 201662419190 P;;EP 17702951 A;;IB 2017050229 W,2016-01-19,CANCER VACCINES,"The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (b) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (c) vaccine compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/168-335-685-886-93X,Patent Application,yes,54,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,27,22,049-945-652-843-70X;;045-015-312-466-69X;;036-458-467-729-438;;135-122-897-849-384;;019-016-461-231-773;;009-620-944-399-00X;;018-052-579-451-52X;;042-579-622-138-602;;135-020-829-679-590;;019-947-283-191-566;;068-584-249-522-736;;043-492-354-471-517;;130-241-123-998-300;;041-520-949-838-43X;;073-748-251-847-360;;001-927-557-674-695;;035-004-930-426-63X;;084-398-389-111-34X;;124-505-688-379-135;;067-767-763-896-859;;013-528-468-895-549;;001-477-109-701-519,10.3892/ijo.2014.2717;;25354268;;10.1073/pnas.93.1.136;;pmc40193;;8552591;;10.1097/qai.0b013e3181651b9d;;18209683;;10.1089/vim.2010.0056;;pmc3034638;;21319978;;10.1517/14712598.5.5.627;;15934839;;16380176;;10.1016/j.tibtech.2005.12.006;;10.1099/vir.0.83428-0;;pmc2885027;;18343847;;10.1089/hum.2008.188;;19419274;;21602908;;pmc3084703;;10.1371/journal.pone.0018556;;10.1038/sj.mt.6300142;;17375065;;pmc165450;;10.1093/nar/gkg003;;12520041;;10.2144/000112243;;16989088;;2911575;;10.1073/pnas.86.1.317;;pmc286455;;2698098;;10.1111/j.1749-6632.1989.tb27360.x;;2316280;;10.1016/0264-410x(90)90171-h;;215915;;10.1038/277108a0;;2558526;;10.1007/978-1-4757-2046-4_22;;1985215;;pmc240552;;10.1128/jvi.65.1.532-536.1991;;17606980;;10.1093/intimm/dxm057;;17640779;;10.1016/j.vaccine.2007.06.009;;15985318;;10.1016/j.vaccine.2005.05.026;;pmc6383519;;10.1007/s00262-013-1494-7;;24233342,"TANIDA TSUKASA ET AL: ""Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express alpha-gal epitopes, targets pancreatic cancer stem cells"", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 46, no. 1, January 2015 (2015-01-01), pages 78 - 90, XP002769243, ISSN: 1019-6439;;""Uniprot"", Database accession no. P15941-17;;CHANG ET AL., PROC NATL ACAD SCI USA, vol. 93, 1996, pages 136 - 40;;""Genbank"", Database accession no. AAD30037;;HUANG, Y.Z. CHEN ET AL.: ""Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant"", J ACQUIR IMMUNE DEFIC SYNDR, vol. 47, no. 4, 2008, pages 403 - 411;;XU, K.Z. Y. LING ET AL.: ""Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus"", VIRAL IMMUNOL, vol. 24, no. 1, 2011, pages 45 - 56;;SZYMCZAK, A. L.D. A. VIGNALI: ""Development of 2A peptide-based strategies in the design of multicistronic vectors"", EXPERT OPIN BIOL THER, vol. 5, no. 5, 2005, pages 627 - 638, XP055378453, DOI: 10.1517/14712598.5.5.627;;DE FELIPE, P.G. A. LUKE ET AL.: ""E unum pluribus: multiple proteins from a self-processing polyprotein"", TRENDS BIOTECHNOL, vol. 24, no. 2, 2006, pages 68 - 75, XP025052212, DOI: 10.1016/j.tibtech.2005.12.006;;LUKE, G. A.P. DE FELIPE ET AL.: ""Occurrence, function and evolutionary origins of '2A-like' sequences in virus genomes"", J GEN VIROL, vol. 89, 2008, pages 1036 - 1042, XP002552736, DOI: 10.1099/vir.0.83428-0;;IBRAHIMI, A.G. VANDE VELDE ET AL.: ""Highly efficient multicistronic lentiviral vectors with peptide 2A sequences"", HUM GENE THER, vol. 20, no. 8, 2009, pages 845 - 860, XP055162441, DOI: 10.1089/hum.2008.188;;KIM, J. H.S. R. LEE ET AL.: ""High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice"", PLOS ONE, vol. 6, no. 4, 2011, pages e18556, XP055175691, DOI: 10.1371/journal.pone.0018556;;FANG, J.S. YI ET AL.: ""An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo"", MOL THER, vol. 15, no. 6, 2007, pages 1153 - 1159, XP002560535, DOI: 10.1038/SJ.MT.6300142;;BONNAL, S.C. BOUTONNET ET AL.: ""IRESdb: the Internal Ribosome Entry Site database"", NUCLEIC ACIDS RES, vol. 31, no. 1, 2003, pages 427 - 428;;BOCHKOV, Y. A.A. C. PALMENBERG: ""Translational efficiency of EMCV IRES in bicistronic vectors is dependent upon IRES sequence and gene location"", BIOTECHNIQUES, vol. 41, no. 3, 2006, pages 283 - 284,286,288, XP001536676, DOI: 10.2144/000112243;;FISHER-HOCH ET AL., PNAS, vol. 86, 1989, pages 317 - 321;;FLEXNER ET AL., ANN. N.Y. ACAD. SCI., vol. 569, 1989, pages 86 - 103;;FLEXNER ET AL., VACCINE, vol. 8, 1990, pages 17 - 21;;MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108 - 114;;KIT, ADV. EXP. MED. BIOL., vol. 215, 1989, pages 219 - 236;;POZNANSKY, J. VIROL., vol. 65, 1991, pages 532 - 536;;""Liposomes: A Practical Approach"", 1990, IRL PRESS;;CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 745013-59-6;;OKAZAKI T ET AL., INTERNATIONAL IMMUNOLOGY, vol. 19, no. 7, 2007, pages 813 - 824;;SUNSHINE J ET AL., CURR OPIN PHARMACOL., vol. 23, August 2015 (2015-08-01), pages 32 - 8;;SHARPE, M. ET AL.: ""P. Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery"", VACCINE, vol. 25, no. 34, 2007, pages 6392 - 98, XP022169852, DOI: 10.1016/j.vaccine.2007.06.009;;ROBERTS LK ET AL.: ""Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device"", VACCINE, vol. 23, no. 40, 2005, pages 4867 - 78, XP005063270, DOI: 10.1016/j.vaccine.2005.05.026;;JOCHEMS C, CANCER IMMUNOL IMMUNOTHER, vol. 63, 2014, pages 161 - 174",DISCONTINUED
723,TW,B,TW I654302 B,023-415-415-481-299,2019-03-21,2019,TW 106101436 A,2017-01-16,US 201662280636 P;;US 201662419190 P,2016-01-19,Cancer vaccines,,PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/023-415-415-481-299,Granted Patent,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,,,0,0,,,,INACTIVE
724,EP,A4,EP 0944912 A4,051-450-986-681-699,2003-07-16,2003,EP 97950630 A,1997-11-26,US 9721095 W;;US 76647796 A;;US 76647496 A,1996-12-12,GAP JUMPING TO SEAL STRUCTURE,,CANDESCENT INTELLECTUAL PROP,FAHLEN THEODORE S;;LUDWIG PAUL N;;SCHMID ANTHONY P;;PRESSLEY ROBERT J;;CHO STEVEN T;;CONTE ALFRED S;;COOPER ANTHONY J;;POTHOVEN FLOYD R,"CANON KABUSHIKI KAISHA (2007-04-25);;CANDESCENT INTELLECTUAL PROPERTY SERVICES, INC. (2002-01-16)",https://lens.org/051-450-986-681-699,Search Report,no,6,0,13,16,0,B23K26/206;;C03B23/24;;H01J9/26;;H01J31/123;;H01J9/261;;H01J9/385,G09F9/00;;G09F9/30;;H01J9/24;;H01J9/26;;H01J31/12,,1,0,,,See also references of WO 9826440A1,EXPIRED
725,KR,A,KR 20200109395 A,072-704-542-637-178,2020-09-22,2020,KR 20207026620 A,2017-01-16,US 201662280636 P;;US 201662419190 P;;IB 2017050229 W,2016-01-19,CANCER VACCINES,"본 개시내용은 (a) 단리된 면역원성 TAA 폴리펩티드 (즉, 면역원성 MUC1 폴리펩티드, 면역원성 MSLN 폴리펩티드, 및 면역원성 TERT 폴리펩티드), (b) 1종 이상의 면역원성 TAA 폴리펩티드를 코딩하는 단리된 핵산 분자, (c) 면역원성 TAA 폴리펩티드 또는 면역원성 TAA 폴리펩티드를 코딩하는 단리된 핵산 분자를 포함하는 백신 조성물, 및 (d) 폴리펩티드, 핵산 분자, 및 조성물의 용도에 관련된 방법을 제공한다.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/072-704-542-637-178,Patent Application,no,0,0,41,42,1242,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00;;A61K45/06;;A61P35/00;;C07K14/47,,0,0,,,,DISCONTINUED
726,BR,A2,BR 112018013967 A2,119-291-373-803-585,2019-02-05,2019,BR 112018013967 A,2017-01-16,IB 2017050229 W;;US 201662280636 P;;US 201662419190 P,2016-01-19,vacinas contra o câncer,"a presente invenção se refere a (a) polipeptídeos taa imunogênicos isolados (isto é, um polipeptídeo muc1 imunogênico, um polipeptídeo msln imunogênico e um polipeptídeo tert imunogêni-co), (b) moléculas de ácido nucleico isoladas codificando um ou mais polipeptídeos taa imunogênicos, (c) composições de vacina compreendendo um polipeptídeo taa imunogênico ou uma molécula de ácido nucleico isolada codificando um polipeptídeo taa imunogênico, e (d) métodos relacionados a usos dos polipeptídeos, moléculas de ácido nucleico e composições.",PFIZER,DEREK JOHN FALCONER;;HELEN KIM CHO;;JOSEPH JOHN BINDER;;KARIN UTE JOOSS;;KENNETH NELSON WILLS;;MARIANNE MARCELA ANDREA MARTINIC;;PAUL JASON COCKLE;;SIRADANAHALLI GURU,,https://lens.org/119-291-373-803-585,Patent Application,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,DISCONTINUED
727,AU,A1,AU 2017/208848 A1,029-185-391-028-509,2018-07-12,2018,AU 2017/208848 A,2017-01-16,US 201662280636 P;;US 201662419190 P;;IB 2017050229 W,2016-01-19,Cancer vaccines,"The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (b) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (c) vaccine compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/029-185-391-028-509,Patent Application,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,DISCONTINUED
728,RU,C2,RU 2718663 C2,040-400-561-455-894,2020-04-13,2020,RU 2018126487 A,2017-01-16,US 201662280636 P;;US 201662419190 P;;IB 2017050229 W,2016-01-19,ANTICANCER VACCINES,"FIELD: biotechnology.SUBSTANCE: invention relates to the field of biotechnology. Disclosed is a multi-agent structure inducing an immune response against a cancer cell in a mammal, as well as a vector, a composition, a pharmaceutical composition and a method of treating cancer.EFFECT: invention can be used in medicine to increase the immune response to cancer.51 cl, 20 tbl, 7 ex",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/040-400-561-455-894,Granted Patent,no,2,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,1,0,,,"TSUKASA TANIDA et al. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells. Cancer Research 72(8 Supplement): 1559-1559. June 2012. DOI: 10.1158/1538-7445.AM2012-1559.",ACTIVE
729,CN,A,CN 108778321 A,157-916-351-968-704,2018-11-09,2018,CN 201780018354 A,2017-01-16,US 201662280636 P;;US 201662419190 P;;IB 2017050229 W,2016-01-19,CANCER VACCINES,"The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (b) isolatednucleic acid molecules encoding one or more immunogenic TAA polypeptides, (c) vaccine compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/157-916-351-968-704,Patent Application,no,6,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00,,0,0,,,,DISCONTINUED
730,DE,D1,DE 69739707 D1,022-250-091-193-637,2010-01-28,2010,DE 69739707 T,1997-11-26,US 76647796 A;;US 76647496 A;;US 9721095 W,1996-12-12,SPALTSPRUNGVERFAHREN ZUR ABDICHTUNG VON PLATTENSTRUKTUREN,,CANON KK,FAHLEN THEODORE S;;LUDWIG PAUL N;;SCHMID ANTHONY P;;PRESSLEY ROBERT J;;CHO STEVEN T;;CONTE ALFRED S;;COOPER ANTHONY J;;POTHOVEN FLOYD R,,https://lens.org/022-250-091-193-637,Granted Patent,no,0,0,13,16,0,B23K26/206;;C03B23/24;;H01J9/26;;H01J31/123;;H01J9/261;;H01J9/385,H01J9/26;;G09F9/00;;G09F9/30;;H01J9/24;;H01J31/12,,0,0,,,,EXPIRED
731,TW,A,TW 201738377 A,128-188-331-478-48X,2017-11-01,2017,TW 106101436 A,2017-01-16,US 201662280636 P;;US 201662419190 P,2016-01-19,Cancer vaccines,"The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (b) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (c) vaccine compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/128-188-331-478-48X,Patent of Addition,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,C12N15/12;;A61K39/00;;A61P35/00,,0,0,,,,INACTIVE
732,TW,A,TW 201932598 A,162-124-520-681-639,2019-08-16,2019,TW 108100405 A,2017-01-16,US 201662280636 P;;US 201662419190 P,2016-01-19,Cancer vaccines,"The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (b) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (c) vaccine compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;CHO HELEN KIM;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON,,https://lens.org/162-124-520-681-639,Patent of Addition,no,0,0,41,42,0,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,C12N15/12;;A61K39/00;;A61P35/00,,0,0,,,,INACTIVE
733,EP,A1,EP 0944912 A1,048-113-019-884-786,1999-09-29,1999,EP 97950630 A,1997-11-26,US 9721095 W;;US 76647796 A;;US 76647496 A,1996-12-12,GAP JUMPING METHOD OF SEALING PLATE STRUCTURES,,CANDESCENT TECH CORP,FAHLEN THEODORE S;;LUDWIG PAUL N;;SCHMID ANTHONY P;;PRESSLEY ROBERT J;;CHO STEVEN T;;CONTE ALFRED S;;COOPER ANTHONY J;;POTHOVEN FLOYD R,"CANON KABUSHIKI KAISHA (2007-04-25);;CANDESCENT INTELLECTUAL PROPERTY SERVICES, INC. (2002-01-16)",https://lens.org/048-113-019-884-786,Patent Application,yes,0,1,13,16,0,B23K26/206;;C03B23/24;;H01J9/26;;H01J31/123;;H01J9/261;;H01J9/385,G09F9/00;;G09F9/30;;H01J9/24;;H01J9/26;;H01J31/12,,0,0,,,,EXPIRED
734,US,B2,US 11058753 B2,194-929-502-142-091,2021-07-13,2021,US 201916252239 A,2019-01-18,US 201916252239 A;;US 201715407890 A;;US 201662419190 P;;US 201662280636 P,2016-01-19,Cancer vaccines,"The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.",PFIZER,BINDER JOSEPH JOHN;;COCKLE PAUL JASON;;FALCONER DEREK JOHN;;GURU SIRADANAHALLI;;JOOSS KARIN UTE;;MARTINIC MARIANNE MARCELA ANDREA;;WILLS KENNETH NELSON;;CHO HELEN KIM,,https://lens.org/194-929-502-142-091,Granted Patent,yes,47,0,41,42,638,A61K31/711;;C12N15/62;;A61K39/0011;;A61K2039/53;;A61P1/18;;A61P15/00;;A61P35/00;;A61P37/04;;A61P43/00;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70;;A61K31/711;;A61K39/00117;;A61K48/005;;A61P35/00;;C12N15/62;;A61P35/00;;A61K39/00117;;A61K45/06;;C07K14/4727;;A61K2039/53;;A61K2039/585;;A61K2039/575;;A61K2039/70;;A61K2039/812;;A61K2039/852;;A61K2039/892;;A61K39/001157;;A61K39/0011;;A61K39/00;;A61K39/0011;;A61K39/001157;;A61K39/00117;;A61K48/005;;A61K31/711;;C12N15/62;;A61K39/001157;;A61K39/00117;;A61K39/0011;;A61K2039/53;;A61K2039/57;;A61K2039/575;;A61K2039/585;;A61K2039/70,A61K39/00;;A61K31/711;;A61K48/00;;C12N15/62,,13,13,043-492-354-471-517;;068-584-249-522-736;;009-620-944-399-00X;;019-947-283-191-566;;036-458-467-729-438;;042-579-622-138-602;;135-020-829-679-590;;018-052-579-451-52X;;019-016-461-231-773;;135-122-897-849-384;;035-795-780-485-784;;049-945-652-843-70X;;116-350-693-343-141,10.2144/000112243;;16989088;;pmc165450;;10.1093/nar/gkg003;;12520041;;16380176;;10.1016/j.tibtech.2005.12.006;;10.1038/sj.mt.6300142;;17375065;;10.1097/qai.0b013e3181651b9d;;18209683;;10.1089/hum.2008.188;;19419274;;21602908;;pmc3084703;;10.1371/journal.pone.0018556;;10.1099/vir.0.83428-0;;pmc2885027;;18343847;;10.1517/14712598.5.5.627;;15934839;;10.1089/vim.2010.0056;;pmc3034638;;21319978;;10.1158/1538-7445.am2015-2512;;10.3892/ijo.2014.2717;;25354268;;10815887,"Bochkov, Y. A., et al., “Translational efficiency of EMCV IRES in bicistronic vectors is dependent upon IRES sequence and gene location,” Biotechniques, 2006, 283-292, 41(3).;;Bonnal, S., et al., “IRESdb: the Internal Ribosome Entry Site database,” Nucleic Acids Res, 2003, 427-428, 31(1).;;De Felipe, P., et al., “E unum pluribus: multiple proteins from a self-processing polyprotein,” Trends Biotechnol, 2006, 68-75, 24(2).;;Fang, J., et al., “An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo,” Mol Ther, 2007, 1153-1159, 15(6).;;Huang, Y., et al., “Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B′ recombinant,” J Acquired Immune Deficiency Syndrome, 2008, 403-411, 47(4).;;Ibrahimi, A., et al., “Highly efficient multicistronic lentiviral vectors with peptide 2A sequences,” Hum Gene Ther, 2009, 845-860, 20(8).;;Kim, J. H., et al., “High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice,” PLoS One, 2011, 6(4): e18556.;;Luke, G., et al., “Occurrence, function and evolutionary origins of ‘2A-like’ sequences in virus genomes,” J Gen Virol, 2008,1036-1042, 89(Pt 4).;;Szymczak, A. L., et al., “Development of 2A peptide-based strategies in the design of multicistronic vectors,” Expert Opin Biol Ther, 2005, 627-638, 5(5).;;Xu, K., et al., “Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus,” Viral Immunol, 2011, 45-56, 24(1).;;Furukawa, K., et al., “Abstract 2512: Novel immunotherapy using a tumor lysate vaccine with a-gal epitopes against pancreatic cancer”, AACR 106th Annual Meeting, 2015, Suppl 2512. vol. 75, Issue 15.;;Tanida, T., et al., “Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express a-gal epitopes, targets pancreatic cancer stem cells”, International Journal of Oncology, 2015, pp. 78-90, vol. 46.;;Gilewski, T., et al. Vaccination of high-risk Breast Cancer Patients with Mucin-1 (MUC1) Keyhole Limpet Hemocyanin Conjugate plus QS-21. Clinical Cancer Research, vol. 6, 1693-1701 (May 2000).",ACTIVE
735,US,B2,US 10314620 B2,062-231-121-359-130,2019-06-11,2019,US 201715677310 A,2017-08-15,US 201715677310 A;;FR 0611198 A;;US 201514642752 A;;US 95828507 A,2006-12-21,Vertebral support device,"A vertebral support device ( 1 ) is disclosed, which in various embodiments comprises at least two osseous anchoring implants ( 2 ), each designed to be anchored to a vertebra, and at least one linking element ( 3 ) fixed to the osseous anchoring implants ( 2 ) by fasteners ( 20 ) that maintain a fixed angle between the longitudinal axis (L) of the linking element ( 3 ) passing through rigid elements ( 34 ) of the linking element ( 3 ) and the insertion axis (DV) of the implants ( 2 ). The linking element ( 3 ) includes at least one elastic dampening element ( 31 ) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element ( 31 ) accommodates the stresses imposed on the linking element ( 3 ) during movement of the vertebrae and tends to return the support device ( 1 ) to its normal configuration.",LDR MEDICAL,CHO PAUL;;DAVIS REGINALD;;HOFFMAN GREGORY;;MCGEE ALAN;;WILLIAMS JOHN;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM D;;JODAITIS ALEXANDRE;;CHATAIGNER HERVE;;BENITEZ HUGO SANTOS;;ZHONGQIANG CHEN,,https://lens.org/062-231-121-359-130,Granted Patent,yes,141,0,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,51,1,058-543-518-073-972,pmc3611570;;10.1007/s00586-002-0438-2;;12384741,"“U.S. Appl. No. 11/958,285, Applicant's Summary of Examiner Interview filed Jan. 27, 2015”, 3 pgs.;;“U.S. Appl. No. 11/958,285, Final Office Action dated Sep. 19, 2012”, 23 pgs.;;“U.S. Appl. No. 11/958,285, Non Final Office Action dated Mar. 5, 2014”, 28 pgs.;;“U.S. Appl. No. 11/958,285, Non Final Office Action dated Dec. 12, 2011”, 24 pgs.;;“U.S. Appl. No. 11/958,285, Notice of Allowance dated Oct. 28, 2014”, 11 pgs.;;“U.S. Appl. No. 11/958,285, Response filed Mar. 19, 2013 to Final Office Action dated Sep. 19, 2012”, 17 pgs.;;“U.S. Appl. No. 11/958,285, Response filed Jun. 12, 2012 to Non Final Office Action dated Dec. 12, 2011”, 18 pgs.;;“U.S. Appl. No. 11/958,285, Response filed Sep. 5, 2014 to Non Final Office Action dated Mar. 5, 2014”, 17 pgs.;;“U.S. Appl. No. 11/958,285, Response filed Oct. 26, 2011 to Restriction Requirement dated Apr. 26, 2011”, 15 pgs.;;“U.S. Appl. No. 11/958,285, Restriction Requirement dated Apr. 26, 2011”, 9 pgs.;;“Australian Application Serial No. 2007337793, Examiner First Report dated Feb. 14, 2012”, 1 pg.;;“Australian Application Serial No. 2007337793, Response filed Feb. 13, 2013 to Examiner First Report dated Feb. 14, 2012”, 28 pgs.;;“Canadian Application Serial No. 2,669,905, Examiner's Rule 30(2) Requisition dated Oct. 23, 2013”, 2 pgs.;;“Canadian Application Serial No. 2,669,905, Response filed Apr. 23, 2014 to Examiner's Rule 30(2) Requisition dated Oct. 23, 2013”, 15 pgs.;;“Canadian Application Serial No. 2,669,905, Voluntary Amendment filed Nov. 24, 2014”, 23 pgs.;;“Dynesys® Dynamic Stabilization System”, Zimmer Spine, (Jul. 21, 2005).;;“Dynesys® Spine Stabilization System”, University of Pittsburg; Internet, (accessed Oct. 2, 2006).;;“European Application Serial No. 07866577.5, Communication Pursuant to Article 94(3) EPC dated Jan. 16, 2017”, 5 pgs.;;“European Application Serial No. 07866577.5, Communication Pursuant to Article 94(3) EPC dated Sep. 5, 2017”, 6 pgs.;;“European Application Serial No. 07866577.5, Intention to Grant dated Jun. 28, 2018”, 90 pgs.;;“European Application Serial No. 07866577.5, Response filed Mar. 15, 2018 to Communication Pursuant to Article 94(3) EPC dated Sep. 5, 2017”, 16 pgs.;;“European Application Serial No. 07866577.5, Response filed Jun. 7, 2017 to Communication Pursuant to Article 94(3) EPC dated Jan. 16, 2017”, 23 pgs.;;“International Application Serial No. PCT/IB2007/004061, International Preliminary Report on Patentability dated Jan. 15, 2009”, 4 pgs.;;“International Application Serial No. PCT/IB2007/004061, International Search Report dated Sep. 18, 2004”, 3 pgs.;;“The Concept of “Flexible Stabilization””, The Burton Report (Internet) (Dynamic Spine Stabilization), Burtonreport.com, (accessed Oct. 2, 2006).;;“U.S. Food and Drug Administration; 510(k) 031511”, U.S. Food and Drug Administration; USA, (Mar. 5, 2004).;;“U.S. Food and Drug Administration; 510(k) 043565”, U.S. Food and Drug Administration, (Mar. 11, 2005).;;“U.S. Food and Drug Administration; 510(k) 060638”, U.S. Food and Drug Administration, USA, (Apr. 6, 2006).;;Eberlein, R., “FEA of a Spinal Implant, Human Intervertebral Discs and the Human Lumbar Spine-Relevance for the Business Process”, Sulzer Innotec; Vienna, Austria, (Jun. 12, 2002).;;Foley, Kevin T, et al., “Design and Testing of a Novel Posterior Dynamic Stabilization Device”, !MAST Athens Greece, (Jul. 12-15, 2006).;;Stoll, Thomas M, et al., “The dynamic neutralization system for the spine: a multi-center study of a novel non-fusion system”, European Spine Journal, (Sep. 10, 2002).;;Zimmer Spine, “Dynesys® Dynamic Stabilization System: A Guide for Patients”, Zimmer Spine, USA, (Jul. 21, 2005).;;“U.S. Appl. No. 14/642,752, Applicant's Summary of Examiner Interview filed Jul. 3, 2017”, 2 pgs.;;“U.S. Appl. No. 14/642,752, Corrected Notice of Allowance dated May 2, 2017”, 4 pgs.;;“U.S. Appl. No. 14/642,752, Final Office Action dated May 6, 2016”, 25 pgs.;;“U.S. Appl. No. 14/642,752, Non Final Office Action dated Sep. 24, 2015”, 15 pgs.;;“U.S. Appl. No. 14/642,752, Notice of Allowance dated Apr. 3, 2017”, 12 pgs.;;“U.S. Appl. No. 14/642,752, Notice of Allowance dated Apr. 24, 2017”, 6 pgs.;;“U.S. Appl. No. 14/642,752, Notice of Non-Compliant Amendment dated Feb. 12, 2016”, 2 pgs.;;“U.S. Appl. No. 14/642,752, Response filed Jan. 25, 2016 to Non Final Office Action dated Sep. 24, 2015”, 13 pgs.;;“U.S. Appl. No. 14/642,752, Response filed Apr. 12, 2016 to Notice of Non-Compliant Amendment dated Feb. 12, 2016”, 13 pgs.;;“U.S. Appl. No. 14/642,752, Response filed Aug. 8, 2016 to Final Office Action dated May 6, 2016”, 11 pgs.;;“U.S. Appl. No. 14/642,752, Response filed Sep. 15, 2015 to Restriction Requirement dated May 15, 2015”, 8 pgs.;;“U.S. Appl. No. 14/642,752, Restriction Requirement dated May 15, 2015”, 7 pgs.;;“U.S. Appl. No. 14/642,752, Supplemental Preliminary Amendment filed Nov. 8, 2016”, 16 pgs.;;“Definition of abut”, [Online] Retrieved from the internet: <http://www/thefreedictionary.com/abut>, (accessed May 2, 2016).;;“Definition of unitarily”, [Online] Retrieved from the internet: <http://www.thefreedictionary.com/unitarily>, (accessed May 2, 2016).;;“Japanese Application Serial No. 2009-542260, Decision to Grant dated Jun. 7, 2013”.;;“Japanese Application Serial No. 2009-542260, Notification of Reasons for Refusal dated Jun. 15, 2012”.;;“Japanese Application Serial No. 2009-542260, Written Argument and Written Amendment filed Dec. 19, 2012”.;;“Openjurist”, [Online] Retrieved from the internet: <http://openjurist.org/127/f3d/1048/in-re-charles-p-morris>, (accessed Feb. 21, 2015).",INACTIVE
736,US,B2,US 8974497 B2,175-223-377-377-866,2015-03-10,2015,US 95828507 A,2007-12-17,FR 0611198 A,2006-12-21,Vertebral support device,"A vertebral support device ( 1 ) is disclosed, which in various embodiments comprises at least two osseous anchoring implants ( 2 ), each designed to be anchored to a vertebra, and at least one linking element ( 3 ) fixed to the osseous anchoring implants ( 2 ) by fasteners ( 20 ) that maintain a fixed angle between the longitudinal axis (L) of the linking element ( 3 ) passing through rigid elements ( 34 ) of the linking element ( 3 ) and the insertion axis (DV) of the implants ( 2 ). The linking element ( 3 ) includes at least one elastic dampening element ( 31 ) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element ( 31 ) accommodates the stresses imposed on the linking element ( 3 ) during movement of the vertebrae and tends to return the support device ( 1 ) to its normal configuration.",CHO PAUL;;DAVIS REGINALD;;HOFFMAN GREGORY;;MCGEE ALAN;;WILLIAMS JOHN;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM D;;JODAITIS ALEXANDRE;;CHATAIGNER HERVE;;BENITEZ HUGO SANTOS;;ZHONGQIANG CHEN;;LDR MEDICAL,CHO PAUL;;DAVIS REGINALD;;HOFFMAN GREGORY;;MCGEE ALAN;;WILLIAMS JOHN;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM D;;JODAITIS ALEXANDRE;;CHATAIGNER HERVE;;BENITEZ HUGO SANTOS;;ZHONGQIANG CHEN,LDR MEDICAL (2013-06-19),https://lens.org/175-223-377-377-866,Granted Patent,yes,109,24,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,606/255;;606/259;;606/254,46,1,058-543-518-073-972,pmc3611570;;10.1007/s00586-002-0438-2;;12384741,"World Intellectual Property Organization; International Preliminary Report on Patentability for International Application No. PCT/IB2007/004061; Jan. 15, 2009; WIPO; Geneva, Switzerland; all pages.;;World Intellectual Property Organization; International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/IB2007/004061; Sep. 18, 2008; WIPO; Geneva, Switzerland; all pages.;;Implant for Osseous Anchoring with Polyaxial Head, U.S. Appl. No. 10/498,234, filed Dec. 7, 2004.;;Intervertebral Disc Prosthesis and Instrumentation for Insertion of the Prosthesis Between the Vertebrae, U.S. Appl. No. 11/362,253, filed Feb. 24, 2006.;;Vertebral Support Device, U.S. Appl. No. 11/958,285, filed Dec. 17, 2007.;;Intervertebral disc prosthesis, surgical methods, and fitting tools, U.S. Appl. No. 12/025,677, filed Feb. 4, 2008.;;Intervertebral Disc Prosthesis, U.S. Appl. No. 12/955,898, filed Nov. 29, 2010.;;Instruments and Methods for Removing Fixation Devices from Intervertebral Implants, U.S. Appl. No. 13/158,761, filed Jun. 13, 2011.;;Intervertebral Disc Prosthesis, U.S. Appl. No. 13/215,123, filed Aug. 22, 2011.;;Vertebral Cage Device With Modular Fixation, U.S. Appl. No. 13/438,352, filed Apr. 3, 2012.;;Plate for osteosynthesis device and method of preassembling such device, U.S. Appl. No. 13/454,927, filed Apr. 24, 2012.;;Anchoring Device and System for an Intervertebral Implant, Intervertebral Implant and Implantation Instrument, U.S. Appl. No. 13/520,041, filed Jun. 29, 2012.;;Anchoring Device and System for an Intervertebral Implant, Intervertebral Implant and Implantation Instrument, U.S. Appl. No. 13/538,078, filed Jun. 29, 2012.;;Transforaminal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage, U.S. Appl. No. 13/585,063, filed Aug. 14, 2012.;;Intervertebral Disc Prosthesis, U.S. Appl. No. 13/603,043, filed Sep. 4, 2012.;;Intersomatic cage, intervertebral prosthesis, anchoring device and implantation instruments, U.S. Appl. No. 13/732,244, filed Dec. 31, 2012.;;Anchoring device and system for an intervertebral implant, intervertebral implant and implantation instrument, U.S. Appl. No. 13/774,547, filed Feb. 22, 2013.;;Transforanimal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage, U.S. Appl. No. 13/854,808, filed Apr. 1, 2013.;;Spinal Osteosynthesis Device and Preparation Method, U.S. Appl. No. 13/873,190, filed Apr. 29, 2013.;;Instrumentation and Methods for Inserting an Intervertebral Disc Prosthesis, U.S. Appl. No. 13/892,933, filed May 13, 2013.;;Intervertebral disc prosthesis insertion assemblies, U.S. Appl. No. 13/919,704, filed Jun. 17, 2013.;;Interspinous Implant and Implantation Instrument, U.S. Appl. No. 14/130,286, filed Dec. 31, 2013.;;Intersomatic cage with unified grafts, U.S. Appl. No. 14/149,357, filed Jan. 7, 2014.;;Nucleus Prostheses, U.S. Appl. No. 14/159,161, filed Jan. 20, 2014.;;Intervertebral disc prosthesis insertion assemblies, U.S. Appl. No. 14/242,177, filed Apr. 1, 2014.;;Vertebral implant, vertebral fastening device of the implant and implant instrumentation, U.S. Appl. No. 14/246,442, filed Apr. 7, 2014.;;Interspinous Implant and Implantation Instrument, U.S. Appl. No. 14/252,754, filed Apr. 14, 2014.;;Anchoring device for a spinal implant, spinal implant and implantation instrumentation, U.S. Appl. No. 14/252,852, filed Apr. 15, 2014.;;Intervertebral Disk Prosthesis, U.S. Appl. No. 14/306,785, filed Jun. 17, 2014.;;Intervertebral Disc Prosthesis and Instrumentation for Insertion of the Prosthesis Between the Vertebrae, U.S. Appl. No. 14/325,317, filed Jul. 7, 2014.;;Anchoring device and system for an intervertebral implant, intervertebral implant and implantation instrument, U.S. Appl. No. 14/380,714, filed Aug. 23, 2014.;;Osseous anchoring implant with a polyaxial head and method for installing the implant, U.S. Appl. No. 14/497,321, filed Sep. 26, 2014.;;National Institute of Industrial Property (France); Search Report in Fench Pub. No. FR2910267; Dec. 18, 2007; National Institute of Industrial Property (France); France; all pages.;;World Intellectual Property Organization; International Preliminary Report on Patentability for PCT Pub'n No. WO 2008/078163; Jan. 15, 2009; WIPO; Geneva, Switzerland; all pages.;;World Intellectual Property Organization; Written Opinion of the International Searching Authority for PCT Pub'n No. WO 2008/078163; Sep. 18, 2008; WIPO; Geneva, Switzerland; all pages.;;World Intellectual Property Organization; International Search Report for PCT Pub'n No. WO 2008/078163; Sep. 18, 2008; WIPO; Geneva, Switzerland; all pages.;;Zimmer Spine; Dynesys® Dynamic Stabilization System: A Guide for Patients; Jul. 21, 2005; Zimmer Spine; USA; all pages.;;R. Eberlein; FEA of a Spinal Implant, Human Intervertebral Discs and the Human Lumbar Spine-Relevance for the Business Process; Jun. 12, 2002; Sulzer Innotec; Vienna, Austria; all pages.;;University of Pittsburg; Dynesys® Spine Stabilization System; accessed Oct. 2, 2006; University of Pittsburg; Internet; all pages.;;Zimmer Spine; Dynesys® Dynamic Stabilization System; Jul. 21, 2005; Zimmer Spine; Internet; all pages.;;Thomas M. Stoll, et al.; The dynamic neutralization system for the spine: a multi-center study of a novel non-fusion system; Sep. 10, 2002; European Spine Journal; Internet; all pages.;;Burtonreport.com; The Concept of ""Flexible Stabilization"" (Dynamic Spine Stabilization); accessed Oct. 2, 2006; Internet; all pages.;;Kevin T. Foley, et al.; Design and Testing of a Novel Posterior Dynamic Stabilization Device; Jul. 12-15, 2006; IMAST; Athens, Greece; all pages.;;U.S. Food and Drug Administration; 510(k) 031511; Mar. 5, 2004; U.S. Food and Drug Administration; USA; all pages.;;U.S. Food and Drug Administration; 510(k) 043565; Mar. 11, 2005; U.S. Food and Drug Administration; USA; all pages.;;U.S. Food and Drug Administration; 510(k) 060638; Apr. 6, 2006; U.S. Food and Drug Administration; USA; all pages.",INACTIVE
737,US,A1,US 2015/0182259 A1,179-431-330-637-829,2015-07-02,2015,US 201514642752 A,2015-03-10,US 201514642752 A;;FR 0611198 A;;US 95828507 A,2006-12-21,Vertebral Support Device,"A vertebral support device ( 1 ) is disclosed, which in various embodiments comprises at least two osseous anchoring implants ( 2 ), each designed to be anchored to a vertebra, and at least one linking element ( 3 ) fixed to the osseous anchoring implants ( 2 ) by fasteners ( 20 ) that maintain a fixed angle between the longitudinal axis (L) of the linking element ( 3 ) passing through rigid elements ( 34 ) of the linking element ( 3 ) and the insertion axis (DV) of the implants ( 2 ). The linking element ( 3 ) includes at least one elastic dampening element ( 31 ) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element ( 31 ) accommodates the stresses imposed on the linking element ( 3 ) during movement of the vertebrae and tends to return the support device ( 1 ) to its normal configuration.",LDR MEDICAL,CHO PAUL;;DAVIS REGINALD;;HOFFMAN GREGORY;;MCGEE ALAN;;WILLIAMS JOHN;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM D;;JODAITIS ALEXANDRE;;CHATAIGNER HERVE;;BENITEZ HUGO SANTOS;;ZHONGQIANG CHEN,LDR MEDICAL (2013-06-19),https://lens.org/179-431-330-637-829,Patent Application,yes,11,7,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,3,0,,,"http://www.thefreedictionary.com/abut, definition of ""abut"", accessed 5/2/2016;;http://www.thefreedictionary.com/unitarily, definition of ""unitarily"", accessed 5/2/2016;;http://openjurist.org/127/f3d/1048/in-re-charles-p-morris, accessed 2/21/2015",ACTIVE
738,US,A1,US 2018/0036038 A1,070-113-438-666-836,2018-02-08,2018,US 201715677310 A,2017-08-15,US 201715677310 A;;FR 0611198 A;;US 201514642752 A;;US 95828507 A,2006-12-21,Vertebral Support Device,"A vertebral support device ( 1 ) is disclosed, which in various embodiments comprises at least two osseous anchoring implants ( 2 ), each designed to be anchored to a vertebra, and at least one linking element ( 3 ) fixed to the osseous anchoring implants ( 2 ) by fasteners ( 20 ) that maintain a fixed angle between the longitudinal axis (L) of the linking element ( 3 ) passing through rigid elements ( 34 ) of the linking element ( 3 ) and the insertion axis (DV) of the implants ( 2 ). The linking element ( 3 ) includes at least one elastic dampening element ( 31 ) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element ( 31 ) accommodates the stresses imposed on the linking element ( 3 ) during movement of the vertebrae and tends to return the support device ( 1 ) to its normal configuration.",LDR MEDICAL,CHO PAUL;;DAVIS REGINALD;;HOFFMAN GREGORY;;MCGEE ALAN;;WILLIAMS JOHN;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM D;;JODAITIS ALEXANDRE;;CHATAIGNER HERVE;;BENITEZ HUGO SANTOS;;ZHONGQIANG CHEN,,https://lens.org/070-113-438-666-836,Patent Application,yes,12,0,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,0,0,,,,INACTIVE
739,US,B2,US 9730733 B2,176-290-179-063-803,2017-08-15,2017,US 201514642752 A,2015-03-10,US 201514642752 A;;FR 0611198 A;;US 95828507 A,2006-12-21,Vertebral support device,"A vertebral support device ( 1 ) is disclosed, which in various embodiments comprises at least two osseous anchoring implants ( 2 ), each designed to be anchored to a vertebra, and at least one linking element ( 3 ) fixed to the osseous anchoring implants ( 2 ) by fasteners ( 20 ) that maintain a fixed angle between the longitudinal axis (L) of the linking element ( 3 ) passing through rigid elements ( 34 ) of the linking element ( 3 ) and the insertion axis (DV) of the implants ( 2 ). The linking element ( 3 ) includes at least one elastic dampening element ( 31 ) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element ( 31 ) accommodates the stresses imposed on the linking element ( 3 ) during movement of the vertebrae and tends to return the support device ( 1 ) to its normal configuration.",LDR MEDICAL,CHO PAUL;;DAVIS REGINALD;;HOFFMAN GREGORY;;MCGEE ALAN;;WILLIAMS JOHN;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM D;;JODAITIS ALEXANDRE;;CHATAIGNER HERVE;;BENITEZ HUGO SANTOS;;ZHONGQIANG CHEN,LDR MEDICAL (2013-06-19),https://lens.org/176-290-179-063-803,Granted Patent,yes,18,3,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,93,0,,,"http://www.thefreedictionary.com/abut, definition of “abut”, accessed May 2, 2016.;;http://www.thefreedictionary.com/unitarily, definition of “unitarily”, accessed May 2, 2016.;;http://openjurist.org/127/f3d/1048/in-re-charles-p-morris, accessed Feb. 21, 2015.;;U.S. Appl. No. 09/635,436, filed Aug. 11, 2000, Apparatus and Method for Fusing Opposing Spinal Vertebrae, Bramlet, Dale G. et al.;;U.S. Appl. No. 10/060,862, filed Jan. 30, 2002, Intervertebral nucleus prosthesis and surgical procedure for implanting the same, Gau, Michel.;;U.S. Appl. No. 10/276,712, filed Mar. 26, 2003, Intersomatic cage with unified grafts, Huppert, Jean.;;U.S. Appl. No. 10/473,999, filed Apr. 12, 2004, Spinal Osteosynthesis Device and Preparation Method, Beaurain, Jacques et al.;;U.S. Appl. No. 10/476,565, filed Jun. 8, 2004, Intervertebral Disc Prosthesis and Fitting Tools, Beaurain, Jacques et al.;;U.S. Appl. No. 10/483,563, filed May 21, 2004, Vertebral Cage Device With Modular Fixation, Louis, Christian et al.;;U.S. Appl. No. 10/492,753, filed Aug. 9, 2004, Progressive approach osteosynthesis device and preassembly method, Delecrin, Joel et al.;;U.S. Appl. No. 10/492,827, filed Jul. 15, 2004, Plate for osteosynthesis device and method of preassembling such device, Delecrin, Joel et al.;;U.S. Appl. No. 10/494,418, filed Jul. 22, 2004, Osseous anchoring device for a prosthesis, Huppert, Jean et al.;;U.S. Appl. No. 10/498,234, filed Dec. 7, 2004, Implant for Osseous Anchoring with Polyaxial Head, Beaurain, Jacques et al.;;U.S. Appl. No. 10/533,846, filed Nov. 11, 2005, Intervertebral Disk Prosthesis, Beaurain, Jacques et al.;;U.S. Appl. No. 10/570,080, filed Jun. 9, 2006, Osseous anchoring implant with a polyaxial head and method for installing the implant, Renaud, Christian et al.;;U.S. Appl. No. 10/575,065, filed May 30, 2006, Device and method for sectioning a vertebral lamina, Mangione, Paolo.;;U.S. Appl. No. 11/051,710, filed Feb. 4, 2005, Intervertebral Disc Prosthesis, Hovorka, Istvan et al.;;U.S. Appl. No. 11/098,266, filed Apr. 4, 2005, Intervertebral Disc Prosthesis, Zeegers, M. Willem.;;U.S. Appl. No. 11/109,276, filed Apr. 18, 2005, Intervertebral Disc Prosthesis, Zeegers, M. Willem.;;U.S. Appl. No. 11/180,868, filed Jul. 13, 2005, Instrumentation and Methods for Inserting an Intervertebral Disc Prosthesis, Dinville, Herve.;;U.S. Appl. No. 11/341,007, filed Jan. 27, 2006, Intervertebral Disc Prosthesis, Rashbaum, Ralph et al.;;U.S. Appl. No. 11/362,253, filed Feb. 24, 2006, Intervertebral Disc Prosthesis and Instrumentation for Insertion of the Prosthesis Between the Vertebrae, Rashbaum, Ralph et al.;;U.S. Appl. No. 11/378,165, filed Mar. 17, 2006, Transforanimal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage, Davis, Reginald James et al.;;U.S. Appl. No. 11/390,711, filed Mar. 27, 2006, Intervertebral nucleus prosthesis and surgical procedure for implanting the same, Gau, Michel.;;U.S. Appl. No. 11/676,237, filed Feb. 16, 2007, Intervertebral disc prosthesis insertion assemblies, Jodaitis, Alexandre et al.;;U.S. Appl. No. 11/767,386, filed Jun. 22, 2007, Intersomatic cage with unified grafts, Huppert, Jean.;;U.S. Appl. No. 11/874,144, filed Oct. 17, 2007, Modular intervertebral prosthesis, Vila, Thierry et al.;;U.S. Appl. No. 11/958,285, filed Dec. 17, 2007, Vertebral Support Device, Cho, Paul et al.;;U.S. Appl. No. 12/025,677, filed Feb. 4, 2008, Intervertebral disc prosthesis, surgical methods, and fitting tools, Beaurain, Jacques et al.;;U.S. Appl. No. 12/134,884, filed Jun. 6, 2008, Intersomatic cage, intervertebral prosthesis, anchoring device and implantation instruments, Allain, Jerome et al.;;U.S. Appl. No. 12/172,074, filed Jul. 11, 2008, Transverse spinal linking device and system, Cho, Paul.;;U.S. Appl. No. 12/279,664, filed Apr. 22, 2009, Transforaminal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage, Davis, Reginald James et al.;;U.S. Appl. No. 12/360,050, filed Jan. 26, 2009, Intervertebral Disc Prosthesis, Zeegers, M. Willem.;;U.S. Appl. No. 12/391,086, filed Feb. 23, 2009, Intervertebral Disc Prosthesis, Zeegers, M. Willem.;;U.S. Appl. No. 12/409,327, filed Mar. 23, 2009, Spinal Osteosynthesis Device and Preparation Method, Beaurain, Jacques et al.;;U.S. Appl. No. 12/424,364, filed Apr. 15, 2009, Intervertebral disc prosthesis, Beaurain, Jacques et al.;;U.S. Appl. No. 12/430,768, filed Apr. 27, 2009, Vertebral Cage Device With Modular Fixation, Louis, Christian et al.;;U.S. Appl. No. 12/435,955, filed May 5, 2009, Instrumentation and Methods for Inserting an Intervertebral Disc Prosthesis, Dinville, Herve.;;U.S. Appl. No. 12/527,373, filed Mar. 19, 2010, Intervertebral disc prosthesis insertion assemblies, Jodaitis, Alexandre et al.;;U.S. Appl. No. 12/884,664, filed Sep. 17, 2010, Intervertebral implant having extendable bone fixation members, Brett, Darrell C.;;U.S. Appl. No. 12/955,898, filed Nov. 29, 2010, Intervertebral Disc Prosthesis, Rashbaum, Ralph et al.;;U.S. Appl. No. 13/158,761, filed Jun. 13, 2011, Instruments and Methods for Removing Fixation Devices from Intervertebral Implants, Dinville, Herve et al.;;U.S. Appl. No. 13/215,123, filed Aug. 22, 2011, Intervertebral Disc Prosthesis, Zeegers, M. Willem.;;U.S. Appl. No. 13/369,650, filed Feb. 9, 2012, Interspinous Implant and Implantation Instrument, Dinville, Hervé et al.;;U.S. Appl. No. 13/438,352, filed Apr. 3, 2012, Vertebral Cage Device With Modular Fixation, Louis, Christian et al.;;U.S. Appl. No. 13/454,927, filed Apr. 24, 2012, Plate for osteosynthesis device and method of preassembling such device, Delecrin, Joel et al.;;U.S. Appl. No. 13/520,041, filed Nov. 26, 2012, Anchoring Device and System for an Intervertebral Implant, Intervertebral Implant and Implantation Instrument, Dinville, Hervé et al.;;U.S. Appl. No. 13/538,078, filed Jun. 29, 2012, Anchoring Device and System for an Intervertebral Implant, Intervertebral Implant and Implantation Instrument, Dinville, Hervé et al.;;U.S. Appl. No. 13/585,063, filed Aug. 14, 2012, Transforaminal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage, Davis, Reginald James et al.;;U.S. Appl. No. 13/603,043, filed Sep. 4, 2012, Intervertebral Disc Prosthesis, Zeegers, M. Willem.;;U.S. Appl. No. 13/616,448, filed Sep. 14, 2012, Intervertebral Disk Prosthesis, Beaurain, Jacques et al.;;U.S. Appl. No. 13/620,797, filed Sep. 15, 2012, Intervertebral Disc Prosthesis and Instrumentation for Insertion of the Prosthesis Between the Vertebrae, Rashbaum, Ralph et al.;;U.S. Appl. No. 13/732,244, filed Dec. 31, 2012, Intersomatic cage, intervertebral prosthesis, anchoring device and implantation instruments, Allain, Jerome et al.;;U.S. Appl. No. 13/774,547, filed Feb. 22, 2013, Anchoring device and system for an intervertebral implant, intervertebral implant and implantation instrument, Chataigner, Hervé et al.;;U.S. Appl. No. 13/854,808, filed Apr. 1, 2013, Transforanimal intersomatic cage for an intervertebral fusion graft and an instrument for implanting the cage, Davis, Reginald James et al.;;U.S. Appl. No. 13/873,190, filed Apr. 29, 2013, Spinal Osteosynthesis Device and Preparation Method, Beaurain, Jacques et al.;;U.S. Appl. No. 13/892,933, filed May 13, 2013, Instrumentation and Methods for Inserting an Intervertebral Disc Prosthesis, Dinville, Herve.;;U.S. Appl. No. 13/919,704, filed Jun. 17, 2013, Prosthesis for Spinal Treatment, Jodaitis, Alexandre et al.;;U.S. Appl. No. 14/064,434, filed Oct. 28, 2013, Intervertebral implant having extendable bone fixation members, Brett, Darrell C.;;U.S. Appl. No. 14/130,286, filed Jul. 3, 2014, Interspinous Implant and Implantation Instrument, Dinville, Hervé et al.;;U.S. Appl. No. 14/149,357, filed Jan. 7, 2014, Intersomatic cage with unified grafts, Huppert, Jean.;;U.S. Appl. No. 14/159,161, filed Jan. 20, 2014, Nucleus Prostheses, Vila, Thierry et al.;;U.S. Appl. No. 14/242,177, filed Apr. 1, 2014, Intervertebral disc prosthesis insertion assemblies, Jodaitis, Alexandre et al.;;U.S. Appl. No. 14/246,442, filed Apr. 7, 2014, Vertebral implant, vertebral fastening device of the implant and implant instrumentation, Dinville, Hervé et al.;;U.S. Appl. No. 14/252,754, filed Apr. 14, 2014, Interspinous Implant and Implantation Instrument, Dinville, Hervé et al.;;U.S. Appl. No. 14/252,852, filed Apr. 15, 2014, Anchoring device for a spinal implant, spinal implant and implantation instrumentation, Chataigner, Hervé et al.;;U.S. Appl. No. 14/306,785, filed Jun. 17, 2014, Intervertebral Disk Prosthesis, Beaurain, Jacques et al.;;U.S. Appl. No. 14/325,317, filed Jul. 7, 2014, Intervertebral Disc Prosthesis and Instrumentation for Insertion of the Prosthesis Between the Vertebrae, Steib, Jean-Paul.;;U.S. Appl. No. 14/380,714, filed Aug. 23, 2014, Anchoring device and system for an intervertebral implant, intervertebral implant and implantation instrument, Chataigner, Hervé et al.;;U.S. Appl. No. 14/460,536, filed Aug. 15, 2014, Cage Having Spike, Kim, Seo-Kon et al.;;U.S. Appl. No. 14/497,321, filed Sep. 26, 2014, Osseous anchoring implant with a polyaxial head and method for installing the implant, Renaud, Christian et al.;;U.S. Appl. No. 14/513,818, filed Oct. 14, 2014, Intervertebral Disc Prosthesis, Hovorka, Istvan et al.;;U.S. Appl. No. 14/584,674, filed Dec. 29, 2014, Plate for osteosynthesis device and method of preassembling such device, Delecrin, Joel et al.;;U.S. Appl. No. 14/594,770, filed Jan. 12, 2015, Intervertebral Implant Having Extendable Bone Fixation Members, Brett, Darrell C.;;U.S. Appl. No. 14/638,746, filed Mar. 4, 2015, Vertebral implant, device for vertebral attachment of the implant and instrumentation for implantation thereof, Ameil, Marc et al.;;U.S. Appl. No. 14/642,696, filed Mar. 9, 2015, Intervertebral Disc Prosthesis, Zeegers, M. Willem.;;U.S. Appl. No. 14/659,587, filed Mar. 16, 2015, Intervertebral Implant Having Extendable Bone Fixation Members, Rashbaum, Ralph et al.;;U.S. Appl. No. 14/721,818, filed May 26, 2015, Anchoring device and system for an intervertebral implant, intervertebral implant and implantation instrument, Chataigner, Hervé et al.;;U.S. Appl. No. 14/726,557, filed May 31, 2015, Intervertebral Disc Prosthesis, Zeegers, M. Willem.;;U.S. Appl. No. 14/726,558, filed May 31, 2015, Anchoring Device and System for an Intervertebral Implant, Intervertebral Implant and Implantation Instrument, Dinville, Hervé et al.;;U.S. Appl. No. 14/798,900, filed Jul. 14, 2015, Vertebral Cage Device With Modular Fixation, Louis, Christian et al.;;U.S. Appl. No. 14/815,900, filed Jul. 31, 2015, Bone Implants, Lavigne, Christophe et al.;;U.S. Appl. No. 14/827,297, filed Aug. 15, 2015, Devices, Methods, and Systems to Implant and Secure a Fusion Cage or Intervertebral Prosthesis for Spinal Treatment, Stewart, Will et al.;;U.S. Appl. No. 14/891,322, filed Nov. 13, 2015, Vertebral implant, vertebral fastening device of the implant and implant instrumentation, Dinville, Herve et al.;;U.S. Appl. No. 14/931,007, filed Nov. 3, 2015, Instruments and Methods for Removing Fixation Devices from Intervertebral Implants, Dinville, Herve et al.;;U.S. Appl. No. 15/012,815, filed Feb. 1, 2016, Instrumentation and Methods for Inserting an Intervertebral Disc Prosthesis, Dinville, Herve.;;U.S. Appl. No. 15/049,934, filed Feb. 22, 2016, Intervertebral Disk Prosthesis, Beaurain, Jacques et al.;;U.S. Appl. No. 15/049,995, filed Feb. 22, 2016, Intervertebral Disc Prosthesis and Instrumentation for Insertion of the Prosthesis Between the Vertebrae, Steib, Jean-Paul.;;U.S. Appl. No. 61/243,297, filed Sep. 17, 2009, Intervertebral Fusion Cage with Retractable-Extrudable Pins, Brett, Darrell C.;;U.S. Appl. No. 61/260,364, filed Nov. 11, 2009, Intervertebral Fusion Cage with Retractable-Extrudable Pins, Brett, Darrell C.;;Japan Patent Office; Decision to Grant a Patent for Pub'n No. JP2010512901, Application No. JP20090542260; Jun. 7, 2013; Japan Patent Office; Tokyo, Japan; all pages.;;LDR Medical, by its attorneys; Written Argument and Written Amendment for Pub'n No. JP2010512901, Application No. JP20090542260; Dec. 19, 2012; Japan Patent Office; Tokyo, Japan; all pages.;;Japan Patent Office; Notification of Reasons for Refusal for Pub'n No. JP2010512901, Application No. JP20090542260; Jun. 15, 2012; Japan Patent Office; Tokyo, Japan; all pages.",ACTIVE
740,US,A1,US 2008/0255617 A1,070-645-074-865-988,2008-10-16,2008,US 95828507 A,2007-12-17,FR 0611198 A,2006-12-21,Vertebral Support Device,"A vertebral support device ( 1 ) is disclosed, which in various embodiments comprises at least two osseous anchoring implants ( 2 ), each designed to be anchored to a vertebra, and at least one linking element ( 3 ) fixed to the osseous anchoring implants ( 2 ) by fasteners ( 20 ) that maintain a fixed angle between the longitudinal axis (L) of the linking element ( 3 ) passing through rigid elements ( 34 ) of the linking element ( 3 ) and the insertion axis (DV) of the implants ( 2 ). The linking element ( 3 ) includes at least one elastic dampening element ( 31 ) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element ( 31 ) accommodates the stresses imposed on the linking element ( 3 ) during movement of the vertebrae and tends to return the support device ( 1 ) to its normal configuration.",CHO PAUL;;DAVIS REGINALD;;HOFFMAN GREGORY;;MCGEE ALAN;;WILLIAMS JOHN;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM D;;JODAITIS ALEXANDRE;;CHATAIGNER HERVE;;BENITEZ HUGO SANTOS;;ZHONGQIANG CHEN,CHO PAUL;;DAVIS REGINALD;;HOFFMAN GREGORY;;MCGEE ALAN;;WILLIAMS JOHN;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM D;;JODAITIS ALEXANDRE;;CHATAIGNER HERVE;;BENITEZ HUGO SANTOS;;ZHONGQIANG CHEN,LDR MEDICAL (2013-06-19),https://lens.org/070-645-074-865-988,Patent Application,yes,56,73,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70;;A61B17/04,606/246;;606/301;;606/264;;606/278,0,0,,,,INACTIVE
741,EP,A1,EP 4305642 A1,152-928-735-616-528,2024-01-17,2024,EP 22710920 A,2022-02-10,US 202163158189 P;;US 202163182456 P;;US 2022/0070616 W,2021-03-08,ACUTE HEALTH EVENT MONITORING AND VERIFICATION,,MEDTRONIC INC,KRAUSE PAUL G;;STADLER ROBERT W;;DEGROOT PAUL J;;WYSZYNSKI RYAN D;;CONNOLLY MEGAN;;NEITZELL GRANT A;;SARKAR SHANTANU;;KOCH CHRISTOPHER D;;CHO YONG K;;NATERA ANA C;;OUSDIGIAN KEVIN T;;DEMMER WADE M;;JEJURKAR ABHIJIT P,,https://lens.org/152-928-735-616-528,Patent Application,yes,0,0,3,22,0,A61B5/0022;;A61B5/0031;;A61B5/747;;A61N1/362;;A61N1/37258;;A61N1/37282;;A61N1/3956;;G16H40/20;;G16H40/63;;G16H40/67;;A61N1/37;;A61N1/3925;;G16H10/60;;G16H50/20;;G16H50/70;;G16H10/20;;G16H20/10;;G16H20/30;;G16H50/30;;A61B5/686,G16H40/67;;A61B5/00;;A61N1/372;;G16H40/20;;G16H40/63,,0,0,,,,PENDING
742,AU,A1,AU 2022/234473 A1,108-391-281-053-552,2023-10-26,2023,AU 2022/234473 A,2022-02-10,US 202163182456 P;;US 202163158189 P;;US 2022/0070616 W,2021-03-08,ACUTE HEALTH EVENT MONITORING AND VERIFICATION,"Devices, systems, and techniques are disclosed for verifying the occurrence of an acute health event. An example device includes communication circuitry configured to receive a communication indicative of an acute health event of a patient and memory communicatively coupled to the communication circuitry and being configured to store the indication of the acute health event. The device includes processing circuitry communicatively coupled to the communication circuitry and the memory. The processing circuitry is configured to, in response to the communication, verify the acute health event and based on the verification of the acute health event, send an alert regarding the acute health event.",MEDTRONIC INC,KRAUSE PAUL G;;STADLER ROBERT W;;DEGROOT PAUL J;;WYSZYNSKI RYAN D;;CONNOLLY MEGAN;;NEITZELL GRANT A;;SARKAR SHANTANU;;KOCH CHRISTOPHER D;;CHO YONG K;;NATERA ANA C;;OUSDIGIAN KEVIN T;;DEMMER WADE M;;JEJURKAR ABHIJIT P,,https://lens.org/108-391-281-053-552,Patent Application,no,0,0,3,22,0,A61B5/0022;;A61B5/0031;;A61B5/747;;A61N1/362;;A61N1/37258;;A61N1/37282;;A61N1/3956;;G16H40/20;;G16H40/63;;G16H40/67;;A61N1/37;;A61N1/3925;;G16H10/60;;G16H50/20;;G16H50/70;;G16H10/20;;G16H20/10;;G16H20/30;;G16H50/30;;A61B5/686,G16H40/67;;A61B5/00;;A61N1/372;;G16H40/20;;G16H40/63,,0,0,,,,PENDING
743,CN,A,CN 116982118 A,189-037-164-594-700,2023-10-31,2023,CN 202280019889 A,2022-02-10,US 202163182456 P;;US 2022/0070616 W,2021-04-30,Acute health event monitoring and verification,"Devices, systems, and techniques are disclosed for verifying the occurrence of an acute health event. An example apparatus includes a communication circuit configured to receive a communication indicative of an acute health event of a patient; and a memory communicatively coupled to the communication circuitry and configured to store an indication of an acute health event. The apparatus includes processing circuitry communicatively coupled to the communication circuitry and the memory. The processing circuit is configured to, in response to the communication, verify an acute health event, and send an alert regarding the acute health event based on the verification of the acute health event.",MEDTRONIC INC,KRAUSE PAUL G;;STADLER ROBERT W;;DEGROOT PAUL J;;WISZYNSKI RAYMOND D;;CONNOLLY MICHAEL;;NEITZEL GARY A;;SARKAR SHANTANU;;KOCH CRAIG D;;CHO YONG K;;NATERA ADNAN C;;OSTIGIAN KEVIN T;;DEMMER WADE M;;JAYURKAR ASHOK P,,https://lens.org/189-037-164-594-700,Patent Application,no,0,0,1,22,0,,G16H40/67,,0,0,,,,PENDING
744,WO,A1,WO 2022/192827 A1,012-574-189-702-178,2022-09-15,2022,US 2022/0070616 W,2022-02-10,US 202163182456 P;;US 202163158189 P,2021-03-08,ACUTE HEALTH EVENT MONITORING AND VERIFICATION,"Devices, systems, and techniques are disclosed for verifying the occurrence of an acute health event. An example device includes communication circuitry configured to receive a communication indicative of an acute health event of a patient and memory communicatively coupled to the communication circuitry and being configured to store the indication of the acute health event. The device includes processing circuitry communicatively coupled to the communication circuitry and the memory. The processing circuitry is configured to, in response to the communication, verify the acute health event and based on the verification of the acute health event, send an alert regarding the acute health event.",MEDTRONIC INC,KRAUSE PAUL G;;STADLER ROBERT W;;DEGROOT PAUL J;;WYSZYNSKI RYAN D;;CONNOLLY MEGAN;;NEITZELL GRANT A;;SARKAR SHANTANU;;KOCH CHRISTOPHER D;;CHO YONG K;;NATERA ANA C;;OUSDIGIAN KEVIN T;;DEMMER WADE M;;JEJURKAR ABHIJIT P,,https://lens.org/012-574-189-702-178,Patent Application,yes,9,1,3,22,0,A61B5/0022;;A61B5/0031;;A61B5/747;;A61N1/362;;A61N1/37258;;A61N1/37282;;A61N1/3956;;G16H40/20;;G16H40/63;;G16H40/67;;A61N1/37;;A61N1/3925;;G16H10/60;;G16H50/20;;G16H50/70;;G16H10/20;;G16H20/10;;G16H20/30;;G16H50/30;;A61B5/686,G16H40/67;;A61B5/00;;A61N1/372;;G16H40/20;;G16H40/63,,0,0,,,,PENDING
745,US,A1,US 2023/0153309 A1,196-576-044-003-781,2023-05-18,2023,US 202117530149 A,2021-11-18,US 202117530149 A,2021-11-18,TECHNIQUES AND SYSTEMS FOR SMART NATURAL LANGUAGE PROCESSING OF SEARCH RESULTS,"A system, processes, and a computer-readable storage medium are provided method includes receiving a search query including one or more of a textual phrase, a document, or data including metadata from a user. For example, a processor may execute a theme-generating machine learning algorithm to generate a theme of the search query. Profiles of other users are identified as similar to a profile of the user may be located. A search history of each of the located other users may be located in the collected search history. Content in the searchable content that corresponds to the generated theme of the search query and according to a result of the evaluation of the located search history of each of the other users may be obtained. The obtained content may be scored based on a scoring algorithm and output a set of scored search results to the input/output device.",CAPITAL ONE SERVICES LLC,COBLE PIPER ALEXANDRA;;KUHN NATALIE;;CHO PAUL;;PARKER RYAN M;;PETRUNIN SERGEY;;WILLIAMS GARY B;;CAMPBELL ERIC;;CHENG LIN NI LISA;;SULLIVAN MATTHEW KEVIN;;DEMCHALK CHRIS,CAPITAL ONE SERVICES LLC (2021-11-15),https://lens.org/196-576-044-003-781,Patent Application,yes,6,0,1,1,0,G06F16/243;;G06F16/285;;G06F16/24578;;G06F16/243,G06F16/2457;;G06F16/28,,0,0,,,,PENDING
746,US,B2,US 8815829 B2,086-865-084-479-517,2014-08-26,2014,US 200913132920 A,2009-12-09,US 200913132920 A;;US 20126808 P;;US 2009/0067400 W,2008-12-09,3′-azido purine nucleotide prodrugs for treatment of viral infections,"The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, and HBV, in human patients or other animal hosts. The compounds are 3′-azido-2′,3′-dideoxy purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 and HBV.",SCHINAZI RAYMOND F;;MELLORS JOHN W;;SLUIS-CREMER NICOLAS PAUL;;COATS STEVEN J;;WHITAKER RICHARD ANTHONY;;HERMAN BRIAN DAVID;;CHO JONG HYUN;;ZHOU LONGHU;;ZHANG HONGWANG;;RFS PHARMA LLC;;UNIV EMORY;;UNIV PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION,SCHINAZI RAYMOND F;;MELLORS JOHN W;;SLUIS-CREMER NICOLAS PAUL;;COATS STEVEN J;;WHITAKER RICHARD ANTHONY;;HERMAN BRIAN DAVID;;CHO JONG HYUN;;ZHOU LONGHU;;ZHANG HONGWANG,UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (2012-02-09);;RFS PHARMA LLC (2011-12-01);;EMORY UNIVERSITY (2011-12-07),https://lens.org/086-865-084-479-517,Granted Patent,yes,13,23,4,4,0,A61K31/437;;A61K31/437;;A61P31/12;;A61P31/18;;A61P31/20;;C07D473/34;;C07D473/34;;C07D473/16;;C07D473/16;;C07D473/18;;C07D473/18;;C07H19/173;;C07H19/173;;C07H19/20;;C07H19/20;;C07H19/207;;C07H19/207,C07H19/04;;A61K31/437;;A61K31/70;;C07D473/16;;C07D473/18;;C07H19/173;;C07H19/20;;C07H19/207,514/48;;514/47;;535/26.7,21,14,056-311-147-347-640;;123-566-898-994-833;;017-514-798-270-451;;075-147-906-010-676;;098-340-430-193-604;;066-911-572-804-031;;046-056-347-410-917;;109-492-006-725-560;;039-514-144-309-482;;000-242-549-722-222;;045-219-960-888-860;;077-710-288-274-078;;004-816-504-771-632;;119-091-139-346-420,10.2174/0929867053363540;;15638729;;2405846;;10.1016/0006-291x(90)91941-k;;17403997;;pmc1891359;;10.1128/aac.00119-07;;10.1002/ejoc.200500520;;10.1073/pnas.87.23.9426;;pmc55178;;2251284;;15970587;;10.1074/jbc.m503166200;;16389458;;10.1007/s00018-005-5367-x;;3822836;;10.1093/nar/15.4.1699;;pmc340575;;2514268;;10.1007/bf02103614;;10.1089/aid.1988.4.457;;3219235;;10.1002/hlca.19940770222;;1368634;;10.1080/00021369.1990.10870451;;10.1271/bbb1961.54.3093;;10.1128/aac.49.3.1139-1144.2005;;15728915;;pmc549267;;17150922,"Wolff, Manfred E. ""Burger's Medicinal Chemistry, 5ed, Part I"", John Wiley & Sons, 1995, pp. 975-977.;;Banker, G.S. et al, ""Modern Pharmaceutics, 3ed."", Marcel Dekker, New York, 1996, p. 596.;;AN 1991:94697-Karamov et al, Molekulyarnaya Biologiya, 1990, 24(6), 1695-1701, abstract.;;Lima et al., Current Medicinal Chemistry, 2005, vol. 12, 23-49.;;Karlsson, A., et al., ""The metabolism of 3'-azido-2',3'-dideoxyguanosine in CEM cells"", ""Biochemical and Biophysical Research Communications"", 1990, pp. 273-279 (Abstract Only), vol. 166, No. 1.;;Lennerstrand, J., et al. , ""Biochemical Studies on the Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to 1-(beta-D-Dioxolane)Thymine Triphosphate"", ""Antimicrobial Agents and Chemotherapy "", Jun. 2007, pp. 2078-2084, vol. 51, No. 6.;;Seio, K., et al., ""Synthesis and Properties of New Nucleotide Analogues Possessing Squaramide Moieties as New Phosphate Isosters"", ""Eur. J. Org. Chem."", Oct. 19, 2005, pp. 5163-5170.;;Shirasaka, T., et al., ""Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro"", ""Proc. Natl. Acad. Sci."", Dec. 1990, pp. 9426-9430, vol. 87.;;Sluis-Cremer, N., et al. , ""The 3'-Azido Group Is Not the Primary Determinant of 3'-Azido-3'-deoxythymidine (AZT) Responsible for the Excision Phenotype of AZT-resistant HIV-1"", ""The Journal of Biological Chemistry"", Jun. 20, 2005, pp. 29047-29052, vol. 280, No. 32.;;Vivet-Boudou, V., et al. , ""Nucleoside and nucleotide inhibitors of HIV-1 replication"", ""Cellular and Molecular Life Sciences"", Jan. 2, 2006, pp. 163-186, vol. 63, No. 2.;;Zielinski, W., et al., ""Oligoaminonucleoside Phosphoramidates. Oligerimization of Dimers of 3'-Amino-3'-Deoxy-Nucleotides (GC and CG) in Aqueous Solution"", ""Nucleic Acids Research"", 1987, pp. 1699-1715, vol. 15, No. 4.;;Zielinski, W., et al., ""The Template Properties of Tetranucleoside Triphosphoramidates Having Cytosine-Guanosine Residues"", ""J. Mol. Evol."", 1989, pp. 281-283, vol. 29.;;Banker, G., et al. (Ed.), ""Modern Pharmaceutics, 3rd Edition"", Jan. 1996, p. 596, vol. 72, Publisher: Marcel Dekker, Inc.;;Hartmann, H., et al., ""Enhanced in Vitro Inhibition of HIV-1 Replication by 3'-Fluoro-3'-Deoxythymidine Compared to Several Other Nucleoside Analogs"", ""Aids Research and Human Retroviruses"", Dec. 1988, pp. 457-466, vol. 4, No. 6.;;Herrlein, M., et al., ""57. 3'-Amino-Modified Nucleotides Useful as Potent Chain Terminators for Current DNA Sequencing Methods"", ""Helvetica Chimica Acta"", 1994, pp. 586-596, vol. 77.;;Hjuler-Nielsen, H., et al., ""Purine cytokinines in the synthesis of 2',3'-dideoxynucleosides"", ""Bull. Soc. Chim. Fr."", 1992, pp. 523-528, vol. 129.;;Koizumi, F., et al., ""Synthesis and Antimicrobial Activity of 2'-Deoxypuromycin"", ""Agric. Biol. Chem."", 1990, pp. 3093-3097, vol. 54, No. 12.;;Parikh, U., ""In Vitro Activity of Structurally Diverse Nucleoside Analogs against Human Immunodeficiency Virus Type 1 with the K65R Mutation in Reverse Transcriptase"", ""Antimicrobial Agents and Chemotherapy"", Mar. 2005, pp. 1139-1144, vol. 49, No. 3.;;Wolff, M. (Ed.), ""Volume I: Principles and Practice"", ""Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition"", Dec. 19, 1994, pp. 975-977, Publisher: John Wiley & Sons.;;Yamaguchi, T., et al., ""Telomerase inhibition by 3'-azido-2', 3'-dideoxynucleoside 5'-triphophates and telomere shortening in human cultured cells by the corresponding nucleosides"", ""Nucleic Acids Symposium Series"", 2006, pp. 271-272, vol. 50.;;Silverman, R., et al., ""The Organic Chemistry of Drug Design and Drug Action"", 1992, pp. 19-23.",ACTIVE
747,US,A1,US 2023/0253008 A1,018-846-040-545-877,2023-08-10,2023,US 202318302985 A,2023-04-19,US 202318302985 A;;US 202117302466 A,2021-05-04,SYSTEMS AND METHODS FOR UTILIZING MODELS TO PREDICT HAZARDOUS DRIVING CONDITIONS BASED ON AUDIO DATA,"A vehicle device may receive audio data and other vehicle data associated with a vehicle and may transform the audio data to transformed audio data in a frequency domain. The vehicle device may segment the transformed audio data into a plurality of audio segments and may process the plurality of audio segments, with different feature extraction techniques, to extract a plurality of feature vectors. The vehicle device may merge the plurality of feature vectors into a merged feature vector and may create an audio signature for the audio data based on the merged feature vector. The vehicle device may process the audio signature and the other vehicle data, with a model, to determine a classification of the audio signature and may perform one or more actions based on the classification of the audio signature.",VERIZON PATENT & LICENSING INC;;VERIZON CONNECT DEVELOPMENT LTD,JAVERI VIPUL SHYAM;;DARIVEMULA MOURYA C;;JOHN BRITTO JEYANTH PAUL;;NALLA NISHITHA REDDY;;HAMEED AAROON THOWFIQ SHAHUL;;COIMBRA DE ANDRADE DOUGLAS;;CHO JIN SOO;;CRUELDAD IANEMMANUEL P,VERIZON PATENT AND LICENSING INC (2021-04-29);;VERIZON CONNECT DEVELOPMENT LIMITED (2021-04-29),https://lens.org/018-846-040-545-877,Patent Application,yes,2,1,3,3,0,G10L21/0208;;G10L25/51;;G10L25/18;;H04R2499/13;;H04R3/00;;H04R2410/00;;H04R2430/01;;G06N20/00;;G10L25/51;;G10L21/0232;;H04R3/04;;G10L25/24;;G10L25/18;;B60Q9/00;;G08G1/0962;;G06N20/00;;H04R2430/01;;H04R2499/13;;G06F3/165,G10L25/51;;G06F3/16;;G06N20/00;;G08G1/0962;;G10L21/0232;;G10L25/18;;G10L25/24;;H04R3/04,,0,0,,,,PENDING
748,US,B2,US 11646049 B2,055-128-143-504-117,2023-05-09,2023,US 202117302466 A,2021-05-04,US 202117302466 A,2021-05-04,Systems and methods for utilizing models to predict hazardous driving conditions based on audio data,"A vehicle device may receive audio data and other vehicle data associated with a vehicle and may transform the audio data to transformed audio data in a frequency domain. The vehicle device may segment the transformed audio data into a plurality of audio segments and may process the plurality of audio segments, with different feature extraction techniques, to extract a plurality of feature vectors. The vehicle device may merge the plurality of feature vectors into a merged feature vector and may create an audio signature for the audio data based on the merged feature vector. The vehicle device may process the audio signature and the other vehicle data, with a model, to determine a classification of the audio signature and may perform one or more actions based on the classification of the audio signature.",VERIZON CONNECT IRELAND LTD;;VERIZON PATENT & LICENSING INC;;VERIZON CONNECT DEVELOPMENT LTD,JAVERI VIPUL SHYAM;;DARIVEMULA MOURYA C;;BRITTO JEYANTH PAUL JOHN;;NALLA NISHITHA REDDY;;HAMEED AAROON THOWFIQ SHAHUL;;COIMBRA DE ANDRADE DOUGLAS;;CHO JIN SOO;;CRUELDAD IANEMMANUEL P,VERIZON PATENT AND LICENSING INC (2021-04-29);;VERIZON CONNECT IRELAND LIMITED (2021-04-29),https://lens.org/055-128-143-504-117,Granted Patent,yes,1,0,3,3,0,G10L21/0208;;G10L25/51;;G10L25/18;;H04R2499/13;;H04R3/00;;H04R2410/00;;H04R2430/01;;G06N20/00;;G10L25/51;;G10L21/0232;;H04R3/04;;G10L25/24;;G10L25/18;;B60Q9/00;;G08G1/0962;;G06N20/00;;H04R2430/01;;H04R2499/13;;G06F3/165,G10L25/51;;B60Q9/00;;G06F3/16;;G06N20/00;;G08G1/0962;;G10L21/0232;;G10L25/18;;G10L25/24;;H04R3/04,,3,0,,,"Carreira et al., “Quo Vadis, Action Recognition? A New Model and the Kinetics Dataset,” Feb. 12, 2018, arXiv:1705.07750v3, Website: https://arxiv.org/pdf/1705.07750.pdf, 10 Pages.;;Jovanovic, “How does Shazam work? Music Recognition Algorithms, Fingerprinting, and Processing,” 2015, Website: https://www.toptal.com/algorithms/shazam-it-music-processing-fingerprinting-and-recognition, 17 Pages.;;“Creating your own Shazam (identify songs) with Python through audio fingerprinting in Ubuntu 18.04,” Jul. 6, 2019, Website: https://ourcodeworld.com/articles/read/973/creating-your-own-shazam-identify-songs-with-python-through-audio-fingerprinting-in-ubuntu-18-04, 6 Pages.",ACTIVE
749,KR,A,KR 20060011677 A,183-714-793-518-994,2006-02-03,2006,KR 20040060623 A,2004-07-30,KR 20040060623 A,2004-07-30,APPARATUS AND METHOD FOR TRANSMITTING/RECEIVING A HEADER INFORMATION IN A WIRELESS COMMUNICATION SYSTEM WITH MULTI-CHANNEL STRUCTURE,,SAMSUNG ELECTRONICS CO LTD,LEE SUNG JIN;;CHO YOUNG KWON;;DANIEL KATZ MARCOS;;PARK DONG SEEK;;SON JUNG JE;;KOO CHANG HOI;;FITZEK FRANK HANNS PAUL;;MADSEN TATIANA KOZLOVA;;PRASAD RAMJEE,,https://lens.org/183-714-793-518-994,Patent Application,no,0,0,3,3,0,H04L12/2854;;H04L12/2854;;H04L12/2854;;H04L69/00;;H04L69/04;;H04L69/04;;H04L69/04;;H04L69/14;;H04L69/14;;H04L69/14;;H04L69/22;;H04L69/22;;H04L69/22;;H04W28/06;;H04W28/06;;H04W28/06,H04B7/26;;H04L12/28,,0,0,,,,INACTIVE
750,US,A1,US 2022/0358950 A1,100-421-172-289-447,2022-11-10,2022,US 202117302466 A,2021-05-04,US 202117302466 A,2021-05-04,SYSTEMS AND METHODS FOR UTILIZING MODELS TO PREDICT HAZARDOUS DRIVING CONDITIONS BASED ON AUDIO DATA,"A vehicle device may receive audio data and other vehicle data associated with a vehicle and may transform the audio data to transformed audio data in a frequency domain. The vehicle device may segment the transformed audio data into a plurality of audio segments and may process the plurality of audio segments, with different feature extraction techniques, to extract a plurality of feature vectors. The vehicle device may merge the plurality of feature vectors into a merged feature vector and may create an audio signature for the audio data based on the merged feature vector. The vehicle device may process the audio signature and the other vehicle data, with a model, to determine a classification of the audio signature and may perform one or more actions based on the classification of the audio signature.",VERIZON CONNECT IRELAND LTD;;VERIZON PATENT & LICENSING INC,JAVERI VIPUL SHYAM;;DARIVEMULA MOURYA C;;BRITTO JEYANTH PAUL JOHN;;NALLA NISHITHA REDDY;;HAMEED AAROON THOWFIQ SHAHUL;;COIMBRA DE ANDRADE DOUGLAS;;CHO JIN SOO;;CRUELDAD IANEMMANUEL P,VERIZON PATENT AND LICENSING INC (2021-04-29);;VERIZON CONNECT IRELAND LIMITED (2021-04-29),https://lens.org/100-421-172-289-447,Patent Application,yes,1,1,3,3,0,G10L21/0208;;G10L25/51;;G10L25/18;;H04R2499/13;;H04R3/00;;H04R2410/00;;H04R2430/01;;G06N20/00;;G10L25/51;;G10L21/0232;;H04R3/04;;G10L25/24;;G10L25/18;;B60Q9/00;;G08G1/0962;;G06N20/00;;H04R2430/01;;H04R2499/13;;G06F3/165,G10L25/51;;G06F3/16;;G06N20/00;;G08G1/0962;;G10L21/0232;;G10L25/18;;G10L25/24;;H04R3/04,,0,0,,,,ACTIVE
751,MX,A,MX 2009006788 A,013-886-575-252-901,2009-07-06,2009,MX 2009006788 A,2007-12-21,FR 0611198 A;;IB 2007004061 W,2006-12-21,VERTEBRAL SUPPORT DEVICE.,"A vertebral support device (1) is disclosed, which in various embodiments comprises at least two osseous anchoring implants (2), each designed to be anchored to a vertebra, and at least one linking element (3) fixed to the osseous anchoring implants (2) by fasteners (20) that maintain a fixed angle between the longitudinal axis (L) of the linking element (3) passing through rigid elements (34) of the linking element (3) and the insertion axis (DV) of the implants (2). The linking element (3) includes at least one elastic dampening element (31) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element (31) accommodates the stresses imposed on the linking element (3) during movement of the vertebrae and tends to return the support device (1) to its normal configuration.",LDR MEDICAL,CHATAIGNER HERVE;;BENITEZ HUGO SANTOS;;BRADLEY WILLIAM DANIEL;;SCHWARTZ ARNOLD M;;CHO PAUL HENRY;;DAVIS REGINALD JAMES;;HOFFMANN GREGORY;;MCGEE ALAN W;;CHEN ZHONGQIANG;;JODAITIS ALEXANDRE;;WILLIAMS JOHN I,,https://lens.org/013-886-575-252-901,Patent Application,no,0,0,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,0,0,,,,ACTIVE
752,US,B2,US 7768987 B2,111-897-502-818-851,2010-08-03,2010,US 52731306 A,2006-09-26,KR 20050089562 A,2005-09-26,Apparatus and method for operating frequency resources in a mobile communication system,"A frequency resource operating apparatus and method for transmitting and receiving data at a different hopping pattern speed according to a CSI in a BWA communication system are provided. In a method of transmitting and receiving data using CSI in a mobile communication system, a BS sets the CSI of an MS to an initial CSI and sends data to the MS according to the initial CSI. The MS sends a downlink CSI to the BS. The BS groups the MS based on the downlink CSI and sends data to the MS according to a hopping pattern for the group of the MS among hopping patterns preset for predetermined groups.",SAMSUNG ELECTRONICS CO LTD,RAHMAN MUHAMMAD IMADUR;;REYNISSON RAGNAR VIOIR;;FITZEK FRANK HANNS PAUL;;PRASAD RAMJEE;;KOO JIN-KYU;;PARK DONG-SEEK;;CHO YOUNG-KWON;;KIM YOUNG-KYUN;;LIM EUN-TAEK;;JUNG JUN-YOUNG,SAMSUNG ELECTRONICS CO. LTD (2006-12-06),https://lens.org/111-897-502-818-851,Granted Patent,yes,7,8,4,4,0,H04B1/7156;;H04L1/0001;;H04L1/0033;;H04L5/0044;;H04B1/7156;;H04L1/0001;;H04L1/0033;;H04L5/0012;;H04W72/0453;;H04L5/0044;;H04L1/0001;;H04L1/0033;;H04B1/7156;;H04L5/0044,H04B7/208,370/344;;370/252;;370/328;;370/485,0,0,,,,INACTIVE
753,US,A1,US 2012/0135951 A1,130-896-004-016-228,2012-05-31,2012,US 200913132920 A,2009-12-09,US 200913132920 A;;US 20126808 P;;US 2009/0067400 W,2008-12-09,3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS,"The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, and HBV, in human patients or other animal hosts. The compounds are 3′-azido-2′,3′-dideoxy purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 and HBV.",SCHINAZI PH D RAYMOND F;;MELLORS JOHN W;;SLUIS-CREMER NICOLAS PAUL;;COATS PH D STEVEN J;;WHITAKER RICHARD ANTHONY;;HERMAN BRIAN DAVID;;CHO JONG HYUN;;ZHOU LONGHU;;ZHANG HONGWANG,SCHINAZI PH D RAYMOND F;;MELLORS JOHN W;;SLUIS-CREMER NICOLAS PAUL;;COATS PH D STEVEN J;;WHITAKER RICHARD ANTHONY;;HERMAN BRIAN DAVID;;CHO JONG HYUN;;ZHOU LONGHU;;ZHANG HONGWANG,UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (2012-02-09);;RFS PHARMA LLC (2011-12-01);;EMORY UNIVERSITY (2011-12-07),https://lens.org/130-896-004-016-228,Patent Application,yes,0,24,4,4,0,A61K31/437;;A61K31/437;;A61P31/12;;A61P31/18;;A61P31/20;;C07D473/34;;C07D473/34;;C07D473/16;;C07D473/16;;C07D473/18;;C07D473/18;;C07H19/173;;C07H19/173;;C07H19/20;;C07H19/20;;C07H19/207;;C07H19/207,A61K31/7076;;A61P31/18;;A61P31/20;;C07H19/207,514/48;;536/26.7,4,1,056-311-147-347-640,10.2174/0929867053363540;;15638729,"Wolff, Manfred E. ""Burger's Medicinal Chemistry, 5ed, Part I"", John Wiley & Sons, 1995, pages 975-977.;;Banker, G.S. et al, ""Modern Pharmaceutics, 3ed."", Marcel Dekker, New York, 1996, page 596.;;AN 1991:94697 - Karamov et al, Molekulyarnaya Biologiya, 1990, 24(6), 1695-1701, abstract.;;Lima et al., Current Medicinal Chemistry, 2005, vol. 12, 23-49.",ACTIVE
754,FR,B1,FR 2910267 B1,171-748-668-978-166,2009-01-23,2009,FR 0611198 A,2006-12-21,FR 0611198 A,2006-12-21,DISPOSITIF DE SOUTIEN VERTEBRAL,,LDR MEDICAL SOC PAR ACTIONS SI,CHATAIGNER HERVE;;SANTOS BENITEZ HUGO;;BRADLEY WILLIAM DANIEL;;SCHWARTZ ARNOLD M;;CHO PAUL HENRY;;DAVIS REGINALD JAMES;;HOFFMAN GREGORY A;;MCGEE ALAN W;;CHEN ZHONGQIANG;;JODAITIS ALEXANDRE;;WILLIAMS JOHN L,,https://lens.org/171-748-668-978-166,Granted Patent,no,0,0,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,0,0,,,,INACTIVE
755,WO,A3,WO 2008/078163 A3,087-148-425-608-087,2008-11-13,2008,IB 2007004061 W,2007-12-21,FR 0611198 A,2006-12-21,VERTEBRAL SUPPORT DEVICE,"A vertebral support device (1) is disclosed, which in various embodiments comprises at least two osseous anchoring implants (2), each designed to be anchored to a vertebra, and at least one linking element (3) fixed to the osseous anchoring implants (2) by fasteners (20) that maintain a fixed angle between the longitudinal axis (L) of the linking element (3) passing through rigid elements (34) of the linking element (3) and the insertion axis (DV) of the implants (2). The linking element (3) includes at least one elastic dampening element (31) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element (31) accommodates the stresses imposed on the linking element (3) during movement of the vertebrae and tends to return the support device (1) to its normal configuration.",LDR MEDICAL;;CHATAIGNER HERVE;;SANTOS BENITEZ HUGO;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM DANIEL;;CHO PAUL HENRY;;DAVIS REGINALD JAMES;;HOFFMAN GREGORY A;;MCGEE ALAN W;;CHEN ZHONGQIANG;;JODAITIS ALEXANDRE;;WILLIAMS JOHN I,CHATAIGNER HERVE;;SANTOS BENITEZ HUGO;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM DANIEL;;CHO PAUL HENRY;;DAVIS REGINALD JAMES;;HOFFMAN GREGORY A;;MCGEE ALAN W;;CHEN ZHONGQIANG;;JODAITIS ALEXANDRE;;WILLIAMS JOHN I,,https://lens.org/087-148-425-608-087,Search Report,yes,4,0,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,1,0,,,See also references of EP 2091451A2,PENDING
756,CA,A1,CA 2669905 A1,156-225-183-380-311,2008-07-03,2008,CA 2669905 A,2007-12-21,FR 0611198 A;;IB 2007004061 W,2006-12-21,VERTEBRAL SUPPORT DEVICE,"A vertebral support device (1) is disclosed, which in various embodiments comprises at least two osseous anchoring implants (2), each designed to be anchored to a vertebra, and at least one linking element (3) fixed to the os seous anchoring implants (2) by fasteners (20) that maintain a fixed angle b etween the longitudinal axis (L) of the linking element (3) passing through rigid elements (34) of the linking element (3) and the insertion axis (DV) o f the implants (2). The linking element (3) includes at least one elastic da mpening element (31) that that allows the implant-bearing vertebrae some fre edom of movement. The dampening element (31) accommodates the stresses impos ed on the linking element (3) during movement of the vertebrae and tends to return the support device (1) to its normal configuration.",LDR MEDICAL,WILLIAMS JOHN I;;JODAITIS ALEXANDRE;;DAVIS REGINALD JAMES;;CHATAIGNER HERVE;;SANTOS BENITEZ HUGO;;SCHWARTZ ARNOLD M;;CHEN ZHONGQIANG;;HOFFMAN GREGORY A;;BRADLEY WILLIAM DANIEL;;CHO PAUL HENRY;;MCGEE ALAN W,,https://lens.org/156-225-183-380-311,Patent Application,no,0,1,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,0,0,,,,INACTIVE
757,KR,A,KR 20090101912 A,090-493-136-217-608,2009-09-29,2009,KR 20097013313 A,2007-12-21,FR 0611198 A;;IB 2007004061 W,2006-12-21,VERTEBRAL SUPPORT DEVICE,"A vertebral support device (1) is disclosed, which in various embodiments comprises at least two osseous anchoring implants (2), each designed to be anchored to a vertebra, and at least one linking element (3) fixed to the osseous anchoring implants (2) by fasteners (20) that maintain a fixed angle between the longitudinal axis (L) of the linking element (3) passing through rigid elements (34) of the linking element (3) and the insertion axis (DV) of the implants (2). The linking element (3) includes at least one elastic dampening element (31) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element (31) accommodates the stresses imposed on the linking element (3) during movement of the vertebrae and tends to return the support device (1) to its normal configuration.",LDR MEDICAL,CHATAIGNER HERVE;;SANTOS BENITEZ HUGO;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM DANIEL;;CHO PAUL HENRY;;DAVIS REGINALD JAMES;;HOFFMAN GREGORY A;;MCGEE ALAN W;;CHEN ZHONGQIANG;;JODAITIS ALEXANDRE;;WILLIAMS JOHN I,,https://lens.org/090-493-136-217-608,Patent Application,no,0,1,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,,,0,0,,,,INACTIVE
758,CA,C,CA 2669905 C,156-069-488-884-148,2015-04-07,2015,CA 2669905 A,2007-12-21,FR 0611198 A;;IB 2007004061 W,2006-12-21,VERTEBRAL SUPPORT DEVICE,"A vertebral support device (1) is disclosed, which in various embodiments comprises at least two osseous anchoring implants (2), each designed to be anchored to a vertebra, and at least one linking element (3) fixed to the osseous anchoring implants (2) by fasteners (20) that maintain a fixed angle between the longitudinal axis (L) of the linking element (3) passing through rigid elements (34) of the linking element (3) and the insertion axis (DV) of the implants (2). The linking element (3) includes at least one elastic dampening element (31) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element (31) accommodates the stresses imposed on the linking element (3) during movement of the vertebrae and tends to return the support device (1) to its normal configuration.",LDR MEDICAL,CHATAIGNER HERVE;;SANTOS BENITEZ HUGO;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM DANIEL;;CHO PAUL HENRY;;DAVIS REGINALD JAMES;;HOFFMAN GREGORY A;;MCGEE ALAN W;;CHEN ZHONGQIANG;;JODAITIS ALEXANDRE;;WILLIAMS JOHN I,,https://lens.org/156-069-488-884-148,Granted Patent,no,0,0,23,23,0,A61B17/702;;A61B17/7041;;A61B17/705;;A61B17/7031;;A61B17/7034;;A61B17/70;;A61B17/702;;A61B17/7041;;A61B17/705;;A61B17/7031;;A61B17/7034;;A61B17/7032,A61B17/70,,0,0,,,,INACTIVE
759,BR,A2,BR PI0720494 A2,167-115-200-152-583,2014-02-04,2014,BR PI0720494 A,2007-12-21,FR 0611198 A;;IB 2007004061 W,2006-12-21,DISPOSITIVO DE SUPORTE VERTEBRAL,,LDR MEDICAL,CHATAIGNER HERVE;;SANTOS BENITEZ HUGO;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM DANIEL;;CHO PAUL HENRY;;DAVIS REGINALD JAMES;;HOFFMAN GREGORY A;;MCGEE ALAN W;;CHEN ZHONGQUIANG;;JODAITIS ALEXANDRE;;WILLIAMS JOHN I,,https://lens.org/167-115-200-152-583,Patent Application,no,0,0,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,0,0,,,,DISCONTINUED
760,US,S,US D0854078 S,166-317-856-035-493,2019-07-16,2019,US 201729609432 F,2017-06-30,US 201729609432 F,2017-06-30,Toner cartridge,,LEXMARK INT INC,ANDERSON JR JAMES DANIEL;;CARPENTER BRIAN SCOTT;;CHO MASAHITO;;HALE JASON PAUL;;MARTIN KYLE BRADLEY;;MCALPINE ROBERT WATSON;;PAYNE JEREMY KEITH;;PANGBURN THOMAS EUGENE;;ROGERS MATTHEW LEE;;TRIPLETT EDWARD LYNN,LEXMARK INTERNATIONAL INC (2017-06-23),https://lens.org/166-317-856-035-493,Design Right,no,35,8,1,6,0,,,1603;;D18/43,5,0,,,"Amazon. <URL: https://www.amazon.com/LINKYO-Replacement-Toner-Cartridges-2-Pack/dp/B06Y42ZZPG/ref=pd_day0_229_4?_encoding=UTF8&pd_rd_i=B06Y42ZZPG&pd_rd_r=0VFE28T5AST33K86VWBS&pd_rd_w=lsLkS&pd_rd_wg=pOzbE&psc=1&refRID=0VFE28T5AST33K86VWBS.> Apr. 7, 2017. LINKYO Replacement Toner Cartridges.;;Design U.S. Appl. No. 29/609,435, filed Jun. 30, 2017 (Anderson et al.).;;Design U.S. Appl. No. 29/609,439, filed Jun. 30, 2017 (Anderson et al.).;;Rejection dated Jun. 19, 2018 for Brazilian Registered Design Application No. BR3020170055168.;;Machine translation of rejection dated Jun. 19, 2018 for Brazilian Registered Design Application No. BR3020170055168.",ACTIVE
761,EP,A2,EP 2091451 A2,003-551-390-101-640,2009-08-26,2009,EP 07866577 A,2007-12-21,IB 2007004061 W;;FR 0611198 A,2006-12-21,VERTEBRAL SUPPORT DEVICE,,LDR MEDICAL,CHATAIGNER HERVE;;SANTOS BENITEZ HUGO;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM DANIEL;;CHO PAUL HENRY;;DAVIS REGINALD JAMES;;HOFFMAN GREGORY A;;MCGEE ALAN W;;CHEN ZHONGQIANG;;JODAITIS ALEXANDRE;;WILLIAMS JOHN I,,https://lens.org/003-551-390-101-640,Patent Application,yes,2,1,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,0,0,,,,DISCONTINUED
762,AU,B2,AU 2007/337793 B2,176-214-439-730-621,2013-04-04,2013,AU 2007/337793 A,2007-12-21,FR 0611198 A;;IB 2007004061 W,2006-12-21,Vertebral support device,"A vertebral support device (1) is disclosed, which in various embodiments comprises at least two osseous anchoring implants (2), each designed to be anchored to a vertebra, and at least one linking element (3) fixed to the osseous anchoring implants (2) by fasteners (20) that maintain a fixed angle between the longitudinal axis (L) of the linking element (3) passing through rigid elements (34) of the linking element (3) and the insertion axis (DV) of the implants (2). The linking element (3) includes at least one elastic dampening element (31) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element (31) accommodates the stresses imposed on the linking element (3) during movement of the vertebrae and tends to return the support device (1) to its normal configuration.",LDR MEDICAL,JODAITIS ALEXANDRE;;CHO PAUL HENRY;;SCHWARTZ ARNOLD M;;HOFFMAN GREGORY A;;CHEN ZHONGQIANG;;WILLIAMS JOHN I;;BRADLEY WILLIAM DANIEL;;SANTOS BENITEZ HUGO;;CHATAIGNER HERVE;;DAVIS REGINALD JAMES;;MCGEE ALAN W,,https://lens.org/176-214-439-730-621,Granted Patent,no,1,0,23,23,0,A61B17/702;;A61B17/7041;;A61B17/705;;A61B17/7031;;A61B17/7034;;A61B17/70;;A61B17/702;;A61B17/7041;;A61B17/705;;A61B17/7031;;A61B17/7034;;A61B17/7032,A61B17/70,,0,0,,,,INACTIVE
763,WO,A2,WO 2008/078163 A2,036-774-041-430-177,2008-07-03,2008,IB 2007004061 W,2007-12-21,FR 0611198 A,2006-12-21,VERTEBRAL SUPPORT DEVICE,"A vertebral support device (1) is disclosed, which in various embodiments comprises at least two osseous anchoring implants (2), each designed to be anchored to a vertebra, and at least one linking element (3) fixed to the osseous anchoring implants (2) by fasteners (20) that maintain a fixed angle between the longitudinal axis (L) of the linking element (3) passing through rigid elements (34) of the linking element (3) and the insertion axis (DV) of the implants (2). The linking element (3) includes at least one elastic dampening element (31) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element (31) accommodates the stresses imposed on the linking element (3) during movement of the vertebrae and tends to return the support device (1) to its normal configuration.",LDR MEDICAL;;CHATAIGNER HERVE;;SANTOS BENITEZ HUGO;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM DANIEL;;CHO PAUL HENRY;;DAVIS REGINALD JAMES;;HOFFMAN GREGORY A;;MCGEE ALAN W;;CHEN ZHONGQIANG;;JODAITIS ALEXANDRE;;WILLIAMS JOHN I,CHATAIGNER HERVE;;SANTOS BENITEZ HUGO;;SCHWARTZ ARNOLD M;;BRADLEY WILLIAM DANIEL;;CHO PAUL HENRY;;DAVIS REGINALD JAMES;;HOFFMAN GREGORY A;;MCGEE ALAN W;;CHEN ZHONGQIANG;;JODAITIS ALEXANDRE;;WILLIAMS JOHN I,,https://lens.org/036-774-041-430-177,Patent Application,yes,0,33,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,1,0,,,See references of EP 2091451A2,PENDING
764,CN,A,CN 112954501 A,062-408-324-811-845,2021-06-11,2021,CN 202010979573 A,2020-09-17,US 201962946288 P;;US 202017021879 A,2019-12-10,SPEAKER ASSEMBLY,"The invention relates to a speaker assembly. An electronic device can include a housing defining an aperture and a display positioned in the aperture. The display and the housing can define an internal volume in which a speaker assembly is positioned. The speaker assembly can include a speaker module and a speaker enclosure in fluid communication, with the speaker enclosure at least partially defining a speaker volume.",APPLE INC,WANG PAUL X;;FENG CHANJUAN;;WILK CHRISTOPHER;;MATHEW DINESH C;;HENDREN KEITH J;;NEVILL STUART M;;BOOTHE DANIEL K;;RUNDLE NICHOLAS A;;CHO SHO;;TSANG THOMAS H;;MIKOLAJCZYK REBECCA J,,https://lens.org/062-408-324-811-845,Patent Application,no,12,0,4,4,0,H04R1/025;;H04R1/026;;H04R9/02;;H04R9/06;;H04R1/2826;;H04R1/023;;H04R1/26;;H04R1/2857;;H04R1/2888;;H04R2499/15;;G06F1/1605;;H04R1/028;;H04R2499/15;;H04R3/12;;G06F1/1688,H04R1/02;;H04R9/02;;H04R9/06,,3,0,,,"郭心怡: ""微型压电超声换能器的研究与设计"", 《中国优秀硕士学位论文全文数据库》;;BURHANUDDIN YEOP MAJLIS等: ""Compact electrodynamics MEMS-speaker"", 《2017 CHINA SEMICONDUCTOR TECHNOLOGY INTERNATIONAL CONFERENCE (CSTIC)》;;京士柏: ""弥补电视的声音短板SONY 索尼回音壁HT-CT290"", 《家庭影院技术》, no. 8",PENDING
765,FR,A1,FR 2910267 A1,000-372-311-599-936,2008-06-27,2008,FR 0611198 A,2006-12-21,FR 0611198 A,2006-12-21,DISPOSITIF DE SOUTIEN VERTEBRAL,"La présente invention concerne un dispositif (1) de soutien vertébral, comportant au moins deux implants (2) d'ancrage osseux, destinés à être ancrés chacun dans une vertèbre selon un axe (DV), dit dorso-ventral, et au moins un élément (3) de liaison comportant un axe (L) longitudinal et reliant entre eux les implants (2) d'ancrage osseux, caractérisé en ce que l'élément (3) de liaison comporte au moins deux éléments (34) rigides reliés chacun à un implant (2) d'ancrage osseux par les moyens (20) de fixation et articulés entre eux par au moins un élément (31) amortisseur élastique, comportant, d'une part, au moins une portion (32), dite centrale, élastique située entre les deux éléments (34) rigides et coopérant avec ces derniers pour amortir les contraintes en compression exercées sur l'élément (3) de liaison et, d'autre part, au moins une portion (33), dite longitudinale, comportant deux extrémités, chacune maintenue fixe par rapport aux implants (2) d'ancrage osseux et/ou aux éléments (34) rigides par des moyens (330, 331 ) de fixation de la portion longitudinale (33), de façon à amortir les contraintes en extension exercées sur l'élément (3) de liaison.",LDR MEDICAL SOC PAR ACTIONS SI,CHATAIGNER HERVE;;SANTOS BENITEZ HUGO;;BRADLEY WILLIAM DANIEL;;SCHWARTZ ARNOLD M;;CHO PAUL HENRY;;DAVIS REGINALD JAMES;;HOFFMAN GREGORY A;;MCGEE ALAN W;;CHEN ZHONGQIANG;;JODAITIS ALEXANDRE;;WILLIAMS JOHN L,,https://lens.org/000-372-311-599-936,Patent Application,no,4,1,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,0,0,,,,INACTIVE
766,CN,B,CN 101605501 B,102-128-983-483-980,2011-04-20,2011,CN 200780047507 A,2007-12-21,IB 2007004061 W;;FR 0611198 A,2006-12-21,Vertebral support device,"A vertebral support device ( 1 ) is disclosed, which in various embodiments comprises at least two osseous anchoring implants ( 2 ), each designed to be anchored to a vertebra, and at least one linking element ( 3 ) fixed to the osseous anchoring implants ( 2 ) by fasteners ( 20 ) that maintain a fixed angle between the longitudinal axis (L) of the linking element ( 3 ) passing through rigid elements ( 34 ) of the linking element ( 3 ) and the insertion axis (DV) of the implants ( 2 ). The linking element ( 3 ) includes at least one elastic dampening element ( 31 ) that that allows the implant-bearing vertebrae some freedom of movement. The dampening element ( 31 ) accommodates the stresses imposed on the linking element ( 3 ) during movement of the vertebrae and tends to return the support device ( 1 ) to its normal configuration.",LDR MEDICAL,HERVE CHATAIGNER;;HUGO SANTOS BENITEZ;;SCHWARTZ ARNOLD M;;DANIEL BRADLEY WILLIAM;;HENRY CHO PAUL;;JAMES DAVIS REGINALD;;HOFFMAN GREGORY A;;MCGEE ALAN W;;ZHONGQIANG CHEN;;ALEXANDRE JODAITIS;;WILLIAMS JOHN I,,https://lens.org/102-128-983-483-980,Granted Patent,no,0,0,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,0,0,,,,INACTIVE
767,AU,A1,AU 2007/337793 A1,028-612-989-104-825,2008-07-03,2008,AU 2007/337793 A,2007-12-21,FR 0611198 A;;IB 2007004061 W,2006-12-21,Vertebral support device,,LDR MEDICAL,CHEN ZHONGQIANG;;JODAITIS ALEXANDRE;;BRADLEY WILLIAM DANIEL;;DAVIS REGINALD JAMES;;CHATAIGNER HERVE;;SCHWARTZ ARNOLD M;;WILLIAMS JOHN I;;CHO PAUL HENRY;;MCGEE ALAN W;;BENITEZ HUGO SANTOS;;HOFFMAN GREGORY A,,https://lens.org/028-612-989-104-825,Patent Application,no,0,1,23,23,0,A61B17/70;;A61B17/7031;;A61B17/7031;;A61B17/702;;A61B17/702;;A61B17/7032;;A61B17/7034;;A61B17/7034;;A61B17/7041;;A61B17/7041;;A61B17/705;;A61B17/705,A61B17/70,,0,0,,,,INACTIVE
768,AU,B2,AU 687582 B2,011-994-159-397-170,1998-02-26,1998,AU 1995/029149 A,1995-07-05,US 27168594 A;;US 27168694 A;;US 27169294 A;;US 27169394 A;;US 27169494 A;;US 33561794 A;;US 9508253 W,1994-07-07,Catalytic system for the reduction of nitrogen oxides,,MOBIL OIL CORP,AUDEH COSTANDI AMIN;;DEGNAN THOMAS FRANCIS;;FARNOS MARIA DOLORES;;HATZIKOS GEORGE HARRY;;MCWILLIAMS JOHN PAUL;;SHARMA SANJAY BHARDWAJ;;SHIHABI DAVID SAID;;SOCHA RICHARD FRANCIS;;STEVENSON SCOTT ANDREW;;TIMKEN HYE KYUNG CHO;;VARTULI JAMES CLARKE,,https://lens.org/011-994-159-397-170,Granted Patent,no,3,0,6,11,0,B01D53/8621;;B01D53/865;;B01D53/9413;;B01D53/9436;;B01D2251/208;;B01D2255/20738;;B01D2255/50;;B01D2255/912;;B01J29/072;;B01J29/46;;B01J37/0203;;B01J2229/26;;B01J2229/42;;F01N3/2066;;F01N2610/02;;Y02T10/12,B01D53/86;;B01D53/94;;B01J29/072;;B01J29/46;;B01J37/02;;F01N3/20,,0,0,,,,EXPIRED
769,EP,A1,EP 0935498 A1,009-771-401-638-500,1999-08-18,1999,EP 95924763 A,1995-07-05,US 9508253 W;;US 27168594 A;;US 27168694 A;;US 27169294 A;;US 27169394 A;;US 27169494 A;;US 33561794 A,1994-07-07,CATALYTIC SYSTEM FOR THE REDUCTION OF NITROGEN OXIDES,,MOBIL OIL CORP,AUDEH COSTANDI AMIN;;DEGNAN THOMAS FRANCIS;;FARNOS MARIA DOLORES;;HATZIKOS GEORGE HARRY;;MCWILLIAMS JOHN PAUL;;SHARMA SANJAY BHARDWAJ;;SHIHABI DAVID SAID;;SOCHA RICHARD FRANCIS;;STEVENSON SCOTT ANDREW;;TIMKEN HYE KYUNG CHO;;VARTULI JAMES CLARKE,,https://lens.org/009-771-401-638-500,Patent Application,yes,0,0,6,11,0,B01D53/8621;;B01D53/865;;B01D53/9413;;B01D53/9436;;B01D2251/208;;B01D2255/20738;;B01D2255/50;;B01D2255/912;;B01J29/072;;B01J29/46;;B01J37/0203;;B01J2229/26;;B01J2229/42;;F01N3/2066;;F01N2610/02;;Y02T10/12,B01D53/86;;B01D53/94;;B01J29/072;;B01J29/46;;B01J37/02;;F01N3/20,,0,0,,,,DISCONTINUED
770,KR,A,KR 20060019676 A,060-529-208-173-485,2006-03-06,2006,KR 20040068282 A,2004-08-28,KR 20040068282 A,2004-08-28,APPARATUS AND METHOD FOR TRANSMITTING/RECEIVING A SUB-CARRIER SIGNAL FOR A SITE DIVERSITY IN A COMMUNICATION SYSTEM USING AN ORTHOGONAL FREQUENCY DIVISION MULTIPLE ACCESS SCHEME,,SAMSUNG ELECTRONICS CO LTD,SUH CHANG HO;;YOON SEOK HYUN;;HONG SUNG KWON;;CHO YOUNG KWON;;KIM YOUNG KYUN;;PARK DONG SEEK;;RO JUNG MIN;;WIJTING CARL SIMON;;FITZEK FRANK HANNS PAUL;;THEEUWES JEROEN;;PRASAD RAMJEE;;POPOVSKI PETAR,,https://lens.org/060-529-208-173-485,Patent Application,no,0,2,4,4,0,H04W48/20;;H04W72/0453;;H04W72/54;;H04B7/022;;H04W48/20;;H04W72/0453;;H04W72/1263;;H04W72/54;;H04W48/20;;H04W72/0453;;H04W72/54,H04L27/26;;H04J11/00;;H04W72/08,,0,0,,,,INACTIVE
771,US,B2,US 7209460 B2,033-897-820-184-762,2007-04-24,2007,US 21431205 A,2005-08-29,KR 20040068282 A,2004-08-28,Apparatus and method for assigning subcarrier in OFDMA communication system,"A subcarrier assignment apparatus and a subcarrier assignment method, in which each of a plurality of Base Stations (BSs) constituting an Orthogonal Frequency Division Multiple Access (OFDMA) communication system provides services in the capacity of a serving BS to Mobile Stations (MSs). Channel quality information for the respective MSs are fed-back from the respective BSs. Subcarriers are assigned to the respective MSs according to a corresponding scheduling scheme in consideration of the channel quality information for the respective MSs, which are fed-back from the respective BSs, and then BSs which manage the subcarriers assigned to the respective MSs according to the corresponding scheduling scheme are selected. These operations provide site diversity to each of the MSs, and thus system capacity is maximized.",SAMSUNG ELECTRONICS CO LTD,FITZEK FRANK HANNS PAUL;;WIJTING CARL SIMON;;THEEUWES JEROEN;;POPOVSKI PETAR;;PRASAD RAMJEE;;SUH CHANG-HO;;YOON SEOK-HYUN;;HONG SUNG-KWON;;CHO YOUNG-KWON;;KIM YOUNG-KYUN;;PARK DONG-SEEK;;RO JUNG-MIN,SAMSUNG ELECTRONICS CO. LTD (2005-12-19),https://lens.org/033-897-820-184-762,Granted Patent,yes,3,13,4,4,0,H04W48/20;;H04W72/0453;;H04W72/54;;H04B7/022;;H04W48/20;;H04W72/0453;;H04W72/1263;;H04W72/54;;H04W48/20;;H04W72/0453;;H04W72/54,H04W72/08,370/329;;370/328;;370/208;;370/340;;370/341;;370/203;;370/430;;455/450;;455/452.1;;455/452.2;;455/509;;455/511;;455/515;;375/220,0,0,,,,ACTIVE
772,CA,A1,CA 2193951 A1,041-404-802-056-494,1996-01-25,1996,CA 2193951 A,1995-07-05,US 27168594 A;;US 27168694 A;;US 27169294 A;;US 27169394 A;;US 27169494 A;;US 33561794 A,1994-07-07,CATALYTIC SYSTEM FOR THE REDUCTION OF NITROGEN OXIDES,A catalytic process for the treatment of exhaust containing NOx along with other undesirable compounds is described. One embodiment of the process comprises a catalytic stage to selectively catalytically reduce NOx over an intermediate pore size zeolite catalyst that has been treated or modified to contain iron and then has been hydrothermally treated at least one time.,MOBIL OIL CORP,AUDEH COSTANDI AMIN;;DEGNAN THOMAS FRANCIS;;FARNOS MARIA DOLORES;;SHIHABI DAVID SAID;;MCWILLIAMS JOHN PAUL;;STEVENSON SCOTT ANDREW;;HATZIKOS GEORGE HARRY;;VARTULI JAMES CLARKE;;SHARMA SANJAY BHARDWAJ;;TIMKEN HYE KYUNG CHO;;SOCHA RICHARD FRANCIS,,https://lens.org/041-404-802-056-494,Patent Application,no,0,1,6,11,0,B01D53/8621;;B01D53/865;;B01D53/9413;;B01D53/9436;;B01D2251/208;;B01D2255/20738;;B01D2255/50;;B01D2255/912;;B01J29/072;;B01J29/46;;B01J37/0203;;B01J2229/26;;B01J2229/42;;F01N3/2066;;F01N2610/02;;Y02T10/12,B01D53/86;;B01D53/94;;B01J29/072;;B01J29/46;;B01J37/02;;F01N3/20,,0,0,,,,DISCONTINUED
773,AU,A,AU 1995/029149 A,192-880-647-157-764,1996-02-09,1996,AU 1995/029149 A,1995-07-05,US 27168594 A;;US 27168694 A;;US 27169294 A;;US 27169394 A;;US 27169494 A;;US 33561794 A;;US 9508253 W,1994-07-07,Catalytic system for the reduction of nitrogen oxides,,MOBIL OIL CORP,AUDEH COSTANDI AMIN;;DEGNAN THOMAS FRANCIS;;FARNOS MARIA DOLORES;;HATZIKOS GEORGE HARRY;;MCWILLIAMS JOHN PAUL;;SHARMA SANJAY BHARDWAJ;;SHIHABI DAVID SAID;;SOCHA RICHARD FRANCIS;;STEVENSON SCOTT ANDREW;;TIMKEN HYE KYUNG CHO;;VARTULI JAMES CLARKE,,https://lens.org/192-880-647-157-764,Patent Application,no,0,0,6,11,0,B01D53/8621;;B01D53/865;;B01D53/9413;;B01D53/9436;;B01D2251/208;;B01D2255/20738;;B01D2255/50;;B01D2255/912;;B01J29/072;;B01J29/46;;B01J37/0203;;B01J2229/26;;B01J2229/42;;F01N3/2066;;F01N2610/02;;Y02T10/12,B01D53/86;;B01D53/94;;B01J29/072;;B01J29/46;;B01J37/02;;F01N3/20,,0,0,,,,EXPIRED
774,WO,A1,WO 1996/001689 A1,096-469-188-822-381,1996-01-25,1996,US 9508253 W,1995-07-05,US 27168594 A;;US 27168694 A;;US 27169294 A;;US 27169394 A;;US 27169494 A;;US 33561794 A,1994-07-07,CATALYTIC SYSTEM FOR THE REDUCTION OF NITROGEN OXIDES,A catalytic process for the treatment of exhaust containing NOx along with other undesirable compounds is described. One embodiment of the process comprises a catalytic stage to selectively catalytically reduce NOx over an intermediate pore size zeolite catalyst that has been treated or modified to contain iron and then has been hydrothermally treated at least one time.,MOBIL OIL CORP,AUDEH COSTANDI AMIN;;DEGNAN THOMAS FRANCIS;;FARNOS MARIA DOLORES;;HATZIKOS GEORGE HARRY;;MCWILLIAMS JOHN PAUL;;SHARMA SANJAY BHARDWAJ;;SHIHABI DAVID SAID;;SOCHA RICHARD FRANCIS;;STEVENSON SCOTT ANDREW;;TIMKEN HYE KYUNG CHO;;VARTULI JAMES CLARKE,,https://lens.org/096-469-188-822-381,Patent Application,yes,4,20,6,11,0,B01D53/8621;;B01D53/865;;B01D53/9413;;B01D53/9436;;B01D2251/208;;B01D2255/20738;;B01D2255/50;;B01D2255/912;;B01J29/072;;B01J29/46;;B01J37/0203;;B01J2229/26;;B01J2229/42;;F01N3/2066;;F01N2610/02;;Y02T10/12,B01D53/86;;B01D53/94;;B01J29/072;;B01J29/46;;B01J37/02;;F01N3/20,,1,0,,,See also references of EP 0935498A4,PENDING
775,KR,A,KR 20210016769 A,088-753-902-059-597,2021-02-17,2021,KR 20190094955 A,2019-08-05,KR 20190094955 A,2019-08-05,AEROSOL GENERATING DEVICE,"An aerosol generating device comprises: a body housing comprising a heater, a battery, and a control unit; and a cover having an empty space into which a part of an upper end of the body housing can be inserted, thereby being coupled to protect the upper end of the body housing and charging auxiliary power to charge the batter of the body housing. The present invention can promote more improved user convenience for the aerosol generating device.",KT & G CORP,YOON SUNG WOOK;;LEE JU HWAN;;LEE WON KYEONG;;HAN DAE NAM;;KWON DONG BUM;;KIM TAE HUN;;SUNWOO PAUL JOON;;SEONG JIN SOO;;LEE JAE MIN;;LEE JONG SUB;;JUNG HYUNG JIN;;CHO BYUNG SUNG,,https://lens.org/088-753-902-059-597,Patent Application,no,9,1,2,2,0,A24F40/90;;A24F15/18;;A24F40/50;;A24F40/60;;A24F40/65,A24F47/00,,0,0,,,,ACTIVE
776,EP,A1,EP 4203770 A1,082-191-187-770-506,2023-07-05,2023,EP 21786625 A,2021-08-27,US 202063071997 P;;US 2021/0048037 W,2020-08-28,DETECTION OF PATIENT CONDITIONS USING SIGNALS SENSED ON OR NEAR THE HEAD,,COVIDIEN LP,SCHULHAUSER RANDAL C;;GIFTAKIS JONATHON E;;PANKEN ERIC J;;WAINWRIGHT JOHN;;VIRAG NATHALIE;;KRAUSE PAUL G;;CHO YONG K;;DEFOE SCOTT;;SCHEINER AVRAM;;IPPOLITO EKATERINA M;;ANDERSON DAVID A;;GREENHUT SAUL E;;BOONE MARK R;;O'BRIEN RICHARD J,,https://lens.org/082-191-187-770-506,Patent Application,yes,0,0,4,4,0,A61B5/0006;;A61B5/0031;;A61B5/165;;A61B5/291;;A61B5/318;;A61B5/372;;A61B5/4094;;A61B5/6803;;A61B5/686;;A61B5/7264;;A61B5/742;;A61B5/291;;A61B5/0205;;A61B5/02125;;A61B5/02405;;A61B5/0245;;A61B5/1102;;A61B5/1117;;A61B5/4035;;A61B5/4094;;A61B5/4561;;A61B5/6814;;A61B5/6822;;A61B5/7264;;A61B2562/0219,A61B5/00;;A61B5/16;;A61B5/291;;A61B5/318;;A61B5/372,,0,0,,,,PENDING
777,WO,A1,WO 2022/047215 A1,104-184-638-047-677,2022-03-03,2022,US 2021/0048037 W,2021-08-27,US 202063071997 P,2020-08-28,DETECTION OF PATIENT CONDITIONS USING SIGNALS SENSED ON OR NEAR THE HEAD,"A system comprises a sensor device and processing circuitry. The sensor device comprises a housing configured to be disposed above shoulders of a patient, a plurality of electrodes on the housing, a motion sensor, and sensing circuitry configured to sense a brain electrical signal and a cardiac electrical signal via the electrodes, and a motion signal via the motion sensor. The processing circuitry is configured to determine values over time of one or more parameters from the brain electrical signal, determine values over time of one or more parameters from the cardiac electrical signal, and generate at least one of a detection, prediction, or a classification a condition of the patient based on the values and the motion signal.",COVIDIEN LP,SCHULHAUSER RANDAL C;;GIFTAKIS JONATHON E;;PANKEN ERIC J;;WAINWRIGHT JOHN;;VIRAG NATHALIE;;KRAUSE PAUL G;;CHO YONG K;;DEFOE SCOTT;;SCHEINER AVRAM;;IPPOLITO EKATERINA M;;ANDERSON DAVID A;;GREENHUT SAUL E;;BOONE MARK R;;O'BRIEN RICHARD J,,https://lens.org/104-184-638-047-677,Patent Application,yes,9,0,4,4,0,A61B5/0006;;A61B5/0031;;A61B5/165;;A61B5/291;;A61B5/318;;A61B5/372;;A61B5/4094;;A61B5/6803;;A61B5/686;;A61B5/7264;;A61B5/742;;A61B5/291;;A61B5/0205;;A61B5/02125;;A61B5/02405;;A61B5/0245;;A61B5/1102;;A61B5/1117;;A61B5/4035;;A61B5/4094;;A61B5/4561;;A61B5/6814;;A61B5/6822;;A61B5/7264;;A61B2562/0219,A61B5/00;;A61B5/16;;A61B5/291;;A61B5/318;;A61B5/372,,0,0,,,,PENDING
778,US,A1,US 2022/0061678 A1,113-986-331-051-621,2022-03-03,2022,US 202117459713 A,2021-08-27,US 202117459713 A;;US 202063071997 P,2020-08-28,DETECTION OF PATIENT CONDITIONS USING SIGNALS SENSED ON OR NEAR THE HEAD,"A system comprises a sensor device and processing circuitry. The sensor device comprises a housing configured to be disposed above shoulders of a patient, a plurality of electrodes on the housing, a motion sensor, and sensing circuitry configured to sense a brain electrical signal and a cardiac electrical signal via the electrodes, and a motion signal via the motion sensor. The processing circuitry is configured to determine values over time of one or more parameters from the brain electrical signal, determine values over time of one or more parameters from the cardiac electrical signal, and generate at least one of a detection, prediction, or a classification a condition of the patient based on the values and the motion signal.",COVIDIEN LP,SCHULHAUSER RANDAL C;;GIFTAKIS JONATHON E;;PANKEN ERIC J;;WAINWRIGHT JOHN;;VIRAG NATHALIE;;KRAUSE PAUL G;;CHO YONG K;;DEFOE SCOTT;;SCHEINER AVRAM;;IPPOLITO EKATERINA M;;ANDERSON DAVID A;;GREENHUT SAUL E;;BOONE MARK R;;O'BRIEN RICHARD J,COVIDIEN LP (2021-09-24),https://lens.org/113-986-331-051-621,Patent Application,yes,2,1,4,4,0,A61B5/0006;;A61B5/0031;;A61B5/165;;A61B5/291;;A61B5/318;;A61B5/372;;A61B5/4094;;A61B5/6803;;A61B5/686;;A61B5/7264;;A61B5/742;;A61B5/291;;A61B5/0205;;A61B5/02125;;A61B5/02405;;A61B5/0245;;A61B5/1102;;A61B5/1117;;A61B5/4035;;A61B5/4094;;A61B5/4561;;A61B5/6814;;A61B5/6822;;A61B5/7264;;A61B2562/0219,A61B5/0205;;A61B5/00;;A61B5/11,,0,0,,,,PENDING
779,WO,A1,WO 2024/011233 A1,136-769-800-654-331,2024-01-11,2024,US 2023/0069796 W,2023-07-07,US 202263359167 P,2022-07-07,HYBRID PROTEIN DESIGN,"A method may include applying a protein sequence computation model to generate, based on an input protein sequence, a plurality of proposed protein sequences. A set of possible amino acid residues for each position in at least a portion of an output protein sequence may be identified based on the plurality of proposed protein sequences. A first protein structure having the output protein sequence may be generated by applying a protein structure computation model to select, for each position in at least the portion of the output protein sequence, an amino acid residue from a corresponding set of possible amino acid residues. The protein structure computation model may further determine the conformation of the amino acid residues selected for inclusion in the output protein sequence. In some cases, the first protein structure may be grafted onto a second protein structure to form a third protein structure.",GENENTECH INC;;HOFFMANN LA ROCHE;;HOFFMANN LA ROCHE,KELOW SIMON PAUL;;BERENBERG DANIEL JOSEPH;;NERLI SANTRUPTI;;LEAVER-FAY ANDREW PHILIP;;MAGUIRE JACK BARTON;;CHUNGYOUN MICHAEL FLORIAN;;WATKINGS ANDREW MARTIN;;LEE JAE;;RA STEPHEN ROBERT;;DWYER HENRI VINCENT;;LEE MINJI MARIA;;CHO KYUNGHYUN;;BONNEAU RICHARD A;;GLIGORIJEVIC VLADIMIR,,https://lens.org/136-769-800-654-331,Patent Application,yes,0,0,1,1,0,G16B35/10,G16B35/10,,3,3,020-302-752-068-921;;115-659-907-387-772;;045-253-338-472-24X,10.1007/978-1-4939-6637-0_12;;pmc5667548;;27914055;;10.1111/febs.12056;;23121732;;30463010;;10.1016/j.celrep.2018.10.081,"""Computational Protein Design"", vol. 1529, 2 November 2017, SPRINGER NEW YORK, New York, NY, ISBN: 978-1-4939-6637-0, ISSN: 1064-3745, article BRENDER JEFFREY R. ET AL: ""An Evolution-Based Approach to De Novo Protein Design"", pages: 243 - 264, XP093086426, DOI: 10.1007/978-1-4939-6637-0_12;;TLATLI RYM ET AL: ""Grafting of functional motifs onto protein scaffolds identified by PDB screening - an efficient route to design optimizable protein binders"", THE FEBS JOURNAL, vol. 280, no. 1, 29 November 2012 (2012-11-29), GB, pages 139 - 159, XP055887478, ISSN: 1742-464X, Retrieved from the Internet <URL:https://febs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/febs.12056> DOI: 10.1111/febs.12056;;GUY NIMROD ET AL: ""Computational Design of Epitope-Specific Functional Antibodies"", CELL REPORTS, vol. 25, no. 8, 1 November 2018 (2018-11-01), US, pages 2121 - 2131.e5, XP055681491, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2018.10.081",PENDING
780,CN,A,CN 116056638 A,030-256-266-892-673,2023-05-02,2023,CN 202180052994 A,2021-08-27,US 202063071997 P;;US 2021/0048037 W,2020-08-28,DETECTING A PATIENT CONDITION USING SIGNALS SENSED ON OR NEAR THE HEAD,"A system includes a sensor device and processing circuitry. The sensor device includes a housing configured to be disposed over a shoulder of a patient, a plurality of electrodes on the housing, a motion sensor, and sensing circuitry configured to sense electroencephalogram and electrocardiosignals via the electrodes and to sense motion signals via the motion sensor. The processing circuitry is configured to determine values of the one or more parameters over time from the electroencephalogram signal, determine values of the one or more parameters over time from the electrocardiosignal, and generate at least one of a detection, a prediction, or a classification of a condition of the patient based on the values and the motion signal.",COVIDIEN CO LTD,SCHULHAUSER RANDAL C;;JFTAKIS JAMES E;;PANKEN ERIC J;;WAINWRIGHT JOHN;;VIRAG NIMROD;;KRAUSE PAUL G;;CHO YONG K;;DUFAU STEPHANE;;SCHEINER ANDREAS;;IPPOLITO ENRIQUE MARIA;;ANDERSON DAVID A;;GREENHUT SAUL E;;BOONE MARK R;;O 'BRIEN RICHARD J,,https://lens.org/030-256-266-892-673,Patent Application,no,0,0,4,4,0,A61B5/0006;;A61B5/0031;;A61B5/165;;A61B5/291;;A61B5/318;;A61B5/372;;A61B5/4094;;A61B5/6803;;A61B5/686;;A61B5/7264;;A61B5/742;;A61B5/291;;A61B5/0205;;A61B5/02125;;A61B5/02405;;A61B5/0245;;A61B5/1102;;A61B5/1117;;A61B5/4035;;A61B5/4094;;A61B5/4561;;A61B5/6814;;A61B5/6822;;A61B5/7264;;A61B2562/0219,A61B5/16,,0,0,,,,PENDING
781,US,A1,US 2024/0077309 A1,160-314-777-175-963,2024-03-07,2024,US 18153940,2023-01-12,,,PHYSICAL ACTIVITY USER INTERFACES,"The present disclosure generally relates to displaying information related to a physical activity. In some embodiments, methods and user interfaces for managing the display of information related to a physical activity are described.",Apple Inc.,Nicholas D. FELTON;;James B. CARY;;Edward CHAO;;Kevin W. CHEN;;Christopher P. FOSS;;Eamon F. GILRAVI;;Austen J. GREEN;;Bradley W. GRIFFIN;;Anders K. HAGLUNDS;;Lori HYLAN-CHO;;Stephen P. JACKSON;;Matthew S. KOONCE;;Paul T. NIXON;;Robert M. PEARSON,,https://lens.org/160-314-777-175-963,Patent Application,yes,0,0,1,1,0,G01C5/06;;B63C11/02;;G01F23/18;;G06F3/016;;B63C2011/021,G01C5/06;;B63C11/02;;G01F23/18;;G06F3/01,,0,0,,,,UNKNOWN
782,US,A1,US 2017/0312153 A1,032-533-954-264-545,2017-11-02,2017,US 201715583254 A,2017-05-01,US 201715583254 A;;US 201662330477 P,2016-05-02,PATIENT LIFT ORTHOSIS,"A patient lift orthosis system including an input controller and at least one orthosis. The at least one orthosis including an upper orthosis assembly and a lower orthosis assembly rotatably attached to the upper orthosis assembly via a joint. The at least one orthosis further including an output controller attached to at least one of the upper orthosis assembly, the lower orthosis assembly, and the joint, the output controller being in communication with the input controller. The at least one orthosis further including an actuator attached to at least one of the upper orthosis assembly, the lower orthosis assembly, and the joint, the actuator being in communication with the output controller. The output controller is configured to actuate the actuator to rotate one of the upper orthosis assembly and the lower orthosis assembly about the joint based upon an input communicated from the input controller.",EXORISE L L C,PAUL SCOTT M;;MOON KEVIN BRIAN;;MAHOSKI BROOKE MICHELE;;CADE ROWAN PATRICK;;BERNSTEIN THOMAS CLIFFORD BRUNOSKI;;MCNALLY EMILY JANE;;SCHOLTZ ALEXIS KAYLA;;CHO SUE MIN;;LI ZHOU;;ELDRIDGE BAXTER RHODES;;NAHILL MARY THERESA;;KELLOGG SUSANNA ELAINE;;ORTIZ RONANN HARL CARRERO;;GRAMUGLIA MATTHEW JOSEPH,,https://lens.org/032-533-954-264-545,Patent Application,yes,0,9,2,2,0,A61F5/0123;;A61F5/0123;;A61G5/14;;A61G2203/10;;A61G2203/30;;A61G2203/34;;A61G2203/70,A61G5/14;;A61F5/01,,0,0,,,,DISCONTINUED
783,WO,A1,WO 2017/192561 A1,138-300-897-593-823,2017-11-09,2017,US 2017/0030603 W,2017-05-02,US 201662330477 P;;US 201715583254 A,2016-05-02,PATIENT LIFT ORTHOSIS,"A patient lift orthosis system including an input controller and at least one orthosis. The at least one orthosis including an upper orthosis assembly and a lower orthosis assembly rotatably attached to the upper orthosis assembly via a joint. The at least one orthosis further including an output controller attached to at least one of the upper orthosis assembly, the lower orthosis assembly, and the joint, the output controller being in communication with the input controller. The at least one orthosis further including an actuator attached to at least one of the upper orthosis assembly, the lower orthosis assembly, and the joint, the actuator being in communication with the output controller. The output controller is configured to actuate the actuator to rotate one of the upper orthosis assembly and the lower orthosis assembly about the joint based upon an input communicated from the input controller.",EXORISE L L C,PAUL SCOTT M;;MOON KEVIN BRIAN;;MAHOSKI BROOKE MICHELE;;CADE ROWAN PATRICK;;BERNSTEIN THOMAS CLIFFORD BRUNOSKI;;MCNALLY EMILY JANE;;SCHOLTZ ALEXIS KAYLA;;CHO SUE MIN;;LI ZHOU;;ELDRIDGE BAXTER RHODES;;NAHILL MARY THERESA;;KELLOGG SUSANNA ELAINE;;ORTIZ RONANN HARL CARRERO;;GRAMUGLIA MATTHEW JOSEPH,,https://lens.org/138-300-897-593-823,Patent Application,yes,11,0,2,2,0,A61F5/0123;;A61F5/0123;;A61G5/14;;A61G2203/10;;A61G2203/30;;A61G2203/34;;A61G2203/70,A61F5/01;;A61G5/14;;A61G7/10;;A61H1/00;;A61H1/02;;A61H3/00;;A61N1/04;;B25J9/00;;B25J11/00;;B25J17/00,,0,0,,,,PENDING
784,WO,A4,WO 2023/203412 A4,080-113-783-092-864,2023-12-28,2023,IB 2023053409 W,2023-04-04,US 202263363458 P,2022-04-22,CLOSED LOOP ADJUSTMENT OF HEART FAILURE THERAPY,"A medical system includes an implantable cardiac device configured to monitor one or more cardio-thoracic parameters of a patient and one or more external devices configured to receive, from the implantable cardiac device, cardio-thoracic data indicative of the one or more cardio-thoracic parameters over a period of time; determine a long term heart failure risk (HFR) score for the patient based on the cardio-thoracic data; based on a change in the long term HFR score for the patient, determine a modification to a therapy plan of a second implanted device in the patient; and cause the second implanted device to implement the modified therapy plan.",MEDTRONIC INC,KRAUSE PAUL G;;CHO YONG K;;CINBIS CAN;;KUHN JONATHAN L;;STIGEN TYLER;;TAYLOR AMANDA D;;SARKAR SHANTANU;;EISELE III VAL D;;WYSZYNSKI RYAN D;;LANCTIN DAVID;;YOON HYUN J;;NELSON STEVEN G;;ARNEBECK KATE;;PATEL NIRAV A;;REINKE MATTHEW T;;UHL TAYLOR;;HOFFMAN MATTHEW J,,https://lens.org/080-113-783-092-864,Patent Application,yes,0,0,2,2,0,A61B5/686;;A61B5/4836;;A61B5/6869;;A61B5/0538;;G16H50/30;;A61B5/7275;;A61B5/0245;;A61B5/33;;A61B5/349;;A61B2562/16;;A61N1/37282;;A61N1/37252;;A61N1/37247;;A61N1/36521;;A61N1/3787;;A61N1/36535;;A61N1/36542;;G16H20/10;;G16H20/30;;G16H40/67;;G16H50/20,A61N1/362;;A61B5/00;;A61B5/0245;;A61B5/0538;;A61B5/33,,0,0,,,,PENDING
785,WO,A1,WO 2023/203412 A1,163-375-573-297-203,2023-10-26,2023,IB 2023053409 W,2023-04-04,US 202263363458 P,2022-04-22,CLOSED LOOP ADJUSTMENT OF HEART FAILURE THERAPY,"A medical system includes an implantable cardiac device configured to monitor one or more cardio-thoracic parameters of a patient and one or more external devices configured to receive, from the implantable cardiac device, cardio-thoracic data indicative of the one or more cardio-thoracic parameters over a period of time; determine a long term heart failure risk (HFR) score for the patient based on the cardio-thoracic data; based on a change in the long term HFR score for the patient, determine a modification to a therapy plan of a second implanted device in the patient; and cause the second implanted device to implement the modified therapy plan.",MEDTRONIC INC,KRAUSE PAUL G;;CHO YONG K;;CINBIS CAN;;KUHN JONATHAN L;;STIGEN TYLER;;TAYLOR AMANDA D;;SARKAR SHANTANU;;EISELE III VAL D;;WYSZYNSKI RYAN D;;LANCTIN DAVID;;YOON HYUN J;;NELSON STEVEN G;;ARNEBECK KATE;;PATEL NIRAV A;;REINKE MATTHEW T;;UHL TAYLOR;;HOFFMAN MATTHEW J,,https://lens.org/163-375-573-297-203,Patent Application,yes,6,0,2,2,0,A61B5/686;;A61B5/4836;;A61B5/6869;;A61B5/0538;;G16H50/30;;A61B5/7275;;A61B5/0245;;A61B5/33;;A61B5/349;;A61B2562/16;;A61N1/37282;;A61N1/37252;;A61N1/37247;;A61N1/36521;;A61N1/3787;;A61N1/36535;;A61N1/36542;;G16H20/10;;G16H20/30;;G16H40/67;;G16H50/20,A61N1/362;;A61B5/00;;A61B5/0245;;A61B5/0538;;A61B5/33,,0,0,,,,PENDING
786,WO,A1,WO 2010/125402 A1,012-798-181-218-456,2010-11-04,2010,GB 2010050725 W,2010-04-30,US 17429309 P,2009-04-30,IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES,"The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N + -O - or CR 3 ; Y is N, N + -O - or CR 3a ; R 1 and R 2 are independently selected from hydrogen and various substituents as defined in the claims; or R 1 and R 2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R 3 is selected from hydrogen and various substituents; and R 3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.",NOVARTIS AG;;ASTEX THERAPEUTICS LTD;;HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GRIALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS,HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GRIALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS,,https://lens.org/012-798-181-218-456,Patent Application,yes,2,14,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D233/22;;A61K31/4164;;A61K31/4178;;A61P35/00;;C07D235/12;;C07D401/06;;C07D401/10;;C07D401/14;;C07D409/10;;C07D409/14;;C07D413/14;;C07D417/10,,23,22,012-865-156-438-120;;001-661-891-531-467;;015-505-100-135-710;;051-255-997-632-880;;005-521-719-112-587;;012-572-030-448-789;;007-364-858-655-289;;000-820-736-344-337;;064-792-862-161-861;;053-577-087-541-386;;046-777-072-258-96X;;007-378-255-811-868;;075-596-410-145-597;;015-714-720-040-924;;050-476-538-810-273;;013-322-445-914-037;;143-158-089-688-29X;;037-370-591-087-508;;046-777-072-258-96X;;004-150-043-044-433;;053-577-087-541-386;;007-421-226-677-859,7768349;;0007768349;;10.1096/fasebj.9.8.7768349;;10.1126/science.1862342;;0001862342;;1862342;;1322797;;10.1016/0092-8674(92)90166-a;;10.1016/0092-8674(93)90144-f;;8387896;;pmc395100;;8194527;;10.1002/j.1460-2075.1994.tb06519.x;;pmc1850739;;12163365;;10.1016/s0002-9440(10)64196-x;;10.1002/jps.2600660104;;833720;;10.1080/00397917709409270;;10.1021/cr00039a007;;10.3987/com-04-10206;;15002962;;10.1021/cc034046a;;12739949;;10.1021/cc0201041;;10.1023/b:pham.0000016235.32639.23;;15032302;;10.1002/jps.2600600902;;4935981;;10.1016/0076-6879(87)52071-7;;3657592;;10733493;;10.1016/s1525-1578(10)60494-1;;15096562;;pmc1867470;;14633913;;10.1373/clinchem.2003.024695;;15002962;;10.1021/cc034046a;;10.1021/ja0428309;;16045341;;10.3987/com-04-10206;;9692848;;10.1016/s0022-1759(98)00028-3,"HANKS, S.K.; HUNTER, T., FASEB J., vol. 9, 1995, pages 576 - 596;;KNIGHTON ET AL., SCIENCE, vol. 253, 1991, pages 407 - 414;;HILES ET AL., CELL, vol. 70, 1992, pages 419 - 429;;KUNZ ET AL., CELL, vol. 73, 1993, pages 585 - 596;;GARCIA-BUSTOS ET AL., EMBO J., vol. 13, 1994, pages 2352 - 2361;;AM J PATHOL., vol. 161, no. 2, August 2002 (2002-08-01), pages 405 - 411;;BERGE ET AL.: ""Pharmaceutically Acceptable Salts"", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514;;A. SUZUKI, CHEM. REV., vol. 95, 1995, pages 2457;;YONEZAWA ET AL., HETEROCYCLES, vol. 63, no. 12, 2004, pages 2735 - 2746;;J COMB CHEM., vol. 6, no. 2, 2004, pages 159 - 64;;LEISTER W; STRAUSS K; WISNOSKI D; ZHAO Z; LINDSLEY C.: ""Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries"", J COMB CHEM., vol. 5, no. 3, 2003, pages 322 - 9, XP001198955, DOI: doi:10.1021/cc0201041;;R. G. STRICKLY: ""Solubilizing Excipients in oral and injectable formulations"", PHARMACEUTICAL RESEARCH, vol. 21, no. 2, 2004, pages 201 - 230;;CHIOU; RIEGELMAN, J. PHARM. SCI., vol. 60, 1971, pages 1281 - 1300;;ANGERER, METH. ENZYMOL., vol. 152, 1987, pages 649;;YATABE ET AL., BLOOD, vol. 95, no. 7, 1 April 2000 (2000-04-01), pages 2253 - 61;;JONES ET AL., J MOL DIAGN., vol. 6, no. 2, May 2004 (2004-05-01), pages 84 - 9;;HOWE ET AL., CLIN CHEM., vol. 50, no. 1, January 2004 (2004-01-01), pages 80 - 7;;ROSENTRETER U; HUBER U.: ""Optimal fraction collecting in preparative LCMS"", J COMB CHEM., vol. 6, no. 2, 2004, pages 159 - 64;;LEISTER W; STRAUSS K; WISNOSKI D; ZHAO Z; LINDSLEY C.: ""Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries"", J COMB. CHEM., vol. 5, no. 3, 2003, pages 322 - 9, XP001198955, DOI: doi:10.1021/cc0201041;;J. AM. CHEM. SOC., vol. 127, 2005, pages 10539;;YONEZAWA, YASUCHIKA; KONN, AKIHITO; SHIN, CHUNG-GI.: ""Useful synthesis of 2,3,6-tri- and 2,3,5,6-tetrasubstituted pyridine derivatives from aspartic acid"", HETEROCYCLES, vol. 63, no. 12, 2004, pages 2735 - 2746, XP002320179;;NOCIARI, M. M; SHALEV, A.; BENIAS, P.; RUSSO, C., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 213, 1998, pages 157 - 167",PENDING
787,US,B2,US 8598217 B2,069-466-176-029-789,2013-12-03,2013,US 201013266976 A,2010-04-30,US 201013266976 A;;US 17429309 P;;GB 2010050725 W,2009-04-30,Imidazole derivatives and their use as modulators of cyclin dependent kinases,"The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N + —O − or CR 3 ; Y is N, N + —O − or CR 3a ; R 1 and R 2 are independently selected from hydrogen and various substituents as defined in the claims; or R 1 and R 2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R 3 is selected from hydrogen and various substituents; and R 3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.",HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GIRALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS;;ASTEX THERAPEUTICS LTD;;NOVARTIS AG,HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GIRALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS,ASTEX THERAPEUTICS LTD (2011-12-08);;NOVARTIS AG (2011-12-16);;NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC (2011-12-15),https://lens.org/069-466-176-029-789,Granted Patent,yes,18,0,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,A61K31/496;;A61K31/4178;;A61K31/4184;;A61K31/4353;;A61K31/4439;;A61K31/4545;;A61K31/4725;;A61P35/00;;C07D401/06;;C07D403/10;;C07D413/06;;C07D417/10;;C07D471/04,514/396;;514/397;;514/399;;514/400;;514/303;;514/341;;514/394;;514/365;;514/234.5;;514/318;;514/319;;514/322;;514/323;;514/307;;514/218;;514/81;;514/253.05;;514/253.09;;544/364;;544/139;;544/131;;544/363;;546/274.7;;546/273.1;;546/118;;546/144;;546/199;;548/303.1;;548/312.1,0,0,,,,INACTIVE
788,US,A1,US 2012/0101064 A1,163-630-355-825-026,2012-04-26,2012,US 201013266976 A,2010-04-30,US 201013266976 A;;US 17429309 P;;GB 2010050725 W,2009-04-30,IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES,"The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N + —O − or CR 3 ; Y is N, N + —O − or CR 3a ; R 1 and R 2 are independently selected from hydrogen and various substituents as defined in the claims; or R 1 and R 2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R 3 is selected from hydrogen and various substituents; and R 3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.",HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GRIALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS;;ASTEX THERAPEUTICS LTD;;NOVARTIS AG,HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GRIALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS,ASTEX THERAPEUTICS LTD (2011-12-08);;NOVARTIS AG (2011-12-16);;NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC (2011-12-15),https://lens.org/163-630-355-825-026,Patent Application,yes,0,10,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,A61K31/675;;A61K31/4178;;A61K31/427;;A61K31/437;;A61K31/4439;;A61K31/4545;;A61K31/4725;;A61K31/496;;A61K31/5377;;A61K31/551;;A61P35/00;;A61P35/02;;C07D401/06;;C07D401/14;;C07D403/10;;C07D409/10;;C07D413/06;;C07D417/10;;C07D471/04;;C07F9/6561,514/81;;546/274.7;;514/341;;544/364;;514/253.09;;546/194;;514/318;;544/139;;514/234.5;;548/204;;514/365;;548/312.4;;514/397;;548/315.1;;546/273.4;;544/131;;546/144;;514/307;;544/363;;514/253.05;;540/575;;514/218;;546/118;;514/303;;546/23,0,0,,,,INACTIVE
789,MX,A,MX 2011011516 A,001-662-482-231-572,2011-11-18,2011,MX 2011011516 A,2010-04-30,US 17429309 P;;GB 2010050725 W,2009-04-30,IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES.,"The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+-O- or CR3; Y is N, N+-O- or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.",ASTEX THERAPEUTICS LTD,KIM SUNKYU;;HOWARD STEVEN;;WOODHEAD ANDREW JAMES;;PEREZ LAWRENCE BLAS;;WANG YAPING;;YANG FAN;;BRAIN CHRISTOPHER THOMAS;;LUZZIO MICHAEL JOSEPH;;CHESSARI GIANNI;;CONGREVE MILES STUART;;CHEN CHRISTINE HIU-TUNG;;CHO YOUNG SHIN;;LAGU BHARAT;;DAGOSTIN CLAUDIO;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JOANNE;;REILLY MARC O;;GRIALDES JOHN;;LU YIPIN,,https://lens.org/001-662-482-231-572,Patent Application,no,0,0,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D233/22;;A61K31/4164;;A61K31/4178;;A61P35/00;;C07D235/12;;C07D401/06;;C07D401/10;;C07D401/14;;C07D409/10;;C07D409/14;;C07D413/14;;C07D417/10,,0,0,,,,ACTIVE
790,EA,B1,EA 020017 B1,113-161-771-390-815,2014-08-29,2014,EA 201101566 A,2010-04-30,US 17429309 P;;GB 2010050725 W,2009-04-30,IMDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES,"The invention provides compounds of the formula (I) and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N-Oor CR; Y is N, N-Oor CR; Rand Rare independently selected from hydrogen and various substituents as defined in the claims; or Rand Rtogether with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; Ris selected from hydrogen and various substituents; and Ris selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.",NOVARTIS AG;;ASTEX THERAPEUTICS LTD,HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GRIALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS;;LU YIPIN,,https://lens.org/113-161-771-390-815,Granted Patent,no,2,0,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D233/22;;A61K31/4164;;A61K31/4178;;A61P35/00;;C07D235/12;;C07D401/06;;C07D401/10;;C07D401/14;;C07D409/10;;C07D409/14;;C07D413/14;;C07D417/10,,0,0,,,,ACTIVE
791,BR,A2,BR PI1016190 A2,136-098-707-820-687,2017-03-28,2017,BR PI1016190 A,2010-04-30,GB 2010050725 W;;US 17429309 P,2009-04-30,compostos farmacêuticos.,,NOVARTIS AG,ALISON JO-ANNE WOOLFORD;;ANDREW JAMES WOODHED;;ASTEX THERAPEUTICS LIMITED;;BHARAT LAGU;;CHRISTINE HIU-TUNG CHEN;;CHRISTOPHER THOMAS BRAIN;;CLAUDIO DAGOSTIN;;FAN YANG;;GIANNI CHESSARI;;JOHN GRIALDES;;LAWRENCE BLAS PEREZ;;MARC O'REILLY;;MICHAEL JOSEPH LUZZIO;;MILES STUART CONGREVE;;PAUL NEIL MORTENSON;;STEVEN DOUGLAS HISCOCK;;STEVEN HOWARD;;SUNKYU KIM;;YAPING WANG;;YOUNG SHIN CHO,,https://lens.org/136-098-707-820-687,Patent Application,no,0,0,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D233/22;;A61K31/4164;;A61K31/4178;;A61P35/00;;C07D235/12;;C07D401/06;;C07D401/10;;C07D401/14;;C07D409/10;;C07D409/14;;C07D413/14;;C07D417/10,,0,0,,,,DISCONTINUED
792,PT,E,PT 2424843 E,116-757-136-233-788,2014-06-02,2014,PT 10719772 T,2010-04-30,US 17429309 P,2009-04-30,IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES,,NOVARTIS AG;;ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;WOOLFORD ALISON JO-ANNE;;CHESSARI GIANNI;;CONGREVE MILES STUART;;HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;O'REILLY MARC;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GRIALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS;;LU YIPIN,,https://lens.org/116-757-136-233-788,Granted Patent,no,0,0,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D233/22;;A61K31/4164;;A61K31/4178;;A61P35/00;;C07D235/12;;C07D401/06;;C07D401/10;;C07D401/14;;C07D409/10;;C07D409/14;;C07D413/14;;C07D417/10,,0,0,,,,ACTIVE
793,KR,A,KR 20120004542 A,040-426-710-503-702,2012-01-12,2012,KR 20117028530 A,2010-04-30,US 17429309 P,2009-04-30,IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES,,NOVARTIS AG;;ASTEX THERAPEUTICS LTD,HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GRIALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS;;LU YIPIN,,https://lens.org/040-426-710-503-702,Patent Application,no,0,0,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D401/14;;A61K31/4439;;A61P35/00,,0,0,,,,DISCONTINUED
794,AU,A1,AU 2010/243353 A1,162-337-068-883-515,2011-11-10,2011,AU 2010/243353 A,2010-04-30,US 17429309 P;;GB 2010050725 W,2009-04-30,Imidazole derivatives and their use as modulators of Cyclin dependent Kinases,"The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N-O or CR; Y is N, N-O or CR; R and R are independently selected from hydrogen and various substituents as defined in the claims; or R and R together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R is selected from hydrogen and various substituents; and R is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of proliferative diseases such as cancers.",NOVARTIS AG;;ASTEX THERAPEUTICS LTD,STEVEN HOWARD;;NEIL MORTENSON PAUL;;DOUGLAS HISCOCK STEVEN;;JO-ANNE WOOLFORD ALISON;;JAMES WOODHEAD ANDREW;;GIANNI CHESSARI;;MARC O'REILLY;;STUART CONGREVE MILES;;CLAUDIO DAGOSTIN;;SHIN CHO YOUNG;;FAN YANG;;HIU-TUNG CHEN CHRISTINE;;THOMAS BRAIN CHRISTOPHER;;BHARAT LAGU;;YAPING WANG;;SUNKYU KIM;;JOHN GRIALDES;;JOSEPH LUZZIO MICHAEL;;BLAS PEREZ LAWRENCE;;LU YIPIN,,https://lens.org/162-337-068-883-515,Patent Application,no,0,0,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D233/22;;A61K31/4164;;A61K31/4178;;A61P35/00;;C07D235/12;;C07D401/06;;C07D401/10;;C07D401/14;;C07D409/10;;C07D409/14;;C07D413/14;;C07D417/10,,0,0,,,,ACTIVE
795,CA,A1,CA 2759083 A1,076-363-865-656-544,2010-11-04,2010,CA 2759083 A,2010-04-30,US 17429309 P;;GB 2010050725 W,2009-04-30,IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES,"The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+-O- or CR3; Y is N, N+-O- or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.",NOVARTIS AG,HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GRIALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS;;YIPIN LU,,https://lens.org/076-363-865-656-544,Patent Application,no,0,0,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D233/22;;A61K31/4164;;A61K31/4178;;A61P35/00;;C07D235/12;;C07D401/06;;C07D401/10;;C07D401/14;;C07D409/10;;C07D409/14;;C07D413/14;;C07D417/10,,0,0,,,,DISCONTINUED
796,CN,A,CN 102803225 A,021-630-089-003-177,2012-11-28,2012,CN 201080029384 A,2010-04-30,GB 2010050725 W;;US 17429309 P,2009-04-30,Imidazole derivatives and their use as modulators of cyclin dependent kinases,"The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+-O- or CR3; Y is N, N+-O- or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.",NOVARTIS AG;;ASTEX THERAPEUTICS LTD,STEVEN HOWARD;;NEIL MORTENSON PAUL;;DOUGLAS HISCOCK STEVEN;;JO-ANNE WOOLFORD ALISON;;JAMES WOODHEAD ANDREW;;GIANNI CHESSARI;;MARC O'REILLY;;STUART CONGREVE MILES;;CLAUDIO DAGOSTIN;;SHIN CHO YOUNG;;FAN YANG;;HIU-TUNG CHEN CHRISTINE;;THOMAS BRAIN CHRISTOPHER;;BHARAT LAGU;;YAPING WANG;;SUNKYU KIM;;JOHN GRIALDES;;JOSEPH LUZZIO MICHAEL;;BLAS PEREZ LAWRENCE;;YIPIN LU,,https://lens.org/021-630-089-003-177,Patent Application,no,2,2,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D233/22;;A61K31/4164;;A61K31/4178;;A61P35/00;;C07D235/12;;C07D401/06;;C07D401/10;;C07D401/14;;C07D409/10;;C07D409/14;;C07D413/14;;C07D417/10,,0,0,,,,DISCONTINUED
797,PL,T3,PL 2424843 T3,158-062-522-513-051,2014-07-31,2014,PL 10719772 T,2010-04-30,US 17429309 P;;EP 10719772 A;;GB 2010050725 W,2009-04-30,IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES,,NOVARTIS AG;;ASTEX THERAPEUTICS LTD,HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GRIALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS;;LU YIPIN,,https://lens.org/158-062-522-513-051,Patent Application,no,0,0,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D233/22;;A61K31/4164;;A61K31/4178;;A61P35/00;;C07D235/12;;C07D401/06;;C07D401/10;;C07D401/14;;C07D409/10;;C07D409/14;;C07D413/14;;C07D417/10,,0,0,,,,PENDING
798,ES,T3,ES 2458872 T3,128-657-950-408-21X,2014-05-07,2014,ES 10719772 T,2010-04-30,US 17429309 P;;GB 2010050725 W,2009-04-30,Derivados de imidazol y su uso como moduladores de quinasas dependientes de ciclina,"Un compuesto de la fórmula (I):**Fórmula** o una sal, tautómero, solvato o N-óxido del mismo; donde: Q es CH o N; X es N, N+-O- o CR3; 10 Y es N, N+-O- o CR3a; R1 y R2 se seleccionan independientemente entre hidrógeno; halógeno; ciano; hidroxilo; alquilo C1-8; alcoxilo C1-8; alquenilo C2-8; alquinilo C2-8; cicloalquilo C3-8; cicloalquenilo C2-8; arilo; heterociclilo; heteroarilo; OR5; C>=OR5; C(>=O)OR5; OC>=OR5; S(O)nR5; NR7R8; N(R7)C(>=O)R8; C(>=O)NR7R8; SO2NR9R10; donde cada uno de los restos alquilo C1-8, alcoxilo C1-8, alquenilo C2-8 y alquinilo C2-8 está opcionalmente sustituido con uno o más sustituyentes R11; y el cicloalquilo C3-8, cicloalquenilo C2-6, arilo, heterociclilo y heteroarilo están cada uno opcionalmente sustituidos con uno o más sustituyentes R12; n es 0, 1 ó 2; m es 0, 1, 2 ó 3; o R1 y R2 junto con los átomos a los que están unidos, se unen para formar un anillo aromático o no aromático de 4 a 7 miembros, donde dicho anillo aromático o no aromático contiene 0, 1 ó 2 miembros heteroátomos en el anillo seleccionados entre O, N y S, donde el anillo aromático o no aromático está opcionalmente sustituido con uno o más sustituyentes R13; R3 se selecciona entre hidrógeno; hidroxi; halógeno; ciano; OR5; C(>=O)R5; OC(>=O)R5; C(>=O)OR5; S(O)nR5; NR7R8; N(R7)C(>=O)R8; C(>=O)NR7R8; SO2NR9R10; alquilo C1-6; alquenilo C2-6; alquinilo C2-6; cicloalquilo C3-6; arilo de 5 ó 6 miembros; y heteroarilo de 5 ó 6 miembros; R3a se selecciona entre hidrógeno; halógeno; ciano; OR5; C(>=O)R5; OC(>=O)R5; C(>=O)OR5; S(O)nR5; NR7R8; N(R7)C(>=O)R8; C(>=O)NR7R8; SO2NR9R10; alquilo C1-6; alquenilo C2-6; alquinilo C2-6; cicloalquilo C3-6; arilo de 5 ó 6 miembros; y heteroarilo de 5 ó 6 miembros.",NOVARTIS AG;;ASTEX THERAPEUTICS LTD,HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GRIALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS;;LU YIPIN,,https://lens.org/128-657-950-408-21X,Granted Patent,no,0,0,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D233/22;;A61K31/4164;;A61K31/4178;;A61P35/00;;C07D235/12;;C07D401/06;;C07D401/10;;C07D401/14;;C07D409/10;;C07D409/14;;C07D413/14;;C07D417/10,,0,0,,,,ACTIVE
799,AU,B2,AU 2010/243353 B2,124-699-497-602-144,2014-09-11,2014,AU 2010/243353 A,2010-04-30,US 17429309 P;;GB 2010050725 W,2009-04-30,Imidazole derivatives and their use as modulators of Cyclin dependent Kinases,"The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N",ASTEX THERAPEUTICS LTD;;NOVARTIS AG,HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GRIALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS;;YIPIN LU,,https://lens.org/124-699-497-602-144,Granted Patent,no,2,0,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D233/22;;A61K31/4164;;A61K31/4178;;A61P35/00;;C07D235/12;;C07D401/06;;C07D401/10;;C07D401/14;;C07D409/10;;C07D409/14;;C07D413/14;;C07D417/10,,0,0,,,,ACTIVE
800,EP,B1,EP 2424843 B1,067-207-074-984-866,2014-03-26,2014,EP 10719772 A,2010-04-30,GB 2010050725 W;;US 17429309 P,2009-04-30,IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES,,NOVARTIS AG;;ASTEX THERAPEUTICS LTD,HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GRIALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS;;LU YIPIN,,https://lens.org/067-207-074-984-866,Granted Patent,yes,2,0,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D233/22;;A61K31/4164;;A61K31/4178;;A61P35/00;;C07D235/12;;C07D401/06;;C07D401/10;;C07D401/14;;C07D409/10;;C07D409/14;;C07D413/14;;C07D417/10,,0,0,,,,ACTIVE
801,EP,A1,EP 2424843 A1,028-639-997-400-165,2012-03-07,2012,EP 10719772 A,2010-04-30,GB 2010050725 W;;US 17429309 P,2009-04-30,IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES,,NOVARTIS AG;;ASTEX THERAPEUTICS LTD,HOWARD STEVEN;;MORTENSON PAUL NEIL;;HISCOCK STEVEN DOUGLAS;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;O'REILLY MARC;;CONGREVE MILES STUART;;DAGOSTIN CLAUDIO;;CHO YOUNG SHIN;;YANG FAN;;CHEN CHRISTINE HIU-TUNG;;BRAIN CHRISTOPHER THOMAS;;LAGU BHARAT;;WANG YAPING;;KIM SUNKYU;;GRIALDES JOHN;;LUZZIO MICHAEL JOSEPH;;PEREZ LAWRENCE BLAS;;LU YIPIN,,https://lens.org/028-639-997-400-165,Patent Application,yes,0,0,18,18,0,A61K31/4439;;A61P35/00;;A61P35/02;;A61P43/00;;C07D401/14;;C07D471/04;;C07D471/04;;C07D233/22;;C07D233/22;;C07D233/24;;C07D233/24;;C07D235/12;;C07D235/12;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/14;;C07D405/14;;C07D409/10;;C07D409/10;;C07D409/14;;C07D409/14;;C07D413/10;;C07D413/10;;C07D413/14;;C07D413/14;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14;;C07D487/04;;C07D487/04;;C07D519/00;;C07D519/00,C07D233/22;;A61K31/4164;;A61K31/4178;;A61P35/00;;C07D235/12;;C07D401/06;;C07D401/10;;C07D401/14;;C07D409/10;;C07D409/14;;C07D413/14;;C07D417/10,,1,0,,,See references of WO 2010125402A1,ACTIVE
802,EP,A2,EP 1917360 A2,160-770-279-234-552,2008-05-07,2008,EP 06801998 A,2006-08-22,US 2006/0032606 W;;US 71085405 P;;US 81701106 P,2005-08-24,COMPOSITIONS PROVIDING TOLERANCE TO MULTIPLE HERBICIDES AND METHODS OF USE THEREOF,,PIONEER HI BRED INT;;DU PONT,MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D JR;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q,,https://lens.org/160-770-279-234-552,Patent Application,yes,3,0,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,C12N15/82;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,0,0,,,,DISCONTINUED
803,CA,A1,CA 2625371 A1,103-959-672-612-937,2007-03-01,2007,CA 2625371 A,2006-08-22,US 71085405 P;;US 81701106 P;;US 2006/0032606 W,2005-08-24,COMPOSITIONS PROVIDING TOLERANCE TO MULTIPLE HERBICIDES AND METHODS OF USE THEREOF,,DU PONT;;PIONEER HI BRED INT,MCCUTCHEN BILLY FRED;;MEHRE WAYNE J;;WONG JAMES F H;;SAUNDERS DAVID W;;HEGSTAD JEFFREY M;;CHO HYEON-JE;;HUTCHISON JAMES M;;LU ALBERT L;;LIU DONGLONG;;GUIDA ANTHONY D JR;;MOY YORK;;GREEN JERRY M;;CLAUS JON S;;HECKERT MATTHEW J;;CHICOINE TIMOTHY K;;CASTLE LINDA A;;PEEPLES KENNETH A;;OLSON PAUL D;;HAZEL CHRISTINE B;;VOGT MARK D;;WILKINSON JACK Q,,https://lens.org/103-959-672-612-937,Patent Application,no,0,0,46,71,89,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,C12N15/82;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,0,0,,,,INACTIVE
804,US,A1,US 2008/0234130 A1,110-884-249-563-269,2008-09-25,2008,US 50775106 A,2006-08-22,US 50775106 A;;US 71085405 P;;US 81701106 P,2005-08-24,Compositions providing tolerance to multiple herbicides and methods of use thereof,"Methods and compositions are provided related to improved plants that are tolerant to more than one herbicide. Particularly, the invention provides plants that are tolerant of glyphosate and are tolerant to at least one ALS inhibitor, and methods of use thereof. The glyphosate/ALS inhibitor-tolerant plants comprise a polynucleotide that encodes a polypeptide that confers tolerance to glyphosate and a polynucleotide that encodes an ALS inhibitor-tolerant polypeptide. In specific embodiments, a plant of the invention expresses a GAT polypeptide and an HRA polypeptide. Methods to control weeds, improve plant yield, and increase transformation efficiencies are provided.",PIONEER HI BRED INT;;DU PONT,MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,E.I. DU PONT DE NEMOURS AND COMPANY (2006-10-31);;PIONEER HI-BRED INTERNATIONAL INC (2006-10-31),https://lens.org/110-884-249-563-269,Patent Application,yes,85,69,46,71,89,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,A01N43/64;;A01N43/48;;A01N43/647;;A01N57/18;;A01N59/26;;A01P13/00;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06;;C12N15/11,504/128;;504/130;;800/278;;504/187;;504/227;;504/261;;504/235;;504/209,0,0,,,,DISCONTINUED
805,WO,A2,WO 2007/024782 A2,172-961-932-694-744,2007-03-01,2007,US 2006/0032606 W,2006-08-22,US 71085405 P;;US 81701106 P,2005-08-24,COMPOSITIONS PROVIDING TOLERANCE TO MULTIPLE HERBICIDES AND METHODS OF USE THEREOF,"Methods and compositions are provided related to improved plants that are tolerant to more than one herbicide. Particularly, the invention provides plants that are tolerant of glyphosate and are tolerant to at least one ALS inhibitor, and methods of use thereof. The glyphosate/ALS inhibitor-tolerant plants comprise a polynucleotide that encodes a polypeptide that confers tolerance to glyphosate and a polynucleotide that encodes an ALS inhibitor-tolerant polypeptide. In specific embodiments, a plant of the invention expresses a GAT polypeptide and an HRA polypeptide. Methods to control weeds, improve plant yield, and increase transformation efficiencies are provided.",PIONEER HI BRED INT;;DU PONT;;MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D JR;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D JR;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,,https://lens.org/172-961-932-694-744,Patent Application,yes,0,562,46,71,89,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,0,0,,,,PENDING
806,CR,A,CR 9757 A,121-718-349-846-456,2008-05-09,2008,CR 9757 A,2008-02-22,US 71085405 P;;US 81701106 P,2005-08-24,COMPOSICIONES QUE PROPORCIONAN TOLERANCIA A MULTIPLES HERBICIDAS Y METODOS PARA USARLAS,"Metodos y composiciones relacionadas con plantas mejoradas que presentan tolerancia a mas de un herbicida. Particularmente, en la invencion se proveen plantas que presentan tolerancia de glifosato y presentan tolerancia a al menos un inhibidor de la ALS, y metodos para usarlas. Las plantas con tolerancia a glisofato/inhibidores de la ALS comprenden un polinucleotido que codifica un polipeptido con tolerancia a glifosato y un polinucleotido que codifica un polipeptido con tolerancia a un inhibidor de la ALS.",PIONEER HI BRED INT;;DU PONT,MCCUTCHEN BILLY FRED;;CASTLE LINDA;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F,,https://lens.org/121-718-349-846-456,Patent Application,no,0,0,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,A63B/;;A63B69/00;;A63B69/36;;A63B71/06;;C12N15/82,,0,0,,,,DISCONTINUED
807,BR,A2,BR PI0615088 A2,197-863-966-165-400,2009-07-14,2009,BR PI0615088 A,2006-08-22,US 71085405 P;;US 81701106 P;;US 2006/0032606 W,2005-08-24,composições que fornecem toleráncia a herbicidas múltiplos e métodos de uso das mesmas,"COMPOSIçõES QUE FORNECEM TOLERáNCIA A HERBICIDAS MúLTIPLOS E MéTODOS DE USO DAS MESMA. São fornecidos métodos e composições relacionados a melhores plantas que são tolerantes a mais de um herbicida. Particularmente, a invenção fornece plantas que são tolerantes de glicofosato e são tolerantes a pelo menos um inibidor de ALS, e métodos de uso desses. As plantas tolerantes a glicofosato/inibidor de ALS compreendem um polinucleotídeo que codifica um polipeptídeo que confere tolerância a glicofosato e um polinucleotídeo que codifica um polipeptídeo inibidor-tolerante a ALS. Em modalidades específicas, uma planta da invenção expressa um polipeptídeo GAT e um polipeptídeo HRA. Métodos para controlar ervas daninhas, melhorar o rendimento da planta, e aumentar as eficiências de transformação são fornecidos.",PIONEER HI BRED INT;;DU PONT,MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D JR;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,,https://lens.org/197-863-966-165-400,Patent Application,no,0,0,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,C12N15/82;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,0,0,,,,DISCONTINUED
808,TW,A,TW 200730625 A,097-315-712-780-128,2007-08-16,2007,TW 95130877 A,2006-08-22,US 71085405 P;;US 81701106 P,2005-08-24,Compositions providing tolerance to multiple herbicides and methods of use thereof,"Methods and compositions are provided related to improved plants that are tolerant to more than one herbicide. Particularly, the invention provides plants that are tolerant of glyphosate and are tolerant to at least one ALS inhibitor, and methods of use thereof. The glyphosate/ALS inhibitor-tolerant plants comprise a polynucleotide that encodes a polypeptide that confers tolerance to glyphosate and a polynucleotide that encodes an ALS inhibitor-tolerant polypeptide. In specific embodiments, a plant of the invention expresses a GAT polypeptide and an HRA polypeptide. Methods to control weeds, improve plant yield, and increase transformation efficiencies are provided.",PIONEER HI BRED INT;;DU PONT,MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,,https://lens.org/097-315-712-780-128,Patent of Addition,no,0,1,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,C12N15/82;;A01H1/00;;A01N57/18;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,0,0,,,,PENDING
809,AU,B2,AU 2006/283504 B2,179-312-856-103-555,2011-08-25,2011,AU 2006/283504 A,2006-08-22,US 71085405 P;;US 81701106 P;;US 2006/0032606 W,2005-08-24,Compositions providing tolerance to multiple herbicides and methods of use thereof,"Methods and compositions are provided related to improved plants that are tolerant to more than one herbicide. Particularly, the invention provides plants that are tolerant of glyphosate and are tolerant to at least one ALS inhibitor, and methods of use thereof. The glyphosate/ALS inhibitor-tolerant plants comprise a polynucleotide that encodes a polypeptide that confers tolerance to glyphosate and a polynucleotide that encodes an ALS inhibitor-tolerant polypeptide. In specific embodiments, a plant of the invention expresses a GAT polypeptide and an HRA polypeptide. Methods to control weeds, improve plant yield, and increase transformation efficiencies are provided.",DU PONT;;PIONEER HI BRED INT,HEGSTAD JEFFREY M;;HECKERT MATTHEW J;;SAUNDERS DAVID W;;CLAUS JON S;;GUIDA JR ANTHONY D;;YORK MOY;;MEHRE WAYNE J;;OLSON PAUL D;;VOGT MARK D;;LU ALBERT L;;WONG JAMES F H;;WILKINSON JACK Q;;HYEON-JE CHO;;CASTLE LINDA A;;HAZEL CHRISTINE B;;CHICOINE TIMOTHY K;;FRED MCCUTCHEN BILLY;;GREEN JERRY M;;DONGLONG LIU;;PEEPLES KENNETH A;;HUTCHISON JAMES M,,https://lens.org/179-312-856-103-555,Granted Patent,no,2,0,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,C12N15/82;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,0,0,,,,ACTIVE
810,UY,A1,UY 29761 A1,013-379-261-236-742,2007-03-30,2007,UY 29761 A,2006-08-22,US 71085405 P;;US 81701106 P,2005-08-24,COMPOSICIONES QUE PROPORCIONAN TOLERANCIA A MÚLTIPLES HERBICIDAS Y MÉTODOS PARA USARLAS,"Métodos y composiciones relacionadas con plantas mejoradas que presentan tolerancia a más de un herbicida. Particularmente, plantas que presentan tolerancia de glifosato y a al menos un inhibidor de la ALS, y métodos para usarlas. Las plantas con tolerancia a glifosato/inhibidores de la ALS comprenden un polinucleótido que codifica un polipéptido confiriendo tolerancia a un inhibidor y un polinucleótido confiriendo tolerancia a un inhibidor de la ALS. En realizaciones específicas, una planta de la invención expresa un polipéptido GAT y un polipéptico HRA. Métodos para controlar malezas, mejorar rendimiento de plantas e incrementar eficiencias de transformación.",DU PONT;;PIONEER HI BRED INT,MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D JR;;HAZEL CHRISTINE B;;HECKERT MATTJEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,,https://lens.org/013-379-261-236-742,Patent Application,no,0,0,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,A01H1/00;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,0,0,,,,DISCONTINUED
811,ME,A,ME P3508 A,071-548-105-609-971,2010-02-10,2010,ME P3508 A,2006-08-22,US 71085405 P;;US 81701106 P;;RS P20080076 A;;US 2006/0032606 W,2005-08-24,COMPOSITIONS PROVIDING TOLERANCE TO MULTIPLE HERBICIDES AND METHODS OF USE THEREOF,"Methods and compositions are provided related to improved plants that are tolerant to more than one herbicide. Particularly, the invention provides plants that are tolerant of glyphosate and are tolerant to at least one ALS inhibitor, and methods of use thereof. The glyphosate/ALS inhibitor-tolerant plants comprise a polynucleotide that encodes a polypeptide that confers tolerance to glyphosate and a polynucleotide that encodes an ALS inhibitor-tolerant polypeptide. In specific embodiments, a plant of the invention expresses a GAT polypeptide and an HRA polypeptide. Methods to control weeds, improve plant yield, and increase transformation efficiencies are provided.",PIONEER HI BRED INT;;DU PONT,MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D JR;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,,https://lens.org/071-548-105-609-971,Patent Application,no,0,0,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,A63B/;;A63B69/00;;A63B69/36;;A63B71/06;;C12N15/82,,0,0,,,,PENDING
812,RS,A,RS 20080076 A,076-376-978-945-089,2009-07-15,2009,RS P20080076 A,2006-08-22,US 71085405 P;;US 81701106 P;;US 2006/0032606 W,2005-08-24,COMPOSITIONS PROVIDING TOLERANCE TO MULTIPLE HERBICIDES AND METHODS OF USE THEREOF,"Methods and compositions are provided related to improved plants that are tolerant to more than one herbicide. Particularly, the invention provides plants that are tolerant of glyphosate and are tolerant to at least one ALS inhibitor, and methods of use thereof. The glyphosate/ALS inhibitor-tolerant plants comprise a polynucleotide that encodes a polypeptide that confers tolerance to glyphosate and a polynucleotide that encodes an ALS inhibitor-tolerant polypeptide. In specific embodiments, a plant of the invention expresses a GAT polypeptide and an HRA polypeptide. Methods to control weeds, improve plant yield, and increase transformation efficiencies are provided.",PIONEER HI BREND INTERNATIONAL INC;;DU PONT,MCCUTCHEN BILLY FRED;;CASTLE LINDA A.;;CHICOINE TIMOTHY K.;;CHO HYEON-JE;;CLAUS JON S.;;GREEN JERRY M.;;GUIDA ANTHONY D.;;HAZEL CHRISTINE B.;;HEGSTAD JEFFREY M.;;HUTCHISON JAMES M.;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J.;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W.;;VOGT MARK D.;;WILKINSON JACK Q;;WONG JAMES F H;;HECKERT MATTHEW J,,https://lens.org/076-376-978-945-089,Patent Application,no,0,0,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,C12N15/82;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,0,0,,,,PENDING
813,ZA,B,ZA 200801554 B,119-244-753-505-959,2008-11-26,2008,ZA 200801554 A,2008-02-15,US 71085405 P,2005-08-24,Compositions providing tolerance to multiple herbicides and methods of use thereof,,PIONEER HI BRED INT;;DU PONT,FRED MCCUTCHEN BILLY;;HYEON-JE CHO;;GUIDA JR ANTHONY D;;HEGSTAD JEFFREY M;;LU ALBERT L;;OLSON PAUL D;;VOGT MARK D;;CASTLE LINDA A;;CLAUS JON S;;HAZEL CHRISTINE B;;HUTCHISON JAMES M;;MEHRE WAYNE J;;PEEPLES KENNETH A;;WILKINSON JACK Q;;CHICOINE TIMOTHY K;;GREEN JERRY M;;HECKERT MATTHEW J;;DONGLONG LIU;;YORK MOY;;SAUNDERS DAVID W;;WONG JAMES F H,,https://lens.org/119-244-753-505-959,Granted Patent,no,0,0,5,71,0,H04L5/0073;;H04L5/0023;;H04L5/0048;;H04L5/0057,C12N/,,0,0,,,,ACTIVE
814,AU,A1,AU 2006/283504 A1,163-866-542-856-160,2007-03-01,2007,AU 2006/283504 A,2006-08-22,US 71085405 P;;US 81701106 P;;US 2006/0032606 W,2005-08-24,Compositions providing tolerance to multiple herbicides and methods of use thereof,,DU PONT;;PIONEER HI BRED INT,HEGSTAD JEFFREY M;;HECKERT MATTHEW J;;SAUNDERS DAVID W;;CLAUS JON S;;GUIDA ANTHONY D JR;;MOY YORK;;MEHRE WAYNE J;;OLSON PAUL D;;VOGT MARK D;;LU ALBERT L;;WONG JAMES F H;;WILKINSON JACK Q;;CHO HYEON-JE;;CASTLE LINDA A;;HAZEL CHRISTINE B;;CHICOINE TIMOTHY K;;MCCUTCHEN BILLY FRED;;GREEN JERRY M;;LIU DONGLONG;;PEEPLES KENNETH A;;HUTCHISON JAMES M,,https://lens.org/163-866-542-856-160,Patent Application,no,0,0,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,C12N15/82;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,0,0,,,,ACTIVE
815,MA,B1,MA 29777 B1,160-764-074-765-906,2008-09-01,2008,MA 30746 A,2008-03-17,US 71085405 P;;US 81701106 P,2005-08-24,COMPOSITIONS ASSURANT UNE TOLERANCE A DE MULTIPLES HERBICIDES ET METHODES D'UTILISATION,"Méthodes et compositions concernant des plantes tolérantes à plus d'un herbicide. L'invention concerne en particulier des plantes tolérantes au glyphosphate et à au moins un inhibiteur de l'ASL, ainsi que des méthodes d'utilisation. Les plantes tolérantes au glyphosate/inhibiteur d'ALS renferment un polynucléotide qui confère une tolérance au glyphosphate et un polynucléotide codant pour un polypeptide tolérant à un inhibiteur d'ALS. Dans des modes de réalisation spécifiques, une plante de l'invention exprime un polypeptide GAT et un polypeptide HRA. Sont décrites des méthodes de lutte contre les mauvaises herbes ainsi que des méthodes propres à améliorer les rendements et à accroître les efficacités de transformations.",WONG JAMES F H;;PIONEER HI-BRED INTERNATIONAL INC,MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D JR;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,,https://lens.org/160-764-074-765-906,Granted Patent,no,0,0,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,0,0,,,,ACTIVE
816,MX,A,MX 2008002616 A,128-022-592-018-780,2008-03-14,2008,MX 2008002616 A,2006-08-22,US 71085405 P;;US 81701106 P;;US 2006/0032606 W,2005-08-24,COMPOSITIONS PROVIDING TOLERANCE TO MULTIPLE HERBICIDES AND METHODS OF USE THEREOF.,"Methods and compositions are provided related to improved plants that are tolerant to more than one herbicide. Particularly, the invention provides plants that are tolerant of glyphosate and are tolerant to at least one ALS inhibitor, and methods of use thereof. The glyphosate/ALS inhibitor-tolerant plants comprise a polynucleotide that encodes a polypeptide that confers tolerance to glyphosate and a polynucleotide that encodes an ALS inhibitor-tolerant polypeptide. In specific embodiments, a plant of the invention expresses a GAT polypeptide and an HRA polypeptide. Methods to control weeds, improve plant yield, and increase transformation efficiencies are provided.",PIONEER HI BRED INT,CASTLE LINDA A;;MCCUTCHEN BILLY FRED;;LU ALBERT L;;HAZEL CHRISTINE B;;LIU DONGLONG;;MEHRE WAYNE J;;OLSON PAUL D;;WONG JAMES F H;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D JR;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;MOY YORK;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q,,https://lens.org/128-022-592-018-780,Patent Application,no,0,0,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,C12N15/82;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,0,0,,,,ACTIVE
817,WO,A3,WO 2007/024782 A3,052-006-100-241-965,2007-08-09,2007,US 2006/0032606 W,2006-08-22,US 71085405 P;;US 81701106 P,2005-08-24,COMPOSITIONS PROVIDING TOLERANCE TO MULTIPLE HERBICIDES AND METHODS OF USE THEREOF,"Methods and compositions are provided related to improved plants that are tolerant to more than one herbicide. Particularly, the invention provides plants that are tolerant of glyphosate and are tolerant to at least one ALS inhibitor, and methods of use thereof. The glyphosate/ALS inhibitor-tolerant plants comprise a polynucleotide that encodes a polypeptide that confers tolerance to glyphosate and a polynucleotide that encodes an ALS inhibitor-tolerant polypeptide. In specific embodiments, a plant of the invention expresses a GAT polypeptide and an HRA polypeptide. Methods to control weeds, improve plant yield, and increase transformation efficiencies are provided.",PIONEER HI BRED INT;;DU PONT;;MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D JR;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D JR;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,,https://lens.org/052-006-100-241-965,Search Report,yes,3,0,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,C12N15/82;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,1,1,039-908-538-222-277,10.1016/j.jbiotec.2003.10.011;;14736458,"MIKI BRIAN ET AL: ""Selectable marker genes in transgenic plants: Applications, alternatives and biosafety."", JOURNAL OF BIOTECHNOLOGY, vol. 107, no. 3, 5 February 2004 (2004-02-05), pages 193 - 232, XP009060957, ISSN: 0168-1656",PENDING
818,EC,A,EC SP088304 A,009-470-709-406-619,2008-04-28,2008,EC SP088304 A,2008-03-24,US 71085405 P;;US 81701106 P,2005-08-24,COMPOSICIONES PARA PROPORCIONAR MÚLTIPLE TOLERANCIA A HERBICIDAS Y MÉTODOS DE USO DE LAS MISMAS,"Se proporcionan métodos y composiciones relativas a plantas mejoradas que son tolerantes a más de un herbicida. Particularmente, la invención proporciona plantas que son tolerantes al glifosato y son tolerantes a al menos un inhibidor de la ALS, y los métodos de uso de los mismos. Las plantas tolerantes al glifosato/ inhibidor de la ALS comprenden un polinucleótido que codifica un polipéptido que confiere tolerancia al glifosato y un polinucleótido que codifica un polipéptido tolerante al inhibidor de la ALS. En realizaciones específicas, una planta de la invención expresa un polipéptido GAT y un polipéptido HRA. Se proporcionan métodos para controlar las malas hierbas, mejorar el rendimiento de las plantas y aumentar la eficiencia de la transformación.",PIONNER HI BRED INTERNAT INC;;DU PONT,CLAUS JON STUART;;MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;GREEN JERRY M;;GUIDA ANTHONY D JR;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,,https://lens.org/009-470-709-406-619,Patent Application,no,0,0,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,A63B/;;A63B69/00;;A63B69/36;;A63B71/06;;C12N15/82,,0,0,,,,PENDING
819,UA,C2,UA 96578 C2,088-987-478-140-485,2011-11-25,2011,UA A200803582 A,2006-08-22,US 71085405 P,2005-08-24,MONOCOTYLEDONOUS TRANSGENIC PLANT CONTAINING POLYNUCLEOTIDE ENCODING POLYPEPTIDE PROVIDING TOLERANCE TO GLYPHOSATE,"The invention relates to monocotyledonous transgenic plant containing polynucleotide encoding polypeptide glyphosate-N-acetyltransferase, where polynucleotide is functionally related with a promoter providing expression in the plant and at least with one copy of enhancer sequence, modulating the level of transcription, wherein enhancer is heterological towards promoter, providing tolerance of plant to glyphosate at its normal rate of application effective for inhibition of control plant growth which does not contain polynucleotide, encoding glyphosate-N-acetyltransferase. The invention also relates to the seeds of said plant.",PIONEER HI BRED INT;;DU PONT,MCCUTCHEN BILLY FRED;;CASTLE LINDA;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D;;HAZEL CHRISTINE B;;HEKERT METYU J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,,https://lens.org/088-987-478-140-485,Limited Patent,no,0,0,5,71,0,H04L5/0073;;H04L5/0023;;H04L5/0048;;H04L5/0057,C12N15/82;;A01H5/00,,0,0,,,,EXPIRED
820,SV,A,SV 2008002826 A,175-445-569-368-351,2008-08-21,2008,SV 2008002826 A,2008-02-22,SV 2008002826 A,2008-02-22,COMPOSICIONES QUE PROPORCIONAN TOLERANCIA A MULTIPLES HERBICIDAS Y METODOS PARA USARLAS,"MÉTODOS Y COMPOSICIONES RELACIONADAS CON PLANTAS MEJORADAS QUE PRESENTAN TOLERANCIA A MÁS DE UN HERBICIDA. PARTICULARMENTE, EN LA INVENCIÓN SE PROVEEN PLANTAS QUE PRESENTAN TOLERANCIA DE GLIFOSATO Y PRESENTAN TOLERANCIA A AL MENOS UN INHIBIDOR DE LA ALS, Y MÉTODOS PARA USARLAS. LAS PLANTAS CON TOLERANCIA A GLIFOSATO/INHIBIDORES DE LA ALS COMPRENDEN UN POLINUCLEOTIDO QUE CODIFICA UN POLIPÉPTIDO QUE CONFIERE TOLERANCIA A GLIFOSATO Y UN POLINUCLEOTIDO QUE CODIFICA UN POLIPÉPTIDO CON TOLERANCIA A UN INHIBIDOR DE LA ALS. EN REALIZACIONES ESPECÍFICAS, UNA PLANTA DE LA INVENCIÓN EXPRESA UN POLIPÉPTIDO GAT Y UN POLIPÉPTIDO HRA. TAMBIÉN SE PROPORCIONAN MÉTODOS PARA CONTROLAR MALEZAS, MEJORAR EL RENDIMIENTO DE LAS PLANTAS E INCREMENTAR LAS EFICIENCIAS DE TRANSFORMACIÓN",PIONEER HI BRED INT;;DU PONT,MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;HAZEL CHISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H;;GUIDA ANTHONY D,,https://lens.org/175-445-569-368-351,Patent Application,no,0,0,1,1,0,,A01N47/00,,0,0,,,,PENDING
821,KR,A,KR 20080052606 A,180-610-120-638-427,2008-06-11,2008,KR 20087007083 A,2008-03-24,US 71085405 P;;US 81701106 P,2005-08-24,COMPOSITIONS PROVIDING TOLERANCE TO MULTIPLE HERBICIDES AND METHODS OF USE THEREOF,"Methods and compositions are provided related to improved plants that are tolerant to more than one herbicide. Particularly, the invention provides plants that are tolerant of glyphosate and are tolerant to at least one ALS inhibitor, and methods of use thereof. The glyphosate/ALS inhibitor-tolerant plants comprise a polynucleotide that encodes a polypeptide that confers tolerance to glyphosate and a polynucleotide that encodes an ALS inhibitor-tolerant polypeptide. In specific embodiments, a plant of the invention expresses a GAT polypeptide and an HRA polypeptide. Methods to control weeds, improve plant yield, and increase transformation efficiencies are provided.",PIONEER HI BRED INT;;DU PONT,MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D JR;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,,https://lens.org/180-610-120-638-427,Patent Application,no,0,1,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,C12N15/82;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06;;C12N15/09,,0,0,,,,DISCONTINUED
822,NZ,A,NZ 568867 A,080-262-289-177-079,2010-12-24,2010,NZ 56886706 A,2006-08-22,US 71085405 P;;US 81701106 P;;US 2006/0032606 W,2005-08-24,Compositions providing tolerance to multiple herbicides and methods of use thereof,"Provided is a monocot transgenic plant or a monocot transgenic plant cell comprising a polynucleotide encoding a glyphosate-N-acetyltransferase polypeptide, wherein said polynucleotide is operably linked to (a) a promoter that drives expression in the monocot plant and (b) at least one copy of an enhancer sequence comprising a specified nucleotide sequence, wherein said enhancer sequence modulates the level of transcription, wherein said enhancer is heterologous to said promoter and, wherein said monocot plant or monocot plant cell is tolerant to glyphosate applied at a level effective to inhibit the growth of a control plant which does not comprise said polynucleotide encoding said glyphosate-N-acetyltransferase. Further provided are an expression cassette comprising said polynucleotide and a method of improving transformation efficiency comprising introducing said polynucleotide into monocot plant or plant cell, contacting said plant or cell with glycophosphate and selecting said plant or cell based on expression of said polynucleotide.",PIONEER HI BRED INT;;DU PONT,MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUSE JON S;;GREEN JERRY M;;GUIDA ANTHONY D;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F,,https://lens.org/080-262-289-177-079,Patent Application,no,0,1,46,71,0,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,C12N15/82;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,0,0,,,,PENDING
823,CA,C,CA 2625371 C,080-350-979-213-663,2012-06-26,2012,CA 2625371 A,2006-08-22,US 71085405 P;;US 81701106 P;;US 2006/0032606 W,2005-08-24,COMPOSITIONS PROVIDING TOLERANCE TO MULTIPLE HERBICIDES AND METHODS OF USE THEREOF,"Methods and compositions are provided related to improved plants that are tolerant to more than one herbicide. Particularly, the invention provides plants that are tolerant of glyphosate and are tolerant to at least one ALS inhibitor, and methods of use thereof. The glyphosate/ALS inhibitor-tolerant plants comprise a polynucleotide that encodes a polypeptide that confers tolerance to glyphosate and a polynucleotide that encodes an ALS inhibitor-tolerant polypeptide. In specific embodiments, a plant of the invention expresses a GAT polypeptide and an HRA polypeptide. Methods to control weeds, improve plant yield, and increase transformation efficiencies are provided.",PIONEER HI BRED INT;;DU PONT,MCCUTCHEN BILLY FRED;;CASTLE LINDA A;;CHICOINE TIMOTHY K;;CHO HYEON-JE;;CLAUS JON S;;GREEN JERRY M;;GUIDA ANTHONY D JR;;HAZEL CHRISTINE B;;HECKERT MATTHEW J;;HEGSTAD JEFFREY M;;HUTCHISON JAMES M;;LIU DONGLONG;;LU ALBERT L;;MEHRE WAYNE J;;MOY YORK;;OLSON PAUL D;;PEEPLES KENNETH A;;SAUNDERS DAVID W;;VOGT MARK D;;WILKINSON JACK Q;;WONG JAMES F H,,https://lens.org/080-350-979-213-663,Granted Patent,no,0,0,46,71,89,C12N9/1092;;C12N9/88;;C12N15/8205;;C12N15/8209;;C12N15/8216;;C12N15/8271;;C12N15/8275;;C12N15/8278;;C12N15/8286;;C12N15/8274;;Y02A40/146;;C12N15/82;;C12N15/09;;C12N15/8209;;C12N15/8286;;C12N15/8216;;C12N9/1092;;C12N15/8205;;C12N15/8278;;C12N15/8275;;C12N9/88;;C12N15/8271;;Y02A40/146;;C12N15/8274,C12N15/82;;A63B/;;A63B69/00;;A63B69/36;;A63B71/06,,0,0,,,,INACTIVE
824,EP,A1,EP 3039977 A1,087-438-161-279-501,2016-07-06,2016,EP 15003546 A,2015-12-13,US 201462091411 P,2014-12-12,SUIT DESIGNS AND DOFFING METHODS FOR PERSONAL PROTECTIVE EQUIPMENT,"The present invention relates to bodysuits for use as personal protective equipment comprising a torso portion comprising a front side (2); a back side including a sealable port (7) through which a wearer can enter and exit the bodysuit when donning or doffing the bodysuit, respectively; a waist region; a neck opening; a pair of upper limb openings; and a pair of lower limb openings; two arm portions each extending from one of the upper limb opening; and two leg portions each extending from one of the lower limb opening and methods for the removal of such bodysuits.
",UNIV JOHNS HOPKINS,YAZDI YOUSEPH;;TAN MELODY;;PETNEY MATTHEW;;PATTERSON WILLIAM ALEXANDER LEMAY;;PARKIDEH SIAVASH;;ANDREWS JILL;;OSEI PATIENCE;;ACHARYA SOUMYADIPTA;;RUPARELIA CHANDRAKANT;;KUMAR SANGHVI HARSHAD;;HARRIGAN TIMOTHY PATRICK;;CHO NAHYUN KATE;;LUU QIAN;;CRAFT BRANDON;;FEARIS PAUL;;MESSAI SAMI;;MA BRIAN;;HAWES MEAGAN;;HEINIS REEVE ILSE;;JOHNSON JASON ONSLOW LEROY;;REISFELD ERIN;;VACHHANI ARJUN SHAILESH;;CAMPBELL TIMOTHY;;RENS NEIL;;CLEGG MADELEINE;;STOKLEY ELIZABETH ANNE;;JEANG JESSICA;;CHIANG CHRISTOPHER;;WILLIBRORD SHASHA;;TOPPER BAILEY;;ASHMAN KIMBER;;PARLATO MICHAEL,THE JOHNS HOPKINS UNIVERSITY (2023-02-15),https://lens.org/087-438-161-279-501,Patent Application,yes,4,1,5,5,0,A41D2300/322;;A41D2400/52;;A62B17/001;;A62B17/006;;A41D13/02;;A41D2400/44;;A41D13/1218;;A41D27/28;;A41D13/02;;A41D2400/44;;A41D2400/70;;A41D2400/52;;A62B17/006;;A62B17/001;;A41D2300/322,A41D13/02,,19,0,,,"BAKER, ARYN: ""Why Protective Gear Is Sometimes Not Enough in the Fight Against Ebola"", 15 October 2014, TIME;;BEAUBIEN, JASON: ""Firestone Did What Governments Have Not: Stopped Ebola In Its Tracks"", 6 October 2014, NATIONAL PUBLIC RADIO;;BENTON, GRACE: ""ICT empowers communities in fight against Ebola"", 14 November 2014, ELEARNING AFRICA NEWS;;""CEPAR Tracking and Responding to EBOLA"", 2014, JOHNS HOPKINS OFFICE OF CRITICAL EVENT PREPAREDNESS AND RESPONSE;;CHENG, MARIA: ""WHO: 10,000 new Ebola cases per week could be seen"", 14 October 2014, ASSOCIATED PRESS;;DAVIS, REBECCA: ""Panic In The Parking Lot: A Hospital Sees Its First Ebola Case"", 14 October 2014, NATIONAL PUBLIC RADIO;;""Dean's Symposium on Ebola"", 14 October 2014, JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH.;;""Ebola Deeply"", 2014, EBOLA DEEPLY;;""Ebola virus disease."", 2014, WORLD HEALTH ORGANIZATION;;""Global Alert and Response"", 2014, WORLD HEALTH ORGANIZATION;;KELION, LEO: ""Ebola text-message system set to expand."", 14 October 2014, BBC;;""Life inside a Liberian Ebola Treatment Unit"", 2014, ABC NEWS;;MARTIN, KIM: ""HC3 Launches Ebola communication network to house Ebola resources, tools"", 8 October 2014, HEALTH COMMUNICATION CAPACITY COLLABORATIVE;;""MSF rejects Ebola cash asks Australia for medics"", 2 October 2014, ALJAZEERA;;PENFOLD, ERICA: ""Ebola and Cultures of Engagement: Chinese Versus Western Health Diplomacy"", 3 October 2014, COUNCIL OF COUNCILS;;""Personal Protective Equipment"", 2014, UNITED STATES DEPARTMENT OF LABOR OCCUPATIONAL SAFETY & HEALTH ADMINISTRATION;;""Understanding the Ebola Virus and How You Can Avoid It"", 2014, ALISON;;WATSON, LEON: ""WHO says Ebola is 'most severe acute health emergency in modern times"", 13 October 2014, THE TELEGRAPH.;;""What should Ebola health care workers wear?"", 17 October 2014, CBS NEWS",ACTIVE
825,US,B2,US 10524525 B2,089-825-769-261-126,2020-01-07,2020,US 201514968087 A,2015-12-14,US 201514968087 A;;US 201462091411 P,2014-12-12,Suit designs and doffing methodologies for personal protective equipment to prevent the spread of infectious agents to healthcare workers,"The present invention relates to bodysuits for use as personal protective equipment comprising a torso portion comprising a front side; a back side including a sealable port through which a wearer can enter and exit the bodysuit when donning or doffing the bodysuit, respectively; a waist region; a neck opening; a pair of upper limb openings; and a pair of lower limb openings; two arm portions each extending from one of the upper limb opening; and two leg portions each extending from one of the lower limb opening and methods for the removal of such body suits.",UNIV JOHNS HOPKINS,YAZDI YOUSEPH;;TAN MELODY;;PETNEY MATTHEW;;LEMAY PATTERSON WILLIAM ALEXANDER;;PARKHIDEH SIAVASH;;ANDREWS JILL;;OSEI PATIENCE;;ACHARYA SOUMYADIPTA;;RUPARELIA CHANDRAKANT;;SANGHVI HARSHADKUMAR;;HARRIGAN TIMOTHY PATRICK;;CHO NAHYUN KATE;;LIU QIAN;;CRAFT BRANDON;;FEARIS PAUL;;MESSAI SAMI;;MA BRIAN;;HAWES MEAGAN;;HEINIS REEVE ILSE;;LEROY JOHNSON JASON ONSLOW;;REISFELD ERIN;;VACHHANI ARJUN SHAILESH;;CAMPBELL TIMOTHY;;RENS NEIL;;CLEGG MADELEINE;;STOKLEY ELIZABETH ANNE;;JEANG JESSICA;;CHIANG CHRISTOPHER;;SHASHA WILLIBRORD;;TOPPER BAILEY;;ASHMAN KIMBERLY;;PARLATO MICHAEL,THE JOHNS HOPKINS UNIVERSITY (2016-02-01),https://lens.org/089-825-769-261-126,Granted Patent,yes,37,0,5,5,0,A41D2300/322;;A41D2400/52;;A62B17/001;;A62B17/006;;A41D13/02;;A41D2400/44;;A41D13/1218;;A41D27/28;;A41D13/02;;A41D2400/44;;A41D2400/70;;A41D2400/52;;A62B17/006;;A62B17/001;;A41D2300/322,A41D13/12;;A41D13/02;;A41D27/28;;A62B17/00,,20,0,,,"“CEPAR Tracking and Responding to Ebola,” Johns Hopkins Office of Critical Event Preparedness and Response, 2 pages, 2014. Retrieved: <http://www.hopkins-cepar.org/>. [Cited in Specification].;;“Dean's Symposium on Ebola,” Johns Hopkins Bloomberg School of Public Health, front page provided, Oct. 14, 2014. Retrieved: <http://www.jhsph.edu/events/2014/ebola-forum/social-media-and-multimedia-links.html>. [Cited in Specification].;;“Ebola Deeply.” Ebola Deeply, front page only, 2014. Retrieved: <http://www.eboladeeply.org>. [Cited in Specification].;;“Ebola virus disease,” World Health Organization, 2 pages, Dec. 14, 2014. Retrieved: <http://www.who.int/csr/disease/ebola/en/>. [Cited in Specification].;;“Ebola.” USAID. Retrieved: <http://www.usaid.gov/ebola>. [Cited in Specification].;;“Ebola Response Roadmap Situation Report,” World Health Organization, pp. 1-14, Dec. 10, 2014. Retrieved: <http://www.who.int/csr/disease/ebola/situation-reports/en/>. [Cited in Specification].;;“MSF rejects Ebola cash asks Australia for medics,” Aljazeera, pp. 1-2, Oct. 2, 2014. Retrieved: <http://www.aljazeera.com/news/africa/2014/10/msf-rej ects-ebola-cash- asks-medics-201410210414437521.html>. [Cited in Specification].;;“Personal Protective Equipment.” United States Department of Labor Occupational Safety & Health Administration, 2 pages, 2014. Retrieved: <https://www.osha.gov/SLTC/personalprotectiveequipment/construction.html>. [Cited in Specification].;;Firger, Jessica, “What should Ebola health care workers wear?” CBS News, pp. 1-4, Oct. 17, 2014. Retrieved: <http://www.cbsnews.com/news/what-should-ebola-health-care-workers-wear/>. [Cited in Specification].;;Baker, Aryn. “Why Protective Gear Is Sometimes Not Enough in the Fight Against Ebola.” Time. Oct. 15, 2014. Retrieved: <http://time.com/3509980/ebola-protection-mistakes/>. [Cited in Specification].;;Beaubien, Jason. “Firestone Did What Governments Have Not: Stopped Ebola in Its Tracks,” National Public Radio, pp. 1-13, Oct. 6, 2014. Retrieved: <http://wwvv.npr.org/blogs/goatsandsoda/2014/10/06/354054915/firestone-did-what-governments-have-not-stopped-ebola-in-its-tracks>. [Cited in Specification].;;Benton, Grace. “ICT empowers communities in fight against Ebola.” eLearning Africa News. Nov. 14, 2014. Retrieved: <http://www.elearning-africa.com/eLA Newsportal/ict-ebola-Sierra-Leone/>. [Cited in Specification].;;Cheng, Maria. “WHO: 10,000 new Ebola cases per week could be seen.” Associated Press. Oct. 14, 2014. Retrieved: <http://bigstory.ap.org/article/77bfl 13 e7b314fa7aa2ec891c2e7c7b9/who-10000-new-ebola-cases-week-could-be-seen>. [Cited in Specification].;;Davis, Rebecca. “Panic in the Parking Lot: A Hospital Sees Its First Ebola Case.” National Public Radio. Oct. 14, 2014. http://www.npr.org/2014/10/14/356045068/u-s-doctor-witnesses-unfolding-ebola-epidemic-at-liberian-hospital.;;Kelion, L., “Ebola text-message system set to expand,” BBC, pp. 1-13, Oct. 14, 2014. Retrieved: <http://www.bbc.com/news/technology-29610865>.;;Martin, Kim, “HC3 Launches Ebola Communication Network to House Ebola Resources, Tools,” Health Communication Capacity Collaborative, pp. 1-8, Oct. 8, 2014. Retrieved: <http://www.healthcommcapacity.org/hc3-launches-ebo la-communi cation-network-house-ebola-resources-tools/>.;;Penfold, Erica et al., “Ebola and Cultures of Engagement: Chinese Versus Western Health Diplomacy,” Council With Council of Councils, pp. 1-6, Oct. 3, 2014. Retrieved: <http://www.cfi..org/councilofcouncils/global_memos/p33560>. [Cited in Specification].;;Watson, Leon, “WHO says Ebola is ‘most severe acute health emergency in modem times,’”The Telegraph, pp. 1-4, Oct. 13, 2014. Retrieved: <http://www.telegraph.co.uk/news/worldnews/ebola/11158504/WHO-says-Ebola-is-mo st-severe-acute-health-emergency-in-modern-times.html>. [Cited in Specification].;;“Life inside a Liberian Ebola Treatment Unit.” ABC News. 2014. Retrieved: <http://abcnews.go.com/International/video/life-inside-liberian-ebola-treatment-unit-25873937>. [Cited in Specification].;;“Understanding the Ebola Virus and How You Can Avoid It.” Alison. 2014. Retrieved: <http://alison.com/coursesiUnderstanding-the-Ebola-Virus-and-How-You-Can-Avoid-It>. [Cited in Specification].",ACTIVE
826,US,A1,US 2016/0165973 A1,178-934-530-628-247,2016-06-16,2016,US 201514968087 A,2015-12-14,US 201514968087 A;;US 201462091411 P,2014-12-12,SUIT DESIGNS AND DOFFING METHODOLOGIES FOR PERSONAL PROTECTIVE EQUIPMENT TO PREVENT THE SPREAD OF INFECTIOUS AGENTS TO HEALTHCARE WORKERS,"The present invention relates to bodysuits for use as personal protective equipment comprising a torso portion comprising a front side; a back side including a sealable port through which a wearer can enter and exit the bodysuit when donning or doffing the bodysuit, respectively; a waist region; a neck opening; a pair of upper limb openings; and a pair of lower limb openings; two arm portions each extending from one of the upper limb opening; and two leg portions each extending from one of the lower limb opening and methods for the removal of such body suits.",UNIV JOHNS HOPKINS,YAZDI YOUSEPH;;TAN MELODY;;PETNEY MATTHEW;;LEMAY WILLIAM ALEXANDER;;PARKIDEH SIAVASH;;ANDREWS JILL;;OSEI PATIENCE;;ACHARYA SOUMYADIPTA;;RUPARELIA CHANDRAKANT;;KUMAR SANGHVI HARSHAD;;HARRIGAN TIMOTHY PATRICK;;CHO NAHYUN KATE;;LIU QIAN;;CRAFT BRANDON;;FEARIS PAUL;;MESSAI SAMI;;MA BRIAN;;HAWES MEGAN;;HEINIS REEVE ILSE;;LEROY JASON ONSLOW;;REISFELD ERIN;;VACHHANI ARJUN SHAILESH;;CAMPBELL TIMOTHY;;RENS NEIL;;CLEGG MADELEINE;;STOKLEY ELIZABETH ANNE;;JEANG JESSICA;;CHIANG CHRISTOPHER;;SHASHA WILLIBRORD;;TOPPER BAILEY;;ASHMAN KIMBER;;PARLATO MICHAEL,THE JOHNS HOPKINS UNIVERSITY (2016-02-01),https://lens.org/178-934-530-628-247,Patent Application,yes,72,19,5,5,0,A41D2300/322;;A41D2400/52;;A62B17/001;;A62B17/006;;A41D13/02;;A41D2400/44;;A41D13/1218;;A41D27/28;;A41D13/02;;A41D2400/44;;A41D2400/70;;A41D2400/52;;A62B17/006;;A62B17/001;;A41D2300/322,A41D13/12;;A41D13/02;;A41D27/28,,0,0,,,,ACTIVE
827,EP,B8,EP 3039977 B8,180-392-880-207-141,2023-03-15,2023,EP 15003546 A,2015-12-13,US 201462091411 P,2014-12-12,SUIT DESIGNS AND DOFFING METHODS FOR PERSONAL PROTECTIVE EQUIPMENT,,UNIV JOHNS HOPKINS,YAZDI YOUSEPH;;TAN MELODY;;PETNEY MATTHEW;;PATTERSON WILLIAM ALEXANDER LEMAY;;PARKIDEH SIAVASH;;ANDREWS JILL;;OSEI PATIENCE;;ACHARYA SOUMYADIPTA;;RUPARELIA CHANDRAKANT;;KUMAR SANGHVI HARSHAD;;HARRIGAN TIMOTHY PATRICK;;CHO NAHYUN KATE;;LUU QIAN;;CRAFT BRANDON;;FEARIS PAUL;;MESSAI SAMI;;MA BRIAN;;HAWES MEAGAN;;HEINIS REEVE ILSE;;JOHNSON JASON ONSLOW LEROY;;REISFELD ERIN;;VACHHANI ARJUN SHAILESH;;CAMPBELL TIMOTHY;;RENS NEIL;;CLEGG MADELEINE;;STOKLEY ELIZABETH ANNE;;JEANG JESSICA;;CHIANG CHRISTOPHER;;WILLIBRORD SHASHA;;TOPPER BAILEY;;ASHMAN KIMBER;;PARLATO MICHAEL,THE JOHNS HOPKINS UNIVERSITY (2023-02-15),https://lens.org/180-392-880-207-141,Amended Patent,yes,4,0,5,5,0,A41D2300/322;;A41D2400/52;;A62B17/001;;A62B17/006;;A41D13/02;;A41D2400/44;;A41D13/1218;;A41D27/28;;A41D13/02;;A41D2400/44;;A41D2400/70;;A41D2400/52;;A62B17/006;;A62B17/001;;A41D2300/322,A41D13/02,,0,0,,,,ACTIVE
828,EP,B1,EP 3039977 B1,147-423-382-123-140,2023-02-01,2023,EP 15003546 A,2015-12-13,US 201462091411 P,2014-12-12,SUIT DESIGNS AND DOFFING METHODS FOR PERSONAL PROTECTIVE EQUIPMENT,,UNIV JOHNS HOPKINS,YAZDI YOUSEPH;;TAN MELODY;;PETNEY MATTHEW;;PATTERSON WILLIAM ALEXANDER LEMAY;;PARKIDEH SIAVASH;;ANDREWS JILL;;OSEI PATIENCE;;ACHARYA SOUMYADIPTA;;RUPARELIA CHANDRAKANT;;KUMAR SANGHVI HARSHAD;;HARRIGAN TIMOTHY PATRICK;;CHO NAHYUN KATE;;LUU QIAN;;CRAFT BRANDON;;FEARIS PAUL;;MESSAI SAMI;;MA BRIAN;;HAWES MEAGAN;;HEINIS REEVE ILSE;;JOHNSON JASON ONSLOW LEROY;;REISFELD ERIN;;VACHHANI ARJUN SHAILESH;;CAMPBELL TIMOTHY;;RENS NEIL;;CLEGG MADELEINE;;STOKLEY ELIZABETH ANNE;;JEANG JESSICA;;CHIANG CHRISTOPHER;;WILLIBRORD SHASHA;;TOPPER BAILEY;;ASHMAN KIMBER;;PARLATO MICHAEL,THE JOHNS HOPKINS UNIVERSITY (2023-02-15),https://lens.org/147-423-382-123-140,Granted Patent,yes,4,0,5,5,0,A41D2300/322;;A41D2400/52;;A62B17/001;;A62B17/006;;A41D13/02;;A41D2400/44;;A41D13/1218;;A41D27/28;;A41D13/02;;A41D2400/44;;A41D2400/70;;A41D2400/52;;A62B17/006;;A62B17/001;;A41D2300/322,A41D13/02,,0,0,,,,ACTIVE
